fluorouracil has been researched along with Cancer of Pancreas in 2205 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The global, randomized NAPOLI-1 phase 3 trial reported a survival benefit with liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after previous gemcitabine-based therapy." | 9.34 | Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. ( Bang, YJ; Belanger, B; Chen, JS; Chen, LT; Chiu, CF; Choi, HJ; Kim, JS; Lee, KH; Li, CP; Oh, DY; Park, JO; Rau, KM; Shan, YS; Shim, HJ, 2020) |
| "Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma (PDA)." | 9.27 | FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. ( Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH, 2018) |
| "The aims of this study is to determine the maximum tolerated dose of capecitabine and oxaliplatin (CAPOX) delivered concurrent with radiation therapy (RT) in the treatment of locally advanced pancreatic adenocarcinoma and to retrospectively compare outcomes with this regimen to concurrent 5-fluorouracil or capecitabine with RT (5FU-RT) or concurrent gemcitabine-based chemotherapy with RT (GEM-RT)." | 9.16 | Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation. ( Anker, C; Hazard, L; Jones, K; Mulvihill, S; Scaife, C; Shaban, A; Weis, J, 2012) |
| "PEFG regimen (P:cisplatin, E:epirubicin, F:5-fluorouracil, G:gemcitabine) significantly prolonged progression-free (PFS) and overall survival (OS) of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine." | 9.16 | A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). ( Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E, 2012) |
| "To determine the safety and efficacy of neoadjuvant gemcitabine/capecitabine followed by surgery for the treatment of locally advanced pancreatic adenocarcinoma (LAPC)." | 9.16 | Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. ( Han, DJ; Kim, JH; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, JH; Seo, DW; Shin, SH, 2012) |
| "To investigate the efficacy and toxicity of the docetaxel and capecitabine combination in patients with previously treated, unresectable adenocarcinoma of the pancreas." | 9.15 | Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. ( Bozionelou, V; Georgoulias, V; Giassas, S; Kalbakis, K; Katopodis, O; Kentepozidis, N; Mavroudis, D; Polyzos, A; Rovithi, M; Vamvakas, L, 2011) |
| "The impact of the addition of gemcitabine to 5-fluorouracil (5-FU) chemoradiation (CRT) on 5-year overall survival (OS) in resected pancreatic adenocarcinoma are presented with updated results of a phase III trial." | 9.15 | Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. ( Abrams, R; Benson, AB; Hoffman, JP; Konski, A; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA, 2011) |
| "Gemcitabine-based chemotherapy is a commonly used first-line treatment for patients with pancreatic and biliary tract cancer." | 9.14 | Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. ( Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS, 2009) |
| "0 Gy/5 weeks can be safely administered to the tumor bed, concurrently with capecitabine (1600 mg/m (2)) in patients with resected pancreatic carcinoma." | 9.14 | Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study. ( Caprino, P; Caravatta, L; Cellini, N; Deodato, F; Di Lullo, L; Giglio, G; Ingrosso, M; Ippolito, E; Macchia, G; Massaccesi, M; Mattiucci, GC; Mignogna, S; Morganti, AG; Picardi, V; Sofo, L; Tambaro, R; Valentini, V, 2010) |
| "In this multicentre phase I-II trial we evaluated the feasibility and efficacy of capecitabine and oxaliplatin followed by the combination of these two drugs with radiotherapy in patients with locally advanced pancreatic or biliary tract cancer." | 9.14 | Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. ( Anderson, H; Glimelius, B; Gunnlaugsson, A; Johnsson, A; Lind, P, 2010) |
| "Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared with fluorouracil." | 9.13 | Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. ( Abrams, RA; Benson, AB; Fromm, ML; Haddock, MG; Hoffman, JP; Konski, A; Kudrimoti, MR; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Schaefer, P; Willett, CG; Winter, KA, 2008) |
| "The goal was to evaluate the impact of postoperative IAC followed or not by systemic gemcitabine in patients after curative resection for pancreatic adenocarcinoma." | 9.12 | Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. ( Cantore, M; Capelli, P; Fiorentini, G; Iacono, C; Lombardi, M; Mambrini, A; Pacetti, P; Pagani, M; Pederzoli, P; Pulica, C; Serio, G; Torri, T, 2006) |
| "PEFG regimen (cisplatin and epirubicin 40 mg/m2 day 1, gemcitabine 600 mg/m2 days 1 and 8, 5-fluorouracil (FU) 200 mg/m2/day continuous infusion) significantly improved the outcome of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine in a previous phase III trial." | 9.12 | Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. ( Balzano, G; Bonetto, E; Cereda, S; Di Carlo, V; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Viganò, MG; Zerbi, A, 2007) |
| "In this phase II trial, we used the combination of gemcitabine and 5-fluorouracil (5-FU) to treat 26 patients: 17 (65%) with advanced pancreatic adenocarcinoma and 9 (35%) with advanced biliary tract adenocarcinoma (10 locally advanced and 16 metastatic); 15 (57." | 9.10 | Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. ( Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO, 2003) |
| "Phase II studies have suggested an improved response rate and acceptable toxicity profile associated with gemcitabine combinations compared to gemcitabine alone for treatment of metastatic adenocarcinoma of the pancreas." | 9.10 | Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. ( Araneo, M; Bruckner, HW; DeGregorio, P; Firoozi, K; Frager, D; Grossbard, ML; Homel, P; Jindal, K; Kozuch, P; Marino, J; Mortazabi, F, 2003) |
| " This study was conducted to prospectively examine the tolerance and early efficacy of adjuvant gemcitabine following radiotherapy with concurrent 5-fluorouracil (5-FU) for nonmetastatic pancreatic adenocarcinoma." | 9.09 | Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. ( Kachnic, LA; Lauve, AD; Manning, MA; Neifeld, JP; Shaw, JE, 2001) |
| "To evaluate the efficacy and toxicity of a cisplatin, epirubicin, gemcitabine, and fluorouracil (PEF-G) schedule on stage IV pancreatic adenocarcinoma." | 9.09 | Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. ( Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A, 2001) |
| "Gemcitabine alone or 5-fluorouracil (5-FU) according to several schedules are used for palliation of metastatic and locally advanced (LA) pancreatic adenocarcinoma." | 9.09 | Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). ( André, T; Balosso, J; Cattan, S; Colin, P; de Gramont, A; Flesch, M; Fonck, M; Hammel, P; Landi, B; Louvet, C; Ruszniewski, P; Selle, F, 2001) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 9.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| "In a randomized trial we compared single-agent epirubicin with the FEM (5-fluorouracil/epirubicin/mitomycin) combination in patients with locally advanced and/or metastatic adenocarcinoma of the pancreas." | 9.07 | Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. ( Coombes, RC; Glees, J; Topham, C, 1993) |
| "Forty-two previously untreated patients with advanced, measurable adenocarcinoma of the pancreas were treated with weekly fluorouracil (5-FU; 600 mg/m2 intravenous [IV]) and leucovorin 500 mg/m2 IV for 6 weeks followed by a 2-week rest." | 9.07 | Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. ( Arbuck, SG; DeCaprio, JA; Gonin, R; Mayer, RJ, 1991) |
| "Twenty-two patients with inoperable adenocarcinoma of the pancreas were treated with 5-fluorouracil (5-FU), mitomycin C (Mito-C), and 1(-2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (MeCCNU)." | 9.06 | Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas. ( Chapman, J; Chinn, B; Groshko, G; Maniscalco, B; Piper, D; Reznik, S; Vaughn, C; Ward, D, 1989) |
| "Thirty-four patients with advanced adenocarcinoma of the gastrointestinal tract have been treated with high-dose 5-fluorouracil modulated by concomitant allopurinol therapy, in combination with either razoxane or adriamycin." | 9.05 | A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract. ( Ashford, RF; Bakowski, M; Evans, M; Hellman, K; Jones, R; Lambert, J; Newton, K; Peters, N; Phillips, R; Smith, BJ, 1983) |
| "Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III)." | 9.05 | MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. ( Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN, 1984) |
| "One hundred and sixteen patients with advanced and metastatic adenocarcinoma of the pancreas were randomized to treatment with combined Streptozotocin and 5-fluorouracil or combined Streptozotocin and cyclophosphamide." | 9.04 | Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. ( Carbone, PP; Douglas, HO; Hanley, J; Moertel, CG, 1977) |
| "The NAPOLI-I trial showed better outcome of nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) compared to 5-FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) progressed to gemcitabine-based therapy." | 8.31 | The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. ( Antonuzzo, L; Barsotti, G; Bergamo, F; Casalino, S; De Toni, C; De Vita, F; Fasano, M; Giommoni, E; Giordano, G; Lonardi, S; Melisi, D; Merz, V; Milella, M; Noventa, S; Pinto, C; Pretta, A; Procaccio, L; Satolli, MA; Scartozzi, M; Spadi, R; Vaccaro, V; Zaniboni, A; Zecchetto, C; Zichi, C, 2023) |
| "Gemcitabine (Gem) alone or with Nab-paclitaxel (Gem-Nab) is used as second-line treatment for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX (FFX) failure; however, no comparative data exist." | 8.12 | Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. ( Artru, P; Auclin, E; Bechade, D; Ducoulombier, A; Edeline, J; Gilabert, M; Hautefeuille, V; Lièvre, A; Morin, C; Pernot, S; Sarabi, M; Taieb, J; Tougeron, D; Wasselin, J; Zaibet, S, 2022) |
| " This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs." | 8.12 | Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022) |
| "FOLFIRINOX (leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin) and gemcitabine plus nab-paclitaxel are the 2 common first-line therapies for metastatic adenocarcinoma of the pancreas (mPC), but they have not been directly compared in a clinical trial, and comparative clinical data analyses on their effectiveness are limited." | 8.12 | Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. ( Amar-Farkash, S; Aran, D; Collisson, EA; Klein-Brill, A; Lawrence, G, 2022) |
| "We evaluated outcomes of treatment with 5-fluorouracil (5-FU), doxorubicin, and streptozocin (FAS) in well-differentiated pancreatic neuroendocrine tumors (PanNETs) and its impact on subsequent therapy (everolimus or temozolomide)." | 8.12 | Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. ( Dagohoy, CG; Dasari, A; Halperin, DM; Lam, M; Rogers, JE; Yao, JC, 2022) |
| "5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) has activity in pancreatic neuroendocrine tumors (pNETs), but its use is limited, partly because of toxicities." | 8.02 | Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide. ( Al-Toubah, T; Morse, B; Pelle, E; Strosberg, J, 2021) |
| "Eighty-three patients were treated with locally advanced or metastatic adenocarcinoma of the pancreas with either FOLFIRINOX or nab-Paclitxel and Gemcitabine (nabPGem) as first- or second line therapy." | 7.91 | Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter? ( Andalibi, H; Heinrich, B; Kafka, A; Klaus, A; Öhler, L; Schima, W; Vogl, UM; Vormittag, L; Winkler, T, 2019) |
| "5-Fluorouracil, doxorubicin, and streptozocin (FAS) leads to a 39 % response rate in advanced pancreatic neuroendocrine tumors (pNETs)." | 7.85 | Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. ( Aloia, T; Bhosale, P; Cloyd, J; Dasari, A; Fleming, JB; Halperin, D; Katz, MH; Kim, M; Lee, JE; Parker, N; Prakash, L; Vauthey, JN; Yao, J, 2017) |
| "To evaluate the outcomes and toxicity of concurrent full-dose gemcitabine and intensity-modulated radiation therapy (IMRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma after induction chemotherapy." | 7.83 | Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. ( Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M, 2016) |
| "In our center, the combination of streptozocin (STZ) and 5-fluorouracil (5-FU) has been used as the first-line treatment in the majority of patients with pancreatic neuroendocrine tumors (pNETs) over the past few decades." | 7.83 | Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity. ( Clewemar Antonodimitrakis, P; Eriksson, B; Granberg, D; Skogseid, B; Sundin, A; Wassberg, C, 2016) |
| "The use of PORT was associated with improved local control in the gemcitabine era for patients with resected, node-positive, pancreatic adenocarcinoma." | 7.81 | Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. ( Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE, 2015) |
| "The aim of this retrospective study was to investigate the relationship between UGT1A1 polymorphisms and toxicities in Chinese patients with pancreatic or biliary tract cancer receiving irinotecan-containing regimens as the second- or third-line chemotherapy." | 7.81 | Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. ( Jiang, JL; Liu, Y; Ma, T; Xi, WQ; Yang, C; Ye, ZB; Zhang, J; Zhou, CF; Zhu, ZG, 2015) |
| "Hand-foot syndrome (HFS) is the most frequently reported side effect of oral capecitabine therapy." | 7.80 | Topical henna ameliorated capecitabine-induced hand-foot syndrome. ( Ilyas, S; Saif, MW; Wasif, K, 2014) |
| "To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 7.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
| "To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts." | 7.78 | FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. ( Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P, 2012) |
| "To evaluate the efficacy and toxicity of irinotecan and oxaliplatin plus 5-fluorouracil (FU) and leucovorin (FOLFIRINOX) as second-line therapy in metastatic pancreatic adenocarcinoma (MPA)." | 7.77 | 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. ( Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M, 2011) |
| "The aim of this study was to retrospectively analyze the efficacy and safety of the combination of 5-fluorouracil (5-FU), dacarbazine, and epirubicin (FDE) in 39 patients with advanced, well-differentiated neuroendocrine tumors (NETs)." | 7.76 | Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors. ( Bruneton, D; Cassier, PA; Chayvialle, JA; Hervieu, V; Lombard-Bohas, C; Pilleul, F; Scoazec, JY; Walter, T, 2010) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 7.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "It is the aim of this study to assess the outcome of patients who received neoadjuvant 5-fluorouracil-cisplatin chemoradiation (CRT) for stage I/III pancreatic adenocarcinoma." | 7.75 | Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience. ( de Chaisemartin, C; Delpero, JR; Giovannini, M; Guiramand, J; Lelong, B; Moureau-Zabotto, L; Moutardier, V; Turrini, O; Viret, F, 2009) |
| "To evaluate retrospectively the efficacy and chronic toxicities of concurrent radiotherapy and chronomodulated infusion 5-fluorouracil (5-FU) in patients with pancreatic adenocarcinoma." | 7.73 | Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma. ( Adams, R; Jones, RS; Keene, KS; Penberthy, DR; Rich, TA; Shepard, RC, 2005) |
| "Four pancreatic adenocarcinoma cell lines were evaluated for their sensitivity to 5-fluorouracil (5-FU) and gemcitabine and two of these, Suit-2 and Panc-1, were chosen for combination experiments because they showed moderate and poor sensitivity, respectively, to 5-FU and gemcitabine." | 7.72 | 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. ( Costello, E; Ghaneh, P; Greenhalf, W; Halloran, CM; Neoptolemos, JP; Shore, S; Wilson, D; Zumstein, L, 2004) |
| "The most commonly used treatment in the palliative first-line therapy of metastatic pancreatic adenocarcinoma is the Gemcitabine (Gem) monotherapy, while several combination therapies are currently being tested in clinical trials." | 7.71 | [Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma]. ( Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A, 2002) |
| "In advanced adenocarcinoma of the pancreas treatment with 5-fluorouracil (5-FU) or ifosfamide results in response rates of approximately 20%." | 7.69 | Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas. ( Bakker, PJ; Gouma, DJ; Huizing, MT; Poorter, RL; Rauws, EA; Rietbroek, RC; Taat, CW; Veenhof, CH, 1995) |
| " Thirteen patients with adenocarcinoma of the pancreas received weekly 5-fluorouracil by rapid intravenous infusion midway through a 2-h infusion of high dose leucovorin during external beam radiation therapy." | 7.68 | Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas. A phase I study. ( Dobelbower, RR; Howard, JM; Konski, AA; Merrick, HW; Schifeling, DJ; Skeel, RT, 1992) |
| "Fluorine-19 NMR spectrometry was used to monitor the metabolism of two antineoplastic fluoropyrimidines, 5-fluorouracil (5FU) and 5'-deoxy-5-fluorouridine (5'dFUrd), in cell cultures of human pancreatic (Capan-1) and colon (HT-29) adenocarcinoma." | 7.67 | Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. ( Faure, F; Hollande, E; Malet-Martino, MC; Martino, R; Palevody, C; Vialaneix, JP, 1986) |
| "The EORTC Gastrointestinal Group has conducted a phase II trial in 47 patients with locally advanced or metastatic adenocarcinoma of the pancreas with epirubicin 90 mg/m2 intravenously on day 1 in combination with 5-fluorouracil 500 mg/m2 in a 2 hr infusion day 1-4, every 4 weeks." | 7.67 | An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas. ( Bleiberg, H; Blijham, G; Dalesio, O; Duez, N; Planting, A; Splinter, T; Weber, W; Wils, J, 1987) |
| "Thirty-nine patients with advanced metastatic adenocarcinoma of the pancreas were treated with a combination of 5-fluorouracil, Adriamycin, and mitomycin-C (FAM)." | 7.66 | 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. ( Hoth, DF; Karlin, DA; Levin, B; MacDonald, JS; Schein, PS; Smith, FP; Woolley, PV, 1980) |
| "The results of combination chemotherapy with intermittent courses of 5-fluorouracil and streptozotocin in ten patients with metastatic carcinoid tumors and in eight patients with islet cell carcinoma are reported." | 7.66 | Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozotocin. ( Bukowski, RM; Chernicoff, D; Groppe, CW; Hewlett, JS, 1979) |
| "For patients with localized pancreatic cancer with minimal vascular involvement, optimal survivability requires a multidisciplinary approach of surgical resection and systemic chemotherapy." | 7.01 | A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. ( DeRemer, DL; Fabregas, JC; George, TJ; Hitchcock, K; Hughes, SJ; Kayaleh, O; Lee, JH; Nassour, I; Ramnaraign, B; Rogers, SC; Russell, K; Sahin, I; Singhal, R; Thomas, RM; Turk, A; Zlotecki, R, 2023) |
| "A combined pancreatic cancer multimodality approach using CIT and radiosensitized radiotherapy is feasible and safe; delivery of immunotherapy can lead to T-cell immunity." | 6.90 | Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. ( Are, C; Berim, LD; Grem, JL; Hollingsworth, MA; Lazenby, A; Lin, C; Ly, QP; Madiyalakan, M; Meza, JL; Nicodemus, CF; Padussis, J; Schwarz, JK; Verma, V, 2019) |
| "In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma." | 6.82 | A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016) |
| "The aims of this study were to establish the maximum tolerated dose (MTD) of oxaliplatin in combination with fixed doses of gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in solid tumors, including advanced pancreatic cancer, and to evaluate the toxicity of the regimen." | 6.78 | Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. ( Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ, 2013) |
| "All patients had pancreatic or biliary tract cancer." | 6.78 | A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. ( Deming, DA; Goggins, T; Groteluschen, D; Hernan, HR; Holen, KD; LoConte, NK; Lubner, SJ; Mulkerin, DL; Oettel, K; Robinson, E; Schelman, WR; Traynor, AM, 2013) |
| "Gemcitabine dose was fixed at 750 mg/m² over 75 min, capecitabine was given twice daily and escalated from 500 to 650 mg/m² at DL2 and docetaxel increased from 30 to 36 mg/m² at DL3." | 6.76 | A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. ( Bekaii-Saab, T; Bloomston, M; Campbell, A; Culler, K; Hejna, G; Hill, ME; Kim, S; Li, X; Zalupski, M, 2011) |
| "Capecitabine was administered at a dose of 1,000 mg/m(2) b." | 6.74 | Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009) |
| "Dipyridamole 75 mg was administered orally three times daily during the FU administration." | 6.73 | Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007) |
| "Pancreatic cancer is chemo-radiosensitive." | 6.72 | Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. ( Bossard, N; Ducreux, M; Girard, N; Mornex, F; Partensky, C; Rouanet, P; Roy, P; Scoazec, JY; Seitz, JF; Smith, D; Valette, PJ; Ychou, M, 2006) |
| "Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials." | 6.71 | Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003) |
| " The purpose of the current study was to determine whether dose intensification of parenteral hydroxyurea in combination with fluorouracil could enhance the response rates of the combination against refractory upper gastrointestinal malignancies." | 6.71 | Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. ( Haynes, H; Kaleya, R; Kaubisch, A; Rozenblit, A; Wadler, S, 2004) |
| "Diarrhea was experienced by six of 10 patients, and only three patients were able to receive six weekly chemotherapy treatments without dose reduction or delay." | 6.69 | Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. ( Blumenson, LE; Creaven, PJ; Meropol, NJ, 1998) |
| "Of 28 enrolled patients with biliary tract cancer, complete responses were observed in 2 patients (7." | 6.69 | Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. ( Choi, CW; Choi, IK; Kim, BS; Kim, CD; Kim, JS; Kim, YH; Seo, JH; Um, SH, 2000) |
| " The maximum tolerated dose (MTD) was defined as the dosage of 5-FU that achieved 60% grade 3/4 toxicity." | 6.68 | A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. ( Chang, J; Cunningham, D; Gore, M; Hill, A; Hill, M; Moore, H; Nicolson, M; Norman, A; O'Brien, M; Oates, J; Rigg, A; Ross, P; Watson, M, 1997) |
| "A total of 554 patients with pancreatic cancer of all stages were screened, and 73 patients treated with Gem-Nab and 48 patients treated with Gem-Ox in the palliative first-line setting were identified and included in this analysis." | 5.91 | Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis. ( Gantschnigg, A; Greil, R; Huemer, F; Schlick, K; Seymer, A; Weiss, L, 2023) |
| "Pancreatic neuroendocrine tumors (pNETs) are rare entities representing 1% to 3% of all malignant pancreatic neoplasms." | 5.72 | Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series. ( Keitel, V; Klose, S; Krause, A; Kreissl, MC; Müller, C; Venerito, M, 2022) |
| "Folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or modified FOLFIRINOX (mFFX) is the first-line standard of care for metastatic pancreatic adenocarcinoma; effective and safe treatment strategies are needed as survival remains poor." | 5.69 | Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial. ( Bai, X; Chen, Y; Fu, Q; Gao, S; Guo, C; Huang, D; Li, X; Liang, T; Que, R; Shen, Y; Wu, J; Xiao, W; Xue, X; Zhang, M; Zhang, Q; Zhang, X, 2023) |
| "The objective of this study was to evaluate the efficacy and safety of induction chemotherapy (ICT), GOFL (gemcitabine, oxaliplatin plus fluorouracil (5-FU)/leucovorin) versus modified FOLFIRINOX (irinotecan, oxaliplatin plus 5-FU/leucovorin), followed by concurrent chemoradiotherapy (CCRT) in locally advanced pancreatic adenocarcinoma (LAPC)." | 5.51 | A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study. ( Ch'ang, HJ; Chang, PY; Chen, LT; Chiang, NJ; Chiu, YF; Li, CP; Lin, J; Lin, SJ; Shan, YS; Su, YY; Yang, SH, 2022) |
| "Most patients had disease progression as the best response to treatment (75." | 5.51 | Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? ( Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC, 2019) |
| " Recently, fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) demonstrated their superiority in first-line therapy." | 5.38 | Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. ( Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V, 2012) |
| " We determined the anticancer effects of VPA combined with 5-FU in these cell lines." | 5.37 | Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. ( Hanaoka, J; Ikemoto, T; Imura, S; Ishibashi, H; Iwahashi, S; Mori, H; Morine, Y; Ochir, TL; Shimada, M; Utsunomiya, T, 2011) |
| "The global, randomized NAPOLI-1 phase 3 trial reported a survival benefit with liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after previous gemcitabine-based therapy." | 5.34 | Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. ( Bang, YJ; Belanger, B; Chen, JS; Chen, LT; Chiu, CF; Choi, HJ; Kim, JS; Lee, KH; Li, CP; Oh, DY; Park, JO; Rau, KM; Shan, YS; Shim, HJ, 2020) |
| "Previously published work has demonstrated that combining gemcitabine with irreversible electroporation (IRE) results in increased drug delivery to pancreatic adenocarcinoma cells in vivo." | 5.34 | Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma. ( Bhutiani, N; Chen, Y; Li, Y; Martin, RCG; Pandit, H; Pulliam, ZR; Shi, X; Tan, M; Yu, Y; Zheng, Q, 2020) |
| "Endoscopic findings showed Type 3 gastric cancer with pyloric stenosis." | 5.34 | [A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil]. ( Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E, 2007) |
| "Gemcitabine (dFdC) is a prodrug that undergoes metabolism by cytidine deaminase to form an inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU)." | 5.31 | Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. ( Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG, 2000) |
| "We investigated the expression patterns of Ki67 and p53 in metastatic pancreatic adenocarcinomas and analyzed their relationship with disease progression-free survival (PFS) and overall survival (OS) in the overall study population and in patients treated with a gemcitabine-containing chemotherapy versus FOLFIRINOX chemotherapy." | 5.30 | Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis. ( Assi, H; Charafeddine, M; Hammoud, MS; Makki, I; Mukherji, D; Nassif, S; Shamseddine, A; Temraz, S; Tfayli, A, 2019) |
| "5-Fluorouracil was given every 3 weeks by 5-day continuous chronomodulated venous infusion (CMVI) with peak 5-FU delivery at 4 a." | 5.29 | Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma. ( Adam, R; Bertheault-Cvitkovic, F; Bismuth, H; Brienza, S; Itzhaki, M; Lévi, F; Misset, JL; Soussan, S, 1993) |
| "Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma (PDA)." | 5.27 | FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. ( Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH, 2018) |
| "The aim of the present study was to assess the effect of Endostar and temozolomide or dacarbazine plus 5-fluorouracil (5-FU) in patients with advanced pancreatic neuroendocrine tumors (pNETs)." | 5.27 | Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors. ( Bai, CM; Cheng, YJ; Gao, X; Meng, CT; Yan, XY; Ying, HY; Zhou, JF; Zhou, N, 2018) |
| "Patients with metastatic adenocarcinoma of the pancreas or biliary tract, previously untreated or having received 1 cytotoxic regimen for advanced disease, were treated with gemcitabine 1000 mg/m intravenously (IV) over 100 minutes, cisplatin 35 mg/m IV over 30 minutes, and 5-FU 2400 mg/m IV over 48 hours on day 1 of a 14-day cycle." | 5.27 | A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. ( Davis, EJ; Griffith, KA; Kim, EJ; McDonnell, KJ; Ruch, JM; Zalupski, MM, 2018) |
| "Of the 31 patients with stomach cancer who were evaluable for response and had had no previous chemotherapy, 12 (39%) achieved complete or partial remission." | 5.26 | Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas. ( Bennetts, RW; Heifetz, LJ; Jones, RD; Karlin, DA; Mahal, PS; Stroehlein, JR, 1982) |
| "0001) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma patients previously treated with gemcitabine-based therapy." | 5.24 | Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. ( Blanc, JF; Botteman, MF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Melisi, D; Pelzer, U; Siveke, JT; Solem, CT; Von Hoff, DD; Wan, Y; Wang-Gillam, A; Yang, Y, 2017) |
| "We sought to assess the benefit-risk balance of FOLFIRINOX versus gemcitabine in patients with metastatic pancreatic adenocarcinoma." | 5.22 | An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. ( Buyse, M; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Ozenne, B; Péron, J; Roche, L; Roy, P; Stanbury, T; Ychou, M, 2016) |
| "Chemoradioimmunotherapy of patients with pancreatic adenocarcinoma from the CapRI trial did not show any benefit of interferon-α in addition to a 5-fluorouracil (5FU)-based treatment." | 5.20 | Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. ( Bazhin, AV; Harig, S; Hartwig, W; Jäger, D; Karakhanova, S; Mosl, B; Ryschich, E; Schmidt, J; Werner, J, 2015) |
| "We performed a multicenter phase II study of sorafenib 200 mg orally twice daily along with oxaliplatin 85 mg/m(2) IV on days 1 and 15, followed by capecitabine 2250 mg/m(2) orally every 8 h for six doses starting on days 1 and 15 of a 28-day cycle in patients who had no more than one previous chemotherapy regimen for their pancreatic adenocarcinoma." | 5.20 | A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. ( Eickhoff, J; Groteluschen, D; LoConte, NK; Lubner, SJ; Makielski, RJ; Mulkerin, DL; Traynor, AM, 2015) |
| "In this phase I study, we sought to determine the feasibility and tolerability of neoadjuvant short course radiotherapy (SC-CRT) delivered with photon RT with concurrent capecitabine for resectable pancreatic adenocarcinoma." | 5.19 | Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. ( Ancukiewicz, M; Blaszkowsky, LS; Fernandez-del Castillo, C; Ferrone, CR; Hong, TS; Kwak, EL; Lillemoe, KD; Mamon, HJ; Napolitano, BN; Ryan, DP; Swanson, RS; Tseng, YD; Wo, JY, 2014) |
| "Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection." | 5.19 | Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. ( Anthoney, A; Bassi, C; Büchler, MW; Campbell, F; Carter, R; Charnley, RM; Costello, E; Cox, TF; Deakin, M; Dervenis, C; Garner, E; Ghaneh, P; Glimelius, B; Goldstein, D; Greenhalf, W; Halloran, CM; Jackson, R; Lacaine, F; Lamb, RF; Mackey, JR; Mayerle, J; McDonald, AC; Middleton, MR; Moore, MJ; Neoptolemos, JP; Oláh, A; Palmer, DH; Rawcliffe, CL; Scarfe, AG; Scarpa, A; Shannon, J; Tebbutt, NC; Valle, JW, 2014) |
| "The purpose of this phase I study was to determine the safety, toxicity, maximum tolerated dose, and pharmacokinetics of capecitabine when administered concurrently with radiotherapy in patients with localised, inoperable pancreatic adenocarcinoma." | 5.19 | A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. ( Crellin, A; Evans, TR; Harden, S; James, A; Lumsden, GR; McDonald, AC; Morrison, R; Paul, J; Roxburgh, P; Sweeting, L, 2014) |
| "To determine the maximum tolerated radiation dose (MTD) of an integrated boost to the tumor subvolume infiltrating vessels, delivered simultaneously with radical dose to the whole tumor and concomitant capecitabine in patients with pretreated advanced pancreatic adenocarcinoma." | 5.17 | Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study. ( Balzano, G; Bettinardi, V; Calandrino, R; Castoldi, R; Cattaneo, GM; Cereda, S; Di Muzio, N; Gianolli, L; Gusmini, S; Longobardi, B; Passoni, P; Reni, M; Slim, N; Staudacher, C, 2013) |
| "The aims of this study is to determine the maximum tolerated dose of capecitabine and oxaliplatin (CAPOX) delivered concurrent with radiation therapy (RT) in the treatment of locally advanced pancreatic adenocarcinoma and to retrospectively compare outcomes with this regimen to concurrent 5-fluorouracil or capecitabine with RT (5FU-RT) or concurrent gemcitabine-based chemotherapy with RT (GEM-RT)." | 5.16 | Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation. ( Anker, C; Hazard, L; Jones, K; Mulvihill, S; Scaife, C; Shaban, A; Weis, J, 2012) |
| "This multisite study sought to optimize the dosing, schedule, and administration of fixed-dose rate (FDR) gemcitabine plus capecitabine for advanced pancreatic and biliary tract cancers using an alternating-week dose schedule of both agents." | 5.16 | Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. ( Bergsland, EK; Coakley, FV; Dito, E; Espinoza, AM; Hanover, CS; Jones, KA; Kelley, RK; Ko, AH; Ong, A; Tempero, MA; Venook, AP, 2012) |
| "PEFG regimen (P:cisplatin, E:epirubicin, F:5-fluorouracil, G:gemcitabine) significantly prolonged progression-free (PFS) and overall survival (OS) of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine." | 5.16 | A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). ( Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E, 2012) |
| "Therapy-naive patients, age 18-75 years, Karnofsky Performance Status (KPS)>60, gross total resection of stage IB-III pancreatic adenocarcinoma, stratified for center and surgical margins, were randomly assigned to receive either gemcitabine 1 g/m2 weekly on days 1, 8, and 15 (arm A) or the PEFG regimen (cisplatin and epirubicin 40 mg/m2, day 1; gemcitabine 600 mg/m2, days 1, 8; 5-fluorouracil 200 mg/m2 daily, days 1-28) (arm B)." | 5.16 | Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. ( Aprile, G; Balzano, G; Cereda, S; Di Carlo, V; Di Muzio, N; Fugazza, C; Magli, A; Milandri, C; Passoni, P; Reni, M; Rognone, A; Saletti, P; Tronconi, MC; Villa, E; Zerbi, A, 2012) |
| "To determine the safety and efficacy of neoadjuvant gemcitabine/capecitabine followed by surgery for the treatment of locally advanced pancreatic adenocarcinoma (LAPC)." | 5.16 | Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. ( Han, DJ; Kim, JH; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, JH; Seo, DW; Shin, SH, 2012) |
| " Given preclinical evidence of synergy when a fluoropyrimidine is added to gemcitabine plus a taxane in a sequence-specific schedule, we conducted a phase I study to evaluate the combination of nab-paclitaxel, gemcitabine, and capecitabine administered biweekly in patients with metastatic pancreatic adenocarcinoma." | 5.16 | A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. ( Dito, E; Jones, KA; Kantoff, E; Ko, AH; Ong, A; Tempero, MA; Truong, TG, 2012) |
| "To investigate the efficacy and toxicity of the docetaxel and capecitabine combination in patients with previously treated, unresectable adenocarcinoma of the pancreas." | 5.15 | Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. ( Bozionelou, V; Georgoulias, V; Giassas, S; Kalbakis, K; Katopodis, O; Kentepozidis, N; Mavroudis, D; Polyzos, A; Rovithi, M; Vamvakas, L, 2011) |
| "The impact of the addition of gemcitabine to 5-fluorouracil (5-FU) chemoradiation (CRT) on 5-year overall survival (OS) in resected pancreatic adenocarcinoma are presented with updated results of a phase III trial." | 5.15 | Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. ( Abrams, R; Benson, AB; Hoffman, JP; Konski, A; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA, 2011) |
| "A phase II study was performed to assess the activity of oxaliplatin plus 5-fluorouracil (5-FU) modulated by leucovorin, as second-line treatment in locally advanced or metastatic pancreas adenocarcinoma pretreated with gemcitabine-containing schedule." | 5.14 | Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. ( Bellone, G; Bertetto, O; Chiappino, I; Ciuffreda, L; Giacobino, A; Milanesi, E; Novarino, A; Rahimi, F; Satolli, MA, 2009) |
| "The feasibility, safety, and efficacy of planned sequential administration of docetaxel and irinotecan with 5-fluorouracil (5-FU)/leucovorin in advanced upper gastrointestinal adenocarcinoma (UGIA) are unknown." | 5.14 | An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer. ( Berglund, A; Byström, P; Frödin, JE; Glimelius, B; Johansson, B; Letocha, H; Nygren, P; Pedersen, D, 2010) |
| "This phase II trial investigated the efficacy and safety of oxaliplatin (O), 5-fluorouracil (5-FU), and folinic acid (FA) (OFF) as second-line treatment for patients with metastatic pancreatic adenocarcinoma after failure of first-line gemcitabine treatment." | 5.14 | Second-line therapy in refractory pancreatic cancer. results of a phase II study. ( Dörken, B; Hilbig, A; Oettle, H; Pelzer, U; Riess, H; Roll, L; Stieler, J, 2009) |
| "Gemcitabine-based chemotherapy is a commonly used first-line treatment for patients with pancreatic and biliary tract cancer." | 5.14 | Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. ( Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS, 2009) |
| "Treatment-naive patients with stage III non-resectable pancreatic adenocarcinoma were treated with PEFG/PEXG (cisplatin, epirubicin, 5-fluorouracil (F)/capecitabine (X), gemcitabine) or PDXG (docetaxel substituting epirubicin) regimen for 6 months followed by radiotherapy (50-60 Gy) with concurrent F or X or G." | 5.14 | Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. ( Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E; Zerbi, A, 2009) |
| "0 Gy/5 weeks can be safely administered to the tumor bed, concurrently with capecitabine (1600 mg/m (2)) in patients with resected pancreatic carcinoma." | 5.14 | Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study. ( Caprino, P; Caravatta, L; Cellini, N; Deodato, F; Di Lullo, L; Giglio, G; Ingrosso, M; Ippolito, E; Macchia, G; Massaccesi, M; Mattiucci, GC; Mignogna, S; Morganti, AG; Picardi, V; Sofo, L; Tambaro, R; Valentini, V, 2010) |
| "Chemotherapy-naive patients with locally advanced or metastatic, histologically proven adenocarcinoma of the pancreas were treated with a 21-day regimen of gemcitabine [1000 mg/m² day (d) 1, d8], escalating doses of oxaliplatin (80-130 mg/m² d1) and capecitabine (650-800 mg/m² b." | 5.14 | Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial. ( Cescato, C; Herrmann, R; Hess, V; Jost, L; Lee, L; Lohri, A; Pestalozzi, B; Potthast, S; Pratsch, S; Stillhart, P; Widmer, L; Winterhalder, R, 2010) |
| "In this multicentre phase I-II trial we evaluated the feasibility and efficacy of capecitabine and oxaliplatin followed by the combination of these two drugs with radiotherapy in patients with locally advanced pancreatic or biliary tract cancer." | 5.14 | Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. ( Anderson, H; Glimelius, B; Gunnlaugsson, A; Johnsson, A; Lind, P, 2010) |
| "Gemcitabine is the standard chemotherapy for patients with metastatic pancreatic adenocarcinoma." | 5.14 | Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). ( Bedenne, L; Bonnetain, F; Cattan, S; Chauffert, B; Dahan, L; Gasmi, M; Hammel, P; Legoux, JL; Michel, P; Mitry, E; Phelip, JM; Raoul, JL; Rougier, P; Seitz, JF; Ychou, M, 2010) |
| "Patients with localized, potentially resectable pancreatic adenocarcinoma were treated with 50 Gy irradiation combined with 5-fluorouracil by continuous infusion (300 mg ." | 5.13 | Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial. ( Le Scodan, R; Mercier, C; Mornex, F; Partensky, C; Roy, P; Scoazec, JY; Valette, PJ; Ychou, M, 2008) |
| " Thirty patients with biopsy proven locally advanced unresectable adenocarcinoma of the pancreas were assessable after receiving 5-fluorouracil and radiation therapy with or without (32)P, followed by gemcitabine." | 5.13 | 32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: a randomized trial. ( Al-Saadi, S; Black, T; Bloomston, M; Bowers, C; Briggs, J; Carey, L; Carroll, R; Chervenick, P; Chheda, H; Cooper, J; Goldin, S; Grundy, S; Kudryk, B; Luzardo, G; Rosemurgy, A; Zervos, E; Zwiebel, B, 2008) |
| "Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared with fluorouracil." | 5.13 | Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. ( Abrams, RA; Benson, AB; Fromm, ML; Haddock, MG; Hoffman, JP; Konski, A; Kudrimoti, MR; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Schaefer, P; Willett, CG; Winter, KA, 2008) |
| "A randomized phase II study evaluating oxaliplatin alone (OXA), infusional 5-fluorouracil alone (5-FU) and an oxaliplatin/infusional 5-FU combination (OXFU) in untreated advanced pancreatic adenocarcinoma has been conducted." | 5.12 | Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. ( Boige, V; Bouché, O; Breau, JL; Bugat, R; Cvitkovic, E; Ducreux, M; Etienne, PL; Mitry, E; Morvan, F; Ould-Kaci, M; Rougier, P; Seitz, JF; Tigaud, JM, 2006) |
| "The goal was to evaluate the impact of postoperative IAC followed or not by systemic gemcitabine in patients after curative resection for pancreatic adenocarcinoma." | 5.12 | Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. ( Cantore, M; Capelli, P; Fiorentini, G; Iacono, C; Lombardi, M; Mambrini, A; Pacetti, P; Pagani, M; Pederzoli, P; Pulica, C; Serio, G; Torri, T, 2006) |
| "PEFG regimen (cisplatin and epirubicin 40 mg/m2 day 1, gemcitabine 600 mg/m2 days 1 and 8, 5-fluorouracil (FU) 200 mg/m2/day continuous infusion) significantly improved the outcome of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine in a previous phase III trial." | 5.12 | Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. ( Balzano, G; Bonetto, E; Cereda, S; Di Carlo, V; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Viganò, MG; Zerbi, A, 2007) |
| "A phase III trial suggested that a PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen might improve the outcome compared to gemcitabine in advanced pancreatic adenocarcinoma." | 5.12 | Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. ( Bonetto, E; Bordonaro, R; Cereda, S; Cordio, S; Di Carlo, V; Galli, L; Johnson, CD; Milandri, C; Passoni, P; Reni, M; Spreafico, A; Staudacher, C, 2006) |
| "Gemcitabine is considered the gold standard treatment for unresectable pancreatic adenocarcinoma." | 5.11 | Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. ( Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rabbi, C; Rosati, G; Zamagni, D, 2004) |
| "The present study was conducted to evaluate the efficacy and safety of the combination of Oxaliplatin, Leucovorin and 5-FU as second line therapy, following relapse to Gemcitabine, in patients with advanced adenocarcinoma of the pancreas." | 5.11 | Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. ( Felekouras, E; Gouveris, P; Kopterides, P; Kopteridis, P; Kosmas, C; Loukeris, D; Papalambros, E; Sigala, F; Skopelitis, H; Tsavaris, N; Zorbala-Sypsa, A, 2005) |
| "In this phase II trial, we used the combination of gemcitabine and 5-fluorouracil (5-FU) to treat 26 patients: 17 (65%) with advanced pancreatic adenocarcinoma and 9 (35%) with advanced biliary tract adenocarcinoma (10 locally advanced and 16 metastatic); 15 (57." | 5.10 | Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. ( Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO, 2003) |
| "Phase II studies have suggested an improved response rate and acceptable toxicity profile associated with gemcitabine combinations compared to gemcitabine alone for treatment of metastatic adenocarcinoma of the pancreas." | 5.10 | Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. ( Araneo, M; Bruckner, HW; DeGregorio, P; Firoozi, K; Frager, D; Grossbard, ML; Homel, P; Jindal, K; Kozuch, P; Marino, J; Mortazabi, F, 2003) |
| "Gemcitabine is considered the golden standard treatment for unresectable pancreatic adenocarcinoma." | 5.10 | Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer. ( Aitini, E; Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rosati, G; Zamagni, D, 2003) |
| " Ten patients with unresectable adenocarcinoma of the pancreas received preoperative chemotherapy [5-fluorouracil (5-FU)], bypass surgery and postoperative chemotherapy (5-FU, doxorubicin and cisplatin) plus sandostatin and radiotherapy (45 Gy, 25 fractions, 5 days a week)." | 5.10 | Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma. ( Golematis, BC; Kouloulias, VE; Kouvaris, JR; Mystakidou, K; Nikita, KS; Uzunoglu, NK; Vlahos, LJ, 2002) |
| "Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S stereoisomer of leucovorin 250 mg m(-2) and glutathione 1." | 5.09 | Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). ( Barni, S; Battelli, N; Casaretti, R; Cascinu, S; Catalano, G; Cellerino, R; Comella, G; Frontini, L; Labianca, R; Pirovano, M; Zonato, S, 1999) |
| "Biweekly intravenous infusions of low-dose cisplatin (CDDP) and 5-fluorouracil (5-FU) were evaluated in 80 patients with advanced or recurrent gastric, colorectal, pancreatic or gallbladder adenocarcinoma." | 5.09 | [Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma]. ( Kamata, T; Kanno, M; Koyasaki, N; Morita, A; Nakamoto, A; Onishi, I; Takeda, T, 2000) |
| " Those with locally invasive, unresectable, regional pancreatic adenocarcinoma initially were treated with simultaneous split-course RT plus 5-fluorouracil, streptozotocin, and cisplatin (RT-FSP) followed by selective surgery (Group 1)." | 5.09 | Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. ( Bruckner, H; Cooperman, A; Kiefer, L; Paradiso, J; Snady, H, 2000) |
| "Chemotherapy-naïve patients with measurable advanced adenocarcinoma of the pancreas were treated with gemcitabine 1,000 mg/m(2) intravenously weekly x 3 followed by 1 week of rest every 4 weeks and 200 mg/m(2)/day CI fluorouracil until disease progression or limiting toxicity." | 5.09 | Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. ( Aebi, S; Borner, MM; Büchler, MW; Friess, H; Ludwig, CU; Maurer, CA; Pampallona, S; Rauch, DP, 2001) |
| " This study was conducted to prospectively examine the tolerance and early efficacy of adjuvant gemcitabine following radiotherapy with concurrent 5-fluorouracil (5-FU) for nonmetastatic pancreatic adenocarcinoma." | 5.09 | Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. ( Kachnic, LA; Lauve, AD; Manning, MA; Neifeld, JP; Shaw, JE, 2001) |
| "To evaluate the efficacy and toxicity of a cisplatin, epirubicin, gemcitabine, and fluorouracil (PEF-G) schedule on stage IV pancreatic adenocarcinoma." | 5.09 | Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. ( Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A, 2001) |
| "Gemcitabine alone or 5-fluorouracil (5-FU) according to several schedules are used for palliation of metastatic and locally advanced (LA) pancreatic adenocarcinoma." | 5.09 | Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). ( André, T; Balosso, J; Cattan, S; Colin, P; de Gramont, A; Flesch, M; Fonck, M; Hammel, P; Landi, B; Louvet, C; Ruszniewski, P; Selle, F, 2001) |
| "From August 1995 through March 1996, seven patients with unresectable adenocarcinoma of the pancreas underwent CS, with preoperative chemotherapy (5-fluorouracil [FU] for 96 h), plus 45-Gy external beam postoperative irradiation with a 6-MeV linear accelerator (1." | 5.09 | Cytoreductive surgery combined with intraoperative chemo-hyperthermia and postoperative radiotherapy in the management of advanced pancreatic adenocarcinoma: feasibility aspects and efficacy. ( Golematis, VC; Kouloulias, VE; Kouvaris, JR; Nikita, KS; Papavasiliou, CG; Uzunoglu, NK; Vlahos, LJ, 2001) |
| "Forty-nine patients with localized unresectable adenocarcinoma of the pancreas were treated in a multimodality program of initial IORT and perioperative chemotherapy (fluorouracil [5-FU]/leucovorin) followed by combined external-beam radiation (40 to 55 Gy) and continued chemotherapy." | 5.08 | Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. ( Barbot, D; Biermann, W; Cantor, R; Mohiuddin, M; Regine, WF; Rosato, F; Stevens, J, 1995) |
| "A total of 20 patients with advanced pancreatic adenocarcinoma were enrolled in a phase II trial testing the activity of 5-fluorouracil given at 370 mg/m2 as a rapid i." | 5.08 | 5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. GLISP (Gruppo Ligure Studio Pancreas). ( Aschele, C; Bolli, E; Connio, M; Guglielmi, A; Ligas, B; Mondini, G; Mori, A; Rosso, R; Saccomanno, S; Sobrero, A, 1995) |
| "Fourteen patients with surgically resected periampullary adenocarcinoma were treated with adjuvant therapy consisting of prophylactic hepatic irradiation and pancreatic bed irradiation and concurrent infusional 5-fluorouracil and leucovorin (5-FU/LV)." | 5.08 | Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy. ( Abrams, RA; Cameron, JL; Carducci, MA; Grochow, LB; Hruban, RH; Yeo, CJ; Zahurak, ML, 1996) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 5.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| "Evidence suggests that interferon-alpha (IFN-alpha) augments the antineoplastic activity of 5-fluorouracil (5-FU) in human adenocarcinoma cell lines in vitro and may enhance the efficacy of 5-FU in patients with advanced colorectal carcinoma." | 5.08 | Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. ( Benson, AB; Bushunow, PW; Dutcher, JP; Flynn, PJ; Hansen, R; Kirkwood, J; Lipsitz, S; Sparano, JA; Wadler, S, 1996) |
| "One hundred twenty-six patients with advanced symptomatic pancreas cancer completed a lead-in period to characterize and stabilize pain and were randomized to receive either gemcitabine 1,000 mg/m2 weekly x 7 followed by 1 week of rest, then weekly x 3 every 4 weeks thereafter (63 patients), or to fluorouracil (5-FU) 600 mg/m2 once weekly (63 patients)." | 5.08 | Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. ( Andersen, J; Burris, HA; Cripps, MC; Dorr, FA; Green, MR; Modiano, MR; Moore, MJ; Nelson, R; Portenoy, RK; Rothenberg, ML; Stephens, CD; Storniolo, AM; Tarassoff, P; Von Hoff, DD, 1997) |
| "From December 1983 through December 1990, 27 patients with primary unresectable but localized pancreatic adenocarcinoma received high-dose (50 to 54 Gy) external beam irradiation with or without concomitant bolus 5-fluorouracil followed by surgical exploration and intraoperative electron beam irradiation (20 Gy) at the Mayo Clinic." | 5.07 | High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer. ( Cha, SS; Donohue, JH; Garton, GR; Gunderson, LL; Martin, JK; McIlrath, DC; Nagorney, DM, 1993) |
| "In a randomized trial we compared single-agent epirubicin with the FEM (5-fluorouracil/epirubicin/mitomycin) combination in patients with locally advanced and/or metastatic adenocarcinoma of the pancreas." | 5.07 | Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. ( Coombes, RC; Glees, J; Topham, C, 1993) |
| "Forty-two previously untreated patients with advanced, measurable adenocarcinoma of the pancreas were treated with weekly fluorouracil (5-FU; 600 mg/m2 intravenous [IV]) and leucovorin 500 mg/m2 IV for 6 weeks followed by a 2-week rest." | 5.07 | Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. ( Arbuck, SG; DeCaprio, JA; Gonin, R; Mayer, RJ, 1991) |
| "One hundred eighty-seven patients with histologically proven advanced pancreatic adenocarcinoma were randomly assigned to therapy with 5-fluorouracil (5-FU) alone, to the Mallinson regimen (combined and sequential 5-FU, cyclophosphamide, methotrexate, vincristine, and mitomycin C), or to combined 5-FU, doxorubicin, and cisplatin (FAP)." | 5.06 | A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. ( Barlow, JF; Cullinan, S; Foley, JF; Kardinal, CG; Krook, JE; Moertel, CG; Norris, BD; Schutt, AJ; Tschetter, LK; Wieand, HS, 1990) |
| "Twenty-two patients with inoperable adenocarcinoma of the pancreas were treated with 5-fluorouracil (5-FU), mitomycin C (Mito-C), and 1(-2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (MeCCNU)." | 5.06 | Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas. ( Chapman, J; Chinn, B; Groshko, G; Maniscalco, B; Piper, D; Reznik, S; Vaughn, C; Ward, D, 1989) |
| "One hundred thirty-three patients with advanced pancreatic adenocarcinoma and measurable disease were treated with 5-fluorouracil (5-FU) plus doxorubicin plus mitomycin C (FAM), streptozotocin plus mitomycin C plus 5-FU (SMF) in the regimen originally reported, and streptozotocin plus mitomycin C plus 5-FU with 5-FU and streptozotocin administered in five-day courses." | 5.06 | Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group. ( , 1986) |
| "Thirty-four patients with advanced adenocarcinoma of the gastrointestinal tract have been treated with high-dose 5-fluorouracil modulated by concomitant allopurinol therapy, in combination with either razoxane or adriamycin." | 5.05 | A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract. ( Ashford, RF; Bakowski, M; Evans, M; Hellman, K; Jones, R; Lambert, J; Newton, K; Peters, N; Phillips, R; Smith, BJ, 1983) |
| "Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III)." | 5.05 | MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. ( Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN, 1984) |
| "One-hundred-ninety-four eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high-dose (6000 rads) radiation therapy alone, to moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU), and to high-dose radiation plus 5-FU." | 5.05 | Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. ( Barkin, J; Bateman, J; Brooks, J; Chaffey, J; Childs, DS; Corson, JM; Douglas, HO; Frytak, S; Hahn, RG; Holbrook, MA; Kalser, M; Knowlton, A; Lavin, PT; Lessner, H; Livstone, E; Lokich, J; Mann-Kaplan, R; Moertel, CG; Nave, H; Novak, JW; O'Connell, MJ; Ramming, K; Reitemeier, RJ; Rubin, J; Schutt, AJ; Spiro, H; Thomas, P; Weiland, LH; Zamcheck, N, 1981) |
| "One hundred ninety-one patients with pathologically confirmed, locally unresectable adenocarcinoma of the stomach (57 patients) and pancreas (91 patients), were randomly allocated to therapy with 5-fluorouracil (5-FU) alone, 600 mg/m2 intravenously (IV) once weekly, or radiation therapy, 4,000 rad, plus adjuvant 5-FU, 600 mg/m2 IV, the first three days of radiotherapy, then follow-up maintenance 5-FU, 600 mg/m2, weekly." | 5.05 | Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. ( Catton, GE; Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Moertel, CG, 1985) |
| "One hundred and sixteen patients with advanced and metastatic adenocarcinoma of the pancreas were randomized to treatment with combined Streptozotocin and 5-fluorouracil or combined Streptozotocin and cyclophosphamide." | 5.04 | Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. ( Carbone, PP; Douglas, HO; Hanley, J; Moertel, CG, 1977) |
| "In a prospective, multi-centre, randomized study of 109 patients with metastatic gastro-intestinal adenocarcinomas the response rate, survival time and side-effects of two drug combinations, carmustin +5-fluorouracil and carmustin + ftorafur, were compared (same carmustin dosage in both groups)." | 5.04 | [A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)]. ( Arnold, H; Drings, P; Geldmacher, J; Hartwich, G; Kredel, L; Mayer, M; Neidhardt, B; Queisser, W; Rösch, W; Schaefer, J; von Oldershausen, HF; Wahrendorf, J, 1979) |
| "Nucleoside analogs such as gemcitabine and 5-fluorouracil are currently the cornerstone of chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC)." | 4.90 | Role of solute carrier transporters in pancreatic cancer: a review. ( Lemstrová, R; Melichar, B; Mohelnikova-Duchonova, B; Souček, P, 2014) |
| "Metastatic pancreatic ductal adenocarcinoma has a grim prognosis and gemcitabine has been the reference treatment for 15 years." | 4.87 | Metastatic pancreatic cancer: old drugs, new paradigms. ( Adenis, A; Conroy, T; Gavoille, C, 2011) |
| "A patient with resected adenocarcinoma of the pancreas was treated with adjuvant radio-chemo-immunotherapy using a combination of low-dose Cisplatin, 5-Fluorouracil and Interferon alpha together with external beam radiation." | 4.83 | Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon alpha: report on several cases and review of the literature [ISRCTN62866759]. ( Buchler, MW; Fritz, S; Hoffmann, K; Jager, D; Lindel, K; Marten, A; Schmidt, J, 2006) |
| "Gemcitabine administered as a weekly 1,000 mg/m2 30 minutes infusion is considered as the standard treatment of non resectable pancreatic adenocarcinoma." | 4.81 | [Gemcitabine-based combinations in inoperable pancreatic cancers]. ( André, T; Artru, P; Louvet, C, 2002) |
| "The current standard therapy for metastatic pancreatic adenocarcinoma is the single-agent gemcitabine, by the increasingly used fixed rate infusion of 10 mg/m2/min." | 4.81 | Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review. ( Bruckner, HW; Evans, A; Kozuch, P; Petryk, M, 2001) |
| " Until ongoing phase III trials confirm these benefits, the current standard treatment for metastatic pancreatic adenocarcinoma remains single agent gemcitabine." | 4.81 | A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma. ( Bruckner, HW; Kozuch, P; Petryk, M, 2002) |
| " Clinical benefit response (CBR), a new way to assess clinical efficacy based on marked, sustained improvement in pain intensity, analgesic consumption, and performance status, was used to evaluate a new chemotherapeutic agent, gemcitabine (2',2'-difluorodeoxycytidine [Gemzar])." | 4.79 | New developments in chemotherapy for patients with advanced pancreatic cancer. ( Rothenberg, ML, 1996) |
| "For patients with localized pancreatic adenocarcinoma, the combination of radiation therapy and 5-fluorouracil has been shown to enhance patient survival." | 4.78 | Current approaches to multimodality management of advanced pancreatic cancer. ( Douglass, HO, 1993) |
| " Studies show a definite therapeutic advantage for folinic acid/5-fluorouracil (5-FU) regimen compared with single agent 5-FU given intravenously in the management of advanced colorectal cancer." | 4.78 | Clinical trials with 5-fluorouracil, folinic acid and cisplatin in patients with gastrointestinal malignancies. ( Avvento, L; Madajewicz, S, 1990) |
| "Using WES after a doublet chemotherapy regimen comprising irinotecan and 5-fluorouracil (n = 15), seven single nucleotide polymorphisms (SNPs) were identified as candidate biomarkers for irinotecan-associated toxicity of neutropenia." | 4.31 | Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. ( Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S, 2023) |
| "Retrospective study included all resected patients with pancreatic adenocarcinoma who underwent neoadjuvant chemotherapy with FOLFIRINOX or gemcitabine/Abraxane." | 4.31 | Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer. ( Caron, M; Fitzgerald, TL; Nicolais, LM; Verdini, N, 2023) |
| "The NAPOLI-I trial showed better outcome of nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) compared to 5-FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) progressed to gemcitabine-based therapy." | 4.31 | The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. ( Antonuzzo, L; Barsotti, G; Bergamo, F; Casalino, S; De Toni, C; De Vita, F; Fasano, M; Giommoni, E; Giordano, G; Lonardi, S; Melisi, D; Merz, V; Milella, M; Noventa, S; Pinto, C; Pretta, A; Procaccio, L; Satolli, MA; Scartozzi, M; Spadi, R; Vaccaro, V; Zaniboni, A; Zecchetto, C; Zichi, C, 2023) |
| "Gemcitabine (Gem) alone or with Nab-paclitaxel (Gem-Nab) is used as second-line treatment for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX (FFX) failure; however, no comparative data exist." | 4.12 | Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. ( Artru, P; Auclin, E; Bechade, D; Ducoulombier, A; Edeline, J; Gilabert, M; Hautefeuille, V; Lièvre, A; Morin, C; Pernot, S; Sarabi, M; Taieb, J; Tougeron, D; Wasselin, J; Zaibet, S, 2022) |
| "Large pragmatic studies of patients who received 5-fluorouracil with leucovorin, irinotecan, and oxaliplatin ([m]FOLFIRINOX) as initial treatment for localized pancreatic ductal adenocarcinoma (PDAC) are lacking." | 4.12 | FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. ( Besselink, MG; Doppenberg, D; Groot Koerkamp, B; Janssen, QP; Jarnagin, WR; Katz, MHG; O' Reilly, EM; Paniccia, A; Prakash, LR; Tzeng, CD; van Dam, JL; van Eijck, CHJ; Wei, AC; Zureikat, AH, 2022) |
| "Recent studies have suggested the suboptimal efficacy of liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients previously treated with conventional irinotecan." | 4.12 | Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin. ( Bai, LY; Chan, DC; Chen, JS; Chen, LT; Chen, YY; Cheng, FM; Chiang, NJ; Chiu, SC; Chiu, TJ; Chou, WC; Chuang, SC; Hsueh, SW; Li, CP; Peng, CM; Shan, YS; Su, YY; Yang, SH; Yen, CJ, 2022) |
| " This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs." | 4.12 | Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022) |
| "FOLFIRINOX (leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin) and gemcitabine plus nab-paclitaxel are the 2 common first-line therapies for metastatic adenocarcinoma of the pancreas (mPC), but they have not been directly compared in a clinical trial, and comparative clinical data analyses on their effectiveness are limited." | 4.12 | Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. ( Amar-Farkash, S; Aran, D; Collisson, EA; Klein-Brill, A; Lawrence, G, 2022) |
| "Nab -paclitaxel and gemcitabine (GnP) or FOLFIRINOX (a combination of leucovorin, fluorouracil, irinotecan, and oxaliplatin [FFX]) is currently recognized as the standard first-line regimen for unresectable pancreatic ductal adenocarcinoma (PDAC)." | 4.12 | Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. ( Fujita, Y; Hayashi, K; Hirano, A; Hori, Y; Inoue, T; Kataoka, H; Kato, A; Kato, H; Miyabe, K; Naiki-Ito, A; Naitoh, I; Natsume, M; Nishi, Y; Okumura, F; Sano, H; Takada, H; Takahashi, S; Yoshida, M, 2022) |
| "To evaluate response rate, toxicity, and efficacy of the novel combination of nab-paclitaxel, oxaliplatin, 5-fluorouracil, and leucovorin [FOLFOX-A] in patients with advanced pancreatic ductal adenocarcinoma [PDAC]." | 4.12 | The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318. ( Almhanna, K; Beard, RE; Breakstone, R; Dionson, S; Dipetrillo, T; Kastura, M; Leonard, KL; Olszewski, A; Raufi, A; Renaud, J; Safran, H; Sturtevant, A; Wood, R, 2022) |
| "The value of neoadjuvant radiotherapy (RT) after 5-fluorouracil with leucovorin, oxaliplatin, and irinotecan, with or without dose modifications [(m)FOLFIRINOX], for patients with borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) is uncertain." | 4.12 | Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. ( Besselink, MG; Crane, CH; Doppenberg, D; Ellsworth, SG; Groot Koerkamp, B; Janssen, QP; Jarnagin, WR; Katz, MHG; O'Reilly, EM; Paniccia, A; Prakash, LR; Reyngold, M; Tzeng, CD; van Dam, JL; van Eijck, CHJ; Wei, AC; Zureikat, AH, 2022) |
| "There is increased use of neoadjuvant fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) in the management of localized pancreatic ductal adenocarcinoma (PDAC), yet there are few validated biomarkers of treatment response." | 4.12 | Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma. ( Court, CM; D'Angelica, MI; Drebin, JA; Ecker, BL; Gonen, M; Janssen, QP; Jarnagin, WR; O'Reilly, EM; Tao, AJ; Wei, AC, 2022) |
| "We evaluated outcomes of treatment with 5-fluorouracil (5-FU), doxorubicin, and streptozocin (FAS) in well-differentiated pancreatic neuroendocrine tumors (PanNETs) and its impact on subsequent therapy (everolimus or temozolomide)." | 4.12 | Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. ( Dagohoy, CG; Dasari, A; Halperin, DM; Lam, M; Rogers, JE; Yao, JC, 2022) |
| "5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) has activity in pancreatic neuroendocrine tumors (pNETs), but its use is limited, partly because of toxicities." | 4.02 | Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide. ( Al-Toubah, T; Morse, B; Pelle, E; Strosberg, J, 2021) |
| "FOLFOX (5-Fluorouracile and oxaliplatin) exhibits promising activity in advanced well-differentiated neuroendocrine tumors (NETs)." | 4.02 | Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors. ( Cavaglione, G; Charrier, N; Mineur, L; Niccoli, P; Oziel-Taieb, S; Piana, G; Poizat, F; Raoul, JL; Zemmour, C, 2021) |
| "The use of FOLFIRINOX (a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) is one of the therapeutic standards in pancreatic adenocarcinoma." | 4.02 | Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis. ( Ben Abdelghani, M; Caron, B; Duclos, B; Kurtz, JE; Nguimpi-Tambou, M; Noirclerc, M; Reimund, JM; Sondag, D, 2021) |
| "A combination of nab-paclitaxel plus gemcitabine (N+G) has recently become a standard first-line treatment in patients with metastatic pancreatic adenocarcinoma (MPA), but there are currently no published data concerning second-line treatment after N+G." | 3.96 | Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. ( Artru, P; Béchade, D; Desrame, J; Hautefeuille, V; Le Roy, B; Locher, C; Lourenco, N; Pernot, S; Pointet, AL; Pozet, A; Soularue, E; Taieb, J; Tougeron, D; Trouilloud, I; Williet, N, 2020) |
| "FOLFIRINOX [fluorouracil (5-FU), irinotecan, oxaliplatin] and gemcitabine plus nab-paclitaxel are standard treatments for patients with pancreatic ductal adenocarcinoma (PDAC)." | 3.96 | FOLFIRINOX ( Begg, SKS; Birnbaum, DJ; Castillo, CF; Clark, JW; Lillemoe, KD; Liss, AS; Mino-Kenudson, M; Schilling, O; Warshaw, AL; Wellner, UF, 2020) |
| "We aimed to evaluate the efficacy and safety of 5-fluorouracil-based neoadjuvant chemoradiotherapy (NACRT) in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC)." | 3.91 | Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study. ( Abe, Y; Aiura, K; Endo, Y; Fukada, J; Hori, S; Itano, O; Kitagawa, Y; Kitago, M; Masugi, Y; Nakano, Y; Oshima, G; Shinoda, M; Yagi, H, 2019) |
| " The aim of this study is to determine if SBRT with either chemotherapy (CMT) (Fluorouracil (5FU) or capecitabine) or Nelfinavir (NFV) to pancreatic adenocarcinoma induces lymphopenia to the same degree as CFRT with 5FU or capecitabine and how any associated difference affects patient survival outcomes." | 3.91 | Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer. ( Baine, MJ; Li, S; Li, X; Lin, C; Wu, G; Zhao, N, 2019) |
| "Eighty-three patients were treated with locally advanced or metastatic adenocarcinoma of the pancreas with either FOLFIRINOX or nab-Paclitxel and Gemcitabine (nabPGem) as first- or second line therapy." | 3.91 | Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter? ( Andalibi, H; Heinrich, B; Kafka, A; Klaus, A; Öhler, L; Schima, W; Vogl, UM; Vormittag, L; Winkler, T, 2019) |
| "nab-Paclitaxel plus gemcitabine (nab-P + G) and FOLFIRINOX (FFX) are among the most common first-line (1L) therapies for metastatic adenocarcinoma of the pancreas (MPAC), but real-world data on their comparative effectiveness are limited." | 3.88 | Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States. ( Kim, S; Marshall, JL; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Ung, B; Xiang, CQ; Yang, H, 2018) |
| "Improved outcomes with FOLFIRINOX or gemcitabine with nab-paclitaxel in the treatment of metastatic pancreatic adenocarcinoma (PDAC) have prompted incorporation of these regimens into neoadjuvant treatment of locally advanced unresectable PDAC." | 3.88 | Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. ( Allen, JN; Blaszkowsky, LS; Clark, JW; Fernandez-Del Castillo, C; Ferrone, CR; Hong, TS; Keane, FK; Kwak, EL; Lillemoe, KD; Ryan, DP; Wo, JY, 2018) |
| " All patients were offered 3 months of induction chemotherapy (FOLFIRINOX or gemcitabine depending on performance status), followed by exploratory laparotomy for resection or IRE in patients with Response Evaluation Criteria in Solid Tumors (RECIST) 1." | 3.85 | Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. ( Besselink, MG; Busch, OR; de Rooij, T; Dijkgraaf, MG; Martin, RC; Rombouts, SJ; Schoorlemmer, A; van Delden, OM; van Gulik, TM; van Hooft, JE; van Laarhoven, HW; van Lienden, KP; Vogel, JA; Wilmink, JW, 2017) |
| "5-Fluorouracil, doxorubicin, and streptozocin (FAS) leads to a 39 % response rate in advanced pancreatic neuroendocrine tumors (pNETs)." | 3.85 | Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. ( Aloia, T; Bhosale, P; Cloyd, J; Dasari, A; Fleming, JB; Halperin, D; Katz, MH; Kim, M; Lee, JE; Parker, N; Prakash, L; Vauthey, JN; Yao, J, 2017) |
| "To assess anatomic changes on computed tomography (CT) after neoadjuvant FOLFIRINOX (5-fluorouracil/leucovorin/irinotecan/oxaliplatin) chemotherapy for secondary resected borderline resectable (BR) and locally advanced (LA) pancreatic adenocarcinoma and their accuracy to predict resectability and pathological response." | 3.85 | CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. ( Antunes, C; Bachet, JB; Cassinotto, C; Lucidarme, O; Pietrasz, D; Sa Cunha, A; Wagner, M; Zappa, M, 2017) |
| "To evaluate the outcomes and toxicity of concurrent full-dose gemcitabine and intensity-modulated radiation therapy (IMRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma after induction chemotherapy." | 3.83 | Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. ( Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M, 2016) |
| "In our center, the combination of streptozocin (STZ) and 5-fluorouracil (5-FU) has been used as the first-line treatment in the majority of patients with pancreatic neuroendocrine tumors (pNETs) over the past few decades." | 3.83 | Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity. ( Clewemar Antonodimitrakis, P; Eriksson, B; Granberg, D; Skogseid, B; Sundin, A; Wassberg, C, 2016) |
| "A 17 year-old male with metastatic pancreatic adenocarcinoma, under chemotherapy containing 5-fluorouracil, presented severe left ventricular dysfunction requiring mechanical ventilation and inotropes administration." | 3.83 | Transient global ventricular dysfunction in an adolescent affected by pancreatic adenocarcinoma. ( Chinali, M; De Pasquale, MD; De Sio, L; Giordano, U; Grimaldi, C; Mastronuzzi, A; Serra, A, 2016) |
| "First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA) compared with gemcitabine." | 3.81 | FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. ( Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I, 2015) |
| "The use of PORT was associated with improved local control in the gemcitabine era for patients with resected, node-positive, pancreatic adenocarcinoma." | 3.81 | Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. ( Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE, 2015) |
| "The aim of this retrospective study was to investigate the relationship between UGT1A1 polymorphisms and toxicities in Chinese patients with pancreatic or biliary tract cancer receiving irinotecan-containing regimens as the second- or third-line chemotherapy." | 3.81 | Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. ( Jiang, JL; Liu, Y; Ma, T; Xi, WQ; Yang, C; Ye, ZB; Zhang, J; Zhou, CF; Zhu, ZG, 2015) |
| "The combination of 5-fluorouracil (5-FU), irinotecan and oxaliplatin (FOLFIRINOX) is considered the first-line chemotherapy for fit patients with advanced pancreatic ductal adenocarcinoma (PDAC) but carries an unfavourable adverse event (AE) profile." | 3.81 | Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience. ( Basu, B; Calder, J; Corrie, P; Ghorani, E; Hewitt, C; Wong, HH, 2015) |
| "Hand-foot syndrome (HFS) is the most frequently reported side effect of oral capecitabine therapy." | 3.80 | Topical henna ameliorated capecitabine-induced hand-foot syndrome. ( Ilyas, S; Saif, MW; Wasif, K, 2014) |
| " A 65-year-old man started chemotherapy for metastatic pancreatic adenocarcinoma with oxaliplatin-irinotecan-leucovorin-5-fluorouracil (FOLFIRINOX)." | 3.80 | A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria. ( Dasanu, CA; Joseph, R, 2014) |
| "Gemcitabine/capecitabine can be given at the standard dose in patients with severe hyperbilirubinemia, though the present data suggest that gemcitabine's activity may be limited due to poor intracellular activation." | 3.80 | Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. ( Beijnen, JH; Cerny, T; Gillessen, S; Hitz, F; Huitema, AD; Joerger, M; Koeberle, D; Rosing, H; Schellens, JH, 2014) |
| "A 71-year-old patient receiving combination chemotherapy (irinotecan, oxaliplatin and 5-fluorouracil (5-FU)) for metastatic pancreas cancer was admitted after her first cycle of chemotherapy with a severe and unexpectedly prolonged episode of neutropenic sepsis associated with pancytopenia and marked mucositis." | 3.80 | A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer. ( Gillmore, R; Suarez Martinez-Falero, B, 2014) |
| "From March 2009 through April 2012, 22 patients were treated with proton therapy and concomitant capecitabine (1000 mg PO twice daily) for resected (n = 5); marginally resectable (n = 5); and unresectable/inoperable (n = 12) biopsy-proven pancreatic and ampullary adenocarcinoma." | 3.79 | Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. ( Asbun, HJ; Awad, ZT; George, TJ; Ho, MW; Hoppe, BS; Huh, S; Mendenhall, NP; Morris, CG; Nichols, RC; Zaiden, RA, 2013) |
| "We describe a case of multifocal anaplastic pancreatic carcinoma treated with neoadjuvant FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil and leucovorin) and total pancreatectomy with subsequent patient disease-free survival currently at 12 months." | 3.79 | Multifocal anaplastic pancreatic carcinoma requiring neoadjuvant chemotherapy and total pancreatectomy: report of a case. ( Gajdos, C; Jones, EL; Jones, TS; McManus, M; Shah, R, 2013) |
| "To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 3.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
| "Pancreatic cancer is a major cause of death from cancer in both men and women in the USA and Europe." | 3.79 | Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team. ( Garcia, L; Goodwin, AL; Von Hoff, DD, 1998) |
| "Studies treating adenocarcinoma of the pancreas with gemcitabine alone or in combination with a doublet have demonstrated modest improvements in survival." | 3.78 | A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. ( Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L, 2012) |
| "To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts." | 3.78 | FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. ( Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P, 2012) |
| "To evaluate the efficacy and toxicity of irinotecan and oxaliplatin plus 5-fluorouracil (FU) and leucovorin (FOLFIRINOX) as second-line therapy in metastatic pancreatic adenocarcinoma (MPA)." | 3.77 | 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. ( Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M, 2011) |
| "Between January 2006 and November 2009, 17 patients (median age of 61 years) with advanced pancreatic adenocarcinoma, after receiving gemcitabine-containing chemotherapy as first-line median ECOG performance status 1 and with adequate organ function, were treated with either weekly docetaxel at 25 mg/m(2) or 3-weekly docetaxel regimen (docetaxel at 75 mg/m(2) or docetaxel-gemcitabine-capecitabine or docetaxel-gemcitabine) until progressive disease." | 3.76 | Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. ( Kaley, K; Penney, R; Saif, MW; Syrigos, K, 2010) |
| "The aim of this study was to retrospectively analyze the efficacy and safety of the combination of 5-fluorouracil (5-FU), dacarbazine, and epirubicin (FDE) in 39 patients with advanced, well-differentiated neuroendocrine tumors (NETs)." | 3.76 | Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors. ( Bruneton, D; Cassier, PA; Chayvialle, JA; Hervieu, V; Lombard-Bohas, C; Pilleul, F; Scoazec, JY; Walter, T, 2010) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 3.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "It is the aim of this study to assess the outcome of patients who received neoadjuvant 5-fluorouracil-cisplatin chemoradiation (CRT) for stage I/III pancreatic adenocarcinoma." | 3.75 | Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience. ( de Chaisemartin, C; Delpero, JR; Giovannini, M; Guiramand, J; Lelong, B; Moureau-Zabotto, L; Moutardier, V; Turrini, O; Viret, F, 2009) |
| "As surgery and chemotherapy may act as adjuvants providing antitumor immunity benefits, we ran phenotypical and functional immunomonitoring in patients with resectable pancreatic adenocarcinoma and advanced metastatic disease receiving combined treatment (cisplatin, gemcitabine, 5-FU)." | 3.75 | Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy. ( Addeo, A; Bellone, G; Brondino, G; Campra, D; Ciuffreda, L; Fronda, GR; Giacobino, A; Novarino, A; Prati, A; Vizio, B, 2009) |
| " The authors of this report reviewed their experience in a consecutive, unselected series of patients who received adjuvant 5-fluorouracil (5-FU) and radiation therapy (RT) for resected pancreatic adenocarcinoma." | 3.75 | Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. ( Hattangadi, JA; Hong, TS; Mamon, HJ; Yeap, BY, 2009) |
| "For patients with locally advanced gastric cancer, combined-modality therapy has resulted in long-term survival for approximately 15% of cases." | 3.75 | The role of chemotherapy in the management of gastric and pancreatic carcinomas. ( Schein, PS, 1985) |
| "A 60-year-old man with pancreatic cancer was admitted due to massive ascites in the course of gemcitabine treatment." | 3.74 | [An autopsy case of pancreatic cancer with poor performance status due to peritonitis carcinomatosa treated successfully with continuous infusion of low-dose 5-FU with octreotide]. ( Kayahara, M; Kitagawa, S; Minato, H; Mouri, H; Ohta, T; Ohtsubo, K; Tsuchiyama, T; Watanabe, H, 2008) |
| "To evaluate retrospectively the efficacy and chronic toxicities of concurrent radiotherapy and chronomodulated infusion 5-fluorouracil (5-FU) in patients with pancreatic adenocarcinoma." | 3.73 | Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma. ( Adams, R; Jones, RS; Keene, KS; Penberthy, DR; Rich, TA; Shepard, RC, 2005) |
| "To establish a 5-fluorouracil (5-FU)-resistant pancreatic adenocarcinoma (PAC) cell strain, and to investigate its biological characteristics." | 3.73 | [Establishment, characterization, and biological analysis of pancreatic adenocarcinoma cell strain SW1990/FU]. ( Chen, G; Guo, JC; Liao, Q; Zhang, LY; Zhao, YP, 2005) |
| "We believe this case to be the second case of radiation recall presenting as diffuse gastritis in a patient receiving capecitabine after previous treatment with XRT." | 3.73 | Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase. ( Black, G; Diasio, R; Johnson, M; Russo, S; Saif, MW, 2006) |
| "Four pancreatic adenocarcinoma cell lines were evaluated for their sensitivity to 5-fluorouracil (5-FU) and gemcitabine and two of these, Suit-2 and Panc-1, were chosen for combination experiments because they showed moderate and poor sensitivity, respectively, to 5-FU and gemcitabine." | 3.72 | 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. ( Costello, E; Ghaneh, P; Greenhalf, W; Halloran, CM; Neoptolemos, JP; Shore, S; Wilson, D; Zumstein, L, 2004) |
| "The most commonly used treatment in the palliative first-line therapy of metastatic pancreatic adenocarcinoma is the Gemcitabine (Gem) monotherapy, while several combination therapies are currently being tested in clinical trials." | 3.71 | [Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma]. ( Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A, 2002) |
| " Programs including streptozotocin and 5-fluorouracil or doxorubicin are generally regarded as first line treatment for pancreatic endocrine tumors with liver metastases, whereas midgut carcinoid tumors often are resistant to systemic chemotherapy." | 3.71 | Nonsurgical treatment of advanced malignant neuroendocrine pancreatic tumors and midgut carcinoids. ( Skogseid, B, 2001) |
| "Patients with radiographically resectable localized adenocarcinoma of the pancreatic head were entered onto a preoperative protocol that consisted of a 2-week course of fluorouracil (5-FU) 300 mg/m2 daily 5 days per week and concomitant rapid-fractionation radiation 30 Gy, 3 Gy daily 5 days per week." | 3.70 | Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. ( Abbruzzese, JL; Charnsangavej, C; Cleary, KR; Evans, DB; Goswitz, MS; Janjan, NA; Lee, JE; Lenzi, R; Pisters, PW; Raijman, I; Rich, TA; Wolff, RA, 1998) |
| " However, new chemotherapy, based on the synergistic antitumor activities of 5-fluorouracil (5-FU) and cisplatin (CDDP) producing biochemical modulation in solid cancers diagnosed as adenocarcinoma, has recently been reported to be effective." | 3.70 | Biochemical modulation therapy for pancreatic cancer. ( Denno, R; Hirata, K; Katsuramaki, T; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Takashima, T; Yamamitsu, S, 1998) |
| "(1) The clinical file of gemcitabine in locally advanced metastatic adenocarcinoma of the pancreas mainly comprises one comparative trial versus 5 fluorouracil that shows the superiority of gemcitabine on a mixed end point (pain, functional capacities, weight)." | 3.70 | Gemcitabine and cancer of the pancreas: new preparation. Helpful or not? ( , 1999) |
| "(1) To determine the toxicity of an intensified postoperative adjuvant regimen for periampullary adenocarcinoma (pancreatic and nonpancreatic) utilizing concurrent 5-fluorouracil (5-FU), leucovorin (LV), dipyridamole (DPM), and mitomycin-C (MMC) combined with split-course locoregional external beam radiotherapy (EBRT) to 50 Gy." | 3.70 | Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. ( Abrams, RA; Cameron, JL; Chakravarthy, A; Donehower, RC; Grochow, LB; Hruban, RH; Hurwitz, H; Jaffee, EM; Korman, LT; Lillemoe, KD; O'Reilly, S; Yeo, CJ; Zahurek, ML, 2000) |
| " In order to test a combination therapy of UCN-01 and 5-fluorouracil (5-FU), growth inhibition of CRL 1420 (MIA PaCa-2; undifferentiated pancreatic carcinoma) by four different treatments was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay." | 3.70 | UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA. ( Abe, S; Furukawa, T; Kitajima, M; Kubota, T; Kumai, K; Otani, Y; Watanabe, M, 2000) |
| "In advanced adenocarcinoma of the pancreas treatment with 5-fluorouracil (5-FU) or ifosfamide results in response rates of approximately 20%." | 3.69 | Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas. ( Bakker, PJ; Gouma, DJ; Huizing, MT; Poorter, RL; Rauws, EA; Rietbroek, RC; Taat, CW; Veenhof, CH, 1995) |
| "Between 1977 and 1994, 173 patients (60 men, 113 women, aged 43-77 years [mean, 59 years]) with unresectable adenocarcinoma of the exocrine pancreas were treated, 106 with neutron irradiation alone and 67 with concomitant chemotherapy (fluorouracil [5-FU])." | 3.69 | Pancreatic cancer: treatment with neutron irradiation alone and with chemotherapy. ( Bennett, BR; Cohen, L; Hatcher, MA; Hendrickson, FR; Kroc, TK; Lennox, AJ, 1996) |
| "To evaluate the effect of biochemical modulation by PALA and methotrexate on the therapeutic activity of 5-fluorouracil (5-FU) in patients with advanced pancreatic adenocarcinoma." | 3.69 | Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma. ( Berns, T; Harstrick, A; Hiddemann, W; Köhne, CH; Preusser, P; Schmoll, HJ; Seeber, S; Strumberg, D; Wilke, H, 1997) |
| "In order to determine whether preresectional chemoradiotherapy (CTRT) would influence resectability, local control, and survival of patients with localized pancreatic adenocarcinoma, a 5 1/2-year prospective study of 39 patients treated with preoperative radiation therapy, 5-Fluorouracil (5-FU), and Mitomycin C has been performed." | 3.68 | A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma. ( Agarwal, P; Eisenberg, BL; Engstrom, P; Hoffman, JP; Litwin, S; Paul, AR; Scher, R; Solin, LJ; Watts, P; Weese, JL, 1993) |
| " Thirteen patients with adenocarcinoma of the pancreas received weekly 5-fluorouracil by rapid intravenous infusion midway through a 2-h infusion of high dose leucovorin during external beam radiation therapy." | 3.68 | Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas. A phase I study. ( Dobelbower, RR; Howard, JM; Konski, AA; Merrick, HW; Schifeling, DJ; Skeel, RT, 1992) |
| " Twenty-eight patients with cytologic or histologic proof of localized adenocarcinoma of the pancreatic head received preoperative chemoradiation (fluorouracil, 300 mg/m2 per day, and 50." | 3.68 | Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. ( Ames, FC; Byrd, DR; Charnsangavej, C; Cleary, KR; Connelly, JH; Evans, DB; Fenoglio, CJ; Levin, B; Rich, TA, 1992) |
| "Fifty-six previously untreated patients with biopsy-proven, locally advanced or metastatic and measurable adenocarcinoma of the pancreas were treated with the combination of a protracted intravenous infusion of 5-fluorouracil (5-FU) and low dose weekly bolus cisplatin administered continuously for 10 weeks followed by a 2-week rest period." | 3.68 | Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study. ( Ahlgren, J; Cantrell, JE; Difino, S; Fryer, J; Harvey, J; Lokich, J; Rothman, H, 1991) |
| "Hexamethylmelamine, mitomycin C and 5-fluorouracil infusion (HexMF) achieved a median survival of 9 months for the 45 patients with either metastatic stage III or unresectable stage II carcinoma of the pancreas." | 3.67 | Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion. ( Bruckner, HW; Butwell, N; Gorbaty, MI; Kalman, J; McKenna, A; Spigelman, M; Storch, J, 1989) |
| "Fluorine-19 NMR spectrometry was used to monitor the metabolism of two antineoplastic fluoropyrimidines, 5-fluorouracil (5FU) and 5'-deoxy-5-fluorouridine (5'dFUrd), in cell cultures of human pancreatic (Capan-1) and colon (HT-29) adenocarcinoma." | 3.67 | Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. ( Faure, F; Hollande, E; Malet-Martino, MC; Martino, R; Palevody, C; Vialaneix, JP, 1986) |
| "A 55-year-old female, in which an unresectable Borrmann II-type gastric cancer (moderately differentiated adenocarcinoma) extending from vicinity of the cardia to the lower portion of the corpus, with direct invasion into the pancreas and extensive lymph node metastases, confirmed by laparotomy, was treated postoperatively by 3 courses of chemotherapy with cisplatinum in combination with mitomycin C and 5-fluorouracil." | 3.67 | Cure of advanced gastric cancer by combined chemotherapy with cisplatinum, mitomycin C, and 5-fluorouracil. ( Azuma, S; Furuta, T; Kawata, R; Ohashi, H; Saji, S; Sakata, K; Shimokawa, K; Suzuki, M; Tanemura, H, 1988) |
| "The EORTC Gastrointestinal Group has conducted a phase II trial in 47 patients with locally advanced or metastatic adenocarcinoma of the pancreas with epirubicin 90 mg/m2 intravenously on day 1 in combination with 5-fluorouracil 500 mg/m2 in a 2 hr infusion day 1-4, every 4 weeks." | 3.67 | An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas. ( Bleiberg, H; Blijham, G; Dalesio, O; Duez, N; Planting, A; Splinter, T; Weber, W; Wils, J, 1987) |
| "Twelve patients with adenocarcinoma of the pancreas and two patients with carcinoma of the extrahepatic biliary tree received combined therapy with 125I implant, precision high-dose (PHD) photon external beam therapy, and systemic 5-fluorouracil (5-FU)." | 3.67 | 125I interstitial implant, precision high-dose external beam therapy, and 5-FU for unresectable adenocarcinoma of pancreas and extrahepatic biliary tree. ( Ahuja, RK; Dobelbower, RR; Merrick, HW; Skeel, RT, 1986) |
| "Nineteen patients with unresectable and metastatic adenocarcinoma of the pancreas and ampulla of Vater were treated with intermittent regional infusion of the celiac axis (CAI) with the combination of 5-fluorouracil, adriamycin, mitomycin-C, and streptozotocin (FAM-S)." | 3.66 | Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study. ( Bukowski, RM; Hewlett, JS; Livingston, RB; Theodors, A; Weick, JK, 1982) |
| "Thirty-nine patients with advanced metastatic adenocarcinoma of the pancreas were treated with a combination of 5-fluorouracil, Adriamycin, and mitomycin-C (FAM)." | 3.66 | 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. ( Hoth, DF; Karlin, DA; Levin, B; MacDonald, JS; Schein, PS; Smith, FP; Woolley, PV, 1980) |
| "The results of combination chemotherapy with intermittent courses of 5-fluorouracil and streptozotocin in ten patients with metastatic carcinoid tumors and in eight patients with islet cell carcinoma are reported." | 3.66 | Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozotocin. ( Bukowski, RM; Chernicoff, D; Groppe, CW; Hewlett, JS, 1979) |
| "From May 1972 until May 1976, 105 patients were entered on Central Oncology Group protocol 7230 to compare the combination of streptozotocin, tubercidin, and 5-fluorouracil (5-FU) versus 5-FU alone in the treatment of adenocarcinoma and islet cell carcinoma of the pancreas." | 3.66 | 5-FU versus combination therapy with tubercidin, streptozotocin, and 5-FU in the treatment of pancreatic carcinomas: COG protocol 7230. ( Aust, JB; Awrich, A; Fletcher, WS; Grage, TB; Hill, GJ; Klotz, JH; Minton, JP; Multhauf, PM, 1979) |
| "We analyzed the incidence, time to first onset, and time to resolution for adverse events that require special attention and other selected toxicities in the nal-IRI combination group (n = 46)." | 3.30 | Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial. ( Furuse, J; Furuya, M; Ikeda, M; Ioka, T; Okusaka, T; Teng, Z; Ueno, M, 2023) |
| "Pancreatic cancer is the fourth leading cause of cancer-related death in the US with an increasing incidence in older adults (OA) over age 70." | 3.30 | The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defin ( Boutin, R; Catalano, P; Dotan, E; Ioffe, D; Lenchik, L; Li, D; Marques, HS; O'Dwyer, PJ; Simon, MA; Wagner, LI; Wong, TZ; Yao, X; Zhen, DB, 2023) |
| "Patients with borderline-resectable pancreatic cancer were enrolled and randomly assigned to receive neoadjuvant chemotherapy with either FOLFIRINOX or gemcitabine with nab-paclitaxel (GEM/nab-PTX)." | 3.11 | Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). ( Ebata, T; Fujii, T; Ishikawa, T; Kawashima, H; Kodera, Y; Maeda, O; Nagino, M; Ogawa, H; Ohno, E; Takami, H; Yamada, S; Yamaguchi, J; Yokoyama, Y, 2022) |
| "Patients with stage II or stage IIIC colon cancer with positive ctDNA results (tested as standard of care with commercial testing) will be eligible for enrollment in cohort B." | 3.11 | Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US. ( Dasari, A; Deming, D; George, TJ; Kopetz, S; Lieu, CH; Lin, Y; Lucas, PC; Sahin, IH; Yothers, G, 2022) |
| "The prognosis of patients with advanced pancreatic cancer is poor despite the recent introduction of immune checkpoint inhibitors." | 3.01 | Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy. ( Miyashita, M; Ogasawara, M; Ota, S; Yamagishi, Y, 2021) |
| "For patients with localized pancreatic cancer with minimal vascular involvement, optimal survivability requires a multidisciplinary approach of surgical resection and systemic chemotherapy." | 3.01 | A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. ( DeRemer, DL; Fabregas, JC; George, TJ; Hitchcock, K; Hughes, SJ; Kayaleh, O; Lee, JH; Nassour, I; Ramnaraign, B; Rogers, SC; Russell, K; Sahin, I; Singhal, R; Thomas, RM; Turk, A; Zlotecki, R, 2023) |
| "5, 5, or 10 μg/kg) + 5-flurouracil/leucovorin/oxaliplatin (FOLFOX), dosed per manufacturers prescribing information, until tumor progression." | 3.01 | Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). ( Aljumaily, R; Autio, KA; Bauer, TM; Bendell, J; Falchook, GS; Hecht, JR; Hung, A; Infante, JR; Javle, M; Leveque, J; Naing, A; Oft, M; Pant, S; Papadopoulos, KP; Patel, MR; Rao, S; Ratti, N; VanVlasselaer, P; Verma, R; Wainberg, ZA; Wong, DJ, 2021) |
| "Tumor resectability of pancreatic cancer staged as unresectable at primary diagnosis should be reassessed after neoadjuvant treatment." | 3.01 | R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial. ( Adler, W; Bechstein, WO; Boeck, S; Croner, RS; Fietkau, R; Ghadimi, M; Golcher, H; Grützmann, R; Hohenberger, WM; Imhoff, D; Jacobasch, L; Keilholz, L; Lubgan, D; Neumann, UP; Oettle, H; Pirkl, A; Reinacher-Schick, A; Rutzner, S; Semrau, S; Uhl, W; Wittel, UA, 2021) |
| " Dose reduction was defined as any decrease from initial dose; dose delay was any dosing delay >3 days from target date." | 3.01 | Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. ( Bekaii-Saab, T; Belanger, B; Blanc, JF; Chen, LT; de Jong, FA; Macarulla, T; Mirakhur, B; Siveke, JT, 2021) |
| "Resectable pancreatic cancer is defined as no arterial and ≤ 90 degrees venous involvement; borderline resectable pancreatic cancer is defined as ≤90 degrees arterial and ≤ 270 degrees venous involvement without occlusion." | 3.01 | Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled t ( Besselink, MG; Bonsing, BA; Bos, H; Bosscha, KP; Coene, PPLO; de Hingh, IHJT; de Vos-Geelen, J; Groot Koerkamp, B; Homs, MYV; Janssen, QP; Karsten, TM; Liem, MSL; Loosveld, OJL; Patijn, GA; van Dam, JL; van der Kolk, MB; van Eijck, CHJ; van Santvoort, HC; van Tienhoven, G; Wilmink, JW; Zonderhuis, BM, 2021) |
| "Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis." | 3.01 | Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. ( Aparicio, T; Bachet, JB; Bignon, AL; Bouché, O; Dahan, L; Desrame, J; François, E; Le Malicot, K; Lecaille, C; Lepage, C; Malka, D; Petorin, C; Phelip, JM; Rebischung, C; Rinaldi, Y; Seitz, JF; Turpin, A; Williet, N, 2021) |
| " We hypothesized that pelareorep in combination with pembrolizumab and chemotherapy in patients with PDAC would be safe and effective." | 2.94 | Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. ( Arora, SP; Cheetham, K; Coffey, M; Eng, KH; Fields, P; Fountzilas, C; Kalinski, P; Mahalingam, D; Moseley, JL; Nuovo, G; Raber, P; Wilkinson, GA; Zhang, B, 2020) |
| "This Phase IIb (NCT02195180) open-label study evaluated erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy in second-line advanced pancreatic adenocarcinoma." | 2.94 | Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. ( Andre, T; Bachet, JB; Bouche, O; Cros, J; De La Fouchardiere, C; El Hajbi, F; El Hariry, I; Fabienne, P; Faroux, R; Guimbaud, R; Gupta, A; Hamm, A; Hammel, P; Kay, R; Lecomte, T; Louvet, C; Metges, JP; Mineur, L; Rebischung, C; Tougeron, D; Tournigand, C, 2020) |
| " On the basis of preclinical data, sequential dosing was evaluated in cohort 4 (ipafricept day 1 followed nab-paclitaxel + gemcitabine day 3)." | 2.94 | Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. ( Astsaturov, I; Brachmann, RK; Cardin, DB; Cohen, SJ; Denlinger, CS; Dotan, E; Kapoun, AM; Lenz, HJ; Messersmith, W; O'Neil, B; Shahda, S; Stagg, RJ; Uttamsingh, S; Weekes, C, 2020) |
| "BACKGROUND Pancreatic cancer (PC) is a common digestive system tumor." | 2.94 | A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer. ( Cui, H; Dai, G; Deng, G; Guan, J; Lou, C; Yuan, J; Zhang, W; Zhang, Y; Zhou, A; Zhou, J, 2020) |
| "A combined pancreatic cancer multimodality approach using CIT and radiosensitized radiotherapy is feasible and safe; delivery of immunotherapy can lead to T-cell immunity." | 2.90 | Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. ( Are, C; Berim, LD; Grem, JL; Hollingsworth, MA; Lazenby, A; Lin, C; Ly, QP; Madiyalakan, M; Meza, JL; Nicodemus, CF; Padussis, J; Schwarz, JK; Verma, V, 2019) |
| "However, treatment for locally advanced pancreatic cancer is still controversial." | 2.90 | FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan. ( Fukutomi, A; Kamei, K; Kobayashi, M; Kobayashi, S; Matsumoto, I; Matsuoka, H; Mizuno, N; Omae, K; Ozaka, M; Suzuki, S; Todaka, A; Ueno, H; Uesugi, K, 2019) |
| "Pancreatic cancer is a highly lethal disease predominantly affecting older patients." | 2.90 | Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial. ( Blanc, JF; Chen, J; Chen, LT; de Jong, FA; Macarulla, T; Mirakhur, B; Siveke, JT; Wang-Gillam, A, 2019) |
| "Patients with locally advanced pancreatic cancer have historically poor outcomes." | 2.90 | Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. ( Allen, JN; Baglini, CV; Berger, DL; Blaszkowsky, LS; Boucher, Y; Clark, JW; Corcoran, RB; DeLaney, TF; Drapek, LC; Duda, DG; Faris, JE; Fernández-Del Castillo, C; Ferrone, CR; Goyal, L; Hong, TS; Jain, RK; Jiang, W; Kwak, EL; Lillemoe, KD; Ly, L; Murphy, JE; Nipp, RD; Parikh, AR; Qadan, M; Ryan, DP; Talele, N; Ting, DT; Weekes, CD; Wo, JY; Yeap, BY; Zhu, AX, 2019) |
| "The outlook for patients with advanced pancreatic cancer remains poor, despite significant advances in our understanding of pancreatic tumor biology." | 2.87 | HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. ( Corrie, PG; Doherty, GJ; Tempero, M, 2018) |
| "PRODIGE 41-BEVANEC is an academic randomized, phase II study designed to evaluate the efficacy of bevacizumab in combination with FOLFIRI after failure of CT1 in unknown primary NEC and GEP-NEC." | 2.87 | Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study. ( Assenat, E; Bouarioua, N; Cadiot, G; Coriat, R; Dahan, L; Dubreuil, O; Elhajbi, F; Ferru, A; Gangloff, A; Granger, V; Hautefeuille, V; Hentic, O; Kurtz, JE; Le Malicot, K; Lepage, C; Lepere, C; Lievre, A; Lombard-Bohas, C; Malka, D; Roquin, G; Scoazec, JY; Smith, D; Walter, T, 2018) |
| "Patients with pancreatic cancer commonly suffer from exocrine pancreatic insufficiency, and the ingestion of digestive enzyme supplements may improve absorption." | 2.87 | Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. ( Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K, 2018) |
| "Recent studies on metastatic pancreatic cancer have shown that combination chemotherapy with oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine plus nab-paclitaxel (GnP) prolonged the overall survival compared with gemcitabine alone." | 2.87 | Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407). ( Fukuda, H; Fukutomi, A; Furuse, J; Ikeda, M; Ioka, T; Ishii, H; Katayama, H; Mizuno, N; Mizusawa, J; Okusaka, T; Ozaka, M; Ueno, H; Ueno, M, 2018) |
| "Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy." | 2.87 | FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. ( Artru, P; Assenat, E; Bachet, JB; Ben Abdelghani, M; Biagi, JJ; Bouhier-Leporrier, K; Breysacher, G; Castan, F; Choné, L; Conroy, T; Cripps, C; Di Fiore, F; Faroux, R; Francois, E; Gourgou, S; Hammel, P; Hebbar, M; Jouffroy-Zeller, C; Juzyna, B; Kavan, P; Khemissa-Akouz, F; Lecomte, T; Legoux, JL; Malka, D; O'Callaghan, CJ; Raoul, JL; Rat, P; Sauvanet, A; Texereau, P; Volet, J; Wei, AC; Ychou, M, 2018) |
| "Even clearly resectable pancreatic cancer still has an unfavorable prognosis." | 2.87 | Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. ( Algül, H; Atzpodien, J; Berger, AW; Daum, S; Dickhut, A; Ettrich, TJ; Gallmeier, E; Geissler, M; König, A; Kornmann, M; Muche, R; Perkhofer, L; Prasnikar, N; Reinacher-Schick, A; Seufferlein, T; Tannapfel, A; Uhl, W; Wille, K; Wittel, U, 2018) |
| "KRAS mutations are common in pancreatic cancer, but directly targeting the KRAS protein has thus far been unsuccessful." | 2.84 | Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. ( Al Baghdadi, T; Blanke, CD; Cardin, D; Chung, V; Doyle, LA; Dy, IA; Guthrie, KA; Hendifar, AE; Hochster, HS; Hui, L; Lowy, AM; McDonough, S; Philip, PA; Seery, TE; Tejani, MA; Wang-Gillam, A, 2017) |
| " The most frequent grade 3/4 adverse events were nausea (18." | 2.84 | Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience. ( Bodoky, G; Harsanyi, L; Hegyi, P; Lakatos, G; Nehéz, L; Petranyi, A; Szűcs, A, 2017) |
| "In 2020, GLOBOCAN reported that pancreatic cancer accounts for 4." | 2.82 | Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment. ( Islam, MK; Lian, HK; Lim, JCW; Sagineedu, SR; Selvarajoo, N; Stanslas, J, 2022) |
| "Irinotecan is a topoisomerase inhibitor, widely used in treatment of malignancies including pancreatic ductal adenocarcinoma (PDAC) as part of the FOLFIRINOX regimen prescribed as a first-line treatment in several countries." | 2.82 | Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs. ( Innocenti, F; Milano, G; Minami, H, 2022) |
| " Pooled analyses for progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and grade 3/4 treatment-emergent adverse events (TRAEs) were undertaken." | 2.82 | Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis. ( Li, X; Lu, W; Tang, K; Wang, L, 2022) |
| "Pancreatic cancer is highly aggressive and lethal." | 2.82 | Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. ( Nishimoto, A, 2022) |
| "In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma." | 2.82 | A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016) |
| " We aimed to establish the safety, tolerability, and recommended phase 2 oral dose of the CCR2 inhibitor PF-04136309 in combination with FOLFIRINOX chemotherapy (oxaliplatin and irinotecan plus leucovorin and fluorouracil)." | 2.82 | Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. ( Belt, BA; Cusworth, BM; DeNardo, DG; Fields, RC; Fowler, KJ; Goedegebuure, SP; Hawkins, WG; Lim, KH; Linehan, DC; Lockhart, AC; Nieman, RK; Nywening, TM; Panni, RZ; Sanford, DE; Strasberg, SM; Suresh, R; Tan, BR; Toriola, AT; Wang-Gillam, A; Worley, LA; Yano, M, 2016) |
| "A challenge in borderline resectable pancreatic cancer (BRPC) management is the high rate of positive posterior margins (PM)." | 2.82 | A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). ( Brutcher, E; Cassidy, RJ; Chen, Z; El-Rayes, BF; Hawk, N; Kooby, D; Landry, J; Maithel, SK; Sarmiento, JM; Shaib, WL; Zhang, C, 2016) |
| "Gemcitabine was given on a weekly basis, following the siG12D-LODERTM insertion, until disease progression." | 2.80 | RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. ( Dancour, A; David, EB; Domb, A; Eliakim, R; Gabai, RM; Galun, E; Golan, T; Goldes, Y; Goldin, E; Harari, G; Hen, N; Hubert, A; Khvalevsky, EZ; Kopleman, Y; Lahav, M; Raskin, S; Segal, A; Shemi, A, 2015) |
| "Mucositis was the most common dose-limiting toxicity." | 2.80 | A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors. ( Evande, RE; Grem, JL; Kos, ME; Meza, JL; Schwarz, JK, 2015) |
| "Patients with pancreatic cancer and an Eastern Cooperative Oncology Group performance status of 0-2 received PHY906 and capecitabine." | 2.79 | First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. ( Bussom, S; Cheng, YC; Elligers, K; Jiang, Z; Kaley, K; Lamb, L; Li, J; Liu, SH; Saif, MW, 2014) |
| "Advanced pancreatic cancer (APC), beside its high mortality, causes the highest rates of venous thromboembolic events (VTE)." | 2.79 | Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. ( Bahra, M; Dörken, B; Gebauer, B; Hilbig, A; Pelzer, U; Riess, H; Sinn, M; Stieler, JM, 2014) |
| "Pancreatic cancer is one of the leading causes of cancer-related deaths worldwide." | 2.79 | Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. ( Belani, CP; Gusani, N; Jiang, Y; Kaifi, J; Kimchi, ET; Mackley, HB; Staveley-O'Carroll, KF; Zhu, J, 2014) |
| " Bevacizumab, an inhibitor of VEGF, was assessed in combination with chemotherapy in pancreatic neuroendocrine tumour (P-NET)." | 2.79 | Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial. ( Baudin, E; Bitoun, L; Dahan, L; Dromain, C; Ducreux, M; Koné, S; Lepère, C; Lombard-Bohas, C; Mitry, E; O'Toole, D; Scoazec, JY; Seitz, JF; Smith, D; Vilgrain, V, 2014) |
| "A total of 18 patients, 14 with colorectal cancer and 4 with pancreatic cancer, were included in this study." | 2.79 | Oxaliplatin and ototoxicity: is it really safe for hearing? ( Babacan, NA; Doğan, M; Kaçan, T; Kiliçkap, S; Koç, S; Seker, MM; Uysal, IO; Yüce, S, 2014) |
| "However, its role in pancreatic cancer (PC) has not yet been investigated." | 2.78 | Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. ( Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C, 2013) |
| "Thirty patients with advanced pancreatic cancer who were pretreated with gemcitabine received oxaliplatin (85 mg/m(2)) on days 1 and 15 followed by leucovorin (20 mg/m(2)) and 5-fluorouracil (500 mg/m(2)) on days 1, 8, and 15." | 2.78 | Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. ( El-Hadaad, HA; Wahba, HA, 2013) |
| " Here we report the first phase 2 study of erlotinib in combination with adjuvant chemoradiation and chemotherapy for resected PDAC." | 2.78 | Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. ( Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L, 2013) |
| "Capecitabine was administered orally twice a day at a dose of 1, 250 mg/m(2) for 14-day followed by 7-day rest and oral thalidomide 100 mg was given daily without interruption until disease progression or occurrence of unacceptable toxicity." | 2.78 | [Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer]. ( Li, CH; Ma, TH; Shi, SB; Tang, XY, 2013) |
| "The aims of this study were to establish the maximum tolerated dose (MTD) of oxaliplatin in combination with fixed doses of gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in solid tumors, including advanced pancreatic cancer, and to evaluate the toxicity of the regimen." | 2.78 | Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. ( Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ, 2013) |
| "All patients had pancreatic or biliary tract cancer." | 2.78 | A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. ( Deming, DA; Goggins, T; Groteluschen, D; Hernan, HR; Holen, KD; LoConte, NK; Lubner, SJ; Mulkerin, DL; Oettel, K; Robinson, E; Schelman, WR; Traynor, AM, 2013) |
| "Patients with untreated metastatic pancreatic cancer received oral capecitabine at 1,000 mg/m(2) twice daily on days 1-14, of a 21-day treatment cycle; and oral erlotinib at 150 mg daily." | 2.78 | Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study). ( Aldana, GQ; DE LA Cámara Gómez, J; Fernández, MJ; Fernández, MS; Folgar, SC; López, MR; López, R; Méndez, CM; Reinoso, CR; Vázquez, MR, 2013) |
| "To confirm the efficacy and toxicity of Erlotinib in combination with Gemcitabine and Capecitabine when used as a first-line therapy in metastatic/recurrent pancreatic cancer (PC)." | 2.77 | A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. ( Bang, YJ; Kang, HJ; Kim, BS; Kim, JS; Lee, KH; Lee, KW; Oh, DY; Park, YS; Ryoo, HM; Sohn, CH; Song, HS; Zang, DY, 2012) |
| " Gastrointestinal adverse events (nausea, vomiting and diarrhea) were commonly observed in both treatment groups." | 2.77 | A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. ( Bodoky, G; Ciuleanu, TE; La Stella, PJ; Pover, G; Spigel, DR; Tebbutt, NC; Timcheva, C, 2012) |
| "Capecitabine was administered at 850 mg/m(2) twice daily every day per week radiotherapy (45 Gy in 25 fractions) over the 5 weeks." | 2.77 | Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review. ( Choi, DW; Choi, SH; Heo, JS; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS, 2012) |
| "To evaluate the activity and tolerance of gemcitabine in combination with docetaxel and capecitabine in previously untreated patients with advanced pancreatic cancer." | 2.77 | Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study. ( Amarantidis, K; Chamalidou, E; Chelis, L; Chiotis, A; Courcoutsakis, N; Dimopoulos, P; Kakolyris, S; Prassopoulos, P; Tentes, A; Xenidis, N, 2012) |
| "Locally advanced inoperable pancreatic cancer (LAPC) has a poor prognosis." | 2.77 | The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. ( Ackland, SP; Borg, M; Brown, C; Bydder, S; Carroll, S; Cummins, MM; Gebski, VJ; Goldstein, D; Harvey, J; Horvath, L; Hruby, G; Porter, IW; Selva-Nayagam, S; Shapiro, J; Spry, N; Underhill, C; van Hazel, GA; Wratten, C, 2012) |
| "New therapeutic options for metastatic pancreatic cancer are urgently needed." | 2.77 | Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. ( Bitzer, M; Boeck, S; Buechler, P; Endlicher, E; Geissler, M; Harder, J; Heinemann, V; Hofheinz, R; Ihorst, G; Kloeppel, G; Moehler, M; Reinacher-Schick, A; Röcken, C; Schmoor, C, 2012) |
| "Fifty-three patients with unresectable pancreatic cancer, treated with gemcitabine and capecitabine (GC) or gemcitabine and erlotinib (GE) as first line between October 2006 and July 2010, were reviewed." | 2.77 | Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer. ( Hong, TH; Jeon, EK; Ko, YH; Lee, IS; Lee, MA; Won, HS; You, YK, 2012) |
| "Gemcitabine was given for 3 cycles after CRT." | 2.77 | Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. ( Bang, YJ; Chie, EK; Ha, SW; Hwang, JH; Im, SA; Kim, JH; Kim, JS; Kim, TY; Lim, JH; Yoon, YB, 2012) |
| "Gemcitabine was administered intravenously at 1,000 mg/m(2)/week (days 1, 8 and 15) and oral capecitabine from day 1 to day 21 at 1,660 mg/m(2)/day." | 2.77 | Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ( Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H, 2012) |
| "Eighty patients with stage IV pancreatic cancer were screened for the *2/*2 TYMS allele." | 2.76 | Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. ( Baker, SD; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, D; Messersmith, WA; Murphy, KM; Nallapareddy, S; Norris-Kirby, A; Rudek, MA; Weekes, CD, 2011) |
| "Capecitabine was given as 825 mg/m(2) b." | 2.76 | Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. ( Adams, J; Blaszkowsky, LS; DeLaney, TF; Fernandez-Del Castillo, C; Hong, TS; Kwak, EL; Mamon, HJ; Mino-Kenudson, M; Ryan, DP; Winrich, B; Yeap, B, 2011) |
| "Gemcitabine dose was fixed at 750 mg/m² over 75 min, capecitabine was given twice daily and escalated from 500 to 650 mg/m² at DL2 and docetaxel increased from 30 to 36 mg/m² at DL3." | 2.76 | A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. ( Bekaii-Saab, T; Bloomston, M; Campbell, A; Culler, K; Hejna, G; Hill, ME; Kim, S; Li, X; Zalupski, M, 2011) |
| "In gemcitabine-pretreated pancreatic cancer, salvage chemotherapy has not been established, and the prognostic factors are not completely known." | 2.76 | Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lee, KH; Lim, KH; Oh, DY, 2011) |
| "Neutropenia was the most common Grade 3-4 toxicity of both ICT and CCRT, with a frequency of 28% and 26." | 2.76 | Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study. ( Ch'ang, HJ; Chang, JY; Chang, MC; Chen, JS; Chen, LT; Cheng, AL; Chiu, YF; Hsieh, RK; Hsu, CH; Hwang, TL; Lin, PW; Lin, YL; Shan, YS; Tien, YW; Wang, HP; Whang-Peng, J, 2011) |
| "Patients with advanced pancreatic cancer who were refractory to prior gemcitabine- and 5-FU- based chemotherapy were enrolled in this study." | 2.75 | Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. ( Jeong, CY; Kang, JH; Kim, HG; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY, 2010) |
| "Capecitabine was administered at 850 mg/m twice daily every day with 5 days per week radiotherapy (1." | 2.75 | Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. ( Choi, DW; Choi, SH; Heo, JS; Jun, HJ; Kang, WK; Kim, HS; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS; Yi, SY, 2010) |
| "Capecitabine was increased until the appearance of dose limiting toxicities (DLTs)." | 2.75 | Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. ( Cheng, YC; Elligers, K; Grant, N; Jiang, ZL; Lamb, L; Lansigan, F; Liu, SH; Mezes, M; Ruta, S; Saif, MW, 2010) |
| "Gemcitabine was given intravenously at a dose of 1000 mg/m(2) over 30 min on days 1, 8 and 15, repeated every 4 weeks." | 2.75 | Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. ( Boku, N; Fukuda, H; Fukutomi, A; Furuse, J; Hamamoto, Y; Ikeda, M; Ishii, H; Nakamura, K; Ohkawa, S; Okusaka, T, 2010) |
| " Main adverse events grades 2/3/4 were (n): leukocytopenia 3/2/2, anemia 13/4/0, thrombocytopenia 3/1/0, nausea/vomiting 2/1/0, diarrhea 5/1/0, hand-foot-skin reaction 7/0/0." | 2.75 | Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010) |
| "Nineteen patients with advanced pancreatic cancer including primarily unresectable disease and recurrence after curative surgery were included in the study." | 2.75 | Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer. ( Choi, H; Choi, IB; Han, CW; Jang, JW; Ji, JS; Kang, YN; Kay, CS; Kim, BW; Kim, JY; Lee, BI, 2010) |
| "The European Study Group for Pancreatic Cancer (ESPAC)-3 trial, an open-label, phase 3, randomized controlled trial conducted in 159 pancreatic cancer centers in Europe, Australasia, Japan, and Canada." | 2.75 | Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. ( Bassi, C; Büchler, MW; Buckels, JA; Butturini, G; Cunningham, D; Dervenis, C; Doi, R; Friess, H; Gallinger, S; Ghaneh, P; Goldstein, D; Izbicki, JR; Lerch, MM; Lind, PA; Mariette, C; McKay, CJ; Moore, MJ; Neoptolemos, JP; Oláh, A; Padbury, R; Palmer, DH; Rawcliffe, CL; Smith, D; Stocken, DD; Thompson, J; Valle, JW; Wente, MN, 2010) |
| "5-Fluorouracil 1,000 mg/m(2) was infused (days 1, 2, and 3) and paclitaxel 175 mg/m(2) (day 1) was administered every 4 weeks." | 2.74 | Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. ( Bang, S; Chung, JB; Kim, YJ; Park, JY; Park, SW; Song, SY, 2009) |
| "Liver perfusion chemotherapy (LPC) for pancreatic cancer has been rarely undertaken in a postoperative adjuvant setting." | 2.74 | Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study. ( Aono, T; Hatakeyama, K; Kawachi, Y; Kurosaki, I; Nihei, K; Shimizu, T; Tsuchiya, Y; Yokoyama, N, 2009) |
| "Small retrospective studies in pancreatic cancer suggest that levels of hENT1 protein or messenger RNA may have prognostic value." | 2.74 | Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. ( Abrams, R; Ammar, A; Benson, AB; Cass, CE; Dicker, AP; Elsaleh, H; Farrell, JJ; Garcia, M; Lai, R; Macdonald, J; Mackey, JR; Regine, WF, 2009) |
| "The incidence of liver metastasis in group A was 34% which was lower than 50% in group B." | 2.74 | Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. ( Fu, DL; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yao, L; Yu, XJ, 2009) |
| "Capecitabine was administered at a dose of 1,000 mg/m(2) b." | 2.74 | Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009) |
| "The European Study Group for Pancreatic Cancer (ESPAC-1) study is the largest study of adjuvant treatment for pancreatic ductal adenocarcinoma to date and confirmed a survival advantage for adjuvant chemotherapy but not for chemoradiation." | 2.74 | Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data. ( Bassi, C; Bramhall, SR; Büchler, MW; Carter, R; Dervenis, C; Friess, H; Ghaneh, P; Kelemen, D; Neoptolemos, JP; Olah, A; Spry, N; Stocken, DD, 2009) |
| "A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg(-1), capecitabine 1300 mg m(-2) daily for 2 weeks and gemcitabine 1000 mg m(-2) weekly 2 times; cycles were repeated every 21 days." | 2.74 | Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. ( Garrett, C; Gibbs, J; Iyer, R; Javle, M; Kuvshinoff, B; Litwin, A; Pande, A; Phelan, J; Yu, J, 2009) |
| "Patients with locally advanced pancreatic cancer without duodenal invasion were treated with 50." | 2.74 | Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. ( Crane, CH; Curran, W; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, K; Wolff, RA, 2009) |
| "Pancreatic cancer is an extremely aggressive malignancy." | 2.74 | An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinica ( Büchler, MW; Decker-Baumann, C; Harig, S; Jäger, D; Karapanagiotou-Schenkel, I; Märten, A; Ose, J; Rötzer, I; Schmidt, J; Wente, MN, 2009) |
| "Patients with preoperative findings of pancreatic cancer invading the pancreatic capsule without involvement of the superior mesenteric or common hepatic arteries, or distant metastasis, were included in this randomized controlled trial, with their consent." | 2.73 | Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial. ( Aikou, T; Aiura, K; Aoki, T; Asano, T; Doi, R; Funakoshi, A; Hatori, T; Higashide, S; Hirata, K; Hishinuma, S; Hosotani, R; Ikeda, S; Imaizumi, T; Imamura, M; Kakita, A; Maetani, S; Maguchi, H; Matsusue, S; Noda, H; Ogata, Y; Ozaki, M; Sasaki, M; Sunamura, M; Takao, S; Takasaki, K; Tanaka, M; Wakasugi, H; Yamaguchi, K; Yoshida, S, 2008) |
| "Advanced pancreatic cancer, in addition to its high mortality, is characterized by one of the highest rates of venous thromboembolic events (VTE) as compared to other types of cancer." | 2.73 | Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). ( Bramlage, P; Dörken, B; Hilbig, A; Kauschat-Brüning, D; Oettle, H; Opitz, B; Pelzer, U; Riess, H; Scholten, T; Stieler, J, 2008) |
| "In patients with pancreatic cancer, CAI/RT had no significant effect on local recurrence (log-rank P = 0." | 2.73 | Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. ( Hermans, JJ; Hop, WC; Incrocci, L; Jeekel, J; Kazemier, G; Morak, MJ; van Dekken, H; van der Gaast, A; van Eijck, CH, 2008) |
| "Extrahepatic biliary tract and pancreatic cancer are relatively rare malignant tumors." | 2.73 | [Assessment of the value of PEF (cisplatin, epirubicin, 5 fluorouracil) in advanced extrahepatic biliary tract and pancreatic cancer]. ( Pawlega, J; Zygulska, AL, 2008) |
| "Thirty-three patients with metastatic pancreatic cancer (22 men and 11 women) were treated and 31 were evaluable." | 2.73 | Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. ( Dietrich, M; Goel, A; Grossbard, ML; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Rodriguez, T, 2007) |
| "Dipyridamole 75 mg was administered orally three times daily during the FU administration." | 2.73 | Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007) |
| " This approach to treatment of locally advanced pancreatic cancer is safe and promising, with good local control for a substantial proportion of patients, and merits testing in a randomised trial." | 2.73 | Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. ( Davies, T; Goldstein, D; Harvey, J; Kotasek, D; Michael, M; Reece, W; Shapiro, J; Spry, N; Underhill, C; Van Hazel, G; Walpole, E, 2007) |
| "The role of adjuvant chemoradiation in pancreatic cancer remains unclear." | 2.73 | Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. ( Debois, M; Erdmann, J; Hop, WC; Jeekel, J; Klinkenbijl, JH; Smeenk, HG; Tran, KC; van Cutsem, E; van Dekken, H; van Eijck, CH, 2007) |
| " Treatment of patients diagnosed with pancreatic cancer with radiotherapy and 5-fluorouracil was a safer approach than treatment with radiotherapy and gemcitabine, which induced more severe toxic adverse effects." | 2.73 | The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer. ( Brasiūniene, B; Juozaityte, E, 2007) |
| "Gemcitabine was given at 1,000 mg/m(2) weekly for 3 weeks followed by 1 week rest then 5-6 weeks of radiotherapy and concurrent CI 5FU (200 mg/m(2)/day)." | 2.73 | 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome. ( Borg, M; Carroll, S; Davies, T; Goldstein, D; Graham, P; Harvey, J; Iacopetta, B; Kneebone, A; Macleod, C; Millar, JL; Ngan, SY; Reece, WH; Spry, N; Zissiadis, Y, 2008) |
| "Data of 211 patients with advanced pancreatic cancer who underwent FLEC regimen were analyzed." | 2.73 | Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy. ( Ballardini, M; Bassi, C; Cantore, M; Fiorentini, G; Guadagni, S; Iacono, C; Mambrini, A; Orlandi, M; Pacetti, P; Torri, T, 2008) |
| "PEFG regimen in gemcitabine refractory pancreatic cancer had an acceptable toxicity profile and interesting activity, and may constitute a treatment option in this setting." | 2.73 | PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. ( Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Zerbi, A, 2008) |
| "Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in PC patients." | 2.73 | Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. ( Boeck, S; Bruns, CJ; Golf, A; Haas, M; Heinemann, V; Issels, RD; Laessig, D; Moosmann, N; Schulz, C; Wilkowski, R, 2007) |
| "The annual incidence of pancreatic cancer is nearly 50,000 patients." | 2.72 | Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King. ( Amini, A; Attiyeh, MA; Chung, V; Melstrom, LG, 2021) |
| "Treatment of localized pancreatic cancer has also evolved to prioritize preoperative (neoadjuvant) multimodality therapy over a surgery-first approach." | 2.72 | Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective. ( Evans, DB; Tsai, S; Ward, EP, 2021) |
| "For patients with localized pancreatic cancer, neoadjuvant therapy (NT) is increasingly delivered before surgery to maximize the receipt of multimodality therapy and the odds of a margin-negative resection." | 2.72 | Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma. ( Brown, ZJ; Cloyd, JM, 2021) |
| "The prognosis of pancreatic cancer (PC) is extremely poor, and most patients with metastatic PC still receive palliative care." | 2.72 | The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis. ( Chen, P; Hong, J; Jin, J; Ng, DM; Xu, Y; Yang, T; Zhang, B; Zhou, F; Zhou, X, 2021) |
| "Capecitabine and gefitinib were administered throughout the radiation course." | 2.72 | Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. ( Bendell, JC; Blobe, GC; Clary, BM; Czito, BG; Fernando, NH; Honeycutt, W; Hurwitz, HI; Ludwig, KA; Mantyh, CR; Morse, MA; Pappas, TN; Tyler, DS; Willett, CG; Yu, D, 2006) |
| "Eniluracil is an effective inactivator of dihydropyrimidine dehydrogenase (DPD)." | 2.72 | A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract. ( Cohen, DP; Czito, BG; Fernando, N; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Morse, MA; Pappas, TN; Petros, WP; Tyler, DS; Yu, D, 2006) |
| "Patients with invasive ductal pancreatic cancer who underwent radical surgery with clear histological margins at 11 Japanese institutions were enrolled and randomly assigned to one of two groups: surgery-alone group (no further treatment after surgery) and the surgery + chemotherapy group [two courses of postoperative adjuvant systemic chemotherapy with cisplatin (80 mg/m(2), Day 1) and 5-fluorouracil (500 mg/m(2)/day, Days 1-5)]." | 2.72 | A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. ( Kakizoe, T; Kiuchi, T; Kosuge, T; Mukai, K, 2006) |
| "Capecitabine was administered on days 14 through 52 (650 mg/m2 orally twice daily for the first six patients; 825 mg/m2 for the remaining patients)." | 2.72 | Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. ( Abbruzzese, JL; Amos, C; Charnsangavej, C; Crane, CH; Delclos, ME; Ellis, LM; Evans, DB; Ho, L; Lee, JE; Ng, C; O'Reilly, M; Pisters, PW; Tamm, EP; Wolff, RA; Xiong, HQ, 2006) |
| " The dose intensity of gemcitabine of the 35 patients with 5-FU dosage set at MTD was 593 mg/m2 per week." | 2.72 | Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. ( Chang, JY; Chao, Y; Chen, LT; Cheng, AL; Chuang, TR; Hsu, C; Hsu, CH; Jan, CM; Liu, TW; Shiah, HS; Whang-Peng, J; Yu, WL, 2006) |
| "Pancreatic cancer is chemo-radiosensitive." | 2.72 | Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. ( Bossard, N; Ducreux, M; Girard, N; Mornex, F; Partensky, C; Rouanet, P; Roy, P; Scoazec, JY; Seitz, JF; Smith, D; Valette, PJ; Ychou, M, 2006) |
| " We thus conducted a phase I/II study of gemcitabine and infusional 5-FU in Japanese patients to determine a recommended dosage for this combination and clarify efficacy and toxicity." | 2.72 | A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer. ( Funakoshi, A; Furuse, J; Ishii, H; Okusaka, T; Sumii, T; Ueno, H, 2006) |
| "In Lithuania, about 400 cases of pancreatic cancer are diagnosed each year, and more than 50% of patients are diagnosed with stage IV disease." | 2.72 | [Effect of combined treatment methods on quality of life in patients with pancreatic cancer]. ( Brasiūnas, V; Brasiūniene, B; Juozaityte, E, 2006) |
| "Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials." | 2.71 | Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003) |
| "Gemcitabine was given at a fixed dose of 1,000 mg/m(2) on days 1 and 8 of a 21-day cycle." | 2.71 | Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. ( Borner, M; Herrmann, R; Hess, V; Ludwig, C; Morant, R; Roth, AD; Salzberg, M, 2003) |
| "Metastatic or non-resectable (stage IV) pancreatic cancer has a rapidly fatal outcome (median survival: 3-6 months), thus making gene therapy a viable therapeutic option." | 2.71 | First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. ( Cornelio, GH; Gordon, EM; Hall, FL; Levy, JP; Liu, L; Lorenzo, CC; Reed, RA, 2004) |
| "In locally advanced pancreatic cancer, the utilization of chemotherapy and radiotherapy is increasing, although in view of the reported long-term results of several contemporary trials, further improvements are certainly needed." | 2.71 | Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study. ( Adsay, V; Al-Sukhun, S; Ben-Josef, E; Forman, JD; Heilbrun, LK; Levin, K; Philip, PA; Shields, AF; Soulen, R; Vaitkevicius, VK; Weaver, D; Zalupski, MM, 2003) |
| " The purpose of the current study was to determine whether dose intensification of parenteral hydroxyurea in combination with fluorouracil could enhance the response rates of the combination against refractory upper gastrointestinal malignancies." | 2.71 | Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. ( Haynes, H; Kaleya, R; Kaubisch, A; Rozenblit, A; Wadler, S, 2004) |
| "Weight gain was observed in 12 of 33 (36%) patients." | 2.71 | Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. ( Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N, 2004) |
| ") infusion] alone, OXA combined with 5-FU (1000 mg/m2/day, continuous i." | 2.71 | Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. ( Boige, V; Bouché, O; Breau, JL; Bugat, R; Cvitkovic, E; Ducreux, M; Etienne, PL; Mitry, E; Morvan, F; Ould-Kaci, M; Rougier, P; Seitz, JF; Tigaud, JM, 2004) |
| "The irinotecan starting dose was 80 mg/m and escalated by 20 mg/m in cohorts of three patients until the maximum tolerated dose (MTD) was defined." | 2.71 | Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors. ( Dietrich, M; Grossbard, ML; Kozuch, P; Malamud, S; Mathew, S; Rachamalla, R, 2004) |
| "Mitomycin C (MMC) in combination with infusional 5-fluorouracil (FU) plus folinic acid (FA) is an effective treatment for metastatic gastrointestinal cancer." | 2.71 | Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer. ( Gnad, U; Hartmann, JT; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Saussele, S; Weisser, A; Willer, A, 2004) |
| "The median time to disease progression was 8 weeks, and the median overall survival was 15 weeks." | 2.71 | Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. ( Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Gelibter, A; Malaguti, P; Milella, M; Pellicciotta, M; Ruggeri, EM; Terzoli, E, 2004) |
| "To evaluate the efficacy, toxicity and survival of intraoperative 125I brachytherapy combined with chemotherapy for advanced pancreatic cancer." | 2.71 | [Intraoperative 125I brachytherapy combined with chemotherapy for pancreatic cancer]. ( Duan, XN; Liu, YH; Shen, WJ; Wan, YL; Wang, DM; Yang, YM; Yu, SP; Zhou, G, 2004) |
| "Advanced pancreatic cancer has limited treatment options." | 2.71 | Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer. ( Baranda, J; Garcia, AA; Leichman, CG; Leichman, L; Lenz, HJ; Pandit, L, 2003) |
| "Gemcitabine was infused intravenously at a dose of 1000 mg once weekly for 3 consecutive weeks of every 4 weeks." | 2.71 | 5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer. ( Chikamoto, A; Hiraoka, T; Ikeda, O; Imuta, M; Kanemitsu, K; Kudo, K; Nakahara, O; Takamori, H; Tanaka, H; Tsuji, T; Yamashita, Y, 2005) |
| " Patients in study arm A will be treated as outpatients with 5-Fluorouracil; Cisplatin and 3 million units Interferon alpha-2b for 5 1/2 weeks combined with external beam radiation." | 2.71 | Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759]. ( Büchler, MW; Debus, J; Diehl, V; Fritz, S; Goldschmidt, H; Herrmann, T; Hoffmann, K; Knaebel, HP; Krempien, R; Lindel, K; Mansmann, U; Märten, A; Schmidt, J; Schmitz-Winnenthal, H; Seiler, C, 2005) |
| "Gemcitabine has been the standard regimen for advanced pancreatic cancer, but the effect on the response rate and survival is still disappointing, leading to many trials of combination chemotherapy." | 2.71 | [A phase II study of combination chemotherapy with gemcitabine, 5-fluorouracil, and cisplatin for advanced pancreatic cancer]. ( Choi, SB; Kim, SR; Lee, HY; Yuh, YJ, 2005) |
| "Fifteen patients with LA pancreatic cancer received three-dimensional conformal XRT to a dose of 50." | 2.71 | Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. ( Blanquicett, C; Carpenter, M; Diasio, RB; Eloubeidi, MA; Fiveash, J; Johnson, MR; Russo, S; Saif, MW; Steg, A; Thornton, J, 2005) |
| "Patients with pancreatic cancer often present initially in advanced disease with many compromising factors, and yet they may still be responsive to chemotherapy." | 2.70 | Palliative MEFLEP therapy in advanced pancreatic cancer: excellent response in a patient with Her-2/neu amplification. ( Chao, Y; Chen, LT; King, KL; Lan, C; Li, AF; Lin, WC; Liu, JM; Perng, CL; Tiu, CM; Whang-Peng, J, 2002) |
| "Eniluracil is a potent, irreversible inactivator of dihydropyrimidine dehydrogenase, the major catabolic enzyme for 5-fluorouracil (5-FU)." | 2.70 | Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. ( Abbruzzese, JL; Benedetti, JK; George, CS; Giguere, JK; Macdonald, JS; Neubauer, MA; Pruitt, BT; Rothenberg, ML; Seay, TE; Tanaka, MS, 2002) |
| " The current study was conducted to evaluate the efficacy and toxicity of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma." | 2.70 | Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma. ( Ishikawa, O; Matsuno, S; Okada, S; Okusaka, T; Saisho, H; Sato, K; Sato, T; Tokuuye, K; Wakasugi, H, 2001) |
| "The role of adjuvant treatment in pancreatic cancer remains uncertain." | 2.70 | Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. ( Almond, J; Bassi, C; Beger, H; Büchler, MW; Dervenis, C; Dunn, JA; Falconi, M; Fernandez-Cruz, L; Friess, H; Kerr, DJ; Lacaine, F; Link, K; Neoptolemos, JP; Pap, A; Pederzoli, P; Spooner, D; Stocken, DD, 2001) |
| "Treatment with capecitabine resulted in clinically significant beneficial effects on tumor-related symptoms and yielded objective response activity in patients with metastatic or locally advanced pancreatic cancer." | 2.70 | Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. ( Cartwright, TH; Chen, YM; Cohn, A; Cox, JV; Schulz, JJ; Szatrowski, TP; Varkey, JA, 2002) |
| "Gemcitabine was administered as a 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break." | 2.70 | Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. ( Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ, 2002) |
| "Diarrhea was experienced by six of 10 patients, and only three patients were able to receive six weekly chemotherapy treatments without dose reduction or delay." | 2.69 | Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. ( Blumenson, LE; Creaven, PJ; Meropol, NJ, 1998) |
| " Toxicity was significant, with more than 50% of patients requiring treatment breaks and dosage reductions." | 2.69 | Continuous venous infusion 5-fluorouracil and interferon-alpha in pancreatic carcinoma. ( Flett, MQ; John, WJ, 1998) |
| "Because of the poor response of pancreatic cancer to conventional therapy, the authors performed a phase II pilot study to evaluate whether beta-interferon and retinoids, added to active chemotherapeutic agents, could increase response rate and survival in a group of patients who had metastatic disease." | 2.69 | Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids. ( Casucci, D; Frati, L; Gulino, A; Rea, S; Recchia, F; Sica, G, 1998) |
| " 5-FU was given via protracted venous infusion (PVI) at a fixed dosage of 200 mg/m2/d, and gemcitabine was administered weekly for 3 consecutive weeks every 4 weeks." | 2.69 | Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. ( Alonso, S; Castellano, D; Cortes-Funes, H; Diaz-Puente, M; Gravalos, C; Hidalgo, M; Hitt, R; Paz-Ares, L, 1999) |
| "In patients with carcinoid tumor, a combination of cisplatin (150 mg) and doxorubicin (50 mg) was used." | 2.69 | Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. ( Ajani, JA; Carrasco, CH; Chuang, V; Dumas, P; Kim, YH; Lawrence, D; Richli, W; Wallace, S, 1999) |
| " Pharmacodynamic studies were performed to assess drug effects on levels of deoxyuridine triphosphate (dUTP) and thymidine triphosphate (TTP) pools in peripheral-blood mononuclear cells (PBMCs) before and 6 hours after treatment using a highly sensitive DNA polymerase assay." | 2.69 | Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract. ( Berkenblit, R; Damle, S; Haynes, H; Kaleya, R; Ladner, RD; Murgo, A; Schechner, R; Wadler, S, 1999) |
| "Gemcitabine (Gemzar) has a significant impact upon survival and quality of life for patients with pancreatic cancer, compared with 5-fluorouracil (5-FU)." | 2.69 | Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer. ( Arning, M; Diebold, T; Hochmuth, K; Huhn, D; Langrehr, J; Neuhaus, P; Oettle, H; Pelzer, U; Riess, H; Schmidt, CA; Vogl, TJ, 1999) |
| "One hundred fourteen patients (55%) had pancreatic cancer (54 in the observation group and 60 in the treatment group)." | 2.69 | Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. ( Arnaud, JP; Couvreur, ML; de Wit, LT; Gonzalez, DG; Hennipman, A; Jeekel, J; Klinkenbijl, JH; Sahmoud, T; van Pel, R; Veenhof, CH; Wils, J, 1999) |
| "Gemcitabine has recently been compared favorably to 5-fluorouracil (5-FU) as the standard chemotherapy for advanced pancreas cancer." | 2.69 | A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). ( Adak, S; Berlin, JD; Blaszkowsky, L; Flinker, D; Harris, JE; Vaughn, DJ, 2000) |
| "Gemcitabine was administered by intravenous (i." | 2.69 | Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. ( Bianco, AR; Damiano, V; De Lorenzo, S; Fabbrocini, A; Libroia, A; Matano, E; Tagliaferri, P, 2000) |
| "Of 28 enrolled patients with biliary tract cancer, complete responses were observed in 2 patients (7." | 2.69 | Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. ( Choi, CW; Choi, IK; Kim, BS; Kim, CD; Kim, JS; Kim, YH; Seo, JH; Um, SH, 2000) |
| " The present study was initiated to investigate the efficacy of gemcitabine in combination with 5-FU-FA." | 2.69 | A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. ( Arning, M; Arnold, D; Herrenberger, J; Huhn, D; Kindler, M; Korsten, EW; Langrehr, J; Musch, R; Oettle, H; Pelzer, U; Reitzig, P; Riess, H; Stroszczynski, C, 2000) |
| "Forty-seven patients with pancreatic cancer were treated with two different schedules of 5-fluorouracil (5FU) and leucovorin (LCV): standard and dose-intense schedules." | 2.69 | A comparison of two dose regimens in pancreatic cancer. ( Figer, A; Gal, R; Klein, B; Koren, R; Levin, I; Mishaeli, M; Sadikov, E, 2000) |
| "Mitomycin C was infused over 25 minutes followed by 5-FU over 10 minutes." | 2.68 | Regional chemotherapy for inoperable pancreatic carcinoma. ( George, WJ; Muchmore, JH; Preslan, JE, 1996) |
| "5-Fluorouracil was administered as continuous infusion in a dosis of 25 mg/kg/24 h the first and the third week concomitantly to radiotherapy." | 2.68 | Pilot study in locally advanced unresectable pancreas carcinoma using a combination of accelerated radiotherapy and continuous infusion of 5-fluorouracil. ( Bakker, P; González González, D; Luderhoff, EC, 1996) |
| " The maximum tolerated dose (MTD) was defined as the dosage of 5-FU that achieved 60% grade 3/4 toxicity." | 2.68 | A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. ( Chang, J; Cunningham, D; Gore, M; Hill, A; Hill, M; Moore, H; Nicolson, M; Norman, A; O'Brien, M; Oates, J; Rigg, A; Ross, P; Watson, M, 1997) |
| " However, the toxicities observed with this dosage schedule were considerable and further studies are needed to develop a less toxic regimen." | 2.68 | Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin. ( Buzaid, AC; Cohen, N; Greenberg, BR; Slater, D; Sporn, JR, 1997) |
| "5-fluorouracil was given at a dose of 1000 mg/m2 for 5 consecutive days and cisplatin was given on day 2 at a dose of 100 mg/m2." | 2.68 | The French experience with infusional 5-FU in gastric and pancreatic cancer. ( Ducreux, M; Rougier, P, 1996) |
| "Advanced pancreatic cancer is a rapidly fatal disease whose course has been little influenced by chemotherapy." | 2.68 | Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program Study. ( Ahlgren, JD; Auerbach, M; Fryer, D; Fryer, JG; Lokich, JJ; Wampler, GL, 1997) |
| "5-Fluorouracil was administered by intravenous bolus injection at an initial dose of 400 mg/m2/day for 5 consecutive days." | 2.67 | A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. ( Kelsen, D; Kemeny, N; Saltz, L; Schwartz, G, 1994) |
| "Chemoradiation for duodenal cancer has produced a complete pathologic response in all patients and survival has been excellent, suggesting efficacy of this regimen for duodenal cancer." | 2.67 | Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. ( Coia, L; Eisenberg, B; Hanks, G; Hoffman, J; Paul, A; Scher, R; Solin, L; Weese, J; Weiner, L, 1994) |
| "Hycanthone was administered 60 mg/m2 intravenously within 2 to 4 hr during each day of the 5-day course of infusions during the first and fifth weeks of radiation therapy." | 2.67 | Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. ( Earle, JD; Foley, JF; Krook, JE; Kvols, LK; McKenna, PJ; Schutt, AJ; Tschetter, LK; Twito, DI; Wieand, HS, 1994) |
| "Grade 3-4 toxicities included oral mucositis in 19 patients, granulocytopenia in 16, fatigue in 8, and diarrhea in 3." | 2.67 | Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. ( Abbruzzese, JL; Ajani, JJ; Belt, RJ; Dakhil, SR; Dubovsky, D; Graham, S; Levin, B; Pazdur, R; Pilat, S; Winn, R, 1992) |
| "One patient with metastatic colon cancer who received 5-FU at 540 mg/m2 achieved a partial response." | 2.67 | Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor. ( Moore, DF; Pazdur, R, 1992) |
| "Twenty-nine patients with advanced cancer (75% colon or pancreatic cancer) were treated." | 2.67 | A phase I trial of fluorouracil, leucovorin, and recombinant interferon alpha-2b in patients with advanced malignancy. ( Alberts, DS; Hersh, EM; Marcus, SG; Modiano, MR; Taylor, CW; Woodson, ME, 1992) |
| "A phase II trial of chemotherapy in carcinoid and islet cell pancreatic tumours has been conducted with the FAP protocol: 5-fluorouracil 400 mg/m2 per day (5-FU) for 3 days, 50 mg/m2 doxorubicin on day 2, and 90 mg/m2 cisplatin on day 2, repeated every 4 weeks." | 2.67 | Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin. ( Droz, JP; Ducreux, M; Kac, J; Oliveira, J; Rougier, P; Theodore, C, 1991) |
| " When combined with synchronous therapy, it results in prolonged survival and an ameliorated quality of life." | 2.67 | Surgical palliation combined with synchronous therapy in pancreatic carcinoma. ( Chaichik, S; Inbar, M; Kahn, PJ; Kaplan, O; Rozin, R; Skornick, Y, 1990) |
| "Most pancreatic cancers cannot be resected at the time of diagnosis." | 2.67 | [Chemotherapy of cancer of the exocrine pancreas]. ( Bonneterre, J, 1990) |
| "After resection for pancreatic cancer patients should receive intensive chemotherapy with mFOLFIRINOX, gemcitabine plus capecitabine or gemcitabine/5-fluorouracil (5-FU) monotherapy." | 2.66 | [Neoadjuvant and adjuvant treatment of pancreatic cancer]. ( Büchler, MW; Hackert, T; Jäger, D; Neoptolemos, JP; Springfeld, C, 2020) |
| "Pancreatic cancer is the fourth-leading cause of cancer-related death." | 2.66 | Second-line treatment for metastatic pancreatic cancer. ( Kasi, A; Paluri, RK; Posey, JA; Young, C, 2020) |
| "Pancreatic cancer has a poor prognosis and few choices of therapy." | 2.66 | Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with oth ( Bendell, J; Feeney, K; Gracián, AC; Hecht, JR; Hung, A; Lee, MA; Lin, Y; Lonardi, S; Muñoz, A; Ryoo, BY; Wainberg, ZA, 2020) |
| "Since pancreatic cancer is still increasing and has a poor prognosis, there is great interest in improving treatment results by combined modality approaches." | 2.65 | Combined modality treatment of pancreatic cancer: implications for the surgeon. ( Ghosh, BC; Kisner, DL; Metzger, UF, 1983) |
| "Forty-seven patients with unoperable pancreatic cancer were included in a controlled, prospective study of combination chemotherapy." | 2.65 | Treatment of unresectable pancreatic carcinoma with 5-fluorouracil, vincristine, and CCNU. ( Andrén-Sandberg, A; Holmberg, JT; Ihse, I, 1983) |
| " The optimal dosage was considered to be between 17 mg/kg and 24 mg/kg." | 2.65 | [Joint clinical Phase II study of SF-SP]. ( Hanatani, Y; Sato, H; Sato, T, 1984) |
| "Although chemotherapy of pancreatic cancer is a developing field, clinically meaningful responses correlated with improved patient survival can be obtained with existing regimens." | 2.65 | Chemotherapy of pancreatic carcinoma. ( Schein, PS; Smith, FP; Zimmerman, SE, 1981) |
| "In patients without metastases median survival was 48 weeks in the treated group and 12 weeks in controls." | 2.65 | Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. ( Cocking, JB; Cwynarski, MT; Diffey, BL; Fox, CA; Hanley, J; Jackson, GA; Mallinson, CN; Rake, MO; Wass, VJ, 1980) |
| "The survival rate for pancreatic cancer is sadly less than 8%." | 2.61 | Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer. ( Ahmad, S; Hasan, B; Hussain, I; Jain, AG; Jehanzeb, S; Khan, AK; Khetpal, N; Rahman, AU; Rashid, MU; Sarvepalli, D; Ullah, W, 2019) |
| "Locally advanced pancreatic cancer (LAPC) has several definitions, but it is essentially a non-metastatic tumor, in which the initial surgical resection is not considered beneficial due to the extensive vascular involvement and consequent high chance of a nonradical resection." | 2.61 | [New progress in the treatment of locally advance pancreatic cancer]. ( de Santibañes, E; de Santibañes, M; Mazza, O; Pekolj, J; Sanchez Clariá, R, 2019) |
| "Pancreatic cancer is the twelfth most common cancer in the United States, representing 3." | 2.61 | Updates in pancreatic cancer: Modest gains and hopeful targets. ( Draper, A, 2019) |
| "In borderline resectable pancreatic cancer (BRPC), neoadjuvant treatment regimens have been introduced with the rationale to downstage and downsize the tumor in order to enable resection and eliminate -microscopic distant metastases." | 2.61 | Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma. ( D'Haese, JG; Friess, H; Gloor, B; Hartmann, D; Kaufmann, B; Radenkovic, D; Stupakov, P, 2019) |
| "Pancreatic cancer is a lethal disease with a very poor prognosis." | 2.61 | Selecting chemotherapy for pancreatic cancer: Far away or so close? ( Shi, S; Yu, X, 2019) |
| "For unknown reasons, the incidence of pancreatic cancer is slowly rising and so too are mortality rates." | 2.61 | Systemic treatment of pancreatic cancer revisited. ( Boige, V; Conroy, T; Ducreux, M; Hollebecque, A; Laurent-Puig, P; Malka, D; Seufferlein, T; Smolenschi, C; Van Laethem, JL, 2019) |
| "Patients with pancreatic cancer encounter monthly medical costs 15 times higher than those without, with costs highest in the later stages of the disease." | 2.61 | Managing the economic impact of advanced pancreatic cancer. ( Soefje, SA, 2019) |
| "Pancreatic cancer is one of the most lethal of all malignancies." | 2.61 | Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. ( Furukawa, K; Kuboki, S; Ohtsuka, M; Takano, S; Takayashiki, T; Yoshitomi, H, 2019) |
| "Early detection of pancreatic cancer remains impossible and only 20% of patients are suitable for surgery once diagnosed." | 2.61 | Adjuvant treatment of pancreatic cancer. ( Conroy, T; Ducreux, M, 2019) |
| "Pancreatic cancer is one of the leading causes of cancer death worldwide." | 2.61 | Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges. ( Fu, DL; Jin, C; Warshaw, AL; Yang, F, 2019) |
| "Despite all efforts in pancreatic cancer treatment, the five-year survival rates at diagnosis over the past 20 years have only increased from 5% to 8%." | 2.58 | A look at the progress of treating pancreatic cancer over the past 20 years. ( Friess, H; Goess, R, 2018) |
| " Alternatively, the concept of prior dosing allows for the application of dialyzable chemotherapeutic drugs using a normal dose, with an HD followed shortly after to mimic normal renal function." | 2.58 | Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review . ( Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T, 2018) |
| "FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even though it induces significant adverse effects." | 2.58 | The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. ( Fan, Z; Liu, B; Lu, T; Tong, H, 2018) |
| "Locally advanced pancreatic cancer (LAPC) is an emerging entity lacking in level III evidence-based recommendations for its treatment." | 2.58 | Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment? ( de Liguori Carino, N; McNamara, MG; O'Reilly, DA; Pihlak, R; Radhakrishna, G; Siriwardena, AK; Valle, JW, 2018) |
| "The management of pancreatic cancer has grown rapidly in the last decade." | 2.55 | Randomized Clinical Trials in Pancreatic Cancer. ( Goel, N; Reddy, SS, 2017) |
| "Most patients with pancreatic cancer remain asymptomatic until the disease reaches an advanced stage." | 2.53 | Pancreatic cancer. ( Itoi, T; Kamisawa, T; Takaori, K; Wood, LD, 2016) |
| "35% of patients with pancreatic cancer have unresectable locally advanced disease at diagnosis." | 2.53 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. ( Allen, P; Beumer, BR; Chau, I; Conroy, T; El-Rayes, BF; Faris, JE; Hohla, F; Hong, TS; Hosein, PJ; Koerkamp, BG; Lacy, J; Marthey, L; Mellon, EA; Moorcraft, SY; Sadot, E; Shridhar, R; Suker, M; Taieb, J; van Eijck, CH; Wang-Gillam, A, 2016) |
| "Patients with advanced and metastatic pancreatic cancer refractory to gemcitabine based therapy have a dismal prognosis and limited therapeutic options." | 2.53 | The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. ( Grapsa, D; Passero, FC; Saif, MW; Syrigos, KN, 2016) |
| "Pancreatic cancer is an aggressive cancer that continues to have single-digit 5-year mortality rates despite advancements in the field." | 2.53 | Localized Pancreatic Cancer: Multidisciplinary Management. ( Chiorean, EG; Coveler, AL; Herman, JM; Simeone, DM, 2016) |
| "Pancreatic cancer is an extremely aggressive disease; although progress has been made in the last few years, the prognosis of these patients remains dismal." | 2.53 | FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. ( Caparello, C; Falcone, A; Funel, N; Garajova, I; Giovannetti, E; Kazemier, G; Le Large, TY; Meijer, LL; Peters, GJ; Vasile, E, 2016) |
| "Pancreatic cancer is one of the deadliest cancers, ranking fourth among cancer-related deaths." | 2.53 | Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. ( Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR, 2016) |
| "Although pancreatic cancer is but the eleventh most prevalent cancer in the US, it is predicted that of all the patients newly diagnosed with this disease in 2014, only 27% will still be alive at the end of the first year, which is reduced to 6% after 5 years." | 2.52 | Pancreatic cancer, treatment options, and GI-4000. ( Ampie, L; Bade, NA; Hartley, ML; Marshall, JL; Prins, PA, 2015) |
| "Treatment of locally advanced pancreatic cancer is palliative, based on chemotherapy and according to response, chemoradiotherapy can be applied." | 2.49 | Locally advanced pancreatic cancer. ( Huber, KE; Oikonomopoulos, GM; Saif, MW; Syrigos, KN, 2013) |
| "Metastatic pancreatic cancer is a rapidly fatal disease with few therapeutic options." | 2.49 | First-line treatment for advanced pancreatic cancer. ( Kim, R; Kothari, N; Saif, MW, 2013) |
| "In non-metastatic, non-resectable pancreatic cancer, treatment primarily aims to induce disease control, but may achieve conversion to surgical resectability in some patients." | 2.49 | Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. ( Boeck, S; Haas, M; Heinemann, V, 2013) |
| "Pancreatic cancer is usually detected at an advanced stage and responds poorly to treatment." | 2.47 | Pancreatic cancer in 2010: new insights for early intervention and detection. ( Costello, E; Neoptolemos, JP, 2011) |
| "Pancreatic cancer is the fourth leading cause of cancer death, and it is estimated that over 43,000 people would be diagnosed with and over 36,000 people would die of pancreatic cancer in the United States in 2010." | 2.47 | Treatment of early-stage pancreatic cancer. ( Berlin, JD; Cardin, DB; Castellanos, EH, 2011) |
| "Gemcitabine has been adopted as the standard first-line agent for advanced pancreatic cancer, but the progression free survival with gemcitabine is short." | 2.47 | [Second line chemotherapy for pancreatic cancer]. ( Park, JY, 2011) |
| "Nearly as many deaths occur from pancreatic cancer as are diagnosed each year reflecting the poor prognosis typically associated with this disease." | 2.46 | Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. ( Bayraktar, S; Bayraktar, UD; Rocha-Lima, CM, 2010) |
| "Advanced pancreatic cancer is usually treated with first-line gemcitabine (GEM) (alone or in combination)." | 2.46 | What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies. ( Barni, S; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F, 2010) |
| "Metastatic pancreatic cancer is often one of the most challenging malignancies a medical oncologist faces." | 2.46 | Palliative chemotherapy for pancreatic malignancies. ( Mehta, SP, 2010) |
| "Median survival for pancreatic cancer patients has reached a plateau due to inherent and acquired resistance to these agents." | 2.46 | Challenges of drug resistance in the management of pancreatic cancer. ( Clynes, M; McDermott, R; O'Connor, R; Sheikh, R; Walsh, N, 2010) |
| "Pancreatic cancer is the fourth most common cause of cancer death in higher-income countries, with 5-year survival only 10% even in people presenting with early-stage cancer." | 2.46 | Pancreatic cancer. ( Alrawashdeh, W; Kocher, HM, 2010) |
| "Small numbers of pancreatic cancer patients given gastrazole by continuous intravenous infusion showed prolonged survival compared with best supportive care or placebo, and equivalent survival to those given 5 fluouracil." | 2.45 | Reflections on some pilot trials of gastrin receptor blockade in pancreatic cancer. ( Black, JW, 2009) |
| "Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug." | 2.45 | The role of capecitabine in the management of tumors of the digestive system. ( Gennatas, C; Gennatas, S; Michalaki, V, 2009) |
| "Pancreatic cancer is the fourth leading cause of cancer death in the United States." | 2.45 | Medical management of pancreatic adenocarcinoma. ( Cunha, JE; Fernandes, Gdos S; Freitas, D; Hoff, PM, 2009) |
| " While clinical efficacy was limited with the viral mutants alone, outcomes were improved in combination with chemotherapeutics." | 2.45 | Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. ( Halldén, G, 2009) |
| "Pancreatic cancer has a poor prognosis." | 2.45 | WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. ( Goldstein, D; Karapetis, C; Steer, CB; Strickland, A; Yip, D, 2009) |
| "In advanced pancreatic cancer, level one evidence has established a significant survival advantage with chemotherapy, compared to best supportive care." | 2.44 | Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. ( Cunningham, D; Ghaneh, P; Neoptolemos, JP; Starling, N; Sultana, A; Tudur Smith, C, 2008) |
| "Pancreatic cancer is the fourth leading cause of cancer deaths in the United States." | 2.44 | Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. ( Boehm, KA; Cartwright, T; Richards, DA, 2008) |
| "Pancreatic cancer is a devastating disease with a poor prognosis for most patients." | 2.44 | The case for routine use of adjuvant therapy in pancreatic cancer. ( Kennedy, EP; Yeo, CJ, 2007) |
| "Pancreatic cancer is refractory to most chemotherapy." | 2.44 | Pancreatic cancer: an update. ( Kindler, HL, 2007) |
| "Treatment of locally advanced pancreatic cancer is challenging." | 2.44 | Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? ( Kim, R; Saif, MW, 2007) |
| "The early diagnosis of pancreatic cancer is difficult because of the lack of specific early symptoms,and surgery with curative intent can be performed in only 20% of patients." | 2.44 | [Treatments of pancreatic cancer from the standpoint of medical oncology]. ( Furuse, J; Ishii, H; Nakachi, K; Shimizu, S; Suzuki, E, 2007) |
| "A new era in the treatment of advanced pancreatic cancer commenced a decade ago with the advent of gemcitabine as a standard of care." | 2.44 | Cytotoxic therapy for advanced pancreatic adenocarcinoma. ( Abou-Alfa, GK; O'Reilly, EM, 2007) |
| "Gemcitabine is a well-tolerated anti-tumour drug with broad-spectrum activity." | 2.44 | [Gemcitabine and digestive carcinomas]. ( André, T; Blanchard, P; Huguet, F, 2007) |
| "Pancreatic cancer is one of the major causes of cancer death." | 2.44 | Neoadjuvant and adjuvant strategies for pancreatic cancer. ( Ghaneh, P; Neoptolemos, JP; Raraty, M; Smith, R; Tudor-Smith, C, 2008) |
| "Colorectal cancers have been the first cancers to benefit from an efficient anti-angiogenic treatment, represented by bevacizumab, which has been approved for first-line metastatic treatment in combination with reference chemotherapies and which is under study in the adjuvant setting." | 2.44 | [Angiogenesis targeting in gastro-intestinal cancers]. ( Meric, JB, 2007) |
| "However, the role of radiotherapy in pancreatic cancer is increasingly doubted, especially after the introduction of gemcitabine to both domains." | 2.44 | [Radiation therapy in pancreatic cancer]. ( Chie, EK, 2008) |
| "Gemcitabine is a key agent for the first-line therapy of advanced pancreatic cancer." | 2.44 | [Chemotherapy for pancreatic cancer]. ( Kim, YT, 2008) |
| "Gemcitabine has been a standard treatment for advanced pancreatic cancer since it was shown a decade ago to result in a superior clinical benefit response and survival compared with bolus 5-fluorouracil (5-FU)." | 2.44 | Pancreatic cancer--is the wall crumbling? ( Chua, YJ; Zalcberg, JR, 2008) |
| "Gemcitabine-based therapy is an acceptable standard for unresectable locally advanced/metastatic pancreatic cancer, but average median survival is only 6 months." | 2.44 | New directions in the management of advanced pancreatic cancer: a review. ( Rocha-Lima, CM, 2008) |
| "Combined chemoradiotherapy of pancreatic cancer is a safe treatment with an acceptable profile of side effects when applied with modern planning and radiation techniques as well as considering tissue tolerance." | 2.43 | Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose. ( Dühmke, E; Heinemann, V; Thoma, M; Weingandt, H; Wilkowski, R, 2005) |
| "The poor outcome of pancreatic cancer with conventional treatment options emphasizes the need for continued research." | 2.43 | Docetaxel in the management of advanced pancreatic cancer. ( Lopes, G; Rocha Lima, CM, 2005) |
| "Gemcitabine is an acceptable control arm for future trials investigating scheduling and combinations with novel agents." | 2.43 | Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. ( Goldstein, D; Karapetis, C; Steer, CB; Strickland, A; Yip, D, 2006) |
| "Capecitabine is an oral prodrug of 5-fluorouracil, which is converted to 5-fluorouracil by three sequential enzymatic reactions." | 2.43 | Capecitabine in carcinoma of the pancreas. ( Neoptolemos, JP; Smith, DB, 2006) |
| "In advanced pancreatic cancer, oxaliplatin has been found to be clinically effective in phase II trials in which it was combined with either 5-fluorouracil (5-FU) or gemcitabine, the current standard chemotherapy for this disease." | 2.42 | The role of oxaliplatin in the management of upper gastrointestinal tract malignancies. ( Scheithauer, W; Van Cutsem, E, 2003) |
| "Assessment of response to therapy of pancreatic cancer has been a difficult challenge." | 2.42 | Developments in the systemic therapy of pancreatic cancer. ( el-Rayes, BF; Philip, PA; Shields, AF; Vaitkevicius, V, 2003) |
| "Recent advances have been made in the treatment of pancreas cancer." | 2.42 | [Adjuvant and additive therapy for cancer of the pancreas]. ( Büchler, MW; Dunn, JA; Friess, H; Ghaneh, P; Hickey, H; Neoptolemos, JP; Raraty, MG; Stocken, DD, 2003) |
| "In patients with resectable pancreatic cancer, particularly in UICC-stage II neoadjuvant radiochemotherapy, this results in an improvement in survival: the median survival is between 15 and 30 months." | 2.42 | [Pancreatic cancer. The relative importance of neoadjuvant therapy]. ( Beger, HG; Gansauge, F; Poch, B; Schwarz, M, 2003) |
| "Advances in chemotherapy for pancreatic cancer have been limited." | 2.42 | Chemotherapeutic advances in pancreatic cancer. ( Berlin, JD; Rothenberg, ML, 2003) |
| "The prognosis of pancreatic cancer is poor at any stage." | 2.42 | [Adjuvant treatment of pancreatic cancer]. ( Oettle, H, 2003) |
| "Gemcitabine has thus become the de facto standard of care for advanced pancreatic cancer, and current efforts are directed toward finding strategies that can capitalize on and extend these clinical benefits." | 2.42 | Chemotherapy for advanced pancreatic cancer. ( Haller, DG, 2003) |
| "Capecitabine is an oral 5-fluorouracil (5-FU) prodrug that is more convenient than using infusional 5-FU, appears to have a similar therapeutic profile, and can be combined with daily irradiation." | 2.42 | COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas. ( Rich, TA; Shepard, R, 2003) |
| "Gemcitabine has replaced 5-fluorouracil-based chemotherapy as the standard of care." | 2.42 | New perspectives in the management of pancreas cancer. ( Haller, DG, 2003) |
| "Patients with pancreatic cancer are treated with combined treatment modalities." | 2.42 | [The update on pancreatic cancer chemotherapy]. ( Brasiūnas, V; Brasiūniene, B; Inciūra, A; Juozaityte, E, 2003) |
| "Yet, because early detection of pancreatic cancer is so difficult and diagnosis is delayed, pancreatic cancer in most patients is surgically unresectable." | 2.42 | Systemic chemotherapy for pancreatic cancer. ( Kosuge, T; Okusaka, T, 2004) |
| "Gemcitabine has recently emerged as the standard single agent in advanced stages of the disease and pharmacokinetic refinements such as the use of a fixed-dose infusion rate may further improve still rather modest result figures." | 2.42 | Emerging drugs in pancreatic cancer. ( Boige, V; Ducreux, M; Malka, D, 2004) |
| "Pancreatic cancer is the fifth leading cause of cancer-related mortality in Japan, with an estimated annual incidence rate of approximately 20,000 cases." | 2.42 | New approaches for pancreatic cancer in Japan. ( Aoki, K; Matsumura, Y; Okusaka, T, 2004) |
| "Pancreatic cancer is one of the most frequently reported gastrointestinal tumors and has been reported to have a 5-year survival rate of < 5%." | 2.41 | Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. ( Oettle, H; Riess, H, 2002) |
| "Metastatic pancreatic cancer is one of the leading causes of cancer-related deaths in North America and Europe." | 2.41 | Metastatic pancreatic cancer. ( Kulke, MH, 2002) |
| "The late diagnosis of pancreatic cancer, at a locally advanced and metastatic stage explains in part its poor prognosis." | 2.41 | [Gemcitabine and pancreatic cancer]. ( Azria, D; Prost, P; Ychou, M, 2002) |
| "Fewer than 20% of patients with pancreatic cancer present with disease macroscopically confined to the pancreas, and approximately 40% already have locally advanced disease." | 2.41 | Future directions in the treatment of pancreatic cancer. ( Haller, DG, 2002) |
| "Gemcitabine has modest activity in this disease." | 2.41 | Systemic therapy for advanced pancreatic cancer. ( El-Rayes, BF; Philip, PA, 2002) |
| "Gemcitabine is a new fluorine-substituted cytarabine compound." | 2.41 | Clinical update of gemcitabine in pancreas cancer. ( Au, E, 2000) |
| "Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease." | 2.41 | Gemcitabine: progress in the treatment of pancreatic cancer. ( Heinemann, V, 2001) |
| "The conclusions of this overview in pancreatic cancer are based on 10 randomised studies with, and 18 randomised studies without, an untreated control group." | 2.41 | A systematic overview of chemotherapy effects in pancreatic cancer. ( Glimelius, B; Hafström, L; Nygren, P; Permert, J, 2001) |
| "Capecitabine is a thymidine phosphorylase (TP)-activated oral fluoropyrimidine, rationally designed to generate 5-fluorouracil (5-FU) preferentially within tumors." | 2.41 | Vision of the future: capecitabine. ( Twelves, C, 2001) |
| "Because pancreatic cancer has a poor survival rate and only 20% of patients present with potentially resectable disease, a key goal of therapy is to provide palliation." | 2.41 | Pancreatic cancer: what the oncologist can offer for palliation. ( Moore, MJ, 2002) |
| "Pancreatic cancer is one of the deadliest malignancies and is fatal in more than 95% of affected individuals." | 2.41 | Management of locally advanced adenocarcinoma of the pancreas. ( Ryan, DP; Willett, CG, 2002) |
| "Gemcitabine has become a new standard for treatment of advanced pancreatic cancer." | 2.41 | Present and future treatment of pancreatic cancer. ( Heinemann, V, 2002) |
| "The status of chemotherapy for pancreatic cancer (PC) has been difficult to assess because of the problem of evaluating tumor response, which id dependent on the accurate measurement of tumor size using imaging modalities such as computed tomography." | 2.40 | [Evaluation of antitumor effect of chemotherapy for pancreatic cancer]. ( Okada, S, 1997) |
| "Eniluracil is a potent inactivator of dihydropyrimidine dehydrogenase (DPD), which is the first enzyme in the degradative pathway of systemically administered 5-fluorouracil (5-FU)." | 2.40 | Clinical development of eniluracil: current status. ( Hohneker, JA, 1998) |
| "Pancreatic cancer is widely regarded by medical personnel and the lay public as one of the most dreaded of all diagnoses." | 2.40 | Practical recommendations for the management of adenocarcinoma of the pancreas. ( Sporn, JR, 1999) |
| "5-Fluorouracil has long been the mainstay of the treatment of pancreatic cancer, although the response rate to this agent is < 10% and the influence on survival and quality of life is negligible." | 2.40 | Intravenous and intra-arterial chemotherapeutic possibilities in biliopancreatic cancer. ( van Groeningen, CJ, 1999) |
| "Pancreatic cancer is a major cause of cancer death; and despite advances in the standards of surgery and supportive care, the median and long-term survival rates have not shown similar dramatic improvements." | 2.40 | Adjuvant therapy for pancreatic cancer. ( Ghaneh, P; Howes, N; Jones, L; Kawesha, A; Neoptolemos, JP, 1999) |
| "Both gastric and pancreatic cancer remain leading causes of cancer death in the United States and worldwide." | 2.40 | Adjuvant/neoadjuvant chemoradiation for gastric and pancreatic cancer. ( Leach, SD; Lowy, AM, 1999) |
| "For Dukes' C colon cancer, postoperative adjuvant chemotherapy with a combination of fluorouracil and levamisole is now recommended as standard therapy." | 2.39 | Adjuvant postoperative therapy of gastrointestinal malignancies. ( Ilson, DH; Kelsen, DP, 1994) |
| "In general, patients with pancreatic cancer who are irradiated appear to do better than those who are not." | 2.39 | Radiotherapy for carcinoma of the pancreas. ( Thomas, PR, 1996) |
| "Pancreatic cancer is an aggressive disease and its patients typically have a short survival, usually marked by pain and rapid debilitation." | 2.39 | Chemotherapy for pancreatic carcinoma. ( Ahlgren, JD, 1996) |
| " Thus, we should perform effective adjuvant therapies in combination with surgery, in order to completely prevent these two types of cancer relapse." | 2.39 | [Adjuvant therapies in combination with pancreatectomy for carcinoma of the pancreas]. ( Furukawa, H; Imaoka, S; Ishikawa, O; Iwanaga, T; Kabuto, T; Matayoshi, Y; Nakaizumi, A; Ohigashi, H; Sasaki, Y; Uehara, H, 1996) |
| "Recently, the goal of chemotherapy for pancreatic cancer is thought to be quality of life." | 2.39 | [Chemotherapy for pancreatic cancer]. ( Sakata, Y; Suzuki, H; Takemori, H, 1996) |
| "In advanced pancreatic cancer, chemotherapy has no curative potential, and the goal is to palliate symptoms or delay their onset so as to improve the quality of life of patients." | 2.38 | [Chemotherapy for advanced pancreatic carcinoma]. ( Shimada, Y; Yokoyama, T, 1992) |
| "Work has been done in gastric cancer, pancreatic cancer, and colon and rectal cancer, all of which demonstrate an advantage in certain clinical situations for combined-modality therapy." | 2.38 | Combined radiotherapy and chemotherapy in the treatment of gastrointestinal malignancies. ( Tepper, JE, 1992) |
| "However, in gastric cancer, 5-FU/FA and 5-FU/IFN seem to induce higher complete and overall remission rates in advanced gastric cancer compared with 5-FU alone." | 2.38 | Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer. ( Achterrath, W; Fink, U; Harstrick, A; Knipp, H; Köhne-Wömpner, CH; Meyer, HJ; Preusser, P; Schmoll, HJ; Stahl, M; Wilke, H, 1992) |
| "Several advances in the radiotherapy of pancreatic cancer have been made for the patient with resectable disease." | 2.38 | Radiotherapy in the treatment of pancreatic cancer. ( Bronn, DG; Dobelbower, RR, 1990) |
| "Fluorouracil has been used for a long time, remission rates reported range from 0% to 80%." | 2.36 | [Chemotherapy of gastrointestinal tumors (review of the literature)]. ( Mayr, AC, 1978) |
| "Locally advanced (unresectable) pancreatic cancer (LAPC) is surgically unresectable and often treated with chemotherapy." | 1.91 | Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. ( Chie, EK; Jang, JY; Kang, JS; Kim, H; Kim, YT; Kwon, W; Lee, M; Lee, SH; Oh, DY; Ryu, JK, 2023) |
| "Treatments for patients suffering from pancreatic cancer with oligo-hepatic metastasis have always been a cause of certain controversy." | 1.91 | Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions. ( Lou, J; Lu, W; Tang, K; Wang, L, 2023) |
| "Original FOLFIRINOX (oFFX) is more toxic than other regimens for patients with metastatic pancreatic cancer (mPC); therefore, a modified FFX (mFFX) regimen with a reduced dosage has been used in Japanese clinical practice." | 1.91 | Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study. ( Arima, S; Fukahori, M; Honda, T; Ide, Y; Ido, A; Kawahira, M; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Tsuruta, N; Ueda, Y; Ureshino, N, 2023) |
| "Of patients with colon cancer treated with an initial lower 5-FU dose, 18% had a therapeutic 5-FU blood level." | 1.91 | Initiating Treatment with Low Fluorouracil Dose and Titrating According to Blood Levels in Patients Treated with a 46-Hour Continuous Infusion. ( Baranseh, J; Khatib, AW; Selub, SM; Shai, A; Uryvaey, A, 2023) |
| "Individuals diagnosed with advanced pancreatic cancer between April 2015 and December 2019 were identified through the provincial cancer registry and followed until March 2021." | 1.91 | Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data. ( Arora, P; Boyne, DJ; Brenner, DR; Cheung, WY; Gupta, A; Hernán, MA; Mackay, E; Wasiak, R, 2023) |
| "Pancreatic cancer is projected to be the second leading cause of cancer-related death by 2030 in the US." | 1.91 | Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer. ( Agyare, E; Bulusu, R; Ebesoh, D; Frimpong, EK; Han, B; Inkoom, A; Ndemazie, NB; Okoro, J; Rogers, S; Zhu, XY, 2023) |
| "Patients with advanced pancreatic cancer treated with FOLFIRINOX chemotherapy alone or with FOLFIRINOX chemotherapy followed by stereotactic body radiotherapy between 2015 and 2021 in 2 tertiary referral centers were included." | 1.91 | Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival: A Retrospective, Multicenter, Cohort Study. ( Aziz, MH; Bonsing, BA; Groot Koerkamp, B; Homs, MYV; Luelmo, SAC; Michiels, N; Mieog, JSD; Papageorgiou, G; van 't Land, FR; van Eijck, CHJ, 2023) |
| "5-Fluorouracil (5-FU) dosage was adjusted throughout neoadjuvant treatment according to pharmacokinetic parameters and Irinotecan (CPT-11) pharmacokinetic variables were retrospectively estimated." | 1.91 | Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma. ( Aldaz, A; Arbea, L; Chopitea, A; Martí-Cruchaga, P; Pardo, F; Ponz-Sarvise, M; Rodríguez-Rodríguez, J; Rotellar, F; Sala-Elarre, P; Subtil, JC; Urrizola, A; Vilalta-Lacarra, A; Zozaya, G, 2023) |
| "The expression status of IGHG1 in pancreatic cancer was analyzed through bioinformatics tools." | 1.91 | Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy. ( Fu, L; Han, W; Lv, K; Tian, Y; Zhou, X, 2023) |
| "Participants had a confirmed pancreatic cancer diagnosis and received at least one systemic chemotherapy, including FOLFIRINOX, gemcitabine plus nab-paclitaxel, gemcitabine, and S-1." | 1.91 | Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study. ( Akazawa, M; Asami, H; Shibahara, R; Takumoto, Y, 2023) |
| "Patients with metastatic pancreatic cancer refractory to first-line chemotherapy (CTx) have few treatment options." | 1.91 | Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study. ( Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Okabe, Y; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N, 2023) |
| "The treatment of pancreatic cancer has evolved; however, real-world data on treatment trends remain scarce." | 1.91 | Trends in treatment patterns and survival outcomes in pancreatic cancer: A nationwide population-based study in Korea. ( Choi, JK; Han, JH; Lee, KJ; Park, BK; Seo, JH; Son, KJ, 2023) |
| "A total of 554 patients with pancreatic cancer of all stages were screened, and 73 patients treated with Gem-Nab and 48 patients treated with Gem-Ox in the palliative first-line setting were identified and included in this analysis." | 1.91 | Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis. ( Gantschnigg, A; Greil, R; Huemer, F; Schlick, K; Seymer, A; Weiss, L, 2023) |
| " Using cell models of colorectal and pancreatic cancers, we show that cotreatment with Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone, AcB), a natural flavone from Achyrocline bogotensis, allows for four-fold reduction in 5-Fu dosage without loss of efficacy." | 1.91 | Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone) synergizes with 5-fluorouracil allowing for dose reduction and reduced off-target toxicity in the treatment of colonic and pancreatic cancers. ( Cartwright, BM; Corso, JN; Krishnan, K; Lightner, J; Palau, VE; Torrenegra, RD; Whitted, C, 2023) |
| "Patients diagnosed with advanced pancreatic cancer in 7 tertiary hospitals in Turkey were included." | 1.91 | Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data. ( Çubukçu, E; Dede, DŞ; Deligönül, A; Dizdar, Ö; Doğan, A; Emre Yildirim, M; Eraslan, E; Erol, C; Esen, SA; Günel, N; Odabaş, H; Öksüzoğlu, ÖB; Özdemir, N; Özet, A; Şahin, AB; Şahin, TK; Sütcüoğlu, O; Turan, N; Uçar, G; Üner, A; Yazici, O; Yilmaz, F, 2023) |
| "Novel chemotherapeutics in pancreatic cancer have shown limited success, illustrating the urgent need for new treatments." | 1.91 | Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer. ( Abbas, AE; Azzoli, CG; Cruz, A; El-Deiry, WS; George, A; Huntington, KE; Liguori, NR; Sevilla Uruchurtu, AS; Tummala, T; Zhang, L; Zhou, L, 2023) |
| "A total of 83 patients with pancreatic cancer, including locally advanced and advanced pancreatic cancer, who had lost the opportunity for radical surgery and were admitted to Zhejiang Provincial People's Hospital between January 2015 and July 2021 were collected." | 1.72 | Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer? ( Chen, Z; Wang, M; Yang, L; Zhu, P, 2022) |
| "Herein, we report a case of pancreatic cancer who benefited from a combination of anti-PD-1 immunotherapy and chemotherapy." | 1.72 | Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review. ( Chen, YW; Chen, ZL; Deng, YY; Pan, SY; Wang, MX; Yang, L; Zhu, PF, 2022) |
| "While irresectable pancreatic cancer has still a dismal overall prognosis, evidence about the optimal chemotherapy sequence is scarce." | 1.72 | Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study. ( Elango, S; Finkelmeier, F; Koch, C; Pession, U; Queck, A; Schmidt, J; Trebicka, J; Trojan, J; Waidmann, O; Walter, D, 2022) |
| "Although second-line treatment for pancreatic cancer has been proven to have survival benefit, it is not clear which is the most preferred regimen." | 1.72 | Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis. ( Asama, H; Fukushima, T; Kawano, K; Kobayashi, S; Konno, N; Maeda, S; Morimoto, M; Nagashima, S; Oishi, R; Sano, Y; Tanaka, S; Tezuka, S; Ueno, M, 2022) |
| "Advanced pancreatic cancer (APC) disproportionately impacts older adults." | 1.72 | Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy. ( Dawe, DE; Kim, CA; Lambert, P; McAndrew, EN; Rittberg, R; Zhang, H, 2022) |
| "Pancreatic neuroendocrine tumors (pNETs) are rare entities representing 1% to 3% of all malignant pancreatic neoplasms." | 1.72 | Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series. ( Keitel, V; Klose, S; Krause, A; Kreissl, MC; Müller, C; Venerito, M, 2022) |
| "PANC-1 human pancreatic cancer cells were treated with 5-fluorouracil (5-FU) at 0." | 1.72 | 5-fluorouracil suppresses stem cell-like properties by inhibiting p38 in pancreatic cancer cell line PANC-1. ( Cao, C; Dong, C; Liu, R; Shi, X; Su, L; Zhao, J, 2022) |
| "The prognosis of initially unresectable pancreatic cancer (UR-PC) has improved since the introduction of FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GNP) treatment." | 1.72 | Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. ( Inoue, Y; Ito, H; Mie, T; Oba, A; Ono, Y; Ozaka, M; Saiura, A; Sasahira, N; Sasaki, T; Sato, T; Takahashi, Y; Ushida, Y, 2022) |
| "Pancreatic cancer is one of the most recalcitrant cancers, and more effective therapy is needed." | 1.72 | Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease. ( Aoki, Y; Han, Q; Hoffman, RM; Hozumi, C; Kubota, Y; Masaki, N; Tsunoda, T; Yamamoto, J, 2022) |
| "Pancreatic acinar cell carcinoma is rare; it accounts for 1% of all malignant pancreatic exocrine tumors." | 1.72 | Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: A case report. ( Hanazaki, K; Iguchi, M; Kitagawa, H; Kohsaki, T; Maeda, H; Munekage, M; Namikawa, T; Tanioka, N; Uchida, K; Uemura, S; Yamaguchi, S; Yamamoto, S, 2022) |
| "The preferred regimen for unresectable pancreatic cancer following gemcitabine-based chemotherapy is not well-established." | 1.72 | Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study. ( Fukushima, T; Hamaguchi, T; Kobayashi, S; Morimoto, M; Nagashima, S; Oishi, R; Shin, M; Tezuka, S; Ueno, M; Yamachika, Y, 2022) |
| " We followed up these patients and analyzed the relapse-free survival (RFS), overall survival (OS), and chemotherapy-induced adverse events (AEs)." | 1.72 | A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma. ( Dai, H; Feng, W; Tang, C; Yao, L, 2022) |
| " The rate of adverse reactions such as hematological toxicity, neutropenia, anemia, thrombocytopenia, nonhematological toxicity, vomiting, fatigue, infection, diarrhea, intestinal obstruction, and peripheral neuropathy was lower in 10." | 1.72 | Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer. ( Dai, S; Jiang, C; Wu, Z; Zhou, L, 2022) |
| "The number of elderly patients with pancreatic cancer has increased in an aging society; therefore, there is an urgent need to develop specific treatments for elderly patients with pancreatic cancer." | 1.72 | Management of elderly patients with unresectable pancreatic cancer. ( Furuse, J; Ishii, H; Kobayashi, S; Ueno, M, 2022) |
| " The prognosis, predictive factors (including systemic inflammation-based prognostic indicators), and adverse events were investigated." | 1.72 | Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study. ( Aihara, R; Araki, K; Hatanaka, T; Hosaka, H; Hoshino, T; Hosouchi, Y; Ijima, M; Ishida, F; Ishii, N; Kakizaki, S; Kobatake, T; Kurihara, E; Naganuma, A; Shirabe, K; Suzuki, Y; Tamura, Y; Uraoka, T; Yasuoka, H; Yoshida, S, 2022) |
| "From 2016 to 2020, of 1551 pancreatic cancer patients, 615 received palliative-intent chemotherapy." | 1.72 | Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. ( Ananda, S; Burge, M; Clarke, K; Gibbs, P; Jennens, R; Lee, B; Lipton, L; Michael, M; Nikfarjam, M; Pattison, S; Santucci, J; Shapiro, J; Tacey, M; Thomson, B; Wong, R; Zielinski, R, 2022) |
| "Isoliquiritigenin (ISL) is a bioactive flavonoid obtained from the Traditional Chinese herbal medicine Glycyrrhiza glabra, and it possesses a broad range of pharmacological effects." | 1.72 | Isoliquiritigenin inhibits pancreatic cancer progression through blockade of p38 MAPK-regulated autophagy. ( Bai, JX; Chen, WQ; Ko, JK; Liu, B; Yung, KK; Zhang, SQ; Zhang, Z, 2022) |
| "4000 patients are diagnosed with pancreatic cancer in Poland, and the number of deaths is close to the number of diagnoses." | 1.72 | Predicting the chemosensitivity of pancreatic cancer cells as a personalized therapy. ( Kulbacka, J; Michel, O; Płochocki, M; Rudno-Rudzińska, J, 2022) |
| "Pancreatic panniculitis is characterized by subcutaneous fat necrosis and is a rare presentation of an underlying pancreatic disease, appearing in approximately 2-3% of all patients with a pancreatic disease." | 1.72 | Painful lower limb nodules as first symptom of resectable pancreatic acinar cell cancer: a case report. ( Besselink, MG; Busch, OR; Haenen, SM; Post, HC; Roshani, S; Sarasqueta, AF; Tol, JAMG; van der Linden, MMD; van Steen, SCJ; Wilmink, JW; Wolkerstorfer, A, 2022) |
| " However, systematic evaluation of potential pharmacodynamic interactions among multi-drug therapy has not been reported previously." | 1.72 | FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures. ( Allen-Coyle, TJ; Clynes, M; Conlon, NT; Garner, W; Mager, DE; Niu, J; O'Sullivan, F; Roche, S; Straubinger, RM; Welsch, E, 2022) |
| "FOLFIRINOX and FOLFOXIRI are combination chemotherapy treatments that incorporate the same drug cocktail (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) but exploit an altered dosing regimen when used in the management of pancreatic and colorectal cancer, respectively." | 1.62 | A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction. ( Callan, B; Callan, JF; Gao, J; Griffith, DM; Logan, KA; Love, M; McHale, AP; McKaig, T; Nesbitt, H; Taylor, M, 2021) |
| "5-Fluorouracil treatment responses between naïve and treated organoids were similar." | 1.62 | Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma. ( Chang, J; Doukas, M; Farshadi, EA; Koerkamp, BG; Pothof, J; Sampadi, B; Van 't Land, F; van der Sijde, F; van Eijck, CHJ; Vietsch, EE, 2021) |
| "The incidence of pancreatic cancer is age dependent." | 1.62 | Reviewing the Outcomes of Different Treatment Approaches in Elderly Pancreatic Cancer Patients. ( Amundsen, T; Doyle, J; Hall, JA; Raiyani, C; Wong, L, 2021) |
| "However, pancreatic cancer is non-immunogenic, and single agent immunotherapies are unfavorable to its prognosis." | 1.62 | Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report. ( Ye, Y; Zheng, S, 2021) |
| "The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP))." | 1.62 | Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. ( Asama, H; Hashimoto, M; Hikichi, T; Irie, H; Kato, T; Kobashi, R; Konno, N; Nakamura, J; Ohira, H; Okubo, Y; Sato, Y; Sugimoto, M; Suzuki, R; Takagi, T; Takasumi, M, 2021) |
| "In patients with BR or LA pancreatic cancer, FOLFIRINOX is a valuable neoadjuvant treatment that enables curative surgery in approximately one-quarter of patients and significantly improves overall survival." | 1.62 | Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX. ( Choi, YH; Jang, JY; Kim, SW; Kim, YT; Kwon, W; Lee, SH; Paik, WH; Ryu, JK; Shin, BS; You, MS, 2021) |
| "Patients with borderline resectable pancreatic cancer are at high risk of incomplete resection with upfront surgery." | 1.62 | Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy. ( Ahmed, S; Chalchal, H; Luo, Y; Moser, M; Shaw, J; Templeton, S; Wall, C; Zaidi, A, 2021) |
| "• Margin-negative resection rate of pancreatic cancer following FOLFIRINOX therapy did not differ among each resectability (67-73%, p = 0." | 1.62 | CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. ( Byun, JH; Hong, SM; Jang, JK; Kang, JH; Kim, HJ; Kim, JH; Kim, KP; Kim, SC; Lee, MG; Lee, SS; Seo, DW; Son, JH; Yoo, C, 2021) |
| "The incidence of pancreatic cancer is increasing in developed countries." | 1.62 | Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting. ( Camara, JC; Franco, F; Gutiérrez-Abad, D; Juez, I; León, A; López-Alfonso, A; Marrupe, D; Martín-Valadés, JI; Martínez-Amores, B; Pérez, M; Royuela, A; Ruiz-Casado, A, 2021) |
| "Sarcopenia was diagnosed in thirty-three (48 %) subjects." | 1.62 | The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy. ( Ichikawa, H; Iwasa, Y; Iwashita, T; Mita, N; Shimizu, M; Shiraki, M; Uemura, S, 2021) |
| "To evaluate somatic mutations, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in patients with Pancreatic ductal adenocarcinoma (PDAC) with pathologic complete response (pCR) to neoadjuvant therapy (NAT) and find their associations with outcome." | 1.62 | Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis. ( Miao, Y; Pu, N; Thompson, E; Wolfgang, C; Yin, L; Yu, J, 2021) |
| "Gemcitabine monotherapy was given to 13% (41/326) of patients and nab-paclitaxel/gemcitabine to 10% (33/326), with a median of two (IQR 3-5) and three (IQR 3-5) cycles respectively." | 1.62 | Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. ( Besselink, MG; Blomjous, JG; Bollen, TL; Bosscha, K; Brada, LJ; Bruijnen, RC; Busch, OR; Creemers, GJ; Daams, F; de Hingh, IH; de Meijer, VE; de Vos-Geelen, J; de Vries, JJJ; Festen, S; Hermans, JJ; Jan de Groot, D; Kerver, ED; Liem, MS; Los, M; Meijerink, MR; Mekenkamp, LJ; Mohammad, NH; Molenaar, IQ; Nederend, J; Nio, CY; Patijn, GA; Patuleia, SIS; Polée, MB; Pruijt, JF; Renken, NS; Rombouts, SJ; Schouten, TJ; Stommel, MWJ; van Dam, R; van der Leij, C; van Leeuwen, MS; van Lienden, KP; van Santvoort, HC; Verweij, ME; Vulink, A; Walma, MS; Wessels, FJ; Willem de Groot, J; Wilmink, JW, 2021) |
| "We used pancreatic, liver and colon cancer cell lines and isolated CSCs using Aldefluor technology to analyze PARP-1 expression." | 1.62 | Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study. ( Cepero, A; Martin-Guerrero, SM; Martin-Oliva, D; Melguizo, C; Munoz-Gamez, JA; Ortiz, R; Prados, J; Quinonero, F; Urbano, D, 2021) |
| " Using pharmacokinetic analysis, it is possible to directly evaluate enzyme activity and consider what kind of enzyme variation causes the increase in the AUC of SN-38." | 1.62 | Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms. ( Ayukawa, H; Endo, S; Furuse, J; Furuta, T; Hirano, R; Kaneko, S; Kawai, K; Kobayashi, T; Minowa, Y; Nagashima, F; Naruge, D; Okano, N; Shibasaki, H; Yokokawa, A, 2021) |
| "Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies." | 1.62 | SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). ( Carrato, A; Feliu, J; Garcia-Carbonero, R; Gómez-España, MA; Martín, AM; Maurel, J; Mercadé, TM; Montes, AF; Pazo-Cid, R; Vera, R, 2021) |
| "Advanced, unresectable pancreatic cancer is often treated with either gemcitabine plus nab-paclitaxel (Gem/NabP) or FOLFIRINOX, although these regimens have never been compared in a head-to-head trial." | 1.62 | Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans. ( Bates, SE; Conroy, T; Fojo, T; Juzyna, B; Mutetwa, T; Nadkarni, G; Park, YA; Polak, P; Sigel, C; Sigel, K; Wisnivesky, JP; Ychou, M; Yeh, C; Zhou, M, 2021) |
| "Chemotherapy, nodal status and resection margin according to UICC R status are univariate factors for OS after PDAC." | 1.62 | Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data. ( Obonyo, D; Stricker, I; Tannapfel, A; Uslar, VN; Weyhe, D, 2021) |
| "ZFP91 overexpression is prevalent in pancreatic cancer and negatively correlated with overall survival." | 1.62 | Zinc finger protein 91 accelerates tumour progression by activating β-catenin signalling in pancreatic cancer. ( Fu, X; He, J; Qiu, Y; Song, T; Tang, N; Xu, S, 2021) |
| "KRas is frequently mutated in pancreatic cancers." | 1.62 | GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. ( Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS, 2021) |
| "Pancreatic cancer is the 8th commonest cancer and the 5th commonest cause of cancer-related death in Australia, with a 9% average 5-year survival." | 1.62 | Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. ( Ashrafi-Zadeh, A; Chan, DL; Chua, TC; Clarke, S; Diakos, C; Gill, A; Hruby, G; Jamieson, NB; Kneebone, A; Maloney, S; Mittal, A; Nahm, CB; Pavlakis, N; Samra, JS; Wijetunga, AR, 2021) |
| " Irreversible electroporation (IRE) is a nonthermal ablative technique that provides an alternative in patients with LAPC and can be safely combined with chemotherapy." | 1.62 | Irreversible Electroporation (IRE) Combined With Chemotherapy Increases Survival in Locally Advanced Pancreatic Cancer (LAPC). ( Astras, G; Davakis, S; Dimitrokallis, N; Felekouras, E; Karamouzis, MV; Kountourakis, P; Moris, D; Oikonomou, D; Papalampros, A; Papamichael, D; Petrou, AS; Schizas, D, 2021) |
| "Patients with locally advanced pancreatic cancer (LAPC) are increasingly treated with FOLFIRINOX, resulting in improved survival and resection of tumors that were initially unresectable." | 1.62 | Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms. ( Besselink, MG; Bosscha, K; Brada, LJH; Bruijnen, RC; Busch, OR; Daamen, LA; de Hingh, IH; de Meijer, VE; de Vries, JJJ; Festen, S; Liem, MLS; Los, M; Mohammad, NH; Patijn, GA; Polée, MB; Quintus Molenaar, I; Stommel, MWJ; van Dam, RM; van Lienden, KP; van Roessel, S; van Santvoort, HC; Walma, MS; Wessels, FJ; Wilmink, HW; Yung Nio, C, 2021) |
| "In patients with locally advanced pancreatic cancer (LAPC), the cross-sectional area of skeletal muscle (SM) and adipose tissue (AT) at the level of third lumbar vertebra was measured." | 1.62 | Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients. ( Hwang, JH; Kim, J; Kim, MA; Lee, JC; Shin, DW, 2021) |
| "Treatment options for patients with pancreatic cancer are limited and survival prospects have barely changed over the past 4 decades." | 1.62 | Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer. ( Able, S; Allen, PD; Bau, L; Browning, RJ; Callan, JF; Kamila, S; Kartsonaki, C; Kersemans, V; Kinchesh, P; Logan, K; McHale, AP; Ruan, JL; Smart, S; Stride, E; Taylor, MA; Vallis, KA; Wallington, S, 2021) |
| "This study aimed to examine the efficacy of metabolically supported administration of chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy (HBOT) in patients with metastatic pancreatic cancer." | 1.56 | Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer. ( Iyikesici, MS, 2020) |
| "At the time of disease progression, sTGF-β was increased compared with that of diagnosis (mean, 26." | 1.56 | The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy. ( Bang, JH; Bang, YJ; Jin, MH; Nam, AR; Oh, DY; Park, H; Park, JE, 2020) |
| "We obtained 93 pancreatic cancer specimens (tumor and adjacent nontumor tissues) from patients who underwent surgery and gemcitabine chemotherapy and analyzed them by immunohistochemistry." | 1.56 | ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells. ( Brabletz, T; Bronze, MS; Cui, X; Ding, K; Edil, BH; Fernandez-Zapico, ME; Fung, KA; Houchen, CW; Li, M; Li, YP; Liu, M; Postier, RG; Stemmler, MP; Tian, X; Yang, J; Yang, Z; Zhan, H; Zhang, Y; Zhou, Z, 2020) |
| " However, their use in the elderly is discouraged because of adverse events." | 1.56 | The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. ( Bai, XL; Chen, W; Chen, YW; Fu, QH; Gao, SL; Guo, CX; Huang, DB; Li, X; Liang, TB; Ma, T; Que, RS; Su, W; Tang, TY; Zhang, Q; Zhang, XC, 2020) |
| " These data indicate that the use of modified dosing FOLFIRINOX in advanced PC pts older than 75 appears to maintain similar toxicity and efficacy when compared to younger pts." | 1.56 | Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. ( Fogelman, DR; Hess, KR; Ho, L; Javle, MM; Mizrahi, JD; Overman, MJ; Pant, S; Raghav, KPS; Rogers, JE; Shroff, RT; Varadhachary, GR; Wolff, RA, 2020) |
| " Demographics, clinical and dosing characteristics, and treatment outcomes were collected." | 1.56 | Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. ( Ahn, D; Barzi, A; Bekaii-Saab, T; Corvino, FA; Mamlouk, K; Miksad, R; Pulgar, S; Surinach, A; Torres, AZ; Valderrama, A; Wang, S, 2020) |
| "We report a case with steatohepatitis mimicking liver metastasis as toxicity that was not seen in study patient population." | 1.56 | Steatohepatitis due to FOLFIRINOX regimen in adjuvant pancreas cancer treatment mimicking liver metastasis. ( Bozkurt Duman, B; Çil, T, 2020) |
| " Particularly, the expression of tumour-suppressing gene Ccdc80 was induced by vactosertib and further induced by vactosertib in combination with nal-IRI/5-FU/LV." | 1.56 | Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models. ( An, H; Heo, JS; Hong, CP; Hong, E; Kang, JM; Kim, SJ; Lee, S; Ooshima, A; Park, J; Park, JO; Park, S; Park, SH, 2020) |
| "Locally advanced pancreatic cancer (LAPC) is a devastating disease and irreversible electroporation (IRE) is a non-thermal ablation method that is especially suitable for the treatment of LAPC." | 1.56 | Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score matching analysis. ( He, C; Li, S; Lin, X; Wang, J; Zhang, Y, 2020) |
| "MUC1 may be a therapeutic target in pancreatic cancer treatment." | 1.56 | MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer. ( Fu, X; Mao, L; Qiu, YD; Tang, N; Xie, WQ, 2020) |
| "Unresectable pancreatic cancer (UR-PC) has a poor prognosis." | 1.56 | Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy. ( Endo, I; Kumamoto, T; Matsuyama, R; Murakami, T; Sawada, Y; Tsuchiya, N; Yabushita, Y, 2020) |
| " This pharmacokinetic/pharmacodynamic (PK/PD) study was performed to determine the effect of different G-CSF regimens on the incidence and duration of neutropenia following FOLFIRINOX administration in order to propose an optimal G-CSF dosing schedule." | 1.56 | Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach. ( Bengrine-Lefevre, L; Ghiringhelli, F; Macaire, P; Paris, J; Schmitt, A; Vincent, J, 2020) |
| "Locally advanced pancreatic cancer (LAPC) remains a challenge for current treatments." | 1.56 | Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation. ( Cai, Z; He, C; Li, S; Lin, X; Wang, J; Zhang, Y, 2020) |
| " Against this backdrop, the efficacy of nanoliposomal irinotecan(nal-IRI)in combination with fluorouracil and folinic acid(FF)for progressive metastatic pancreatic cancer after previous gemcitabine therapy was confirmed in Europe in 2015 ahead of Japan." | 1.56 | [Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer]. ( Ueno, M, 2020) |
| "To evaluate the prognostic value of posttreatment fibrosis in human PDAC patients, and to compare a type I collagen targeted MRI probe, CM-101, to the standard contrast agent, Gd-DOTA, for their abilities to identify FOLFIRINOX-induced fibrosis in a murine model of PDAC." | 1.56 | Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. ( Arora, G; Axtell, AL; Bardeesy, N; Caravan, P; Chawla, A; Chen, YI; Deshpande, V; Erstad, DJ; Farrar, CT; Ferreira, DS; Ferrone, CR; Fuchs, BC; Ghoshal, S; Graham-O'Regan, KA; Humblet, V; Jones, C; Jordan, VC; Kontos, F; Lanuti, M; Li, S; Michelakos, T; Qadan, M; Rotile, NJ; Sojoodi, M; Tanabe, KK; Taylor, MS, 2020) |
| " No toxic death was observed." | 1.56 | Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX. ( Bengrine, L; Fumet, JD; Ghiringhelli, F; Granconato, L; Hennequin, A; Palmier, R; Vincent, J, 2020) |
| " Adverse events occurred in 88." | 1.56 | Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms. ( Arsenic, R; Dal Buono, A; Denecke, T; Jann, H; Merola, E; Pape, UF; Pavel, ME; Wiedenmann, B, 2020) |
| "Patients with borderline or resectable pancreatic cancer treated with neoadjuvant intent between November 2011 and December 2017 were reviewed." | 1.56 | Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer. ( Ahmad, S; Barrord, M; Choe, K; Esslinger, H; Kharofa, J; Latif, T; Olowokure, O; Patel, S; Poreddy, S; Smith, M; Sussman, J, 2020) |
| "Here, we report the case of a Lynch syndrome PDA patient with an exceptional response to a single cycle of pembrolizumab immunotherapy." | 1.56 | Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma. ( Khan, GN; Patil, NR, 2020) |
| "Pancreatic cancer is associated with a poor prognosis due to challenges in early detection, severe progression of the primary tumor, metastatic lesions, and resistance to antitumor agents." | 1.56 | Probiotic‑derived ferrichrome inhibits the growth of refractory pancreatic cancer cells. ( Ando, K; Fujiya, M; Goto, T; Ijiri, M; Iwama, T; Kashima, S; Kita, A; Konishi, H; Murakami, Y; Ogawa, N; Okumura, T; Sakatani, A; Takauji, S; Tanaka, H; Ueno, N, 2020) |
| "By using the Korean Pancreatic Cancer (K-PaC) registry, we compared the clinical outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) in patients with metastatic pancreatic cancer (MPC)." | 1.56 | Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. ( Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY, 2020) |
| "Patients with resectable pancreatic cancer, borderline resectable pancreatic cancer, and locally advanced pancreatic cancer were eligible for this study." | 1.56 | Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. ( Abu Hilal, M; Alseidi, A; Balduzzi, A; Balzano, G; Bassi, C; Berrevoet, F; Besselink, MG; Bonds, M; Bossuyt, PM; Busch, OR; Butturini, G; Conlon, KC; Del Chiaro, M; Falconi, M; Frigerio, I; Fusai, GK; Gagnière, J; Griffin, O; Groot Koerkamp, B; Hackert, T; Halimi, A; Janssen, QP; Keck, T; Klaiber, U; Kleeff, J; Klompmaker, S; Labori, KJ; Lesurtel, M; Malleo, G; Marino, MV; Mortensen, MB; Nikov, A; Pandé, R; Pfeiffer, P; Pietrasz, D; Roberts, KJ; Sa Cunha, A; Salvia, R; Strobel, O; Tarvainen, T; van Laarhoven, HWM; van Roessel, S; van Veldhuisen, E; Wilmink, JW, 2020) |
| " Whereas reductions of NTx dosage was more common in elderly patients in comparison 1 (p = 0." | 1.56 | Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the ( Ceyhan, GO; Damm, M; Kordes, M; Maggino, L; Moir, J; Rosendahl, J; Schorn, S; Weniger, M, 2020) |
| "Objectives: Pancreatic cancer (PC) is a costly disease with a limited life-expectancy as it generally presents as an advanced, metastatic disease." | 1.56 | The economic burden of metastatic pancreatic cancer. ( Antico, G; Cole, A; Doleh, Y; Malangone-Monaco, E; Noxon, V; Pishvaian, MJ, 2020) |
| "Diltiazem co-treatment, either with gemcitabine or 5-FU, synergistically reduced cell viability, induced apoptosis, and caused cell cycle arrest." | 1.56 | Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein. ( El-Husseiny, AA; El-Mahdy, HA; Gamal El-Din, AM; Kandil, YI, 2020) |
| " In the NAPOLI-1 trial, liposomal irinotecan in combination with fluorouracil (nal-iri/5FU) was shown to improve overall survival when compared to fluorouracil alone for metastatic pancreatic cancer." | 1.51 | Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience. ( Arango, MJ; Noonan, AM; Porter, K; Reardon, J; Tossey, JC; VanDeusen, JB, 2019) |
| "Primary systemic therapy in resectable pancreatic cancer is currently under investigation." | 1.51 | Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer. ( Joseph, NE; Marsh, RW; Polish, A, 2019) |
| "Most patients had disease progression as the best response to treatment (75." | 1.51 | Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? ( Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC, 2019) |
| "Thirteen patients with metastatic pancreatic cancer underwent clinical, sonographic, and electrophysiological evaluation before, 3 and 7 months after treatment with 12 two-week cycles of FOLFIRINOX." | 1.51 | Prospective Study of the Clinical, Electrophysiologic, and Sonographic Characteristics of Oxaliplatin-Induced Neuropathy. ( Fisse, AL; Gold, R; Höffken, N; Lönneker, N; Pitarokoili, K; Reinacher-Schick, A; Trampe, N; Yoon, MS, 2019) |
| "Seventy-four patients with resectable pancreatic cancer (RPC) (from April 2012 to November 2017) and 19 patients with LAPC-S (from April 2012 to March 2014) were set as observational cohorts, and data were collected retrospectively." | 1.51 | Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. ( Bai, X; Chen, Y; Gao, S; Guo, C; Huang, P; Li, G; Li, Q; Li, X; Liang, T; Lou, J; Ma, T; Que, R; Shen, Y; Wei, Q; Wei, S; Yu, R; Yuan, Y; Zhang, Q, 2019) |
| "On the other hand, sarcopenia is one of the important prognostic factors of pancreatic cancer." | 1.51 | Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. ( Endo, I; Goto, A; Ichikawa, Y; Kobayashi, N; Kubota, K; Kurita, Y; Nakajima, A; Tokuhisa, M, 2019) |
| "Advanced pancreatic cancer (aPC) has a poor prognosis with limited survival benefit from current standard treatment." | 1.51 | Long-term survival of a patient with advanced pancreatic cancer under adjunct treatment with ( Kempenich, R; Kienle, GS; Lang-Avérous, G; Werthmann, PG, 2019) |
| "Survival benefits after synchronous metastasectomy have been reported for selected patients." | 1.51 | CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. ( Büchler, MW; Hackert, T; Heckler, M; Heger, U; Klaiber, U; Mihaljevic, AL; Sun, H; Tanaka, M, 2019) |
| "Irinotecan was administered whenever initial serum bilirubin was <1." | 1.51 | Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. ( Almohamad, W; Biondani, P; Chebib, A; Gumus, Y; Haydar, M; Karaboué, A; Krimi, S; Morère, JF; Teyar, N; Ulusakarya, A, 2019) |
| "Patients with newly diagnosed advanced pancreatic cancer in Saskatchewan, Canada, from 2011 to 2016, who received FOLFIRINOX or GnP were assessed." | 1.51 | Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study. ( Ahmed, S; Chalchal, H; Haider, K; Moser, M; Olson, C; Papneja, N; Shaw, J; Tan, K; Zaidi, A, 2019) |
| "Thus, pancreatic cancer of the tail often presents late with a very poor prognosis." | 1.51 | The seemingly innocuous presentation of metastatic pancreatic tail cancer: a case report. ( Rahman, M; Washington, L, 2019) |
| "Data were analyzed from a prospective pancreatic cancer database." | 1.48 | Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. ( Chabot, JA; Hecht, EM; Kluger, MD; Rashid, MF; Rosario, VL; Schrope, BA; Steinman, JA, 2018) |
| "Mismatch repair status in pancreatic cancer patients is not only a prognostic indicator but also a potential guiding factor for the use of 5-fluorouracil-based adjuvant chemotherapy." | 1.48 | Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer. ( Liang, C; Liang, D; Meng, Q; Ni, Q; Shi, S; Xu, J; Yu, X; Zhang, B, 2018) |
| "For patients with disease progression with FOLFIRINOX who have a good performance status, NG might be a reasonable second-line option." | 1.48 | Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience. ( Kellett, C; Kim, CA; Lambert, P; Zhang, H, 2018) |
| "Since pancreatic cancer is becoming more common as a result of population aging, there is a need for diversification of chemotherapy." | 1.48 | Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. ( Akao, J; Otsuka, N; Shimizu, K; Tahara, J; Takayama, Y; Tokushige, K, 2018) |
| "The maximal effect was seen in pancreatic cancer cells with more than 10 000 receptor molecules per cell." | 1.48 | Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase. ( Chen, LH; Feng, L; Hu, CY; Mostofa, AGM; Suthe, SR; Wang, MH; Wang, WL; Weng, TH; Wu, ZG; Yao, HP, 2018) |
| "Approximately 30% of all pancreatic cancer patients have locally advanced (AJCC stage 3) disease." | 1.48 | Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It. ( Besselink, MG; Boggi, U; Hackert, T; Klompmaker, S; Salvia, R; Weiss, M; Yamaue, H; Zeh, HJ, 2018) |
| "Indiana University Simon Cancer Center pancreatic cancer database was used to identify patients with metastatic PDAC, treated with FOLFIRINOX and had tissue available for DNA sequencing." | 1.48 | Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. ( Gbolahan, O; Hancock, BA; O'Neil, BH; Radovich, M; Sehdev, A; Shahda, S; Stanley, M; Wan, J; Wu, HH, 2018) |
| "Pancreatic cancer is one of the most aggressive and mortal cancers." | 1.48 | Identification of antitumoral agents against human pancreatic cancer cells from Asteraceae and Lamiaceae plant extracts. ( Fornari, T; García-Carrascosa, E; García-Risco, M; Gómez de Cedrón, M; Herranz, N; Mouhid, L; Ramírez de Molina, A; Reglero, G; Vargas, T, 2018) |
| "One-third of the patients with pancreatic cancer present with locally advanced unresectable pancreatic cancer (LAPC)." | 1.48 | FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. ( Eskens, FALM; Groot Koerkamp, B; Nuyttens, JJ; Suker, M; van Eijck, CHJ, 2018) |
| "A 5-fluorouracil (5-FU) concentration and 4-methylumbelliferone (MU) dosage was analyzed by high-performance liquid chromatography (HPLC)." | 1.48 | 4-Methylumbelliferone Decreases the Hyaluronan-rich Extracellular Matrix and Increases the Effectiveness of 5-Fluorouracil. ( Endo, M; Hakamada, K; Kakizaki, I; Kudo, D; Nagase, H; Shimoda, H; Suto, A; Suto, S; Yoshida, E, 2018) |
| "MMR-D pancreatic cancer have been reported to respond to checkpoint inhibitor therapy." | 1.48 | Acquired resistance to immunotherapy in MMR-D pancreatic cancer. ( Diaz, LA; Hellmann, MD; Hu, ZI; O'Reilly, EM; Shia, J; Stadler, ZK; Vyas, M; Wolchok, JD, 2018) |
| "Undifferentiated carcinoma of pancreas (pancreatic cancer - PC) is a rare subtype of malignant PC." | 1.48 | Undifferentiated Carcinoma of the Pancreas - a Case Report. ( Bumberová, M; Dolinský, J; Janega, P; Jurišová, S; Kašperová, B; Macúch, J; Mego, M, 2018) |
| "To obtain improved efficacy against pancreatic cancer, we investigated the efficacy and safety of a locally-applied 5-fluorouracil (5-FU)-loaded polymeric patch on pancreatic tumors in an orthotopic nude-mouse model." | 1.46 | Locally-applied 5-fluorouracil-loaded slow-release patch prevents pancreatic cancer growth in an orthotopic mouse model. ( Cho, DW; Choi, YJ; Hoffman, RM; Jeong, SY; Jun, E; Kim, SC; Lee, CM; Lee, YN; Shim, IK; Yi, HG; Yi, HJ, 2017) |
| "The economic burden of metastatic pancreatic cancer (mPC) is substantial while treatment options are limited." | 1.46 | Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX. ( Bonafede, M; Cai, Q; McBride, A; Parisi, M; Patel, M; Pelletier, C; Princic, N; Tran, O, 2017) |
| "Pancreatic cancer has a high rate of local recurrence and poor prognosis even with adjuvant chemotherapy after curative resection." | 1.46 | Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft. ( Jun, E; Kim, SC; Lee, CM; Lee, S; Oh, J; Shim, IK, 2017) |
| "The most common sites of metastases were liver (63%) and peritoneum (22%)." | 1.46 | Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study. ( Cheung, WY; Gill, S; Ho, MY; Kennecke, HF; Lim, HJ; Renouf, DJ, 2017) |
| "In the mouse xenograft pancreatic cancer model, triple VEGFRs silencing significantly reduced tumor growth, had synergistic effect with standard chemotherapy, and was associated with inhibition of epithelial mesenchymal transition (EMT)." | 1.46 | Triple-amiRNA VEGFRs inhibition in pancreatic cancer improves the efficacy of chemotherapy through EMT regulation. ( Huang, F; Huang, J; Jin, Q; Li, J; Lu, Y; Mei, H; Tang, Z; Wang, Z; Zhang, X, 2017) |
| "Locally advanced unresectable pancreatic cancer (LAPC) historically portends a poor prognosis." | 1.46 | Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? ( Bahary, N; Bednar, F; Hogg, ME; Ocuin, LM; Steve, J; Winters, S; Zeh, HJ; Zenati, MS; Zureikat, AH, 2017) |
| "Histology revealed an undifferentiated anaplastic carcinoma, on the basis of a poorly differentiated ductal adenocarcinoma." | 1.46 | Granulocyte Colony-stimulating Factor Producing Anaplastic Carcinoma of the Pancreas: Case Report and Review of the Literature. ( Gloor, B; Rau, T; Vinzens, S; Wochner, A; Zindel, J; Zweifel, M, 2017) |
| "Metastatic pancreatic cancer (mPC) is associated with low survival, with less than 10% of patients surviving 5 years." | 1.46 | The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens. ( Kaura, S; Khan, ZM; MacEwan, JP; Yin, W, 2017) |
| "Pancreatic cancer has become the third leading cause of cancer death with minimal improvements in outcome for over 40 years." | 1.46 | BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. ( Bailey, P; Biankin, AV; Brody, JR; Chang, DK; Laheru, D; Pishvaian, MJ; Wolfgang, CL, 2017) |
| "Human pancreatic cancer cell lines such as PANC-1 have an altered metabolism, enabiling them to tolerate and survive under extreme conditions of nutrient starvation." | 1.43 | Chemical Constituents of Mangifera indica and Their Antiausterity Activity against the PANC-1 Human Pancreatic Cancer Cell Line. ( Awale, S; Do, TN; Esumi, H; Le, TH; Nguyen, HX; Nguyen, MT; Nguyen, NT, 2016) |
| "Advanced pancreatic cancer (APC), one of the most aggressive tunors, was considered to be resistant to chemotherapy for decades." | 1.43 | EARLY INCREASE of CA 19-9 in ADVANCED PANCREATIC CANCER RECEIVING FOLFIRINOX. Is it a sign of efficacy?. ( Farhat, F; Kattan, J; Kourie, HR; Tabchi, S, 2016) |
| "At diagnosis, 30% of patients with pancreatic cancer are unresectable stage 3 locally advanced." | 1.43 | Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. ( Azad, N; Blackford, A; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, R; Edil, BH; Faisal, F; Fishman, EK; Herman, J; Hruban, RH; Laheru, D; Le, DT; Olino, K; Rasheed, Z; Schulick, R; Tsai, HL; Wolfgang, C; Xia, C; Zheng, L, 2016) |
| "The aim of this research was to study the pharmacokinetic characteristics of a slow-release 5-fluorouracil implant as well as to evaluate the clinical drug activity of this preparation in pancreatic cancer patients." | 1.43 | Pharmacokinetic study and clinical evaluation of a slow-release 5-fluorouracil implant in pancreatic cancer patients. ( Li, JQ; Liang, JX; Wang, SL; Yang, JC, 2016) |
| "Resection of exocrine pancreatic cancer is necessary for cure, but locoregional and distant relapse is common." | 1.43 | Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer. ( Haddock, MG; Hallemeier, CL; Harmsen, WS; Kendrick, ML; Merrell, KW; Miller, RC; Quevedo, JF, 2016) |
| "Over-expression of ABCA8b in mouse pancreatic cancer cells led to a marked decrease in the sensitivity to chemotherapeutic drugs both in vitro and in vivo." | 1.43 | Enriched environment housing enhances the sensitivity of mouse pancreatic cancer to chemotherapeutic agents. ( Fan, Y; Gan, Y; Gu, J; Li, G; Tu, H; Wang, Q; Wu, Y; Yao, M; Yuan, H; Zhang, J, 2016) |
| "At multivariate analysis liver metastases (p = 0." | 1.43 | First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. ( Caparello, C; Catanese, S; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Vasile, E; Vivaldi, C, 2016) |
| "Treating metastatic pancreatic cancer (MPC) remains a challenging issue." | 1.43 | Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX. ( Cavaglione, G; Evesque, L; Follana, P; François, E; Gal, J; Reure, J; Saint, A, 2016) |
| "RT/gemcitabine was equivalent in toxicity to RT/5-FU but was associated with superior OS and DMFS." | 1.43 | Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience. ( Blake, A; Hayes, JP; Helenowski, I; Huang, J; Kim, T; McGinn, CJ; Mulcahy, M; Rakhra, S; Robertson, J; Small, W; Strauss, JB, 2016) |
| " Here, we report combination therapies in which TOP3 was combined with gemcitabine or TS-1." | 1.43 | Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model. ( Hoang, NT; Kadonosono, T; Kizaka-Kondoh, S; Kuchimaru, T, 2016) |
| "5 weeks (range 3-4 weeks), indicating that Vistogard might be able to delay 5-FU toxicity despite higher doses than standard bolus dose of 5-FU used in gastrointestinal malignancies and the appearance of a potentially less toxic adverse effect of 5-FU at an unusual site (cutaneous) in one patient." | 1.43 | Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency. ( Diasio, RB; Saif, MW, 2016) |
| "The drug-resistance of pancreatic cancer cells results in poor therapeutic effect." | 1.43 | MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells. ( Liu, S; Ma, Y; Sun, G; Wang, F; Wang, L; Wang, W; Wei, X; Yang, Y; Yu, J; Zhang, J; Zhao, L; Zhao, Y, 2016) |
| "Since recurrence and metastasis of pancreatic cancer has a worse prognosis, chemotherapy has been typically performed to attack the remained malignant cells after resection." | 1.43 | A 3D-printed local drug delivery patch for pancreatic cancer growth suppression. ( Cho, DW; Choi, YJ; Hong, JM; Kang, KS; Kim, SC; Lee, CM; Park, MN; Pati, RG; Shim, IK; Yi, HG, 2016) |
| "436 patients with unresectable pancreatic cancers received HIFU treatment; the other 253 patients received non-HIFU treatment." | 1.43 | A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer. ( Chen, QW; Cheng, CS; Meng, ZQ; Ning, ZY; Shi, WD; Song, LB; Wang, K; Wang, P; Xie, J; Xu, LT; Zhang, CY; Zhu, XY; Zhuang, LP, 2016) |
| "For patients with metastatic pancreatic cancer, FOLFIRINOX (fluorouracil [5-FU], leucovorin [LV], irinotecan [IRI], and oxaliplatin) has shown improved survival rates compared with gemcitabine but with significant toxicity, particularly in patients with a high tumor burden." | 1.42 | Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. ( Bekaii-Saab, T; Blazer, M; Bloomston, M; Ellison, EC; Goldberg, RM; Muscarella, P; Phillips, G; Reardon, J; Schmidt, C; Williams, TM; Wu, C; Wuthrick, E, 2015) |
| "A gemcitabine (GEM)-resistant human pancreatic cancer cell line (PANC-1RG7) was established in vitro by gradually increasing GEM concentrations and cloning cell cultures to develop a cellular model of acquired drug resistance studies." | 1.42 | Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression. ( Fu, M; Huang, H; Wang, C; Xie, J; Yang, A; Zhang, W, 2015) |
| "Pancreatic cancer is known for its typically late presentation and poor survival rates, with overall 5-year survival of less than 5%." | 1.42 | Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report. ( Brais, RJ; Chatzizacharias, NA; Corrie, P; Davies, S; Elias, A; Harper, SJF; Huguet, E; Jah, A; Jamieson, NV; Praseedom, RK; Xanthis, A, 2015) |
| "5-fluorouracil (5-FU) is a principal first-line therapy, but treatment only extends survival modestly and is seldom curative." | 1.42 | Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment. ( Dembinski, JL; Krauss, S; Lund, K; Mills, IG; Solberg, N; Urbanucci, A, 2015) |
| "The bleak prognosis associated with pancreatic cancer (PDAC) drives the need for the development of novel treatment methodologies." | 1.42 | Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer. ( Guillen, KP; Harrison, RG; Kurkjian, C; Restuccia, A, 2015) |
| "In Europe, pancreatic cancer (PC) accounts for approximately 2." | 1.42 | Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study. ( André, T; Ball, DE; Bapat, B; Kaye, JA; Smyth, EN, 2015) |
| "The inhibition of the growth of pancreatic cancer cells induced by tamoxifen was effectively reduced by α-tocopherol, a membrane stabilizer." | 1.42 | Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells. ( Honma, Y; Kato, N; Miyake, T; Suzumiya, J; Urano, T, 2015) |
| "Using different pancreatic cancer cell lines, we evaluated the effect of RA alone or in combination with chemotherapy regulating cancer stem cells properties and pathways." | 1.42 | Retinoic Acid Reduces Stem Cell-Like Features in Pancreatic Cancer Cells. ( Bujanda, L; Er, TK; Herreros-Villanueva, M, 2015) |
| "Stable disease and further disease progression were achieved in 36 and 14 patients, respectively." | 1.42 | Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer. ( Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ, 2015) |
| "The effects of miR‑138‑3p regulation on pancreatic cancer cell migration and sensitivity to chemotherapy were examined." | 1.42 | Upregulation of microRNA‑138‑5p inhibits pancreatic cancer cell migration and increases chemotherapy sensitivity. ( Chen, M; Huang, Y; Jiang, J; Wang, M; Yu, C, 2015) |
| "Pancreatic cancer is the fourth leading cause of cancer related death with median survival ranging from 3 to 6 months for metastatic disease." | 1.42 | Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country. ( Jabbar, AA; Zahir, MN, 2015) |
| "The increased mortality due to pancreatic cancer arises due to many factors such as development of multidrug resistance, presence of cancer stem cells, development of a stromal barrier and a hypoxic environment due to hypo-perfusion." | 1.42 | Dual drug loaded chitosan nanoparticles-sugar--coated arsenal against pancreatic cancer. ( David, KI; Jaidev, LR; Krishnan, UM; Sethuraman, S, 2015) |
| "Patients with advanced pancreatic cancer who received FOLFIRINOX with G-CSF prophylaxis during the first cycle of treatment from January 2014 to August 2014 were investigated and the frequency of adverse events during the first cycle was measured." | 1.42 | Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study. ( Asaishi, K; Goto, M; Higuchi, K; Kii, T; Kuwakado, S; Miyamoto, T; Nishitani, H; Shimamoto, F; Terazawa, T, 2015) |
| "The SCAN pancreatic cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy for pancreatic adenocarcinoma in Singapore." | 1.42 | Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma. ( , 2015) |
| "Advanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy." | 1.40 | Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma. ( Ajouz, H; Elias, E; Faraj, W; Haydar, A; Khalife, M; Mukherji, D; Saleh, A; Shamseddine, A; Temraz, S; Yakan, AS, 2014) |
| "However, the number of long-term esophageal cancer survivors has been increasing due to advances in early detection and therapy." | 1.40 | Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer. ( Dasanu, CA; Nandy, N, 2014) |
| "Patients with low-grade resected pancreatic cancer may have better outcomes with 5-fluorouracil-based chemotherapy without radiation when compared with 5-fluorouracil with radiation." | 1.40 | Survival outcomes in patients with early stage, resected pancreatic cancer - a comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens. ( Jaiyesimi, I; Kizilbash, SH; Liang, JJ; Lipscomb, J; Ward, KC, 2014) |
| "The role of autophagy in pancreatic cancer is still not clear." | 1.40 | Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs. ( Bläuer, M; Hashimoto, D; Hirota, M; Ikonen, NH; Laukkarinen, J; Sand, J, 2014) |
| "A metastatic pancreatic cancer was diagnosed in a 60-year-old patient with a performance status of 0." | 1.40 | Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. ( Colussi, O; Landi, B; Lepère, C; Pernot, S; Portal, A; Rougier, P; Siauve, N; Taieb, J; Verrière, B; Zaanan, A, 2014) |
| "Borderline resectable pancreatic cancer is best treated by multimodality therapy." | 1.40 | Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? ( Christians, KK; Erickson, B; Evans, DB; George, B; Kelly, T; Mahmoud, A; Ritch, P; Thomas, JP; Tsai, S; Wang, H; Wiebe, L, 2014) |
| "In the field of treatment of pancreatic cancer, there has been significant progress lately." | 1.40 | FOLFIRINOX: from the ACCORD study to 2014. ( Oikonomopoulos, GM; Saif, MW; Skoura, E; Syrigos, KN, 2014) |
| "Treatment for advanced pancreatic cancer is still very unsatisfactory." | 1.40 | Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines. ( Ayuk, F; Bokemeyer, C; Brammer, I; Kröger, N; Mina, S; Nitsch, E; Pace, A; Schuch, G; Zander, A, 2014) |
| "Worldwide, pancreatic cancer (PC) ranks 13th in cancer incidence, but eighth as a cause of cancer death." | 1.40 | Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer. ( Kræmer, PC; Ladekarl, M; Schmidt, HH, 2014) |
| "They were divided into locally advanced pancreatic cancer (LAPC) and metastatic pancreatic cancer (MPC)." | 1.40 | Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea. ( Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY, 2014) |
| "Pancreatic cancer is a lethal disease and its prognosis remains dismal." | 1.40 | First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward. ( Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN, 2014) |
| "Twenty-five percent of patients with pancreatic cancer present with locally advanced disease that is unresectable, and the treatment strategy for these patients is controversial, with options including chemotherapy alone, concurrent chemoradiation, or induction chemotherapy followed by chemoradiation." | 1.40 | Locally advanced unresectable pancreatic cancer. ( Chang, BW; Johung, KL; Saif, MW, 2014) |
| "The human pancreatic cancer cell line MIA PaCa-2 was treated with three different concentrations of Res." | 1.40 | Effect of resveratrol on proliferation and apoptosis of human pancreatic cancer MIA PaCa-2 cells may involve inhibition of the Hedgehog signaling pathway. ( Dang, X; Li, W; Ma, Q; Ma, Z; Qin, Y, 2014) |
| "Genistein is a soy-derived isoflavone with pleiotropic biological effects that can enhance the antitumor effect of chemotherapeutic agents." | 1.40 | Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells. ( Fleming, JB; Kang, Y; Li, X; Roife, D; Suzuki, R; Zhang, R, 2014) |
| "We report a patient with pancreatic cancer who developed gastrointestinal bleeding secondary to radiation recall gastritis related to erlotinib exposure." | 1.40 | Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer. ( Graziani, C; Hegde, S; Saif, MW, 2014) |
| "If surgical resection of pancreatic cancer initially diagnosed as unresectable can be carried out in patients responding favorably to TPPAE-HSAIC, the likelihood of long-term survival might be increased." | 1.40 | Clinical Significance of Adjuvant Surgical Resection for Initially Unresectable Pancreatic Cancer Responsive to Arterial Infusion Chemotherapy. ( Akiyama, T; Doi, T; Hirano, S; Hirata, K; Homma, H; Kogawa, K; Mezawa, S; Morii, K; Ohi, M; Takahashi, M; Takeuchi, M; Tanaka, S, 2014) |
| "Borderline resectable pancreatic cancer remains an area that requires multi-disciplinary approach." | 1.39 | Advancements in the management of pancreatic cancer: 2013. ( Saif, MW, 2013) |
| "Unresectable locally advanced pancreatic cancer (LAPC) has an extremely poor prognosis." | 1.39 | Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy. ( Einsele, H; Germer, CT; Hartlapp, I; Isbert, C; Kenn, W; Kunzmann, V; Müller, J; Scheurlen, M; Steger, U, 2013) |
| "Pancreatic cancer is the fourth most common cause of cancer-related mortality." | 1.39 | Pancreatic tumor mass in a xenograft mouse model is decreased by treatment with therapeutic stem cells following introduction of therapeutic genes. ( Choi, KC; Kim, DJ; Kim, SU; Lee, HR; Yi, BR, 2013) |
| "Capecitabine (CAP) is a 5-FU pro-drug approved for the treatment of several cancers and it is used in combination with gemcitabine (GEM) in the treatment of patients with pancreatic adenocarcinoma (PDAC)." | 1.39 | Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. ( Bapiro, TE; Bramhall, JL; Cook, N; Courtin, A; Jodrell, DI; Krippendorff, BF; Neesse, A; Richards, FM; Tuveson, DA, 2013) |
| "About a third of all pancreatic cancer is found to be locally advanced at the time of diagnosis, where the tumor is inoperable but remains localized to the pancreas and regional lymphatics." | 1.39 | Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. ( Huber, KE; Saif, MW; Savir, G, 2013) |
| "Pretreatment of BxPC-3 human pancreatic cancer cells with low concentrations of Api or Lut effectively aid in the anti-proliferative activity of chemotherapeutic drugs." | 1.39 | Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro. ( Gonzalez de Mejia, E; Johnson, JL, 2013) |
| "Traditional post-surgical chemotherapy for pancreatic cancer is notorious for its devastating side effects due to the high dosage required." | 1.39 | Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery. ( Chen, H; Deng, X; Jin, J; Li, H; Peng, C; Shen, B; Zhan, Q; Zhang, X, 2013) |
| "Current therapy for pancreatic cancer is multimodal, involving surgery and chemotherapy." | 1.39 | A spheroid-based 3-D culture model for pancreatic cancer drug testing, using the acid phosphatase assay. ( Hu, Y; Liao, Q; Wen, Z; You, L; Zhao, Y; Zhou, L, 2013) |
| "Synchronous gastric and pancreatic cancers represent a very rare association." | 1.39 | Double pancreatic and gastric adenocarcinomas: a rare association. ( Cuenod, CA; Dubreuil, O; Fabre, M; Kourie, HR; Landi, B; Markoutsaki, N; Palazzo, L; Rahmi, G; Rougier, P; Roussel, H; Taieb, J; Van der Stiegel, M, 2013) |
| "Necrolytic migratory erythema is an obligatory paraneoplastic syndrome." | 1.39 | Necrolytic migratory erythema in a patient with neuroendocrine carcinoma. ( Enk, AH; Gronau, M; Hassel, JC; Jäger, D, 2013) |
| "Exposure of colon and pancreatic cancer cells to 5-FU, CPT-11 or MTX in vitro significantly antagonizes both HSV-1 replication and lytic oncolysis." | 1.39 | Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis. ( Choi, EW; Cusack, JC; Donahue, JM; Fuchs, BC; Kasuya, H; Kawasaki, H; Kulu, Y; Kuruppu, DK; Tanabe, KK, 2013) |
| "Patients with resected pancreatic cancer (PC) have a poor prognosis." | 1.38 | Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience. ( Gill, S; Kim, C; Owen, D, 2012) |
| "One of the hallmarks of pancreatic cancer is its inherent insensitivity to chemotherapy." | 1.38 | Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer. ( Bu, HJ; Chen, Y; Liu, QH; Ni, CY; Yu, DH; Zhang, J; Zhao, CY; Zhu, MH, 2012) |
| "Patients with locally unresectable pancreatic cancer (AJCC stage III) have a median survival of 10-14 months." | 1.38 | Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. ( Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH, 2012) |
| "Mouse and human pancreatic cancer cells, irradiated in vitro by alpha particles with or without chemotherapy, were evaluated for cell growth inhibition." | 1.38 | Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224radium-loaded wires releasing alpha-emitting atoms. ( Arazi, L; Bittan, H; Cooks, T; Efrati, M; Horev-Drori, G; Keisari, Y; Kelson, I; Lazarov, E; Schmidt, M, 2012) |
| "Survival for patients with pancreatic cancer remains poor." | 1.38 | Intensity-modulated radiotherapy for pancreatic adenocarcinoma. ( Abelson, JA; Chang, DT; Chung, M; Fisher, GA; Ford, JM; Koong, AC; Kunz, P; Minn, AY; Murphy, JD; Norton, JA; Poultsides, GA; Visser, BC, 2012) |
| "Melatonin has antitumor activity via several mechanisms including its antiproliferative and proapoptotic effects in addition to its potent antioxidant action." | 1.38 | Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells. ( Bejarano, I; Cig, B; Espino, J; Naziroglu, M; Pariente, JA; Rodríguez, AB; Uguz, AC, 2012) |
| "In our cohort of patients with resected pancreatic cancer, Gem chemotherapy did not improve OS after chemoradiotherapy." | 1.38 | Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine. ( Baschnagel, A; Jury, R; Margolis, J; Nadeau, L; Robertson, JM; Shah, C; Stein, J, 2012) |
| "Pancreatic cancer has the poorest prognosis of all gastrointestinal cancers, driving the need for new therapeutic approaches." | 1.38 | 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I. ( Büchler, MW; Jäger, D; Khallouf, H; Märten, A; Schmidt, J; Serba, S; Teichgräber, V, 2012) |
| "The vast majority of patients with pancreatic cancer present with locally advanced unresectable or metastatic disease, and in this setting only a palliative treatment can be offered." | 1.38 | Conventional chemotherapy of advanced pancreatic cancer. ( Colucci, G; Di Maio, M; Giuliani, F; Perrone, F, 2012) |
| "Cyclopamine treatment under hypoxia significantly decreased chemosensitivity to 5-FU and gemcitabine under hypoxia in both in vitro and in vivo models." | 1.38 | Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer. ( Iwasaki, H; Kai, M; Katano, M; Morifuji, Y; Onishi, H; Suyama, K, 2012) |
| "Pancreatic cancer is one of the most malignant tumors with high mortality and poor prognosis even with the aggressive conventional therapies." | 1.38 | A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA. ( Chen, Y; Liang, X; Lin, C; Luan, Q; Ma, F; Meng, X; Pei, W; Qian, H; Wang, H; Zhan, Q; Zhang, X; Zhao, P; Zhao, Z; Zhou, S, 2012) |
| "Pancreatic cancer has a dismal prognosis." | 1.38 | Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer. ( Dicheva, BM; Eggermont, AM; Hop, WC; Koning, GA; Seynhaeve, AL; Ten Hagen, TL; van Dekken, H; van der Zee, JA; van Eijck, CH, 2012) |
| "Human pancreatic cancer cells Panc-1, Mia-paca2, Bxpc-3 and SW1990, infected with lentivirus, were analyzed by real-time polymerase chain reaction (PCR)." | 1.38 | Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion. ( Jiang, C; Li, YX; Shen, H; Yi, XP, 2012) |
| "Unresectable pancreatic cancer (UPC) has low survival." | 1.38 | Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. ( Golden, DW; Liauw, SL; Minsky, BD; Novak, CJ, 2012) |
| "Panc-1 pancreatic cancer cells were incubated in the presence of 5-fluorouracil (5-FU) for 24 h, and further incubated without 5-FU for 28 days." | 1.38 | Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells. ( Adachi, M; Funakoshi, S; Hamamoto, Y; Hibi, T; Higuchi, H; Igarashi, T; Iizuka, H; Izumiya, M; Kabashima, A; Nakamura, S; Sakai, G; Takaishi, H, 2012) |
| " Recently, fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) demonstrated their superiority in first-line therapy." | 1.38 | Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. ( Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V, 2012) |
| "The lapatinib-treated cells showed a dose-dependent inhibition of cell proliferation and induction of apoptosis at the same concentrations that blocked ErbB1/ErbB2 phosphorylation." | 1.38 | Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer. ( Drebin, JA; Pippin, JA; Singla, S, 2012) |
| "The standard treatment for metastatic pancreatic cancer is chemotherapy." | 1.38 | [Resection of the remnant pancreas for recurrent pancreatic cancer after distal pancreatectomy-a case report]. ( Akahori, T; Hokutoh, D; Kinoshita, S; Nakajima, Y; Nomi, T; Sho, M; Yamato, I; Yasuda, S, 2012) |
| "Several factors may influence pancreatic cancer resistance, and expression of ATP-binding cassette transport proteins is one of the major mechanisms of drug resistance." | 1.37 | Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. ( Grube, M; Guitton, J; Hübner, T; Jedlitschky, G; Köck, K; Kowalczyk, DW; Kroemer, HK; Lerch, MM; Mayerle, J; Mews, S; Nambaru, PK; Payen, L; Rimmbach, C; Ritter, CA; Rosskopf, D; Sendler, M; Weiss, FU, 2011) |
| "Temozolomide is an active agent in metastatic pancreatic endocrine carcinomas." | 1.37 | First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. ( Chen, DT; Choi, J; Coppola, D; Fine, RL; Helm, J; Kvols, L; Nasir, A; Strosberg, JR, 2011) |
| "Evasion of apoptosis is a hallmark of pancreatic cancer." | 1.37 | Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. ( Bachem, MG; Debatin, KM; Fulda, S; Haag, C; Möller, P; Stadel, D; Zhou, S, 2011) |
| "Even after curative resection of pancreatic cancer, there is a high probability of systemic recurrence." | 1.37 | Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer. ( Baba, H; Beppu, T; Hirota, M; Ikeda, O; Kanemitsu, K; Oya, N; Takamori, H; Tanaka, H; Yamashita, Y, 2011) |
| "Chemotherapy of pancreatic cancer often fails due to the development of intrinsic and acquired resistance during drug treatment." | 1.37 | Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. ( Li, Y; Paxton, JW; Reid, G; Revalde, JL, 2011) |
| "Of the 58 patients with distant metastasis, DM6m had developed in 27 (46." | 1.37 | CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. ( Han, SS; Hong, EK; Kim, DY; Kim, SH; Kim, TH; Lee, WJ; Moon, SH; Park, JW; Park, SJ; Woo, SM; Yoo, T, 2011) |
| "When capecitabine and melatonin were combined, a well-differentiated pancreatic adenocarcinoma was observed in 10% of animals." | 1.37 | Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer. ( Arjona, A; Montilla, P; Muntané, J; Padillo, J; Perea, D; Ruiz-Rabelo, J; Túnez, I; Vázquez, R, 2011) |
| " We determined the anticancer effects of VPA combined with 5-FU in these cell lines." | 1.37 | Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. ( Hanaoka, J; Ikemoto, T; Imura, S; Ishibashi, H; Iwahashi, S; Mori, H; Morine, Y; Ochir, TL; Shimada, M; Utsunomiya, T, 2011) |
| "We found no correlation between pancreatic cancer cell sensitivity to either GEM- or 5-FU." | 1.37 | Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. ( Fujita, H; Kurata, N; Mahawithitwong, P; Manabe, T; Mizumoto, K; Ohtsuka, T; Ohuchida, K; Onimaru, M; Sakai, H; Tanaka, M, 2011) |
| "Omeprazole has recently been described as a modulator of tumour chemoresistance, although its underlying molecular mechanisms remain controversial." | 1.37 | Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. ( Ellinger, S; Henne-Bruns, D; Klapperstueck, T; Knippschild, U; Kreyes, A; Landfester, K; Udelnow, A; Walther, P; Wohlrab, J; Würl, P, 2011) |
| "SIRT1 was overexpressed in pancreatic cancer tissues at both the mRNA and protein levels, with increased SIRT1 positivity associated with tumors from patients over 60 years old, tumors larger than 4 cm, higher TNM (extent of tumor (T), the extent of spread to lymph nodes (N), and presence of distant metastasis (M)) stage or the presence of lymph node or hepatic metastases." | 1.37 | SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. ( Chen, Q; Cui, J; Deng, SC; Liu, L; Liu, Y; Qin, Q; Tian, K; Wang, B; Wang, CY; Wang, GB; Yin, T; Zhang, JG; Zhao, G, 2011) |
| "Thrombocytopenia was the most frequently observed grade 4 toxicity in both groups (11% after FM versus 12% after GC)." | 1.37 | Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients. ( Brunner, TB; Fietkau, R; Sauer, R, 2011) |
| "The PL45 pancreatic cancer cell line was incubated with 20 µmol/L 5-Fu for 12 and 24 hours to induce apoptosis, and the expression patterns of CA19-9 and CK8/18 were measured, and the extent of apoptosis was evaluated." | 1.37 | Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy. ( Han, C; He, P; Ren, C; Wang, B; Wang, D; Zhang, J; Zhao, P; Zhao, X, 2011) |
| " In combination with gemcitabine, median survival was further prolonged." | 1.37 | An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. ( Bhattacharyya, M; Eddouadi, A; Francis, J; Halldén, G; Lemoine, NR, 2011) |
| "Gemcitabine alone was given to 60 (38%) patients, and gemcitabine with high-dose infusional fluorouracil (5-FU) with (n = 25) or without (n = 39) oxaliplatin was given to 64 (40%) patients." | 1.37 | Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials. ( Cheng, AL; Hsu, C; Hsu, CH; Kuo, SH; Kuo, YH; Tien, YW; Yang, SH, 2011) |
| "In two patients with locally invasive pancreatic cancer, the pancreatic blood supply was altered under angiographic guidance, and an intra-arterial catheter with a subcutaneous port was left in place for the administration of 5-fluorouracil (5-FU) 1,000 mg/m(2)." | 1.37 | Intra-arterial chemoinfusion prior to chemoradiotherapy with full-dose systemic gemcitabine for management of locally advanced pancreatic cancer. ( Anai, H; Hasegawa, M; Kichikawa, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T, 2011) |
| "Malignant glucagonoma is an exceptional pancreatic endocrine tumour, with frequent dermatologic symptoms, diabetes and degradation of the general health status." | 1.36 | [Dramatic efficacy of chemotherapy with 5-fluorouracil and dacarbazine in a patient with metastatic glucagonoma and cardiac insufficiency]. ( de Mestier, L; Dove, P; Hammel, P; Hentic, O; Lévy, P; Ruszniewski, P, 2010) |
| "Gemcitabine was the most frequently used drug, followed by 5-fluorouracil." | 1.36 | Patterns of radiotherapy practice for pancreatic cancer in Japan: results of the Japanese Radiation Oncology Study Group (JROSG) survey. ( Ito, Y; Karasawa, K; Kazumoto, T; Nemoto, K; Nishimura, Y; Nishino, S; Ogawa, K; Ogawa, Y; Ogo, E; Okuno, Y; Onishi, H; Shibuya, H; Shibuya, K; Uchida, N, 2010) |
| "The treatment of locally advanced pancreatic cancer varies enormously both within the UK and internationally." | 1.36 | Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment. ( Brewster, AE; Crosby, TD; Hudson, E; Hurt, C; Iqbal, N; Joseph, G; Mort, D; Mukherjee, S, 2010) |
| "Patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy are still in relatively good clinical conditions and may still require second-line chemotherapy, which is frequently administered in daily clinical practice given to without solid scientific support." | 1.36 | Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. ( Arcara, C; Borsellino, N; Colucci, G; Gebbia, V; Giuliani, F; Maiello, E, 2010) |
| "Borderline resectable pancreatic cancer is an emerging stage of disease defined by computed tomogrpahy criteria, patient (Katz type B), or disease characteristics (Katz type C)." | 1.36 | Management of borderline resectable pancreatic cancer. ( Christians, K; Evans, DB; Lal, A, 2010) |
| "Adjuvant therapy for pancreatic cancer remains a controversial topic, with a paucity of randomized controlled trials in this area and various limitations in the trials that have been conducted to date, leaving many questions as to a true "standard of care" for patients with resectable or potentially resectable disease." | 1.36 | Update on adjuvant trials for pancreatic cancer. ( Backlund, DC; Berlin, JD; Parikh, AA, 2010) |
| "The maximum concentration (Cmax), the area under the curve from the drug administration to the infinite time (AUCinf), and the elimination half-life (T1/2) of GEM were not significantly different between GEM administration with and without S-1." | 1.36 | Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer. ( Amano, R; Hirakawa, K; Hirakawa, T; Nakao, S; Nakata, B; Okita, Y; Shinto, O; Tamura, T; Yamada, N, 2010) |
| "We retrospectively assessed the benefits of 5-fluorouracil (5-FU)- and heparin-based portal infusion chemotherapy combined with systemic administration of mitomycin C (MMC) and cisplatin (CDDP) for 4 weeks following surgery (PI4W)." | 1.36 | Beneficial effects of 5-Fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative resection of pancreatic cancer. ( Aiura, K; Kitagawa, Y; Matsui, J; Takahashi, S; Ueda, M, 2010) |
| "The high risk of recurrence following surgical resection provides the rationale for adjuvant therapy." | 1.36 | Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. ( Del Chiaro, M; Funel, N; Giaccone, G; Giovannetti, E; Hwang, JH; Kang, GH; Kim, MA; Kim, SW; Kim, YT; Leon, LG; Park, JK; Peters, GJ; Steinberg, SM; Voortman, J, 2010) |
| "Patients with locally advanced pancreatic cancer (LAPC) are most commonly managed with chemotherapy or concurrent chemoradiotherapy (CRT), which may or may not include non-involved regional lymph nodes in the clinical target volume." | 1.36 | Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer. ( Dickinson, C; Green, MM; Jackson, AS; Jain, P; Price, PM; Saleem, A; Taylor, MB; Valle, J; Watkins, GR; Whitfield, GA, 2010) |
| "Two patients with advanced gastric cancer and metastatic pancreatic cancer who received 5-fluorouracil-based chemotherapy presented with acute mental change and hyperammonemia." | 1.36 | Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity. ( Kim, SR; Lee, J; Lee, SY; Park, CH; Park, JO; Park, S, 2010) |
| "Three pancreatic cancer cell lines (SW1990, ASPC-1 and PCT-3) were cultured in three-dimensional collagen gels as well as in traditional two-dimensional monolayers." | 1.36 | Assessment of pancreatic carcinoma cell chemosensitivity using a three-dimensional culture system. ( Hu, Y; Liao, Q; Zhang, Q; Zhao, YP; Zhou, T, 2010) |
| "Localized pancreatic cancer is a systemic disease that requires nonoperative therapies to minimize the local and systemic recurrences that almost invariably occur in the absence of such therapy, even following complete surgical resection." | 1.36 | Current status of adjuvant therapy for pancreatic cancer. ( Fleming, JB; Katz, MH; Lee, JE; Pisters, PW, 2010) |
| "Pancreatic cancer is a major health problem because of its aggressiveness and the lack of effective systemic therapies." | 1.36 | Effects of capecitabine and celecoxib in experimental pancreatic cancer. ( Arjona-Sánchez, A; Cruz, A; Muñoz, Mdel C; Muntané, J; Padillo, FJ; Perea, MD; Ruiz-Rabelo, J; Túnez, I; Vázquez, R, 2010) |
| "Most chemotherapeutic regimens for pancreatic cancer (PC) use combination therapy." | 1.36 | Additive growth inhibition after combined treatment of 2-methoxyestradiol and conventional chemotherapeutic agents in human pancreatic cancer cells. ( Baumunk, D; Fotopoulou, C; Schmidt, SC; Schumacher, G, 2010) |
| " Using the indwelling catheter-port system with the unification of the pancreatic blood supply, we initially conducted an arterial infusion of weekly high-dose 5-FU (1,000 mg/m2/qw) combined with systemic gemcitabine (1,000 mg/m2/qw)." | 1.36 | [Locally advanced pancreatic cancer successfully treated by arterial infusion chemotherapy combined with stereotactic radiotherapy--a case report]. ( Anai, H; Hasegawa, M; Kichikawa, K; Maeda, S; Masada, T; Morimoto, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T; Yamamoto, K, 2010) |
| "Human pancreatic cancer cells such as PANC-1 are known to exhibit marked tolerance to nutrition starvation that enables them to survive for prolonged period of time even under extremely nutrient-deprived conditions." | 1.35 | Constituents of Brazilian red propolis and their preferential cytotoxic activity against human pancreatic PANC-1 cancer cell line in nutrient-deprived condition. ( Awale, S; Esumi, H; Kadota, S; Li, F; Onozuka, H; Tezuka, Y, 2008) |
| "Gemcitabine is a pyrimidine antimetabolite with activity in a number of cancers." | 1.35 | Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. ( Cornfeld, D; Lansigan, F; Saif, MW; Shaib, W; Syrigos, K, 2008) |
| "We report a patient with pancreatic cancer, challenged with maintaining the international normalized ratio (INR) with gemcitabine-capecitabine combination, and later with gemcitabine monotherapy with concomitant warfarin, as well as, a brief review of the literature." | 1.35 | Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer. ( Saif, MW; Wasif, N, 2008) |
| "Patients with locally advanced pancreatic cancer were treated with concurrent radiation therapy (1." | 1.35 | Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer. ( Boku, N; Fukutomi, A; Hashimoto, T; Hironaka, S; Nishimura, T; Onozawa, Y; Taira, K; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2008) |
| "Current treatments for pancreatic cancer have failed to effectively manage the disease, and hence, more effective treatment approaches are urgently needed." | 1.35 | Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours. ( Campbell, RB; Kalra, AV, 2009) |
| "Pancreatic cancer is characterized by high resistance to chemotherapy." | 1.35 | ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. ( Faissner, R; Guo, C; Hagmann, W; Jesnowski, R; Löhr, JM, 2009) |
| "Pancreatic cancer is the fourth most common cause of cancer related death in Western countries." | 1.35 | A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer. ( Büchler, P; Endlicher, E; Geissler, M; Gregor, M; Harder, J; Heinemann, V; Hofheinz, R; Kanzler, S; Klöppel, G; Mihaljevic, A; Schmiegel, W; Seufferlein, T, 2009) |
| "Sixty-eight consecutive patients with pancreatic cancer who underwent pancreatic resection were included." | 1.35 | Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. ( Kitade, H; Kwon, AH; Matsui, Y; Mergental, H; Satoi, S; Takahashi, K; Takai, S; Tanigawa, N; Toyokawa, H; Yanagimoto, H, 2009) |
| "5-fluorouracil (5-FU) is an antimetabolite that acts during the S phase of the cell cycle." | 1.35 | Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene. ( Harold, L; Rajebi, MR; Saif, MW; Shahrokni, A, 2009) |
| "Twenty-nine patients with pancreatic cancer (PC) and 43 with biliary tract cancer (BTC; 27 cases of bile duct cancer, 8 of gallbladder cancer and 8 of cancer of the papillary area) were included." | 1.35 | Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers. ( Kubota, K; Sawada, T; Shimoda, M, 2009) |
| "Majority of the patients with pancreatic cancer present with advanced disease that is lethal and notoriously difficult to treat." | 1.35 | Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. ( Li, J; Saif, MW, 2009) |
| "When sirolimus was added to this regimen at a dosage to achieve a serum level of at least 10 ng/dL at the time of the gemcitabine and docetaxel infusion, their tumors regressed." | 1.35 | Sirolimus can reverse resistance to gemcitabine, capecitabine and docetaxel combination therapy in pancreatic cancer. ( Sherman, WH, 2009) |
| "Treatment of MIA PaCa-2 human pancreatic cancer cells with test compounds showed time- and concentration-dependent cytotoxicity with IC50 values in the micromolar range." | 1.35 | Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells. ( Banti, I; Breschi, MC; Fogli, S; Lapucci, A; Nencetti, S; Orlandini, E, 2009) |
| "All 35 patients had metastatic pancreatic cancer (94% liver, 6% lung sites)." | 1.35 | The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. ( Andrade, R; Chabot, J; Desai, M; Fine, RL; Fogelman, DR; Guba, S; Schreibman, SM; Sherman, W; Strauss, J, 2008) |
| "We found that all pancreatic cancer cell lines were highly resistant to the cytotoxic effects of TNF and that scFv23/TNF was highly cytotoxic to TNF-resistant HER-2/neu-expressing pancreatic cancer cell lines at levels rivaling that of conventional chemotherapeutic agents." | 1.35 | The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. ( Kurzrock, R; Lyu, MA; Rosenblum, MG, 2008) |
| " Here, it was tried to evaluate the antiangiogenic effect of IFN-alpha in combination with chemotherapy." | 1.35 | Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma. ( Büchler, MW; Hackert, T; Jäger, D; Märten, A; Ryschich, E; Schmidt, J; Tibensky, I; Zhu, Y, 2008) |
| "Treatment with the combination of (177)Lu-octreotate and capecitabine was feasible and safe considering acute and subacute side effects." | 1.35 | Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. ( de Herder, WW; Kam, BL; Krenning, EP; Kwekkeboom, DJ; van Aken, MO; van Essen, M, 2008) |
| "Syndrome of DPD deficiency manifests as diarrhea, stomatitis, mucositis, and neurotoxicity and in some cases death." | 1.34 | DPYD*2A mutation: the most common mutation associated with DPD deficiency. ( Diasio, RB; Ezzeldin, H; Saif, MW; Sellers, S; Vance, K, 2007) |
| "To discover how pancreatic cancer cells adapt to glucose deprivation as well as hypoxia, we sought glucose deprivation-inducible genes by means of a DNA microarray system." | 1.34 | Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. ( Asaka, M; Cui, H; Darmanin, S; Hamuro, J; Higashino, F; Kobayashi, M; Koide, H; Kondo, T; Nakagawa, K; Natsuisaka, M; Okada, F; Shindoh, M, 2007) |
| "The combined treatment of the pancreatic cancer cells with L1BR1 and these anticancer drugs enhanced apoptosis significantly." | 1.34 | Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. ( Fujii, T; Goshima, F; Kanazumi, N; Kasuya, H; Nakao, A; Nishiyama, Y; Nomoto, S; Nomura, N; Shikano, T; Takeda, S; Watanabe, I, 2007) |
| "Sulfasalazine may enhance the inhibitory proliferation and apoptosis effect on BxPC-3 cells induced by 5-FU, which is closely related to synergistically the cell cycle arrested in G0/G1-phase." | 1.34 | Effects of 5-fluouracil combined with sulfasalazine on human pancreatic carcinoma cell line BxPC-3 proliferation and apoptosis in vitro. ( Guo, KJ; Guo, RX; He, SG; Huang, Z, 2007) |
| "Endoscopic findings showed Type 3 gastric cancer with pyloric stenosis." | 1.34 | [A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil]. ( Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E, 2007) |
| " Thus,we devised a new intermittent dosage regimen utilizing the cell cycle difference of normal GI tract, bone marrow cell and pancreatic cancer cell, making use of 5-FU (-->S-1), CDDP and paclitaxel in March 2002." | 1.34 | [The first report from Sapporo Tsukisamu Hospital--chemotherapy and chemoradiotherapy for patients with advanced pancreatic cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Koito, K; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007) |
| " The authors administered arterial infusion of 5-fluorouracil (5-FU) combined with concurrent radiation therapy to enhance the antitumor effect of chemotherapy." | 1.34 | Arterial infusion of 5-fluorouracil combined with concurrent radiotherapy for unresectable pancreatic cancer: results from a pilot study. ( Anai, H; Kichikawa, K; Morimoto, K; Sakaguchi, H; Tamamoto, T; Tanaka, T; Yamamoto, K, 2007) |
| "Advanced pancreatic cancer has a poor prognosis." | 1.34 | [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer]. ( Di, LJ; Gong, JF; Jin, ML; Li, J; Shen, L; Zhang, XD, 2007) |
| "Human pancreatic cancer cells revealed high and relatively moderate MUC1 levels for Capan-1 and HPAF-II, respectively, compared to MUC1 negative control (U-87 MG glioblastoma) that showed relatively non-specific anti-MUC1 uptake." | 1.34 | Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. ( Campbell, RB; Kalra, AV, 2007) |
| "Treatment with capecitabine and erlotinib in gemcitabine-refractory patients was associated with an overall objective radiologic response rate of 10% and a median survival duration of 6." | 1.34 | Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. ( Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX, 2007) |
| "Nonfunctioning islet cell tumor of the pancreas is frequently found in young female." | 1.34 | [Management of nonfunctioning islet cell tumors of the pancreas]. ( Ding, XW; Hao, XS; Liang, H; Pan, Y; Wang, BG; Wang, XN, 2007) |
| "Capecitabine has shown efficacy in treatment of metastatic pancreatic cancer." | 1.34 | Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation? ( Diasio, R; Johnson, M; Kang, SP; Ledbetter, L; Saif, MW; Steg, A, 2007) |
| "For inoperable pancreatic cancer, the goals of treatment are to palliate symptoms and prolong life." | 1.34 | Inoperable pancreatic cancer: standard of care. ( Benson, AB; Small, W; Wahl, AO; Wisinski, KB, 2007) |
| "In our cohort of patients with advanced pancreatic cancer treated with second-line chemotherapy, TTP1 <6 months is a strong negative prognostic factor for TTP2 and residual survival." | 1.34 | Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer. ( Abel, U; Herrmann, C; Herrmann, T; Jaeger, D; Stremmel, W, 2007) |
| "Treatment of pancreatic cancer cells with 5-FU induced Caspase-dependent processing of pro-IL18 leading to the secretion of biologically active IL-18." | 1.33 | Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response. ( Addeo, A; Bellone, G; Bertetto, O; Carbone, A; Emanuelli, G; Gaspari, F; Mauri, FA; Novarino, A; Prati, A; Robecchi, A; Rodeck, U; Smirne, C; Sozzi, M, 2005) |
| "Here, in 38 patients with pancreatic cancer we analyzed immunohistochemical TP expression in pancreatic cancer tissue (PCT) and adjacent nonmalignant pancreatic tissue (ANMPT)." | 1.33 | Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages. ( Catalano, V; Jirillo, E; Mazzone, F; Passantino, L; Patruno, R; Pellecchia, A; Penna, A; Ranieri, G; Valerio, P; Zito, AF, 2005) |
| "With these fluorescent tools, tumors and metastasis in host organs can be externally imaged down to the single-cell level." | 1.33 | Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. ( Hoffman, RM, 2005) |
| "Treatment of locally advanced pancreatic cancer with high-dose radiotherapy has not been curative, and can be difficult to tolerate." | 1.33 | Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. ( Abbruzzese, JL; Crane, CH; Delclos, ME; Evans, DB; Ho, L; Tamm, EP; Wolff, RA; Wong, AA; Xiong, HQ, 2005) |
| "Data on 262 patients with advanced pancreatic cancer treated from 1987 to 2003 were analyzed retrospectively." | 1.33 | Impact of different treatment methods on survival in advanced pancreatic cancer. ( Barauskas, G; Brasiūniene, B; Juozaityte, E, 2005) |
| "Neuropilin-1 is expressed in pancreatic cancer, but not in nonmalignant pancreatic tissue." | 1.33 | Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. ( Belcheva, A; Ellis, LM; Evans, DB; Fan, F; Gallick, GE; Gray, MJ; Klagsbrun, M; Liu, W; McCarty, MF; Somcio, R; Stoeltzing, O; Wey, JS, 2005) |
| "The outcome after resection of advanced pancreatic cancers is extremely poor because of the high incidence of the postoperative development of liver metastasis and local recurrence." | 1.33 | Feasibility and efficacy of combination therapy with preoperative and postoperative chemoradiation, extended pancreatectomy, and postoperative liver perfusion chemotherapy for locally advanced cancers of the pancreatic head. ( Doki, Y; Eguchi, H; Imaoka, S; Ishikawa, O; Kasugai, T; Miyashiro, I; Murata, K; Nishiyama, K; Noura, S; Ohigashi, H; Sasaki, Y; Takachi, K; Yamada, T, 2005) |
| "The actual cost of pancreatic cancer treatment was surveyed especially with respect to the difference after April 2001, which was the date that gemcitabine was introduced in Japan." | 1.33 | Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine. ( Furuse, J; Gotohda, N; Ishii, H; Kinoshita, T; Konishi, M; Nakachi, K; Nakagohri, T; Suzuki, E; Takahashi, S; Yoshino, M, 2005) |
| "The use of chemoradiotherapy for pancreatic cancer has been advocated for its potential ability to downstage locally advanced tumors." | 1.33 | Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. ( Adhoute, X; Béllannée, G; Brunet, R; Collet, D; Laurent, C; Masson, B; Rault, A; Sa Cunha, A; Vendrely, V, 2005) |
| "Hepatocellular carcinoma (HCC) and pancreatic cancer are at the forefront of chemotherapy-resistant tumors with poor prognosis." | 1.33 | 5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. ( Imazeki, F; Kanda, T; Nagao, K; Saisho, H; Tada, M; Yokosuka, O, 2005) |
| "Resiniferatoxin induced apoptosis in pancreatic cancer cells indicates that vanilloids may be useful in the treatment of human pancreatic cancer." | 1.33 | Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. ( Büchler, MW; di Mola, FF; Di Sebastiano, P; Felix, K; Friess, H; Giese, NA; Hartel, M; Hinz, U; Mascetta, G; Selvaggi, F; Wente, MN, 2006) |
| "Two retrovirally complemented pancreatic cancer cell lines having defects in the Fanconi anemia pathway, PL11 (FANCC-mutated) and Hs766T (FANCG-mutated), as well as several parental pancreatic cancer cell lines with or without mutations in the Fanconi anemia/BRCA2 pathway, were assayed for in vitro and in vivo sensitivities to various chemotherapeutic agents." | 1.33 | In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. ( Brody, JR; Cunningham, SC; DeMarzo, AM; Dezentje, DA; Gallmeier, E; Hruban, RH; Isacoff, WH; Kern, SE; Offerhaus, GJ; Swartz, MJ; van der Heijden, MS, 2005) |
| "Pancreatic cancer is the fifth leading cause of cancer-related death worldwide." | 1.33 | Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer. ( Incrocci, L; Jeekel, J; Kazemier, G; Smeenk, HG; Tran, KT; van Dekken, H; van Eijck, CH, 2005) |
| "The human pancreatic cancer cell lines Hs 700T, PANC-1, and MIA PaCa-2 were treated in vitro with NV1066 at multiplicities of infection (MOI; ratio of the number of viral particles per tumor cell) ranging from 0." | 1.33 | 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. ( Adusumilli, PS; Chan, MK; Chou, TC; Eisenberg, DP; Fong, Y; Hendershott, KJ; Mullerad, M; Yu, Z, 2005) |
| "To estimate the risk of venous thrombosis associated with pancreatic malignancies we followed a cohort of patients with pancreatic cancer (n = 202)." | 1.33 | High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. ( Blom, JW; Osanto, S; Rosendaal, FR, 2006) |
| "Celecoxib was initiated in the diet at 100 ppm (equivalent to 20 mg/kg/d p." | 1.33 | Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. ( Blanquicett, C; Buchsbaum, DJ; Carpenter, MD; Chhieng, DC; Diasio, RB; Eloubeidi, M; Johnson, MR; Russo, S; Saif, MW; Sellers, JC; Vickers, SM, 2005) |
| "Eighteen consecutive pancreatic cancer patients presenting with isolated locoregional recurrence after surgical resection." | 1.33 | Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. ( Bruns, C; Dühmke, E; Heinemann, V; Thoma, M; Wilkowski, R, 2006) |
| "Human pancreatic cancer cell lines AsPC-1, BxPC-3, Mia-PaCa 2, and PANC-1 were cultured in media containing varying concentrations of OSU-03012, 5-fluorouracil (5-FU), and gemcitabine, and changes in Akt phosphorylation and cell viability were evaluated using western blotting and a 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay, respectively." | 1.33 | A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. ( Bekaii-Saab, TS; Chen, CS; Li, J; Melvin, WS; Muscarella, P; Zhu, J, 2006) |
| "Human pancreatic cancer cells were cultured alone or in combination with the chemotherapeutic agents 5-FU and gemcitabine." | 1.33 | Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines. ( Danquah, G; Jacobs, MJ; Mittal, VK; Ng, J; ReMine, SG; Saidi, RF; Williams, F, 2006) |
| "Since pancreatic cancer is characterized by an aggressive tumor with a high recurrent rate, postoperative chemotherapy is effective for an improvement of survival." | 1.33 | Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer? ( Hirono, S; Ina, S; Kawai, M; Tani, M; Terasawa, H; Uchiyama, K; Yamaue, H, 2006) |
| "Gemcitabine uptake was significantly increased when cells were treated with 5-FU." | 1.33 | Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model. ( Dono, K; Hayashi, N; Monden, M; Nagano, H; Nakahira, S; Nakamori, S; Okami, J; Sakon, M; Takahashi, Y; Takeda, S; Tsujie, M; Umeshita, K, 2006) |
| "At present, the advanced pancreatic cancer is known to be one of the most resistant malignancies on chemotherapy." | 1.33 | [Long-term repeatable chemotherapy for patients with advanced pancreatic cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasada, T; Yamada, Y; Yamamitsu, S, 2006) |
| " These indications of an antagonistic interaction between GEM and 5-FU in some pancreatic cancer context urge further investigation of both genetic and non-genetic differences to identify the variables most relevant for optimal selection and dosing of treatment for the individual patient." | 1.33 | Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line Capan-2. ( Bellone, G; Bertetto, O; Buffolino, A; Busso, V; Carbone, A; Emanuelli, G; Novarino, A; Scirelli, T; Smirne, C; Tosetti, L, 2006) |
| "Experimentally, we studied a diploid colorectal cancer line heterozygous at TS to mimic three common TS genotypes of cancers." | 1.33 | Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. ( Brody, JR; Gallmeier, E; Hucl, T; Kern, SE; Murphy, KM; Winter, JM, 2006) |
| "Human pancreatic cancer cells HPAF-II and Capan-1, and endothelial cells HMEC-1 and HUVEC were used in this study." | 1.33 | Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting. ( Campbell, RB; Kalra, AV, 2006) |
| "Three drug resistant pancreatic cancer cell sublines induced by fluorouracil (5-FU), adriamycin (ADM) and gemcitabine respectively, SW1990/FU, SW1990/ADM and SW1990/Gz, were tested for the cell cycle and radio-sensitivity with flow cytometry and clonogenic assay." | 1.33 | [A pilot study on the impact of the drug resistance on the radioresistance in human pancreatic cancer cell lines]. ( Chen, G; Guo, JC; Jiang, H; Niu, BZ; Wu, WW; Zhang, LY; Zhao, YP, 2006) |
| "Patients with locally advanced pancreatic cancer who received gemcitabine chemotherapy or 5-FU-based CCRT showed better survival than those who received supportive care only." | 1.33 | Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. ( Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Yoon, WJ; Yoon, YB, 2006) |
| "Although patients with locally advanced pancreatic cancer (LAPC) have an extremely poor prognosis, they are a heterogeneous group." | 1.33 | Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. ( Abbruzzese, JL; Crane, CH; Das, P; Delclos, ME; Evans, DB; Gould, MS; Guha, S; Janjan, NA; Krishnan, S; Palla, S; Rana, V; Varadhachary, G; Wolff, RA, 2006) |
| "As leukopenia was seen after the first cycle, the administration doses were reduced and GTX has been continued for a total 13 cycles." | 1.33 | [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine]. ( Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H, 2006) |
| "The prognosis and QOL of unresectable pancreatic cancer are very poor." | 1.32 | [A case of advanced pancreatic cancer with multiple liver metastasis that improved remarkably with use of low-dose cisplatin and TS-1]. ( Endo, W; Fujito, T; Goda, F; Hojo, S; Maeura, Y; Matsuyama, J; Yamazaki, K; Yano, Y, 2003) |
| "Because of the resistance of pancreatic cancer against radiation and/or chemotherapy surgery is still the only possibility for cure." | 1.32 | [Operative management in the treatment of pancreatic cancer]. ( Büchler, MW; Fischer, L; Friess, H; Uhl, W; Z'graggen, K, 2003) |
| "To evaluate the effectiveness of small-field radiotherapy in combination with concomitant 5-fluorouracil (5FU) or cisplatin for locally advanced pancreatic carcinoma." | 1.32 | Small-field radiotherapy in combination with concomitant chemotherapy for locally advanced pancreatic carcinoma. ( Ikeda, H; Ikeda, M; Kagami, Y; Murayama, S; Okada, S; Okusaka, T; Sumi, M; Tokuuye, K; Ueno, H, 2003) |
| "A human pancreatic cancer cell line PC-3 was transfected with lipofectin-mediated recombinant p14ARF gene, and was then administered with 5-Fu." | 1.32 | p14ARF upregulation of p53 and enhanced effects of 5-fluorouracil in pancreatic cancer. ( Gan, J; Jin, C; Luo, J; Ni, Q; Shen, Z; Zhang, N; Zhang, Q; Zhang, Y, 2003) |
| " Furthermore, he was administered tegafur/uracil (400 mg/day) 5 days weekly as pharmacokinetic modulating chemotherapy (PMC)." | 1.32 | [A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy]. ( Baba, Y; Hayashi, S; Ishikawa, T; Kamimura, T; Nomura, K; Oota, H; Yoshida, T, 2003) |
| "Using a cell selection method, a human pancreatic cancer cell line resistant to gemcitabine was established." | 1.32 | Establishment of gemcitabine-resistant human pancreatic cancer cells and effect of brefeldin-a on the resistant cell line. ( Ito, H; Katoh, A; Kimura, F; Miyazaki, M; Ohtsuka, M; Shimamura, F; Shimizu, H; Togawa, A; Yoshidome, H, 2003) |
| "Pancreatic cancer is one of the most lethal malignant tumors." | 1.32 | Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. ( Adachi, Y; Carbone, DP; Imai, K; Ito, H; Itoh, F; Lee, CT; Min, Y; Nadaf, S; Yamamoto, H, 2003) |
| "It is known that pancreatic cancer is resistant to chemotherapy and that cancer cells are surrounded by extracellular matrix (ECM) proteins including collagen I, collagen IV, fibronectin, and laminin." | 1.32 | Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. ( Miyake, H; Miyamoto, H; Murakami, T; Sugino, H; Tashiro, S; Tsuchida, K, 2004) |
| "Ten patients with unresectable pancreatic cancer were enrolled in this study." | 1.32 | Role of positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer. ( Andoh, H; Asanuma, Y; Furuya, T; Hatazawa, J; Koyama, K; Sato, T; Shibata, S; Shimosegawa, E; Yamamoto, Y; Yoshioka, M, 2004) |
| "We treated various pancreatic cancer cell lines with receptor-selective ligands and cytotoxic agents and monitored the effects on cell proliferation, markers of apoptosis and cell cycle." | 1.32 | Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid. ( Balasubramanian, S; Chandraratna, RA; Eckert, RL, 2004) |
| "Capecitabine was given at 1,600 mg/m(2)/day in two divided doses, 5 days per week, concurrently with radiotherapy." | 1.32 | Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. ( Ben-Josef, E; Bossenberger, T; Burmeister, J; El-Rayes, BF; McDermott, P; Philip, PA; Shields, AF; Vaishampayan, U; Vaitkevicius, V, 2004) |
| "The use of neoadjuvant chemotherapy for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors, especially for patients with Stage IV b (Japan criteria)." | 1.32 | [Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics]. ( Hirano, H; Ikuma, H; Imai, T; Kadowaki, S; Mitsui, Y; Miyashita, K; Murata, T; Nakamura, T; Nobuoka, Y; Tanigawa, K; Taoka, H; Umino, W; Yamashita, M; Yoshimine, S, 2004) |
| "Pancreatic cancer is considered a disease with a poor prognosis even if aggressive resection is performed." | 1.32 | Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer. ( Inoue, S; Kaneko, T; Kawase, Y; Nakao, A; Nakayama, S; Takeda, S, 2004) |
| "Capecitabine (CAP) is a pro-drug of 5-FU and peripheral neuropathy associated with CAP has not been reported." | 1.32 | Peripheral neuropathy associated with capecitabine. ( Diasio, RB; McGee, PJ; Saif, MW; Wood, TE, 2004) |
| "Human pancreatic cancer cell lines Capan-1(p53mut), Capan-2(p53wt), FAMPAC(p53mut), PANC1(p53mut), and rat pancreatic cancer cell lines AS(p53wt) and DSL6A(p53null) were used for in vitro studies." | 1.32 | The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. ( Antolovic, D; Eisold, S; Hinz, U; Klar, E; Linnebacher, M; Ryschich, E; Schmidt, J, 2004) |
| "Advanced pancreatic cancer is mainly treated by chemotherapy with poor prognosis." | 1.32 | [Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer]. ( Chen, YT; Hong, GB; Jiang, RJ; Luo, JH; Xu, LF; Xu, LY; Zhou, JX, 2004) |
| "Drug resistance and toxic side effects are major limiting factors in the clinical use of antineoplastic chemotherapy." | 1.31 | Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2. ( Aulmann, M; Dihlmann, S; Eisold, S; Linnebacher, M; Ridder, R; Ryschich, E; Schlehofer, JR; Schmidt, J; von Knebel Doeberitz, M, 2002) |
| "These findings reveal that pancreatic cancer cell lines are generally resistant to 5-FU and are more sensitive towards gemcitabine." | 1.31 | Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. ( Büchler, MW; Friess, H; Kleeff, J; Liu, S; Shi, X, 2002) |
| "Islet cell carcinomas have an incidence of 5 per million per year; 50 per cent of these are nonfunctioning islet cell tumors." | 1.31 | Nonfunctioning islet cell carcinoma of the pancreas: case report. ( Elster, E; Golocovsky, M; Pearl, J, 2002) |
| "Pathological study revealed primary pancreatic cancer with lung metastasis." | 1.31 | [Resection of pancreatic cancer and simultaneous lung metastasis--a case report of successful in tumor dormancy mainly by postoperative 5-fluorouracil-based chemotherapy]. ( Arii, S; Baba, H; Goseki, N; Kumagai, J; Nosaka, T; Takamatsu, S; Teramoto, K, 2002) |
| "Preoperative chemoradiation for pancreatic cancer is associated with low rates of hepatic toxicity and biliary stent-related complications." | 1.31 | Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. ( Abbruzzese, JL; Crane, CH; Evans, DB; Hudec, WA; Janjan, NA; Lahoti, S; Lee, JE; Lenzi, R; Pisters, PW; Raijman, I; Rich, TA; Wolff, RA, 2000) |
| "5-Fluorouracil (5-FU) was given as a bolus (500-1000 mg/m2/day) during the first and last weeks of RT in 22 patients, whereas continuous 5-FU (225 mg/m2/day) was given to 3 patients." | 1.31 | Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results. ( Latona, C; Paulino, AC, 2000) |
| "5-fluorouracil has been the only drug with some efficacy for a longtime." | 1.31 | [Has there been progress in the treatment of metastatic pancreatic cancer?]. ( Bours, V; Fillet, G; Jerusalem, G, 2000) |
| " The DPD activity of pancreatic tumors may be a useful clinical marker of the responsibility of fluorinated pyrimidine dosing in pancreatic cancer." | 1.31 | Dihydropyrimidine dehydrogenase activity in human pancreatic tumor tissues. ( Kayahara, M; Kitagawa, H; Kurata, T; Mikami, K; Nagakawa, T; Ohta, T; Otsuji, S, 2000) |
| "Most nonendocrine pancreatic neoplasms are adenocarcinomas of ductal cell or acinar origin." | 1.31 | Squamous cell carcinoma of the pancreas with cystic degeneration. ( Colarian, J; Fowler, D; Poolos, S; Schor, J, 2000) |
| "Gemcitabine (dFdC) is a prodrug that undergoes metabolism by cytidine deaminase to form an inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU)." | 1.31 | Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. ( Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG, 2000) |
| "Our experience of arterial infusion chemotherapy combined with regional hyperthermia in the treatment of non-resectable pancreatic cancer was presented." | 1.31 | [Intra-arterial infusion chemotherapy in combination with microwave hyperthermia for cancer of head of pancreas and liver metastasis--a case of 16 years survival]. ( Endo, Y; Ikeda, H; Matumoto, Y; Miura, T, 2000) |
| "For both of the two patients with pancreatic cancer, although they were responsive to the therapy, there was no prolongation of survival." | 1.31 | [Hepatic arterial infusion chemotherapy for unresectable liver metastasis of gastrointestinal cancers]. ( Hirakawa, K; Nishino, H; Ohira, M; Shimizu, S; Tamamori, Y; Tanaka, H; Yamada, N, 2000) |
| "We treated a case of unresectable gastric cancer in which peritoneal lavage cytology and the primary tumor responded to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection." | 1.31 | [A case of stage IV gastric cancer responding to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection]. ( Hattori, T; Hirano, K; Kase, H; Kobayashi, K; Ogawa, M; Teramoto, T; Tokura, N; Washizawa, N, 2000) |
| "Gemcitabine treatment appeared most effective." | 1.31 | [Experience with chemotherapy for advanced pancreatic carcinoma]. ( Gershanovich, ML; Ignashov, AM; Ivanova, NE; Kokhanenko, NIu; Osipenko, SK; Rybakov, GV, 2000) |
| "Transient hypotension was the most common side effect occurring in association with amifostine." | 1.31 | Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001) |
| "The expression of TS in the nuclei of pancreatic cancer cells in 72 primary lesions of resectable IDC and 30 distant metastases of unresectable IDC was examined by immunostaining using anti-TS polyclonal antibody and immunoreactivity was classified into three categories: negative (-), low (+) and high (2+)." | 1.31 | Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. ( Dong, M; Itakura, M; Nio, Y; Takamura, M; Yamaguchi, K; Yamasawa, K, 2002) |
| " Compared with the cell necrosis, the dosage of drugs was less and the time was shorter for inducing apoptosis." | 1.30 | [Apoptosis of human pancreatic carcinoma cell lines induced by combinations of chemotherapeutic drugs]. ( Cai, L; Liao, Q; Wu, Y; Zhao, Y; Zhu, Y, 1999) |
| "5-Fluorouracil was administered at an initial daily dose of 125 mg/m2, with dose escalation planned in 25-mg increments, depending on patient tolerance." | 1.30 | Pilot study of continuous-infusion 5-fluorouracil, oral leucovorin, and upper-abdominal radiation therapy in patients with locally advanced residual or recurrent upper gastrointestinal or extrapelvic colon cancer. ( Burch, PA; Garton, GR; Kugler, JW; Martenson, JA; Pitot, HC; Santala, RG; Schroeder, G; Stella, PJ; Swaminathan, R; Wright, K, 1997) |
| "We developed a pancreatic cancer model whereby a human pancreatic cell line, MIA PaCa-2, was orthotopically transplanted to the pancreas of nude mice as cell suspension (1 x 10(6) cells)." | 1.30 | [Comparison between intraperitoneal and intravenous 5-fluorouracil administration using pancreatic cancer model of nude mouse]. ( Endo, M; Maruyama, M; Yuasa, Y, 1997) |
| "For advanced pancreatic cancer, there is no typical chemotherapy regimen non single chemotherapeutic agent." | 1.30 | [Effect of combination chemotherapy of low-dose CDDP. Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis]. ( Kobayashi, A; Yamaguchi, M, 1998) |
| "This study included seven cases of pancreatic cancer considered unresectable." | 1.30 | [Does neoadjuvant radiochemotherapy augment the resectability of pancreatic cancers?]. ( Alexandre, M; Bousquet, J; Chipponi, J; Cure, H; Pezet, D; Slim, K; Verrelle, P, 1998) |
| "Nineteen patients (16 with colon cancer and 3 with breast cancer) who were treated with systemic 5-FU with complaints of tearing were studied retrospectively." | 1.30 | The treatment of punctal and canalicular stenosis in patients on systemic 5-FU. ( Fezza, JP; Klippenstein, KA; Wesley, RE, 1999) |
| "Invest, 101: 344-352, 1998) to suppress pancreatic cancer cell growth and increase cytotoxic actions of cisplatinum." | 1.30 | Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. ( Arber, N; Beger, HG; Danenberg, KD; Danenberg, PV; Korc, M; Kornmann, M, 1999) |
| " There were two EBRT dosage groups: Low EBRT, 23." | 1.30 | Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. ( Abrams, RA; Cameron, JL; Chakravarthy, A; Grochow, LB; Haulk, TL; Hruban, RH; Lillemoe, KD; Ord, S; Pitt, HA; Sohn, TA; Yeo, CJ; Zahurak, ML, 1999) |
| "Nevertheless, pancreatic cancer cells are sensitive to fluorouracil (5-FU) in a time- and dose-dependent manner, suggesting that improved retention of drug in the tumor may improve patient prognosis." | 1.30 | Drug retention and distribution after intratumoral chemotherapy with fluorouracil/epinephrine injectable gel in human pancreatic cancer xenografts. ( Chen, JY; Jones, RE; Kanekal, S; Orenberg, EK; Patawaran, MB; Smith, JP; Yu, NY, 1999) |
| "Pancreatic cancer is one of the most common tumor of the gastrointestinal tract." | 1.30 | [Contribution of gemcitabine in the treatment of advanced pancreatic cancer]. ( Brunet, R; Fonck, M, 1999) |
| "CAV is cytotoxic to MIA PaCa-2 human pancreatic cancer cells." | 1.29 | Combination therapy with 5-fluorouracil and L-canavanine: in vitro and in vivo studies. ( Ang, CY; Crooks, PA; Desai, PB; John, WJ; Rosenthal, GA; Swaffar, DS; Thomas, DA, 1995) |
| "The development of diabetic ketoacidosis is an unusual complication of a glucagon-secreting pancreatic islet cell neoplasm, with only four reported cases in the literature." | 1.29 | Case report: diabetic ketoacidosis in a patient with glucagonoma. ( Anthony, LB; May, ME; Sharp, SC, 1995) |
| "levamisole/5-FU) treatment." | 1.29 | Enhancement of antitumor effects of combined chemoimmunotherapy. ( Fowler, WC; Gerçel-Taylor, C; Taylor, DD; Weese, JL, 1993) |
| "5-Fluorouracil was given every 3 weeks by 5-day continuous chronomodulated venous infusion (CMVI) with peak 5-FU delivery at 4 a." | 1.29 | Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma. ( Adam, R; Bertheault-Cvitkovic, F; Bismuth, H; Brienza, S; Itzhaki, M; Lévi, F; Misset, JL; Soussan, S, 1993) |
| "Pancreatic cancer is a disease with essentially no effective treatment." | 1.29 | A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. ( Furukawa, T; Hoffman, RM; Kitajima, M; Kubota, T; Watanabe, M, 1993) |
| "The patient was a 44-year-old male with gastric cancer accompanied by pancreatic invasion and metastasis to the periaortic lymph nodes." | 1.29 | [A patient with stage IV gastric cancer responding to combination chemotherapy with 5-FU, leucovorin and CDDP]. ( Kobayashi, O; Motohashi, H; Okada, K; Okugawa, T; Rino, Y; Sairenji, M, 1993) |
| "5-Fluorouracil was given concurrently by continuous infusion at a dose of 300 mg m-2 day-1." | 1.29 | Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms. ( Abbruzzese, JL; Buchholz, DJ; Cleary, KR; Evans, OB; Lee, JE; Rich, TA, 1995) |
| "Recent studies have revealed decreased pancreatic cancer cell growth upon administration of peptide YY (PYY)." | 1.29 | Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth. ( Balasubramaniam, A; Garvey, L; Liu, CD; McFadden, DW; Rongione, AJ, 1996) |
| " From the dose-response curves, the 50% growth inhibition (IC50) level for each drug was estimated." | 1.29 | In vitro chemosensitivity of human pancreatic cancer cell lines. ( Oka, T; Sawabe, Y; Yamagishi, H; Yamaguchi, N; Yamamura, Y, 1996) |
| "Determined by clonogenic assay in human colon cancer HT-29 cells, the cell survivals for AZT, 10 microM, dipyridamole, 5 microM, and methotrexate (MTX), 0." | 1.28 | Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells. ( Taniki, T; Weber, G; Zhen, YS, 1992) |
| "Ductal pancreatic cancers were induced with N-nitrosobis(2-oxopropyl)amine (BOP) in female Syrian golden hamsters." | 1.28 | Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters. ( Lapis, K; Schally, AV; Szepeshazi, K, 1991) |
| "Locally advanced unresectable pancreatic cancer is sometimes encountered without manifest distant metastases." | 1.28 | Treatment perspectives in locally advanced unresectable pancreatic cancer. ( Jeekel, J; Treurniet-Donker, AD, 1991) |
| "Four patients with unresectable pancreatic cancer and one with metastatic liver tumor after curative pancreatic resection for carcinoma of the pancreas had undergone intra-arterial infusion chemotherapy using an implantable drug delivery system." | 1.28 | [Long-term arterial infusion chemotherapy in unresectable pancreatic cancer]. ( Asamura, M; Kakizaki, K; Kikuti, H; Takahashi, N; Yamauchi, H, 1989) |
| "Six patients with hepatocellular carcinoma (HCC) and 9 patients with metastatic liver carcinoma (MLC) (4 with stomach cancer, 4 with pancreas cancer and 1 with colon cancer) were treated with rapid hepatic artery infusion of adriamycin." | 1.27 | [Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma]. ( Hino, I; Kimura, I; Kuroda, S; Numoto, A; Ohnoshi, T; Takahashi, M; Tsuji, M; Ueoka, H, 1984) |
| "One partial remission out of 7 cases of stomach cancer was obtained, and its duration was 40 weeks." | 1.27 | [Clinical trial on the effect of tegafur (SF-SP)]. ( Akazawa, S; Futatsuki, K; Hattori, M; Ishibashi, I; Kanda, Y; Sendai, H; Shimada, S, 1984) |
| "The sensitivity of two human pancreatic adenocarcinomas (Capan-1 and Capan-2) to heat and heat combined with chemotherapy was studied using xenografts of the tumors in the foot of athymic nude mice." | 1.27 | Sensitivity of xenografts of human pancreatic adenocarcinoma in nude mice to heat and heat combined with chemotherapy. ( Cahan, A; Fogh, J; Fortner, JG; Shiu, MH, 1983) |
| "Fourty eight patients with cancer of head of pancreas have been treated by the intra-arterial infusion of 5-FU and Mitomycin C alone or in combination with regional hyperthermia, employing microwave machine operating at a frequency of 2450 MHz." | 1.27 | [Hyperthermia: microwave hyperthermia in combination with intra-arterial infusion chemotherapy of cancer of the pancreas]. ( Endo, Y; Funatomi, H; Hatta, Y; Hirose, N; Miura, T; Sassa, T; Taguchi, S; Yoshikawa, N, 1985) |
| "Chemoradiotherapy was recommended to 40 pancreatic cancer patients following exploratory and palliative operations." | 1.27 | [Chemoradiation treatment of pancreatic cancer]. ( Barkanov, AI; Itin, AB, 1985) |
| "Uric acid nephrolithiasis developed in a 75-year-old man who had received a large cumulative dose of streptozotocin for treatment of metastatic islet cell carcinoma of the pancreas." | 1.27 | Uric acid nephrolithiasis and acute renal failure secondary to streptozotocin nephrotoxicity. ( Goldsmith, GH; Hricik, DE, 1988) |
| "Moreover, human pancreatic cancer cells were completely eliminated after incubation with 5-fluorouracil (0." | 1.27 | [Combined effect of interferons alpha, beta and gamma on tumor growth in vitro]. ( Kimoto, Y, 1986) |
| "One hundred forty-three patients with pancreatic cancer were treated with a number of chemotherapeutic agents, while ninety-eight patients did not receive any chemotherapy." | 1.27 | [Clinical study on the effect of chemotherapy in the treatment of pancreatic cancer]. ( Fujimoto, T; Ishida, T; Kurogoh, F; Ohyanagi, H; Okumura, S; Saitoh, Y; Shimada, Y; Tagashira, Y; Uchida, K; Yamamoto, M, 1988) |
| "The incidence of pancreatic cancer has been increasing in recent years." | 1.27 | [Chemotherapy of pancreatic cancer]. ( Nakamura, K; Ozaki, H; Tajiri, H; Yoshimori, M, 1985) |
| "Fluorodeoxyuridylate (FdUMP) was assayed by isotope dilution of [3H]FdUMP binding to bacterial TS; free and total TS was determined by [3H]FdUMP binding; and deoxyuridylate (dUMP) was assayed by conversion to [14C]thymidylate." | 1.27 | Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. ( Berne, M; Bernstein, L; Frösing, R; Gustavsson, BG; Hayes, AA; Spears, CP, 1988) |
| "Six patients with an upper gastrointestinal hemorrhage or a small bowel obstruction all had local recurrence." | 1.27 | Results in the management of locally unresectable pancreatic carcinoma. ( Parker, RG; Selch, MT, 1986) |
| "A case of pancreatic cancer with liver metastasis is reported, in which chemotherapy had a marked effect, with the responses clearly documented." | 1.27 | A case of pancreatic cancer with liver metastasis which responded to chemotherapy. ( Hijikata, A; Mukai, T; Nakamura, K; Ohkura, H; Saito, D; Tajiri, H; Yamaguchi, H; Yoshida, S; Yoshida, T; Yoshimori, M, 1987) |
| "These included 7 cases of pancreatic cancer, 2 cases of gall bladder cancer with infiltration to the liver, and 3 cases of hepatoma." | 1.27 | [Clinical study on concentration of FT-207 and 5-FU in serum, lymph nodes and tissues after rectal administration of FT-207 suppositories for malignant diseases of the liver, biliary tract and pancreas]. ( Hasegawa, H; Takada, T; Uchiyama, K; Yasuda, H, 1985) |
| "Four patients with metastatic glucagonoma are described." | 1.26 | Glucagonoma and its angiographic diagnosis. ( Keller, FS; Lieberman, DA; Rösch, J; Wawrukiewicz, AS, 1982) |
| "One of the responding patients with colon cancer and two with breast cancer had failed to respond to prior therapy with 5-FU; one of the responding patients with breast cancer had previously received an inadequate trial of a similar regimen." | 1.26 | Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU. ( Ervin, TJ; Kufe, DW; Meshad, MW; Weiss, GR, 1982) |
| "Of the 31 patients with stomach cancer who were evaluable for response and had had no previous chemotherapy, 12 (39%) achieved complete or partial remission." | 1.26 | Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas. ( Bennetts, RW; Heifetz, LJ; Jones, RD; Karlin, DA; Mahal, PS; Stroehlein, JR, 1982) |
| "Less than 20% of advanced colorectal cancers respond to chemotherapy." | 1.26 | Chemotherapy for gastrointestinal malignancy. ( Balint, JA; Van der Veer, LD, 1980) |
| "The therapy of cancer of the colon still remains unsatisfactory: the rate of remissions could be increased, but survival remains unaltered." | 1.26 | [Current state of therapy for gastrointestinal tumors]. ( Hartmann, D; Obrecht, JP, 1978) |
| "Two young women with cancer of the pancreas are described." | 1.26 | Cancer of the pancreas in young adults. ( Butterfield, D; Hobbs, JB; Kune, GA; Sali, A, 1978) |
| "Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts." | 1.25 | Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 255 (11.56) | 18.7374 |
| 1990's | 263 (11.93) | 18.2507 |
| 2000's | 585 (26.53) | 29.6817 |
| 2010's | 700 (31.75) | 24.3611 |
| 2020's | 402 (18.23) | 2.80 |
| Authors | Studies |
|---|---|
| Awale, S | 4 |
| Li, F | 2 |
| Onozuka, H | 1 |
| Esumi, H | 3 |
| Tezuka, Y | 2 |
| Kadota, S | 2 |
| Tabuchi, Y | 1 |
| Ando, Y | 1 |
| Kanemura, H | 1 |
| Kawasaki, I | 1 |
| Ohishi, T | 1 |
| Koida, M | 1 |
| Fukuyama, R | 1 |
| Nakamuta, H | 1 |
| Ohta, S | 2 |
| Nishide, K | 1 |
| Ohishi, Y | 1 |
| Zhang, H | 4 |
| Nambaru, PK | 1 |
| Hübner, T | 1 |
| Köck, K | 1 |
| Mews, S | 1 |
| Grube, M | 1 |
| Payen, L | 1 |
| Guitton, J | 1 |
| Sendler, M | 2 |
| Jedlitschky, G | 1 |
| Rimmbach, C | 1 |
| Rosskopf, D | 1 |
| Kowalczyk, DW | 1 |
| Kroemer, HK | 1 |
| Weiss, FU | 2 |
| Mayerle, J | 8 |
| Lerch, MM | 6 |
| Ritter, CA | 1 |
| Riganas, S | 2 |
| Papanastasiou, I | 2 |
| Foscolos, GB | 2 |
| Tsotinis, A | 2 |
| Bourguignon, JJ | 1 |
| Serin, G | 2 |
| Mirjolet, JF | 4 |
| Dimas, K | 2 |
| Kourafalos, VN | 2 |
| Eleutheriades, A | 2 |
| Moutsos, VI | 2 |
| Khan, H | 2 |
| Georgakopoulou, S | 2 |
| Zaniou, A | 2 |
| Prassa, M | 2 |
| Theodoropoulou, M | 2 |
| Pondiki, S | 2 |
| Vamvakides, A | 2 |
| Ueda, JY | 1 |
| Athikomkulchai, S | 1 |
| Dibwe, DF | 1 |
| Abdelhamed, S | 1 |
| Yokoyama, S | 1 |
| Saiki, I | 1 |
| Miyatake, R | 1 |
| Mantelas, A | 1 |
| Lee, Y | 1 |
| Wang, W | 6 |
| Kim, H | 10 |
| Giri, AG | 1 |
| Won, DH | 1 |
| Hahn, D | 1 |
| Baek, KR | 1 |
| Lee, J | 9 |
| Yang, I | 1 |
| Choi, H | 2 |
| Nam, SJ | 1 |
| Kang, H | 4 |
| Win, NN | 1 |
| Ito, T | 4 |
| Aimaiti, S | 1 |
| Imagawa, H | 1 |
| Ngwe, H | 1 |
| Abe, I | 1 |
| Morita, H | 1 |
| Nguyen, HX | 1 |
| Do, TN | 1 |
| Le, TH | 1 |
| Nguyen, MT | 1 |
| Nguyen, NT | 1 |
| Park, C | 1 |
| Oh, E | 1 |
| Sung, Y | 1 |
| Park, KH | 1 |
| Cascioferro, S | 1 |
| Petri, GL | 1 |
| Parrino, B | 1 |
| Carbone, D | 1 |
| Funel, N | 5 |
| Bergonzini, C | 1 |
| Mantini, G | 2 |
| Dekker, H | 1 |
| Geerke, D | 1 |
| Peters, GJ | 3 |
| Cirrincione, G | 1 |
| Giovannetti, E | 7 |
| Diana, P | 1 |
| Wang, M | 3 |
| Zhu, P | 1 |
| Chen, Z | 5 |
| Yang, L | 3 |
| Zhu, PF | 1 |
| Chen, YW | 3 |
| Wang, MX | 1 |
| Deng, YY | 1 |
| Pan, SY | 1 |
| Chen, ZL | 1 |
| Lahner, H | 1 |
| Mathew, A | 1 |
| Klocker, AL | 1 |
| Unger, N | 1 |
| Theysohn, J | 1 |
| Rekowski, J | 1 |
| Jöckel, KH | 1 |
| Theurer, S | 1 |
| Schmid, KW | 1 |
| Herrmann, K | 1 |
| Führer, D | 1 |
| Gao, J | 1 |
| Logan, KA | 1 |
| Nesbitt, H | 3 |
| Callan, B | 3 |
| McKaig, T | 1 |
| Taylor, M | 2 |
| Love, M | 2 |
| McHale, AP | 4 |
| Griffith, DM | 1 |
| Callan, JF | 4 |
| Reher, D | 1 |
| Fehrenbach, U | 1 |
| Kayser, A | 1 |
| Pape, UF | 3 |
| Henes, FO | 2 |
| Cremer, B | 1 |
| Hörsch, D | 1 |
| Izbicki, J | 1 |
| Lohse, AW | 2 |
| Rinke, A | 2 |
| Schrader, J | 2 |
| Hadj Bachir, E | 1 |
| Poiraud, C | 1 |
| Paget, S | 1 |
| Stoup, N | 1 |
| El Moghrabi, S | 1 |
| Duchêne, B | 2 |
| Jouy, N | 1 |
| Bongiovanni, A | 1 |
| Tardivel, M | 1 |
| Weiswald, LB | 1 |
| Vandepeutte, M | 1 |
| Beugniez, C | 1 |
| Escande, F | 1 |
| Leteurtre, E | 1 |
| Poulain, L | 1 |
| Lagadec, C | 1 |
| Pigny, P | 1 |
| Jonckheere, N | 2 |
| Renaud, F | 1 |
| Truant, S | 1 |
| Van Seuningen, I | 2 |
| Vincent, A | 1 |
| Farshadi, EA | 1 |
| Chang, J | 2 |
| Sampadi, B | 1 |
| Doukas, M | 1 |
| Van 't Land, F | 1 |
| van der Sijde, F | 5 |
| Vietsch, EE | 3 |
| Pothof, J | 1 |
| Koerkamp, BG | 5 |
| van Eijck, CHJ | 15 |
| Lee, M | 2 |
| Kang, JS | 3 |
| Kwon, W | 5 |
| Lee, SH | 11 |
| Ryu, JK | 10 |
| Kim, YT | 12 |
| Oh, DY | 11 |
| Chie, EK | 7 |
| Jang, JY | 9 |
| Catenacci, DVT | 1 |
| Peng, H | 1 |
| James, CA | 1 |
| Cullinan, DR | 1 |
| Hogg, GD | 1 |
| Mudd, JL | 1 |
| Zuo, C | 1 |
| Takchi, R | 1 |
| Caldwell, KE | 1 |
| Liu, J | 3 |
| DeNardo, DG | 2 |
| Fields, RC | 4 |
| Gillanders, WE | 1 |
| Goedegebuure, SP | 2 |
| Hawkins, WG | 5 |
| Kharat, AA | 1 |
| Nelson, R | 2 |
| Au, T | 1 |
| Biskupiak, J | 1 |
| Doyle, J | 1 |
| Amundsen, T | 1 |
| Hall, JA | 1 |
| Raiyani, C | 1 |
| Wong, L | 1 |
| Ako, S | 1 |
| Kato, H | 6 |
| Nouso, K | 1 |
| Kinugasa, H | 1 |
| Terasawa, H | 2 |
| Matushita, H | 1 |
| Takada, S | 1 |
| Saragai, Y | 1 |
| Mizukawa, S | 1 |
| Muro, S | 1 |
| Uchida, D | 1 |
| Tomoda, T | 1 |
| Matsumoto, K | 2 |
| Horiguchi, S | 1 |
| Nobuoka, D | 1 |
| Yoshida, R | 2 |
| Umeda, Y | 1 |
| Yagi, T | 2 |
| Okada, H | 1 |
| Lee, YS | 2 |
| Lee, JC | 7 |
| Kim, JH | 10 |
| Kim, J | 10 |
| Hwang, JH | 11 |
| Homs, MYV | 10 |
| van Bekkum, ML | 1 |
| van den Bosch, TPP | 1 |
| Bosscha, K | 4 |
| Besselink, MG | 24 |
| Bonsing, BA | 4 |
| de Groot, JWB | 3 |
| Karsten, TM | 2 |
| Groot Koerkamp, B | 12 |
| Haberkorn, BCM | 2 |
| Luelmo, SAC | 3 |
| Mekenkamp, LJM | 2 |
| Mustafa, DAM | 3 |
| Wilmink, JW | 20 |
| Garnier, J | 5 |
| Magallon, C | 1 |
| Ewald, J | 6 |
| Palen, A | 1 |
| Marchese, U | 6 |
| Delpero, JR | 11 |
| Turrini, O | 11 |
| McIntyre, CA | 1 |
| Cohen, NA | 1 |
| Goldman, DA | 1 |
| Gonen, M | 5 |
| Sadot, E | 2 |
| O'Reilly, EM | 20 |
| Varghese, AM | 4 |
| Yu, KH | 6 |
| Balachandran, VP | 2 |
| Soares, KC | 2 |
| D'Angelica, MI | 4 |
| Drebin, JA | 5 |
| Kingham, TP | 2 |
| Allen, PJ | 2 |
| Wei, AC | 8 |
| Jarnagin, WR | 6 |
| Park, SJ | 5 |
| Shin, K | 1 |
| Hong, TH | 2 |
| Suh, JH | 1 |
| Lee, MA | 3 |
| Yu, HY | 1 |
| Lee, CY | 1 |
| Lin, LG | 1 |
| Chao, Y | 4 |
| Li, CP | 8 |
| Schafthuizen, L | 1 |
| van 't Land, FR | 2 |
| Moskie, M | 2 |
| van Laarhoven, HWM | 4 |
| van Dijk, M | 1 |
| Raphael, MJ | 2 |
| Raskin, W | 1 |
| Habbous, S | 3 |
| Tai, X | 1 |
| Beca, J | 1 |
| Dai, WF | 4 |
| Arias, J | 4 |
| Forbes, L | 1 |
| Gavura, S | 4 |
| Biagi, JJ | 6 |
| Earle, CC | 4 |
| Chan, KKW | 4 |
| Shafiekhani, S | 1 |
| Dehghanbanadaki, H | 1 |
| Fatemi, AS | 1 |
| Rahbar, S | 1 |
| Hadjati, J | 1 |
| Jafari, AH | 1 |
| Gebauer, F | 1 |
| Damanakis, AI | 1 |
| Popp, F | 1 |
| Quaas, A | 1 |
| Kütting, F | 1 |
| Lutz, K | 1 |
| Held, S | 2 |
| Deuß, B | 1 |
| Göser, T | 1 |
| Waldschmidt, D | 3 |
| Bruns, C | 4 |
| Carotenuto, P | 1 |
| Amato, F | 1 |
| Lampis, A | 1 |
| Rae, C | 1 |
| Hedayat, S | 1 |
| Previdi, MC | 1 |
| Zito, D | 1 |
| Raj, M | 1 |
| Guzzardo, V | 1 |
| Sclafani, F | 1 |
| Lanese, A | 1 |
| Parisi, C | 1 |
| Vicentini, C | 1 |
| Said-Huntingford, I | 1 |
| Hahne, JC | 1 |
| Hallsworth, A | 1 |
| Kirkin, V | 1 |
| Young, K | 1 |
| Begum, R | 1 |
| Wotherspoon, A | 1 |
| Kouvelakis, K | 1 |
| Azevedo, SX | 1 |
| Michalarea, V | 1 |
| Upstill-Goddard, R | 1 |
| Rao, S | 5 |
| Watkins, D | 3 |
| Starling, N | 6 |
| Sadanandam, A | 1 |
| Chang, DK | 3 |
| Biankin, AV | 5 |
| Jamieson, NB | 3 |
| Scarpa, A | 3 |
| Cunningham, D | 31 |
| Chau, I | 10 |
| Workman, P | 1 |
| Fassan, M | 1 |
| Valeri, N | 1 |
| Braconi, C | 1 |
| Assenat, E | 7 |
| de la Fouchardière, C | 7 |
| Portales, F | 3 |
| Ychou, M | 19 |
| Debourdeau, A | 1 |
| Desseigne, F | 6 |
| Iltache, S | 1 |
| Fiess, C | 1 |
| Mollevi, C | 1 |
| Mazard, T | 1 |
| Queck, A | 1 |
| Elango, S | 1 |
| Koch, C | 1 |
| Walter, D | 1 |
| Schmidt, J | 14 |
| Trebicka, J | 1 |
| Trojan, J | 1 |
| Pession, U | 1 |
| Finkelmeier, F | 1 |
| Waidmann, O | 1 |
| Ye, Y | 2 |
| Zheng, S | 2 |
| Sugimoto, M | 2 |
| Takagi, T | 2 |
| Suzuki, R | 3 |
| Konno, N | 2 |
| Asama, H | 2 |
| Sato, Y | 4 |
| Irie, H | 1 |
| Okubo, Y | 1 |
| Nakamura, J | 1 |
| Takasumi, M | 1 |
| Hashimoto, M | 2 |
| Kato, T | 1 |
| Kobashi, R | 1 |
| Hikichi, T | 1 |
| Ohira, H | 1 |
| Schneider, MA | 2 |
| Büchler, MW | 37 |
| Ota, S | 1 |
| Miyashita, M | 1 |
| Yamagishi, Y | 1 |
| Ogasawara, M | 1 |
| Su, YY | 2 |
| Chiu, YF | 2 |
| Yang, SH | 3 |
| Lin, J | 2 |
| Lin, SJ | 1 |
| Chang, PY | 1 |
| Chiang, NJ | 3 |
| Shan, YS | 7 |
| Ch'ang, HJ | 4 |
| Chen, LT | 18 |
| De Felice, F | 1 |
| Musio, D | 1 |
| Tombolini, V | 2 |
| Cortesi, E | 1 |
| Tezuka, S | 2 |
| Ueno, M | 11 |
| Oishi, R | 2 |
| Nagashima, S | 2 |
| Sano, Y | 1 |
| Kawano, K | 1 |
| Tanaka, S | 2 |
| Fukushima, T | 2 |
| Kobayashi, S | 6 |
| Morimoto, M | 2 |
| Maeda, S | 3 |
| Shibuki, T | 6 |
| Mizuta, T | 6 |
| Shimokawa, M | 6 |
| Koga, F | 6 |
| Ueda, Y | 6 |
| Nakazawa, J | 6 |
| Komori, A | 6 |
| Otsu, S | 6 |
| Arima, S | 6 |
| Fukahori, M | 6 |
| Makiyama, A | 6 |
| Taguchi, H | 6 |
| Honda, T | 6 |
| Mitsugi, K | 6 |
| Nio, K | 6 |
| Ide, Y | 6 |
| Ureshino, N | 6 |
| Shirakawa, T | 6 |
| Otsuka, T | 6 |
| Rivoire, M | 1 |
| Thezenas, S | 2 |
| Guimbaud, R | 5 |
| Ghiringhelli, F | 4 |
| Mercier-Blas, A | 1 |
| Mineur, L | 6 |
| Francois, E | 7 |
| Khemissa, F | 1 |
| Chauvenet, M | 1 |
| Kianmanesh, R | 1 |
| Fonck, M | 3 |
| Houyau, P | 1 |
| Aparicio, T | 8 |
| Galais, MP | 1 |
| Audemar, F | 1 |
| Lopez-Crapez, E | 1 |
| Jouffroy, C | 1 |
| Adenis, A | 7 |
| Adam, R | 2 |
| Bouché, O | 13 |
| Ay, S | 1 |
| Atcı, MM | 1 |
| Arıkan, R | 1 |
| Dülgar, Ö | 1 |
| Özyükseler, DT | 1 |
| Paksoy, N | 1 |
| Doğan, İ | 1 |
| Öztosun, B | 1 |
| Taştekin, D | 1 |
| Öven, BB | 1 |
| Gümüş, M | 1 |
| Mizuno, D | 1 |
| Suemori, K | 1 |
| Miyauchi, S | 1 |
| Iga, N | 1 |
| Uno, F | 1 |
| Kawai, H | 1 |
| Ishizaki, M | 1 |
| Nishi, H | 1 |
| Yamashita, K | 1 |
| Okada, T | 1 |
| Katada, Y | 1 |
| Kitagawa, S | 2 |
| Iwamoto, R | 1 |
| Kinoshita, S | 2 |
| Mineta, S | 1 |
| Tanaka, H | 9 |
| Kubota, H | 1 |
| Higashida, M | 1 |
| Sanuki, F | 1 |
| Endo, S | 4 |
| Yoshimatsu, K | 1 |
| Fujiwara, Y | 1 |
| Ueno, T | 2 |
| McAndrew, EN | 1 |
| Lambert, P | 2 |
| Rittberg, R | 1 |
| Dawe, DE | 1 |
| Kim, CA | 3 |
| Lalonde, CS | 1 |
| Wang, L | 8 |
| Quigley, B | 1 |
| Patel, P | 2 |
| Maithel, SK | 7 |
| El-Rayes, BF | 11 |
| Akce, M | 1 |
| Lee, LD | 1 |
| Pozios, I | 1 |
| Liu, V | 1 |
| Nachbichler, SB | 1 |
| Böhmer, D | 1 |
| Kamphues, C | 1 |
| Beyer, K | 1 |
| Bruns, CJ | 7 |
| Kreis, ME | 1 |
| Seeliger, H | 2 |
| Müller, C | 2 |
| Kreissl, MC | 1 |
| Klose, S | 1 |
| Krause, A | 1 |
| Keitel, V | 1 |
| Venerito, M | 1 |
| Zaibet, S | 1 |
| Hautefeuille, V | 7 |
| Auclin, E | 3 |
| Lièvre, A | 6 |
| Tougeron, D | 5 |
| Sarabi, M | 3 |
| Gilabert, M | 7 |
| Wasselin, J | 1 |
| Edeline, J | 4 |
| Artru, P | 10 |
| Bechade, D | 2 |
| Morin, C | 1 |
| Ducoulombier, A | 1 |
| Taieb, J | 17 |
| Pernot, S | 4 |
| Takumoto, Y | 2 |
| Sasahara, Y | 1 |
| Narimatsu, H | 1 |
| Akazawa, M | 2 |
| Zhao, J | 2 |
| Shi, X | 3 |
| Dong, C | 1 |
| Liu, R | 1 |
| Su, L | 1 |
| Cao, C | 2 |
| Meneses-Medina, MI | 1 |
| Gervaso, L | 1 |
| Cella, CA | 2 |
| Pellicori, S | 1 |
| Gandini, S | 1 |
| Sousa, MJ | 1 |
| Fazio, N | 1 |
| Ingram, MA | 1 |
| Lauren, BN | 1 |
| Pumpalova, Y | 1 |
| Park, J | 4 |
| Lim, F | 1 |
| Bates, SE | 3 |
| Kastrinos, F | 1 |
| Manji, GA | 2 |
| Kong, CY | 3 |
| Hur, C | 3 |
| Hochster, HS | 8 |
| Alexander, HR | 1 |
| Janssen, QP | 10 |
| van Dam, JL | 4 |
| Doppenberg, D | 3 |
| Prakash, LR | 4 |
| O' Reilly, EM | 1 |
| Paniccia, A | 3 |
| Katz, MHG | 14 |
| Tzeng, CD | 5 |
| Zureikat, AH | 6 |
| Delahoussaye, AM | 1 |
| Abi Jaoude, J | 1 |
| Green, M | 1 |
| Fujimoto, TN | 1 |
| Molkentine, J | 1 |
| Garcia Garcia, CJ | 1 |
| Gay, JP | 1 |
| Feng, N | 1 |
| Marszalek, J | 1 |
| Fowlkes, N | 1 |
| Taniguchi, CM | 1 |
| Chiu, TJ | 1 |
| Chiu, SC | 1 |
| Hsueh, SW | 1 |
| Bai, LY | 1 |
| Cheng, FM | 1 |
| Chuang, SC | 1 |
| Chan, DC | 1 |
| Yen, CJ | 1 |
| Peng, CM | 2 |
| Chen, YY | 1 |
| Chen, JS | 5 |
| Chou, WC | 2 |
| Zhu, X | 3 |
| Cao, Y | 1 |
| Liu, W | 3 |
| Ju, X | 1 |
| Zhao, X | 2 |
| Jiang, L | 1 |
| Jin, G | 1 |
| Roviello, G | 2 |
| Aprile, G | 2 |
| Catalano, M | 1 |
| Ramello, M | 1 |
| Conca, R | 1 |
| Petrioli, R | 4 |
| Yamaguchi, J | 1 |
| Yokoyama, Y | 1 |
| Fujii, T | 2 |
| Yamada, S | 1 |
| Takami, H | 2 |
| Kawashima, H | 1 |
| Ohno, E | 1 |
| Ishikawa, T | 5 |
| Maeda, O | 1 |
| Ogawa, H | 1 |
| Kodera, Y | 2 |
| Nagino, M | 1 |
| Ebata, T | 1 |
| Elias, R | 1 |
| Cockrum, P | 4 |
| Surinach, A | 6 |
| Wang, S | 5 |
| Chul Chu, B | 1 |
| Shahrokni, A | 2 |
| Canton, C | 1 |
| Boussari, O | 1 |
| Boulin, M | 1 |
| Le Malicot, K | 4 |
| Dahan, L | 5 |
| Lopez, A | 2 |
| Lepage, C | 5 |
| Bachet, JB | 15 |
| Ushida, Y | 2 |
| Inoue, Y | 3 |
| Oba, A | 2 |
| Mie, T | 5 |
| Ito, H | 5 |
| Ono, Y | 2 |
| Sato, T | 9 |
| Ozaka, M | 11 |
| Sasaki, T | 8 |
| Saiura, A | 2 |
| Sasahira, N | 7 |
| Takahashi, Y | 4 |
| Selvarajoo, N | 1 |
| Stanslas, J | 1 |
| Islam, MK | 1 |
| Sagineedu, SR | 1 |
| Lian, HK | 1 |
| Lim, JCW | 1 |
| Kim, G | 1 |
| Wainberg, Z | 1 |
| Temraz, S | 4 |
| Nassar, F | 1 |
| Hammoud, MS | 2 |
| Mukherji, D | 5 |
| Dbouk, H | 1 |
| Farhat, F | 4 |
| Charafeddine, M | 3 |
| Faraj, W | 3 |
| Khalifeh, MJ | 1 |
| Abou-Alfa, GK | 4 |
| Shamseddine, A | 4 |
| Kamposioras, K | 1 |
| Papaxoinis, G | 1 |
| Dawood, M | 1 |
| Appleyard, J | 1 |
| Collinson, F | 1 |
| Lamarca, A | 2 |
| Ahmad, U | 1 |
| Hubner, RA | 8 |
| Wright, F | 1 |
| Pihlak, R | 2 |
| Damyanova, I | 1 |
| Razzaq, B | 1 |
| Valle, JW | 10 |
| McNamara, MG | 2 |
| Anthoney, A | 6 |
| Ng, M | 1 |
| Chen, S | 1 |
| Ong, WS | 1 |
| Balachander, A | 1 |
| Seet, A | 1 |
| Yeong, J | 1 |
| Sutiman, N | 1 |
| Lim, TKH | 1 |
| Lee, B | 4 |
| Guo, YA | 1 |
| Leong, WF | 1 |
| Lee, SS | 7 |
| Lam, J | 1 |
| Choo, SP | 1 |
| Skanderup, AJ | 1 |
| Biswas, SK | 1 |
| Tai, D | 1 |
| Chowbay, B | 1 |
| Milano, G | 4 |
| Innocenti, F | 1 |
| Minami, H | 1 |
| Yamai, T | 2 |
| Ikezawa, K | 2 |
| Kawamoto, Y | 2 |
| Hirao, T | 2 |
| Higashi, S | 2 |
| Daiku, K | 1 |
| Abe, Y | 3 |
| Urabe, M | 2 |
| Kai, Y | 3 |
| Takada, R | 2 |
| Nakabori, T | 2 |
| Uehara, H | 3 |
| Ohkawa, K | 2 |
| Lu, W | 2 |
| Li, X | 13 |
| Tang, K | 2 |
| Campoverde, LE | 1 |
| Batalini, F | 1 |
| Bulushi, Y | 1 |
| Bullock, A | 3 |
| Kubota, Y | 1 |
| Han, Q | 1 |
| Hozumi, C | 1 |
| Masaki, N | 1 |
| Yamamoto, J | 1 |
| Aoki, Y | 1 |
| Tsunoda, T | 1 |
| Hoffman, RM | 5 |
| Hyung, J | 2 |
| Lee, H | 2 |
| Jin, H | 1 |
| Lee, S | 5 |
| Lee, HJ | 2 |
| Gong, G | 1 |
| Song, TJ | 2 |
| Hwang, DW | 2 |
| Kim, SC | 10 |
| Jeong, JH | 3 |
| Ryoo, BY | 6 |
| Kim, K | 4 |
| Yoo, C | 8 |
| Maurici, CE | 1 |
| Colenbier, R | 1 |
| Wylleman, B | 1 |
| Brancato, L | 1 |
| van Zwol, E | 1 |
| Van den Bossche, J | 1 |
| Timmermans, JP | 1 |
| Mori da Cunha, MGMC | 1 |
| Bogers, J | 1 |
| Mittal, A | 3 |
| El Dika, I | 1 |
| Epstein, AS | 1 |
| Ilson, DH | 3 |
| Kelsen, DP | 4 |
| Ku, GY | 3 |
| Li, J | 13 |
| Park, W | 1 |
| Chou, JF | 1 |
| Capanu, M | 1 |
| Cooper, B | 1 |
| Bartlett, A | 1 |
| McCarthy, D | 1 |
| Sangar, V | 1 |
| McCarthy, B | 1 |
| Uemura, S | 2 |
| Maeda, H | 1 |
| Tanioka, N | 1 |
| Yamaguchi, S | 1 |
| Munekage, M | 1 |
| Kitagawa, H | 2 |
| Namikawa, T | 1 |
| Yamamoto, S | 1 |
| Kohsaki, T | 1 |
| Iguchi, M | 1 |
| Uchida, K | 2 |
| Hanazaki, K | 1 |
| Klein-Brill, A | 1 |
| Amar-Farkash, S | 1 |
| Lawrence, G | 1 |
| Collisson, EA | 1 |
| Aran, D | 1 |
| Kato, A | 1 |
| Naitoh, I | 1 |
| Naiki-Ito, A | 2 |
| Hayashi, K | 2 |
| Okumura, F | 1 |
| Fujita, Y | 2 |
| Sano, H | 1 |
| Nishi, Y | 1 |
| Miyabe, K | 1 |
| Inoue, T | 4 |
| Hirano, A | 1 |
| Takada, H | 1 |
| Yoshida, M | 2 |
| Hori, Y | 1 |
| Natsume, M | 1 |
| Takahashi, S | 7 |
| Kataoka, H | 2 |
| Hamaguchi, T | 1 |
| Yamachika, Y | 1 |
| Shin, M | 1 |
| Yao, L | 2 |
| Tang, C | 1 |
| Feng, W | 1 |
| Dai, H | 1 |
| Kim, HY | 1 |
| Na, HY | 1 |
| Lee, JS | 3 |
| Kim, JW | 7 |
| Yoon, YS | 2 |
| Han, HS | 2 |
| Breakstone, R | 2 |
| Almhanna, K | 2 |
| Raufi, A | 1 |
| Beard, RE | 1 |
| Leonard, KL | 1 |
| Renaud, J | 2 |
| Kastura, M | 1 |
| Dionson, S | 1 |
| Wood, R | 1 |
| Sturtevant, A | 2 |
| Dipetrillo, T | 2 |
| Olszewski, A | 2 |
| Safran, H | 9 |
| Arciero, V | 1 |
| Luo, J | 2 |
| Parmar, A | 1 |
| Beca, JM | 3 |
| Isaranuwatchai, W | 2 |
| Tadrous, M | 1 |
| Mittmann, N | 2 |
| Zhou, L | 4 |
| Wu, Z | 1 |
| Jiang, C | 3 |
| Dai, S | 1 |
| Ishii, H | 11 |
| Furuse, J | 14 |
| Lou, J | 4 |
| Yasuoka, H | 1 |
| Naganuma, A | 1 |
| Kurihara, E | 1 |
| Kobatake, T | 1 |
| Ijima, M | 1 |
| Tamura, Y | 1 |
| Suzuki, Y | 3 |
| Hoshino, T | 1 |
| Ishida, F | 1 |
| Hosaka, H | 1 |
| Hatanaka, T | 1 |
| Yoshida, S | 4 |
| Aihara, R | 1 |
| Hosouchi, Y | 1 |
| Ishii, N | 1 |
| Araki, K | 1 |
| Shirabe, K | 2 |
| Uraoka, T | 1 |
| Kakizaki, S | 1 |
| Crane, CH | 19 |
| Ellsworth, SG | 5 |
| Reyngold, M | 2 |
| Walpole, I | 1 |
| Shapiro, J | 4 |
| Thomson, B | 2 |
| Lipton, L | 3 |
| Ananda, S | 2 |
| Usatoff, V | 1 |
| Mclachlan, SA | 1 |
| Knowles, B | 1 |
| Fox, A | 1 |
| Wong, R | 2 |
| Cooray, P | 1 |
| Burge, M | 2 |
| Clarke, K | 2 |
| Pattison, S | 2 |
| Nikfarjam, M | 2 |
| Tebbutt, N | 2 |
| Harris, M | 1 |
| Nagrial, A | 2 |
| Zielinski, R | 2 |
| Chee, CE | 1 |
| Gibbs, P | 3 |
| Shi, Q | 2 |
| Meyers, J | 1 |
| Herman, JM | 21 |
| Chuong, M | 1 |
| Wolpin, BM | 5 |
| Ahmad, S | 3 |
| Marsh, R | 1 |
| Schwartz, L | 2 |
| Behr, S | 1 |
| Frankel, WL | 2 |
| Collisson, E | 2 |
| Leenstra, J | 1 |
| Williams, TM | 4 |
| Vaccaro, G | 2 |
| Venook, A | 1 |
| Meyerhardt, JA | 3 |
| Ecker, BL | 2 |
| Court, CM | 2 |
| Tao, AJ | 2 |
| Mattiucci, GC | 5 |
| Salvatore, L | 1 |
| D'Aviero, A | 2 |
| Bagalà, C | 2 |
| Bensi, M | 1 |
| Castronovo, FM | 1 |
| Cellini, F | 2 |
| De Franco, P | 1 |
| Di Stefano, B | 1 |
| Macchia, G | 6 |
| Masiello, V | 1 |
| Menghi, R | 1 |
| Quero, G | 1 |
| Reina, S | 1 |
| Morganti, AG | 6 |
| Alfieri, S | 2 |
| Tortora, G | 1 |
| Valentini, V | 6 |
| Lee, W | 1 |
| Song, G | 1 |
| Bae, H | 1 |
| Otsu, T | 1 |
| Inokawa, Y | 1 |
| Hayashi, M | 1 |
| Kurimoto, K | 1 |
| Tanaka, N | 1 |
| Shimizu, D | 1 |
| Hattori, N | 2 |
| Kanda, M | 2 |
| Tanaka, C | 1 |
| Nakayama, G | 1 |
| Hino, K | 1 |
| Nishina, T | 1 |
| Numata, Y | 1 |
| Asagi, A | 1 |
| Yoshimatsu, M | 1 |
| Sakaguchi, C | 1 |
| Nakasya, A | 1 |
| Nishide, N | 1 |
| Kajiwara, T | 2 |
| Terao, T | 1 |
| Nadano, S | 1 |
| Marui, K | 1 |
| Okujima, Y | 1 |
| Kokubu, M | 1 |
| Imamura, Y | 1 |
| Kanemitsu, K | 3 |
| Koizumi, M | 1 |
| Kumagi, T | 1 |
| Hiasa, Y | 1 |
| Hyodo, I | 2 |
| Yuen, JG | 1 |
| Fesler, A | 1 |
| Hwang, GR | 1 |
| Chen, LB | 1 |
| Ju, J | 1 |
| Santucci, J | 1 |
| Tacey, M | 1 |
| Michael, M | 4 |
| Jennens, R | 1 |
| Zhang, Z | 2 |
| Chen, WQ | 1 |
| Zhang, SQ | 1 |
| Bai, JX | 1 |
| Liu, B | 4 |
| Yung, KK | 1 |
| Ko, JK | 1 |
| Conroy, T | 18 |
| Castan, F | 4 |
| Turpin, A | 5 |
| Ben Abdelghani, M | 3 |
| Mitry, E | 8 |
| Evesque, L | 2 |
| Lecomte, T | 9 |
| Bauguion, L | 1 |
| Monard, L | 1 |
| Lambert, A | 1 |
| Hammel, P | 15 |
| Marschner, N | 1 |
| Hegewisch-Becker, S | 3 |
| Reiser, M | 1 |
| von der Heyde, E | 1 |
| Bertram, M | 1 |
| Hollerbach, SH | 1 |
| Kreher, S | 1 |
| Wolf, T | 1 |
| Binninger, A | 1 |
| Chiabudini, M | 1 |
| Kaiser-Osterhues, A | 1 |
| Jänicke, M | 1 |
| Gong, J | 2 |
| Thomassian, S | 1 |
| Kim, S | 4 |
| Gresham, G | 1 |
| Moshayedi, N | 1 |
| Ye, JY | 1 |
| Yang, JC | 2 |
| Jacobs, JP | 1 |
| Lo, S | 1 |
| Nissen, N | 2 |
| Gaddam, S | 1 |
| Tighiouart, M | 1 |
| Osipov, A | 1 |
| Hendifar, A | 1 |
| Dik, WA | 1 |
| Debets, R | 1 |
| Oostvogels, AAM | 1 |
| Smits-Te Nijenhuis, MAW | 1 |
| O'Leary, BR | 1 |
| Ruppenkamp, EK | 1 |
| Steers, GJ | 1 |
| Du, J | 2 |
| Carroll, RS | 1 |
| Wagner, BA | 1 |
| Buettner, GR | 1 |
| Cullen, JJ | 1 |
| Hamad, A | 3 |
| Crossnohere, N | 1 |
| Ejaz, A | 1 |
| Tsung, A | 1 |
| Pawlik, TM | 13 |
| Sarna, A | 1 |
| Santry, H | 1 |
| Wills, C | 1 |
| Cloyd, JM | 4 |
| Okamoto, T | 2 |
| Takeda, T | 5 |
| Mori, C | 2 |
| Furukawa, T | 6 |
| Kasuga, A | 3 |
| Matsuyama, M | 3 |
| Dong, LP | 1 |
| Liu, YM | 1 |
| Lu, WJ | 1 |
| Tang, KZ | 1 |
| Irisawa, A | 1 |
| Takeno, M | 1 |
| Watanabe, K | 4 |
| Takahashi, H | 3 |
| Mitsunaga, S | 1 |
| Ikeda, M | 13 |
| Capula, M | 1 |
| Perán, M | 1 |
| Xu, G | 1 |
| Donati, V | 1 |
| Yee, D | 1 |
| Gregori, A | 1 |
| Assaraf, YG | 1 |
| Deng, D | 1 |
| Rudno-Rudzińska, J | 1 |
| Michel, O | 1 |
| Płochocki, M | 1 |
| Kulbacka, J | 1 |
| Tanaka, M | 7 |
| Heckler, M | 2 |
| Mihaljevic, AL | 2 |
| Ei, S | 1 |
| Klaiber, U | 6 |
| Heger, U | 3 |
| Hackert, T | 10 |
| Nishimoto, A | 1 |
| Tsuruta, N | 1 |
| Kawahira, M | 2 |
| Ido, A | 3 |
| Haenen, SM | 1 |
| Tol, JAMG | 1 |
| van Steen, SCJ | 1 |
| Busch, OR | 14 |
| Sarasqueta, AF | 1 |
| Roshani, S | 1 |
| Wolkerstorfer, A | 1 |
| van der Linden, MMD | 1 |
| Post, HC | 1 |
| Nojima, M | 1 |
| Ishitsuka, T | 1 |
| Yamada, M | 2 |
| Nakagawa, H | 1 |
| Udagawa, S | 1 |
| Yamada, Y | 7 |
| Allen-Coyle, TJ | 1 |
| Niu, J | 1 |
| Welsch, E | 1 |
| Conlon, NT | 1 |
| Garner, W | 1 |
| Clynes, M | 2 |
| O'Sullivan, F | 1 |
| Straubinger, RM | 1 |
| Mager, DE | 1 |
| Roche, S | 1 |
| Sahin, IH | 1 |
| Lin, Y | 4 |
| Yothers, G | 1 |
| Lucas, PC | 1 |
| Deming, D | 1 |
| George, TJ | 4 |
| Kopetz, S | 1 |
| Lieu, CH | 1 |
| Dasari, A | 4 |
| Schuth, S | 1 |
| Le Blanc, S | 1 |
| Krieger, TG | 1 |
| Jabs, J | 1 |
| Schenk, M | 2 |
| Giese, NA | 3 |
| Eils, R | 1 |
| Conrad, C | 2 |
| Strobel, O | 6 |
| Khatib, AW | 1 |
| Selub, SM | 1 |
| Uryvaey, A | 1 |
| Baranseh, J | 1 |
| Shai, A | 1 |
| Ghabi, EM | 1 |
| Shoucair, S | 1 |
| Ding, D | 2 |
| Javed, AA | 3 |
| Thompson, ED | 2 |
| Zheng, L | 8 |
| Cameron, JL | 15 |
| Wolfgang, CL | 15 |
| Shubert, CR | 1 |
| Lafaro, KJ | 2 |
| Burkhart, RA | 4 |
| Burns, WR | 2 |
| He, J | 8 |
| Kanesada, K | 1 |
| Tsunedomi, R | 1 |
| Hazama, S | 1 |
| Ogihara, H | 1 |
| Hamamoto, Y | 3 |
| Shindo, Y | 1 |
| Matsui, H | 1 |
| Tokumitsu, Y | 1 |
| Iida, M | 2 |
| Suzuki, N | 1 |
| Takeda, S | 4 |
| Ioka, T | 8 |
| Nagano, H | 3 |
| Chen, Q | 2 |
| Cui, SP | 1 |
| Wang, D | 2 |
| Lang, R | 1 |
| Sarradin, V | 1 |
| Betrian, S | 1 |
| Chaltiel, L | 1 |
| Brac De La Perriere, C | 1 |
| Delord, JP | 1 |
| Okusaka, T | 19 |
| Teng, Z | 3 |
| Furuya, M | 3 |
| Saif, A | 3 |
| Verbus, E | 3 |
| Erickson, B | 4 |
| Kamgar, M | 5 |
| Tsai, S | 10 |
| Evans, D | 3 |
| Hernandez, JM | 3 |
| Hall, WA | 8 |
| Evans, DB | 33 |
| Dincer, N | 3 |
| Ugurluer, G | 3 |
| Ozyar, E | 3 |
| Grossberg, AJ | 3 |
| Jethwa, KR | 3 |
| Hintz, B | 3 |
| Lee, VJ | 3 |
| Botta, GP | 3 |
| Huynh, TR | 2 |
| Spierling-Bagsic, SR | 2 |
| Agelidis, A | 2 |
| Schaffer, R | 2 |
| Lin, R | 2 |
| Sigal, D | 2 |
| van Veldhuisen, E | 5 |
| Klompmaker, S | 3 |
| Hilal, MA | 1 |
| Alseidi, A | 4 |
| Balduzzi, A | 2 |
| Balzano, G | 13 |
| Bassi, C | 19 |
| Berrevoet, F | 4 |
| Bonds, M | 2 |
| Butturini, G | 5 |
| Conlon, KC | 2 |
| Frigerio, IM | 1 |
| Fusai, GK | 2 |
| Gagnière, J | 2 |
| Griffin, O | 2 |
| Halimi, A | 3 |
| Keck, T | 4 |
| Kleeff, J | 8 |
| Labori, KJ | 2 |
| Lesurtel, M | 2 |
| Malleo, G | 8 |
| Marino, MV | 2 |
| Molenaar, IQ | 6 |
| Mortensen, MB | 4 |
| Nikov, A | 2 |
| Pagnanelli, M | 1 |
| Pandé, R | 2 |
| Pfeiffer, P | 5 |
| Pietrasz, D | 5 |
| Rangelova, E | 3 |
| Roberts, KJ | 2 |
| Cunha, AS | 5 |
| Salvia, R | 8 |
| Tarvainen, T | 2 |
| Chehade, L | 1 |
| Elias, C | 1 |
| Salem, Z | 1 |
| Darazi, MA | 1 |
| Ndemazie, NB | 2 |
| Inkoom, A | 2 |
| Ebesoh, D | 2 |
| Bulusu, R | 2 |
| Frimpong, E | 1 |
| Trevino, J | 1 |
| Han, B | 2 |
| Agyare, E | 2 |
| Auvray Kuentz, M | 1 |
| de Mestier, L | 4 |
| Coutzac, C | 1 |
| Nardon, V | 1 |
| Drouillard, A | 1 |
| Malka, D | 13 |
| Tran-Minh, ML | 1 |
| Trouilloud, I | 7 |
| Williet, N | 4 |
| Touchefeu, Y | 3 |
| Zaanan, A | 4 |
| Boyne, DJ | 1 |
| Brenner, DR | 1 |
| Gupta, A | 2 |
| Mackay, E | 1 |
| Arora, P | 1 |
| Wasiak, R | 1 |
| Cheung, WY | 5 |
| Hernán, MA | 2 |
| Chiang, CH | 3 |
| Chiu, JH | 1 |
| Ma, KS | 1 |
| Chen, BS | 1 |
| Luan, YZ | 1 |
| Cheng, TC | 1 |
| Hsieh, CL | 1 |
| Dayyani, F | 1 |
| Macarulla, T | 10 |
| Johnson, A | 1 |
| Wainberg, ZA | 4 |
| van Eijck, CWF | 1 |
| de Koning, W | 1 |
| van der Burg, SH | 1 |
| Nakachi, K | 3 |
| Ohba, A | 1 |
| Imaoka, H | 1 |
| Terashima, T | 1 |
| Mizusawa, J | 2 |
| Katayama, H | 2 |
| Kataoka, T | 2 |
| Miwa, H | 1 |
| Mizukoshi, E | 1 |
| Okano, N | 3 |
| Mizuno, N | 4 |
| Yamamoto, T | 2 |
| Komatsu, Y | 2 |
| Todaka, A | 4 |
| Kamata, K | 1 |
| Furukawa, M | 3 |
| Fujimori, N | 1 |
| Katanuma, A | 1 |
| Takayama, Y | 2 |
| Tsumura, H | 1 |
| Fukuda, H | 3 |
| Addeo, P | 4 |
| Averous, G | 1 |
| de Mathelin, P | 1 |
| Faitot, F | 1 |
| Cusumano, C | 1 |
| Paul, C | 1 |
| Dufour, P | 2 |
| Bachellier, P | 4 |
| Kawakami, T | 1 |
| Oshima, K | 1 |
| Fushiki, K | 1 |
| Hamauchi, S | 1 |
| Tsushima, T | 1 |
| Yokota, T | 1 |
| Onozawa, Y | 2 |
| Yasui, H | 2 |
| Yamazaki, K | 3 |
| Su, J | 1 |
| Zhou, F | 3 |
| Reni, M | 15 |
| Macchini, M | 2 |
| Porcu, L | 1 |
| Klimova, D | 1 |
| Jakubechova, J | 1 |
| Altanerova, U | 1 |
| Nicodemou, A | 1 |
| Styk, J | 1 |
| Szemes, T | 1 |
| Repiska, V | 1 |
| Altaner, C | 1 |
| Fong, ZV | 1 |
| Verdugo, FL | 1 |
| Fernandez-Del Castillo, C | 14 |
| Ferrone, CR | 16 |
| Allen, JN | 9 |
| Blaszkowsky, LS | 13 |
| Clark, JW | 13 |
| Parikh, AR | 2 |
| Ryan, DP | 17 |
| Weekes, CD | 3 |
| Hong, TS | 17 |
| Wo, JY | 12 |
| Lillemoe, KD | 16 |
| Qadan, M | 8 |
| Kuhara, K | 1 |
| Usui, T | 1 |
| Kono, T | 1 |
| Shimojima, Y | 1 |
| Nishiguchi, R | 1 |
| Okayama, S | 1 |
| Asaka, S | 1 |
| Yokomizo, H | 1 |
| Shimakawa, T | 1 |
| Ohigashi, S | 1 |
| Shiozawa, S | 1 |
| Boucher, Y | 4 |
| Posada, JM | 1 |
| Subudhi, S | 1 |
| Kumar, AS | 1 |
| Rosario, SR | 1 |
| Gu, L | 1 |
| Kumra, H | 1 |
| Mino-Kenudson, M | 3 |
| Talele, NP | 1 |
| Duda, DG | 3 |
| Fukumura, D | 1 |
| Pittet, MJ | 1 |
| Jain, RK | 4 |
| Thalji, SZ | 1 |
| George, B | 3 |
| Aldakkak, M | 2 |
| Christians, KK | 3 |
| Clarke, CN | 2 |
| Erickson, BA | 3 |
| Tolat, PP | 1 |
| Smith, ZL | 1 |
| Walch, HS | 1 |
| Iacobuzio-Donahue, CA | 3 |
| Vakiani, E | 2 |
| Saluja, R | 1 |
| Raphael, M | 1 |
| Coburn, N | 2 |
| de Geus, SWL | 1 |
| Sachs, TE | 1 |
| Zhu, XY | 2 |
| Frimpong, EK | 1 |
| Okoro, J | 1 |
| Rogers, S | 1 |
| Lamarre, N | 1 |
| Kim, I | 2 |
| Kim, KP | 5 |
| Kang, MJ | 2 |
| Cheon, J | 2 |
| Kang, BW | 1 |
| Ryu, H | 1 |
| Kim, KW | 1 |
| Fulop, DJ | 1 |
| Zylberberg, HM | 1 |
| Wu, YL | 1 |
| Aronson, A | 1 |
| Labiner, AJ | 1 |
| Wisnivesky, J | 1 |
| Cohen, DJ | 1 |
| Sigel, KM | 1 |
| Lucas, AL | 1 |
| Dotan, E | 2 |
| Catalano, P | 2 |
| Lenchik, L | 1 |
| Boutin, R | 1 |
| Yao, X | 2 |
| Marques, HS | 1 |
| Ioffe, D | 1 |
| Zhen, DB | 2 |
| Li, D | 3 |
| Wagner, LI | 1 |
| Simon, MA | 1 |
| Wong, TZ | 1 |
| O'Dwyer, PJ | 5 |
| Shinohara, Y | 1 |
| Ueno, S | 1 |
| Aziz, MH | 1 |
| Michiels, N | 1 |
| Mieog, JSD | 2 |
| Papageorgiou, G | 1 |
| Eshmuminov, D | 1 |
| Aminjonov, B | 1 |
| Palm, RF | 1 |
| Schmocker, RK | 2 |
| Abdallah, R | 2 |
| Shaib, WL | 2 |
| Choi, YJ | 5 |
| Rose, JB | 1 |
| Patel, S | 2 |
| Wilson, GC | 2 |
| Maloney, S | 2 |
| Timmermann, L | 1 |
| Sahora, K | 2 |
| Rössler, F | 1 |
| Lopez-Lopez, V | 1 |
| Boyer, E | 1 |
| Maggino, L | 6 |
| Malinka, T | 1 |
| Park, JY | 7 |
| Prakash, L | 4 |
| Ahmad, SA | 7 |
| Helton, S | 1 |
| Hoffe, SE | 2 |
| Clavien, PA | 1 |
| Held, U | 1 |
| Lehmann, K | 1 |
| Fu, Q | 3 |
| Chen, Y | 8 |
| Huang, D | 1 |
| Guo, C | 3 |
| Zhang, X | 10 |
| Xiao, W | 1 |
| Xue, X | 1 |
| Zhang, Q | 9 |
| Gao, S | 4 |
| Que, R | 4 |
| Shen, Y | 2 |
| Wu, J | 1 |
| Zhang, M | 1 |
| Bai, X | 4 |
| Liang, T | 4 |
| Akdeniz, N | 1 |
| Kaplan, MA | 1 |
| İnanç, M | 1 |
| Uncu, D | 1 |
| Ergün, Y | 1 |
| Küçüköner, M | 1 |
| Demirci, A | 1 |
| Şendur, MAN | 1 |
| Beşiroğlu, M | 1 |
| Topçu, A | 1 |
| Yerlikaya, H | 1 |
| Urakçi, Z | 1 |
| Kiliçkap, S | 2 |
| Işikdoğan, A | 1 |
| Ninomiya, R | 1 |
| Abe, S | 2 |
| Chiyoda, T | 1 |
| Kogure, R | 1 |
| Kimura, A | 1 |
| Komagome, M | 1 |
| Maki, A | 1 |
| Beck, Y | 1 |
| Takaori, A | 1 |
| Hashimoto, D | 2 |
| Ikeura, T | 1 |
| Nakamaru, K | 1 |
| Masuda, M | 2 |
| Nakayama, S | 3 |
| Yamaki, S | 1 |
| Fujimoto, K | 1 |
| Matsuo, Y | 3 |
| Akagawa, S | 1 |
| Ishida, M | 2 |
| Yamaguchi, K | 4 |
| Imoto, S | 1 |
| Hirota, K | 1 |
| Uematsu, S | 1 |
| Satoi, S | 6 |
| Sekimoto, M | 2 |
| Naganuma, M | 1 |
| Khoury, R | 1 |
| Ibrahim, R | 1 |
| Ibrahim, T | 2 |
| Cesne, AL | 1 |
| Assi, T | 3 |
| Vilalta-Lacarra, A | 1 |
| Aldaz, A | 1 |
| Sala-Elarre, P | 1 |
| Urrizola, A | 1 |
| Chopitea, A | 1 |
| Arbea, L | 1 |
| Rotellar, F | 1 |
| Pardo, F | 1 |
| Martí-Cruchaga, P | 1 |
| Zozaya, G | 1 |
| Subtil, JC | 1 |
| Rodríguez-Rodríguez, J | 1 |
| Ponz-Sarvise, M | 3 |
| Tian, Y | 1 |
| Han, W | 1 |
| Fu, L | 1 |
| Lv, K | 1 |
| Zhou, X | 2 |
| Shibahara, R | 1 |
| Asami, H | 1 |
| Okabe, Y | 2 |
| Pilgrim, CHC | 1 |
| Finn, N | 1 |
| Stuart, E | 1 |
| Philip, J | 1 |
| Steel, S | 1 |
| Croagh, D | 1 |
| Tebbutt, NC | 6 |
| Nicolais, LM | 1 |
| Caron, M | 1 |
| Verdini, N | 1 |
| Fitzgerald, TL | 1 |
| Procaccio, L | 1 |
| Merz, V | 2 |
| Fasano, M | 1 |
| Vaccaro, V | 2 |
| Giommoni, E | 1 |
| Pretta, A | 1 |
| Noventa, S | 1 |
| Satolli, MA | 3 |
| Giordano, G | 1 |
| Zichi, C | 1 |
| Pinto, C | 1 |
| Zecchetto, C | 2 |
| Barsotti, G | 1 |
| De Vita, F | 1 |
| Milella, M | 6 |
| Antonuzzo, L | 1 |
| Scartozzi, M | 1 |
| Zaniboni, A | 2 |
| Spadi, R | 2 |
| Casalino, S | 1 |
| Bergamo, F | 1 |
| De Toni, C | 1 |
| Melisi, D | 4 |
| Lonardi, S | 3 |
| Petrelli, F | 4 |
| Parisi, A | 1 |
| Tomasello, G | 1 |
| Mini, E | 1 |
| Arru, M | 1 |
| Russo, A | 1 |
| Garrone, O | 1 |
| Khakoo, S | 1 |
| Ardito, R | 1 |
| Ghidini, M | 3 |
| Mangieri, CW | 1 |
| Valenzuela, CD | 1 |
| Solsky, IB | 1 |
| Erali, RA | 1 |
| Pardee, T | 1 |
| Lima, CMSR | 2 |
| Howerton, R | 1 |
| Clark, CJ | 1 |
| Shen, P | 2 |
| Park, BK | 1 |
| Seo, JH | 2 |
| Han, JH | 1 |
| Lee, KJ | 2 |
| Son, KJ | 1 |
| Choi, JK | 1 |
| Chen, KT | 2 |
| Madison, R | 1 |
| Moore, J | 1 |
| Jin, D | 1 |
| Fleischmann, Z | 1 |
| Newberg, J | 1 |
| Schrock, A | 1 |
| Bhardwaj, N | 1 |
| Lofgren, KT | 1 |
| Frampton, G | 1 |
| Hegde, P | 1 |
| Fabrizio, D | 1 |
| Pishvaian, MJ | 3 |
| Ebot, E | 1 |
| Singhi, A | 1 |
| Sokol, E | 1 |
| Jiang, X | 1 |
| Lee, MJ | 1 |
| Luo, T | 1 |
| Tillman, L | 1 |
| Lin, W | 1 |
| Watsuji, K | 1 |
| Seiki, Y | 1 |
| Kotani, M | 1 |
| Kimura, M | 1 |
| Nozaki, K | 1 |
| Takagi, M | 1 |
| Schlick, K | 4 |
| Gantschnigg, A | 3 |
| Seymer, A | 1 |
| Huemer, F | 1 |
| Greil, R | 6 |
| Weiss, L | 2 |
| Zwart, ES | 1 |
| van Ee, T | 1 |
| Farina, A | 1 |
| Versteijne, E | 1 |
| Meijer, LL | 3 |
| van Kooyk, Y | 1 |
| Mebius, RE | 1 |
| Kazemier, G | 7 |
| Leonhardt, CS | 1 |
| Pils, D | 1 |
| Gustorff, C | 1 |
| Warshaw, AL | 10 |
| Prager, G | 1 |
| Schindl, M | 1 |
| Castillo, CF | 4 |
| Hank, T | 1 |
| Cartwright, BM | 1 |
| Corso, JN | 1 |
| Lightner, J | 1 |
| Whitted, C | 1 |
| Torrenegra, RD | 1 |
| Krishnan, K | 1 |
| Palau, VE | 1 |
| Singhal, R | 1 |
| Rogers, SC | 1 |
| Lee, JH | 3 |
| Ramnaraign, B | 1 |
| Sahin, I | 1 |
| Fabregas, JC | 1 |
| Thomas, RM | 2 |
| Hughes, SJ | 1 |
| Nassour, I | 1 |
| Hitchcock, K | 1 |
| Russell, K | 1 |
| Kayaleh, O | 1 |
| Turk, A | 1 |
| Zlotecki, R | 1 |
| DeRemer, DL | 1 |
| de Carvalho, LFA | 1 |
| Gryspeerdt, F | 1 |
| Rashidian, N | 1 |
| Van Hove, K | 1 |
| Maertens, L | 1 |
| Ribeiro, S | 1 |
| Hoorens, A | 1 |
| Coveler, AL | 3 |
| Pillarisetty, VG | 1 |
| Koh, WJ | 1 |
| Park, JO | 10 |
| King, GG | 1 |
| Sham, JG | 1 |
| Hannan, LM | 1 |
| Mann, GN | 1 |
| Baker, KK | 1 |
| Redman, MW | 1 |
| Swanson, PE | 1 |
| Chiorean, EG | 7 |
| Whiting, SH | 1 |
| Huang, W | 1 |
| Huang, P | 3 |
| Guo, H | 2 |
| Huang, Z | 2 |
| Wei, M | 1 |
| Guo, J | 2 |
| Lin, C | 7 |
| Li, Y | 5 |
| Luo, B | 1 |
| Grierson, PM | 1 |
| Suresh, R | 3 |
| Tan, B | 1 |
| Pedersen, KS | 2 |
| Amin, M | 1 |
| Park, H | 3 |
| Trikalinos, NA | 1 |
| Boice, N | 1 |
| Brown, A | 1 |
| Bansod, S | 1 |
| Wang-Gillam, A | 18 |
| Lim, KH | 3 |
| Sütcüoğlu, O | 1 |
| Doğan, A | 1 |
| Yilmaz, F | 1 |
| Şahin, AB | 1 |
| Şahin, TK | 1 |
| Esen, SA | 1 |
| Erol, C | 1 |
| Üner, A | 1 |
| Özet, A | 2 |
| Turan, N | 1 |
| Eraslan, E | 1 |
| Deligönül, A | 1 |
| Odabaş, H | 1 |
| Günel, N | 1 |
| Uçar, G | 1 |
| Dede, DŞ | 1 |
| Dizdar, Ö | 1 |
| Çubukçu, E | 1 |
| Öksüzoğlu, ÖB | 1 |
| Emre Yildirim, M | 1 |
| Yazici, O | 1 |
| Özdemir, N | 1 |
| Lopez-Blazquez, C | 1 |
| Lacalle-Gonzalez, C | 1 |
| Sanz-Criado, L | 1 |
| Ochieng' Otieno, M | 1 |
| Garcia-Foncillas, J | 1 |
| Martinez-Useros, J | 1 |
| Seelen, LWF | 1 |
| de Wilde, RF | 2 |
| van Santvoort, HC | 7 |
| Tummala, T | 1 |
| Sevilla Uruchurtu, AS | 1 |
| Cruz, A | 2 |
| Huntington, KE | 1 |
| George, A | 1 |
| Liguori, NR | 1 |
| Zhang, L | 1 |
| Abbas, AE | 1 |
| Azzoli, CG | 1 |
| El-Deiry, WS | 1 |
| Endo, Y | 3 |
| Kitago, M | 2 |
| Aiura, K | 4 |
| Shinoda, M | 2 |
| Yagi, H | 1 |
| Oshima, G | 1 |
| Hori, S | 1 |
| Nakano, Y | 2 |
| Itano, O | 2 |
| Fukada, J | 1 |
| Masugi, Y | 2 |
| Kitagawa, Y | 3 |
| Tran, NH | 1 |
| Sahai, V | 1 |
| Griffith, KA | 3 |
| Nathan, H | 2 |
| Kaza, R | 1 |
| Cuneo, KC | 1 |
| Shi, J | 2 |
| Kim, E | 1 |
| Sonnenday, CJ | 1 |
| Cho, CS | 1 |
| Lawrence, TS | 4 |
| Zalupski, MM | 9 |
| Tossey, JC | 1 |
| Reardon, J | 3 |
| VanDeusen, JB | 1 |
| Noonan, AM | 1 |
| Porter, K | 1 |
| Arango, MJ | 1 |
| Fujiwara-Tani, R | 1 |
| Kishi, S | 1 |
| Mori, S | 3 |
| Luo, Y | 2 |
| Ohmori, H | 1 |
| Kawahara, I | 1 |
| Goto, K | 1 |
| Nishiguchi, Y | 1 |
| Mori, T | 1 |
| Sho, M | 9 |
| Kondo, M | 1 |
| Kuniyasu, H | 1 |
| Tsujie, M | 3 |
| Fumita, S | 1 |
| Ishikawa, H | 1 |
| Kitani, K | 1 |
| Fukuda, S | 1 |
| Manabe, H | 1 |
| Akashi, Y | 1 |
| Wakasa, T | 1 |
| Shiono, H | 1 |
| Tamura, T | 2 |
| Yukawa, M | 1 |
| Inoue, M | 1 |
| Philip, PA | 11 |
| Buyse, ME | 1 |
| Alistar, AT | 1 |
| Rocha Lima, CM | 3 |
| Luther, S | 1 |
| Pardee, TS | 1 |
| Van Cutsem, E | 4 |
| Verma, V | 3 |
| Lazenby, A | 2 |
| Ly, QP | 3 |
| Berim, LD | 1 |
| Schwarz, JK | 3 |
| Madiyalakan, M | 1 |
| Nicodemus, CF | 1 |
| Hollingsworth, MA | 3 |
| Meza, JL | 3 |
| Are, C | 4 |
| Padussis, J | 1 |
| Grem, JL | 6 |
| Iyikesici, MS | 1 |
| Voskanyan, SE | 1 |
| Shabalin, MV | 1 |
| Artemiyev, AI | 1 |
| Kolyshev, IY | 1 |
| Bogoevich, Z | 1 |
| Kucherov, NN | 1 |
| Bashkov, AN | 1 |
| Naydenov, EV | 1 |
| Bonnet, E | 1 |
| Mastier, C | 1 |
| Lardy-Cléaud, A | 1 |
| Rochefort, P | 1 |
| Guibert, P | 1 |
| Cattey-Javouhey, A | 1 |
| Fornaro, L | 3 |
| Leone, F | 1 |
| Vienot, A | 4 |
| Casadei-Gardini, A | 2 |
| Vivaldi, C | 4 |
| Lombardi, P | 2 |
| De Luca, E | 1 |
| Vernerey, D | 4 |
| Sperti, E | 1 |
| Musettini, G | 2 |
| Neuzillet, C | 6 |
| Falcone, A | 3 |
| Pasquini, G | 2 |
| Clerico, M | 1 |
| Passardi, A | 4 |
| Buscaglia, P | 1 |
| Meurisse, A | 3 |
| Aglietta, M | 1 |
| Brac, C | 2 |
| Vasile, E | 5 |
| Montagnani, F | 2 |
| Polish, A | 1 |
| Joseph, NE | 1 |
| Marsh, RW | 2 |
| Kaissis, G | 1 |
| Ziegelmayer, S | 1 |
| Lohöfer, F | 1 |
| Steiger, K | 1 |
| Algül, H | 3 |
| Muckenhuber, A | 1 |
| Yen, HY | 1 |
| Rummeny, E | 1 |
| Friess, H | 20 |
| Schmid, R | 2 |
| Weichert, W | 1 |
| Siveke, JT | 11 |
| Braren, R | 2 |
| Gaszynski, R | 1 |
| Gray, A | 1 |
| Merrett, N | 1 |
| Pointet, AL | 2 |
| Pozet, A | 1 |
| Lourenco, N | 2 |
| Locher, C | 1 |
| Desrame, J | 4 |
| Soularue, E | 1 |
| Le Roy, B | 1 |
| Shimmura, H | 1 |
| Kuramochi, H | 1 |
| Jibiki, N | 1 |
| Katagiri, S | 1 |
| Nishino, T | 1 |
| Araida, T | 1 |
| Chinnaiyan, SK | 1 |
| Soloman, AM | 1 |
| Perumal, RK | 1 |
| Gopinath, A | 1 |
| Balaraman, M | 1 |
| Wu, G | 1 |
| Baine, MJ | 1 |
| Zhao, N | 1 |
| Li, S | 6 |
| Kruger, S | 6 |
| Schirle, K | 1 |
| Haas, M | 10 |
| Crispin, A | 1 |
| Schirra, J | 1 |
| D'Haese, JG | 2 |
| Kunz, WG | 1 |
| Ricke, J | 1 |
| Ormanns, S | 5 |
| Kirchner, T | 5 |
| Kobold, S | 2 |
| Ilmer, M | 1 |
| Gebauer, L | 1 |
| Westphalen, CB | 4 |
| von Bergwelt-Baildon, M | 2 |
| Werner, J | 10 |
| Heinemann, V | 25 |
| Boeck, S | 18 |
| Sarvepalli, D | 1 |
| Rashid, MU | 1 |
| Rahman, AU | 1 |
| Ullah, W | 1 |
| Hussain, I | 1 |
| Hasan, B | 1 |
| Jehanzeb, S | 1 |
| Khan, AK | 1 |
| Jain, AG | 1 |
| Khetpal, N | 1 |
| Tsang, ES | 1 |
| Spratlin, J | 1 |
| Kong, S | 1 |
| Xu, Y | 5 |
| Gill, S | 5 |
| Mahalingam, D | 1 |
| Wilkinson, GA | 1 |
| Eng, KH | 1 |
| Fields, P | 1 |
| Raber, P | 1 |
| Moseley, JL | 1 |
| Cheetham, K | 1 |
| Coffey, M | 1 |
| Nuovo, G | 1 |
| Kalinski, P | 1 |
| Zhang, B | 3 |
| Arora, SP | 1 |
| Fountzilas, C | 1 |
| Daunys, S | 1 |
| Matulis, D | 1 |
| Petrikaitė, V | 1 |
| Bang, JH | 2 |
| Nam, AR | 2 |
| Park, JE | 1 |
| Jin, MH | 1 |
| Bang, YJ | 8 |
| Chikhladze, S | 1 |
| Lederer, AK | 1 |
| Kousoulas, L | 1 |
| Reinmuth, M | 1 |
| Sick, O | 1 |
| Fichtner-Feigl, S | 1 |
| Wittel, UA | 2 |
| Liu, M | 2 |
| Zhang, Y | 8 |
| Yang, J | 2 |
| Cui, X | 1 |
| Zhou, Z | 1 |
| Zhan, H | 1 |
| Ding, K | 1 |
| Tian, X | 1 |
| Yang, Z | 1 |
| Fung, KA | 1 |
| Edil, BH | 7 |
| Postier, RG | 1 |
| Bronze, MS | 1 |
| Fernandez-Zapico, ME | 1 |
| Stemmler, MP | 1 |
| Brabletz, T | 1 |
| Li, YP | 1 |
| Houchen, CW | 1 |
| Li, M | 2 |
| Cheng, S | 1 |
| Redmond-Misner, R | 1 |
| Qiao, L | 1 |
| Earle, C | 1 |
| Berry, SR | 1 |
| Welch, S | 1 |
| Meyers, BM | 1 |
| Schwartz, D | 1 |
| McLeod, R | 1 |
| Kennedy, ED | 1 |
| Harrison, JM | 1 |
| Horick, NK | 1 |
| Keane, FK | 2 |
| Fabienne, P | 1 |
| Metges, JP | 1 |
| Andre, T | 10 |
| Louvet, C | 12 |
| El Hajbi, F | 2 |
| Faroux, R | 2 |
| Rebischung, C | 2 |
| Tournigand, C | 4 |
| Cros, J | 2 |
| Kay, R | 1 |
| Hamm, A | 1 |
| El Hariry, I | 1 |
| Huang, DB | 1 |
| Guo, CX | 1 |
| Fu, QH | 1 |
| Zhang, XC | 1 |
| Tang, TY | 1 |
| Su, W | 2 |
| Chen, W | 2 |
| Ma, T | 5 |
| Gao, SL | 1 |
| Que, RS | 1 |
| Bai, XL | 1 |
| Liang, TB | 1 |
| Wattenberg, MM | 1 |
| Asch, D | 1 |
| Yu, S | 1 |
| Domchek, SM | 1 |
| Nathanson, KL | 1 |
| Rosen, MA | 1 |
| Beatty, GL | 1 |
| Siegelman, ES | 1 |
| Reiss, KA | 2 |
| Lee, KH | 10 |
| Chiu, CF | 3 |
| Kim, JS | 7 |
| Shim, HJ | 1 |
| Rau, KM | 1 |
| Choi, HJ | 2 |
| Belanger, B | 8 |
| Farren, MR | 1 |
| Sayegh, L | 1 |
| Ware, MB | 1 |
| Chen, HR | 1 |
| Liang, Y | 1 |
| Krasinskas, A | 1 |
| Zaidi, M | 1 |
| Sarmiento, JM | 2 |
| Kooby, D | 3 |
| El-Rayes, B | 2 |
| Shaib, W | 2 |
| Lesinski, GB | 1 |
| Medrano, J | 1 |
| Launay, S | 2 |
| Poizat, F | 5 |
| Giovannini, M | 10 |
| Law, HC | 1 |
| Lagundžin, D | 1 |
| Clement, EJ | 1 |
| Qiao, F | 1 |
| Wagner, ZS | 1 |
| Krieger, KL | 1 |
| Costanzo-Garvey, D | 1 |
| Caffrey, TC | 1 |
| DiMaio, DJ | 1 |
| Grandgenett, PM | 1 |
| Cook, LM | 1 |
| Fisher, KW | 1 |
| Yu, F | 1 |
| Woods, NT | 1 |
| Lof, S | 1 |
| Korrel, M | 1 |
| van Hilst, J | 1 |
| Boggi, U | 3 |
| Casadei, R | 1 |
| Dokmak, S | 1 |
| Edwin, B | 1 |
| Falconi, M | 6 |
| de Pastena, M | 2 |
| Tomazic, A | 1 |
| Wilmink, H | 1 |
| Zerbi, A | 8 |
| Abu Hilal, M | 3 |
| Macarulla Mercadé, T | 1 |
| Bodoky, G | 10 |
| Blanc, JF | 12 |
| Dean, A | 2 |
| de Santibañes, M | 1 |
| Sanchez Clariá, R | 1 |
| de Santibañes, E | 1 |
| Pekolj, J | 1 |
| Mazza, O | 1 |
| van Roessel, S | 3 |
| Strijker, M | 1 |
| Steyerberg, EW | 1 |
| Groen, JV | 1 |
| Mieog, JS | 1 |
| Groot, VP | 2 |
| Marchegiani, G | 4 |
| Suhool, A | 1 |
| Zarantonello, L | 1 |
| Samra, JS | 2 |
| Gill, AJ | 1 |
| Bolm, L | 1 |
| van Eijck, CH | 7 |
| Del Chiaro, M | 5 |
| Mizrahi, JD | 2 |
| Rogers, JE | 3 |
| Hess, KR | 4 |
| Wolff, RA | 21 |
| Varadhachary, GR | 7 |
| Javle, MM | 2 |
| Shroff, RT | 1 |
| Ho, L | 4 |
| Fogelman, DR | 6 |
| Raghav, KPS | 1 |
| Overman, MJ | 2 |
| Pant, S | 5 |
| Nielsen, MFB | 1 |
| Sørensen, MD | 1 |
| Wirenfeldt, M | 1 |
| Kristensen, BW | 1 |
| Schrøder, HD | 1 |
| Detlefsen, S | 2 |
| Barzi, A | 1 |
| Miksad, R | 1 |
| Corvino, FA | 2 |
| Torres, AZ | 1 |
| Mamlouk, K | 3 |
| Pulgar, S | 1 |
| Valderrama, A | 1 |
| Bekaii-Saab, T | 10 |
| Ahn, D | 1 |
| Neyaz, A | 1 |
| Tabb, ES | 1 |
| Shih, A | 1 |
| Zhao, Q | 1 |
| Shroff, S | 1 |
| Taylor, MS | 3 |
| Rickelt, S | 1 |
| Ting, DT | 3 |
| Deshpande, V | 7 |
| Latenstein, AEJ | 1 |
| Mackay, TM | 1 |
| Creemers, GJ | 3 |
| Haj Mohammad, N | 1 |
| Ten Tije, BJ | 1 |
| de Vos-Geelen, J | 4 |
| van der Geest, LGM | 1 |
| Bozkurt Duman, B | 1 |
| Çil, T | 1 |
| Otten, JMMB | 1 |
| Fijnheer, R | 1 |
| Hong, E | 1 |
| Park, S | 2 |
| Ooshima, A | 1 |
| Hong, CP | 1 |
| Heo, JS | 6 |
| An, H | 1 |
| Kang, JM | 1 |
| Park, SH | 3 |
| Kim, SJ | 1 |
| Rasmussen, LS | 1 |
| Fristrup, CW | 1 |
| Jensen, BV | 1 |
| Weber, B | 1 |
| Yilmaz, MK | 1 |
| Poulsen, LØ | 1 |
| Ladekarl, M | 2 |
| Østerlind, K | 1 |
| Larsen, JS | 1 |
| Skuladottir, H | 1 |
| Hansen, CP | 1 |
| Mortensen, FV | 1 |
| Sall, M | 1 |
| Bøgsted, M | 1 |
| Falkmer, UG | 1 |
| He, C | 2 |
| Wang, J | 5 |
| Lin, X | 3 |
| Petito, LC | 1 |
| García-Albéniz, X | 1 |
| Logan, RW | 1 |
| Howlader, N | 1 |
| Mariotto, AB | 1 |
| Dahabreh, IJ | 1 |
| Moureau-Zabotto, L | 5 |
| O'Kane, GM | 2 |
| Grünwald, BT | 1 |
| Jang, GH | 2 |
| Masoomian, M | 1 |
| Picardo, S | 1 |
| Grant, RC | 2 |
| Denroche, RE | 2 |
| Zhang, A | 2 |
| Wang, Y | 7 |
| Lam, B | 1 |
| Krzyzanowski, PM | 1 |
| Lungu, IM | 1 |
| Bartlett, JMS | 1 |
| Peralta, M | 1 |
| Vyas, F | 1 |
| Khokha, R | 1 |
| Biagi, J | 1 |
| Chadwick, D | 1 |
| Ramotar, S | 1 |
| Hutchinson, S | 1 |
| Dodd, A | 3 |
| Wilson, JM | 2 |
| Notta, F | 2 |
| Zogopoulos, G | 2 |
| Gallinger, S | 3 |
| Knox, JJ | 3 |
| Fischer, SE | 2 |
| Keum, J | 1 |
| Lee, HS | 3 |
| Jo, JH | 2 |
| Chung, MJ | 4 |
| Park, SW | 6 |
| Song, SY | 5 |
| Bang, S | 5 |
| Loi, M | 2 |
| Magallon-Baro, A | 1 |
| Suker, M | 6 |
| Van Eijck, C | 2 |
| Hoogeman, M | 1 |
| Nuyttens, JJ | 4 |
| Doleh, Y | 2 |
| Lal, LS | 1 |
| Blauer-Petersen, C | 1 |
| Antico, G | 2 |
| Pishvaian, M | 1 |
| Lipner, MB | 1 |
| Peng, XL | 1 |
| Jin, C | 4 |
| Gao, Y | 1 |
| East, MP | 1 |
| Rashid, NU | 1 |
| Moffitt, RA | 1 |
| Herrera Loeza, SG | 1 |
| Morrison, AB | 1 |
| Golitz, BT | 1 |
| Vaziri, C | 1 |
| Graves, LM | 1 |
| Johnson, GL | 1 |
| Yeh, JJ | 3 |
| Choi, YH | 1 |
| You, MS | 1 |
| Shin, BS | 1 |
| Paik, WH | 5 |
| Kim, SW | 5 |
| Fu, X | 2 |
| Tang, N | 2 |
| Xie, WQ | 1 |
| Mao, L | 1 |
| Qiu, YD | 2 |
| Thanikachalam, K | 1 |
| Damarla, V | 1 |
| Seixas, T | 1 |
| Dobrosotskaya, I | 1 |
| Wollner, I | 2 |
| Kwon, D | 1 |
| Winters, K | 1 |
| Raoufi, M | 1 |
| Siddiqui, F | 1 |
| Khan, G | 1 |
| Perri, G | 2 |
| Caravati, A | 1 |
| Fogelman, D | 3 |
| Koay, EJ | 2 |
| Herman, J | 3 |
| Kim, M | 4 |
| Ikoma, N | 2 |
| Tzeng, CW | 4 |
| Lee, JE | 18 |
| Matsumoto, T | 2 |
| Kurioka, Y | 1 |
| Okazaki, U | 1 |
| Kimura, S | 1 |
| Miura, K | 2 |
| Tsuduki, T | 1 |
| Takagi, S | 1 |
| Takatani, M | 1 |
| Morishita, H | 1 |
| Attard, JA | 1 |
| Isaac, J | 1 |
| Roberts, K | 1 |
| Faulkner, T | 1 |
| Chatzizacharias, NA | 2 |
| Tsuchiya, N | 1 |
| Matsuyama, R | 1 |
| Murakami, T | 2 |
| Yabushita, Y | 1 |
| Sawada, Y | 1 |
| Kumamoto, T | 1 |
| Endo, I | 6 |
| Fanchon, LM | 1 |
| Russell, J | 1 |
| Pillarsetty, N | 1 |
| O'Donoghue, I | 1 |
| Gangangari, K | 1 |
| Humm, JL | 1 |
| Springfeld, C | 4 |
| Jäger, D | 14 |
| Neoptolemos, JP | 26 |
| Golan, T | 4 |
| Barenboim, A | 2 |
| Lahat, G | 2 |
| Nachmany, I | 2 |
| Goykhman, Y | 2 |
| Shacham-Shmueli, E | 1 |
| Halpern, N | 1 |
| Brazowski, E | 2 |
| Geva, R | 4 |
| Wolf, I | 2 |
| Goldes, Y | 2 |
| Ben-Haim, M | 1 |
| Klausner, JM | 3 |
| Lubezky, N | 2 |
| Laurent-Badr, Q | 1 |
| Barbe, C | 1 |
| Brugel, M | 1 |
| Volet, J | 3 |
| Grelet, S | 1 |
| Desot, E | 1 |
| Botsen, D | 1 |
| Deguelte, S | 1 |
| Pitta, A | 1 |
| Abdelli, N | 1 |
| Brasseur, M | 1 |
| Dwarkasing, RS | 1 |
| Eskens, FALM | 3 |
| Macaire, P | 1 |
| Paris, J | 1 |
| Vincent, J | 2 |
| Bengrine-Lefevre, L | 2 |
| Schmitt, A | 2 |
| Cai, Z | 1 |
| Wolfe, AR | 1 |
| Prabhakar, D | 1 |
| Yildiz, VO | 1 |
| Dillhoff, M | 3 |
| Abushahin, L | 2 |
| Alexandra Diaz, D | 1 |
| Miller, ED | 1 |
| Noonan, A | 1 |
| Templeton, S | 1 |
| Moser, M | 2 |
| Wall, C | 1 |
| Shaw, J | 2 |
| Chalchal, H | 2 |
| Zaidi, A | 2 |
| Ahmed, S | 3 |
| Bockorny, B | 2 |
| Semenisty, V | 2 |
| Borazanci, E | 2 |
| Stemmer, SM | 3 |
| Borad, MJ | 1 |
| Ramirez, RA | 1 |
| Abad, DG | 2 |
| Feliu, J | 4 |
| Muñoz, A | 4 |
| Peled, A | 2 |
| Lustig, TM | 1 |
| Bohana-Kashtan, O | 1 |
| Shaw, SM | 1 |
| Sorani, E | 2 |
| Chaney, M | 2 |
| Kadosh, S | 2 |
| Vainstein Haras, A | 1 |
| Von Hoff, DD | 9 |
| Hidalgo, M | 7 |
| Probst, EA | 1 |
| Smith, AL | 1 |
| Abad, JD | 1 |
| Phung, T | 1 |
| Abdul-Rahim, O | 1 |
| Khushman, M | 1 |
| Vidra, R | 1 |
| Bodea, R | 1 |
| Mercea, V | 1 |
| Nemes, A | 1 |
| Kang, J | 2 |
| Choi, JH | 1 |
| Ahn, DW | 1 |
| Jeong, JB | 1 |
| Pan, CH | 1 |
| Otsuka, Y | 1 |
| Sridharan, B | 1 |
| Woo, M | 1 |
| Leiton, CV | 1 |
| Babu, S | 1 |
| Torrente Gonçalves, M | 1 |
| Kawalerski, RR | 1 |
| K Bai, JD | 1 |
| Scampavia, L | 1 |
| Spicer, T | 1 |
| Escobar-Hoyos, LF | 1 |
| Shroyer, KR | 1 |
| Mas, L | 2 |
| Schwarz, L | 2 |
| Frampton, JE | 1 |
| Paluri, RK | 1 |
| Kasi, A | 2 |
| Young, C | 1 |
| Posey, JA | 2 |
| Mundry, CS | 1 |
| Eberle, KC | 1 |
| Singh, PK | 1 |
| Mehla, K | 1 |
| Rowan, CG | 1 |
| Oestreicher, N | 1 |
| Yeganegi, H | 1 |
| Colombo, PE | 1 |
| Quenet, F | 1 |
| Alric, P | 1 |
| Mourregot, A | 1 |
| Neron, M | 1 |
| Rouanet, P | 2 |
| Carrier, G | 1 |
| Wu, AA | 1 |
| Bever, KM | 1 |
| Ho, WJ | 1 |
| Fertig, EJ | 1 |
| Niu, N | 1 |
| Parkinson, RM | 1 |
| Durham, JN | 1 |
| Onners, B | 1 |
| Ferguson, AK | 1 |
| Wilt, C | 1 |
| Ko, AH | 10 |
| Laheru, DA | 8 |
| Anders, RA | 1 |
| Sugar, EA | 3 |
| Jaffee, EM | 4 |
| Le, DT | 4 |
| Erstad, DJ | 2 |
| Sojoodi, M | 2 |
| Jordan, VC | 1 |
| Farrar, CT | 1 |
| Axtell, AL | 1 |
| Rotile, NJ | 1 |
| Jones, C | 1 |
| Graham-O'Regan, KA | 2 |
| Ferreira, DS | 1 |
| Michelakos, T | 4 |
| Kontos, F | 2 |
| Chawla, A | 1 |
| Ghoshal, S | 2 |
| Chen, YI | 1 |
| Arora, G | 1 |
| Humblet, V | 1 |
| Bardeesy, N | 2 |
| Lanuti, M | 2 |
| Tanabe, KK | 3 |
| Caravan, P | 2 |
| Fuchs, BC | 3 |
| Begg, SKS | 1 |
| Birnbaum, DJ | 1 |
| Wellner, UF | 1 |
| Schilling, O | 1 |
| Liss, AS | 1 |
| Fumet, JD | 1 |
| Bengrine, L | 1 |
| Hennequin, A | 1 |
| Granconato, L | 1 |
| Palmier, R | 1 |
| Parikh, P | 1 |
| Moezardalan, K | 1 |
| Anantharaman, A | 1 |
| Azarm, A | 1 |
| Lai, J | 1 |
| Rinaldi, Y | 2 |
| Khemissa Akouz, F | 1 |
| Wahiba, B | 1 |
| Louafi, S | 2 |
| Gratet, A | 1 |
| Miglianico, L | 1 |
| Laharie, H | 1 |
| Bouhier Leporrier, K | 1 |
| Thirot Bidault, A | 2 |
| Texereau, P | 2 |
| Coriat, R | 5 |
| Terrebonne, E | 4 |
| Gouttebel, MC | 1 |
| Liao, Y | 1 |
| Lam, LM | 1 |
| He, L | 1 |
| Tsang, YS | 1 |
| Di, YS | 1 |
| Liang, ST | 1 |
| Xia, Q | 1 |
| Nicolle, R | 1 |
| Blum, Y | 1 |
| Duconseil, P | 1 |
| Vanbrugghe, C | 1 |
| Brandone, N | 1 |
| Roques, J | 1 |
| Bigonnet, M | 1 |
| Gayet, O | 1 |
| Rubis, M | 1 |
| Elarouci, N | 1 |
| Armenoult, L | 1 |
| Ayadi, M | 1 |
| de Reyniès, A | 1 |
| Grandval, P | 1 |
| Garcia, S | 1 |
| Canivet, C | 1 |
| Bournet, B | 1 |
| Buscail, L | 2 |
| Moutardier, V | 5 |
| Iovanna, J | 3 |
| Dusetti, N | 2 |
| Kim, EJ | 2 |
| Kim, YJ | 4 |
| Lee, HI | 1 |
| Jeong, SH | 2 |
| Nam, HJ | 1 |
| Cho, JH | 1 |
| Tingle, SJ | 1 |
| Severs, GR | 1 |
| Moir, JAG | 1 |
| White, SA | 1 |
| Feeney, K | 1 |
| Gracián, AC | 1 |
| Hung, A | 2 |
| Bendell, J | 3 |
| Hecht, JR | 5 |
| Barnes, CA | 1 |
| Dua, K | 1 |
| Ritch, PS | 2 |
| Kulkarni, N | 1 |
| Merola, E | 1 |
| Dal Buono, A | 1 |
| Denecke, T | 2 |
| Arsenic, R | 1 |
| Jann, H | 1 |
| Wiedenmann, B | 2 |
| Pavel, ME | 1 |
| Cecchini, M | 1 |
| Miccio, JA | 1 |
| Pahade, J | 1 |
| Lacy, J | 6 |
| Salem, RR | 2 |
| Johnson, SB | 1 |
| Blakaj, A | 1 |
| Stein, S | 2 |
| Kortmansky, JS | 3 |
| Johung, KL | 2 |
| Barrord, M | 1 |
| Olowokure, O | 1 |
| Sussman, J | 1 |
| Smith, M | 3 |
| Poreddy, S | 1 |
| Esslinger, H | 1 |
| Latif, T | 1 |
| Choe, K | 1 |
| Kharofa, J | 2 |
| Patil, NR | 1 |
| Khan, GN | 1 |
| Ye, L | 1 |
| Hines, OJ | 4 |
| Qiao, W | 2 |
| Wolff, R | 4 |
| Overman, M | 1 |
| Javle, M | 5 |
| Gu, J | 2 |
| Bhutiani, N | 1 |
| Zheng, Q | 1 |
| Pandit, H | 1 |
| Yu, Y | 1 |
| Pulliam, ZR | 1 |
| Tan, M | 1 |
| Martin, RCG | 2 |
| Pazderová, N | 1 |
| Urbán, V | 1 |
| Makovník, M | 1 |
| Macák, D | 1 |
| Janega, P | 2 |
| Chovanec, M | 1 |
| Rejleková, K | 1 |
| Mardiak, J | 1 |
| Mego, M | 2 |
| Cardin, DB | 2 |
| Lenz, HJ | 4 |
| Messersmith, W | 1 |
| O'Neil, B | 1 |
| Cohen, SJ | 3 |
| Denlinger, CS | 1 |
| Shahda, S | 3 |
| Astsaturov, I | 1 |
| Kapoun, AM | 1 |
| Brachmann, RK | 1 |
| Uttamsingh, S | 1 |
| Stagg, RJ | 1 |
| Weekes, C | 1 |
| Kita, A | 1 |
| Fujiya, M | 1 |
| Konishi, H | 1 |
| Kashima, S | 1 |
| Iwama, T | 1 |
| Ijiri, M | 1 |
| Murakami, Y | 2 |
| Takauji, S | 1 |
| Goto, T | 1 |
| Sakatani, A | 1 |
| Ando, K | 1 |
| Ueno, N | 2 |
| Ogawa, N | 1 |
| Okumura, T | 1 |
| Pardillos Tomé, A | 1 |
| Bajador Andreu, E | 1 |
| Comín Orce, A | 1 |
| Marcilla Córdoba, F | 1 |
| Weniger, M | 2 |
| Moir, J | 2 |
| Damm, M | 2 |
| Kordes, M | 2 |
| Rosendahl, J | 2 |
| Ceyhan, GO | 2 |
| Schorn, S | 2 |
| Duong, M | 2 |
| Sohal, DPS | 3 |
| Gandhi, NS | 2 |
| Beg, MS | 2 |
| Wade, JL | 2 |
| Guthrie, KA | 4 |
| Lowy, AM | 5 |
| Li, H | 3 |
| Jiang, W | 4 |
| Liu, XN | 1 |
| Yuan, LY | 1 |
| Li, TJ | 1 |
| Xu, SS | 1 |
| Zhang, WH | 1 |
| Gao, HL | 1 |
| Han, X | 2 |
| Wang, WQ | 1 |
| Wu, CT | 1 |
| Yu, XJ | 2 |
| Xu, HX | 1 |
| Liu, L | 6 |
| Kim, BH | 2 |
| Lee, KB | 2 |
| Kang, JH | 4 |
| Byun, JH | 2 |
| Kim, HJ | 5 |
| Byun, Y | 2 |
| Kim, HS | 2 |
| Han, Y | 2 |
| Lee, K | 1 |
| Jang, JK | 1 |
| Son, JH | 1 |
| Hong, SM | 2 |
| Seo, DW | 4 |
| Lee, MG | 2 |
| Franco, F | 1 |
| Camara, JC | 1 |
| Martín-Valadés, JI | 1 |
| López-Alfonso, A | 1 |
| Marrupe, D | 1 |
| Gutiérrez-Abad, D | 1 |
| Martínez-Amores, B | 1 |
| León, A | 1 |
| Juez, I | 1 |
| Pérez, M | 1 |
| Royuela, A | 1 |
| Ruiz-Casado, A | 1 |
| Vroomen, LG | 1 |
| Ruarus, AH | 1 |
| Derksen, TC | 1 |
| de Jong, MC | 1 |
| Puijk, RS | 1 |
| Sorgedrager, NS | 1 |
| Vogel, JA | 3 |
| Scheffer, HJ | 1 |
| van Lienden, KP | 6 |
| Meijerink, MR | 2 |
| Iwashita, T | 1 |
| Ichikawa, H | 1 |
| Iwasa, Y | 1 |
| Mita, N | 1 |
| Shiraki, M | 1 |
| Shimizu, M | 1 |
| Chevalier, H | 2 |
| Peugniez, C | 1 |
| Borg, C | 2 |
| Woo, SM | 4 |
| Shin, DW | 3 |
| Yang, SY | 1 |
| Kim, MJ | 1 |
| Lee, WJ | 4 |
| Cha, HS | 1 |
| Park, P | 1 |
| Collienne, M | 1 |
| Kuhns, M | 1 |
| Hauber, HP | 1 |
| Arnold, D | 5 |
| Habib, JR | 1 |
| Frigerio, I | 1 |
| Sa Cunha, A | 3 |
| Bossuyt, PM | 1 |
| Papadopoulos, KP | 1 |
| Falchook, GS | 1 |
| Patel, MR | 1 |
| Infante, JR | 1 |
| Aljumaily, R | 2 |
| Wong, DJ | 1 |
| Autio, KA | 1 |
| Bauer, TM | 1 |
| Ratti, N | 1 |
| VanVlasselaer, P | 1 |
| Verma, R | 1 |
| Leveque, J | 1 |
| Oft, M | 1 |
| Naing, A | 1 |
| Fietkau, R | 4 |
| Grützmann, R | 2 |
| Croner, RS | 1 |
| Jacobasch, L | 1 |
| Neumann, UP | 2 |
| Reinacher-Schick, A | 5 |
| Imhoff, D | 1 |
| Keilholz, L | 1 |
| Oettle, H | 14 |
| Hohenberger, WM | 1 |
| Golcher, H | 1 |
| Bechstein, WO | 1 |
| Uhl, W | 3 |
| Pirkl, A | 1 |
| Adler, W | 1 |
| Semrau, S | 2 |
| Rutzner, S | 1 |
| Ghadimi, M | 1 |
| Lubgan, D | 2 |
| Roger, E | 1 |
| Gout, J | 1 |
| Arnold, F | 1 |
| Beutel, AK | 1 |
| Müller, M | 1 |
| Abaei, A | 1 |
| Barth, TFE | 1 |
| Rasche, V | 1 |
| Seufferlein, T | 9 |
| Perkhofer, L | 3 |
| Kleger, A | 2 |
| Baltatzis, M | 1 |
| Rodriquenz, MG | 1 |
| Siriwardena, AK | 2 |
| De Liguori Carino, N | 2 |
| Kawaguchi, S | 1 |
| Terada, S | 1 |
| Shirane, N | 1 |
| Malangone-Monaco, E | 1 |
| Cole, A | 1 |
| Noxon, V | 1 |
| Kobayashi, N | 4 |
| Omae, K | 2 |
| Horita, Y | 1 |
| Ueno, H | 10 |
| Uesugi, K | 2 |
| Sudo, K | 2 |
| Hayashi, H | 4 |
| Kamei, K | 2 |
| Yamaguchi, A | 2 |
| Suzuki, S | 3 |
| Ishihara, S | 1 |
| Uchiyama, T | 1 |
| Fukutomi, A | 5 |
| Cui, J | 2 |
| Qu, S | 1 |
| Raufi, AG | 2 |
| Leonard, K | 1 |
| Charpentier, K | 1 |
| Beard, R | 1 |
| Cavanaugh, L | 1 |
| MacKinnon, K | 1 |
| Safran, HP | 1 |
| Boldrini, L | 1 |
| Nardangeli, A | 1 |
| Buwenge, M | 1 |
| Deodato, F | 3 |
| Dinapoli, N | 1 |
| Frascino, V | 1 |
| Assi, HA | 1 |
| Shikdar, S | 1 |
| Alhyari, L | 1 |
| Vuijk, FA | 1 |
| de Muynck, LDAN | 1 |
| Franken, LC | 1 |
| Bhairosingh, SS | 1 |
| Kuppen, PJK | 1 |
| Sier, CFM | 1 |
| Vahrmeijer, AL | 1 |
| Verheij, J | 1 |
| Fariňa-Sarasqueta, A | 1 |
| Swijnenburg, RJ | 1 |
| El-Mahdy, HA | 1 |
| El-Husseiny, AA | 1 |
| Kandil, YI | 1 |
| Gamal El-Din, AM | 1 |
| Granata, V | 3 |
| Fusco, R | 3 |
| Palaia, R | 3 |
| Belli, A | 1 |
| Petrillo, A | 3 |
| Izzo, F | 3 |
| Kim, GP | 2 |
| Yin, L | 1 |
| Pu, N | 1 |
| Thompson, E | 1 |
| Miao, Y | 1 |
| Wolfgang, C | 3 |
| Yu, J | 5 |
| Nakamori, S | 8 |
| Sugimori, K | 1 |
| Kanai, M | 2 |
| Kawabe, K | 2 |
| Sato, A | 2 |
| Shimizu, S | 4 |
| Chugh, P | 1 |
| Tang, R | 2 |
| Cui, H | 2 |
| Guan, J | 1 |
| Deng, G | 1 |
| Yuan, J | 1 |
| Lou, C | 1 |
| Zhang, W | 2 |
| Zhou, A | 1 |
| Zhou, J | 3 |
| Dai, G | 2 |
| Foster, L | 1 |
| Satyadas, T | 1 |
| Siriwardena, A | 1 |
| Joo, I | 2 |
| Han, JK | 2 |
| Mirakhur, B | 3 |
| de Jong, FA | 7 |
| Lei, F | 1 |
| Xi, X | 1 |
| Rachagani, S | 1 |
| Seshacharyulu, P | 1 |
| Talmon, GA | 1 |
| Ponnusamy, MP | 1 |
| Batra, SK | 1 |
| Bronich, TK | 1 |
| Teriaca, MA | 1 |
| Al-Toubah, T | 1 |
| Morse, B | 1 |
| Pelle, E | 1 |
| Strosberg, J | 2 |
| Hue, JJ | 1 |
| Sugumar, K | 1 |
| Bingmer, K | 1 |
| Ammori, JB | 1 |
| Winter, JM | 8 |
| Hardacre, JM | 3 |
| Walma, MS | 5 |
| Brada, LJ | 1 |
| Patuleia, SIS | 1 |
| Blomjous, JG | 1 |
| Bollen, TL | 1 |
| Bruijnen, RC | 3 |
| Daams, F | 1 |
| van Dam, R | 1 |
| Festen, S | 3 |
| Jan de Groot, D | 1 |
| Willem de Groot, J | 1 |
| Mohammad, NH | 5 |
| Hermans, JJ | 2 |
| de Hingh, IH | 4 |
| Kerver, ED | 1 |
| van Leeuwen, MS | 2 |
| van der Leij, C | 1 |
| Liem, MS | 1 |
| Los, M | 2 |
| de Meijer, VE | 3 |
| Mekenkamp, LJ | 1 |
| Nederend, J | 1 |
| Nio, CY | 2 |
| Patijn, GA | 4 |
| Polée, MB | 3 |
| Pruijt, JF | 1 |
| Renken, NS | 1 |
| Rombouts, SJ | 3 |
| Schouten, TJ | 1 |
| Stommel, MWJ | 3 |
| Verweij, ME | 1 |
| de Vries, JJJ | 3 |
| Vulink, A | 1 |
| Wessels, FJ | 4 |
| Kayahan, N | 1 |
| Karaca, M | 1 |
| Satış, H | 1 |
| Yapar, D | 1 |
| Delitto, D | 1 |
| Wright, MJ | 1 |
| Sekigami, Y | 1 |
| Harrison, J | 1 |
| Catalano, O | 1 |
| Lam, M | 1 |
| Halperin, DM | 1 |
| Dagohoy, CG | 1 |
| Yao, JC | 2 |
| Crucitta, S | 1 |
| Catanese, S | 2 |
| Cucchiara, F | 1 |
| Arrigoni, E | 1 |
| Pecora, I | 1 |
| Rofi, E | 1 |
| Salani, F | 1 |
| Massa, V | 2 |
| Morganti, R | 1 |
| Danesi, R | 2 |
| Del Re, M | 1 |
| Robin, F | 1 |
| Bergeat, D | 1 |
| Boudjema, K | 2 |
| Sulpice, L | 2 |
| Raitses-Gurevich, M | 1 |
| Holter, S | 1 |
| Stossel, C | 1 |
| Atias, D | 1 |
| Halperin, S | 1 |
| Berger, R | 1 |
| Glick, Y | 1 |
| Park, JP | 1 |
| Cuggia, A | 1 |
| Williamson, L | 1 |
| Wong, HL | 1 |
| Schaeffer, DF | 1 |
| Renouf, DJ | 2 |
| Borgida, A | 1 |
| Lv, Y | 1 |
| Diao, R | 1 |
| Yu, T | 1 |
| Sim, HW | 1 |
| Lopez, CD | 1 |
| Muñoz Martin, AJ | 2 |
| Wang, H | 14 |
| Hozak, RR | 1 |
| Gueorguieva, I | 1 |
| Quinonero, F | 1 |
| Cepero, A | 1 |
| Urbano, D | 1 |
| Munoz-Gamez, JA | 1 |
| Martin-Guerrero, SM | 1 |
| Martin-Oliva, D | 1 |
| Prados, J | 1 |
| Melguizo, C | 1 |
| Ortiz, R | 1 |
| Park, HS | 1 |
| Kang, B | 1 |
| Chon, HJ | 1 |
| Im, HS | 1 |
| Lee, CK | 1 |
| Hwang, JE | 1 |
| Bae, WK | 1 |
| Hong, JY | 1 |
| Lim, SH | 1 |
| Wenzel, P | 2 |
| von Figura, G | 1 |
| Ergözen, S | 1 |
| Gümüş, T | 1 |
| Park, R | 1 |
| Al-Jumayli, M | 1 |
| Miller, K | 1 |
| Saeed, A | 2 |
| Yokokawa, A | 1 |
| Kaneko, S | 1 |
| Minowa, Y | 1 |
| Ayukawa, H | 1 |
| Hirano, R | 1 |
| Nagashima, F | 1 |
| Naruge, D | 1 |
| Kobayashi, T | 2 |
| Kawai, K | 1 |
| Furuta, T | 2 |
| Shibasaki, H | 1 |
| Hewitt, DB | 1 |
| Hatoum, H | 1 |
| Musher, B | 1 |
| Seng, J | 1 |
| Al-Rajabi, R | 1 |
| Yeo, CJ | 12 |
| Leiby, B | 1 |
| Banks, J | 1 |
| Balducci, L | 1 |
| LoConte, N | 3 |
| Brenner, W | 1 |
| Elquza, E | 1 |
| Vahanian, N | 1 |
| Rossi, G | 1 |
| Kennedy, E | 1 |
| Link, C | 1 |
| Lavu, H | 2 |
| Jahangiri, Y | 1 |
| Tasaki, Y | 1 |
| Suzuki, M | 2 |
| Katsushima, K | 1 |
| Shinjo, K | 1 |
| Iijima, K | 1 |
| Murofushi, Y | 1 |
| Qiu, C | 1 |
| Takahashi, A | 1 |
| Tanaka, Y | 1 |
| Kawaguchi, T | 2 |
| Sugawara, M | 1 |
| Naito, M | 1 |
| Miyata, K | 2 |
| Kataoka, K | 1 |
| Noda, T | 1 |
| Gao, W | 1 |
| Kimura, K | 2 |
| Kondo, Y | 1 |
| Gómez-España, MA | 1 |
| Montes, AF | 1 |
| Garcia-Carbonero, R | 1 |
| Mercadé, TM | 1 |
| Maurel, J | 1 |
| Martín, AM | 1 |
| Pazo-Cid, R | 1 |
| Vera, R | 1 |
| Carrato, A | 3 |
| Guerra, M | 1 |
| Sigel, K | 1 |
| Zhou, M | 1 |
| Park, YA | 1 |
| Mutetwa, T | 1 |
| Nadkarni, G | 1 |
| Yeh, C | 1 |
| Polak, P | 1 |
| Sigel, C | 1 |
| Juzyna, B | 4 |
| Fojo, T | 1 |
| Wisnivesky, JP | 1 |
| Weyhe, D | 1 |
| Obonyo, D | 1 |
| Uslar, VN | 1 |
| Stricker, I | 1 |
| Tannapfel, A | 2 |
| Xu, S | 1 |
| Song, T | 1 |
| Qiu, Y | 1 |
| Bos, H | 1 |
| Bosscha, KP | 1 |
| Coene, PPLO | 1 |
| de Hingh, IHJT | 1 |
| van der Kolk, MB | 1 |
| Liem, MSL | 2 |
| Loosveld, OJL | 1 |
| Zonderhuis, BM | 1 |
| van Tienhoven, G | 4 |
| Marthey, L | 4 |
| Saint, A | 2 |
| Ksontini, F | 1 |
| Forestier, J | 1 |
| Fabiano, E | 1 |
| Leroy, F | 1 |
| Mavros, MN | 1 |
| Moris, D | 2 |
| Karanicolas, PJ | 1 |
| De Dosso, S | 1 |
| Siebenhüner, AR | 1 |
| Winder, T | 1 |
| Meisel, A | 1 |
| Fritsch, R | 1 |
| Astaras, C | 1 |
| Szturz, P | 1 |
| Borner, M | 2 |
| Oziel-Taieb, S | 1 |
| Zemmour, C | 1 |
| Raoul, JL | 8 |
| Charrier, N | 1 |
| Piana, G | 1 |
| Cavaglione, G | 2 |
| Niccoli, P | 1 |
| Attiyeh, MA | 1 |
| Amini, A | 1 |
| Chung, V | 3 |
| Melstrom, LG | 1 |
| Vitello, DJ | 1 |
| Bentrem, DJ | 1 |
| Rajappa, SJ | 1 |
| Pinninti, R | 1 |
| Ward, EP | 1 |
| Brown, ZJ | 1 |
| Busch, E | 1 |
| Werft, W | 1 |
| Bougatf, N | 1 |
| Berger, AK | 2 |
| Socha, J | 1 |
| Bujko, K | 1 |
| Gutierrez-Sainz, L | 1 |
| Viñal, D | 1 |
| Villamayor, J | 1 |
| Martinez-Perez, D | 1 |
| Garcia-Cuesta, JA | 1 |
| Ghanem, I | 1 |
| Custodio, A | 2 |
| Sams, L | 1 |
| Bararia, D | 1 |
| Haebe, S | 1 |
| Alig, S | 1 |
| Zhang, D | 2 |
| Metzger, P | 1 |
| Weigert, O | 1 |
| Rataj, F | 1 |
| Cho, E | 1 |
| Park, CH | 2 |
| Abrams, SL | 2 |
| Akula, SM | 1 |
| Meher, AK | 1 |
| Steelman, LS | 2 |
| Gizak, A | 1 |
| Duda, P | 1 |
| Rakus, D | 1 |
| Martelli, AM | 2 |
| Ratti, S | 2 |
| Cocco, L | 2 |
| Montalto, G | 2 |
| Cervello, M | 2 |
| Ruvolo, P | 1 |
| Libra, M | 2 |
| Falzone, L | 1 |
| Candido, S | 2 |
| McCubrey, JA | 2 |
| Fukuda, K | 2 |
| Riedl, JM | 2 |
| Posch, F | 2 |
| Horvath, L | 3 |
| Renneberg, F | 2 |
| Schwarzenbacher, E | 2 |
| Moik, F | 2 |
| Barth, DA | 2 |
| Rossmann, CH | 1 |
| Stotz, M | 2 |
| Schaberl-Moser, R | 1 |
| Pichler, M | 3 |
| Stöger, H | 1 |
| Djanani, A | 2 |
| Gerger, A | 2 |
| Wijetunga, AR | 1 |
| Chua, TC | 1 |
| Nahm, CB | 1 |
| Pavlakis, N | 1 |
| Clarke, S | 2 |
| Chan, DL | 1 |
| Diakos, C | 1 |
| Ashrafi-Zadeh, A | 1 |
| Kneebone, A | 3 |
| Hruby, G | 2 |
| Gill, A | 1 |
| Chun, JW | 1 |
| Park, N | 1 |
| Huh, G | 1 |
| Cho, IR | 1 |
| Oikonomou, D | 1 |
| Karamouzis, MV | 1 |
| Dimitrokallis, N | 1 |
| Papamichael, D | 1 |
| Kountourakis, P | 1 |
| Astras, G | 1 |
| Davakis, S | 1 |
| Papalampros, A | 1 |
| Schizas, D | 1 |
| Petrou, AS | 1 |
| Felekouras, E | 2 |
| Hadoux, J | 2 |
| Afchain, P | 2 |
| Walter, T | 5 |
| Monterymard, C | 1 |
| Lorgis, V | 2 |
| Thuillier, F | 1 |
| Baudin, E | 4 |
| Scoazec, JY | 8 |
| Desgrippes, R | 1 |
| Le, VH | 1 |
| Franko, J | 1 |
| Paz, BI | 1 |
| Singh, G | 2 |
| Fakih, M | 1 |
| Shelemey, PT | 1 |
| Amaro, CP | 1 |
| Ng, D | 1 |
| Falck, V | 1 |
| Tam, VC | 1 |
| Rapposelli, IG | 1 |
| Bartolini, G | 1 |
| Bernardini, L | 1 |
| Frassineti, GL | 1 |
| Cucchetti, A | 1 |
| Mahajan, UM | 1 |
| Li, Q | 4 |
| Alnatsha, A | 1 |
| Maas, J | 1 |
| Orth, M | 1 |
| Maier, SH | 1 |
| Peterhansl, J | 1 |
| Regel, I | 1 |
| Wagh, PR | 1 |
| Mishra, N | 1 |
| Xue, Y | 1 |
| Allawadhi, P | 1 |
| Beyer, G | 2 |
| Kühn, JP | 1 |
| Marshall, T | 1 |
| Appel, B | 1 |
| Lämmerhirt, F | 1 |
| Belka, C | 1 |
| Müller, S | 1 |
| Lauber, K | 1 |
| Brada, LJH | 2 |
| Daamen, LA | 2 |
| van Dam, RM | 2 |
| Liem, MLS | 1 |
| Yung Nio, C | 1 |
| Wilmink, HW | 1 |
| Quintus Molenaar, I | 1 |
| Öman, M | 3 |
| Wettergren, Y | 1 |
| Odin, E | 1 |
| Westermark, S | 1 |
| Naredi, P | 3 |
| Hemmingsson, O | 1 |
| Taflin, H | 1 |
| Kivits, IG | 1 |
| Nuyttens, JJME | 1 |
| Qi, H | 1 |
| van Santvoort, HJ | 1 |
| Hong, J | 1 |
| Ng, DM | 1 |
| Yang, T | 1 |
| Jin, J | 2 |
| Chen, P | 1 |
| Hashimoto, S | 1 |
| Mohindroo, C | 1 |
| Hasanov, M | 1 |
| Dong, W | 1 |
| Baydogan, S | 1 |
| Lotze, MT | 1 |
| Kim, MP | 2 |
| McAllister, F | 3 |
| Oberstein, P | 1 |
| Alistar, A | 1 |
| Guillén-Ponce, C | 1 |
| Fernandez, MS | 2 |
| Gliko-Kabir, I | 1 |
| Shemesh-Darvish, L | 1 |
| Ickowicz, D | 1 |
| Vainstein-Haras, A | 1 |
| Hatzl, S | 1 |
| Fandler-Höfler, S | 1 |
| Gressenberger, P | 1 |
| Gary, T | 1 |
| Jost, PJ | 1 |
| Ay, C | 1 |
| Kim, MA | 2 |
| Browning, RJ | 1 |
| Able, S | 1 |
| Ruan, JL | 1 |
| Bau, L | 1 |
| Allen, PD | 1 |
| Kersemans, V | 1 |
| Wallington, S | 1 |
| Kinchesh, P | 1 |
| Smart, S | 1 |
| Kartsonaki, C | 1 |
| Kamila, S | 3 |
| Logan, K | 1 |
| Taylor, MA | 3 |
| Stride, E | 3 |
| Vallis, KA | 1 |
| Phelip, JM | 3 |
| Petorin, C | 1 |
| Lecaille, C | 2 |
| Bignon, AL | 1 |
| Seitz, JF | 8 |
| Chen, J | 3 |
| Hua, Q | 1 |
| Zhao, L | 2 |
| Yu, D | 3 |
| Pi, G | 1 |
| Zhang, T | 1 |
| Lin, Z | 1 |
| Arscott, WT | 1 |
| Nead, KT | 1 |
| Bear, A | 1 |
| Venigalla, S | 1 |
| Shabason, J | 1 |
| Lukens, JN | 1 |
| Plastaras, JP | 3 |
| Wojcieszynski, A | 1 |
| Metz, J | 1 |
| O'Hara, M | 1 |
| Teitelbaum, U | 1 |
| Loaiza-Bonilla, A | 2 |
| Drebin, J | 1 |
| Lee, MK | 1 |
| Shroff, SG | 1 |
| Ben-Josef, E | 5 |
| Magermans, LG | 1 |
| Latifi, D | 1 |
| Nio, YC | 1 |
| Molenaar, QI | 1 |
| Wilmink, HJW | 1 |
| Baron, MK | 1 |
| Wang, X | 4 |
| Nevala-Plagemann, C | 1 |
| Moser, JC | 1 |
| Haaland, B | 1 |
| Garrido-Laguna, I | 1 |
| Caron, B | 1 |
| Reimund, JM | 1 |
| Sondag, D | 1 |
| Noirclerc, M | 1 |
| Duclos, B | 1 |
| Kurtz, JE | 2 |
| Nguimpi-Tambou, M | 1 |
| Girot, P | 1 |
| Senellart, H | 2 |
| Bouarioua, N | 2 |
| Hentic, O | 7 |
| Ferru, A | 2 |
| Roquin, G | 2 |
| Cadiot, G | 3 |
| Pracht, M | 2 |
| Girot, JB | 1 |
| Ducreux, M | 17 |
| Bennouna, J | 6 |
| Matysiak-Budnik, T | 1 |
| Batra, A | 1 |
| Tang, PA | 1 |
| Kato, S | 2 |
| Patel, H | 1 |
| Fanta, P | 1 |
| Okamura, R | 1 |
| Kurzrock, R | 2 |
| MacDonald, K | 1 |
| Alrawashdh, N | 1 |
| McBride, A | 3 |
| Abraham, I | 2 |
| Singh, H | 1 |
| Perez, K | 3 |
| Aguirre, AJ | 1 |
| Tavares Barroso, M | 1 |
| Costa, B | 1 |
| Rebelo de Almeida, C | 1 |
| Castillo Martin, M | 1 |
| Couto, N | 1 |
| Carvalho, T | 1 |
| Fior, R | 1 |
| Pijnappel, EN | 1 |
| Dijksterhuis, WPM | 1 |
| van der Geest, LG | 1 |
| Ahn, S | 1 |
| Kim, HW | 2 |
| Kim, YH | 5 |
| Paik, KH | 1 |
| Pelzer, U | 9 |
| Cubillo, A | 2 |
| Wan, Y | 1 |
| Solem, CT | 1 |
| Botteman, MF | 1 |
| Yang, Y | 6 |
| Beinse, G | 1 |
| Fein, F | 2 |
| Heyd, B | 1 |
| Cleau, D | 1 |
| d'Engremont, C | 1 |
| Dupont-Gossart, AC | 2 |
| Lakkis, Z | 1 |
| Rousseau, B | 2 |
| Bonnetain, F | 9 |
| Lamb, YN | 1 |
| Scott, LJ | 1 |
| Chanez, B | 1 |
| Rho, YS | 1 |
| Giovanini, M | 1 |
| Batist, G | 1 |
| Kavan, P | 2 |
| Abrams, TA | 1 |
| Meyer, G | 1 |
| Schrag, D | 3 |
| Fuchs, CS | 3 |
| Antonios, A | 1 |
| Gharios, J | 1 |
| Tohme, C | 1 |
| Shimamura, T | 1 |
| Tokuhisa, M | 2 |
| Goto, A | 2 |
| Ichikawa, Y | 3 |
| Shim, IK | 3 |
| Yi, HJ | 1 |
| Yi, HG | 2 |
| Lee, CM | 3 |
| Lee, YN | 1 |
| Jeong, SY | 1 |
| Jun, E | 2 |
| Cho, DW | 2 |
| Baechmann, S | 1 |
| Remold, A | 1 |
| Modest, DP | 2 |
| Jung, A | 3 |
| de Rooij, T | 1 |
| van Delden, OM | 2 |
| Dijkgraaf, MG | 1 |
| van Gulik, TM | 1 |
| van Hooft, JE | 1 |
| van Laarhoven, HW | 2 |
| Martin, RC | 2 |
| Schoorlemmer, A | 1 |
| Park, JJ | 1 |
| Hajj, C | 1 |
| Shi, W | 1 |
| Cuaron, JJ | 1 |
| Lowery, MA | 2 |
| Goodman, KA | 2 |
| Wu, AJ | 1 |
| Loc, WS | 1 |
| Linton, SS | 1 |
| Wilczynski, ZR | 1 |
| Matters, GL | 1 |
| McGovern, CO | 1 |
| Abraham, T | 1 |
| Fox, T | 1 |
| Gigliotti, CM | 1 |
| Tang, X | 1 |
| Tabakovic, A | 1 |
| Martin, JA | 1 |
| Clawson, GA | 1 |
| Smith, JP | 4 |
| Butler, PJ | 1 |
| Kester, M | 1 |
| Adair, JH | 1 |
| Epelboym, I | 1 |
| Zenati, MS | 3 |
| Steve, J | 3 |
| Lee, KK | 1 |
| Bahary, N | 6 |
| Hogg, ME | 3 |
| Zeh, HJ | 6 |
| Wang, XF | 1 |
| Huang, WF | 1 |
| Nie, J | 1 |
| Zhou, Y | 1 |
| Tan, DW | 1 |
| Jiang, JH | 1 |
| Cinar, P | 1 |
| Miyagawa, F | 1 |
| Sugano, Y | 1 |
| Asada, H | 1 |
| Sheng, Y | 1 |
| Beguin, E | 1 |
| Owen, J | 2 |
| Barnsley, LC | 1 |
| O'Kane, C | 1 |
| Nomikou, N | 2 |
| Hamoudi, R | 1 |
| Kelly, P | 1 |
| O'Rourke, D | 1 |
| Romero Carrasco, MC | 1 |
| Ihle, M | 1 |
| Hampp, S | 1 |
| Ruess, DA | 1 |
| Hessmann, E | 1 |
| Russell, R | 1 |
| Lechel, A | 1 |
| Azoitei, N | 1 |
| Lin, Q | 1 |
| Liebau, S | 1 |
| Hohwieler, M | 1 |
| Bohnenberger, H | 1 |
| Lesina, M | 1 |
| Gieldon, L | 1 |
| Schröck, E | 1 |
| Gaedcke, J | 1 |
| Wagner, M | 3 |
| Wiesmüller, L | 1 |
| Sipos, B | 2 |
| Reinhardt, HC | 1 |
| Frappart, PO | 1 |
| Bonafede, M | 1 |
| Cai, Q | 1 |
| Princic, N | 1 |
| Tran, O | 1 |
| Pelletier, C | 1 |
| Parisi, M | 2 |
| Patel, M | 2 |
| Cong, J | 1 |
| Zhang, N | 2 |
| Soukup, K | 1 |
| Hong, T | 1 |
| DeLeo, A | 1 |
| Cai, L | 5 |
| Sabbatino, F | 2 |
| Ferrone, S | 1 |
| Levina, V | 1 |
| Fuchs, B | 1 |
| Tanabe, K | 1 |
| Lillemoe, K | 1 |
| Ferrone, C | 1 |
| Liauw, SL | 2 |
| Kluger, MD | 1 |
| Rashid, MF | 1 |
| Rosario, VL | 1 |
| Schrope, BA | 3 |
| Steinman, JA | 1 |
| Hecht, EM | 1 |
| Chabot, JA | 4 |
| Goel, N | 1 |
| Reddy, SS | 1 |
| Zhang, SH | 1 |
| Liu, GF | 1 |
| Li, XF | 1 |
| Yu, SN | 1 |
| Oh, J | 1 |
| Robert, M | 1 |
| Jarlier, M | 1 |
| Gourgou, S | 2 |
| Berriochoa, CA | 1 |
| Abdel-Wahab, M | 1 |
| Leyrer, CM | 1 |
| Khorana, A | 1 |
| Matthew Walsh, R | 1 |
| Kumar, AMS | 1 |
| Ghaneh, P | 18 |
| Halloran, CM | 5 |
| Raraty, M | 2 |
| Jackson, R | 3 |
| Melling, J | 1 |
| Jones, O | 1 |
| Palmer, DH | 4 |
| Cox, TF | 3 |
| Smith, CJ | 1 |
| O'Reilly, DA | 2 |
| Izbicki, JR | 6 |
| Scarfe, AG | 3 |
| McDonald, AC | 4 |
| Carter, R | 6 |
| Goldstein, D | 11 |
| Padbury, R | 3 |
| Shannon, J | 3 |
| Dervenis, C | 10 |
| Glimelius, B | 12 |
| Deakin, M | 4 |
| Oláh, A | 7 |
| Rawcliffe, CL | 4 |
| Campbell, F | 3 |
| Kozak, GM | 1 |
| Epstein, JD | 1 |
| Deshmukh, SP | 1 |
| Scott, BB | 1 |
| Keith, SW | 1 |
| Capodanno, Y | 1 |
| Buishand, FO | 1 |
| Pang, LY | 1 |
| Kirpensteijn, J | 1 |
| Mol, JA | 1 |
| Argyle, DJ | 1 |
| Fleeman, N | 1 |
| Abdulla, A | 1 |
| Bagust, A | 2 |
| Beale, S | 2 |
| Richardson, M | 2 |
| Stainthorpe, A | 2 |
| Boland, A | 2 |
| Kotas, E | 2 |
| McEntee, J | 1 |
| Palmer, D | 5 |
| Fu, J | 1 |
| Zheng, H | 1 |
| Cui, Q | 1 |
| Chen, C | 1 |
| Bao, S | 1 |
| Sun, J | 1 |
| Li, L | 2 |
| Yang, B | 1 |
| Hou, Y | 1 |
| Pi, J | 1 |
| Adamska, A | 1 |
| Elaskalani, O | 1 |
| Emmanouilidi, A | 1 |
| Abdol Razak, NB | 1 |
| Metharom, P | 1 |
| Falasca, M | 2 |
| Pergolini, I | 1 |
| Honselmann, KC | 1 |
| Murphy, JE | 4 |
| Nipp, RD | 3 |
| Parikh, A | 1 |
| Doherty, GJ | 1 |
| Tempero, M | 1 |
| Corrie, PG | 2 |
| Lund, K | 2 |
| Olsen, CE | 1 |
| Wong, JJW | 1 |
| Olsen, PA | 1 |
| Solberg, NT | 1 |
| Høgset, A | 1 |
| Krauss, S | 5 |
| Selbo, PK | 1 |
| Lombard-Bohas, C | 3 |
| Smith, D | 9 |
| Dubreuil, O | 3 |
| Lepere, C | 3 |
| Gangloff, A | 1 |
| Elhajbi, F | 1 |
| Granger, V | 1 |
| Michalski, CW | 3 |
| Blair, AB | 1 |
| Gemenetzis, G | 1 |
| Hruban, RH | 11 |
| Waters, KM | 1 |
| Poling, J | 1 |
| Laheru, D | 9 |
| Makary, MA | 2 |
| Weiss, MJ | 3 |
| Goess, R | 1 |
| Liang, D | 1 |
| Shi, S | 2 |
| Liang, C | 1 |
| Meng, Q | 1 |
| Ni, Q | 3 |
| Xu, J | 3 |
| Yu, X | 2 |
| Lee, BM | 1 |
| Chung, SY | 1 |
| Chang, JS | 2 |
| Seong, J | 2 |
| Bonucci, M | 1 |
| Pastore, C | 1 |
| Ferrera, V | 1 |
| Fiorentini, C | 1 |
| Fabbri, A | 1 |
| Elander, NO | 1 |
| Aughton, K | 1 |
| Costello, E | 8 |
| Mackey, JR | 3 |
| Charnley, RM | 2 |
| Greenhalf, W | 7 |
| Caca, K | 1 |
| Freiberg-Richter, J | 1 |
| Fischer von Weikersthal, L | 3 |
| Kullmann, F | 2 |
| Fuchs, M | 1 |
| Kanzler, S | 2 |
| Kunzmann, V | 2 |
| Ettrich, TJ | 2 |
| Chin, V | 1 |
| Sjoquist, K | 1 |
| O'Connor, CA | 1 |
| Chantrill, L | 1 |
| Scholten, RJ | 1 |
| Yip, D | 4 |
| Hann, A | 2 |
| Nosalski, E | 1 |
| Hermann, PC | 1 |
| Egger, J | 2 |
| Keller, F | 1 |
| Draper, A | 1 |
| Abe, K | 1 |
| Uwagawa, T | 1 |
| Haruki, K | 1 |
| Takano, Y | 1 |
| Onda, S | 1 |
| Sakamoto, T | 1 |
| Gocho, T | 1 |
| Yanaga, K | 1 |
| Greenhalgh, J | 1 |
| Duarte, R | 1 |
| Banks, L | 1 |
| Byrne, JD | 2 |
| Jajja, MRN | 1 |
| O'Neill, AT | 1 |
| Schorzman, AN | 2 |
| Keeler, AW | 2 |
| Luft, JC | 2 |
| Zamboni, WC | 3 |
| DeSimone, JM | 2 |
| Usón Junior, PLS | 1 |
| Rother, ET | 1 |
| Maluf, FC | 1 |
| Bugano, DDG | 1 |
| Hwang, I | 1 |
| Chang, HM | 3 |
| Park, DH | 3 |
| Lee, SK | 4 |
| Kim, MH | 4 |
| Shin, SH | 3 |
| Song, KB | 1 |
| Omichi, K | 1 |
| Mizuno, T | 1 |
| Kawaguchi, Y | 1 |
| Chun, YS | 1 |
| Aloia, TA | 4 |
| Halperin, D | 2 |
| Yao, J | 2 |
| Vauthey, JN | 9 |
| Kellett, C | 1 |
| Todaro, V | 1 |
| Boninsegna, E | 1 |
| Negrelli, R | 1 |
| Sureka, B | 1 |
| Bonamini, D | 2 |
| Manfredi, R | 1 |
| Pozzi Mucelli, R | 1 |
| Walston, S | 1 |
| Salloum, J | 1 |
| Grieco, C | 1 |
| Wuthrick, E | 2 |
| Diaz, DA | 1 |
| Barney, C | 1 |
| Manilchuk, A | 1 |
| Schmidt, C | 3 |
| Inoko, K | 2 |
| Hiraoka, K | 1 |
| Inagaki, A | 1 |
| Takahashi, M | 5 |
| Kushibiki, T | 1 |
| Hontani, K | 1 |
| Takano, H | 2 |
| Sato, S | 2 |
| Takeuchi, S | 2 |
| Nakamura, T | 5 |
| Tsuchikawa, T | 2 |
| Shichinohe, T | 2 |
| Gruber, HE | 1 |
| Jolly, DJ | 1 |
| Kasahara, N | 1 |
| Hirano, S | 3 |
| Dhir, M | 1 |
| Singhi, AD | 1 |
| Tahara, J | 1 |
| Shimizu, K | 1 |
| Otsuka, N | 1 |
| Akao, J | 1 |
| Tokushige, K | 1 |
| Foucher, ED | 1 |
| Ghigo, C | 1 |
| Chouaib, S | 1 |
| Galon, J | 1 |
| Olive, D | 1 |
| Tong, H | 1 |
| Fan, Z | 1 |
| Lu, T | 1 |
| Huang, KW | 1 |
| Yang, PC | 1 |
| Pua, U | 1 |
| Kim, MD | 1 |
| Li, SP | 1 |
| Song, TQ | 1 |
| Liang, PC | 1 |
| Pokorny, AMJ | 1 |
| Chin, VT | 1 |
| Nagrial, AM | 1 |
| Chantrill, LA | 1 |
| Razavi, AA | 1 |
| Yao, HP | 1 |
| Feng, L | 1 |
| Weng, TH | 1 |
| Hu, CY | 1 |
| Suthe, SR | 1 |
| Mostofa, AGM | 1 |
| Chen, LH | 1 |
| Wu, ZG | 1 |
| Wang, WL | 1 |
| Wang, MH | 1 |
| Glassman, DC | 1 |
| Palmaira, RL | 1 |
| Covington, CM | 1 |
| Desai, AM | 1 |
| Harding, JJ | 1 |
| Mukhopadhyay, A | 1 |
| Faridi, KF | 1 |
| Asnani, A | 1 |
| Osborn, EA | 1 |
| Yang, JX | 1 |
| Phillips, CT | 1 |
| York, M | 1 |
| Canale, TD | 1 |
| Cho, H | 1 |
| Kays, JK | 1 |
| Stanley, M | 2 |
| Bell, TM | 1 |
| O'Neill, BH | 1 |
| Kohli, MD | 1 |
| Couch, ME | 1 |
| Koniaris, LG | 2 |
| Zimmers, TA | 1 |
| Lertpiriyapong, K | 1 |
| Yang, LV | 1 |
| Murata, RM | 1 |
| Rosalen, PL | 1 |
| Gharaibeh, M | 1 |
| Alberts, DS | 2 |
| Erstad, B | 1 |
| Slack, M | 1 |
| Alsaid, N | 1 |
| Bootman, JL | 1 |
| Díaz, R | 1 |
| García, A | 1 |
| Laquente, B | 1 |
| Sastre, J | 2 |
| Álvarez, R | 1 |
| Cao, J | 1 |
| Ma, J | 1 |
| Sun, L | 1 |
| Qin, T | 1 |
| Zhou, C | 1 |
| Cheng, L | 1 |
| Chen, K | 1 |
| Qian, W | 2 |
| Duan, W | 1 |
| Wang, F | 3 |
| Wu, E | 1 |
| Wang, Z | 3 |
| Ma, Q | 2 |
| Han, L | 2 |
| Tuech, JJ | 1 |
| Michel, P | 4 |
| Weiss, M | 1 |
| Yamaue, H | 5 |
| Das, S | 1 |
| Berlin, J | 2 |
| Cardin, D | 3 |
| Sehdev, A | 1 |
| Gbolahan, O | 1 |
| Hancock, BA | 1 |
| Wan, J | 1 |
| Wu, HH | 1 |
| Radovich, M | 1 |
| O'Neil, BH | 1 |
| Nakache, R | 1 |
| Rosen, G | 1 |
| Isakov, O | 1 |
| Radhakrishna, G | 2 |
| Kao, CT | 1 |
| Aziz, M | 1 |
| Girardi, DM | 1 |
| Faria, LDBB | 1 |
| Teixeira, MC | 1 |
| Costa, FP | 2 |
| Hoff, PMG | 1 |
| Fernandes, GS | 1 |
| Tfayli, A | 2 |
| Assi, H | 1 |
| Makki, I | 1 |
| Nassif, S | 1 |
| Pitarokoili, K | 1 |
| Höffken, N | 1 |
| Lönneker, N | 1 |
| Fisse, AL | 1 |
| Trampe, N | 1 |
| Gold, R | 1 |
| Yoon, MS | 1 |
| Signorovitch, JE | 1 |
| Yang, H | 1 |
| Patterson-Lomba, O | 1 |
| Xiang, CQ | 1 |
| Ung, B | 1 |
| Marshall, JL | 2 |
| Mouhid, L | 1 |
| Gómez de Cedrón, M | 1 |
| Vargas, T | 1 |
| García-Carrascosa, E | 1 |
| Herranz, N | 1 |
| García-Risco, M | 1 |
| Reglero, G | 1 |
| Fornari, T | 1 |
| Ramírez de Molina, A | 1 |
| Yoshida, E | 1 |
| Kudo, D | 1 |
| Nagase, H | 1 |
| Suto, A | 1 |
| Shimoda, H | 1 |
| Suto, S | 1 |
| Kakizaki, I | 1 |
| Endo, M | 2 |
| Hakamada, K | 2 |
| Wei, T | 1 |
| Li, G | 4 |
| Tran Cao, HS | 2 |
| Garajová, I | 2 |
| Caparello, C | 3 |
| Le Large, TYS | 1 |
| Frampton, AE | 1 |
| Cheng, YJ | 1 |
| Meng, CT | 1 |
| Ying, HY | 1 |
| Zhou, JF | 1 |
| Yan, XY | 1 |
| Gao, X | 1 |
| Zhou, N | 1 |
| Bai, CM | 1 |
| Mou, Y | 1 |
| Hou, S | 1 |
| Cao, D | 1 |
| Li, A | 1 |
| Kaufmann, B | 1 |
| Hartmann, D | 2 |
| Stupakov, P | 1 |
| Radenkovic, D | 1 |
| Gloor, B | 2 |
| Magnes, T | 1 |
| Ratzinger, L | 1 |
| Jaud, B | 1 |
| Melchardt, T | 1 |
| Egle, A | 1 |
| Dean, AP | 1 |
| Jameson, GS | 1 |
| Schwartsmann, G | 2 |
| Braiteh, FS | 1 |
| Tabchi, S | 1 |
| Kourie, HR | 4 |
| Kattan, J | 5 |
| Becker, C | 1 |
| Hu, ZI | 1 |
| Hellmann, MD | 1 |
| Wolchok, JD | 1 |
| Vyas, M | 1 |
| Shia, J | 1 |
| Stadler, ZK | 1 |
| Diaz, LA | 4 |
| Wei, S | 1 |
| Yu, R | 2 |
| Yuan, Y | 2 |
| Wei, Q | 2 |
| Kurita, Y | 1 |
| Kubota, K | 2 |
| Nakajima, A | 1 |
| Xu, X | 1 |
| Wu, Q | 1 |
| Ge, K | 1 |
| Jia, C | 1 |
| Gromski, MA | 1 |
| Choi, JG | 1 |
| Tramontano, A | 1 |
| Ali, A | 1 |
| Zhan, T | 1 |
| Pandharipande, P | 1 |
| Dowling, EC | 1 |
| Hebbar, M | 1 |
| Choné, L | 1 |
| Sauvanet, A | 2 |
| Breysacher, G | 1 |
| Di Fiore, F | 1 |
| Cripps, C | 2 |
| Bouhier-Leporrier, K | 1 |
| Khemissa-Akouz, F | 2 |
| Legoux, JL | 2 |
| O'Callaghan, CJ | 1 |
| Jouffroy-Zeller, C | 1 |
| Rat, P | 1 |
| Berger, AW | 1 |
| Daum, S | 1 |
| König, A | 2 |
| Dickhut, A | 1 |
| Wittel, U | 1 |
| Wille, K | 1 |
| Geissler, M | 7 |
| Gallmeier, E | 3 |
| Atzpodien, J | 1 |
| Kornmann, M | 3 |
| Muche, R | 2 |
| Prasnikar, N | 1 |
| Vogl, UM | 1 |
| Andalibi, H | 1 |
| Klaus, A | 1 |
| Vormittag, L | 1 |
| Schima, W | 1 |
| Heinrich, B | 1 |
| Kafka, A | 1 |
| Winkler, T | 1 |
| Öhler, L | 1 |
| Van Laethem, JL | 3 |
| Laurent-Puig, P | 1 |
| Smolenschi, C | 1 |
| Boige, V | 8 |
| Hollebecque, A | 1 |
| Matsumoto, I | 1 |
| Matsuoka, H | 2 |
| Kobayashi, M | 3 |
| Innominato, P | 2 |
| Komarzynski, S | 1 |
| Karaboué, A | 2 |
| Ulusakarya, A | 2 |
| Bouchahda, M | 1 |
| Haydar, M | 2 |
| Bossevot-Desmaris, R | 1 |
| Mocquery, M | 1 |
| Plessis, V | 1 |
| Lévi, F | 2 |
| Romero, D | 1 |
| Soefje, SA | 1 |
| Setola, SV | 1 |
| Albino, V | 1 |
| Piccirillo, M | 2 |
| Grimm, R | 1 |
| Hasuike, Y | 2 |
| Higuchi, I | 1 |
| Mori, Y | 1 |
| Hosomi, S | 1 |
| Ishikawa, A | 1 |
| Akiyama, Y | 1 |
| Tanigawa, T | 2 |
| Kitamura, T | 1 |
| Giuliani, J | 2 |
| Bonetti, A | 1 |
| Jiménez Gordo, AM | 1 |
| López Gómez, M | 1 |
| Yu, K | 1 |
| Ramanathan, RK | 2 |
| McDonough, SL | 1 |
| Hingorani, SR | 1 |
| Thumar, J | 1 |
| Shields, AF | 7 |
| Behl, D | 1 |
| Mehan, PT | 1 |
| Gaur, R | 1 |
| Seery, T | 1 |
| Sasson, A | 1 |
| Hahn, SM | 1 |
| Massih, SA | 1 |
| Kanso, M | 1 |
| Wefer, A | 1 |
| Persson, S | 1 |
| Valente, R | 1 |
| Tanaka, K | 3 |
| Orsini, N | 1 |
| Segersvärd, R | 1 |
| Arnelo, U | 1 |
| Werthmann, PG | 1 |
| Kempenich, R | 1 |
| Lang-Avérous, G | 1 |
| Kienle, GS | 1 |
| Yoshitomi, H | 1 |
| Takano, S | 1 |
| Furukawa, K | 1 |
| Takayashiki, T | 1 |
| Kuboki, S | 1 |
| Ohtsuka, M | 2 |
| Kim, SY | 2 |
| Sun, H | 2 |
| Ozaki, K | 1 |
| Ikuta, Y | 1 |
| Masuda, T | 2 |
| Akaboshi, S | 1 |
| Ogata, K | 1 |
| Matumoto, K | 1 |
| Ogawa, K | 2 |
| Kamio, T | 1 |
| Baba, H | 5 |
| Takamori, H | 3 |
| Pouypoudat, C | 1 |
| Buscail, E | 1 |
| Cossin, S | 1 |
| Cassinotto, C | 3 |
| Marty, M | 1 |
| Dupin, C | 1 |
| Laurent, C | 3 |
| Dabernat, S | 1 |
| Chiche, L | 1 |
| Vendrely, V | 3 |
| Teyar, N | 1 |
| Krimi, S | 1 |
| Biondani, P | 1 |
| Gumus, Y | 1 |
| Chebib, A | 1 |
| Almohamad, W | 1 |
| Morère, JF | 1 |
| van Rijssen, LB | 2 |
| Bruijnen, RCG | 1 |
| Yo, LS | 1 |
| de Vries, J | 1 |
| Yamamoto, KN | 1 |
| Nakamura, A | 1 |
| Liu, LL | 1 |
| Tramontano, AC | 1 |
| Kartoun, U | 1 |
| Shimizu, T | 3 |
| Asakuma, M | 1 |
| Haeno, H | 1 |
| Uchiyama, K | 4 |
| Michor, F | 1 |
| Kourie, H | 1 |
| Gaujoux, S | 1 |
| Bruzzi, M | 1 |
| El-Hajjar, A | 1 |
| Vaillant, JC | 1 |
| Kašperová, B | 1 |
| Jurišová, S | 1 |
| Macúch, J | 1 |
| Bumberová, M | 1 |
| Dolinský, J | 1 |
| Blaeker, M | 1 |
| Zimmermann-Fraedrich, K | 1 |
| Pace, A | 2 |
| Perez, D | 1 |
| Benten, D | 1 |
| Buettner, S | 1 |
| Beumer, BR | 2 |
| Bali, MA | 1 |
| Boone, BA | 2 |
| Frakes, JM | 1 |
| Grose, D | 1 |
| Hosein, PJ | 3 |
| Khan, K | 2 |
| Kim, SS | 3 |
| Margonis, GA | 1 |
| McCarter, MD | 1 |
| McKay, CJ | 2 |
| Mellon, EA | 2 |
| Moorcraft, SY | 3 |
| Okada, KI | 1 |
| Parikh, PJ | 2 |
| Peters, NA | 1 |
| Rabl, H | 2 |
| Samra, J | 1 |
| Tinchon, C | 2 |
| Yokoyama, T | 2 |
| Makino, H | 2 |
| Hirakata, A | 1 |
| Ueda, J | 1 |
| Takata, H | 1 |
| Okusa, M | 1 |
| Kawashima, M | 2 |
| Tsujino, T | 2 |
| Hosone, M | 1 |
| Matsushita, A | 1 |
| Nakamura, Y | 1 |
| Yoshida, H | 1 |
| Han, S | 1 |
| Choi, SH | 7 |
| Choi, DW | 5 |
| Han, IW | 1 |
| Park, DJ | 1 |
| Ryu, Y | 1 |
| Liu, QH | 2 |
| Yong, HM | 1 |
| Zhuang, QX | 1 |
| Zhang, XP | 1 |
| Hou, PF | 1 |
| Chen, YS | 1 |
| Zhu, MH | 2 |
| Bai, J | 1 |
| Yeap, BY | 3 |
| Drapek, LC | 1 |
| Ly, L | 1 |
| Baglini, CV | 1 |
| Kwak, EL | 9 |
| Corcoran, RB | 1 |
| Faris, JE | 4 |
| Zhu, AX | 6 |
| Goyal, L | 2 |
| Berger, DL | 1 |
| Talele, N | 1 |
| DeLaney, TF | 3 |
| Saade Lemus, P | 1 |
| Anderson, K | 1 |
| Ishigame, T | 1 |
| Kimura, T | 1 |
| Tsukida, S | 1 |
| Suzushino, S | 1 |
| Muto, M | 1 |
| Sato, N | 2 |
| Kofunato, Y | 1 |
| Okada, R | 1 |
| Kenjo, A | 1 |
| Shimura, T | 1 |
| Marubashi, S | 1 |
| Das, M | 1 |
| Papneja, N | 1 |
| Tan, K | 1 |
| Olson, C | 1 |
| Haider, K | 3 |
| Rahman, M | 2 |
| Washington, L | 1 |
| Hajjar, AH | 1 |
| Eid, R | 1 |
| Haddad, FG | 1 |
| Panaro, F | 1 |
| Kellil, T | 1 |
| Vendrell, J | 1 |
| Sega, V | 1 |
| Souche, R | 1 |
| Piardi, T | 1 |
| Leon, P | 1 |
| Rosso, E | 2 |
| Navarro, F | 1 |
| Vreeland, TJ | 1 |
| Javadi, S | 1 |
| Varadhachary, G | 7 |
| Yang, F | 2 |
| Fu, DL | 2 |
| Ariake, K | 1 |
| Motoi, F | 4 |
| Mizuma, M | 1 |
| Ohtsuka, H | 1 |
| Nakagawa, K | 2 |
| Hata, T | 1 |
| Mitachi, K | 1 |
| Naitoh, T | 1 |
| Kamei, T | 1 |
| Unno, M | 1 |
| Macedo, FI | 1 |
| Ryon, E | 1 |
| Lee, RM | 1 |
| Kooby, DA | 3 |
| Williams, G | 1 |
| Maduekwe, U | 1 |
| Patel, SH | 1 |
| Abbott, DE | 3 |
| Schwartz, P | 1 |
| Weber, SM | 1 |
| Scoggins, CR | 1 |
| Dudeja, V | 1 |
| Franceschi, D | 1 |
| Livingstone, AS | 3 |
| Merchant, NB | 1 |
| Charton, E | 1 |
| Chibaudel, B | 2 |
| Cohen, R | 1 |
| Debourdeau, P | 1 |
| Dauba, J | 1 |
| Guerin-Meyer, V | 1 |
| Anota, A | 1 |
| Viviani, E | 1 |
| Nessi, C | 1 |
| Ciprani, D | 1 |
| Esposito, A | 1 |
| Landoni, L | 1 |
| Casetti, L | 1 |
| Tuveri, M | 1 |
| Paiella, S | 1 |
| Casciani, F | 1 |
| Sereni, E | 1 |
| Binco, A | 1 |
| Secchettin, E | 1 |
| Auriemma, A | 1 |
| Simionato, F | 1 |
| D'Onofrio, M | 1 |
| Eun Park, J | 1 |
| Hua Jin, M | 1 |
| Hinz, U | 3 |
| Sachsenmaier, M | 1 |
| Hasegawa, N | 1 |
| Abei, M | 1 |
| Yokoyama, KK | 1 |
| Seo, E | 1 |
| Kawashima, R | 1 |
| Yamada, T | 4 |
| Nakade, K | 1 |
| Hamada, H | 2 |
| Obata, Y | 1 |
| Hubmann, E | 1 |
| Pichler, A | 1 |
| Keil, F | 1 |
| Uggowitzer, M | 1 |
| Jilek, K | 1 |
| Leitner, G | 1 |
| Bauernhofer, T | 1 |
| Tanaka, T | 10 |
| Sakaguchi, H | 5 |
| Kichikawa, K | 7 |
| Worsnop, F | 1 |
| Diener, MK | 1 |
| Combs, SE | 4 |
| Mukherjee, S | 2 |
| Hurt, CN | 1 |
| Bridgewater, J | 2 |
| Falk, S | 4 |
| Cummins, S | 1 |
| Wasan, H | 1 |
| Crosby, T | 1 |
| Jephcott, C | 1 |
| Roy, R | 1 |
| McDonald, A | 1 |
| Ray, R | 1 |
| Joseph, G | 2 |
| Staffurth, J | 1 |
| Abrams, RA | 12 |
| Griffiths, G | 1 |
| Maughan, T | 1 |
| Saif, MW | 52 |
| Oikonomopoulos, GM | 2 |
| Huber, KE | 2 |
| Syrigos, KN | 8 |
| Kothari, N | 1 |
| Kim, R | 4 |
| Skoura, E | 2 |
| Nichols, RC | 1 |
| Zaiden, RA | 1 |
| Awad, ZT | 1 |
| Asbun, HJ | 1 |
| Huh, S | 1 |
| Ho, MW | 1 |
| Mendenhall, NP | 1 |
| Morris, CG | 1 |
| Hoppe, BS | 1 |
| Hartlapp, I | 1 |
| Müller, J | 1 |
| Kenn, W | 1 |
| Steger, U | 1 |
| Isbert, C | 1 |
| Scheurlen, M | 1 |
| Germer, CT | 1 |
| Einsele, H | 1 |
| Gu, WJ | 1 |
| Liu, HL | 1 |
| Sohal, DP | 1 |
| Metz, JM | 1 |
| Sun, W | 1 |
| Giantonio, BJ | 1 |
| Ginsberg, G | 1 |
| Kochman, ML | 1 |
| Teitelbaum, UR | 1 |
| Harlacker, K | 1 |
| Heitjan, DF | 1 |
| Feldman, MD | 1 |
| Drudi, F | 1 |
| Tassinari, D | 1 |
| Ridolfi, C | 1 |
| Gianni, L | 1 |
| Tamburini, E | 1 |
| Fantini, M | 1 |
| Santelmo, C | 1 |
| Barzotti, E | 1 |
| Lotti, N | 1 |
| Ravaioli, A | 1 |
| Scheithauer, W | 12 |
| Wittwer, C | 2 |
| Kern, C | 1 |
| Stieber, P | 2 |
| Nagel, D | 2 |
| Holdenrieder, S | 2 |
| Gumz, B | 1 |
| Pasche, B | 1 |
| El-Hadaad, HA | 1 |
| Wahba, HA | 1 |
| Ove, R | 2 |
| Ng, J | 2 |
| Russo, S | 5 |
| McDermott, S | 1 |
| Guimaraes, AR | 1 |
| Szymonifka, J | 1 |
| Huynh, MA | 1 |
| Wargo, JA | 1 |
| Dias, LE | 1 |
| Thayer, SP | 1 |
| Sahani, DV | 1 |
| Jones, TS | 1 |
| Jones, EL | 1 |
| McManus, M | 1 |
| Shah, R | 1 |
| Gajdos, C | 1 |
| Rahma, OE | 1 |
| Duffy, A | 1 |
| Liewehr, DJ | 1 |
| Steinberg, SM | 2 |
| Greten, TF | 6 |
| Goldberg, RM | 4 |
| Fu, Z | 1 |
| Yin, H | 1 |
| Fan, KY | 1 |
| Wild, AT | 3 |
| Hacker-Prietz, A | 2 |
| Wood, LD | 2 |
| Blackford, AL | 1 |
| Ellsworth, S | 1 |
| De Jesus-Acosta, A | 3 |
| Donehower, RC | 6 |
| Schulick, RD | 6 |
| Choti, MA | 3 |
| Cooper, AB | 2 |
| Katz, MH | 12 |
| Kim, DJ | 1 |
| Yi, BR | 1 |
| Lee, HR | 2 |
| Kim, SU | 1 |
| Choi, KC | 1 |
| Kim, TH | 3 |
| Han, SS | 2 |
| Moon, SH | 2 |
| Koh, YH | 1 |
| Kim, JY | 2 |
| Kim, DY | 2 |
| Park, JW | 2 |
| Courtin, A | 1 |
| Richards, FM | 1 |
| Bapiro, TE | 1 |
| Bramhall, JL | 1 |
| Neesse, A | 2 |
| Cook, N | 2 |
| Krippendorff, BF | 1 |
| Tuveson, DA | 1 |
| Jodrell, DI | 1 |
| Savir, G | 1 |
| Strimpakos, AS | 3 |
| Johnson, JL | 1 |
| Gonzalez de Mejia, E | 1 |
| Zhan, Q | 3 |
| Shen, B | 1 |
| Deng, X | 1 |
| Chen, H | 3 |
| Peng, C | 1 |
| Wen, Z | 1 |
| Liao, Q | 10 |
| Hu, Y | 3 |
| You, L | 1 |
| Zhao, Y | 9 |
| Moretto, R | 1 |
| Raimondo, L | 1 |
| De Stefano, A | 1 |
| Matano, E | 2 |
| De Placido, S | 1 |
| Carlomagno, C | 1 |
| Krasinskas, AM | 2 |
| Lembersky, BC | 1 |
| Gibson, MK | 1 |
| Stoller, RG | 1 |
| Silvestris, N | 1 |
| Brunetti, AE | 1 |
| Russano, M | 1 |
| Nardulli, P | 1 |
| Shi, SB | 1 |
| Ma, TH | 1 |
| Tang, XY | 1 |
| Li, CH | 1 |
| Kaley, K | 4 |
| Brennan, M | 1 |
| Garcon, MC | 1 |
| Rodriguez, G | 1 |
| Rodriguez, T | 2 |
| Ilyas, S | 1 |
| Wasif, K | 1 |
| Schueneman, AJ | 1 |
| Uram, J | 1 |
| Bigelow, E | 1 |
| Ky, V | 1 |
| Hav, M | 1 |
| Troisi, RI | 1 |
| Ferdinande, L | 1 |
| Monsaert, E | 1 |
| Vanderstraeten, E | 1 |
| De Bosschere, K | 1 |
| Van Damme, N | 1 |
| Laurent, S | 1 |
| Geboes, K | 1 |
| Chauhan, VP | 1 |
| Martin, JD | 1 |
| Liu, H | 3 |
| Lacorre, DA | 1 |
| Jain, SR | 1 |
| Kozin, SV | 1 |
| Stylianopoulos, T | 1 |
| Mousa, AS | 1 |
| Adstamongkonkul, P | 1 |
| Popović, Z | 1 |
| Bawendi, MG | 1 |
| Joseph, R | 1 |
| Dasanu, CA | 2 |
| Mahaseth, H | 1 |
| Brutcher, E | 2 |
| Kauh, J | 1 |
| Hawk, N | 2 |
| Landry, J | 5 |
| Joerger, M | 1 |
| Huitema, AD | 1 |
| Koeberle, D | 3 |
| Rosing, H | 1 |
| Beijnen, JH | 1 |
| Hitz, F | 1 |
| Cerny, T | 1 |
| Schellens, JH | 2 |
| Gillessen, S | 1 |
| Rajagopalan, MS | 1 |
| Heron, DE | 1 |
| Wegner, RE | 1 |
| Lembersky, B | 1 |
| Brand, R | 1 |
| Moser, AJ | 1 |
| Quinn, AE | 1 |
| Burton, SA | 1 |
| Mamon, HJ | 5 |
| Tseng, YD | 1 |
| Napolitano, BN | 1 |
| Ancukiewicz, M | 2 |
| Swanson, RS | 2 |
| Pisters, PW | 14 |
| Abbruzzese, JL | 22 |
| Fleming, JB | 11 |
| Hohla, F | 2 |
| Hopfinger, G | 1 |
| Romeder, F | 1 |
| Rinnerthaler, G | 1 |
| Bezan, A | 1 |
| Stättner, S | 1 |
| Hauser-Kronberger, C | 1 |
| Ulmer, H | 1 |
| Passoni, P | 12 |
| Cattaneo, GM | 2 |
| Slim, N | 3 |
| Cereda, S | 12 |
| Castoldi, R | 1 |
| Longobardi, B | 1 |
| Bettinardi, V | 1 |
| Gianolli, L | 1 |
| Gusmini, S | 1 |
| Staudacher, C | 6 |
| Calandrino, R | 1 |
| Di Muzio, N | 2 |
| Devarajan, K | 1 |
| Milestone, BN | 1 |
| Cooper, HS | 1 |
| Denlinger, C | 1 |
| Meyer, JE | 1 |
| Hoffman, JP | 12 |
| Annels, NE | 1 |
| Shaw, VE | 1 |
| Gabitass, RF | 1 |
| Billingham, L | 1 |
| Corrie, P | 4 |
| Eatock, M | 3 |
| Valle, J | 3 |
| Wadsley, J | 2 |
| Pandha, H | 1 |
| Middleton, G | 3 |
| Lamb, L | 2 |
| Elligers, K | 2 |
| Jiang, Z | 1 |
| Bussom, S | 1 |
| Liu, SH | 2 |
| Cheng, YC | 2 |
| Lamb, RF | 1 |
| Garner, E | 1 |
| Moore, MJ | 9 |
| Lacaine, F | 4 |
| Middleton, MR | 2 |
| Ouyang, J | 1 |
| Ouyang, L | 2 |
| Faisal, F | 1 |
| Tsai, HL | 1 |
| Blackford, A | 2 |
| Olino, K | 1 |
| Xia, C | 1 |
| Cosgrove, D | 2 |
| Azad, N | 1 |
| Rasheed, Z | 1 |
| Donehower, R | 2 |
| Fishman, EK | 1 |
| Schulick, R | 2 |
| Weber, TF | 1 |
| Ajouz, H | 1 |
| Haydar, A | 1 |
| Yakan, AS | 1 |
| Saleh, A | 1 |
| Elias, E | 1 |
| Khalife, M | 1 |
| Schad, F | 1 |
| Atxner, J | 1 |
| Buchwald, D | 1 |
| Happe, A | 1 |
| Popp, S | 1 |
| Kröz, M | 1 |
| Matthes, H | 1 |
| Nandy, N | 1 |
| Cox, T | 3 |
| Stocken, DD | 9 |
| O'Reilly, D | 1 |
| Robinson, BA | 1 |
| Karapetis, C | 3 |
| Scarfe, A | 1 |
| Sand, J | 2 |
| Lind, PA | 3 |
| Sumpter, K | 1 |
| Hiroshima, Y | 1 |
| Zhao, M | 1 |
| Maawy, A | 1 |
| Uehara, F | 1 |
| Miwa, S | 1 |
| Yano, S | 2 |
| Momiyama, M | 1 |
| Suetsugu, A | 1 |
| Chishima, T | 1 |
| Bouvet, M | 1 |
| Meyer, T | 3 |
| Caplin, ME | 1 |
| Armstrong, G | 1 |
| Lao-Sirieix, SH | 1 |
| Hardy, R | 1 |
| Talbot, DC | 1 |
| Reed, N | 1 |
| Shaw, A | 1 |
| Navalkissoor, S | 1 |
| Luong, TV | 1 |
| Alkhateeb, A | 1 |
| Zubritsky, L | 1 |
| Kinsman, B | 1 |
| Leitzel, K | 1 |
| Campbell-Baird, C | 1 |
| Ali, SM | 1 |
| Connor, J | 1 |
| Lipton, A | 2 |
| Lee, SJ | 1 |
| Kim, DU | 1 |
| Kizilbash, SH | 1 |
| Ward, KC | 1 |
| Liang, JJ | 1 |
| Jaiyesimi, I | 1 |
| Lipscomb, J | 1 |
| Chan, SL | 1 |
| Chan, ST | 1 |
| Chan, EH | 1 |
| He, ZX | 1 |
| Zhang, JG | 3 |
| Hong, DF | 1 |
| Zhang, CW | 1 |
| Sun, XD | 1 |
| Wang, ZF | 1 |
| Shi, Y | 1 |
| Liu, JW | 1 |
| Shen, GL | 1 |
| Zhang, YB | 1 |
| Cheng, J | 1 |
| Wang, CY | 3 |
| Zhao, G | 3 |
| Bläuer, M | 1 |
| Hirota, M | 2 |
| Ikonen, NH | 1 |
| Laukkarinen, J | 1 |
| Schempf, U | 1 |
| König, C | 1 |
| Malek, NP | 2 |
| Bitzer, M | 3 |
| Plentz, RR | 3 |
| Portal, A | 1 |
| Siauve, N | 1 |
| Landi, B | 6 |
| Colussi, O | 1 |
| Rougier, P | 14 |
| Verrière, B | 1 |
| Soares, HP | 1 |
| Bayraktar, S | 2 |
| Blaya, M | 1 |
| Lopes, G | 2 |
| Merchan, J | 1 |
| Macintyre, J | 2 |
| Mayo, C | 1 |
| Green, MR | 3 |
| Silva, O | 1 |
| Levi, J | 1 |
| Walker, G | 1 |
| Rocha-Lima, CM | 4 |
| Coinu, A | 2 |
| Borgonovo, K | 3 |
| Cabiddu, M | 3 |
| Ghilardi, M | 3 |
| Barni, S | 7 |
| Mahmoud, A | 1 |
| Ritch, P | 2 |
| Thomas, JP | 2 |
| Wiebe, L | 1 |
| Kelly, T | 1 |
| Harrabi, SB | 1 |
| Kondratska, K | 1 |
| Kondratskyi, A | 1 |
| Yassine, M | 1 |
| Lemonnier, L | 1 |
| Lepage, G | 1 |
| Morabito, A | 1 |
| Skryma, R | 1 |
| Prevarskaya, N | 1 |
| Esnaola, NF | 1 |
| Chaudhary, UB | 1 |
| O'Brien, P | 1 |
| Garrett-Mayer, E | 1 |
| Camp, ER | 1 |
| Thomas, MB | 1 |
| Cole, DJ | 1 |
| Montero, AJ | 1 |
| Hoffman, BJ | 1 |
| Romagnuolo, J | 1 |
| Orwat, KP | 1 |
| Marshall, DT | 1 |
| Karakhanova, S | 2 |
| Mosl, B | 2 |
| Harig, S | 5 |
| von Ahn, K | 1 |
| Fritz, J | 1 |
| Bazhin, AV | 2 |
| Watkins, DJ | 1 |
| Thomas, J | 2 |
| Webb, J | 2 |
| Brown, G | 2 |
| Barbachano, Y | 1 |
| Oates, J | 8 |
| Gaertner, J | 1 |
| Becker, G | 1 |
| Bernhard, J | 3 |
| Dietrich, D | 4 |
| Herrmann, R | 7 |
| Patel, K | 2 |
| Gormley, PE | 1 |
| Kern, SE | 5 |
| Cunningham, SC | 3 |
| Marks, E | 1 |
| Jia, Y | 1 |
| Tejani, MA | 3 |
| Pineda, DM | 1 |
| Jimbo, M | 3 |
| Lal, S | 1 |
| Moughan, J | 3 |
| Winter, KA | 5 |
| Abdelmohsen, K | 1 |
| Gorospe, M | 1 |
| Acosta, Ade J | 1 |
| Lankapalli, RH | 1 |
| Witkiewicz, AK | 2 |
| Brody, JR | 6 |
| Hilbig, A | 3 |
| Stieler, JM | 2 |
| Bahra, M | 1 |
| Sinn, M | 2 |
| Gebauer, B | 1 |
| Dörken, B | 6 |
| Riess, H | 11 |
| García Alfonso, P | 1 |
| Rupérez Blanco, AB | 1 |
| Pérez Ramírez, S | 1 |
| Blanco Codesido, M | 1 |
| Martín Jiménez, M | 1 |
| Nitsch, E | 1 |
| Mina, S | 1 |
| Brammer, I | 1 |
| Schuch, G | 1 |
| Bokemeyer, C | 1 |
| Zander, A | 1 |
| Kröger, N | 1 |
| Ayuk, F | 1 |
| Suarez Martinez-Falero, B | 1 |
| Gillmore, R | 2 |
| Kesavan, M | 1 |
| Claringbold, PG | 1 |
| Turner, JH | 1 |
| Schapira, L | 1 |
| Cashavelly, BJ | 1 |
| Kim, CY | 1 |
| Riley, JP | 1 |
| Wold, MC | 1 |
| Penson, RT | 1 |
| Kræmer, PC | 1 |
| Schmidt, HH | 1 |
| Roxburgh, P | 1 |
| Lumsden, GR | 1 |
| Paul, J | 1 |
| Harden, S | 1 |
| Sweeting, L | 1 |
| James, A | 1 |
| Crellin, A | 3 |
| Morrison, R | 1 |
| Evans, TR | 2 |
| Ren, G | 1 |
| Xia, T | 1 |
| Holmes, HM | 1 |
| des Bordes, JK | 1 |
| Parker, NH | 1 |
| Raponi, M | 1 |
| Isaacson, J | 1 |
| Laubender, RP | 2 |
| Kleespies, A | 3 |
| Mann, E | 1 |
| Bartosiewicz, M | 1 |
| Borger, DR | 1 |
| Shinagare, S | 1 |
| Wadlow, RC | 2 |
| Adams, J | 2 |
| Winrich, B | 2 |
| Grillo, T | 1 |
| Jiang, Y | 1 |
| Mackley, HB | 1 |
| Kimchi, ET | 1 |
| Zhu, J | 3 |
| Gusani, N | 1 |
| Kaifi, J | 1 |
| Staveley-O'Carroll, KF | 1 |
| Belani, CP | 1 |
| Habermehl, D | 2 |
| Kessel, KA | 1 |
| Bergmann, F | 3 |
| Naumann, P | 1 |
| Debus, J | 4 |
| Markoutsaki, T | 1 |
| Gauthier, M | 3 |
| Thirot-Bidault, A | 2 |
| Joubert, F | 1 |
| Fanica, D | 1 |
| Grey, A | 1 |
| Cooper, A | 1 |
| McNeil, C | 1 |
| O'Toole, S | 1 |
| Thompson, J | 3 |
| Grimison, P | 1 |
| Niess, H | 1 |
| Camaj, P | 2 |
| Renner, A | 1 |
| Ischenko, I | 2 |
| Krebs, S | 1 |
| Mysliwietz, J | 1 |
| Jäckel, C | 1 |
| Nelson, PJ | 1 |
| Blum, H | 1 |
| Jauch, KW | 3 |
| Ellwart, JW | 1 |
| Silcocks, P | 1 |
| Propper, D | 1 |
| Coxon, F | 1 |
| Ross, P | 3 |
| Madhusudan, S | 1 |
| Roques, T | 1 |
| Wadd, N | 1 |
| Harrison, M | 1 |
| Iveson, T | 2 |
| Robinson, A | 1 |
| McAdam, K | 1 |
| Evans, J | 1 |
| Archer, C | 1 |
| Hickish, T | 4 |
| Garcia-Alonso, A | 1 |
| Nicolson, M | 3 |
| Steward, W | 2 |
| Shaw, V | 1 |
| Naisbitt, D | 1 |
| Rawcliffe, C | 1 |
| Nanson, G | 1 |
| Neoptolemos, J | 2 |
| Heil, G | 1 |
| Schwaner, I | 2 |
| Seraphin, J | 2 |
| Görner, M | 1 |
| Mölle, M | 1 |
| Lakner, V | 1 |
| Bischoff, S | 1 |
| Chung, JB | 3 |
| Isayama, H | 2 |
| Aoki, T | 3 |
| Hamada, T | 1 |
| Nakai, Y | 2 |
| Sakamoto, Y | 1 |
| Hasegawa, K | 1 |
| Morikawa, T | 1 |
| Fukayama, M | 1 |
| Kokudo, N | 1 |
| Koike, K | 1 |
| Baey, C | 2 |
| Llacer, C | 1 |
| Peiffert, D | 2 |
| Mornex, F | 10 |
| Abbas, M | 1 |
| Pignon, JP | 4 |
| Cellier, P | 1 |
| Viret, F | 7 |
| Sa-Cunha, A | 1 |
| Cueff, A | 1 |
| Manfredi, S | 1 |
| Solub, D | 1 |
| Carbonnel, F | 1 |
| Ramfidis, VS | 2 |
| Psyrri, A | 1 |
| Chang, BW | 2 |
| Kaddis, N | 1 |
| Lemstrová, R | 1 |
| Souček, P | 1 |
| Melichar, B | 1 |
| Mohelnikova-Duchonova, B | 1 |
| Yan, H | 1 |
| Zhen, H | 1 |
| Cao, B | 1 |
| Donahue, TR | 3 |
| Nguyen, AH | 2 |
| Tatishchev, S | 1 |
| Toste, P | 1 |
| Farrell, JJ | 4 |
| Lambertz, A | 1 |
| Klink, CD | 1 |
| Röth, A | 1 |
| Schmitz, D | 1 |
| Pich, A | 1 |
| Feher, K | 1 |
| Bremus-Köbberling, E | 1 |
| Junge, K | 1 |
| Rajeev, SP | 1 |
| McDougall, S | 1 |
| Terlizzo, M | 1 |
| Daousi, C | 1 |
| Cuthbertson, DJ | 1 |
| Qin, Y | 1 |
| Ma, Z | 1 |
| Dang, X | 1 |
| Li, W | 1 |
| Kang, Y | 2 |
| Roife, D | 2 |
| Zhang, R | 2 |
| Papadatos-Pastos, D | 1 |
| Thillai, K | 1 |
| Rabbie, R | 1 |
| Sarker, D | 1 |
| Shao, T | 1 |
| Zheng, Y | 1 |
| Zhao, B | 1 |
| Li, T | 1 |
| Cheng, K | 1 |
| Cai, W | 1 |
| Bayoglu, IV | 1 |
| Varol, U | 1 |
| Yildiz, I | 1 |
| Muslu, U | 1 |
| Alacacioglu, A | 1 |
| Kucukzeybek, Y | 1 |
| Akyol, M | 1 |
| Demir, L | 1 |
| Dirican, A | 1 |
| Cokmert, S | 1 |
| Yildiz, Y | 1 |
| Karabulut, B | 1 |
| Uslu, R | 1 |
| Tarhan, MO | 1 |
| Turner, K | 1 |
| Levi Sandri, GB | 1 |
| Boucher, E | 1 |
| Hénno, S | 1 |
| Le Prisé, E | 1 |
| Meunier, B | 1 |
| Luo, HY | 1 |
| Liu, GL | 1 |
| Wang, DS | 1 |
| Wang, ZQ | 1 |
| Zeng, ZL | 1 |
| Xu, RH | 1 |
| Blazer, M | 1 |
| Wu, C | 2 |
| Phillips, G | 1 |
| Muscarella, P | 2 |
| Ellison, EC | 2 |
| Bloomston, M | 5 |
| Huang, WK | 1 |
| Kuo, YC | 1 |
| Tsang, NM | 1 |
| Hsu, HC | 1 |
| Shen, WC | 1 |
| Yang, TS | 1 |
| Maier-Stocker, C | 1 |
| Wang, C | 1 |
| Fu, M | 2 |
| Yang, A | 1 |
| Huang, H | 1 |
| Xie, J | 2 |
| Wang, WB | 1 |
| Zhao, YP | 6 |
| Zhang, TP | 1 |
| Shu, H | 2 |
| Peckitt, C | 1 |
| O'Toole, D | 2 |
| Dromain, C | 2 |
| Vilgrain, V | 1 |
| Bitoun, L | 1 |
| Koné, S | 1 |
| Dupont-Gossard, AC | 1 |
| Lobry, C | 1 |
| Asnacios, A | 2 |
| Manet-Lacombe, S | 1 |
| Okada, M | 1 |
| Shibuya, K | 3 |
| Seino, M | 1 |
| Takeda, H | 1 |
| Seino, S | 1 |
| Yoshioka, T | 2 |
| Kitanaka, C | 1 |
| Li, SQ | 1 |
| Truty, MJ | 1 |
| Chatterjee, D | 1 |
| Cardwell, J | 1 |
| Sherman, WH | 2 |
| Chu, K | 1 |
| Chabot, J | 3 |
| Allendorf, J | 1 |
| Hecht, E | 1 |
| Jin, B | 1 |
| Leung, D | 1 |
| Remotti, H | 2 |
| Addeo, G | 1 |
| Postolov, I | 1 |
| Tsai, W | 1 |
| Fine, RL | 5 |
| Graziani, C | 1 |
| Hegde, S | 1 |
| Tréhoux, S | 1 |
| Xiao, J | 1 |
| Peng, F | 1 |
| Yu, C | 2 |
| Li, Z | 1 |
| Jiang, J | 2 |
| Sun, C | 1 |
| Yüce, S | 1 |
| Seker, MM | 1 |
| Koç, S | 1 |
| Uysal, IO | 1 |
| Kaçan, T | 1 |
| Doğan, M | 2 |
| Babacan, NA | 1 |
| Neofytou, K | 1 |
| Giakoustidis, A | 1 |
| Smyth, EC | 1 |
| Mudan, S | 1 |
| McDonnell, EI | 1 |
| Santos, DD | 1 |
| Fiaschi, AI | 1 |
| Laera, L | 1 |
| Marrelli, D | 1 |
| Roviello, F | 1 |
| Francini, E | 1 |
| Strosberg, JR | 2 |
| Dropkin, E | 1 |
| Strickler, JH | 1 |
| Elias, A | 1 |
| Xanthis, A | 1 |
| Davies, S | 1 |
| Brais, RJ | 1 |
| Jamieson, NV | 1 |
| Praseedom, RK | 1 |
| Huguet, E | 1 |
| Harper, SJF | 1 |
| Jah, A | 1 |
| Marsh, Rde W | 2 |
| Talamonti, MS | 2 |
| Ryschich, E | 5 |
| Hartwig, W | 2 |
| Fuchshuber, P | 1 |
| Oussoultzoglou, E | 1 |
| De Blasi, V | 1 |
| Simone, G | 1 |
| Belletier, C | 1 |
| McDonald, AM | 1 |
| Dulaney, CR | 1 |
| López-Araujo, J | 1 |
| Keene, KS | 2 |
| Christein, JD | 1 |
| Heslin, MJ | 1 |
| Wood, TE | 2 |
| Jacob, R | 1 |
| Kordes, S | 2 |
| Klümpen, HJ | 2 |
| Weterman, MJ | 2 |
| Richel, DJ | 2 |
| Oh, TG | 1 |
| Yoshioka, M | 2 |
| Shibata, S | 2 |
| Uchinami, H | 1 |
| Watanabe, G | 3 |
| Miyazawa, H | 1 |
| Nanjo, H | 1 |
| Yamamoto, Y | 3 |
| Dembinski, JL | 2 |
| Solberg, N | 1 |
| Urbanucci, A | 1 |
| Mills, IG | 1 |
| Lonati, V | 1 |
| Aitini, E | 3 |
| Guillen, KP | 1 |
| Restuccia, A | 1 |
| Kurkjian, C | 1 |
| Harrison, RG | 1 |
| Smyth, EN | 1 |
| Bapat, B | 1 |
| Ball, DE | 1 |
| Kaye, JA | 1 |
| Lastoria, S | 1 |
| Hartley, ML | 1 |
| Bade, NA | 1 |
| Prins, PA | 1 |
| Ampie, L | 1 |
| Dilz, LM | 1 |
| Steffen, IG | 1 |
| Prasad, V | 1 |
| von Weikersthal, LF | 2 |
| Pavel, M | 2 |
| Miyake, T | 1 |
| Honma, Y | 1 |
| Urano, T | 1 |
| Kato, N | 1 |
| Suzumiya, J | 1 |
| Baghdadi, M | 1 |
| Wada, H | 1 |
| Abe, H | 2 |
| Nakanishi, S | 1 |
| Usui, Y | 2 |
| Higuchi, K | 2 |
| Seino, K | 2 |
| Uchihara, T | 1 |
| Yamashita, Y | 3 |
| Hualin, W | 1 |
| Takeishi, K | 1 |
| Itoh, S | 2 |
| Harimoto, N | 1 |
| Yoshizumi, T | 2 |
| Aishima, S | 1 |
| Maehara, Y | 1 |
| Khvalevsky, EZ | 1 |
| Hubert, A | 1 |
| Gabai, RM | 1 |
| Hen, N | 1 |
| Segal, A | 1 |
| Domb, A | 1 |
| Harari, G | 1 |
| David, EB | 1 |
| Raskin, S | 1 |
| Goldin, E | 1 |
| Eliakim, R | 1 |
| Lahav, M | 1 |
| Kopleman, Y | 1 |
| Dancour, A | 1 |
| Shemi, A | 1 |
| Galun, E | 1 |
| Capello, M | 1 |
| Babel, I | 1 |
| Maitra, A | 1 |
| Tian, W | 1 |
| Taguchi, A | 1 |
| Hanash, SM | 1 |
| Schneitler, S | 1 |
| Kröpil, P | 1 |
| Riemer, J | 1 |
| Antoch, G | 1 |
| Knoefel, WT | 1 |
| Häussinger, D | 1 |
| Graf, D | 1 |
| Herreros-Villanueva, M | 1 |
| Er, TK | 1 |
| Bujanda, L | 1 |
| Bryant, VL | 1 |
| Elias, RM | 1 |
| McCarthy, SM | 1 |
| Yeatman, TJ | 1 |
| Alexandrow, MG | 1 |
| Makielski, RJ | 1 |
| Lubner, SJ | 2 |
| Mulkerin, DL | 2 |
| Traynor, AM | 2 |
| Groteluschen, D | 2 |
| Eickhoff, J | 1 |
| LoConte, NK | 2 |
| Nanda, RH | 1 |
| Heetfeld, M | 1 |
| Chougnet, CN | 1 |
| Olsen, IH | 1 |
| Borbath, I | 1 |
| Crespo, G | 1 |
| Barriuso, J | 1 |
| Fujii-Nishimura, Y | 1 |
| Nishiyama, R | 1 |
| Ueno, A | 1 |
| Kawachi, S | 1 |
| Kawaida, M | 1 |
| Tanimoto, A | 1 |
| Sakamoto, M | 2 |
| Park, JM | 1 |
| Song, BJ | 1 |
| Badiyan, SN | 1 |
| Olsen, JR | 1 |
| Lee, AY | 1 |
| Yano, M | 2 |
| Menias, CO | 1 |
| Khwaja, S | 1 |
| Strasberg, SM | 3 |
| Linehan, DC | 3 |
| Myerson, RJ | 1 |
| Chen, M | 2 |
| Huang, Y | 1 |
| Ho, MY | 1 |
| Kennecke, HF | 1 |
| Lim, HJ | 1 |
| Umemura, A | 1 |
| Nitta, H | 1 |
| Sasaki, A | 2 |
| Takahara, T | 1 |
| Hasegawa, Y | 1 |
| Wakabayashi, G | 1 |
| Doi, T | 3 |
| Homma, H | 6 |
| Akiyama, T | 4 |
| Mezawa, S | 4 |
| Ohi, M | 1 |
| Morii, K | 1 |
| Kogawa, K | 1 |
| Takeuchi, M | 1 |
| Hirata, K | 7 |
| Yang, C | 1 |
| Liu, Y | 4 |
| Xi, WQ | 1 |
| Zhou, CF | 1 |
| Jiang, JL | 1 |
| Ye, ZB | 1 |
| Zhang, J | 6 |
| Zhu, ZG | 1 |
| Kos, ME | 1 |
| Evande, RE | 1 |
| Chung, KH | 1 |
| Lee, BS | 1 |
| Jang, DK | 1 |
| Kang, CM | 1 |
| Bang, SM | 1 |
| Choi, JY | 1 |
| Seong, JS | 1 |
| Hwang, HK | 1 |
| Regenet, N | 1 |
| Clewemar Antonodimitrakis, P | 1 |
| Sundin, A | 1 |
| Wassberg, C | 1 |
| Granberg, D | 1 |
| Skogseid, B | 3 |
| Eriksson, B | 3 |
| Zahir, MN | 1 |
| Jabbar, AA | 1 |
| David, KI | 1 |
| Jaidev, LR | 1 |
| Sethuraman, S | 1 |
| Krishnan, UM | 1 |
| Nitsche, U | 1 |
| Holzapfel, K | 1 |
| Schlitter, AM | 1 |
| Stöß, C | 1 |
| Kong, B | 1 |
| Esposito, I | 2 |
| Erkan, M | 2 |
| Ghorani, E | 1 |
| Wong, HH | 1 |
| Hewitt, C | 1 |
| Calder, J | 1 |
| Basu, B | 1 |
| Li, JQ | 1 |
| Liang, JX | 1 |
| Wang, SL | 1 |
| Blanco, FF | 1 |
| Wulfkuhle, J | 1 |
| Gallagher, I | 1 |
| Deng, J | 1 |
| Enyenihi, L | 1 |
| Meisner-Kober, N | 1 |
| Londin, E | 1 |
| Rigoutsos, I | 1 |
| Sawicki, JA | 1 |
| Risbud, MV | 1 |
| McCue, PA | 1 |
| Rui, H | 1 |
| Petricoin, E | 1 |
| Tempero, MA | 6 |
| Walker, EJ | 1 |
| Kate Kelley, R | 1 |
| Lewis, S | 1 |
| Chang, WC | 1 |
| Kantoff, E | 2 |
| Vannier, MW | 1 |
| Catenacci, DV | 1 |
| Venook, AP | 3 |
| Kindler, HL | 3 |
| Validire, P | 1 |
| Byun, S | 1 |
| Lee, E | 1 |
| Lee, SY | 2 |
| Farrand, L | 1 |
| Jung, SK | 1 |
| Cho, YY | 1 |
| Um, SJ | 1 |
| Sin, HS | 1 |
| Kwon, YJ | 1 |
| Zhang, C | 2 |
| Tsang, BK | 1 |
| Bode, AM | 1 |
| Lee, KW | 2 |
| Dong, Z | 1 |
| Do, C | 1 |
| Cade, DN | 1 |
| Tapner, MJ | 1 |
| Price, D | 1 |
| Bower, GD | 1 |
| Dowling, R | 1 |
| Lichtenstein, M | 1 |
| van Hazel, GA | 2 |
| Charpentier, KP | 1 |
| Mantripragada, K | 1 |
| Miner, T | 1 |
| Kuritzky, B | 1 |
| Apor, E | 1 |
| Bishop, K | 1 |
| Luppe, D | 1 |
| Mitchell, K | 1 |
| Rosati, K | 1 |
| Davis, EJ | 1 |
| Ruch, JM | 1 |
| McDonnell, KJ | 1 |
| Jameson, G | 1 |
| Braiteh, F | 1 |
| Moyo, V | 1 |
| Dhindsa, N | 1 |
| Bayever, E | 1 |
| Terazawa, T | 1 |
| Goto, M | 2 |
| Miyamoto, T | 1 |
| Asaishi, K | 1 |
| Shimamoto, F | 1 |
| Kuwakado, S | 1 |
| Nishitani, H | 1 |
| Kii, T | 1 |
| Katayama, K | 1 |
| Ashida, R | 1 |
| Teshima, T | 1 |
| Sakon, M | 4 |
| Weng, CC | 1 |
| Kuo, KK | 1 |
| Su, HT | 1 |
| Hsiao, PJ | 1 |
| Wu, DC | 1 |
| Hung, WC | 1 |
| Cheng, KH | 1 |
| McEwan, C | 1 |
| Borden, M | 1 |
| Hamoudi, RA | 1 |
| Crane, C | 1 |
| Regine, WF | 13 |
| Liu, C | 1 |
| Chang, P | 1 |
| Freedman, GM | 1 |
| Guha, C | 3 |
| Orlandi, A | 1 |
| Calegari, MA | 1 |
| Martini, M | 2 |
| Cocomazzi, A | 1 |
| Indellicati, G | 1 |
| Zurlo, V | 1 |
| Basso, M | 3 |
| Cassano, A | 3 |
| Larocca, LM | 1 |
| Barone, C | 3 |
| Kamisawa, T | 1 |
| Itoi, T | 1 |
| Takaori, K | 1 |
| Jajja, MR | 1 |
| Wei, X | 2 |
| Ma, Y | 2 |
| Sun, G | 2 |
| Merrell, KW | 1 |
| Haddock, MG | 3 |
| Quevedo, JF | 1 |
| Harmsen, WS | 1 |
| Kendrick, ML | 1 |
| Miller, RC | 3 |
| Hallemeier, CL | 1 |
| Dholakia, AS | 1 |
| Moningi, S | 1 |
| Lu, Y | 2 |
| Rosati, LM | 1 |
| Assadi, RK | 1 |
| Saeed, AM | 1 |
| Tran, PT | 2 |
| Ford, E | 1 |
| Grossman, SA | 1 |
| Ye, X | 1 |
| Mantripragada, KC | 1 |
| Bupathi, M | 1 |
| Ahn, DH | 1 |
| Ciombor, KK | 1 |
| Stephens, JA | 1 |
| Goldstein, DA | 1 |
| Stein, SM | 2 |
| James, ES | 1 |
| Deng, Y | 1 |
| Cong, X | 2 |
| Staugaard, C | 1 |
| Indukala, D | 1 |
| Boustani, AM | 1 |
| Patel, V | 1 |
| Cha, CH | 1 |
| Chang, B | 1 |
| Su, R | 1 |
| Shen, S | 2 |
| Wu, Y | 3 |
| Gan, Y | 1 |
| Yuan, H | 1 |
| Wang, Q | 1 |
| Fan, Y | 1 |
| Yao, M | 1 |
| Tu, H | 1 |
| Lencioni, M | 1 |
| Ur Rehman, SS | 1 |
| Lim, K | 1 |
| Nywening, TM | 1 |
| Sanford, DE | 1 |
| Belt, BA | 1 |
| Panni, RZ | 1 |
| Cusworth, BM | 1 |
| Toriola, AT | 1 |
| Nieman, RK | 1 |
| Worley, LA | 1 |
| Fowler, KJ | 1 |
| Lockhart, AC | 3 |
| Tan, BR | 5 |
| Zhao, R | 1 |
| Wen, F | 1 |
| Zhang, P | 1 |
| Reure, J | 1 |
| Follana, P | 2 |
| Gal, J | 1 |
| Rakhra, S | 1 |
| Strauss, JB | 1 |
| Robertson, J | 1 |
| McGinn, CJ | 3 |
| Kim, T | 1 |
| Huang, J | 3 |
| Blake, A | 1 |
| Helenowski, I | 1 |
| Hayes, JP | 1 |
| Mulcahy, M | 2 |
| Small, W | 4 |
| Williams, JL | 1 |
| Kadera, BE | 1 |
| Muthusamy, VR | 2 |
| Reber, HA | 2 |
| Chang, JY | 4 |
| Strippoli, A | 1 |
| Rossi, S | 1 |
| D'Argento, E | 1 |
| Schinzari, G | 2 |
| Barile, R | 1 |
| Allen, P | 1 |
| Shridhar, R | 1 |
| Passero, FC | 1 |
| Grapsa, D | 1 |
| Simeone, DM | 1 |
| Hoang, NT | 1 |
| Kadonosono, T | 1 |
| Kuchimaru, T | 1 |
| Kizaka-Kondoh, S | 1 |
| Frankel, W | 1 |
| Martin, R | 1 |
| Conway, W | 1 |
| Truty, M | 1 |
| Kindler, H | 1 |
| Philip, P | 1 |
| Talamonti, M | 3 |
| Diasio, RB | 9 |
| Liu, S | 3 |
| Kang, KS | 1 |
| Hong, JM | 1 |
| Pati, RG | 1 |
| Park, MN | 1 |
| Martinelli, P | 1 |
| Carrillo-de Santa Pau, E | 1 |
| Sainz, B | 1 |
| Rinaldi, L | 1 |
| Malats, N | 1 |
| Büchler, M | 3 |
| Pajic, M | 1 |
| Real, FX | 1 |
| De Pasquale, MD | 1 |
| Mastronuzzi, A | 1 |
| De Sio, L | 1 |
| Serra, A | 1 |
| Grimaldi, C | 1 |
| Chinali, M | 1 |
| Giordano, U | 1 |
| Ellenrieder, V | 2 |
| Nakakura, EK | 1 |
| Wang, ZJ | 1 |
| Kim, GE | 1 |
| Corvera, CU | 1 |
| Harris, HW | 1 |
| Kirkwood, KS | 1 |
| Hirose, R | 1 |
| Ning, ZY | 1 |
| Cheng, CS | 1 |
| Chen, QW | 1 |
| Xu, LT | 1 |
| Zhuang, LP | 1 |
| Zhang, CY | 1 |
| Song, LB | 1 |
| Shi, WD | 1 |
| Wang, P | 1 |
| Wang, K | 1 |
| Meng, ZQ | 1 |
| Chllamma, MK | 1 |
| Dhani, NC | 1 |
| Giby, K | 1 |
| Hedley, DW | 2 |
| Cassidy, RJ | 1 |
| Okada, K | 2 |
| Kawai, M | 3 |
| Hirono, S | 3 |
| Yanagimoto, H | 4 |
| Miyazawa, M | 2 |
| Shimizu, A | 1 |
| Kitahata, Y | 1 |
| Le Large, TY | 1 |
| Ko, YJ | 1 |
| Beaudoin, A | 1 |
| Dhesy-Thind, S | 1 |
| Zulfiqar, M | 1 |
| Zalewski, P | 1 |
| Do, T | 1 |
| Cano, P | 1 |
| Lam, WYH | 1 |
| Dowden, S | 1 |
| Grassin, H | 1 |
| Stewart, J | 1 |
| Moore, M | 4 |
| Burger, PJ | 1 |
| Angele, MK | 1 |
| Bhosale, P | 2 |
| Cloyd, J | 1 |
| Parker, N | 1 |
| Aloia, T | 1 |
| Vogel, A | 1 |
| Ciardiello, F | 1 |
| Patel, DA | 1 |
| Ektare, V | 1 |
| Bohle, W | 1 |
| Zoller, WG | 1 |
| Péron, J | 2 |
| Roy, P | 4 |
| Gourgou-Bourgade, S | 3 |
| Stanbury, T | 1 |
| Roche, L | 1 |
| Ozenne, B | 1 |
| Buyse, M | 1 |
| Ghadban, T | 1 |
| Dibbern, JL | 1 |
| Reeh, M | 1 |
| Miro, JT | 1 |
| Tsui, TY | 1 |
| Wellner, U | 1 |
| Güngör, C | 2 |
| Vashist, YK | 2 |
| Mei, H | 1 |
| Tang, Z | 1 |
| Huang, F | 1 |
| Jin, Q | 1 |
| Tatarian, T | 1 |
| Leiby, BE | 1 |
| Grigoli, A | 1 |
| Dabbish, N | 1 |
| Halloran, C | 1 |
| Antunes, C | 1 |
| Zappa, M | 2 |
| Lucidarme, O | 1 |
| Bednar, F | 1 |
| Winters, S | 1 |
| Ocuin, LM | 1 |
| Huang, X | 1 |
| Knoble, JL | 1 |
| Zeng, M | 1 |
| Aguila, FN | 1 |
| Patel, T | 1 |
| Chambers, LW | 1 |
| Hu, H | 1 |
| McDonough, S | 1 |
| Hui, L | 1 |
| Seery, TE | 1 |
| Dy, IA | 1 |
| Al Baghdadi, T | 1 |
| Hendifar, AE | 1 |
| Doyle, LA | 1 |
| Blanke, CD | 1 |
| Vinzens, S | 1 |
| Zindel, J | 1 |
| Zweifel, M | 1 |
| Rau, T | 1 |
| Wochner, A | 1 |
| Ghosn, M | 4 |
| El Rassy, E | 2 |
| Clancy, TE | 1 |
| Mancias, JD | 1 |
| Rosenthal, MH | 1 |
| Ni, S | 1 |
| Wan, C | 1 |
| Lu, C | 1 |
| Xiao, L | 2 |
| He, Z | 1 |
| Le, N | 1 |
| Vinci, A | 1 |
| Schober, M | 1 |
| Krug, S | 2 |
| Javed, MA | 1 |
| Kohlmann, T | 1 |
| Sund, M | 1 |
| Lakatos, G | 1 |
| Petranyi, A | 1 |
| Szűcs, A | 1 |
| Nehéz, L | 1 |
| Harsanyi, L | 1 |
| Hegyi, P | 1 |
| Lazenby, AJ | 1 |
| Zheng, D | 1 |
| Bhirud, AR | 1 |
| Sasson, AR | 2 |
| Xia, BT | 1 |
| Fu, B | 1 |
| Kim, Y | 2 |
| Dhar, VK | 1 |
| Levinsky, NC | 1 |
| Hanseman, DJ | 1 |
| Habib, DA | 1 |
| Olowokure, OO | 1 |
| Al Humaidi, AH | 1 |
| Choe, KA | 1 |
| Uccello, M | 1 |
| Moschetta, M | 1 |
| Arkenau, HT | 1 |
| MacEwan, JP | 1 |
| Yin, W | 1 |
| Kaura, S | 1 |
| Khan, ZM | 1 |
| Ohman, KA | 1 |
| Tan, MC | 1 |
| El Karak, F | 1 |
| Viaud, J | 1 |
| Le Pabic, E | 1 |
| Leconte, B | 1 |
| Bodère, A | 1 |
| Le Sourd, S | 1 |
| Parisi, MF | 1 |
| Patel, MB | 1 |
| Pelletier, CL | 1 |
| Belk, KW | 1 |
| Dawson, DW | 2 |
| Bailey, P | 1 |
| Brenner, WS | 1 |
| Picus, J | 2 |
| Marsh, S | 1 |
| Gao, F | 2 |
| Fournier, C | 1 |
| Fracasso, PM | 1 |
| James, J | 1 |
| Yen-Revollo, JL | 1 |
| McLeod, HL | 1 |
| Vikram, B | 1 |
| Fujita, T | 2 |
| Sultana, A | 3 |
| Tudur Smith, C | 2 |
| Zhu, Y | 5 |
| Tibensky, I | 2 |
| Märten, A | 11 |
| Smith, CT | 2 |
| Swartz, MJ | 5 |
| Hsu, CC | 4 |
| Winter, J | 2 |
| Sugar, E | 1 |
| Robinson, R | 2 |
| Jaffee, E | 1 |
| Campbell, KA | 1 |
| Asrari, F | 1 |
| Yeo, C | 1 |
| Abrams, R | 3 |
| Gerber, D | 1 |
| Ruhstaller, T | 3 |
| Bajetta, E | 4 |
| Schüller, J | 2 |
| Saletti, P | 4 |
| Bauer, J | 2 |
| Figer, A | 4 |
| Pestalozzi, BC | 1 |
| Köhne, CH | 3 |
| Mingrone, W | 2 |
| Tàmas, K | 2 |
| Kornek, GV | 5 |
| Tada, M | 2 |
| Arizumi, T | 1 |
| Arizumi, M | 1 |
| Kogure, H | 1 |
| Togawa, O | 1 |
| Matsubara, S | 1 |
| Hirano, K | 2 |
| Kawabe, T | 1 |
| Omata, M | 1 |
| Yanagihara, K | 1 |
| Takigahira, M | 1 |
| Arao, T | 1 |
| Aoyagi, Y | 1 |
| Oda, T | 1 |
| Ochiai, A | 1 |
| Nishio, K | 1 |
| Xiong, HQ | 3 |
| Blais, JC | 1 |
| Guba, M | 1 |
| De Toni, EN | 1 |
| Schwarz, B | 1 |
| Graeb, C | 1 |
| Eichhorn, ME | 1 |
| Kurosaki, I | 1 |
| Kawachi, Y | 1 |
| Nihei, K | 1 |
| Tsuchiya, Y | 1 |
| Aono, T | 1 |
| Yokoyama, N | 1 |
| Hatakeyama, K | 2 |
| Cartwright, T | 1 |
| Richards, DA | 1 |
| Boehm, KA | 1 |
| Marti, JL | 1 |
| Hiotis, SP | 1 |
| Donahue, B | 1 |
| Ryan, T | 1 |
| Newman, E | 1 |
| Kinsella, TJ | 1 |
| Seo, Y | 2 |
| Willis, J | 1 |
| Stellato, TA | 1 |
| Siegel, CT | 1 |
| Harpp, D | 1 |
| Willson, JK | 1 |
| Gibbons, J | 1 |
| Sanabria, JR | 1 |
| Schulak, JP | 1 |
| Mouri, H | 1 |
| Tsuchiyama, T | 1 |
| Ohtsubo, K | 1 |
| Kayahara, M | 2 |
| Ohta, T | 3 |
| Minato, H | 1 |
| Watanabe, H | 1 |
| Doi, R | 3 |
| Imamura, M | 3 |
| Hosotani, R | 3 |
| Imaizumi, T | 1 |
| Hatori, T | 1 |
| Takasaki, K | 1 |
| Funakoshi, A | 4 |
| Wakasugi, H | 3 |
| Asano, T | 1 |
| Hishinuma, S | 2 |
| Ogata, Y | 4 |
| Sunamura, M | 4 |
| Takao, S | 2 |
| Aikou, T | 2 |
| Maguchi, H | 1 |
| Kakita, A | 1 |
| Sasaki, M | 4 |
| Ozaki, M | 1 |
| Matsusue, S | 1 |
| Higashide, S | 1 |
| Noda, H | 1 |
| Ikeda, S | 2 |
| Maetani, S | 1 |
| Lansigan, F | 2 |
| Cornfeld, D | 1 |
| Syrigos, K | 3 |
| Wasif, N | 1 |
| Elsaleh, H | 2 |
| Garcia, M | 1 |
| Lai, R | 1 |
| Ammar, A | 1 |
| Benson, AB | 11 |
| Macdonald, J | 2 |
| Cass, CE | 1 |
| Dicker, AP | 2 |
| Nitsche, M | 1 |
| Horstmann, O | 1 |
| Christiansen, H | 1 |
| Hermann, RM | 1 |
| Hess, CF | 1 |
| Becker, H | 1 |
| Pradier, O | 1 |
| Schmidberger, H | 1 |
| Qian, H | 2 |
| Liang, X | 2 |
| Taira, K | 1 |
| Boku, N | 2 |
| Hironaka, S | 1 |
| Yoshino, T | 1 |
| Taku, K | 1 |
| Hashimoto, T | 1 |
| Nishimura, T | 1 |
| Twombly, R | 1 |
| Kalra, AV | 3 |
| Campbell, RB | 3 |
| Stieler, J | 4 |
| Opitz, B | 1 |
| Scholten, T | 2 |
| Kauschat-Brüning, D | 1 |
| Bramlage, P | 1 |
| Im, SA | 4 |
| Kim, TY | 5 |
| Ha, SW | 3 |
| Le Scodan, R | 3 |
| Partensky, C | 5 |
| Mercier, C | 4 |
| Valette, PJ | 4 |
| Hagmann, W | 1 |
| Jesnowski, R | 1 |
| Faissner, R | 1 |
| Löhr, JM | 2 |
| Price, T | 1 |
| Ngan, SY | 2 |
| Ganju, V | 1 |
| Strickland, AH | 1 |
| Muller, A | 1 |
| Khamly, K | 1 |
| Milner, AD | 1 |
| Dilulio, J | 1 |
| Matera, A | 1 |
| Zalcberg, JR | 2 |
| Leong, T | 1 |
| Asiyanbola, B | 1 |
| Gleisner, A | 1 |
| Swartz, M | 1 |
| Morak, MJ | 1 |
| van der Gaast, A | 1 |
| Incrocci, L | 3 |
| van Dekken, H | 4 |
| Jeekel, J | 7 |
| Hop, WC | 4 |
| Muslimov, GF | 1 |
| Owen, E | 1 |
| Black, JW | 1 |
| Mihaljevic, A | 1 |
| Büchler, P | 1 |
| Harder, J | 2 |
| Hofheinz, R | 3 |
| Gregor, M | 1 |
| Schmiegel, W | 1 |
| Endlicher, E | 3 |
| Klöppel, G | 2 |
| Toyokawa, H | 2 |
| Takahashi, K | 4 |
| Matsui, Y | 2 |
| Kitade, H | 1 |
| Mergental, H | 1 |
| Tanigawa, N | 1 |
| Takai, S | 3 |
| Kwon, AH | 1 |
| Gennatas, C | 1 |
| Michalaki, V | 1 |
| Gennatas, S | 1 |
| Niki, T | 1 |
| Soejima, T | 1 |
| Yoshikawa, T | 1 |
| Fujii, O | 1 |
| Ohta, Y | 1 |
| Tsuda, M | 1 |
| Horita, K | 1 |
| Tsujino, K | 1 |
| Hirohata, S | 1 |
| Fujino, Y | 2 |
| Nishisaki, H | 1 |
| Settle, SH | 1 |
| Novarino, A | 6 |
| Chiappino, I | 3 |
| Giacobino, A | 3 |
| Bellone, G | 6 |
| Rahimi, F | 1 |
| Milanesi, E | 1 |
| Bertetto, O | 4 |
| Ciuffreda, L | 3 |
| Berglund, A | 1 |
| Byström, P | 2 |
| Johansson, B | 1 |
| Nygren, P | 2 |
| Frödin, JE | 1 |
| Pedersen, D | 1 |
| Letocha, H | 1 |
| Saltz, LB | 1 |
| Maki, RG | 1 |
| Wang, ML | 1 |
| Foo, KF | 1 |
| Long, J | 1 |
| Ni, QX | 1 |
| Distler, M | 1 |
| Rückert, F | 1 |
| Dittert, DD | 1 |
| Stroszczynski, C | 2 |
| Dobrowolski, F | 1 |
| Kersting, S | 1 |
| Pino, MS | 1 |
| Gelibter, A | 2 |
| Sperduti, I | 2 |
| De Marco, S | 1 |
| Nuzzo, C | 1 |
| Bria, E | 2 |
| Carpanese, L | 1 |
| Ruggeri, EM | 2 |
| Carlini, P | 4 |
| Cognetti, F | 2 |
| Rajebi, MR | 1 |
| Harold, L | 1 |
| Roll, L | 1 |
| Egami, T | 1 |
| Ohuchida, K | 2 |
| Miyoshi, K | 1 |
| Mizumoto, K | 2 |
| Onimaru, M | 2 |
| Toma, H | 1 |
| Huang, CL | 1 |
| Wang, HP | 3 |
| Shiah, HS | 3 |
| Chang, MC | 3 |
| Jan, CM | 2 |
| Tien, YW | 3 |
| Hwang, TL | 2 |
| Lin, JT | 2 |
| Cheng, AL | 5 |
| Whang-Peng, J | 5 |
| Bramhall, SR | 1 |
| Kelemen, D | 1 |
| Spry, N | 6 |
| Yoshizawa, J | 1 |
| Takizawa, A | 1 |
| Takeuchi, O | 1 |
| Hiraku, O | 1 |
| Sasaki, K | 3 |
| Morimoto, Y | 1 |
| Atsuda, K | 1 |
| Inoue, G | 1 |
| Asanuma, F | 1 |
| Oh, SY | 2 |
| Kim, BG | 1 |
| Kwon, HC | 2 |
| Kim, SH | 2 |
| Rho, MH | 1 |
| Rho, MS | 1 |
| Jeong, JS | 1 |
| Rognone, A | 4 |
| Nicoletti, R | 8 |
| Mazza, E | 2 |
| Arcidiacono, PG | 2 |
| Di Carlo, V | 8 |
| Villa, E | 7 |
| Hristov, B | 1 |
| Reddy, S | 1 |
| Lin, SH | 1 |
| Kemp, C | 1 |
| Guiramand, J | 3 |
| Lelong, B | 5 |
| de Chaisemartin, C | 1 |
| Desai, S | 1 |
| Simeone, D | 1 |
| Greenson, JK | 1 |
| Francis, IR | 1 |
| Hampton, J | 1 |
| Colletti, L | 1 |
| Chang, AE | 2 |
| Freitas, D | 1 |
| Fernandes, Gdos S | 1 |
| Hoff, PM | 1 |
| Cunha, JE | 1 |
| Vizio, B | 2 |
| Brondino, G | 2 |
| Addeo, A | 3 |
| Prati, A | 3 |
| Campra, D | 1 |
| Fronda, GR | 1 |
| Zygulska, AL | 1 |
| Pawlega, J | 1 |
| Mambrini, A | 6 |
| Pacetti, P | 3 |
| Del Freo, A | 3 |
| Seta, RD | 1 |
| Pezzuolo, D | 1 |
| Torri, T | 4 |
| Orlandi, M | 3 |
| Tartarini, R | 1 |
| Cantore, M | 7 |
| Lee, GW | 1 |
| Kim, HG | 1 |
| Jeong, CY | 1 |
| Sorscher, SM | 2 |
| Ose, J | 2 |
| Abel, U | 3 |
| Münter, MW | 1 |
| Adler, G | 2 |
| Gress, T | 1 |
| Garrett, C | 1 |
| Pande, A | 1 |
| Kuvshinoff, B | 1 |
| Litwin, A | 1 |
| Phelan, J | 1 |
| Gibbs, J | 1 |
| Iyer, R | 1 |
| Girard, N | 2 |
| Bibeau, F | 2 |
| Hattangadi, JA | 1 |
| Recchia, F | 3 |
| Sica, G | 2 |
| Candeloro, G | 1 |
| Bisegna, R | 1 |
| Bratta, M | 1 |
| Bonfili, P | 1 |
| Necozione, S | 1 |
| Rea, S | 2 |
| Mistafa, O | 1 |
| Stenius, U | 1 |
| Mizutani, S | 2 |
| Miyato, Y | 1 |
| Shidara, Y | 1 |
| Asoh, S | 1 |
| Tokunaga, A | 1 |
| Tajiri, T | 1 |
| Sargent, M | 1 |
| Schafer, C | 1 |
| Shimoda, M | 1 |
| Sawada, T | 1 |
| You, DD | 1 |
| Lee, HG | 1 |
| Arumugam, T | 1 |
| Ramachandran, V | 1 |
| Fournier, KF | 1 |
| Marquis, L | 1 |
| Gallick, GE | 2 |
| Logsdon, CD | 1 |
| McConkey, DJ | 1 |
| Choi, W | 1 |
| Winter, K | 1 |
| Rich, TA | 15 |
| Curran, W | 1 |
| Willett, CG | 12 |
| Guler, M | 1 |
| Hashmi, S | 1 |
| Bell, D | 2 |
| Banti, I | 1 |
| Nencetti, S | 1 |
| Orlandini, E | 1 |
| Lapucci, A | 1 |
| Breschi, MC | 1 |
| Fogli, S | 1 |
| Iott, MJ | 1 |
| Corsini, MM | 2 |
| Soto Iglesias, S | 1 |
| Baltar Arias, R | 1 |
| Vázquez Rodríguez, S | 1 |
| Alvarez, M | 1 |
| Gómez Martínez, P | 1 |
| Alvarez Sánchez, MV | 1 |
| Vázquez Astray, E | 1 |
| Puente, J | 1 |
| Díaz-Rubio, E | 1 |
| Vehling-Kaiser, U | 3 |
| Kettner, E | 3 |
| Winkelmann, C | 3 |
| Klein, S | 3 |
| Kojouharoff, G | 4 |
| Gauler, T | 1 |
| Clemens, MR | 3 |
| Neugebauer, S | 3 |
| Halldén, G | 2 |
| Choi, M | 2 |
| Heilbrun, LK | 4 |
| Venkatramanamoorthy, R | 1 |
| Lawhorn-Crews, JM | 1 |
| Strickland, A | 2 |
| Steer, CB | 2 |
| Hwang, JY | 1 |
| Kim, JE | 2 |
| Kim, TW | 3 |
| Han, DJ | 2 |
| Lee, JL | 3 |
| Yi, SY | 1 |
| Jun, HJ | 1 |
| Lee, JK | 4 |
| Lee, KT | 3 |
| Park, YS | 5 |
| Lim, HY | 3 |
| Kang, WK | 3 |
| Park, HC | 2 |
| Lim, DH | 3 |
| Masellis, AM | 1 |
| Sielaff, TD | 1 |
| Bender, GP | 1 |
| Booth, CM | 1 |
| Ohorodnyk, P | 1 |
| Eisenhauer, EA | 1 |
| Harper, PG | 1 |
| Dunn, J | 1 |
| Tudur-Smith, C | 1 |
| West, J | 1 |
| Adab, F | 1 |
| Leonard, P | 1 |
| Ostrowski, J | 1 |
| Tabernero, J | 1 |
| Thomas, K | 1 |
| Dove, P | 1 |
| Lévy, P | 3 |
| Ruszniewski, P | 4 |
| Ito, Y | 5 |
| Karasawa, K | 2 |
| Ogawa, Y | 1 |
| Onishi, H | 2 |
| Kazumoto, T | 1 |
| Shibuya, H | 1 |
| Okuno, Y | 1 |
| Nishino, S | 1 |
| Ogo, E | 1 |
| Uchida, N | 1 |
| Nemoto, K | 1 |
| Nishimura, Y | 1 |
| Hudson, E | 1 |
| Hurt, C | 1 |
| Mort, D | 1 |
| Brewster, AE | 1 |
| Iqbal, N | 1 |
| Crosby, TD | 1 |
| Wilkowski, R | 5 |
| Ostermaier, S | 1 |
| Sauer, R | 4 |
| Herbst, M | 1 |
| Flentje, M | 2 |
| Miethe, S | 1 |
| Boettcher, HD | 1 |
| Rau, HG | 1 |
| Hinke, A | 1 |
| Georgieva, I | 1 |
| Koychev, D | 1 |
| Holstein, J | 1 |
| Hopfenmüller, W | 1 |
| Zeitz, M | 1 |
| Grabowski, P | 1 |
| Collins, A | 1 |
| Wente, MN | 3 |
| Rötzer, I | 1 |
| Decker-Baumann, C | 1 |
| Karapanagiotou-Schenkel, I | 1 |
| Fujiwara, S | 1 |
| Murata, H | 1 |
| Doh, J | 1 |
| Nomi, T | 2 |
| Akahori, T | 2 |
| Yamato, I | 2 |
| Nishiofuku, H | 5 |
| Tamamoto, T | 4 |
| Hasegawa, M | 3 |
| Nakajima, Y | 7 |
| Haramoto, M | 1 |
| Kohno, M | 1 |
| Nakajima, O | 1 |
| Horibe, T | 1 |
| Kiyohara, M | 1 |
| Fukazawa, H | 1 |
| Togawa, T | 1 |
| Kawakami, K | 1 |
| Lee, WS | 1 |
| Lee, WY | 1 |
| Chun, HK | 1 |
| Simianu, VV | 1 |
| Zyromski, NJ | 1 |
| Nakeeb, A | 1 |
| Callister, MD | 1 |
| Farnell, MB | 1 |
| Gunderson, LL | 5 |
| Ruta, S | 1 |
| Mezes, M | 1 |
| Grant, N | 1 |
| Jiang, ZL | 1 |
| Bayraktar, UD | 1 |
| Manuyakorn, A | 1 |
| Paulus, R | 1 |
| Farrell, J | 1 |
| Dawson, NA | 1 |
| Tze, S | 1 |
| Cheung-Lau, G | 1 |
| Reber, H | 1 |
| Seligson, DB | 1 |
| Horvath, S | 1 |
| Kurdistani, SK | 1 |
| Gebbia, V | 3 |
| Maiello, E | 2 |
| Giuliani, F | 3 |
| Borsellino, N | 2 |
| Arcara, C | 1 |
| Colucci, G | 4 |
| Xie, DR | 1 |
| Yang, Q | 1 |
| Chen, DL | 1 |
| Jiang, ZM | 1 |
| Bi, ZF | 1 |
| Ma, W | 1 |
| Zhang, YD | 1 |
| Lal, A | 1 |
| Christians, K | 1 |
| Backlund, DC | 1 |
| Berlin, JD | 7 |
| Parikh, AA | 1 |
| Nakata, B | 1 |
| Amano, R | 1 |
| Nakao, S | 1 |
| Shinto, O | 1 |
| Hirakawa, T | 1 |
| Okita, Y | 1 |
| Yamada, N | 2 |
| Hirakawa, K | 2 |
| Ohkawa, S | 1 |
| Nakamura, K | 4 |
| Roehrig, S | 1 |
| Wein, A | 4 |
| Albrecht, H | 1 |
| Konturek, PC | 1 |
| Reulbach, U | 1 |
| Männlein, G | 1 |
| Wolff, K | 1 |
| Ostermeier, N | 1 |
| Hohenberger, W | 3 |
| Hahn, EG | 2 |
| Boxberger, F | 2 |
| Kruth, J | 1 |
| Nissen, J | 1 |
| Ernst, T | 1 |
| Kripp, M | 1 |
| Lukan, N | 1 |
| Merx, K | 1 |
| Hofmann, WK | 1 |
| Hochhaus, A | 3 |
| Hofheinz, RD | 2 |
| Nallapareddy, S | 1 |
| Rudek, MA | 1 |
| Norris-Kirby, A | 1 |
| Jimeno, A | 1 |
| Murphy, KM | 2 |
| Baker, SD | 1 |
| Messersmith, WA | 1 |
| McIntosh, D | 1 |
| Shaukat, A | 1 |
| Cooke, EW | 1 |
| Hazard, L | 2 |
| Mehta, SP | 1 |
| Di Marco, M | 1 |
| Di Cicilia, R | 1 |
| Nobili, E | 1 |
| Vecchiarelli, S | 1 |
| Brandi, G | 1 |
| Biasco, G | 1 |
| Manns, MP | 1 |
| Picardi, V | 1 |
| Ippolito, E | 1 |
| Massaccesi, M | 1 |
| Caravatta, L | 1 |
| Di Lullo, L | 1 |
| Giglio, G | 1 |
| Tambaro, R | 1 |
| Mignogna, S | 1 |
| Caprino, P | 1 |
| Ingrosso, M | 1 |
| Sofo, L | 2 |
| Cellini, N | 4 |
| Yovino, S | 2 |
| Poppe, M | 1 |
| Jabbour, S | 1 |
| David, V | 1 |
| Garofalo, M | 1 |
| Pandya, N | 2 |
| Alexander, R | 2 |
| Hanna, N | 3 |
| Yeap, B | 1 |
| Katopodis, O | 1 |
| Polyzos, A | 2 |
| Kentepozidis, N | 1 |
| Giassas, S | 1 |
| Rovithi, M | 1 |
| Bozionelou, V | 1 |
| Kalbakis, K | 1 |
| Vamvakas, L | 1 |
| Mavroudis, D | 1 |
| Georgoulias, V | 2 |
| Chefrour, M | 1 |
| Fischel, JL | 2 |
| Formento, P | 2 |
| Giacometti, S | 1 |
| Ferri-Dessens, RM | 1 |
| Marouani, H | 1 |
| Francoual, M | 1 |
| Renée, N | 4 |
| Ciccolini, J | 1 |
| Hess, V | 3 |
| Pratsch, S | 1 |
| Potthast, S | 1 |
| Lee, L | 1 |
| Winterhalder, R | 1 |
| Widmer, L | 1 |
| Cescato, C | 1 |
| Lohri, A | 1 |
| Jost, L | 1 |
| Stillhart, P | 1 |
| Pestalozzi, B | 2 |
| Gunnlaugsson, A | 1 |
| Anderson, H | 1 |
| Lind, P | 1 |
| Johnsson, A | 2 |
| Hill, ME | 2 |
| Campbell, A | 1 |
| Culler, K | 1 |
| Zalupski, M | 2 |
| Hejna, G | 1 |
| Catalano, PJ | 3 |
| Staley, C | 1 |
| Harris, W | 1 |
| Hoffman, J | 2 |
| Xu, N | 1 |
| Cooper, H | 2 |
| Matsui, J | 1 |
| Ueda, M | 3 |
| Voortman, J | 1 |
| Leon, LG | 1 |
| Park, JK | 2 |
| Kang, GH | 1 |
| Giaccone, G | 1 |
| Greco, E | 1 |
| Basso, D | 1 |
| Fadi, E | 1 |
| Padoan, A | 1 |
| Fogar, P | 1 |
| Zambon, CF | 1 |
| Navaglia, F | 1 |
| Bozzato, D | 1 |
| Moz, S | 1 |
| Pedrazzoli, S | 1 |
| Plebani, M | 1 |
| Ji, JS | 1 |
| Han, CW | 1 |
| Jang, JW | 1 |
| Lee, BI | 1 |
| Kim, BW | 1 |
| Kang, YN | 1 |
| Kay, CS | 1 |
| Choi, IB | 1 |
| Piperdi, M | 1 |
| McDade, TP | 1 |
| Shim, JK | 1 |
| Piperdi, B | 1 |
| Kadish, SP | 1 |
| Sullivan, ME | 1 |
| Whalen, GF | 1 |
| Tseng, JF | 1 |
| Laurence, V | 1 |
| Raouf, S | 1 |
| Tobias, J | 1 |
| Blackman, G | 1 |
| Goodchild, K | 1 |
| Collis, C | 1 |
| Horowitz, DP | 1 |
| Jackson, AS | 1 |
| Jain, P | 1 |
| Watkins, GR | 1 |
| Whitfield, GA | 1 |
| Green, MM | 1 |
| Taylor, MB | 1 |
| Dickinson, C | 1 |
| Price, PM | 2 |
| Saleem, A | 2 |
| Picozzi, VJ | 4 |
| Decker, PA | 1 |
| Traverso, W | 1 |
| Greeno, E | 1 |
| Wilfong, LS | 2 |
| Rothenberg, ML | 6 |
| Posner, MC | 1 |
| Redmond, KJ | 1 |
| Ahn, J | 1 |
| Penney, R | 1 |
| Kim, SR | 2 |
| Muneoka, K | 1 |
| Shirai, Y | 1 |
| Wakai, T | 1 |
| Sakata, J | 1 |
| Kanda, J | 1 |
| Wakabayashi, H | 1 |
| Zhou, T | 1 |
| Mariette, C | 3 |
| Buckels, JA | 1 |
| Choi, J | 2 |
| Nasir, A | 1 |
| Coppola, D | 1 |
| Chen, DT | 1 |
| Helm, J | 3 |
| Kvols, L | 2 |
| Haag, C | 1 |
| Stadel, D | 1 |
| Zhou, S | 2 |
| Bachem, MG | 1 |
| Möller, P | 1 |
| Debatin, KM | 1 |
| Fulda, S | 1 |
| Bruneton, D | 1 |
| Cassier, PA | 1 |
| Hervieu, V | 1 |
| Pilleul, F | 1 |
| Chayvialle, JA | 1 |
| Sheikh, R | 1 |
| Walsh, N | 1 |
| O'Connor, R | 1 |
| McDermott, R | 1 |
| Komori, S | 1 |
| Osada, S | 1 |
| Mori, R | 1 |
| Matsui, S | 2 |
| Sanada, Y | 1 |
| Tomita, H | 1 |
| Tokuyama, Y | 1 |
| Takahashi, T | 3 |
| Yoshida, K | 4 |
| Gasmi, M | 1 |
| Cattan, S | 2 |
| Chauffert, B | 5 |
| Bedenne, L | 4 |
| Cristiano, C | 1 |
| Ferrucci, LM | 1 |
| Thornton, J | 2 |
| Black, G | 2 |
| McCorkle, R | 1 |
| Heimburger, DC | 1 |
| Ikeda, O | 2 |
| Beppu, T | 1 |
| Oya, N | 1 |
| Arjona-Sánchez, A | 1 |
| Ruiz-Rabelo, J | 2 |
| Perea, MD | 1 |
| Vázquez, R | 2 |
| Muñoz, Mdel C | 1 |
| Túnez, I | 2 |
| Muntané, J | 2 |
| Padillo, FJ | 1 |
| Fotopoulou, C | 1 |
| Baumunk, D | 1 |
| Schmidt, SC | 1 |
| Schumacher, G | 1 |
| Belli, C | 3 |
| Longoni, S | 2 |
| Fugazza, C | 3 |
| Brioschi, M | 1 |
| Revalde, JL | 1 |
| Reid, G | 1 |
| Paxton, JW | 1 |
| Wang, CF | 1 |
| Zhao, P | 3 |
| Shan, Y | 1 |
| Zhao, DB | 1 |
| Tian, YT | 1 |
| Bai, XF | 1 |
| Sun, YM | 1 |
| Che, X | 1 |
| Qu, H | 1 |
| Xie, YB | 1 |
| Yoo, T | 1 |
| Hong, EK | 1 |
| Holzman, DC | 1 |
| Arjona, A | 1 |
| Perea, D | 1 |
| Montilla, P | 1 |
| Padillo, J | 1 |
| Stokes, JB | 1 |
| Nolan, NJ | 1 |
| Stelow, EB | 1 |
| Walters, DM | 1 |
| Weiss, GR | 2 |
| de Lange, EE | 1 |
| Adams, RB | 1 |
| Bauer, TW | 1 |
| Anai, H | 4 |
| Sueyoshi, S | 2 |
| Yamamoto, K | 2 |
| Morimoto, K | 2 |
| Masada, T | 1 |
| Yamaoka, K | 1 |
| Inatsugi, N | 1 |
| Yoshikawa, S | 1 |
| Uchida, H | 1 |
| Kuge, H | 1 |
| Yokotani, T | 1 |
| Yamaguchi, T | 4 |
| Kawaguchi, C | 1 |
| Shimobayashi, T | 1 |
| Inagaki, M | 1 |
| Matsuoka, M | 1 |
| Tatsumi, K | 1 |
| Saraya, T | 1 |
| Otsuji, T | 1 |
| Yamochi, Y | 1 |
| Yamanishi, K | 1 |
| Enomoto, Y | 1 |
| Nonomura, A | 1 |
| Kametaka, H | 1 |
| Koyama, T | 1 |
| Seike, K | 1 |
| Hasegawa, A | 1 |
| Jones, K | 1 |
| Shaban, A | 1 |
| Anker, C | 1 |
| Scaife, C | 1 |
| Weis, J | 1 |
| Mulvihill, S | 1 |
| Lustig, R | 1 |
| Konski, AA | 2 |
| Macdonald, JS | 15 |
| Barhoumi, M | 1 |
| Bosset, JF | 3 |
| Azzedine, A | 2 |
| Butel, J | 2 |
| Stremsdoerfer, N | 2 |
| Maingon, P | 2 |
| Han, SW | 2 |
| Kim, C | 1 |
| Owen, D | 1 |
| Coban, I | 1 |
| Kneuertz, PJ | 1 |
| Kauh, JS | 1 |
| Sarmiento, J | 1 |
| Staley, CA | 3 |
| Volkan Adsay, N | 1 |
| Xu, Q | 1 |
| Iwahashi, S | 1 |
| Ishibashi, H | 1 |
| Utsunomiya, T | 1 |
| Morine, Y | 2 |
| Ochir, TL | 1 |
| Hanaoka, J | 1 |
| Mori, H | 1 |
| Ikemoto, T | 2 |
| Imura, S | 2 |
| Shimada, M | 2 |
| Kang, SP | 3 |
| Oberstein, PE | 1 |
| Reitzig, P | 2 |
| Herrenberger, J | 2 |
| Korsten, FW | 1 |
| Kindler, M | 2 |
| Sohn, CH | 1 |
| Zang, DY | 1 |
| Ryoo, HM | 1 |
| Song, HS | 2 |
| Kang, HJ | 1 |
| Kim, BS | 2 |
| Lin, YL | 1 |
| Hsu, CH | 3 |
| Hsieh, RK | 1 |
| Lin, PW | 1 |
| Castellanos, EH | 1 |
| Konski, A | 2 |
| Gavoille, C | 2 |
| Hoffe, S | 2 |
| Malafa, M | 1 |
| Hodul, P | 1 |
| Klapman, J | 2 |
| Centeno, B | 1 |
| Valone, T | 1 |
| Springett, G | 1 |
| Espinoza, AM | 1 |
| Jones, KA | 2 |
| Bergsland, EK | 1 |
| Kelley, RK | 1 |
| Dito, E | 2 |
| Ong, A | 2 |
| Hanover, CS | 1 |
| Coakley, FV | 1 |
| Bécouarn, Y | 2 |
| Péré-Vergé, D | 1 |
| Delbaldo, C | 2 |
| Montoto-Grillot, C | 1 |
| Fiorentini, G | 6 |
| Adler, M | 1 |
| Zhu, CP | 1 |
| Chen, YX | 1 |
| Xie, WF | 1 |
| Timcheva, C | 1 |
| Spigel, DR | 1 |
| La Stella, PJ | 1 |
| Ciuleanu, TE | 1 |
| Pover, G | 1 |
| Kim, ST | 1 |
| Jang, KT | 1 |
| Kurata, N | 1 |
| Fujita, H | 1 |
| Mahawithitwong, P | 1 |
| Sakai, H | 1 |
| Manabe, T | 2 |
| Ohtsuka, T | 1 |
| Robertson, JM | 3 |
| Margolis, J | 2 |
| Balaraman, S | 1 |
| Gustafson, G | 1 |
| Khilanani, P | 1 |
| Nadeau, L | 2 |
| Jury, R | 2 |
| McIntosh, B | 1 |
| Bae, K | 1 |
| Wong, J | 1 |
| Rezzonico, S | 1 |
| Cappio, S | 1 |
| Doglioni, C | 1 |
| Udelnow, A | 1 |
| Kreyes, A | 1 |
| Ellinger, S | 1 |
| Landfester, K | 1 |
| Walther, P | 1 |
| Klapperstueck, T | 1 |
| Wohlrab, J | 1 |
| Henne-Bruns, D | 2 |
| Knippschild, U | 1 |
| Würl, P | 1 |
| Zander, H | 1 |
| Effenberger, KE | 1 |
| Kalinina, T | 1 |
| Yekebas, E | 1 |
| Bockhorn, M | 1 |
| Niedzwiecki, D | 2 |
| Hollis, D | 1 |
| Mayer, RJ | 3 |
| Tepper, JE | 2 |
| Blackstock, AW | 2 |
| Qin, Q | 2 |
| Yin, T | 1 |
| Deng, SC | 2 |
| Wang, B | 3 |
| Tian, K | 2 |
| Wang, GB | 1 |
| Urick, ME | 1 |
| Chung, EJ | 1 |
| Shield, WP | 1 |
| Gerber, N | 1 |
| White, A | 1 |
| Sowers, A | 1 |
| Thetford, A | 1 |
| Camphausen, K | 1 |
| Mitchell, J | 1 |
| Citrin, DE | 1 |
| Lin, E | 1 |
| Kocher, HM | 1 |
| Alrawashdeh, W | 1 |
| Kuramitsu, Y | 1 |
| Murakami, K | 2 |
| Ryozawa, S | 2 |
| Taba, K | 1 |
| Kaino, S | 1 |
| Sakaida, I | 1 |
| Assaf, E | 1 |
| Verlinde-Carvalho, M | 1 |
| Grenier, J | 1 |
| Sellam, Z | 1 |
| Pouessel, D | 1 |
| Bouaita, L | 1 |
| Baumgaertner, I | 1 |
| Sobhani, I | 1 |
| Tayar, C | 1 |
| Paul, M | 1 |
| Culine, S | 1 |
| Brunner, TB | 2 |
| Oliver, GR | 1 |
| Kinsman, K | 1 |
| Flores, EI | 1 |
| Chung, K | 1 |
| Ren, C | 1 |
| Han, C | 1 |
| He, P | 1 |
| Brixi-Benmansour, H | 1 |
| Jouve, JL | 1 |
| Bhattacharyya, M | 1 |
| Francis, J | 1 |
| Eddouadi, A | 1 |
| Lemoine, NR | 2 |
| Dakik, HK | 1 |
| Moskovic, DJ | 1 |
| Carlson, PJ | 1 |
| Tamm, EP | 3 |
| Xenidis, N | 1 |
| Chelis, L | 1 |
| Amarantidis, K | 2 |
| Chamalidou, E | 1 |
| Dimopoulos, P | 1 |
| Courcoutsakis, N | 1 |
| Tentes, A | 2 |
| Chiotis, A | 1 |
| Prassopoulos, P | 1 |
| Kakolyris, S | 2 |
| Barber, TW | 1 |
| Hofman, MS | 1 |
| Thomson, BN | 1 |
| Hicks, RJ | 1 |
| Oberic, L | 1 |
| Celier, P | 1 |
| Berille, J | 2 |
| Hinchliffe, E | 1 |
| Allcock, RL | 1 |
| Mansoor, W | 1 |
| Myers, MA | 1 |
| Simon, M | 1 |
| Bioulac-Sage, P | 1 |
| Trillaud, H | 1 |
| Kosuge, T | 4 |
| Zhao, CY | 1 |
| Yu, DH | 1 |
| Bu, HJ | 1 |
| Ni, CY | 1 |
| Kuo, YH | 1 |
| Hsu, C | 3 |
| Kuo, SH | 1 |
| Balachandran, A | 1 |
| Abdalla, EK | 1 |
| Abbruzzese, J | 1 |
| Chopin-Laly, X | 1 |
| Charnsangavej, C | 6 |
| Chan, AP | 1 |
| Tang, M | 1 |
| Tai, IT | 1 |
| Bickenbach, KA | 1 |
| Tang, LH | 1 |
| O'Reilly, E | 1 |
| Goodman, K | 1 |
| Brennan, MF | 1 |
| Dematteo, RP | 1 |
| Fong, Y | 2 |
| Cummins, MM | 1 |
| Brown, C | 1 |
| Carroll, S | 2 |
| Selva-Nayagam, S | 1 |
| Borg, M | 3 |
| Ackland, SP | 1 |
| Wratten, C | 1 |
| Porter, IW | 1 |
| Bydder, S | 2 |
| Underhill, C | 2 |
| Harvey, J | 4 |
| Gebski, VJ | 1 |
| Horev-Drori, G | 1 |
| Cooks, T | 1 |
| Bittan, H | 1 |
| Lazarov, E | 1 |
| Schmidt, M | 1 |
| Arazi, L | 1 |
| Efrati, M | 1 |
| Kelson, I | 1 |
| Keisari, Y | 1 |
| Lau, PC | 1 |
| Zheng, SF | 1 |
| Ng, WT | 1 |
| Yu, SC | 1 |
| Mayer, P | 1 |
| Harjung, A | 1 |
| Breinig, M | 1 |
| Fischer, L | 2 |
| Ehemann, V | 1 |
| Malz, M | 1 |
| Scherübl, H | 1 |
| Britsch, S | 1 |
| Kern, MA | 1 |
| Bläker, H | 1 |
| Schirmacher, P | 2 |
| Abelson, JA | 1 |
| Murphy, JD | 1 |
| Minn, AY | 1 |
| Chung, M | 1 |
| Fisher, GA | 5 |
| Ford, JM | 4 |
| Kunz, P | 1 |
| Norton, JA | 1 |
| Visser, BC | 1 |
| Poultsides, GA | 1 |
| Koong, AC | 2 |
| Chang, DT | 1 |
| Tronconi, MC | 1 |
| Milandri, C | 4 |
| Magli, A | 1 |
| Senzer, N | 1 |
| Nemunaitis, J | 1 |
| Rosemurgy, A | 3 |
| Chung, T | 1 |
| Chang, KJ | 2 |
| Posner, M | 2 |
| Waxman, I | 1 |
| Reid, A | 1 |
| Erickson, R | 1 |
| Canto, M | 1 |
| Chak, A | 1 |
| Blatner, G | 1 |
| Kovacevic, M | 1 |
| Thornton, M | 1 |
| Zagar, TM | 1 |
| White, RR | 3 |
| Tyler, DS | 6 |
| Papavassiliou, P | 1 |
| Papalezova, KT | 1 |
| Guy, CD | 1 |
| Broadwater, G | 1 |
| Clough, RW | 1 |
| Czito, BG | 3 |
| Maidment, BW | 1 |
| Goloubeva, O | 1 |
| Uguz, AC | 1 |
| Cig, B | 1 |
| Espino, J | 1 |
| Bejarano, I | 1 |
| Naziroglu, M | 1 |
| Rodríguez, AB | 1 |
| Pariente, JA | 1 |
| Stevens, AJ | 1 |
| Ihorst, G | 1 |
| Moehler, M | 2 |
| Buechler, P | 1 |
| Kloeppel, G | 1 |
| Röcken, C | 1 |
| Schmoor, C | 1 |
| Saroufim, A | 1 |
| Chahine, G | 2 |
| Nasr, F | 2 |
| Arvold, ND | 1 |
| Niemierko, A | 1 |
| Baschnagel, A | 1 |
| Shah, C | 1 |
| Stein, J | 1 |
| Khallouf, H | 1 |
| Serba, S | 1 |
| Teichgräber, V | 1 |
| Hung, SW | 1 |
| Mody, HR | 1 |
| Govindarajan, R | 1 |
| Hashimoto, A | 1 |
| Di Maio, M | 1 |
| Perrone, F | 1 |
| Schönekaes, K | 2 |
| Rübe, C | 3 |
| Sulkowski, U | 2 |
| Preusser, P | 4 |
| Prott, FJ | 2 |
| Willich, N | 4 |
| Morifuji, Y | 1 |
| Kai, M | 1 |
| Suyama, K | 1 |
| Iwasaki, H | 1 |
| Katano, M | 1 |
| Ghosh, S | 1 |
| Hossain, MZ | 1 |
| Borges, M | 1 |
| Goggins, MG | 1 |
| Ingersoll, RG | 1 |
| Eshleman, JR | 1 |
| Klein, AP | 1 |
| Short, M | 1 |
| Halkett, G | 1 |
| Reece, W | 2 |
| Zissiadis, Y | 2 |
| Ferrari, D | 1 |
| Cascinu, S | 6 |
| Catalano, V | 3 |
| Valmadre, G | 1 |
| Ferrara, D | 1 |
| Veltri, E | 1 |
| Codignola, C | 1 |
| Labianca, R | 4 |
| Jeon, EK | 1 |
| Won, HS | 1 |
| Ko, YH | 1 |
| Lee, IS | 1 |
| You, YK | 1 |
| Pei, W | 1 |
| Luan, Q | 1 |
| Ma, F | 1 |
| Zhao, Z | 1 |
| Meng, X | 1 |
| Inaba, Y | 1 |
| van der Zee, JA | 1 |
| Dicheva, BM | 1 |
| Seynhaeve, AL | 1 |
| Koning, GA | 1 |
| Eggermont, AM | 1 |
| Ten Hagen, TL | 1 |
| Kawamura, C | 1 |
| Maldonado, JC | 1 |
| Ernani, V | 1 |
| Narayanan, G | 1 |
| Ribeiro, A | 1 |
| Portelance, L | 1 |
| Merchan, JR | 1 |
| Levi, JU | 1 |
| Zafar, SF | 1 |
| Park, JH | 1 |
| Yi, XP | 1 |
| Shen, H | 1 |
| Li, YX | 1 |
| Martin, LK | 1 |
| Kleiber, B | 1 |
| Bekaii-Saab, TS | 2 |
| Gauler, TC | 2 |
| Rubanov, O | 1 |
| Baake, G | 1 |
| Höhler, T | 1 |
| Ko, YD | 1 |
| Levy, A | 1 |
| Chargari, C | 1 |
| Huguet, F | 3 |
| Védrine, L | 1 |
| Deutsch, E | 1 |
| Lim, JH | 1 |
| Yoon, YB | 2 |
| Yerram, SR | 1 |
| Azad, NA | 1 |
| Wei, J | 1 |
| Wu, N | 1 |
| Chu, E | 2 |
| Nakatsukasa, K | 1 |
| Koyama, H | 2 |
| Tokugawa, T | 1 |
| Inaba, S | 1 |
| Hong, GB | 2 |
| Zhou, JX | 2 |
| Sun, HB | 1 |
| Li, CY | 1 |
| Song, LQ | 1 |
| Couvelard, A | 1 |
| Rebours, V | 2 |
| Palazzo, M | 1 |
| Maire, F | 1 |
| Goujon, G | 1 |
| Gillet, A | 1 |
| Flaherty, AM | 1 |
| Peddi, PF | 1 |
| Lubner, S | 1 |
| McWilliams, R | 1 |
| Menias, C | 1 |
| Linehan, D | 1 |
| Raymond, E | 2 |
| Golden, DW | 1 |
| Novak, CJ | 1 |
| Minsky, BD | 1 |
| Izumiya, M | 1 |
| Kabashima, A | 1 |
| Higuchi, H | 1 |
| Igarashi, T | 1 |
| Sakai, G | 1 |
| Iizuka, H | 1 |
| Nakamura, S | 1 |
| Adachi, M | 1 |
| Funakoshi, S | 1 |
| Takaishi, H | 1 |
| Hibi, T | 1 |
| Gentil, J | 1 |
| Singla, S | 1 |
| Pippin, JA | 1 |
| Hoffmann, K | 4 |
| Herrmann, T | 3 |
| Bartsch, D | 1 |
| Klein, J | 1 |
| Mansmann, U | 3 |
| Capussotti, L | 1 |
| Kunz, R | 2 |
| Truong, TG | 1 |
| Cha, BH | 1 |
| Yoo, JY | 1 |
| Kim, N | 1 |
| Lee, DH | 1 |
| Markoutsaki, N | 1 |
| Roussel, H | 1 |
| Rahmi, G | 1 |
| Van der Stiegel, M | 1 |
| Palazzo, L | 1 |
| Fabre, M | 1 |
| Cuenod, CA | 1 |
| Neumann, J | 1 |
| Egg, R | 1 |
| Goritschan, C | 1 |
| Barner, M | 1 |
| Niu, Y | 1 |
| Michl, P | 1 |
| Olszewski, AJ | 1 |
| Grossbard, ML | 5 |
| Chung, MS | 1 |
| Chalasani, SB | 1 |
| Malamud, S | 3 |
| Mirzoyev, T | 2 |
| Kozuch, PS | 1 |
| Bascoul-Mollevi, C | 1 |
| Obel, J | 1 |
| Krishnamurthi, S | 1 |
| Rocha-Lima, CS | 1 |
| Chamorey, E | 1 |
| Etienne-Grimaldi, MC | 1 |
| Michel, C | 1 |
| Mari, V | 1 |
| Douillard, JY | 2 |
| Derbel, O | 1 |
| Penet, AS | 1 |
| Stella, M | 1 |
| Méeus, P | 1 |
| Orlandini, F | 1 |
| Pérol, M | 1 |
| Mayahara, H | 1 |
| Morizane, C | 3 |
| Kondo, S | 1 |
| Murakami, N | 2 |
| Morota, M | 1 |
| Sumi, M | 3 |
| Itami, J | 1 |
| Holen, KD | 1 |
| Schelman, WR | 1 |
| Deming, DA | 1 |
| Hernan, HR | 1 |
| Goggins, T | 1 |
| Oettel, K | 1 |
| Robinson, E | 1 |
| Hokutoh, D | 1 |
| Yasuda, S | 1 |
| Gunturu, KS | 1 |
| Thumar, JR | 1 |
| Gronau, M | 1 |
| Enk, AH | 1 |
| Hassel, JC | 1 |
| Samalin, E | 1 |
| Taylor, GE | 1 |
| Ziegler, MA | 1 |
| Cai, H | 1 |
| Savage, DT | 1 |
| Canto, MI | 1 |
| Reid, T | 1 |
| Shah, RJ | 1 |
| Hall, FM | 1 |
| Kulu, Y | 1 |
| Kawasaki, H | 1 |
| Donahue, JM | 1 |
| Kasuya, H | 2 |
| Cusack, JC | 1 |
| Choi, EW | 1 |
| Kuruppu, DK | 1 |
| Brecht, IC | 1 |
| Welzel, T | 1 |
| Rieken, S | 1 |
| López, R | 1 |
| Méndez, CM | 1 |
| Fernández, MJ | 1 |
| Reinoso, CR | 1 |
| Aldana, GQ | 1 |
| DE LA Cámara Gómez, J | 1 |
| López, MR | 1 |
| Vázquez, MR | 1 |
| Folgar, SC | 1 |
| Didelot, C | 2 |
| Barberi-Heyob, M | 2 |
| Merlin, JL | 2 |
| Maisey, N | 1 |
| Norman, A | 5 |
| Seymour, M | 1 |
| O'Brien, M | 3 |
| Harrington, A | 1 |
| Hill, M | 3 |
| Balart, J | 1 |
| Capellà, G | 1 |
| de los Inocentes, RM | 1 |
| de Andrés, J | 1 |
| Ares, C | 1 |
| Craven-Bartle, J | 1 |
| Lluís, F | 1 |
| Eisold, S | 2 |
| Dihlmann, S | 1 |
| Linnebacher, M | 2 |
| Aulmann, M | 1 |
| Schlehofer, JR | 1 |
| Ridder, R | 1 |
| von Knebel Doeberitz, M | 1 |
| Liu, JM | 1 |
| Li, AF | 1 |
| Perng, CL | 1 |
| Tiu, CM | 1 |
| King, KL | 1 |
| Lin, WC | 1 |
| Lan, C | 1 |
| Kugler, JW | 4 |
| Haller, DG | 7 |
| Bugat, R | 3 |
| Merouche, Y | 1 |
| Berthault-Cvitkovic, F | 1 |
| Luboinski, M | 1 |
| Khoo, VS | 1 |
| Price, P | 1 |
| Mawdsley, S | 1 |
| Hall, M | 2 |
| Glynne-Jones, R | 1 |
| Kliche, KO | 1 |
| Kubsch, K | 1 |
| Raida, M | 1 |
| Masri-Zada, R | 1 |
| Höffken, K | 1 |
| Oonuma, M | 3 |
| Fukuyama, S | 1 |
| Shimamura, H | 1 |
| Yamauchi, J | 1 |
| Egawa, S | 1 |
| Takeda, K | 3 |
| Matsuno, S | 7 |
| Takizawa, M | 1 |
| Hirano, M | 1 |
| Uno, Y | 1 |
| Kikuchi, T | 1 |
| Nozawa, H | 1 |
| Hara, T | 1 |
| Asaumi, Y | 1 |
| Kikkawa, H | 1 |
| Takada, T | 4 |
| Amano, H | 1 |
| Yasuda, H | 3 |
| Nimura, Y | 2 |
| Matsushiro, T | 3 |
| Nagakawa, T | 4 |
| Nakayama, T | 2 |
| O'Meara, AT | 1 |
| Benedetti, JK | 2 |
| Seay, TE | 1 |
| Neubauer, MA | 1 |
| George, CS | 1 |
| Tanaka, MS | 1 |
| Giguere, JK | 1 |
| Pruitt, BT | 1 |
| Kulke, MH | 3 |
| Bearss, D | 1 |
| Azria, D | 2 |
| Jacot, W | 1 |
| Lemanski, C | 1 |
| Senesse, P | 1 |
| Prost, P | 2 |
| Delard, R | 1 |
| Masson, B | 2 |
| Dubois, JB | 1 |
| Pearl, J | 1 |
| Elster, E | 1 |
| Golocovsky, M | 1 |
| Waters, JS | 1 |
| Tait, D | 1 |
| Padhani, AR | 1 |
| Lofts, F | 1 |
| Hill, A | 4 |
| Shibamoto, Y | 1 |
| Mimasu, Y | 1 |
| Tachi, Y | 1 |
| Hatta, H | 1 |
| Nishimoto, S | 1 |
| Happich, K | 1 |
| Schirner, I | 1 |
| Brueckl, WM | 2 |
| Bankhead, C | 1 |
| Onishi, I | 2 |
| Kamata, T | 2 |
| Hayashi, Y | 1 |
| Minatoya, G | 1 |
| Michiwa, Y | 1 |
| Kanno, M | 2 |
| Huguier, M | 3 |
| Goseki, N | 1 |
| Takamatsu, S | 1 |
| Nosaka, T | 1 |
| Teramoto, K | 1 |
| Arii, S | 2 |
| Kumagai, J | 1 |
| Schüll, B | 1 |
| Ulrich-Pur, H | 1 |
| Schmid, K | 1 |
| Raderer, M | 2 |
| Kwasny, W | 2 |
| Depisch, D | 2 |
| Schneeweiss, B | 1 |
| Lang, F | 1 |
| Schneider, T | 1 |
| Osl, F | 1 |
| Friess, T | 1 |
| Stockinger, H | 1 |
| Scheuer, WV | 1 |
| Salzberg, M | 1 |
| Morant, R | 1 |
| Roth, AD | 1 |
| Ludwig, C | 1 |
| Arakawa, Y | 1 |
| Mizunuma, N | 1 |
| Aiba, K | 1 |
| Irie, T | 1 |
| Watanabe, J | 1 |
| Tada, K | 1 |
| Okudaira, T | 1 |
| Seki, M | 1 |
| Muto, T | 2 |
| Hatake, K | 1 |
| Corsi, DC | 1 |
| Pozzo, C | 1 |
| Longo, R | 1 |
| Quirino, M | 1 |
| Battelli, C | 1 |
| Forni, F | 1 |
| Smaniotto, D | 2 |
| Trodella, L | 2 |
| Balducci, M | 2 |
| Kinoshita, T | 2 |
| Nagase, M | 1 |
| Konishi, M | 2 |
| Nakagohri, T | 2 |
| Inoue, K | 4 |
| Ogino, T | 1 |
| Ikeda, H | 5 |
| Maru, Y | 1 |
| Yoshino, M | 2 |
| Fujito, T | 1 |
| Goda, F | 1 |
| Matsuyama, J | 1 |
| Hojo, S | 1 |
| Yano, Y | 1 |
| Endo, W | 1 |
| Maeura, Y | 1 |
| Vaitkevicius, V | 2 |
| Raraty, MG | 1 |
| Hickey, H | 3 |
| Dunn, JA | 4 |
| Beger, HG | 5 |
| Poch, B | 1 |
| Schwarz, M | 1 |
| Gansauge, F | 4 |
| Magnin, V | 2 |
| Giovannini, MH | 1 |
| Monges, G | 2 |
| Bardou, VJ | 1 |
| Alzieu, C | 1 |
| Ji, Z | 1 |
| Chen, X | 1 |
| Wu, T | 1 |
| Hosoya, Y | 1 |
| Nagai, H | 1 |
| Koinuma, K | 1 |
| Yasuda, Y | 1 |
| Kaneko, Y | 1 |
| Saito, K | 1 |
| Saitoh, Y | 2 |
| Hoshida, T | 2 |
| Ottomo, S | 1 |
| Horii, A | 1 |
| Murad, AM | 1 |
| Guimarães, RC | 1 |
| Aragão, BC | 1 |
| Rodrigues, VH | 1 |
| Scalabrini-Neto, AO | 1 |
| Padua, CA | 1 |
| Moore, FC | 1 |
| Herfarth, Ch | 1 |
| Kozarek, RA | 1 |
| Traverso, LW | 4 |
| Mitsutsuji, M | 1 |
| Iwanaga, Y | 1 |
| Tanioka, Y | 1 |
| Kamigaki, T | 2 |
| Ku, Y | 1 |
| Kuroda, Y | 2 |
| Kelleher, M | 1 |
| Andreyev, J | 1 |
| Allen, M | 1 |
| Schramm, H | 1 |
| Z'graggen, K | 1 |
| Kang, YK | 1 |
| Petty, RD | 1 |
| Nicolson, MC | 1 |
| Skaria, S | 1 |
| Sinclair, TS | 1 |
| Samuel, LM | 1 |
| Koruth, M | 1 |
| Tokuuye, K | 5 |
| Kagami, Y | 3 |
| Murayama, S | 1 |
| Okada, S | 8 |
| Correale, P | 2 |
| Messinese, S | 1 |
| Marsili, S | 1 |
| Ceciarini, F | 1 |
| Pozzessere, D | 1 |
| Sabatino, M | 1 |
| Cerretani, D | 1 |
| Pellegrini, M | 1 |
| Di Palma, T | 1 |
| Neri, A | 1 |
| Calvanese, A | 1 |
| Pinto, E | 1 |
| Giorgi, G | 1 |
| Francini, G | 2 |
| Vaishampayan, U | 2 |
| Jain, V | 1 |
| Adsay, V | 2 |
| Day, J | 1 |
| Shepard, R | 1 |
| Kang, W | 2 |
| Tao, W | 2 |
| Micke, O | 3 |
| Bruns, F | 1 |
| Kurowski, R | 1 |
| Horst, E | 2 |
| deVries, AF | 1 |
| Hausler, JW | 1 |
| Schäfer, U | 2 |
| Chi, KH | 1 |
| Chan, WK | 1 |
| Teng, HC | 1 |
| Lee, RC | 1 |
| Chang, FY | 1 |
| Lee, SD | 1 |
| Yen, SH | 1 |
| Claude, L | 2 |
| Gan, J | 1 |
| Shen, Z | 1 |
| Nomura, K | 1 |
| Baba, Y | 3 |
| Hayashi, S | 1 |
| Oota, H | 2 |
| Yoshida, T | 6 |
| Kamimura, T | 4 |
| Fujii, M | 1 |
| Miyake, H | 2 |
| Takamura, K | 1 |
| Tashiro, S | 2 |
| WEISS, AJ | 1 |
| JACKSON, L | 1 |
| SULLIVAN, RD | 2 |
| NORCROSS, JW | 1 |
| WATKINS, E | 1 |
| LANGDON, EA | 1 |
| OTTOMAN, RE | 1 |
| ROCHLIN, DB | 2 |
| SMART, CR | 2 |
| GOLOMB, FM | 2 |
| SAMMONS, BP | 1 |
| WRIGHT, JC | 1 |
| REITEMEIER, RJ | 8 |
| MOERTEL, CG | 21 |
| BLACKBURN, CM | 1 |
| HAHN, RG | 6 |
| KABAKOW, B | 1 |
| ALBAUM, H | 1 |
| ANTOPOL, W | 1 |
| BLINICK, G | 1 |
| SUSSMAN, L | 1 |
| GINZBURG, L | 1 |
| HURLEY, JD | 1 |
| FALKSON, G | 2 |
| SNYMAN, HJ | 1 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| ZUREK, WZ | 1 |
| MCCAFFERY, JF | 1 |
| SILVA, A | 1 |
| CHILDS, DS | 3 |
| HOLBROOK, MA | 4 |
| COLBY, MY | 2 |
| Togawa, A | 1 |
| Kimura, F | 1 |
| Shimizu, H | 1 |
| Shimamura, F | 1 |
| Yoshidome, H | 1 |
| Katoh, A | 1 |
| Miyazaki, M | 1 |
| Hu, YC | 1 |
| Komorowski, RA | 1 |
| Graewin, S | 1 |
| Hostetter, G | 1 |
| Kallioniemi, OP | 1 |
| Pitt, HA | 2 |
| Ahrendt, SA | 1 |
| Whitehouse, PA | 1 |
| Cooper, AJ | 1 |
| Johnson, CD | 2 |
| Araneo, M | 2 |
| Bruckner, HW | 12 |
| Frager, D | 2 |
| Homel, P | 3 |
| Marino, J | 2 |
| DeGregorio, P | 2 |
| Mortazabi, F | 1 |
| Firoozi, K | 1 |
| Jindal, K | 1 |
| Kozuch, P | 6 |
| Min, Y | 1 |
| Adachi, Y | 1 |
| Yamamoto, H | 1 |
| Itoh, F | 1 |
| Lee, CT | 1 |
| Nadaf, S | 1 |
| Carbone, DP | 1 |
| Imai, K | 1 |
| Brasiūniene, B | 5 |
| Juozaityte, E | 5 |
| Brasiūnas, V | 3 |
| Inciūra, A | 1 |
| Bai, YR | 1 |
| Wu, GH | 1 |
| Guo, WJ | 1 |
| Wu, XD | 1 |
| Yao, Y | 1 |
| Zhou, RH | 1 |
| Lu, DQ | 1 |
| Matsumoto, G | 1 |
| Tsuruta, K | 1 |
| Okamoto, A | 1 |
| Jiang, K | 1 |
| Delarue, FL | 1 |
| Sebti, SM | 1 |
| Gordon, EM | 1 |
| Cornelio, GH | 1 |
| Lorenzo, CC | 1 |
| Levy, JP | 1 |
| Reed, RA | 1 |
| Hall, FL | 1 |
| Meyer, F | 2 |
| Grote, R | 1 |
| Lippert, H | 2 |
| Ridwelski, K | 1 |
| Al-Sukhun, S | 1 |
| Vaitkevicius, VK | 4 |
| Soulen, R | 1 |
| Weaver, D | 1 |
| Levin, K | 1 |
| Forman, JD | 1 |
| Kaubisch, A | 1 |
| Kaleya, R | 2 |
| Haynes, H | 2 |
| Rozenblit, A | 1 |
| Wadler, S | 4 |
| Miyamoto, H | 1 |
| Tsuchida, K | 1 |
| Sugino, H | 1 |
| Stathopoulos, GP | 1 |
| Fountzilas, G | 2 |
| Rigatos, SK | 1 |
| Ziras, N | 1 |
| Potamiannou, A | 1 |
| Tsiakopoulos, I | 1 |
| Androulakis, N | 1 |
| Aravantinos, G | 1 |
| Athanasiadis, A | 1 |
| Papakotoulas, P | 1 |
| Furuya, T | 1 |
| Andoh, H | 1 |
| Asanuma, Y | 1 |
| Hatazawa, J | 1 |
| Shimosegawa, E | 1 |
| Koyama, K | 1 |
| Arita, Y | 1 |
| Hisano, T | 1 |
| Nawata, H | 2 |
| Balasubramanian, S | 1 |
| Chandraratna, RA | 1 |
| Eckert, RL | 1 |
| Miura, Y | 2 |
| Kunihiro, O | 1 |
| Kubota, T | 4 |
| Sekido, H | 1 |
| Togo, S | 2 |
| Shimada, H | 3 |
| Ould-Kaci, M | 2 |
| Breau, JL | 2 |
| Etienne, PL | 2 |
| Tigaud, JM | 2 |
| Morvan, F | 2 |
| Cvitkovic, E | 3 |
| Bertelli, GF | 1 |
| Heouaine, A | 1 |
| Ritorto, G | 1 |
| Merlano, M | 1 |
| Kondoh, S | 1 |
| Urayama, N | 1 |
| Satake, M | 1 |
| Kitoh, H | 1 |
| Yamashita, H | 1 |
| Nakashima, T | 1 |
| Gondo, T | 1 |
| Okita, K | 1 |
| Rachamalla, R | 1 |
| Mathew, S | 1 |
| Dietrich, M | 2 |
| Beger, H | 3 |
| Fernandez-Cruz, L | 2 |
| Pederzoli, P | 7 |
| Pap, A | 2 |
| Spooner, D | 2 |
| Kerr, DJ | 3 |
| Whitehead, RP | 1 |
| Ardalan, B | 3 |
| Goodwin, JW | 1 |
| Balcerzak, SP | 2 |
| Samlowski, WE | 1 |
| Shore, S | 1 |
| Zumstein, L | 1 |
| Wilson, D | 1 |
| Willer, A | 1 |
| Weisser, A | 1 |
| Gnad, U | 1 |
| Saussele, S | 1 |
| Kreil, S | 1 |
| Hartmann, JT | 1 |
| Hehlmann, R | 1 |
| Milano, MT | 1 |
| Chmura, SJ | 1 |
| Garofalo, MC | 2 |
| Rash, C | 1 |
| Roeske, JC | 1 |
| Connell, PP | 1 |
| Kwon, OH | 1 |
| Jani, AB | 1 |
| Heimann, R | 1 |
| McDermott, P | 1 |
| Burmeister, J | 1 |
| Bossenberger, T | 1 |
| Wu, WC | 1 |
| Chen, SC | 1 |
| Su, YC | 1 |
| Chuang, WL | 1 |
| Morris, SL | 1 |
| Beasley, M | 1 |
| Leslie, M | 1 |
| Takanashi, K | 2 |
| Machida, T | 1 |
| Katsuki, S | 1 |
| Di Cosimo, S | 1 |
| Malaguti, P | 1 |
| Pellicciotta, M | 1 |
| Terzoli, E | 1 |
| Ema, T | 1 |
| Arai, K | 1 |
| Maeda, Y | 1 |
| Iwasaki, Y | 1 |
| Katayanagi, S | 1 |
| Fackler-Schwalbe, I | 1 |
| Schwalbe, B | 1 |
| Epple, M | 1 |
| Becker, A | 1 |
| Prügl, L | 1 |
| Gassel, WD | 1 |
| Stoffels, D | 1 |
| Südhoff, T | 1 |
| Gerke, H | 1 |
| White, R | 1 |
| Byrne, MF | 1 |
| Stiffier, H | 1 |
| Mitchell, RM | 1 |
| Hurwitz, HI | 4 |
| Morse, MA | 4 |
| Branch, MS | 2 |
| Jowell, PS | 2 |
| Czito, B | 1 |
| Clary, B | 1 |
| Pappas, TN | 5 |
| Baillie, J | 2 |
| Delaunoit, T | 1 |
| Maréchal, R | 1 |
| Hendlisz, A | 2 |
| Eisendrath, P | 1 |
| Legendre, H | 1 |
| Pector, JC | 1 |
| De Becker, D | 1 |
| Bleiberg, H | 3 |
| Costamagna, G | 1 |
| Luzi, S | 1 |
| Barbi, S | 1 |
| Perri, V | 1 |
| Oztop, I | 1 |
| Yilmaz, U | 1 |
| Yavuzsen, T | 1 |
| Yaren, A | 1 |
| Tarhan, O | 1 |
| Sagol, O | 1 |
| Coker, A | 1 |
| Alakavuklar, M | 1 |
| Formentini, A | 1 |
| Matsumura, Y | 1 |
| Aoki, K | 1 |
| Berkel, S | 1 |
| Hummel, F | 1 |
| Gaa, J | 1 |
| Back, W | 1 |
| Queisser, W | 4 |
| Singer, MV | 1 |
| Löhr, M | 1 |
| Van Rijswijk, RE | 1 |
| Jeziorski, K | 1 |
| Wagener, DJ | 5 |
| Reuse, S | 1 |
| Baron, B | 2 |
| Wils, J | 4 |
| Harris, WB | 1 |
| Gillespie, TW | 1 |
| Meyers, M | 1 |
| Bhalla, KN | 1 |
| Allendorf, JD | 2 |
| Ennis, RD | 1 |
| Schreibman, SM | 2 |
| Wang, DM | 1 |
| Liu, YH | 1 |
| Yu, SP | 1 |
| Duan, XN | 1 |
| Yang, YM | 1 |
| Wan, YL | 1 |
| Zhou, G | 1 |
| Shen, WJ | 1 |
| Garcia, AA | 1 |
| Leichman, L | 2 |
| Baranda, J | 1 |
| Pandit, L | 1 |
| Leichman, CG | 1 |
| Wetherington, RW | 1 |
| Ross, EA | 1 |
| Meropol, NJ | 2 |
| Freedman, G | 1 |
| Pingpank, JF | 1 |
| Eisenberg, BL | 3 |
| Alliot, C | 1 |
| Taoka, H | 1 |
| Hirano, H | 1 |
| Mitsui, Y | 1 |
| Umino, W | 1 |
| Nobuoka, Y | 1 |
| Yamashita, M | 1 |
| Tanigawa, K | 1 |
| Yoshimine, S | 1 |
| Imai, T | 1 |
| Kadowaki, S | 1 |
| Miyashita, K | 1 |
| Ikuma, H | 1 |
| Murata, T | 1 |
| Kawase, Y | 1 |
| Inoue, S | 1 |
| Kaneko, T | 2 |
| Nakao, A | 2 |
| McGee, PJ | 1 |
| Mizuno, K | 2 |
| Lordick, F | 2 |
| Antolovic, D | 1 |
| Klar, E | 1 |
| Barauskas, G | 2 |
| Kouvaraki, MA | 1 |
| Ajani, JA | 4 |
| Hoff, P | 1 |
| Lozano, R | 1 |
| Xu, LY | 1 |
| Xu, LF | 1 |
| Chen, YT | 1 |
| Jiang, RJ | 1 |
| Luo, JH | 1 |
| Flandin, I | 1 |
| Kubas, A | 1 |
| Khodri, M | 1 |
| Wautot, V | 1 |
| Mazeron, R | 1 |
| Carbone, A | 2 |
| Rodeck, U | 1 |
| Mauri, FA | 1 |
| Sozzi, M | 1 |
| Gaspari, F | 1 |
| Smirne, C | 2 |
| Robecchi, A | 1 |
| Emanuelli, G | 2 |
| Sorio, C | 1 |
| Capelli, P | 2 |
| Lissandrini, D | 1 |
| Moore, PS | 1 |
| Balzarini, P | 1 |
| Zamboni, G | 1 |
| Luppi, G | 4 |
| Rosati, G | 2 |
| Caudana, R | 2 |
| Piazza, E | 3 |
| Comella, G | 3 |
| Ceravolo, C | 3 |
| Miserocchi, L | 3 |
| Zamagni, D | 2 |
| Rabbi, C | 1 |
| Marangolo, M | 2 |
| Takeyama, O | 1 |
| Koshy, MC | 1 |
| Landry, JC | 1 |
| Cavanaugh, SX | 1 |
| Fuller, CD | 1 |
| Thomas, CR | 2 |
| Tsuji, T | 1 |
| Chikamoto, A | 1 |
| Nakahara, O | 1 |
| Hiraoka, T | 1 |
| Kudo, K | 1 |
| Imuta, M | 1 |
| Passantino, L | 1 |
| Patruno, R | 1 |
| Valerio, P | 1 |
| Penna, A | 1 |
| Mazzone, F | 1 |
| Zito, AF | 1 |
| Pellecchia, A | 1 |
| Jirillo, E | 1 |
| Ranieri, G | 1 |
| Knaebel, HP | 1 |
| Seiler, C | 1 |
| Lindel, K | 2 |
| Schmitz-Winnenthal, H | 1 |
| Fritz, S | 2 |
| Goldschmidt, H | 1 |
| Krempien, R | 1 |
| Diehl, V | 1 |
| Penberthy, DR | 2 |
| Shepard, RC | 1 |
| Adams, R | 2 |
| Jones, RS | 2 |
| Giese, T | 1 |
| Ketterer, K | 1 |
| Thoma, M | 3 |
| Weingandt, H | 1 |
| Dühmke, E | 2 |
| Choi, SB | 1 |
| Lee, HY | 1 |
| Yuh, YJ | 1 |
| Wong, AA | 1 |
| Delclos, ME | 4 |
| Cordio, S | 2 |
| Bonetto, E | 4 |
| Oliani, C | 1 |
| Galli, L | 4 |
| Bordonaro, R | 3 |
| Aldrighetti, L | 1 |
| Zagon, IS | 1 |
| Jaglowski, JR | 1 |
| Verderame, MF | 1 |
| Leure-Dupree, AE | 1 |
| McLaughlin, PJ | 1 |
| Wey, JS | 1 |
| Gray, MJ | 1 |
| Fan, F | 1 |
| Belcheva, A | 1 |
| McCarty, MF | 1 |
| Stoeltzing, O | 1 |
| Somcio, R | 1 |
| Klagsbrun, M | 1 |
| Ellis, LM | 2 |
| Ohigashi, H | 9 |
| Ishikawa, O | 10 |
| Eguchi, H | 1 |
| Sasaki, Y | 9 |
| Noura, S | 1 |
| Murata, K | 1 |
| Takachi, K | 1 |
| Miyashiro, I | 1 |
| Doki, Y | 1 |
| Imaoka, S | 9 |
| Kasugai, T | 1 |
| Nishiyama, K | 1 |
| O'Connor, JK | 1 |
| Sause, WT | 1 |
| Hazard, LJ | 1 |
| Belnap, LP | 1 |
| Noyes, RD | 1 |
| Di Costanzo, F | 3 |
| Doni, L | 1 |
| Massidda, B | 1 |
| Mattioli, R | 1 |
| Iop, A | 1 |
| Barletta, E | 2 |
| Moscetti, L | 1 |
| Tralongo, P | 2 |
| Gasperoni, S | 2 |
| Lutz, MP | 2 |
| Brugge, WR | 1 |
| Sahani, D | 1 |
| Brachtel, EF | 1 |
| Schneider, BJ | 1 |
| Colletti, LM | 1 |
| Normolle, DP | 1 |
| Hejna, GF | 1 |
| Tomikawa, M | 1 |
| Ozawa, I | 1 |
| Katano, S | 1 |
| Tsukiyama, I | 1 |
| Moody, JS | 1 |
| Russo, SM | 1 |
| Tsavaris, N | 2 |
| Kosmas, C | 2 |
| Skopelitis, H | 1 |
| Gouveris, P | 1 |
| Kopterides, P | 1 |
| Kopteridis, P | 1 |
| Loukeris, D | 1 |
| Sigala, F | 1 |
| Zorbala-Sypsa, A | 1 |
| Papalambros, E | 1 |
| Takezako, Y | 1 |
| Dobelbower, R | 1 |
| Lipsitz, S | 3 |
| Sischy, B | 1 |
| Smith, TJ | 1 |
| Kawakami, H | 1 |
| Uno, T | 1 |
| Isobe, K | 1 |
| Aruga, T | 1 |
| Saisho, H | 3 |
| Kawata, T | 1 |
| Alexandrescu, DT | 1 |
| Dutcher, JP | 2 |
| Wiernik, PH | 2 |
| Lundqvist, S | 1 |
| Gustavsson, B | 3 |
| Hafström, LO | 2 |
| Gotohda, N | 1 |
| Suzuki, E | 2 |
| Rault, A | 1 |
| Adhoute, X | 1 |
| Béllannée, G | 1 |
| Brunet, R | 2 |
| Collet, D | 1 |
| Smeenk, HG | 3 |
| de Castro, SM | 1 |
| Jeekel, JJ | 1 |
| Erdmann, J | 2 |
| Gouma, DJ | 2 |
| Kanda, T | 1 |
| Imazeki, F | 1 |
| Yokosuka, O | 1 |
| Nagao, K | 1 |
| Fiore, F | 1 |
| Daniele, B | 1 |
| Ottaiano, A | 1 |
| D'Angelo, R | 1 |
| Ferrari, E | 1 |
| Formato, R | 1 |
| Tortoriello, A | 1 |
| Turitto, G | 1 |
| Bruni, GS | 1 |
| Pignata, S | 1 |
| Iaffaioli, RV | 1 |
| Bosch, X | 1 |
| Christofferson, E | 1 |
| Le, QT | 1 |
| Ho, A | 1 |
| Kuo, T | 1 |
| Greco, R | 1 |
| Norton, J | 1 |
| Yang, GP | 1 |
| Kokkinakis, DM | 1 |
| Liu, X | 1 |
| Neuner, RD | 1 |
| Hartel, M | 1 |
| di Mola, FF | 1 |
| Selvaggi, F | 1 |
| Mascetta, G | 1 |
| Felix, K | 1 |
| Di Sebastiano, P | 1 |
| Maisey, NR | 1 |
| Norman, AR | 5 |
| Massey, A | 1 |
| Videnovic, A | 1 |
| Semenov, I | 1 |
| Chua-Adajar, R | 1 |
| Baddi, L | 1 |
| Blumenthal, DT | 1 |
| Beck, AC | 1 |
| Simuni, T | 1 |
| Futterer, S | 1 |
| Gradishar, W | 1 |
| Tellez, C | 1 |
| Raizer, JJ | 1 |
| van der Heijden, MS | 1 |
| Dezentje, DA | 1 |
| DeMarzo, AM | 1 |
| Offerhaus, GJ | 1 |
| Isacoff, WH | 2 |
| Tran, KT | 1 |
| Cusnir, M | 1 |
| Burdick, RK | 1 |
| Van Echo, DA | 1 |
| Moesinger, R | 1 |
| Eisenberg, DP | 1 |
| Adusumilli, PS | 1 |
| Hendershott, KJ | 1 |
| Yu, Z | 1 |
| Mullerad, M | 1 |
| Chan, MK | 1 |
| Chou, TC | 1 |
| Guo, JC | 2 |
| Chen, G | 3 |
| Zhang, LY | 2 |
| Buckels, J | 1 |
| Eloubeidi, MA | 1 |
| Steg, A | 2 |
| Fiveash, J | 1 |
| Carpenter, M | 1 |
| Blanquicett, C | 2 |
| Johnson, MR | 2 |
| Blom, JW | 1 |
| Osanto, S | 1 |
| Rosendaal, FR | 1 |
| Flores, AM | 1 |
| Buchsbaum, DJ | 1 |
| Eloubeidi, M | 1 |
| Vickers, SM | 1 |
| Chhieng, DC | 1 |
| Carpenter, MD | 1 |
| Sellers, JC | 1 |
| Cheng, TY | 1 |
| Sheth, K | 1 |
| Hung, CF | 1 |
| Clary, BM | 3 |
| Santasusana, JM | 1 |
| García López, JL | 1 |
| García, JJ | 1 |
| Carbonero, AI | 1 |
| Plazas, JG | 1 |
| Rovira, PS | 1 |
| Martos, CF | 1 |
| Guzmán, MC | 1 |
| Jericó, JF | 1 |
| Delgado, FJ | 1 |
| Espinosa, JC | 1 |
| Muñoz, ML | 1 |
| Aguilar, EA | 1 |
| Valera, JS | 1 |
| García Ribas, I | 1 |
| Mena, AC | 1 |
| Medarova, Z | 1 |
| Pham, W | 1 |
| Moore, A | 1 |
| Boz, G | 2 |
| De Paoli, A | 2 |
| Innocente, R | 2 |
| Rossi, C | 2 |
| Tosolini, GC | 1 |
| Trovò, MG | 2 |
| Han, GH | 1 |
| Yin, ZX | 1 |
| Meng, XJ | 1 |
| He, CY | 1 |
| Zhang, HB | 1 |
| Sun, AH | 1 |
| Wu, KC | 1 |
| Ding, J | 1 |
| Fan, DM | 1 |
| Bendell, JC | 2 |
| Fernando, NH | 1 |
| Mantyh, CR | 1 |
| Blobe, GC | 1 |
| Honeycutt, W | 1 |
| Ludwig, KA | 1 |
| Melvin, WS | 1 |
| Chen, CS | 1 |
| Hong, TJ | 1 |
| Cohen, DP | 1 |
| Petros, WP | 1 |
| Lee, CG | 1 |
| Fernando, N | 1 |
| Saidi, RF | 1 |
| Williams, F | 1 |
| Danquah, G | 1 |
| Mittal, VK | 1 |
| ReMine, SG | 1 |
| Jacobs, MJ | 1 |
| Kiuchi, T | 1 |
| Mukai, K | 1 |
| Kakizoe, T | 1 |
| Amos, C | 1 |
| Ng, C | 1 |
| O'Reilly, M | 1 |
| Diasio, R | 3 |
| Bergenfeldt, M | 1 |
| Albertsson, M | 1 |
| Chua, YJ | 2 |
| Johnson, M | 2 |
| de Jager, J | 1 |
| Stebbing, J | 1 |
| Tani, M | 2 |
| Ina, S | 2 |
| Russell, C | 1 |
| Kurzawinski, T | 1 |
| Harper, P | 1 |
| Harrison, P | 1 |
| Daniels, F | 1 |
| Prendeville, J | 1 |
| Ross, PJ | 3 |
| Theis, B | 1 |
| Hull, R | 1 |
| Walker, M | 1 |
| Shankley, N | 1 |
| Kalindjian, B | 1 |
| Murray, G | 1 |
| Gillbanks, A | 1 |
| Black, J | 1 |
| Tinkl, D | 1 |
| Grabenbauer, GG | 1 |
| Jian, Z | 1 |
| Xia, K | 1 |
| Lv, X | 1 |
| Pei, H | 1 |
| Serio, G | 1 |
| Iacono, C | 2 |
| Pulica, C | 1 |
| Lombardi, M | 1 |
| Pagani, M | 1 |
| Liu, TW | 2 |
| Yu, WL | 1 |
| Chuang, TR | 1 |
| Ducreux, MP | 1 |
| Leboulleux, S | 1 |
| Kergoat, P | 1 |
| Elias, D | 1 |
| de Baere, T | 1 |
| Sabourin, JC | 1 |
| Duvillard, P | 1 |
| Lasser, P | 2 |
| Schlumberger, M | 1 |
| Sumii, T | 2 |
| Wang, CC | 1 |
| Lu, YS | 1 |
| Khanna, A | 1 |
| Walker, GR | 1 |
| Arheart, KL | 1 |
| Rocha-Lima, C | 1 |
| Lauwers, GY | 1 |
| Willett, C | 1 |
| Wain, JC | 1 |
| Bossard, N | 1 |
| Terakawa, N | 2 |
| Komiyama, Y | 1 |
| A-Hon, K | 1 |
| Kamiyama, Y | 2 |
| Viganò, MG | 2 |
| Wagner, A | 1 |
| Fujii, Y | 1 |
| Spreafico, A | 1 |
| Tanaka, E | 1 |
| Umeshita, K | 3 |
| Dono, K | 2 |
| Monden, M | 5 |
| Tan, MT | 1 |
| Nakahira, S | 1 |
| Hayashi, N | 1 |
| Okami, J | 1 |
| Smith, DB | 1 |
| Yamamitsu, S | 4 |
| Kimura, H | 2 |
| Inui, N | 2 |
| Hiyama, S | 2 |
| Kimura, Y | 2 |
| Shirasada, T | 1 |
| Busso, V | 1 |
| Scirelli, T | 1 |
| Buffolino, A | 1 |
| Tosetti, L | 1 |
| Suga, H | 1 |
| Ono, N | 1 |
| Saito, F | 1 |
| Nagaoka, S | 1 |
| Tsuruta, O | 1 |
| Toyonaga, A | 1 |
| Sata, M | 1 |
| Ohta, H | 2 |
| Ushiki, T | 1 |
| Togashi, T | 2 |
| Seki, K | 2 |
| Mafune, Y | 1 |
| Ishikawa, N | 1 |
| Hucl, T | 1 |
| Wagner, AD | 1 |
| Buechner-Steudel, P | 1 |
| Schmalenberg, H | 1 |
| Lindig, U | 1 |
| Behrens, R | 1 |
| Kleber, G | 1 |
| Kuss, O | 1 |
| Fleig, WE | 1 |
| Greenblatt, DY | 1 |
| Leung, PS | 1 |
| Jiang, H | 1 |
| Niu, BZ | 1 |
| Wu, WW | 1 |
| Yoon, WJ | 1 |
| Krishnan, S | 2 |
| Rana, V | 2 |
| Janjan, NA | 7 |
| Gould, MS | 2 |
| Das, P | 2 |
| Palla, S | 1 |
| Guha, S | 1 |
| Mansourbakht, T | 1 |
| Fallik, D | 1 |
| Spano, JP | 1 |
| Lledo, G | 2 |
| Ezzeldin, H | 1 |
| Vance, K | 1 |
| Sellers, S | 1 |
| Cengel, KA | 1 |
| Krzyzanowska, MK | 1 |
| Kuntz, KM | 1 |
| Weeks, JC | 1 |
| Neifeld, JP | 2 |
| Honda, K | 1 |
| Fukuhara, T | 1 |
| Kojima, Y | 1 |
| Kushihata, F | 1 |
| Kennedy, EP | 1 |
| Goel, A | 1 |
| Younes, F | 1 |
| Moukadem, W | 1 |
| Gómez Raposo, C | 1 |
| Gómez Senent, S | 1 |
| González Barón, M | 1 |
| Park, BB | 1 |
| Park, K | 1 |
| Darmanin, S | 1 |
| Natsuisaka, M | 1 |
| Kondo, T | 1 |
| Asaka, M | 1 |
| Shindoh, M | 1 |
| Higashino, F | 1 |
| Hamuro, J | 1 |
| Okada, F | 1 |
| Koide, H | 1 |
| Nishiyama, Y | 1 |
| Nomoto, S | 1 |
| Goshima, F | 1 |
| Watanabe, I | 1 |
| Nomura, N | 1 |
| Shikano, T | 1 |
| Kanazumi, N | 1 |
| Desai, M | 1 |
| Sherman, W | 2 |
| Strauss, J | 1 |
| Guba, S | 1 |
| Andrade, R | 1 |
| Miyake, K | 1 |
| Michienzi, S | 1 |
| Bucci, B | 1 |
| Verga Falzacappa, C | 1 |
| Patriarca, V | 1 |
| Stigliano, A | 1 |
| Panacchia, L | 1 |
| Brunetti, E | 1 |
| Toscano, V | 1 |
| Misiti, S | 1 |
| Bendetti, JK | 1 |
| Barstis, JJ | 1 |
| Jazieh, AR | 1 |
| Houhouli, K | 1 |
| Papatheodorou, K | 1 |
| Miloussis, A | 1 |
| Matthaios, D | 1 |
| Chatzaki, E | 1 |
| Lyrantzopoulos, N | 1 |
| Tsaroucha, A | 1 |
| Welch, SA | 1 |
| Cina, S | 1 |
| Gardner, N | 1 |
| Guo, KJ | 1 |
| Guo, RX | 1 |
| He, SG | 1 |
| Nio, Y | 5 |
| Toga, T | 1 |
| Maruyama, R | 1 |
| Fukushima, M | 3 |
| Yamada, E | 1 |
| Ninomiya, M | 1 |
| Nishizaki, M | 1 |
| Sasaki, H | 1 |
| Takakura, N | 1 |
| Caruso, M | 1 |
| Di Maggio, G | 1 |
| Ferraù, F | 1 |
| Verderame, F | 1 |
| Di Cristina, L | 1 |
| Agueli, R | 1 |
| Russo, P | 1 |
| Koito, K | 1 |
| Shirasaka, T | 4 |
| Van Hazel, G | 1 |
| Walpole, E | 1 |
| Kotasek, D | 1 |
| Davies, T | 2 |
| Butler, J | 1 |
| Gong, JF | 1 |
| Zhang, XD | 1 |
| Di, LJ | 1 |
| Jin, ML | 1 |
| Shen, L | 1 |
| Lauerman, M | 1 |
| Bill, A | 1 |
| DiGiorgi, M | 1 |
| Goetz, N | 1 |
| Schrope, B | 1 |
| Blanchard, P | 1 |
| Isaksson, B | 1 |
| Almström, M | 1 |
| Albiin, N | 1 |
| Permert, J | 2 |
| Fürstenberger, G | 1 |
| Schmid, P | 1 |
| Duquesne, A | 1 |
| Ammann, M | 1 |
| Senn, HJ | 1 |
| Botsios, D | 1 |
| Vasiliadis, K | 1 |
| Tsalis, K | 1 |
| Iordanidis, F | 1 |
| Megalopoulos, A | 1 |
| Tsachalis, T | 1 |
| Blouhos, K | 1 |
| Betsis, D | 1 |
| Smith, R | 2 |
| Tudor-Smith, C | 1 |
| Enzinger, PC | 1 |
| Muzikansky, A | 1 |
| Lawrence, C | 1 |
| Hoehler, T | 1 |
| Seipelt, G | 1 |
| Mahlberg, R | 1 |
| Boeck, HP | 1 |
| Schmid, B | 1 |
| Stauch, M | 1 |
| Ko, Y | 1 |
| Schoppmeyer, K | 1 |
| Golf, A | 2 |
| Moureau, L | 1 |
| Bège, T | 1 |
| Meric, JB | 1 |
| Tran, KC | 1 |
| Debois, M | 1 |
| Klinkenbijl, JH | 2 |
| Liang, H | 1 |
| Wang, XN | 1 |
| Wang, BG | 1 |
| Pan, Y | 1 |
| Ding, XW | 1 |
| Hao, XS | 1 |
| Neuhaus, P | 2 |
| Ledbetter, L | 1 |
| Uemura, K | 1 |
| Sudo, T | 1 |
| Hayashidani, Y | 1 |
| Hashimoto, Y | 1 |
| Ohge, H | 1 |
| Sueda, T | 1 |
| Bjerregaard, JK | 1 |
| Lyu, MA | 1 |
| Rosenblum, MG | 1 |
| Macleod, C | 1 |
| Millar, JL | 1 |
| Graham, P | 1 |
| Reece, WH | 1 |
| Iacopetta, B | 1 |
| Do, YR | 1 |
| Ryu, MH | 1 |
| Hong, DS | 1 |
| Cho, JY | 1 |
| Lee, KE | 1 |
| Wisinski, KB | 1 |
| Wahl, AO | 1 |
| Troppmann, M | 1 |
| Kullmann, A | 1 |
| Golder, S | 1 |
| Herold, T | 1 |
| Herfarth, H | 1 |
| Grossmann, J | 1 |
| Schlottmann, K | 1 |
| van Essen, M | 1 |
| Krenning, EP | 1 |
| Kam, BL | 1 |
| de Herder, WW | 1 |
| van Aken, MO | 1 |
| Kwekkeboom, DJ | 1 |
| Araki, H | 1 |
| Sohgawa, M | 1 |
| Ballardini, M | 1 |
| Guadagni, S | 2 |
| Grawe, P | 1 |
| Calzolari, F | 1 |
| Tison, C | 1 |
| Giampalma, E | 1 |
| Cecconetto, L | 1 |
| Golfieri, R | 1 |
| Kamimura, H | 1 |
| Tsuchiya, A | 1 |
| Yonemori, K | 1 |
| Takesako, Y | 1 |
| Luzardo, G | 1 |
| Cooper, J | 1 |
| Bowers, C | 1 |
| Zervos, E | 1 |
| Al-Saadi, S | 1 |
| Carroll, R | 1 |
| Chheda, H | 1 |
| Carey, L | 1 |
| Goldin, S | 1 |
| Grundy, S | 1 |
| Kudryk, B | 1 |
| Zwiebel, B | 1 |
| Black, T | 1 |
| Briggs, J | 1 |
| Chervenick, P | 1 |
| Shibagaki, K | 1 |
| Fujita, K | 1 |
| Takenaka, M | 1 |
| Fukuba, N | 1 |
| Yoshinaga, H | 1 |
| Masuzawa, A | 1 |
| Watanabe, A | 1 |
| Fujiwara, H | 1 |
| Sugawara, A | 1 |
| Mukai, H | 1 |
| Kinoshita, Y | 1 |
| Dupuis, O | 1 |
| Touboul, E | 2 |
| Balosso, J | 4 |
| Brizi, MG | 1 |
| Bossola, M | 1 |
| Pacelli, F | 1 |
| Doglietto, G | 1 |
| Kudrimoti, MR | 1 |
| Fromm, ML | 1 |
| Schaefer, P | 1 |
| Seller, S | 1 |
| Miano, S | 1 |
| Sciandivasci, A | 1 |
| Pascucci, A | 1 |
| Testi, W | 1 |
| Tanzini, G | 1 |
| Nishioka, R | 1 |
| Miyanishi, K | 2 |
| Ishiwatari, H | 1 |
| Hayashi, T | 1 |
| Kawano, Y | 1 |
| Takada, K | 2 |
| Ihara, H | 1 |
| Okuda, T | 1 |
| Matsunaga, T | 1 |
| Kato, J | 1 |
| Niitsu, Y | 3 |
| Sasada, T | 1 |
| Denno, R | 2 |
| Mizukami, Y | 1 |
| Kohno, S | 1 |
| Takabayashi, A | 1 |
| Benedix, F | 1 |
| Schulz, HU | 1 |
| Pech, M | 1 |
| Issels, RD | 1 |
| Schulz, C | 1 |
| Moosmann, N | 1 |
| Laessig, D | 1 |
| Saadati, H | 1 |
| Mey, V | 1 |
| Pollina, LE | 1 |
| Nannizzi, S | 1 |
| Ricciardi, S | 1 |
| Del Tacca, M | 1 |
| Bevilacqua, G | 1 |
| Mosca, F | 1 |
| Campani, D | 1 |
| Herrmann, C | 1 |
| Stremmel, W | 1 |
| Jaeger, D | 1 |
| Gyllenhaal, C | 1 |
| Alschuler, L | 1 |
| Rubin, D | 1 |
| Kranz, S | 1 |
| Roddy, GD | 1 |
| Block, KI | 1 |
| Rhodes, EG | 1 |
| Boesen, EA | 1 |
| Corringham, RE | 1 |
| Matthews, KB | 1 |
| Tuddenham, EG | 1 |
| Kernoff, PB | 1 |
| Steffensrud, S | 1 |
| Erichsen, H | 1 |
| Røysland, P | 1 |
| Halvorsen, TB | 1 |
| Klepp, R | 1 |
| Klepp, O | 1 |
| Wünsch, E | 1 |
| Petersen, H | 1 |
| Ueoka, H | 1 |
| Kuroda, S | 1 |
| Ohnoshi, T | 1 |
| Kimura, I | 1 |
| Numoto, A | 1 |
| Hino, I | 1 |
| Tsuji, M | 1 |
| Wright, J | 1 |
| Abolfathi, A | 1 |
| Penman, E | 1 |
| Marks, V | 1 |
| Gazet, JC | 2 |
| Hafström, L | 2 |
| Ihse, I | 2 |
| Jönsson, PE | 1 |
| Lunderquist, A | 1 |
| Stridbeck, H | 1 |
| Klimenkov, AA | 1 |
| Barkanov, AI | 2 |
| Itin, AB | 4 |
| Bukowski, RM | 9 |
| Schacter, LP | 1 |
| Groppe, CW | 4 |
| Hewlett, JS | 5 |
| Weick, JK | 4 |
| Livingston, RB | 2 |
| Gahbauer, R | 1 |
| Rodriquez-Antunez, A | 1 |
| Hermann, R | 1 |
| Smith, FP | 7 |
| Rustgi, VK | 1 |
| Schertz, G | 1 |
| Woolley, PV | 5 |
| Schein, PS | 12 |
| Theodors, A | 1 |
| Suzuki, T | 3 |
| Kikuchi, K | 1 |
| Kusama, S | 1 |
| Furue, H | 1 |
| Toriyama, K | 1 |
| Wakiya, M | 1 |
| O'Bryan, RM | 1 |
| Bonnet, JD | 1 |
| Chen, TT | 1 |
| Hanley, JA | 1 |
| Johnson, LA | 1 |
| Sordillo, PP | 2 |
| Magill, GB | 3 |
| Aabo, K | 1 |
| Romond, E | 1 |
| Dimitrov, NV | 1 |
| Denny, TN | 1 |
| Suhrland, LG | 1 |
| Wawrukiewicz, AS | 1 |
| Rösch, J | 1 |
| Keller, FS | 1 |
| Lieberman, DA | 1 |
| Ohyama, K | 1 |
| Koike, D | 1 |
| Odake, Y | 1 |
| Takiyama, Y | 1 |
| Saitoh, T | 1 |
| Kagaya, T | 1 |
| Takebe, T | 1 |
| Ishii, K | 2 |
| Hallengren, B | 1 |
| Dymling, JF | 1 |
| Manhem, P | 1 |
| Tennvall, L | 1 |
| Tibblin, S | 1 |
| Becker, HD | 2 |
| Futatsuki, K | 1 |
| Shimada, S | 1 |
| Kanda, Y | 1 |
| Ishibashi, I | 1 |
| Sendai, H | 1 |
| Akazawa, S | 1 |
| Hattori, M | 1 |
| Kemeny, N | 2 |
| Smith, BJ | 1 |
| Ashford, RF | 1 |
| Bakowski, M | 1 |
| Hellman, K | 1 |
| Newton, K | 1 |
| Phillips, R | 1 |
| Lambert, J | 1 |
| Jones, R | 1 |
| Peters, N | 1 |
| Evans, M | 1 |
| Metzger, UF | 1 |
| Kisner, DL | 1 |
| Ghosh, BC | 1 |
| Andrén-Sandberg, A | 2 |
| Holmberg, JT | 1 |
| Sternberg, CN | 1 |
| Cheng, EW | 1 |
| Storch, JA | 1 |
| Brown, JC | 1 |
| Goldberg, J | 1 |
| Chamberlin, K | 1 |
| Shiu, MH | 1 |
| Cahan, A | 1 |
| Fogh, J | 1 |
| Fortner, JG | 2 |
| Wakui, A | 3 |
| Taguchi, T | 3 |
| Sato, H | 1 |
| Hanatani, Y | 1 |
| Ibayashi, J | 1 |
| Kameda, C | 1 |
| Shiomi, M | 1 |
| Saka, M | 1 |
| Katsu, K | 1 |
| Harvey, JH | 1 |
| Hartwich, G | 2 |
| Abderhalden, RT | 1 |
| Klapdor, R | 1 |
| Zimmerman, SE | 1 |
| Martin, F | 2 |
| Bolla, M | 1 |
| Peccoud, A | 1 |
| Fournet, J | 1 |
| Rachail, M | 1 |
| Champetier, JM | 1 |
| Vrousos, C | 1 |
| Bengmark, S | 1 |
| Stablein, D | 1 |
| Korsmeyer, S | 1 |
| Neefe, J | 1 |
| Chun, BK | 1 |
| Dasmahapatra, K | 1 |
| Goldrosen, MH | 1 |
| Douglass, HO | 2 |
| Castro, JR | 1 |
| Saunders, WM | 1 |
| Quivey, JM | 1 |
| Chen, GT | 1 |
| Collier, JM | 1 |
| Woodruff, KH | 1 |
| Lyman, JT | 1 |
| Twomey, P | 2 |
| Frey, C | 2 |
| Phillips, TL | 1 |
| Agnelli, G | 1 |
| Gresele, P | 1 |
| Nenci, GG | 1 |
| Matsuoka, S | 1 |
| Maezawa, S | 1 |
| Sakuma, M | 1 |
| Ohira, S | 1 |
| Saito, T | 2 |
| Ornitz, R | 1 |
| Rogers, C | 1 |
| Chang, BK | 1 |
| Gutman, R | 1 |
| Kinami, Y | 2 |
| Konishi, K | 1 |
| Shinmura, K | 1 |
| Takada, M | 1 |
| Sakuma, H | 1 |
| Miyazaki, I | 2 |
| Heim, ME | 2 |
| Erlichman, C | 3 |
| Speyer, JL | 1 |
| Klecker, R | 1 |
| Chabner, BA | 1 |
| Meguro, S | 1 |
| Kuraishi, Y | 1 |
| Ichiba, K | 1 |
| Abe, M | 1 |
| Yoda, T | 1 |
| Mikouchi, S | 1 |
| Bedikian, AY | 1 |
| Valdivieso, M | 2 |
| Bodey, GP | 2 |
| McCracken, JD | 2 |
| Ray, P | 1 |
| Saiki, JH | 1 |
| Rivkin, SE | 1 |
| Rossof, AH | 1 |
| Moore, TN | 1 |
| Mallinson, CN | 1 |
| Rake, MO | 1 |
| Cocking, JB | 1 |
| Fox, CA | 1 |
| Cwynarski, MT | 1 |
| Diffey, BL | 1 |
| Jackson, GA | 1 |
| Hanley, J | 2 |
| Wass, VJ | 1 |
| Keehn, R | 1 |
| Elliott, D | 1 |
| Higgins, G | 1 |
| Vaughn, CB | 2 |
| Chapman, JL | 1 |
| Garland, M | 1 |
| Pederson, B | 1 |
| Demitrish, MM | 1 |
| Chinn, B | 2 |
| Ward, D | 2 |
| Brady, PR | 1 |
| Hazel, JJ | 1 |
| Thirlwell, MP | 1 |
| Huggins, M | 1 |
| Maksymiuk, A | 1 |
| MacFarlane, JK | 1 |
| Andersen, JR | 1 |
| Friis-Möller, A | 1 |
| Hancke, S | 1 |
| Röder, O | 1 |
| Steen, J | 1 |
| Baden, H | 1 |
| Trux, F | 2 |
| Ervin, TJ | 1 |
| Meshad, MW | 1 |
| Kufe, DW | 1 |
| Olson, M | 1 |
| Cruz, AB | 2 |
| Oishi, N | 2 |
| Ausman, RK | 1 |
| Caballero, GA | 1 |
| Quebbeman, E | 2 |
| Ausman, DC | 1 |
| Karlin, DA | 2 |
| Stroehlein, JR | 1 |
| Bennetts, RW | 1 |
| Jones, RD | 1 |
| Heifetz, LJ | 1 |
| Mahal, PS | 1 |
| Barkin, JS | 2 |
| Kalser, MH | 3 |
| Thomsen, S | 1 |
| Redlhammer, D | 2 |
| Frytak, S | 1 |
| O'Connell, MJ | 3 |
| Rubin, J | 3 |
| Schutt, AJ | 7 |
| Weiland, LH | 1 |
| Lavin, PT | 2 |
| Livstone, E | 1 |
| Spiro, H | 1 |
| Knowlton, A | 1 |
| Kalser, M | 1 |
| Barkin, J | 1 |
| Lessner, H | 1 |
| Mann-Kaplan, R | 1 |
| Ramming, K | 1 |
| Douglas, HO | 2 |
| Thomas, P | 1 |
| Nave, H | 1 |
| Bateman, J | 1 |
| Lokich, J | 3 |
| Brooks, J | 2 |
| Chaffey, J | 1 |
| Corson, JM | 1 |
| Zamcheck, N | 1 |
| Novak, JW | 1 |
| Joss, R | 1 |
| Goldhirsch, A | 1 |
| Tschopp, L | 1 |
| Brunner, K | 1 |
| Garelli, S | 1 |
| Valbonesi, M | 1 |
| Schieppati, G | 1 |
| Banfi, L | 1 |
| Ward, A | 1 |
| Sherlock, D | 1 |
| Van der Veer, LD | 1 |
| Balint, JA | 1 |
| Hoth, DF | 1 |
| Levin, B | 3 |
| Ichiki, AT | 1 |
| Israelsen, KL | 1 |
| Sonoda, T | 2 |
| Collmann, IR | 1 |
| Vergeylen, A | 1 |
| Swaffar, DS | 1 |
| Ang, CY | 1 |
| Desai, PB | 1 |
| Rosenthal, GA | 1 |
| Thomas, DA | 1 |
| Crooks, PA | 1 |
| John, WJ | 3 |
| Harris, JD | 1 |
| Gutierrez, AA | 1 |
| Hurst, HC | 1 |
| Sikora, K | 1 |
| Cleary, KR | 6 |
| Buchholz, DJ | 2 |
| Fenoglio, CJ | 3 |
| Collier, C | 1 |
| Peacock, JL | 1 |
| Mohiuddin, M | 4 |
| Stevens, J | 1 |
| Rosato, F | 2 |
| Barbot, D | 3 |
| Biermann, W | 3 |
| Cantor, R | 2 |
| Hammond, PJ | 1 |
| Bloom, SR | 1 |
| Akaishi, S | 3 |
| Kobari, M | 2 |
| Yusa, T | 1 |
| Yamanami, H | 1 |
| Anthony, LB | 1 |
| Sharp, SC | 1 |
| May, ME | 1 |
| Redei, I | 1 |
| Green, F | 1 |
| Weiner, LM | 2 |
| Scher, R | 3 |
| Vaughn, D | 1 |
| Treat, J | 1 |
| Whittington, R | 2 |
| Neuberg, D | 1 |
| Tester, WJ | 1 |
| Bernhard, H | 3 |
| Jäger-Arand, E | 1 |
| Bernhard, G | 1 |
| Heike, M | 1 |
| Klein, O | 2 |
| Riemann, JF | 1 |
| Meyer zum Büschenfelde, KH | 3 |
| Dippold, W | 2 |
| Knuth, A | 2 |
| Bolli, E | 1 |
| Saccomanno, S | 1 |
| Mondini, G | 1 |
| Aschele, C | 1 |
| Guglielmi, A | 1 |
| Ligas, B | 1 |
| Connio, M | 1 |
| Mori, A | 1 |
| Rosso, R | 1 |
| Sobrero, A | 1 |
| Ohshiro, T | 1 |
| Adachi, E | 1 |
| Nagamine, S | 1 |
| Miyazaki, N | 1 |
| Shiromizu, A | 1 |
| Kounoe, S | 1 |
| Chandrasekaran, B | 1 |
| Kute, TE | 1 |
| Duch, DS | 1 |
| Weese, JL | 3 |
| Solin, LJ | 2 |
| Agarwal, P | 1 |
| Engstrom, P | 2 |
| Paul, AR | 3 |
| Litwin, S | 2 |
| Watts, P | 1 |
| Furukawa, H | 8 |
| Kabuto, T | 8 |
| Kameyama, M | 7 |
| Hiratsuka, M | 7 |
| Weinerman, BH | 1 |
| MacCormick, RE | 1 |
| Saltz, L | 2 |
| Schwartz, G | 1 |
| Kelsen, D | 2 |
| Palmer, KR | 1 |
| Kerr, M | 1 |
| Knowles, G | 1 |
| Cull, A | 1 |
| Carter, DC | 1 |
| Leonard, RC | 1 |
| Yokota, M | 1 |
| Mukuta, T | 1 |
| Blitzer, PH | 1 |
| Dosoretz, DE | 1 |
| Katin, MJ | 1 |
| Rubenstein, JH | 1 |
| Harwin, WN | 1 |
| Raymond, MG | 1 |
| Teufel, TE | 1 |
| Seidenstein, L | 1 |
| Mangano, MM | 1 |
| Salenius, SA | 1 |
| Manyam, V | 1 |
| Bewsher, C | 1 |
| Youngblood, M | 1 |
| Ucar, A | 1 |
| Reddy, R | 1 |
| Markoe, A | 1 |
| Schwade, J | 1 |
| Richman, SP | 2 |
| Donofrio, K | 1 |
| Coia, L | 1 |
| Weese, J | 1 |
| Solin, L | 1 |
| Weiner, L | 1 |
| Eisenberg, B | 1 |
| Paul, A | 1 |
| Hanks, G | 1 |
| Lewandrowski, K | 1 |
| Efird, J | 1 |
| Compton, CC | 1 |
| Jessup, JM | 1 |
| Steele, G | 1 |
| Busse, P | 1 |
| Cady, B | 1 |
| Stone, M | 1 |
| Jenkins, R | 1 |
| Osteen, R | 1 |
| Taylor, DD | 1 |
| Gerçel-Taylor, C | 1 |
| Fowler, WC | 1 |
| Saito, H | 1 |
| Takamura, A | 1 |
| Sakurai, Y | 1 |
| Horio, K | 1 |
| Yamano, M | 1 |
| Sawaguchi, Y | 1 |
| Barbe, L | 1 |
| Lesur, G | 1 |
| Turner, L | 1 |
| Dupont, C | 1 |
| Coggia, M | 1 |
| Dupuy, P | 1 |
| Dorra, M | 1 |
| Bertheault-Cvitkovic, F | 1 |
| Soussan, S | 1 |
| Brienza, S | 1 |
| Itzhaki, M | 1 |
| Misset, JL | 1 |
| Bismuth, H | 1 |
| Garton, GR | 3 |
| Nagorney, DM | 4 |
| Donohue, JH | 1 |
| Martin, JK | 3 |
| McIlrath, DC | 3 |
| Cha, SS | 2 |
| Earle, JD | 2 |
| Foley, JF | 5 |
| Wieand, HS | 4 |
| Kvols, LK | 4 |
| McKenna, PJ | 1 |
| Krook, JE | 3 |
| Tschetter, LK | 3 |
| Twito, DI | 2 |
| Kaizer, L | 1 |
| Fine, S | 1 |
| Watanabe, M | 2 |
| Kitajima, M | 2 |
| Satou, T | 1 |
| Kakizaki, K | 5 |
| Teshima, S | 1 |
| Yamauchi, H | 6 |
| Taniguchi, H | 1 |
| Suganuma, Y | 1 |
| Takeuchi, K | 1 |
| Oguro, A | 1 |
| Torii, T | 1 |
| Masutani, S | 4 |
| Yeung, RS | 1 |
| Engstrom, PF | 4 |
| Kowalyshyn, MJ | 1 |
| Foo, ML | 1 |
| McLlrath, DC | 1 |
| van Heerden, JA | 1 |
| Robinow, JS | 1 |
| Martenson, JA | 2 |
| Oberg, K | 2 |
| Fleming, TR | 4 |
| Taylor, SA | 1 |
| Baker, LH | 1 |
| Fedeli, A | 1 |
| Fedeli, SL | 1 |
| Catalano, G | 5 |
| Bakkevold, KE | 1 |
| Arnesjø, B | 1 |
| Dahl, O | 1 |
| Kambestad, B | 1 |
| Fleming, RA | 1 |
| Milano, GA | 1 |
| Gaspard, MH | 1 |
| Bargnoux, PJ | 1 |
| Thyss, A | 1 |
| Plagne, R | 1 |
| Schneider, M | 1 |
| Demard, F | 1 |
| Topham, C | 2 |
| Glees, J | 2 |
| Coombes, RC | 2 |
| Kalnicki, S | 2 |
| Dalton, J | 3 |
| Schwartz, GK | 2 |
| Chesser, MR | 3 |
| Mandeli, J | 2 |
| Janus, C | 2 |
| Strauss, JF | 1 |
| Hirsch, VJ | 1 |
| Rubey, CN | 1 |
| Pollock, M | 1 |
| Snady, H | 3 |
| Lehrer, D | 1 |
| Harpaz, N | 1 |
| Okugawa, T | 1 |
| Rino, Y | 1 |
| Kobayashi, O | 1 |
| Sairenji, M | 1 |
| Motohashi, H | 1 |
| Beerblock, K | 2 |
| de Gramont, A | 4 |
| Varette, C | 1 |
| Demuynck, B | 2 |
| Bennamoun, M | 1 |
| Cady, J | 1 |
| Delfau, S | 1 |
| Maisani, JE | 1 |
| Krulik, M | 2 |
| Zarba, JJ | 1 |
| Basile, M | 1 |
| Mahjoubi, M | 1 |
| Benahmed, M | 1 |
| Droz, JP | 3 |
| Armand, JP | 1 |
| Evans, OB | 1 |
| Liu, CD | 1 |
| Rongione, AJ | 1 |
| Garvey, L | 1 |
| Balasubramaniam, A | 1 |
| McFadden, DW | 1 |
| Lai, DT | 1 |
| Chu, KM | 1 |
| Thompson, JF | 1 |
| Gallagher, JP | 1 |
| Waugh, R | 1 |
| Storey, DW | 1 |
| Stephen, MS | 1 |
| Hsue, V | 1 |
| Wong, CS | 1 |
| Cummings, BJ | 1 |
| MacLeod, M | 1 |
| Webb, A | 3 |
| Haaz, MC | 1 |
| Etienne, MC | 1 |
| Hord, JD | 1 |
| Janco, RL | 1 |
| Thomas, PR | 2 |
| Schnall, SF | 1 |
| Lofts, FJ | 1 |
| Mansi, JL | 1 |
| Glees, JP | 1 |
| Dalgleish, AG | 1 |
| Knight, MJ | 1 |
| Tagliaventi, M | 1 |
| Zironi, S | 2 |
| Mazzocchi, B | 1 |
| Bella, M | 1 |
| Donati, D | 1 |
| Acito, L | 1 |
| Maggian, P | 1 |
| Angiona, S | 2 |
| Carducci, MA | 1 |
| Zahurak, ML | 2 |
| Grochow, LB | 3 |
| Miyakawa, S | 1 |
| Sakoda, K | 1 |
| Tsukada, K | 1 |
| Ashida, H | 1 |
| Ishikawa, Y | 1 |
| Kotoura, Y | 1 |
| Kinoshita, H | 1 |
| Uchimura, M | 1 |
| Funabiki, T | 1 |
| Link, KH | 2 |
| Rilinger, N | 2 |
| Muchmore, JH | 2 |
| Preslan, JE | 1 |
| George, WJ | 1 |
| Ahlgren, JD | 2 |
| Shewach, DS | 1 |
| Larsson, PA | 1 |
| Carlsson, G | 2 |
| Spears, CP | 3 |
| Djelloul, S | 1 |
| Forgue-Lafitte, ME | 1 |
| Mester, J | 1 |
| Zimber, A | 1 |
| Gespach, C | 1 |
| Poorter, RL | 1 |
| Bakker, PJ | 1 |
| Huizing, MT | 1 |
| Taat, CW | 1 |
| Rietbroek, RC | 1 |
| Rauws, EA | 1 |
| Veenhof, CH | 3 |
| Cohen, L | 1 |
| Hendrickson, FR | 1 |
| Lennox, AJ | 1 |
| Kroc, TK | 1 |
| Hatcher, MA | 1 |
| Bennett, BR | 1 |
| Nose, H | 2 |
| Nakasuka, H | 1 |
| Nakayama, H | 1 |
| Nagahama, H | 2 |
| Lotz, JP | 2 |
| Bouleuc, C | 1 |
| Azzouzi, K | 1 |
| Houry, S | 3 |
| Hannoun, L | 2 |
| See, J | 1 |
| Esteso, A | 1 |
| Avenin, D | 1 |
| Izrael, V | 2 |
| Hughes, MJ | 1 |
| Cassidy, J | 1 |
| Soukop, M | 1 |
| McGregor, K | 1 |
| Blackburn, N | 1 |
| Yosef, H | 1 |
| Kaye, SB | 1 |
| Cripps, MC | 2 |
| Andersen, JS | 1 |
| Portenoy, RK | 2 |
| Burris, HA | 3 |
| Tarassoff, PG | 1 |
| Brown, TD | 1 |
| Casper, ES | 2 |
| Storniolo, AM | 3 |
| Weckbecker, G | 1 |
| Raulf, F | 1 |
| Tolcsvai, L | 1 |
| Majello, E | 1 |
| Testa, A | 1 |
| Pezzella, G | 1 |
| Giuseppe, S | 1 |
| Giotta, F | 1 |
| Riccardi, F | 1 |
| Fortunato, S | 1 |
| Gebbia, N | 1 |
| Stock, E | 1 |
| Orenberg, EK | 2 |
| Yu, NY | 2 |
| Kanekal, S | 2 |
| Brown, DM | 1 |
| Osato, H | 1 |
| Kishimoto, S | 1 |
| Higaki, N | 1 |
| Taniguchi, K | 1 |
| Sugimoto, K | 1 |
| Dohno, K | 1 |
| Gotoh, M | 1 |
| Tsuji, Y | 1 |
| Yasuda, T | 2 |
| Nakano, H | 2 |
| Iwanaga, T | 2 |
| Hoogenraad, WJ | 3 |
| Lusinchi, A | 2 |
| Taal, BG | 1 |
| de Graeff, A | 1 |
| Curran, D | 1 |
| Sahmoud, T | 2 |
| Daly, WJ | 1 |
| Hoffman, K | 1 |
| Sjödén, PO | 1 |
| Jacobsson, G | 1 |
| Sellström, H | 1 |
| Enander, LK | 1 |
| Linné, T | 1 |
| Svensson, C | 1 |
| Nakaizumi, A | 1 |
| Matayoshi, Y | 1 |
| Sakata, Y | 1 |
| Takemori, H | 1 |
| Suzuki, H | 1 |
| Gallagher, JG | 1 |
| Schroeder, G | 4 |
| Dalton, RJ | 1 |
| Morton, RF | 1 |
| Mailliard, JA | 2 |
| Burch, PA | 4 |
| Sparano, JA | 1 |
| Hansen, R | 4 |
| Bushunow, PW | 1 |
| Kirkwood, J | 1 |
| Flynn, PJ | 2 |
| Luderhoff, EC | 1 |
| González González, D | 1 |
| Bakker, P | 1 |
| Shimizu, E | 1 |
| Kikuyama, M | 1 |
| Murohisa, G | 1 |
| Suzuki, F | 1 |
| Tsugiki, M | 1 |
| Souda, K | 1 |
| Kobayashi, Y | 1 |
| Kawasaki, T | 1 |
| Yoshimi, T | 1 |
| Rigg, A | 1 |
| Gore, M | 1 |
| Watson, M | 1 |
| Moore, H | 1 |
| Sawabe, Y | 1 |
| Yamagishi, H | 1 |
| Yamaguchi, N | 2 |
| Yamamura, Y | 1 |
| Oka, T | 1 |
| Sporn, JR | 2 |
| Buzaid, AC | 1 |
| Slater, D | 1 |
| Cohen, N | 1 |
| Greenberg, BR | 1 |
| Ostkamp, K | 1 |
| Wagner, W | 1 |
| Pötter, R | 1 |
| Berns, T | 2 |
| Prendiville, J | 2 |
| Swaminathan, R | 1 |
| Santala, RG | 1 |
| Pitot, HC | 1 |
| Wright, K | 2 |
| Stella, PJ | 1 |
| Yoshimori, M | 4 |
| Weiden, PL | 1 |
| Thompson, T | 1 |
| Burris, H | 1 |
| Andersen, J | 1 |
| Modiano, MR | 2 |
| Tarassoff, P | 1 |
| Dorr, FA | 1 |
| Stephens, CD | 1 |
| Baker, P | 1 |
| Link, K | 2 |
| Sugoh, T | 1 |
| Mikami, K | 2 |
| Mikami, Y | 1 |
| Endoh, M | 1 |
| Konn, M | 1 |
| Popescu, RA | 1 |
| Auerbach, M | 1 |
| Wampler, GL | 1 |
| Lokich, JJ | 4 |
| Fryer, D | 1 |
| Fryer, JG | 1 |
| Kamthan, AG | 1 |
| Morris, JC | 1 |
| Mandeli, JP | 1 |
| Leben, D | 1 |
| Cooperman, A | 2 |
| Carola, E | 1 |
| Hejna, MH | 1 |
| Weinlaender, G | 1 |
| Vorbeck, F | 1 |
| Fiebiger, WC | 1 |
| Harstrick, A | 2 |
| Hiddemann, W | 1 |
| Strumberg, D | 1 |
| Seeber, S | 1 |
| Wilke, H | 2 |
| Schmoll, HJ | 2 |
| Maruyama, M | 1 |
| Yuasa, Y | 1 |
| Fujita, M | 3 |
| Kuroda, C | 1 |
| Görich, J | 1 |
| Leder, GH | 1 |
| Poen, JC | 3 |
| Collins, HL | 1 |
| Niederhuber, JE | 1 |
| Oberhelman, HA | 3 |
| Vierra, MA | 3 |
| Bastidas, AJ | 3 |
| Young, HS | 1 |
| Slosberg, EA | 1 |
| Jeffrey, BR | 1 |
| Longacre, TA | 1 |
| Goffinet, DR | 1 |
| Shimoike, T | 1 |
| Nakano, I | 1 |
| Migita, Y | 1 |
| Yanase, T | 1 |
| Sezai, S | 1 |
| Ballatori, E | 1 |
| Del Favero, A | 1 |
| Roila, F | 1 |
| Rivera, E | 1 |
| Pfreundner, L | 2 |
| Baier, K | 1 |
| Schwab, F | 1 |
| Willner, J | 1 |
| Bratengeier, K | 2 |
| Feustel, H | 2 |
| Fuchs, KH | 1 |
| Blumenson, LE | 1 |
| Creaven, PJ | 1 |
| Flett, MQ | 1 |
| Gottwald, T | 1 |
| Köveker, G | 1 |
| Büsing, M | 1 |
| Lauchart, W | 1 |
| Casucci, D | 1 |
| Gulino, A | 1 |
| Frati, L | 1 |
| Sanz-Altamira, PM | 1 |
| Ferrante, K | 1 |
| Jenkins, RL | 1 |
| Lewis, WD | 1 |
| Huberman, MS | 1 |
| Stuart, KE | 1 |
| Kikuchi, H | 2 |
| Ujiie, S | 1 |
| Kanamaru, R | 2 |
| Andreyev, HJ | 1 |
| Goodwin, AL | 1 |
| Garcia, L | 1 |
| Tentas, K | 1 |
| Tzivras, M | 1 |
| Kalachanis, N | 1 |
| Katsikas, M | 1 |
| Dimitrakopoulos, A | 1 |
| Papastratis, G | 1 |
| Macheras, A | 1 |
| Karatzas, G | 1 |
| Sechas, M | 1 |
| Rink, T | 1 |
| Schröder, O | 1 |
| Dietrich, C | 1 |
| Kirchner, J | 1 |
| Hör, G | 1 |
| Zeuzem, S | 1 |
| Baum, RP | 1 |
| Kollmannsberger, C | 1 |
| Peters, HD | 1 |
| Fink, U | 2 |
| Kobayashi, A | 1 |
| Yamaguchi, M | 1 |
| Blaszkowsky, L | 2 |
| Zhu, Z | 2 |
| Nightingale, CH | 1 |
| Li, DK | 1 |
| Hohneker, JA | 1 |
| Goswitz, MS | 1 |
| Raijman, I | 2 |
| Lenzi, R | 3 |
| Bold, RJ | 1 |
| Mukaiya, M | 1 |
| Oikawa, I | 1 |
| Takashima, T | 1 |
| Katsuramaki, T | 1 |
| Bousquet, J | 1 |
| Slim, K | 1 |
| Pezet, D | 1 |
| Alexandre, M | 1 |
| Verrelle, P | 1 |
| Cure, H | 1 |
| Chipponi, J | 1 |
| Patiutko, IuI | 1 |
| Kotel'nikov, AG | 1 |
| Badalian, KhV | 1 |
| Sagaĭdak, IV | 1 |
| Suwa, H | 1 |
| Okino, T | 1 |
| Monden, K | 1 |
| Kogire, M | 2 |
| Ohshio, G | 1 |
| Fukumoto, M | 1 |
| Ukei, T | 1 |
| Okagawa, K | 1 |
| Uemura, Y | 1 |
| Miyauchi, K | 1 |
| Mizunoya, S | 1 |
| Takahashi, N | 2 |
| Masamune, R | 1 |
| Kunii, Y | 1 |
| Frontini, L | 3 |
| Battelli, N | 1 |
| Casaretti, R | 1 |
| Zonato, S | 2 |
| Pirovano, M | 1 |
| Cellerino, R | 2 |
| Fezza, JP | 1 |
| Wesley, RE | 1 |
| Klippenstein, KA | 1 |
| Graziano, F | 1 |
| Castellano, D | 1 |
| Paz-Ares, L | 1 |
| Gravalos, C | 1 |
| Diaz-Puente, M | 1 |
| Hitt, R | 1 |
| Alonso, S | 1 |
| Cortes-Funes, H | 1 |
| Saito, A | 1 |
| Yamashita, T | 1 |
| Mariko, Y | 1 |
| Nosaka, Y | 1 |
| Tsuchiya, K | 1 |
| Ando, T | 1 |
| Tsuruo, T | 1 |
| Nakanishi, O | 1 |
| Xue, C | 1 |
| Takimoto, CH | 1 |
| Yee, LK | 1 |
| Venzon, DJ | 1 |
| Schuler, B | 1 |
| Grollman, F | 1 |
| Chabuk, C | 1 |
| Hamilton, JM | 1 |
| Chen, AP | 1 |
| Allegra, CJ | 2 |
| Silva, RR | 1 |
| Pancera, G | 1 |
| Giordani, P | 1 |
| Giuliodori, L | 1 |
| Pessi, MA | 2 |
| Fusco, V | 1 |
| Luporini, G | 1 |
| Danenberg, KD | 1 |
| Arber, N | 1 |
| Danenberg, PV | 1 |
| Korc, M | 1 |
| Chakravarthy, A | 2 |
| Sohn, TA | 1 |
| Haulk, TL | 1 |
| Ord, S | 1 |
| van Groeningen, CJ | 1 |
| DeNittis, AS | 1 |
| Stambaugh, MD | 1 |
| Lang, P | 1 |
| Wallner, PE | 1 |
| Lustig, RA | 1 |
| Dillman, RO | 1 |
| Order, SE | 1 |
| Patawaran, MB | 1 |
| Chen, JY | 1 |
| Jones, RE | 1 |
| Kawesha, A | 1 |
| Howes, N | 1 |
| Jones, L | 1 |
| Brunner, T | 2 |
| Fisher, BJ | 1 |
| Perera, FE | 1 |
| Kocha, W | 1 |
| Tomiak, A | 1 |
| Vincent, M | 1 |
| Bauman, GS | 1 |
| Carrasco, CH | 1 |
| Dumas, P | 1 |
| Richli, W | 1 |
| Lawrence, D | 1 |
| Chuang, V | 1 |
| Wallace, S | 1 |
| Paulino, AC | 2 |
| Caudry, M | 1 |
| Bonnel, C | 1 |
| Königer, M | 1 |
| Steinkamp, M | 1 |
| Gress, TM | 1 |
| Leach, SD | 1 |
| Damle, S | 1 |
| Schechner, R | 1 |
| Berkenblit, R | 1 |
| Ladner, RD | 1 |
| Murgo, A | 1 |
| Hochmuth, K | 1 |
| Diebold, T | 1 |
| Langrehr, J | 2 |
| Schmidt, CA | 1 |
| Arning, M | 2 |
| Vogl, TJ | 1 |
| Huhn, D | 2 |
| Carr, JA | 1 |
| Ajlouni, M | 1 |
| Wong, D | 1 |
| Velanovich, V | 1 |
| van Pel, R | 1 |
| Couvreur, ML | 2 |
| Arnaud, JP | 1 |
| Gonzalez, DG | 1 |
| de Wit, LT | 1 |
| Hennipman, A | 1 |
| Hauns, B | 1 |
| Häring, B | 1 |
| Köhler, S | 1 |
| Mross, K | 1 |
| Robben-Bathe, P | 1 |
| Unger, C | 1 |
| Schratter-Sehn, A | 1 |
| Marczell, A | 2 |
| Karner, J | 1 |
| Krauss, G | 1 |
| Locker, G | 1 |
| Minari, Y | 2 |
| Itakura, M | 2 |
| Yamasawa, K | 2 |
| Tamura, K | 1 |
| Hudec, WA | 1 |
| Lahoti, S | 1 |
| David, AK | 1 |
| Vaughn, DJ | 3 |
| Holroyde, CP | 1 |
| Armstead, B | 1 |
| Colonna, M | 1 |
| Bellaïche, A | 1 |
| Parc, R | 1 |
| Adak, S | 1 |
| Flinker, D | 1 |
| Harris, JE | 1 |
| Latona, C | 1 |
| Jerusalem, G | 1 |
| Bours, V | 1 |
| Fillet, G | 1 |
| Collette, M | 1 |
| Tagliaferri, P | 1 |
| Libroia, A | 1 |
| Damiano, V | 1 |
| Fabbrocini, A | 1 |
| De Lorenzo, S | 1 |
| Bianco, AR | 1 |
| Canaletti, R | 1 |
| Sdrobolini, A | 1 |
| Olmeo, N | 1 |
| Pucci, F | 1 |
| Cavicchi, F | 1 |
| Rodinò, C | 1 |
| Contu, A | 1 |
| Au, E | 1 |
| Overholser, JP | 1 |
| Prewett, MC | 1 |
| Hooper, AT | 1 |
| Waksal, HW | 1 |
| Hicklin, DJ | 1 |
| Tsuji, A | 1 |
| Terashima, M | 1 |
| Morita, A | 1 |
| Nakamoto, A | 1 |
| Koyasaki, N | 1 |
| Cornalba, G | 1 |
| Frassoldati, A | 1 |
| Smerieri, F | 1 |
| Kukitsu, T | 1 |
| Oku, T | 1 |
| Kusakabe, T | 1 |
| Bruckner, H | 1 |
| Paradiso, J | 1 |
| Kiefer, L | 1 |
| Kurata, T | 1 |
| Otsuji, S | 1 |
| Nukui, Y | 1 |
| Zanon, C | 1 |
| Alabiso, O | 1 |
| Grosso, M | 1 |
| Buosi, R | 1 |
| Clara, R | 1 |
| Satolli, A | 1 |
| Zai, S | 1 |
| Bortolini, M | 1 |
| Botta, M | 1 |
| Mussa, A | 1 |
| Du, W | 1 |
| Arlauskas, P | 1 |
| Gordon, C | 1 |
| Kellogg, C | 1 |
| Choi, CW | 1 |
| Choi, IK | 1 |
| Kim, CD | 1 |
| Um, SH | 1 |
| Jacobson, JL | 1 |
| Modiano, M | 1 |
| Moore, DF | 2 |
| Gandara, DR | 1 |
| Schroder, LE | 1 |
| Chapman, RA | 1 |
| Colarian, J | 1 |
| Fowler, D | 1 |
| Schor, J | 1 |
| Poolos, S | 1 |
| Inada, T | 1 |
| Fukutomi, K | 1 |
| Igarashi, S | 1 |
| McGrath, P | 1 |
| Strodel, WE | 1 |
| Block, M | 1 |
| Sargent, DJ | 1 |
| Braich, TA | 1 |
| Michalak, JC | 1 |
| Hatfield, AK | 1 |
| Kuross, SA | 1 |
| Beauchamp, RD | 1 |
| Schnelldorfer, T | 1 |
| Gansauge, S | 1 |
| Schlosser, S | 1 |
| Nussler, AK | 1 |
| Kitagata, S | 1 |
| Mai, M | 1 |
| Delauter, BJ | 1 |
| Egorin, MJ | 1 |
| Stover, LL | 1 |
| Zuhowski, EG | 1 |
| Plunkett, W | 1 |
| Kastl, S | 1 |
| Herrmann, O | 1 |
| Riepl, M | 1 |
| Grabenbauer, G | 1 |
| Klein, P | 1 |
| Ghosh, C | 1 |
| Allmer, C | 1 |
| Woodhouse, CL | 1 |
| Addo, F | 1 |
| Bernath, AM | 1 |
| Windschitl, HE | 2 |
| Cobau, CD | 1 |
| Peyrat, JP | 1 |
| Abecassis, J | 1 |
| Millon, R | 1 |
| Korman, LT | 1 |
| Zahurek, ML | 1 |
| O'Reilly, S | 1 |
| Hurwitz, H | 1 |
| Rauchwerger, DR | 1 |
| Firby, PS | 1 |
| Miura, T | 3 |
| Matumoto, Y | 1 |
| Tamamori, Y | 1 |
| Nishino, H | 1 |
| Ohira, M | 1 |
| Otani, Y | 1 |
| Kumai, K | 1 |
| Washizawa, N | 1 |
| Tokura, N | 1 |
| Kase, H | 1 |
| Ogawa, M | 2 |
| Hattori, T | 2 |
| Teramoto, T | 1 |
| Kobayashi, K | 1 |
| Musch, R | 1 |
| Korsten, EW | 1 |
| Graiff, C | 1 |
| Picone, G | 1 |
| Farinati, E | 1 |
| Curti, C | 1 |
| Mehta, VK | 2 |
| Sadikov, E | 1 |
| Mishaeli, M | 1 |
| Koren, R | 1 |
| Gal, R | 1 |
| Levin, I | 1 |
| Klein, B | 1 |
| Hempel, C | 1 |
| Eckel, F | 1 |
| Lersch, C | 1 |
| Lippl, F | 1 |
| Assmann, G | 1 |
| Schulte-Frohlinde, E | 1 |
| Rauch, DP | 1 |
| Maurer, CA | 1 |
| Aebi, S | 2 |
| Pampallona, S | 1 |
| Ludwig, CU | 1 |
| Borner, MM | 1 |
| Kanyama, H | 1 |
| Tomita, N | 1 |
| Yamano, T | 1 |
| Aihara, T | 1 |
| Miyoshi, Y | 1 |
| Ohue, M | 1 |
| Sakita, I | 1 |
| Tamaki, Y | 1 |
| Kaneda, Y | 1 |
| Senter, PD | 1 |
| Kokhanenko, NIu | 1 |
| Gershanovich, ML | 1 |
| Ignashov, AM | 1 |
| Osipenko, SK | 1 |
| Rybakov, GV | 1 |
| Ivanova, NE | 1 |
| Breslin, TM | 1 |
| Harbison, DB | 1 |
| Jean, ME | 1 |
| Dackiw, AP | 1 |
| Sato, K | 1 |
| Guseinov, E | 1 |
| Horák, D | 1 |
| Titova, M | 1 |
| Adamyan, A | 1 |
| Kokov, L | 1 |
| Kubishkin, V | 1 |
| Vishnevskii, V | 1 |
| Skuba, N | 1 |
| Trostenyuk, N | 1 |
| Kachnic, LA | 1 |
| Shaw, JE | 1 |
| Manning, MA | 1 |
| Lauve, AD | 1 |
| Genvresse, I | 1 |
| Lange, C | 1 |
| Schanz, J | 1 |
| Schweigert, M | 1 |
| Harder, H | 1 |
| Possinger, K | 1 |
| Späth-Schwalbe, E | 1 |
| Panucci, MG | 1 |
| Procházková, A | 1 |
| Thormann, W | 1 |
| Hirahara, N | 1 |
| Dong, M | 2 |
| Aboagye, EO | 1 |
| Cunningham, VJ | 1 |
| Osman, S | 1 |
| Selle, F | 1 |
| Flesch, M | 1 |
| Colin, P | 1 |
| Shelton, CH | 1 |
| Minasi, JS | 1 |
| Brentjens, R | 1 |
| Petryk, M | 2 |
| Evans, A | 1 |
| Cooperman, AM | 1 |
| Hammerman, H | 1 |
| Siegel, J | 1 |
| Stark, B | 1 |
| Bank, S | 1 |
| Staren, ED | 1 |
| Iwamura, T | 1 |
| Appert, HE | 1 |
| Howard, JM | 2 |
| Blind, PJ | 1 |
| Marantz, A | 1 |
| Jovtis, S | 1 |
| Almira, E | 1 |
| Balbiani, L | 1 |
| Castilla, JL | 1 |
| Fein, L | 1 |
| Lewi, D | 1 |
| Pasccon, G | 1 |
| Pinckevicius, R | 1 |
| Uranga, G | 1 |
| Abal, M | 1 |
| Muiño, M | 1 |
| Reale, M | 1 |
| Agusto, S | 1 |
| Caroli-Bosc, FX | 1 |
| Gay, F | 1 |
| Forget, F | 1 |
| Twelves, C | 1 |
| Tosolini, G | 1 |
| Talamini, R | 1 |
| Habara, K | 1 |
| Ajiki, T | 1 |
| Ward, S | 1 |
| Morris, E | 1 |
| Bansback, N | 1 |
| Calvert, N | 1 |
| Forman, D | 1 |
| Larvin, M | 1 |
| Radstone, D | 1 |
| Tanada, M | 1 |
| Takashima, S | 2 |
| Endoh, H | 1 |
| Hyoudou, I | 1 |
| Jinno, K | 1 |
| Kataoka, M | 1 |
| Piantadosi, S | 1 |
| Almond, J | 1 |
| Barzdins, A | 1 |
| Robin, A | 1 |
| Seidel, M | 1 |
| Morii, Y | 1 |
| Aramaki, M | 1 |
| Kitano, S | 1 |
| Cartwright, TH | 1 |
| Cohn, A | 1 |
| Varkey, JA | 1 |
| Chen, YM | 1 |
| Szatrowski, TP | 1 |
| Cox, JV | 1 |
| Schulz, JJ | 1 |
| Lee, C | 1 |
| Anscher, MS | 1 |
| Paulson, EK | 1 |
| Gottfried, MR | 1 |
| McGrath, KM | 1 |
| Schilsky, RL | 1 |
| Bertucci, D | 1 |
| Vogelzang, NJ | 1 |
| Ratain, MJ | 1 |
| Escourrou, J | 1 |
| Pages, P | 1 |
| Moreau, J | 1 |
| Faure, P | 1 |
| Cao, G | 1 |
| Takamura, M | 1 |
| Wils, JA | 1 |
| Kok, TC | 2 |
| Planting, A | 2 |
| Ballo, MT | 1 |
| Delclos, M | 1 |
| Milas, L | 1 |
| Mason, K | 1 |
| Wong, AB | 1 |
| Phan, T | 1 |
| Nguyen, Q | 1 |
| Kouloulias, VE | 2 |
| Nikita, KS | 2 |
| Kouvaris, JR | 2 |
| Uzunoglu, NK | 2 |
| Golematis, VC | 1 |
| Papavasiliou, CG | 1 |
| Vlahos, LJ | 2 |
| Yachida, S | 1 |
| Fukushima, N | 1 |
| Matsuno, Y | 1 |
| Hirohashi, S | 1 |
| Shinchi, H | 1 |
| Noma, H | 1 |
| Mataki, Y | 1 |
| Fung, MC | 1 |
| Sakata, T | 1 |
| Takechi, T | 1 |
| Fujioka, A | 1 |
| Matsushima, E | 1 |
| Amado, RG | 1 |
| Rosen, LS | 1 |
| Lin, LS | 1 |
| Rosen, PJ | 1 |
| Ferrari, L | 1 |
| Procopio, G | 1 |
| Catena, L | 1 |
| Ferrario, E | 1 |
| Martinetti, A | 1 |
| Di Bartolomeo, M | 1 |
| Buzzoni, R | 1 |
| Celio, L | 1 |
| Vitali, M | 1 |
| Beretta, E | 1 |
| Seregni, E | 1 |
| Bombardieri, E | 1 |
| Golematis, BC | 1 |
| Mystakidou, K | 1 |
| Xu, ZW | 1 |
| Solioz, M | 1 |
| Barone, RM | 1 |
| Balasegaram, M | 1 |
| Widerlite, L | 1 |
| Mayr, AC | 1 |
| Zeitoun, P | 1 |
| Nasca, S | 1 |
| Chevrel, JP | 1 |
| Damsin, JP | 1 |
| Lebhar, E | 1 |
| Dobelbower, RR | 5 |
| Carbone, PP | 2 |
| Wiggans, RG | 1 |
| Smythe, T | 1 |
| Ueno, W | 1 |
| Gelber, RD | 1 |
| Cubilla, AL | 1 |
| Hajdu, SI | 2 |
| Oberfield, RA | 1 |
| Kraybill, WG | 1 |
| Anderson, DD | 1 |
| Lindell, TD | 1 |
| Fletcher, WS | 5 |
| Seligman, M | 1 |
| Greenstreet, RL | 1 |
| Chernicoff, D | 1 |
| Awrich, A | 1 |
| Klotz, JH | 1 |
| Minton, JP | 1 |
| Hill, GJ | 2 |
| Aust, JB | 1 |
| Grage, TB | 1 |
| Multhauf, PM | 1 |
| Khandekar, JD | 1 |
| Oyer, D | 1 |
| Miller, HJ | 1 |
| Vick, NA | 1 |
| Heal, JM | 1 |
| Sawai, K | 1 |
| Sonoda, Y | 1 |
| Ohkuma, S | 1 |
| Misawa, S | 2 |
| Takino, T | 2 |
| Schaefer, J | 1 |
| Arnold, H | 1 |
| Drings, P | 1 |
| Geldmacher, J | 1 |
| Kredel, L | 1 |
| Mayer, M | 1 |
| Neidhardt, B | 1 |
| von Oldershausen, HF | 1 |
| Rösch, W | 1 |
| Wahrendorf, J | 1 |
| Buroker, T | 1 |
| Kim, PN | 1 |
| Groppe, C | 1 |
| McCracken, J | 1 |
| O'Bryan, R | 1 |
| Panettiere, F | 1 |
| Costanzi, J | 1 |
| Bottomley, R | 1 |
| King, GW | 1 |
| Bonnet, J | 1 |
| Thigpen, T | 1 |
| Whitecar, J | 1 |
| Haas, C | 2 |
| Hoogstraten, B | 2 |
| Heilbrun, L | 1 |
| Hall, SW | 1 |
| Benjamin, RS | 1 |
| Murphy, WK | 1 |
| Solomon, A | 1 |
| Hartman, HA | 1 |
| Kessinger, A | 2 |
| Lemon, HM | 2 |
| Costanzi, JJ | 2 |
| Panettiere, FJ | 1 |
| Wolma, FJ | 1 |
| Stephens, RL | 1 |
| Clark, G | 1 |
| Obrecht, JP | 1 |
| Kaplan, R | 1 |
| Heal, A | 1 |
| Kune, GA | 1 |
| Hobbs, JB | 1 |
| Butterfield, D | 1 |
| Sali, A | 1 |
| Bullen, BR | 1 |
| Giles, GR | 1 |
| Malhotra, A | 1 |
| Bird, GG | 1 |
| Hall, R | 1 |
| Bunch, GA | 1 |
| Brown, GJ | 1 |
| Johnson, RO | 1 |
| Metter, G | 1 |
| Wilson, WL | 1 |
| Davis, HL | 2 |
| Grage, T | 1 |
| Falk, RE | 2 |
| MacGregor, AB | 2 |
| Ambus, U | 2 |
| Landi, S | 2 |
| Miller, AB | 1 |
| Samuel, ES | 1 |
| Langer, B | 2 |
| De Jager, RL | 1 |
| Golbey, RB | 1 |
| Krakoff, IH | 1 |
| Carter, SK | 2 |
| Comis, RL | 1 |
| Hara, Y | 1 |
| Tobita, Y | 1 |
| Kadono, A | 1 |
| Pitman, SW | 1 |
| Skarin, AT | 2 |
| Smolianskaia, AZ | 1 |
| Congy, F | 1 |
| Pelletier, S | 1 |
| Langlois, P | 1 |
| Khayat, D | 1 |
| Homsi, T | 1 |
| Emerit, J | 1 |
| Schifeling, DJ | 1 |
| Merrick, HW | 3 |
| Skeel, RT | 2 |
| Lefkopoulo, M | 1 |
| Klaassen, D | 1 |
| Flückiger, A | 1 |
| Schlup, P | 1 |
| Tangen, C | 1 |
| Lee, R | 1 |
| Einstein, AB | 1 |
| Peterson, R | 1 |
| Byrd, DR | 3 |
| Connelly, JH | 1 |
| Ames, FC | 2 |
| Warszawski, N | 1 |
| Bohndorf, W | 1 |
| Pazdur, R | 2 |
| Ajani, JJ | 1 |
| Belt, RJ | 1 |
| Dakhil, SR | 1 |
| Dubovsky, D | 1 |
| Graham, S | 1 |
| Pilat, S | 1 |
| Winn, R | 1 |
| Shimada, Y | 2 |
| Kajihara, T | 1 |
| Hanaue, H | 1 |
| Jones, DV | 1 |
| Samaan, NA | 1 |
| Sellin, RV | 1 |
| Pfeffel, F | 1 |
| Kornek, G | 1 |
| Wiltschke, C | 1 |
| Funovics, J | 3 |
| Rosvold, E | 1 |
| Schilder, R | 1 |
| Walczak, J | 1 |
| DiFino, SM | 1 |
| Banerjee, TK | 1 |
| Heim, WJ | 1 |
| Ozols, RF | 1 |
| Kunimura, T | 1 |
| Morohoshi, T | 1 |
| Sato, M | 1 |
| Taguchi, S | 2 |
| Hatta, Y | 2 |
| Taylor, CW | 1 |
| Woodson, ME | 1 |
| Marcus, SG | 1 |
| Hersh, EM | 1 |
| Stahl, M | 1 |
| Meyer, HJ | 1 |
| Achterrath, W | 1 |
| Knipp, H | 1 |
| Köhne-Wömpner, CH | 1 |
| Boarman, D | 1 |
| Balis, FM | 1 |
| Murphy, RF | 1 |
| McAtee, N | 1 |
| Komaki, R | 2 |
| Peters, T | 1 |
| Byhardt, RW | 1 |
| Order, S | 1 |
| Gallagher, MJ | 1 |
| Herskovic, A | 1 |
| Pederson, J | 1 |
| Schuricht, A | 1 |
| Zhen, YS | 1 |
| Taniki, T | 1 |
| Weber, G | 2 |
| Oliveira, J | 1 |
| Theodore, C | 1 |
| Kac, J | 1 |
| Kao, GD | 1 |
| Szepeshazi, K | 1 |
| Lapis, K | 1 |
| Schally, AV | 1 |
| Kahn, PJ | 1 |
| Skornick, Y | 1 |
| Inbar, M | 2 |
| Kaplan, O | 2 |
| Chaichik, S | 1 |
| Rozin, R | 1 |
| Verhees, S | 1 |
| Flechtner, H | 1 |
| Fritz, M | 1 |
| Edler, L | 1 |
| Lundqvist, G | 1 |
| Wide, L | 1 |
| Wilander, E | 1 |
| Tohma, H | 1 |
| Shikama, T | 1 |
| Bronn, DG | 1 |
| Grinblatt, DL | 1 |
| Treurniet-Donker, AD | 2 |
| Hudis, C | 1 |
| Dougherty, J | 1 |
| Casper, E | 1 |
| Botet, J | 2 |
| Vinciguerra, V | 1 |
| Rosenbluth, R | 1 |
| Bresler, L | 1 |
| Boissel, P | 1 |
| Grosdidier, J | 1 |
| Mansfield, PF | 1 |
| Crown, J | 2 |
| Murray, P | 1 |
| Rawson, NS | 1 |
| Woods, EM | 1 |
| Fukuda, I | 2 |
| Nishiyama, M | 2 |
| Aogi, K | 1 |
| Saeki, S | 1 |
| Hirabayashi, N | 2 |
| Toge, T | 2 |
| DeCaprio, JA | 1 |
| Gonin, R | 1 |
| Arbuck, SG | 2 |
| Pyrhönen, S | 2 |
| Valtonen, M | 1 |
| Porta, C | 1 |
| Nastasi, G | 1 |
| Spaghi, A | 1 |
| Moroni, M | 1 |
| Morrell, LM | 1 |
| Bach, A | 1 |
| Goodman, P | 1 |
| Tajiri, H | 3 |
| Okazaki, N | 1 |
| Miyaji, M | 1 |
| Nagai, M | 1 |
| Prajda, N | 1 |
| Nakamura, H | 1 |
| Szekeres, T | 1 |
| Olah, E | 1 |
| Abad, A | 1 |
| Rosell, R | 1 |
| Barnadas, A | 1 |
| Carles, J | 1 |
| Ribelles, N | 1 |
| Solano, V | 1 |
| Rothman, H | 1 |
| Cantrell, JE | 1 |
| Difino, S | 1 |
| Ahlgren, J | 1 |
| Fryer, J | 1 |
| Braumann, D | 1 |
| Mainzer, K | 1 |
| Günzl, C | 1 |
| Lewerenz, B | 1 |
| Imai, S | 1 |
| Shiraishi, T | 1 |
| Tsubono, M | 1 |
| Morimoto, H | 1 |
| Tseng, CC | 1 |
| Tobe, T | 1 |
| Yamada, H | 1 |
| Jinushi, K | 1 |
| Kirihara, Y | 1 |
| Takagami, S | 1 |
| Ryuji, K | 1 |
| Yorishima, T | 1 |
| Noso, Y | 1 |
| Hisano, H | 1 |
| Seydel, HG | 1 |
| Stablein, DM | 1 |
| Leichman, LP | 1 |
| Kinzie, JJ | 1 |
| Bonneterre, J | 1 |
| Madajewicz, S | 1 |
| Avvento, L | 1 |
| Reboul, F | 1 |
| Serin, D | 1 |
| Martin, D | 1 |
| Plat, F | 1 |
| Cullinan, S | 1 |
| Norris, BD | 1 |
| Kardinal, CG | 1 |
| Barlow, JF | 1 |
| Gröhn, P | 1 |
| Heinonen, E | 1 |
| Kumpulainen, E | 1 |
| Länsimies, H | 1 |
| Lantto, A | 1 |
| Salmi, R | 1 |
| Numminen, S | 1 |
| Harris, BE | 1 |
| Song, R | 1 |
| Soong, SJ | 1 |
| Wood, D | 1 |
| Silberman, AW | 1 |
| Heifetz, L | 1 |
| Memsic, L | 1 |
| Shabot, MM | 1 |
| van Mierlo, MJ | 1 |
| van Putten, WL | 1 |
| Harvey, HA | 1 |
| Santen, RJ | 1 |
| Stryker, JA | 1 |
| Barnes, SG | 1 |
| Walker, BK | 1 |
| Dixon, RH | 1 |
| Givant, EM | 1 |
| Bartholomew, MJ | 1 |
| Nadjafi, C | 1 |
| Mueller, C | 1 |
| Ludwig, H | 2 |
| Eschwege, F | 1 |
| Delanian, S | 1 |
| Abensour, L | 1 |
| Wibault, P | 1 |
| Fujita, F | 2 |
| Fujii, S | 1 |
| Sassa, T | 1 |
| Yoshikawa, N | 1 |
| Hirose, N | 1 |
| Funatomi, H | 1 |
| Kunitomo, K | 1 |
| Kawahito, M | 1 |
| Miura, M | 1 |
| Komi, N | 1 |
| Vaughn, C | 1 |
| Chapman, J | 1 |
| Groshko, G | 1 |
| Maniscalco, B | 1 |
| Reznik, S | 1 |
| Piper, D | 1 |
| Kikuti, H | 1 |
| Asamura, M | 1 |
| Kalman, J | 1 |
| Spigelman, M | 1 |
| Gorbaty, MI | 1 |
| Butwell, N | 1 |
| Storch, J | 1 |
| McKenna, A | 2 |
| Maruyama, T | 1 |
| Koura, Y | 1 |
| Kurisu, Y | 1 |
| Kuroi, K | 1 |
| Cullinan, SA | 1 |
| Rubin, JR | 1 |
| Everson, LK | 1 |
| Marschke, RF | 1 |
| Roth, S | 1 |
| Sack, H | 1 |
| Thesen, N | 1 |
| Mödder, U | 1 |
| van Hoesel, QG | 1 |
| Yap, SH | 2 |
| Wobbes, T | 2 |
| Strijk, SP | 2 |
| Christiansen, NP | 1 |
| Kennedy, BJ | 1 |
| Splinter, TA | 1 |
| Obertop, H | 1 |
| Hricik, DE | 1 |
| Goldsmith, GH | 1 |
| Lee, SM | 1 |
| Forbes, A | 1 |
| Williams, R | 1 |
| Wilson, JF | 2 |
| Wilson, S | 1 |
| Zimmermann, K | 1 |
| Rapp, T | 1 |
| Binder, J | 1 |
| Frölich, J | 1 |
| Bode, JC | 1 |
| Altimari, AF | 1 |
| Bhoopalam, N | 1 |
| O'Dorsio, T | 1 |
| Lange, CL | 1 |
| Sandberg, L | 1 |
| Prinz, RA | 1 |
| Oster, MW | 1 |
| Gray, R | 1 |
| Panasci, L | 1 |
| Perry, MC | 1 |
| Malet-Martino, MC | 1 |
| Faure, F | 1 |
| Vialaneix, JP | 1 |
| Palevody, C | 1 |
| Hollande, E | 1 |
| Martino, R | 1 |
| Vasen, HF | 1 |
| Sitsen, JM | 1 |
| Nortier, JW | 1 |
| Lips, CJ | 1 |
| Barragry, TP | 1 |
| Wick, MR | 1 |
| Delaney, JP | 1 |
| Yamazaki, H | 1 |
| Horikoshi, N | 1 |
| Ueno, K | 1 |
| Imajo, K | 1 |
| Mukaiyama, T | 1 |
| Miyaoka, K | 1 |
| Zielinski, C | 1 |
| Knoflach, P | 1 |
| Grabner, G | 1 |
| Hart, R | 1 |
| Kimoto, Y | 2 |
| Fieck, JM | 1 |
| Martinez, A | 1 |
| Sweeny, DJ | 1 |
| Barnes, S | 1 |
| Heggie, GD | 1 |
| Kusuyama, T | 1 |
| Origasa, H | 1 |
| Shimozuma, K | 1 |
| Loehrer, PJ | 1 |
| Williams, SD | 1 |
| Nichols, CR | 1 |
| Cantor, RJ | 1 |
| Weiss, SM | 1 |
| Rosato, FE | 1 |
| Yamamoto, M | 1 |
| Ohyanagi, H | 1 |
| Ishida, T | 1 |
| Tagashira, Y | 1 |
| Fujimoto, T | 1 |
| Kurogoh, F | 1 |
| Okumura, S | 1 |
| Tanemura, H | 1 |
| Kawata, R | 1 |
| Shimokawa, K | 1 |
| Azuma, S | 1 |
| Saji, S | 1 |
| Ohashi, H | 1 |
| Sakata, K | 1 |
| Ozaki, H | 2 |
| Raju, PI | 1 |
| Maruyama, Y | 1 |
| DeSimone, P | 1 |
| Gustavsson, BG | 2 |
| Berne, M | 1 |
| Frösing, R | 2 |
| Bernstein, L | 1 |
| Hayes, AA | 1 |
| Cox, JD | 1 |
| Wiley, AL | 1 |
| Wirtanen, GW | 2 |
| Mehta, MP | 1 |
| Ramirez, G | 3 |
| Shahabi, S | 1 |
| Stachura, J | 1 |
| Popiela, T | 1 |
| Pietroń, M | 1 |
| Tomaszewska, R | 1 |
| Kulig, J | 1 |
| Nowak, K | 1 |
| Roldan, GE | 1 |
| Ilstrup, DM | 1 |
| Chitambar, C | 1 |
| Anderson, T | 1 |
| Silberman, H | 1 |
| Okawa, T | 1 |
| Kita, M | 1 |
| Gratzner, H | 1 |
| Lim, LO | 1 |
| Yunis, AA | 1 |
| Dalesio, O | 1 |
| Duez, N | 1 |
| Blijham, G | 1 |
| Splinter, T | 1 |
| Weber, W | 1 |
| Selch, MT | 1 |
| Parker, RG | 1 |
| Steplewski, Z | 1 |
| Koprowski, H | 1 |
| Hijikata, A | 1 |
| Yamaguchi, H | 1 |
| Saito, D | 1 |
| Mukai, T | 1 |
| Ohkura, H | 1 |
| Jones, KG | 1 |
| Lindberg, RD | 1 |
| Epremian, B | 1 |
| Jose, B | 1 |
| Spanos, WJ | 1 |
| Lelcuk, S | 1 |
| Merhav, A | 1 |
| Rozin, RR | 1 |
| Sekine, S | 1 |
| Katsumi, S | 1 |
| Yokogi, K | 1 |
| Watanabe, S | 1 |
| Murai, T | 1 |
| Rikimaru, Y | 1 |
| Abe, R | 1 |
| Schlienger, M | 1 |
| Charron, R | 1 |
| Ahuja, RK | 1 |
| Drexler, LJ | 1 |
| Mitre, RJ | 1 |
| Madan, E | 1 |
| Zidar, BL | 1 |
| Hasegawa, H | 1 |
| Arizuka, S | 1 |
| Ashida, Y | 1 |
| Eckhardt, S | 1 |
| Klaassen, DJ | 1 |
| MacIntyre, JM | 1 |
| Catton, GE | 1 |
| Ellenberg, SS | 1 |
| Fukaya, Y | 1 |
| Kruisselbrink, H | 1 |
| Schillings, P | 1 |
| Massey, WH | 2 |
| Judkins, MP | 1 |
| Dennis, DL | 2 |
| Futorian, ES | 2 |
| Shubin, BM | 2 |
| Paustian, FF | 1 |
| Delevan, J | 1 |
| McLaughlin, CW | 1 |
| Knock, FE | 1 |
| Galt, RM | 1 |
| Oester, YT | 1 |
| Sylvester, R | 1 |
| Green, N | 1 |
| Beron, E | 1 |
| Melbye, RW | 1 |
| George, FW | 1 |
| Haslam, JB | 1 |
| Cavanaugh, PJ | 1 |
| Stroup, SL | 1 |
| Missale, G | 1 |
| Cocconi, G | 1 |
| Pettenati, V | 1 |
| Griffen, WO | 1 |
| Humphrey, L | 1 |
| Sosin, H | 1 |
| Zimmermann, G | 1 |
| Boeckl, O | 1 |
| Falkson, HC | 1 |
| Fichardt, T | 1 |
| Takatani, O | 1 |
| Ansfield, FJ | 2 |
| Arsac, M | 1 |
| Bonnet, G | 1 |
| Mouzon, M | 1 |
| Coltman, CA | 1 |
| Wood, DC | 1 |
| Brooks, JR | 1 |
| Barclay, GA | 1 |
| al-Rais, SH | 1 |
| Moertel, C | 1 |
| Zollinger, RM | 1 |
| Patrassi, N | 1 |
| Basoli, A | 1 |
| Mineo, TC | 1 |
| Carboni, M | 1 |
| Kirsch, WM | 1 |
| Schulz, D | 1 |
| Van Buskirk, JJ | 1 |
| Young, HE | 1 |
| Baer, JW | 1 |
| Zarowitz, H | 1 |
| Waddell, WR | 2 |
| Grover, FL | 1 |
| Tolia, BM | 1 |
| Whitmore, WF | 1 |
| Kovach, JS | 1 |
| Chawla, PL | 1 |
| Frei, E | 1 |
| Gordon, B | 1 |
| al-Sarraf, M | 1 |
| Reed, ML | 1 |
| Vaitkevicious, VK | 1 |
| Mikhaĭlichenko, VA | 1 |
| Tamarkin, MA | 1 |
| Bateman, JR | 1 |
| Pugh, RP | 1 |
| Cassidy, FR | 1 |
| Marshall, GJ | 1 |
| Irwin, LE | 1 |
| Lazichev, IuD | 1 |
| Mitchell, MS | 1 |
| DeConti, RC | 1 |
| Milonov, BV | 1 |
| Kosarev, VA | 1 |
| Nikiforov, AM | 1 |
| Bernhardt, LC | 1 |
| Mackman, S | 1 |
| Curreri, AR | 1 |
| Nadler, SH | 1 |
| Barrett, O | 1 |
| Bourgeois, C | 1 |
| Plecha, FR | 1 |
| Mobarak, MA | 1 |
| Brody, JI | 1 |
| Lisker, SA | 1 |
| Beizer, LH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy With Liposomal Irinotecan Combined With Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patient[NCT04617457] | Phase 2 | 150 participants (Anticipated) | Interventional | 2021-10-10 | Recruiting | ||
| Single-arm, Open-label Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers[NCT05986981] | Phase 2 | 20 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | ||
| A Phase II Randomized Study of Induction Chemotherapy Followed by Concurrent Chemo-radiotherapy in Locally Advanced Pancreatic Cancer[NCT01867892] | Phase 2 | 86 participants (Anticipated) | Interventional | 2013-06-30 | Enrolling by invitation | ||
| Stereotactic Body Radiation Therapy Plus Pembrolizumab and Trametinib vs. Stereotactic Body Radiation Therapy Plus Gemcitabine for Locally Recurrent Pancreatic Cancer After Surgical Resection: an Open-label, Randomized, Controlled, Phase 2 Trial[NCT02704156] | Phase 2 | 170 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| An Open-label, Randomized, Multicenter, Phase II Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers[NCT06135896] | Phase 2 | 98 participants (Anticipated) | Interventional | 2023-12-10 | Not yet recruiting | ||
| Circulating Tumor Cell and Tumor Tissue Models for Predicting Effective Pancreatic Cancer Response[NCT03033927] | 74 participants (Actual) | Observational | 2017-01-24 | Active, not recruiting | |||
| Evaluation of Exceptional Responders With Solid Tumor Cancer[NCT02555735] | 250 participants (Anticipated) | Observational | 2015-10-31 | Enrolling by invitation | |||
| Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas[NCT02839343] | Phase 2 | 126 participants (Actual) | Interventional | 2016-12-31 | Active, not recruiting | ||
| Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma[NCT01526135] | Phase 3 | 493 participants (Actual) | Interventional | 2012-04-16 | Completed | ||
| A Phase I Study of Onivyde and 5-FU in Combination With Xilonix for Advanced Pancreatic Cancer With Cachexia[NCT03207724] | Phase 1 | 16 participants (Actual) | Interventional | 2017-10-16 | Completed | ||
| A Phase II Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients With Borderline Resectable Pancreatic Cancer[NCT01661088] | Phase 2 | 25 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas[NCT03504423] | Phase 3 | 528 participants (Actual) | Interventional | 2018-11-09 | Completed | ||
| Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX[NCT03590275] | 343 participants (Actual) | Observational | 2017-10-02 | Completed | |||
| Phase II, Randomized, Controlled, Clinical Trial Exploring Efficacy and Safety of ERY001 (L-asparaginase Encapsulated in Red Blood Cells) in Association With Gemcitabine or FOLFOX4 in Second-line Therapy for Patients With Progressive Metastatic Pancreatic[NCT02195180] | Phase 2 | 141 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy[NCT01494506] | Phase 3 | 417 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Therapeutic Efficacy and Safety of Concurrent FOLFIRINOX Plus HIFU for Locally Advanced/Borderline Resectable Pancreatic Cancer: A Prospective Single-center, Single-arm, Investigator-initiated, Open-labeled, Exploratory Clinical Trial[NCT05262452] | 60 participants (Anticipated) | Interventional | 2021-08-09 | Recruiting | |||
| A Neoadjuvant Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer[NCT02243358] | Phase 2 | 24 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study[NCT02826486] | Phase 2 | 80 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Chemotherapy and Irreversible Electroporation (IRE) in the Treatment of Advanced Pancreatic Adenocarcinoma[NCT03484299] | Phase 1 | 20 participants (Anticipated) | Interventional | 2018-05-30 | Recruiting | ||
| A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma[NCT02562716] | Phase 2 | 147 participants (Actual) | Interventional | 2016-01-06 | Completed | ||
| Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan[NCT04984174] | 54,000 participants (Anticipated) | Observational | 2021-08-04 | Recruiting | |||
| Phase II Randomized Study of BAX2398 in Combination With 5-Fluorouracil and Calcium Levofolinate in Japanese Patients With Metastatic Pancreatic Cancer, Which Progressed or Recurred After Prior Gemcitabine-Based Therapy[NCT02697058] | Phase 2 | 84 participants (Actual) | Interventional | 2016-03-30 | Completed | ||
| Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen[NCT02923921] | Phase 3 | 567 participants (Actual) | Interventional | 2017-03-01 | Completed | ||
| Sintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer: a Single-arm, Exploratory, Phase II Trial[NCT06050317] | Phase 2 | 25 participants (Anticipated) | Interventional | 2023-08-18 | Recruiting | ||
| A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer[NCT01836432] | Phase 3 | 302 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to Company decision) | ||
| Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining After Curative Surgery of Pancreatic Cancer[NCT02486497] | 40 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line[NCT02352337] | Phase 2 | 276 participants (Actual) | Interventional | 2014-12-23 | Completed | ||
| UCSD Profile Related Evidence Determining Individualized Cancer Therapy (UCSD PREDICT)[NCT02478931] | 10,000 participants (Anticipated) | Observational | 2013-09-05 | Recruiting | |||
| Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study[NCT05277766] | Phase 1 | 45 participants (Anticipated) | Interventional | 2022-11-21 | Recruiting | ||
| An Open Single-center Phase II Clinical Study of Fruquintinib Combined With Chemotherapy in Patients With Liver Metastases From Pancreatic Cancer[NCT05168527] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-09-03 | Recruiting | ||
| Multicenter Non-interventional Study to Investigate Safety, Tolerability and Efficacy of Nab-paclitaxel in Clinical Routine Treatment of First-line Pancreatic Cancer Patients[NCT02555813] | 317 participants (Actual) | Observational | 2015-05-08 | Completed | |||
| European Study Group For Pancreatic Cancer - Trial 3[NCT00058201] | Phase 3 | 1,030 participants (Anticipated) | Interventional | 2001-07-31 | Completed | ||
| Chemotherapy-based Split Stereotactic Body Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: Study Protocol of a Prospective, Single-arm Phase II Trial[NCT04289792] | Phase 2 | 27 participants (Anticipated) | Interventional | 2020-05-09 | Recruiting | ||
| Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances[NCT01729481] | Phase 2 | 150 participants (Actual) | Interventional | 2012-07-31 | Active, not recruiting | ||
| Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy[NCT05298722] | 45 participants (Anticipated) | Interventional | 2022-12-12 | Recruiting | |||
| A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma[NCT02576665] | Phase 1 | 21 participants (Actual) | Interventional | 2016-07-31 | Terminated (stopped due to Sponsor decision) | ||
| Effectiveness and Safety Evaluation of Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis: A Prospective, Single-center, Single-arm, Phase II Clinical Study[NCT04677192] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-01-31 | Not yet recruiting | ||
| Resectable Pancreatic Adenocarcinoma Neo-Adjuvant FOLF(IRIN)OX-based CHEmotherapy - A Multicenter, Randomised Phase II Trial (PANACHE01-PRODIGE48 Study)[NCT02959879] | Phase 2 | 160 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | ||
| A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Immunotherapy of Durvalumab (MEDI4736), Or As Monotherapy [NCT02250326] | Phase 2 | 240 participants (Actual) | Interventional | 2015-01-07 | Completed | ||
| Non-interventional Observational Post-authorization Study to Assess Clinical and Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Routine Clinical Practice Treating Pancreatic Cancer (TRUST)[NCT02670746] | 44 participants (Actual) | Observational | 2015-10-01 | Terminated (stopped due to Due to slow recruitment study is being terminated.) | |||
| A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NS[NCT02027428] | Phase 3 | 427 participants (Actual) | Interventional | 2014-02-11 | Completed | ||
| Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility of Tumor Measurement in CT Versus MRI[NCT05511116] | 48 participants (Actual) | Observational | 2022-07-18 | Active, not recruiting | |||
| Trimodal Prehabilitation in Pancreatic Cancer Patients Candidate to Neoadjuvant Treatment: A Pilot Study[NCT05722223] | 10 participants (Anticipated) | Interventional | 2022-03-15 | Recruiting | |||
| The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. A Pan-European Prospective Multicenter Double Single Arm Cohort Study.[NCT06068023] | 400 participants (Anticipated) | Observational | 2023-07-01 | Recruiting | |||
| Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) Functional CTCs Using EPIDROP[NCT05346536] | 63 participants (Anticipated) | Interventional | 2022-06-16 | Recruiting | |||
| The Outcome After Operation for Pancreatic and Periampullary Tumors in Greeland Inuit.[NCT05595811] | 2,326 participants (Actual) | Observational | 1999-01-01 | Completed | |||
| Postoperative and Long-term Survival in Relation to Life-expectancy After Pancreatic Surgery in Elderly Patients[NCT04893408] | 1,556 participants (Actual) | Observational | 2010-01-01 | Completed | |||
| Phase II Study of Neoadjuvant Folfirinox Chemotherapy Followed by Pembrolizumab Followed by Surgery for Patients With Localized, Resectable Adenocarcinoma of the Pancreas[NCT05132504] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-08-31 | Recruiting | ||
| Phase II Study to Assess the Interest of a Sequential Treatment With Gemcitabine/Nab-paclitaxel (GEMBRAX) and Then FOLFIRINOX Followed by Stereotactic Magnetic Resonance-guided Adaptive Radiotherapy in Patients With Locally Advanced Pancreatic Cancer[NCT04570943] | Phase 2 | 103 participants (Anticipated) | Interventional | 2020-12-15 | Recruiting | ||
| Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Domomedecine Plateform[NCT04263948] | 42 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | |||
| S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma[NCT01959139] | Phase 1/Phase 2 | 126 participants (Actual) | Interventional | 2014-01-23 | Active, not recruiting | ||
| A Phase 1 Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients With Locally Advanced Pancreatic Cancer[NCT01068327] | Phase 1 | 46 participants (Actual) | Interventional | 2007-11-05 | Completed | ||
| Phase II Feasibility Study of FOLFIRINOX-Losartan Followed by Accelerated Short Course Radiation Therapy With Capecitabine for Locally Advanced Pancreatic Cancer[NCT01821729] | Phase 2 | 50 participants (Actual) | Interventional | 2013-07-31 | Active, not recruiting | ||
| The Safety and Efficacy of Re-irradiation With Stereotactic Body Radiotherapy for Relapsed Pancreatic Cancer[NCT02745847] | 30 participants (Anticipated) | Interventional | 2016-05-31 | Active, not recruiting | |||
| A Multi-Center Randomized Phase II Study of Induction Chemotherapy Followed by Gemcitabine or Capecitabine Based Chemoradiotherapy for Locally Advanced Non-Metastatic Pancreatic Cancer[NCT01032057] | Phase 2 | 114 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Phase II Study of Erlotinib (TarcevaTM) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer[NCT00313560] | Phase 2 | 48 participants (Actual) | Interventional | 2006-03-16 | Completed | ||
| Phase 2 Study of Neoadjuvant Modified FOLFIRINOX in Patients With Borderline Resectable Pancreas Adenocarcinoma[NCT02749136] | Phase 2 | 44 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression[NCT04194125] | Phase 2 | 25 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
| Changes in Tumor Vascularity Depicted by Contrast-Enhanced Endoscopic Ultrasonography as a Predictor of Treatment Efficacy in Patients With Locally Advanced and Metastatic Pancreatic Cancer (PEACE)[NCT03513198] | 200 participants (Anticipated) | Observational | 2018-05-01 | Not yet recruiting | |||
| Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis[NCT02869802] | 190 participants (Anticipated) | Observational | 2016-10-06 | Recruiting | |||
| Phase I/II Study of Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer[NCT00889187] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2009-12-31 | Terminated (stopped due to Excess toxicity was identified intraoperatively) | ||
| A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma[NCT04000737] | Phase 2 | 125 participants (Anticipated) | Interventional | 2020-01-10 | Recruiting | ||
| A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy[NCT04281511] | 238 participants (Actual) | Observational [Patient Registry] | 2019-04-03 | Completed | |||
| Multicenter Retrospective Analysis for Efficacy and Safety of Second-Line Nab-Paclitaxel Plus Gemcitabine After Progression on 1st-line FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma[NCT04133155] | 103 participants (Actual) | Observational | 2019-09-16 | Completed | |||
| "A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients CapTere"[NCT00290693] | Phase 2 | 45 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Pilot Study of Intensified Chemotherapy and Simultaneous Treatment With Heparin in Out-patients With Pancreatic Cancer.[NCT01945879] | Phase 1/Phase 2 | 19 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Phase I/II of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer[NCT00438256] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| A Phase III Second Line Trial of Patients With Gemcitabine Resistant Advanced Pancreatic Cancer (CONKO-003)[NCT00786058] | 0 participants | Expanded Access | Approved for marketing | ||||
| Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Advanced Pancreatic Cancer Patients Progressed After First-line Gemcitabine and S-1: A Randomized Controlled Study[NCT02558868] | Phase 2 | 80 participants (Actual) | Interventional | 2015-09-01 | Completed | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma[NCT01065870] | Phase 2/Phase 3 | 64 participants (Anticipated) | Interventional | 2009-12-31 | Recruiting | ||
| Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies[NCT02648711] | Phase 1 | 41 participants (Actual) | Interventional | 2015-10-31 | Terminated (stopped due to Company decision) | ||
| A Clinical Trial Using Electrochemotherapy With Bleomycin for the Treatment of Non-metastatic Unresectable Pancreatic Cancer[NCT03225781] | 1 participants (Actual) | Interventional | 2017-07-01 | Terminated (stopped due to Logistic reasons) | |||
| Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas[NCT01188785] | Phase 1 | 15 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-hour Infusion of 5- Fluorouracil Given Every Other Week in Adult Patients With Solid Tumors[NCT01206465] | Phase 1 | 29 participants (Actual) | Interventional | 2010-09-14 | Completed | ||
| Randomized Phase II Study of Weekly ABI-007 Plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer[NCT01964534] | Phase 2 | 114 participants (Actual) | Interventional | 2013-12-12 | Active, not recruiting | ||
| Multicenter Phase I/IIa Study of NASOX (Nal-IRI + S-1 + Oxaliplatin) as First-line Treatment for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma[NCT04662112] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2021-06-15 | Active, not recruiting | ||
| A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).[NCT05927857] | Phase 1/Phase 2 | 45 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
| Randomized Phase II Trial of Fluorouracil and Folinic Acid With or Without Liposomal Irinotecan (ONIVYDE) for Patients With Metastatic Biliary Tract Cancer Which Progressed Following Gemcitabine Plus Cisplatin[NCT03524508] | Phase 2 | 178 participants (Actual) | Interventional | 2018-09-04 | Completed | ||
| Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer[NCT04743479] | 5,000 participants (Anticipated) | Observational | 2020-12-01 | Recruiting | |||
| Effect of Perioperative Epidural Block and Dexamethasone on Outcome of Patients Undergoing Pancreatic Cancer Surgery: a 2×2 Factorial Randomized Controlled Trial[NCT04025840] | Phase 4 | 260 participants (Anticipated) | Interventional | 2019-09-11 | Recruiting | ||
| Clinical Efficacy of QingyiHuaji Optimized Formula Combined With Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer: a Prospective, Multicenter, Randomized Controlled Clinical Study[NCT05840341] | Phase 3 | 306 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| Shared Decision-making: Investigating the Potential of an Interactive, Web-Based, Information Tool for People With Advanced Pancreatic Cancer[NCT03632850] | 34 participants (Actual) | Observational | 2019-02-19 | Completed | |||
| Phase II Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer[NCT01523457] | Phase 2 | 75 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma[NCT01413022] | Phase 1 | 44 participants (Anticipated) | Interventional | 2012-04-30 | Completed | ||
| An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX[NCT03450018] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2019-01-10 | Recruiting | ||
| Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients With Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study[NCT01821612] | Early Phase 1 | 23 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| A Study of Preoperative FOLFIRINOX For Potentially Curable Pancreatic Cancer[NCT03167112] | Phase 2 | 20 participants (Anticipated) | Interventional | 2017-07-03 | Recruiting | ||
| Phase I Study of Stereotactic Body Radiation Therapy and 5-Fluorouracil, Oxaliplatin and Irinotecan (FOLFIRINOX) in the Neoadjuvant Therapy of Pancreatic Cancer[NCT01446458] | Phase 1 | 13 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Randomized Phase III Study of 5-Fluorouracil-based Regimen With or Without Oxaliplatin as 2nd Line Treatment of Advanced or Metastatic Pancreatic Cancer in Patients Who Have Previously Received Gemcitabine-based Chemotherapy[NCT01121848] | Phase 3 | 108 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy[NCT01658943] | Phase 2 | 137 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma[NCT01525069] | Phase 1 | 27 participants (Actual) | Interventional | 2012-04-03 | Terminated (stopped due to Equipment that was used in the study was discontinued) | ||
| Gemcitabine Plus Capecitabine Versus Gemcitabine Alone In Advanced Pancreatic Cancer. A Randomized Phase III Trial[NCT00030732] | Phase 3 | 319 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial[NCT00073905] | Phase 2 | 44 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma[NCT00003216] | Phase 3 | 518 participants (Anticipated) | Interventional | 1998-07-31 | Completed | ||
| Phase III Prospective Randomized Trial Comparing Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting in the Treatment of Gastrointestinal Cancer[NCT00971399] | Phase 3 | 172 participants (Anticipated) | Interventional | 2009-09-30 | Completed | ||
| Phase I Trial of Irinotecan, Cisplatin, and Fluorouracil in Patients With Advanced Solid Tumor Malignancies[NCT00005791] | Phase 1 | 0 participants | Interventional | 1999-10-31 | Completed | ||
| Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer[NCT00100815] | Phase 2 | 50 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| A Pilot Study to Test the Feasibility of the Combination of Gemcitabine and Anti-PD1 Monoclonal Antibody (CT-011) in the Treatment of Resected Pancreatic Cancer[NCT01313416] | Phase 2 | 2 participants (Actual) | Interventional | 2012-09-30 | Terminated (stopped due to Drug supply issues) | ||
| Phase I Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy[NCT01308034] | Phase 1 | 25 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab For Locally Advanced Pancreatic Cancer[NCT00114179] | Phase 2 | 82 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Randomized Phase II Trial of FOLFIRI3 vs. FOLFOX in Gemcitabine-refractory Advanced Pancreatic Cancer[NCT00786006] | Phase 2 | 61 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Phase III Multicenter Randomized Clinical Trial Comparing Gemcitabine Alone Or In Combination With Capecitabine For The Treatment Of Patients With Advanced Pancreatic Cancer[NCT00032175] | Phase 3 | 508 participants (Anticipated) | Interventional | 2002-04-30 | Completed | ||
| Open-label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution Versus Best Supportive Nutritional Care in Patients With Pancreatic Cancer Receiving 2nd Line Chemotherapy[NCT01362582] | Phase 3 | 32 participants (Actual) | Interventional | 2010-03-31 | Terminated | ||
| A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer[NCT00320749] | Phase 1 | 21 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| A Phase II Study of Interferon-Based Adjuvant Chemoradiation in Patients With Resected Pancreatic Adenocarcinoma[NCT00059826] | Phase 2 | 89 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Phase 2 Study of Temozolomide Plus Capecitabine in Patients With Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors[NCT03079440] | Phase 2 | 31 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
| UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors[NCT04339036] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-10-07 | Recruiting | ||
| Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression[NCT00303758] | Phase 3 | 202 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Pre- and Postoperative Incidence and Prognostic Implication of Positive Peritoneal Lavage and Circulating Tumor DNA in Patients With Pancreatic Cancer[NCT05400681] | 200 participants (Anticipated) | Observational [Patient Registry] | 2020-08-01 | Recruiting | |||
| Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients[NCT00112658] | Phase 2/Phase 3 | 342 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Evaluation of the Effect of Ocoxin-Viusid® Nutritional Supplement in the Life Quality in Patients Diagnosed With Advanced Pancreatic Adenocarcinoma. Phase II[NCT03717298] | Phase 2 | 30 participants (Actual) | Interventional | 2018-10-30 | Completed | ||
| 1911GCCC:Two Parallel, Single-arm, Open Label, Phase 2 Trials of Galeterone Alone or Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy[NCT04098081] | Phase 2 | 58 participants (Anticipated) | Interventional | 2019-12-12 | Recruiting | ||
| Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet Obstruction[NCT05986890] | 16 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | |||
| Phase I Study of Low Kilovoltage Intraoperative Radiation for Patients With Resectable Pancreatic Adenocarcinoma[NCT02599662] | Phase 1 | 12 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Pharmacotyping of Patient-derived Pancreatic Cancer Organoids From Endoscopic Ultrasound-guided Biopsy as a Tool for Predicting Oncological Response[NCT05196334] | 88 participants (Actual) | Observational | 2021-07-01 | Active, not recruiting | |||
| A Phase III, Open Label, Multicentre Randomised Clinical Study Comparing Acelarin (NUC-1031) With Gemcitabine in Patients With Metastatic Pancreatic Carcinoma[NCT03610100] | Phase 2/Phase 3 | 328 participants (Anticipated) | Interventional | 2015-12-31 | Suspended (stopped due to Suspended to recruitment following TSC review on efficacy and toxicities) | ||
| Phase II Trial of Infusional 5 FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND IRINOTECAN (FOLFIRINOX) in First Line Treatment of Advanced Biliary Tract Cancers[NCT03291899] | Phase 2 | 32 participants (Anticipated) | Interventional | 2017-01-03 | Recruiting | ||
| Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer: The SMART Study[NCT04276857] | 27 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)[NCT04787991] | Phase 1 | 45 participants (Anticipated) | Interventional | 2021-08-09 | Active, not recruiting | ||
| A Phase II Trial of Flouro-Gem as a First Line Treatment of Metastatic Adenocarcinoma of the Pancreas (GEFLUPAN)[NCT04769414] | Phase 2 | 48 participants (Actual) | Interventional | 2021-02-20 | Completed | ||
| A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer[NCT01488552] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| An Open-label, Single-centre, Single-arm Phase II Study of Capecitabine Combined With Oxaliplatin and Irinotecan (Xeloxiri) as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma[NCT01558869] | Phase 2 | 37 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Randomized Phase II Trial Evaluating the Efficacy of a Sequential Treatment Gemcitabine Plus Nab-paclitaxel (Gembrax) Followed by Folfirinox Versus Folfirinox Alone in Patients Treated in First Metastatic Line Pancreatic Cancer[NCT05065801] | Phase 2 | 162 participants (Anticipated) | Interventional | 2022-01-30 | Recruiting | ||
| A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma[NCT03943667] | Phase 3 | 211 participants (Actual) | Interventional | 2019-05-23 | Completed | ||
| Phase I/II Study of Oral MEK Inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination With Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi's Sarcoma (KS).[NCT01752569] | Phase 1/Phase 2 | 19 participants (Actual) | Interventional | 2012-06-15 | Terminated (stopped due to Poor recruitment) | ||
| PAXG Out in the Country[NCT04480268] | Phase 4 | 175 participants (Anticipated) | Interventional | 2020-07-08 | Recruiting | ||
| Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors[NCT00416767] | Phase 2 | 20 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Randomized Phase II Trial Evaluating [Radiotherapy-Docetaxel-5 Fluorouracil] Association Versus [Radiotherapy-Docetaxel-Cisplatin] Association in Non Resecables First Line of Chemotherapy in Metastatics Pancreas Cancers Patients[NCT00112697] | Phase 2 | 71 participants (Actual) | Interventional | 2003-10-06 | Completed | ||
| A Randomized Phase II Trial of Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG Regimen for Stage I-III Pancreatic Ductal Adenocarcinoma (PDAC)[NCT04793932] | Phase 2 | 261 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| Folfiri as Second-Line Chemotherapy for Advanced Pancreatic Cancer. A GISCAD Phase II Study[NCT01543412] | Phase 2 | 50 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase II Clinical Trial of the Safety and Efficacy of Fruquintinib in Advanced Pancreatic Cancer Patients Who Failed Second-line Gemcitabine or 5-FU Based Chemotherapy[NCT05257122] | Phase 2 | 32 participants (Anticipated) | Interventional | 2022-02-28 | Not yet recruiting | ||
| Randomized Phase III Trial With Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine in Patients With Advanced Pancreatic Cancer[NCT00440167] | Phase 3 | 280 participants (Anticipated) | Interventional | 2006-06-30 | Active, not recruiting | ||
| A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer[NCT01072981] | Phase 3 | 722 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Phase II Study of Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer[NCT00569387] | Phase 2 | 73 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Open Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors[NCT03863145] | Early Phase 1 | 90 participants (Anticipated) | Interventional | 2022-06-14 | Recruiting | ||
| A Randomized, Phase II/III, Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer[NCT00051467] | Phase 3 | 0 participants | Interventional | Completed | |||
| Randomized Controlled Trial Comparing Adjuvant Chemotherapy Vs. no Chemotherapy for Patients With Carcinoma of Gallbladder Undergoing Curative Resection.[NCT02778308] | 100 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer[NCT00632333] | Phase 1 | 9 participants (Anticipated) | Interventional | 2008-02-29 | Recruiting | ||
| A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516] | 8 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| Clinical Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin in Patients With Unresectable Locally Advanced Pancreatic Cancer[NCT03585062] | Phase 2 | 40 participants (Actual) | Interventional | 2017-11-20 | Terminated (stopped due to The paclitaxel-albumin halt production.) | ||
| A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763] | 13 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors[NCT04790708] | 250 participants (Anticipated) | Interventional | 2018-07-02 | Recruiting | |||
| OGF & Gemcitabine: Novel Treatment for Pancreatic Cancer Phase I, A Safety and Toxicity Study[NCT00783172] | Phase 1 | 4 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Problems with IRB) | ||
| Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)[NCT05913674] | Phase 2 | 25 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | ||
| Mono-Center Phase ǀ Study on Dose Escalation of Stereotactic Body Radiotherapy (SBRT) Treating Pancreatic Cancer Patients With CyberKnife[NCT02716207] | 16 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| 3D-printing Template-assisted CT-guided I125 Seed Implantation and Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer:A Prospective Multicenter Cohort Study[NCT03964064] | 100 participants (Anticipated) | Interventional | 2019-06-11 | Recruiting | |||
| A Prospective Randomized Trial of Regional Versus Systemic Continuous Gemcitabine Chemotherapy in the Treatment of Unresectable Pancreatic Cancer[NCT01665625] | 90 participants (Anticipated) | Interventional | 2012-08-31 | Not yet recruiting | |||
| Phase II Clinical Trial to Assess the Efficacy of ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab in Patients Who Have Failed Prior Treatment With Radiation and Temozolomide[NCT05366062] | Phase 2 | 28 participants (Anticipated) | Interventional | 2022-07-01 | Not yet recruiting | ||
| Randomized Controlled Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy[NCT00639314] | 130 participants (Anticipated) | Interventional | 2005-10-31 | Completed | |||
| Prospective, Randomized, and Controlled Trial That Lost Stent Versus External Stent of Pancreaticojejunostomy After Pancreaticoduodenectomy[NCT00628186] | 100 participants (Actual) | Interventional | 2005-04-30 | Completed | |||
| A Prospective Randomized Controlled Trial Comparing Isolated Roux-en-Y Reconstruction With Billroth-II-type Reconstruction After Pancreaticoduodenectomy[NCT00915863] | 150 participants (Anticipated) | Interventional | 2009-06-30 | Recruiting | |||
| Ph 2 Trial of G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan & Oxaliplatin), Followed by G-FLIP-DM (G-FLIP + Low Doses Docetaxel & MitomycinC), When Used in Combination With Vitamin C, in Patients With Advanced Pancreatic Cancer[NCT01905150] | Phase 2 | 34 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma[NCT00003018] | Phase 2 | 54 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| Concurrent EUS-guided Intra-tumour Injection of OncoSil (32P) With Chemotherapy in Locally Advanced Pancreatic Carcinoma.[NCT05131776] | Phase 2/Phase 3 | 20 participants (Anticipated) | Interventional | 2021-11-01 | Recruiting | ||
| Protocole de Phase II: Etude de Faisabilite de L'Oxaliplatine en Association Chimio-Radiotherapie Concomitante Dans le Traitement Des Cancers du Pancreas Localement Avances Non Resecables[NCT00275119] | Phase 2 | 0 participants | Interventional | 2003-11-30 | Active, not recruiting | ||
| Phase II Study of Adjuvant Gemcitabine Started One Week After Laparoscopic[NCT01045941] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to The study was never initiated) | |||
| A Phase II Trial of Postoperative Proton Radiotherapy With Concomitant Chemotherapy for Patients With Resected Pancreatic Adenocarcinoma[NCT01553019] | Phase 2 | 2 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Non Resectable But Non Metastatic Adenocarcinoma of the Exocrine Pancreas Non Resecables. Randomised Phase III: Initial Radiochimiotherapy (5-FU, Cisplatine, 60 GY Radiotherapy) Followed by Gemcitabine Versus Gemcitabine Alone[NCT00416507] | Phase 3 | 190 participants (Anticipated) | Interventional | 2000-03-31 | Completed | ||
| A Phase II Trial of Gemcitabine, Herceptin, and Radiation for Regionally Confined Adenocarcinoma of the Pancreas[NCT00005926] | Phase 2 | 50 participants | Interventional | 2000-06-30 | Completed | ||
| 09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy[NCT02159248] | Phase 1 | 0 participants (Actual) | Interventional | 2014-03-31 | Withdrawn (stopped due to The study closed prior to enrolling any participants.) | ||
| A Multi-center, II Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Gemcitabine Plus Capecitabine Standard Adjuvant Therapy for Stage II/III Pancreatic Cancer[NCT03959150] | Phase 2/Phase 3 | 231 participants (Anticipated) | Interventional | 2020-01-05 | Recruiting | ||
| Stereotactic Body Radiation Therapy With Sequential S-1 for Patients With Locally Advanced Pancreatic Cancer and Poor Medical Conditions --a Phase II Clinical Trial[NCT02704143] | 63 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
| Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer (With Local Progression or Metastasis)[NCT00498225] | Phase 3 | 834 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Phase I Study of Soluble LAG-3 (IMP321) and Gemcitabine in Patients With Advanced Pancreas Cancer[NCT00732082] | Phase 1 | 18 participants (Actual) | Interventional | 2009-02-28 | Terminated (stopped due to Company manufacturing study drug was unable to continue production.) | ||
| Gimatecan (ST1481) as Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer: an Open-label, Randomized, Controlled Phase II Study[NCT04571489] | Phase 2 | 60 participants (Anticipated) | Interventional | 2020-12-01 | Not yet recruiting | ||
| Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.[NCT03562897] | Phase 2 | 40 participants (Actual) | Interventional | 2018-10-25 | Completed | ||
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499] | Phase 2 | 53 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| A Phase II Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, Panitumumab and External Beam Radiation, in Patients With Localized, Non-Metastatic Pancreatic Adenocarcinoma[NCT01130701] | Phase 2 | 0 participants (Actual) | Interventional | 2010-05-31 | Withdrawn (stopped due to Study never went beyond FDA application for an IND #. FDAA required institutional DSMC which this institution then lacked.) | ||
| A Pilot Study of Immune Checkpoint Inhibition (Durvalumab With or Without Tremelimumab) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer[NCT02311361] | Phase 1/Phase 2 | 65 participants (Actual) | Interventional | 2015-03-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The time from the start of treatment until documentation of any clinical or radiological disease progression or death, whichever occurred first. Progression is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02704156)
Timeframe: 3 years
| Intervention | months (Median) |
|---|---|
| SBRT Plus Gemcitabine | 5.4 |
| SBRT Plus Pembrolizumab and Trametinib | 8.2 |
The time from the start of treatment to death (NCT02704156)
Timeframe: 3 years
| Intervention | months (Median) |
|---|---|
| SBRT Plus Gemcitabine | 12.8 |
| SBRT Plus Pembrolizumab and Trametinib | 14.9 |
The number of patients alive at 1 year and 2 years. (NCT02704156)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 1-year OS rate | 2-year OS rate | |
| SBRT Plus Gemcitabine | 48 | 0 |
| SBRT Plus Pembrolizumab and Trametinib | 53 | 2 |
The proportion of patients without disease progressions at 1 year and 2 years. (NCT02704156)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 1-year PFS rate | 2-year PFS rate | |
| SBRT Plus Gemcitabine | 7 | 0 |
| SBRT Plus Pembrolizumab and Trametinib | 18 | 0 |
The analysis of quality of life is based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30). All scales and subscales range from 0 to 100. Regarding physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning and global health, higher scores may indicate better outcomes. In the case of fatigue, nausea and vomitting, pain, dyspnea, insomina, appetite loss, constipation, diarrhea and financial difficulties, lower scores may indicate better outcomes. Scales of all items are independent and not combined to compute a total score. (NCT02704156)
Timeframe: 3 years
| Intervention | units on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical functioning | Role functioning | Emotional functioning | Cognitive functioning | Social functioning | Global health | Fatigue | Nausea and vomitting | Pain | Dyspnea | Insomina | Appetite loss | Constipation | Diarrhea | Financial difficulties | |
| SBRT Plus Gemcitabine | 86.2 | 81.8 | 73.9 | 84.7 | 85.5 | 83.6 | 29.6 | 29.4 | 23.9 | 16.1 | 14.9 | 31.0 | 14.5 | 15.7 | 16.8 |
| SBRT Plus Pembrolizumab and Trametinib | 83.7 | 84.5 | 72.1 | 83.3 | 84.1 | 83.2 | 26.6 | 28.8 | 26.5 | 13.7 | 17.6 | 33.3 | 16.5 | 15.7 | 17.2 |
Treatment-related adverse effects are determined by National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0. (NCT02704156)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 3 pyrexia | Grade 3 vomitting | Grade 3 and 4 increased ALT or AST | Grade 3 stomatitis | Grade 3 rash | Grade 3 and 4 neutropenia | Grade 3 thrombocytopenia | Grade 3 increased blood bilirubin | Grade 3 hypokalemia | Grade 3 hyponatremia | Grade 3 pneumonia | Grade 3 hypertension | |
| SBRT Plus Gemcitabine | 0 | 2 | 6 | 0 | 0 | 9 | 4 | 0 | 0 | 0 | 0 | 0 |
| SBRT Plus Pembrolizumab and Trametinib | 2 | 1 | 10 | 1 | 2 | 1 | 1 | 4 | 1 | 3 | 1 | 2 |
Defined as time from randomization to the first documentation of event where events considered are 1) disease progression, per RECIST, prior to surgery, 2) surgery with R2 resection, 3) recurrent disease following surgery, or 4) death due to any cause. Will be estimated using the method of Kaplan-Meier in each arm and compared between treatment groups using the log-rank test. The correlation between pathologic complete response (pCR) status and event-free survival time will be assessed by Cox model with landmark approach. (NCT02839343)
Timeframe: 4 years and 7 months
| Intervention | Months (Median) |
|---|---|
| Arm 1 (mFOLFIRINOX + Surgery + FOLFOX) | 15.0 |
| Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx) | 10.2 |
Overall adverse event rates will be compared between treatment groups using Chi-square test (or Fisher's exact test if the data in contingency table is sparse). (NCT02839343)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1 (mFOLFIRINOX + Surgery + FOLFOX) | 66 |
| Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx) | 55 |
Defined as the percentage of patients who are alive at 18 months after randomization divided by the total number of evaluable patients in each arm. An evaluable patient is defined as any patient who signed informed consent, deemed eligible by central review and received any protocol-defined treatment. 95% confidence interval will be estimated based on standard method. Chi-squared test (or Fisher's exact test if the data in contingency table is sparse) will be used to compare 18 month OS rates among treatment arms. OS within each arm will be summarized by Kaplan-Meier method. Median, 1-year and 2-year rates will be estimated based on Kaplan-Meier curves. (NCT02839343)
Timeframe: 18 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1 (mFOLFIRINOX + Surgery + FOLFOX) | 64.6 |
| Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx) | 47.3 |
Defined as the percentage of patients in whom a pCR was confirmed by histopathologic review of the surgical specimen. Chi-square test (or Fisher's exact test if the data in contingency table is sparse) will be used to compare pCR resection rate between two treatment arms. Sensitivity analysis will be conducted among patients in cohort 1) and cohort 2). The association between pCR rate and OS/progression free survival (PFS) will be assessed by log-rank test and Cox model. (NCT02839343)
Timeframe: 24 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1 (mFOLFIRINOX + Surgery + FOLFOX) | 0 |
| Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx) | 11 |
Defined as the percentage of patients in whom an achieved R0 resection was achieved during surgery. (NCT02839343)
Timeframe: 24 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1 (mFOLFIRINOX + Surgery + FOLFOX) | 49 |
| Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx) | 35 |
To estimate overall survival as a function of time from study enrollment. (NCT01661088)
Timeframe: up to 2 years
| Intervention | months (Median) |
|---|---|
| Study Treatment | 24.4 |
To estimate progression-free survival as a function of time from study enrollment. Progression is defined as at least a 20% increase in the LD (longest diameter) of the primary lesion or the appearance of one or more new lesions (NCT01661088)
Timeframe: up to 2 years
| Intervention | months (Median) |
|---|---|
| Study Treatment | 13.1 |
To determine the frequency of achieving an R0 resection using a neoadjuvant regimen of FOLFIRINOX followed by IMRT concurrent with fixed dose rate (FDR)-gemcitabine in patients with borderline resectable pancreatic cancer. R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed. (NCT01661088)
Timeframe: 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Study Treatment | 52 |
Defined as the rate of Complete Response (CR) plus Partial Response (PR): Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least 30% decrease in the sum of diameters of target lesions; (NCT03504423)
Timeframe: 38 months
| Intervention | Participants (Count of Participants) |
|---|---|
| CPI-613, mFolfirinox | 104 |
| Folfirinox | 90 |
Defined as the duration from the date of randomization to the date of death from any cause (NCT03504423)
Timeframe: 38 months
| Intervention | months (Median) |
|---|---|
| CPI-613, mFolfirinox | 11.10 |
| Folfirinox | 11.73 |
"Defined as the duration from the date of randomization to the date of progressive disease or death from any cause.~Progressive Disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression." (NCT03504423)
Timeframe: 38 months
| Intervention | months (Median) |
|---|---|
| CPI-613, mFolfirinox | 7.82 |
| Folfirinox | 7.98 |
The objective response rate was a secondary efficacy endpoint of the study and was defined by the percentage of patients in the study population with a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator. Best overall response was defined per RECIST (version 1.1) recorded from randomization until progression or end of study. RECIST (v 1.1) criteria does not require confirmation of response, but an additional, more stringent analysis was also conducted, with designation of CR (or PR) requiring confirmation of response at least 4 weeks following the initial assessment of CR (or PR). Stable disease (SD) required an assessment of SD at least 6 weeks after starting treatment. Subjects with insufficient data for response classification were classified as Not Evaluable for best overall response, and as a non-responder for objective response, in the ITT population. Treatment groups are as indicated for the primary outcome of OS. (NCT01494506)
Timeframe: Assessment every 6 weeks after initial response; Day 1 to data cut off of 14 Feb 2014; maximum time on study 25 months.
| Intervention | percentage with confirmed response (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 3.31 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 0.67 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 7.69 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 0.84 |
"Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 4.9 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 4.2 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 6.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 4.2 |
"Composite measure based on patient-reported pain (per VAS), patient-reported pain medication, KPS, and weight. Clinical benefit is indicated by either:~(a) improvement in pain (less pain intensity with stable or decreased pain medication; or less pain medication with stable or decreased pain intensity) with stable or improved KPS; or (b) improvement in KPS with stable or improved pain.~With stable for KPS and pain, clinical benefit may be indicated with an observation of positive weight change.~Clinical benefit response (CBR) was classified weekly and a patient was considered a clinical benefit responder if clinical benefit was observed and maintained over a 4 week period." (NCT01494506)
Timeframe: Randomization to treatment discontinuation.The maximum time in follow up was 25 months
| Intervention | percentage of participants with CBR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 14 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 13 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 14 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 |
Tumor marker response (TMR) was evaluated by the change in CA19-9 serum levels. Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of participants with TMR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 23.6 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 28.9 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 8.6 |
"Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: Randomization until disease progression or death from any cause; Until the data cut off of 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 2.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.6 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 3.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.5 |
Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death. (NCT01494506)
Timeframe: Randomization to treatment discontinuation (any cause). The maximum time in follow up was 25 months
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 1.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2.3 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.4 |
This patient recorded outcome consists of 15 subscales in 3 independent domains: global health-related quality of life (HRQoL), functional scales (cognitive, emotional, physical, role and social functioning), and symptom scales (appetite loss, constipation, diarrhea, dyspnea, fatigue, insomnia, nausea and vomiting, and pain). For each subscale, patients were classified as improved, worsened or stable. Improvement is indicated by achievement of subscale score at least 10% improved from baseline and maintained for at least 6 weeks. Worsened is indicated by subscale score at least 10% worse than baseline. Stable is indicated by neither improvement nor worsened. Achievement of improvement prior to worsening was classified as improvement. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of patients in category (Number) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status: Improved | Global Health Status: Stable | Global Health Status: Worsened | Physical Functioning: Improved | Physical Functioning: Stable | Physical Functioning: Worsened | Role Functioning: Improved | Role Functioning: Stable | Role Functioning: Worsened | Emotional Functioning:Improved | Emotional Functioning:Stable | Emotional Functioning:Worsened | Cognitive Functioning:Improved | Cognitive Functioning:Stable | Cognitive Functioning:Worsened | Social Functioning:Improved | Social Functioning:Stable | Social Functioning:Worsened | Fatigue:Improved | Fatigue:Stable | Fatigue:Worsened | Nausea and Vomiting:Improved | Nausea and Vomiting:Stable | Nausea and Vomiting:Worsened | Pain:Improved | Pain:Stable | Pain:Worsened | Dyspnoea:Improved | Dyspnoea:Stable | Dyspnoea:Worsoned | Insomnia:Improved | Insomnia:Stable | Insomnia:Worsened | Appetite Loss:Improved | Appetite Loss:Stable | Appetite Loss:Worsened | Constipation:Improved | Constipation:Stable | Constipation:Worsened | Diarrhoea:Improved | Diarrhoea: Stable | Diarrhoea: Worsened | Financial Difficulties: Improved | Financial Difficulties: Stable | Financial Difficulties: Worsened | |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11 | 41 | 48 | 11 | 37 | 52 | 10 | 39 | 52 | 8 | 59 | 33 | 6 | 42 | 52 | 11 | 43 | 46 | 11 | 30 | 59 | 6 | 42 | 52 | 10 | 37 | 53 | 6 | 69 | 24 | 4 | 49 | 47 | 6 | 42 | 52 | 4 | 63 | 34 | 4 | 58 | 39 | 1 | 67 | 31 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 | 44 | 44 | 11 | 40 | 49 | 11 | 37 | 53 | 9 | 58 | 33 | 7 | 44 | 49 | 11 | 47 | 42 | 12 | 33 | 54 | 4 | 46 | 51 | 11 | 40 | 49 | 5 | 68 | 25 | 5 | 49 | 46 | 5 | 46 | 49 | 4 | 67 | 30 | 4 | 58 | 39 | 0 | 74 | 26 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 17 | 38 | 45 | 10 | 41 | 49 | 15 | 32 | 52 | 20 | 46 | 34 | 11 | 48 | 41 | 13 | 34 | 54 | 14 | 20 | 66 | 13 | 32 | 55 | 27 | 34 | 39 | 7 | 51 | 42 | 18 | 34 | 48 | 11 | 45 | 44 | 13 | 56 | 31 | 6 | 39 | 55 | 8 | 51 | 41 |
| MM-398 Arm A (Mono Therapy Comparison) | 10 | 31 | 57 | 10 | 29 | 61 | 6 | 29 | 66 | 10 | 32 | 56 | 12 | 32 | 54 | 11 | 26 | 62 | 13 | 18 | 69 | 5 | 37 | 58 | 20 | 30 | 50 | 10 | 47 | 44 | 9 | 43 | 48 | 9 | 38 | 53 | 13 | 47 | 39 | 4 | 35 | 59 | 6 | 51 | 42 |
Plasma concentration-time data for MM-398 will be analyzed using population pharmacokinetic methods. (NCT01494506)
Timeframe: 6 weeks after first study drug administration
| Intervention | Total irinotecan = ug/L; SN38= ug/L (Geometric Mean) | |||
|---|---|---|---|---|
| Total Irinotecan-Cavg | Total Irinotecan-Cmax | Total SN38-Cavg | Total SN38-Cmax | |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2120.00 | 28460.00 | 0.68 | 2.58 |
| MM-398 Arm A (Mono Therapy Comparison) | 2550.00 | 40550.00 | 0.82 | 3.93 |
Disease-free survival (DFS) is calculated for patients who undergo surgical resection (R0/R1). DFS will be measured from the date of surgical resection to date of first documentation of recurrence (loco-regional or distant) or death due to any cause. Patients last known to be alive and free of disease will be censored at date of last contact. (NCT02562716)
Timeframe: Up to 4 years
| Intervention | Months (Median) |
|---|---|
| mFOLFIRINOX ->Surg ->mFOLFIRINOX | 10.9 |
| Gem/Nab-P ->Surg ->Gem/Nab-P | 14.2 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT02562716)
Timeframe: Up to 6 months post registration (and within 2 to 4 weeks after the last dose of Cycle 3 preoperative chemotherapy.).
| Intervention | Participants (Count of Participants) |
|---|---|
| mFOLFIRINOX ->Surg ->mFOLFIRINOX | 5 |
| Gem/Nab-P ->Surg ->Gem/Nab-P | 10 |
R0 resection classification is defined as macroscopically complete tumor removal with negative microscopic surgical margins (bile duct, pancreatic parenchyma, and superior mesenteric artery margins). (NCT02562716)
Timeframe: Up to 8 months post registration (and within 4 to 8 weeks after the last dose of Cycle 3 preoperative chemotherapy).
| Intervention | Participants (Count of Participants) |
|---|---|
| mFOLFIRINOX ->Surg ->mFOLFIRINOX | 34 |
| Gem/Nab-P ->Surg ->Gem/Nab-P | 28 |
(NCT02562716)
Timeframe: Up to 8 months post registration (and within 4 to 8 weeks after the last dose of Cycle 3 preoperative chemotherapy).
| Intervention | Participants (Count of Participants) |
|---|---|
| mFOLFIRINOX ->Surg ->mFOLFIRINOX | 40 |
| Gem/Nab-P ->Surg ->Gem/Nab-P | 33 |
OS is the length of time between protocol registration and patient death (NCT02562716)
Timeframe: Up to 4 years for the estimates of median overall survival. Up to 2 years for Statistical Analysis 1 and 2, comparing the observed 2-year overall survival (OS) to the null hypothesis of 40%, in each arm.
| Intervention | Months (Median) |
|---|---|
| mFOLFIRINOX ->Surg ->mFOLFIRINOX | 23.2 |
| Gem/Nab-P ->Surg ->Gem/Nab-P | 23.6 |
Only adverse events that are possibly, probably or definitely related to preoperative and postoperative chemotherapy are reported. (NCT02562716)
Timeframe: Duration of treatment and follow up until death or 4 years post registration.
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal infection | Acute kidney injury | Alanine aminotransferase increased | Allergic reaction | Anemia | Anorexia | Aspartate aminotransferase increased | Biliary tract infection | Blood bilirubin increased | Colonic perforation | Constipation | Dehydration | Diarrhea | Dysesthesia | Dyspnea | Fall | Fatigue | Febrile neutropenia | Hepatobiliary disorders - Other, specify | Hyperglycemia | Hypertension | Hypoalbuminemia | Hypoglycemia | Hypokalemia | Hypomagnesemia | Hyponatremia | Infections and infestations - Other, specify | Infusion related reaction | Insomnia | Leukocytosis | Lung infection | Lymphocyte count decreased | Mucositis oral | Myocardial infarction | Nausea | Neutrophil count decreased | Non-cardiac chest pain | Pancreatitis | Papulopustular rash | Peripheral motor neuropathy | Peripheral sensory neuropathy | Platelet count decreased | Pneumonitis | Rectal hemorrhage | Respiratory failure | Sepsis | Skin infection | Thromboembolic event | Vomiting | Weight loss | White blood cell decreased | |
| Gem/Nab-P->Surg->Gem/Nab-P | 0 | 1 | 2 | 0 | 4 | 0 | 1 | 1 | 3 | 1 | 1 | 0 | 3 | 0 | 1 | 0 | 3 | 2 | 0 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 0 | 1 | 0 | 2 | 2 | 1 | 0 | 1 | 17 | 1 | 0 | 1 | 0 | 3 | 2 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 6 |
| mFOLFIRINOX->Surg->mFOLFIRINOX | 1 | 0 | 3 | 1 | 4 | 2 | 2 | 0 | 1 | 0 | 0 | 1 | 8 | 1 | 0 | 1 | 4 | 0 | 1 | 2 | 0 | 0 | 0 | 3 | 0 | 2 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 3 | 11 | 0 | 1 | 0 | 1 | 5 | 3 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 1 |
DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. (NCT02923921)
Timeframe: Randomization to Progressive Disease (PD) or Date of Death (Up To 30 Months)
| Intervention | Months (Median) |
|---|---|
| Pegilodecakin + FOLFOX | 4.99 |
| FOLFOX | 5.17 |
Overall survival is defined as the time from date of randomization to the date of death (due to any cause). For participants whose last known status is alive at the data cutoff date for the analysis, time will be censored as the last contact date prior to the data cutoff date. (NCT02923921)
Timeframe: Randomization to date of death from any cause (Up To 30 Months)
| Intervention | Months (Median) |
|---|---|
| Pegilodecakin + FOLFOX | 5.78 |
| FOLFOX | 6.28 |
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Participants who discontinued study treatment (for reasons other than progression) before entering concurrent phase were considered to have non-evaluable response. (NCT02923921)
Timeframe: Randomization to PD (Up To 30 Months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Pegilodecakin + FOLFOX | 4.6 |
| FOLFOX | 5.6 |
The 12-month survival rate is defined as the percentage of participants who have not died 12 months after the date of randomization. (NCT02923921)
Timeframe: From randomization to until the date of first documented date of death from any cause within 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pegilodecakin + FOLFOX | 14.7 |
| FOLFOX | 19.1 |
Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. (NCT02923921)
Timeframe: Randomization to Objective Progressive Disease or Start of New Anti-Cancer Therapy (Up To 30 Months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Pegilodecakin + FOLFOX | 42.8 |
| FOLFOX | 36.6 |
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant did not have a complete baseline disease assessment, then PFS was censored at the enrollment date, regardless whether or not objectively determined PD or death had been observed for the participant. (NCT02923921)
Timeframe: Randomization to Progressive Disease (PD) or Date of Death (Up To 30 Months)
| Intervention | Months (Median) |
|---|---|
| Pegilodecakin + FOLFOX | 2.14 |
| FOLFOX | 2.10 |
Dose intensity was the cumulative dose divided by the dosing period in weeks. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | mg/ week (Mean) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 716.66 |
Dose intensity was the cumulative dose divided by the dosing period in weeks). (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | mg/week (Mean) |
|---|---|
| Nab-Paclitaxel + Durvalumab Combination Arm | 279.96 |
Dose intensity was the cumulative dose divided by the dosing period in weeks. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | mg/m^2/week (Mean) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 54.73 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 57.18 |
| Nab-Paclitaxel Alone | 58.61 |
Overall survival was defined as the time in months between randomization/treatment assignment and death from any cause. Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off, whichever was earlier. Participants who were lost to follow-up prior to the end of the study or who were withdrawn from the study were censored at the time of last contact. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; participants were followed for overall survival up to 30 months
| Intervention | Months (Median) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 8.1 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 10.1 |
| Nab-Paclitaxel Alone | 17.0 |
Progression-free survival was defined as the time in months from the date of randomization/assignment to the date of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria documented by computed tomography (CT) scan, not including symptomatic deterioration, or death (any cause) on or prior to the clinical cut-off date, which ever occurred earlier. Participants who did not have disease progression and had not died, regardless of whether they were discontinued from treatment, were censored at the date of last tumor assessment, on or prior to the clinical cut-off date that the participant was progression free. Progressive Disease was defined as at least a 20% increase in the sum of diameters of target lesions from nadir. (NCT02250326)
Timeframe: From date of first dose of IP to DP; up to data cut-off date of 30 August (Aug) 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 December (Dec) 2017 for Durva + nab-paclitaxel; participants were followed for PFS for up to 18 months
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 3.2 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 4.5 |
| Nab-Paclitaxel Alone | 4.2 |
Overall Response was defined as percentage of participants who achieved a radiologic confirmed complete response or partial response according to RECIST V 1.1 criteria and compared with baseline among all tumor assessments, where baseline was the last CT obtained prior to or on Day 1 of treatment. Per RECIST V 1.1 criteria, a CR is defined as a disappearance of all target lesions; a PR is defined as having at least a 30% decrease in the sum of diameters of target lesions from baseline. Responses were evaluated every 6 weeks. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | percentage of participants (Number) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 13.6 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 27.8 |
| Nab-Paclitaxel Alone | 16.3 |
"Disease control rate was defined as the percentage of participants who had a CR, PR or SD during the course of the study, according to RECIST version 1.1 criteria, as evaluated by the investigator. RECIST Version 1.1 criteria is defined as follows:~Complete Response is the disappearance of all target lesions;~Partial Response is at least a 30% decrease in the sum of diameters of target lesions from baseline;~Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease. Responses were evaluated every 6 weeks." (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | Percentage of Participants (Number) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 65.4 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 70.9 |
| Nab-Paclitaxel Alone | 67.5 |
The discontinuation rate was defined as the percentage of participants who had study drug discontinued and was assessed throughout the conduct of the study. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | percentage of participants (Number) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 100.0 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 80.8 |
| Nab-Paclitaxel Alone | 96.2 |
TEAEs were defined as any adverse event or serious adverse event that occurred or worsened on or after the day of the first dose of the IP through 28 days after the last dose of IP for Arms A and C or up to 90 days after the last dose for Arm B, and those SAEs made known to the investigator at any time thereafter that are suspected of being related to IP. A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild l intervention/therapy required Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. (NCT02250326)
Timeframe: TEAEs were collected up to 4 weeks after receiving last dose of IP for nab-paclitaxel and CC-486 + nab-paclitaxel, and up to 90 days after the last IP dose for Durva + nab-paclitaxel; TEAEs were collected up to 86.1 weeks
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAE | Serious TEAE | Grade (GR) 3/4 TEAE | Grade 3 or Higher | Treatment Related TEAE | Treatment Related Serious TEAE | Treatment Related GR 3 or Higher TEAE | TEAE With Action to Reduce/Interrupt IP | Treatment-Related to Reduce or Interrupt IP | TEAE with Action Taken to Withdraw IP | TEAE with Fatal Outcome | Treatment Related TEAE with Fatal Outcome | |
| Nab-Paclitaxel + CC-486 Combination Arm | 79 | 30 | 48 | 49 | 74 | 11 | 32 | 49 | 36 | 8 | 4 | 0 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 78 | 37 | 53 | 55 | 71 | 17 | 32 | 57 | 32 | 9 | 12 | 4 |
| Nab-Paclitaxel Alone | 78 | 29 | 47 | 47 | 68 | 5 | 25 | 38 | 27 | 8 | 3 | 1 |
A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities. (NCT02250326)
Timeframe: Up to 16 Jan 2017 for CC-486 + nab-paclitaxel and up to 23 Dec 2017 for nab-paclitaxel and Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | Percentage of Participants (Number) |
|---|---|
| Nab-Paclitaxel | |
| Nab-Paclitaxel Alone | 10.1 |
A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities. (NCT02250326)
Timeframe: Up to 16 Jan 2017 for CC-486 + nab-paclitaxel and up to 23 Dec 2017 for nab-paclitaxel and Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Nab-Paclitaxel | CC-486 | |
| Nab-Paclitaxel + CC-486 Combination Arm | 10.1 | 20.3 |
A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities. (NCT02250326)
Timeframe: Up to 16 Jan 2017 for CC-486 + nab-paclitaxel and up to 23 Dec 2017 for nab-paclitaxel and Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Nab-Paclitaxel | Durvalumab (Reductions Not Allowed per Protocol) | |
| Nab-Paclitaxel + Durvalumab Combination Arm | 14.1 | 0.0 |
Duration of overall response was measured from the time criteria were first met for CR/PR until the first date the recurrent or progressive disease (PD) was radiologically documented. Participants who did not have PD after the response were censored on the date of last tumor assessment. If a participant died before PD, the participant was censored on the date of death. (NCT02027428)
Timeframe: Between Day 1 of the Induction Period through to the date of disease progression or death; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study.
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 5.95 |
| BSC: Induction + Maintenance | 4.60 |
Overall survival was defined as the duration in months between randomization and death from any cause. Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off (01 August 2019 whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive. (NCT02027428)
Timeframe: From the date of randomization to death from any cause; up to 01 August 2019; survival follow up was 55.89 months
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + Best Supportive Care (BSC) | 17.61 |
| Best Supportive Care (BSC) | 12.16 |
Overall survival was defined as the time in months from Day 1 of treatment for the Induction part to death from any cause. Subjects who were alive at the time of analysis had their OS censored at the date or last contact of 01 August 2019, whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive. (NCT02027428)
Timeframe: Between Day 1 of treatment in the Induction Part to death from any cause; up to 01 August 2019; survival follow up was 55.89 months
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 20.57 |
| BSC: Induction + Maintenance | 15.05 |
Progression-free survival is defined as the time in months from the date of randomization to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by computerized axial tomography [CT scan], not including symptomatic deterioration) or death (any cause) on or prior to 01 Aug 2019. RECIST 1.1 Definition: - Complete response (CR) -disappearance of all target lesions; - Partial response (PR) -at least a 30% decrease in the sum of diameters of target lesions from baseline - Stable disease (SD) -neither sufficient shrinkage to qualify for partial response (PR) nor sufficient increase of lesions to qualify for progressive disease (PD) - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir, and/or the appearance of new lesions. (NCT02027428)
Timeframe: From the date of randomization to the date of disease progression or death of any cause; up to data cut off date of 15 September 2017; up to 27.6 months
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + Best Supportive Care (BSC) | 3.12 |
| Best Supportive Care (BSC) | 2.60 |
PFS was defined as the time in months from Day 1 of treatment for the Induction part to the date of disease progression according to RECIST 1.1 criteria (documented by CT-scan, not including symptomatic deterioration) or death (any cause) on or prior to 01 August 2019, whichever occurred earlier. RECIST 1.1 Definition: - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir; the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of new lesions is also considered progression. (NCT02027428)
Timeframe: Between Day 1 of the Induction Part through to the date of disease progression or death; up to 01 August 2019; the maximum treatment duration was 234.1 weeks for entire study
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 6.47 |
| BSC: Induction + Maintenance | 5.55 |
Overall response in the maintenance period was defined as the percentage of participants who showed an improvement in best overall response from stable disease (SD) or partial response (PR) during Induction to a Complete Response (CR) or PR during Maintenance according to RECIST 1.1 criteria and confirmed in no less than 28 days. Evaluation takes as reference the lesion measurement or status at the last tumor assessment before randomization to Maintenance. The 95% CI was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline. - Stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease. (NCT02027428)
Timeframe: For the induction period the maximum treatment was 19 weeks for the maintenance period the maximum treatment was 150 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 9.6 |
| BSC: Induction + Maintenance | 3.0 |
Overall response was defined as the percentage of participants with a confirmed assessment of complete response (CR) or partial response (PR) according to RECIST 1.1 criteria and confirmed in no less than 28 days. The 95% confidence interval (CI) was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to < 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline. (NCT02027428)
Timeframe: Day 1 of treatment in the induction period and subsequent anticancer therapy, death or discontinuation up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
| Intervention | percentage of participants (Number) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 69.1 |
| BSC: Induction + Maintenance | 57.6 |
Disease control rate was defined as the percentage of participants who had radiologic CR, PR or SD for >= 6 weeks according to RECIST 1.1 criteria as determined by the investigator. Only participants with a confirmed CR/PR are included in this summary. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. RECIST 1.1 Definition: - CR- disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to < 10 mm. - PR- at least a 30% decrease in the sum of diameters of target lesions from baseline; - SD- neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for PD. The 95% CI was calculated using Clopper-Pearson method. (NCT02027428)
Timeframe: Induction is from Day 1 to a maximum treatment time of 19 weeks; entire study from Day 1 induction through maintenance up to PD; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
| Intervention | percentage of participants (Number) |
|---|---|
| All Participants - Induction | 47.9 |
| Nab-Paclitaxel + BSC: Induction + Maintenance | 99.3 |
| BSC: Induction + Maintenance | 100.0 |
Time to confirmed complete or partial response (CR/PR) is defined as the time from day 1 of treatment in Induction to the first occurrence of confirmed CR/PR. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. Only participants with a confirmed CR or PR are included in this summary. (NCT02027428)
Timeframe: Induction is from Day 1 to a maximum treatment time of 19 weeks; entire study from Day 1 Induction through Maintenance up to PD; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
| Intervention | months (Median) |
|---|---|
| All Participants - Induction | 1.446 |
| Nab-Paclitaxel + BSC: Induction + Maintenance | 1.478 |
| BSC: Induction + Maintenance | 1.413 |
TEAE in the Induction part is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and on or before the day of randomization for subjects who entered into the Maintenance part, or, for subjects who did not enter into the Maintenance part, before the treatment discontinuation date plus 28 days or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate Grade, 3 = Severe Grade, 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator. (NCT02027428)
Timeframe: Day 1 of Induction up to Week 23 (maximum treatment in Induction plus 4 weeks if not continuing into Maintenance)
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAE | Serious TEAE | Severity Grade 3/4 TEAE | Severity Grade 3 or higher TEAE | Treatment-related (trt-related) TEAE | Trt-related serious TEAE | TEAE-study drug dose reduced or interrupted | Trt-related TEAE-dose reduced or interrupted | TEAE-study drug withdrawn | Trt-related TEAE-study drug withdrawn | TEAE-outcome of death | Trt-related TEAE-outcome of death | |
| All Participants - Induction | 419 | 177 | 337 | 340 | 408 | 82 | 341 | 301 | 55 | 35 | 32 | 7 |
| TEAE Specific to Carboplatin | NA | NA | NA | NA | 394 | 73 | 291 | 236 | 53 | 29 | NA | 6 |
| TEAE Specific to Nab-Paclitaxel | NA | NA | NA | NA | 407 | 80 | 340 | 292 | 55 | 34 | NA | 7 |
TEAE over entire study is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and before the treatment discontinuation date plus 28 days, or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator. (NCT02027428)
Timeframe: From Day 1 up to 01 August 2019; (maximum treatment length plus 28 days); the maximum treatment duration was 234.1 weeks for entire study
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAE | Serious TEAE | Severity Grade 3/4 TEAE | Severity Grade 3 or higher TEAE | Treatment-related (trt-related) TEAE | Trt-related serious TEAE | TEAE-study drug dose reduced or interrupted | Trt-related TEAE-dose reduced or interrupted | TEAE-study drug withdrawn | Trt-related TEAE- study drug withdrawn | TEAE-outcome of death | Trt-related TEAE-outcome of death | |
| BSC: Induction + Maintenance | 62 | 21 | 48 | 48 | 61 | 8 | 52 | 45 | 0 | 1 | 2 | 0 |
| BSC: TEAE Specific to BSC | NA | NA | NA | NA | 1 | 0 | 1 | 0 | 0 | 0 | NA | 0 |
| BSC: TEAE Specific to Carboplatin | NA | NA | NA | NA | 58 | 7 | 45 | 37 | 1 | 0 | NA | 0 |
| BSC: TEAE Specific to Nab-Paclitaxel | NA | NA | NA | NA | 61 | 8 | 52 | 45 | 1 | 0 | NA | 0 |
| Nab-Paclitaxel + BSC: Induction + Maintenance | 130 | 54 | 108 | 109 | 129 | 22 | 115 | 107 | 22 | 18 | 4 | 0 |
| Nab-Paclitaxel + BSC: TEAE Specific to BSC | NA | NA | NA | NA | 18 | 1 | 17 | 0 | 20 | 2 | NA | 0 |
| Nab-Paclitaxel + BSC: TEAE Specific to Carboplatin | NA | NA | NA | NA | 123 | 16 | 95 | 85 | 1 | 1 | NA | 0 |
| Nab-Paclitaxel + BSC: TEAE Specific to Nab-Paclitaxel | NA | NA | NA | NA | 129 | 22 | 113 | 104 | 22 | 18 | NA | 0 |
"Objective tumor response rate (complete response, unconfirmed complete response, partial response, unconfirmed partial response) in patients with measurable disease were assessed in each arm and compared between arms using Chi-squared test.~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions" (NCT01959139)
Timeframe: Up to 3 years
| Intervention | percent of participants (Number) |
|---|---|
| Phase II: mFOLFIRINOX | 45 |
| Phase II: mFOLFIRINOX + PEGPH20 | 33 |
"Assess safety of mFOLFIRINOX in combination with PEGPH20 and select the optimal dose of PEGPH20 for the Phase II portion.~MTD of PEGPH20 in combination with mFOLFORINOX was evaluated by testing decreasing doses of PEGPH20 from 3mcg/kg on Day 1 and Day 3/4, to 3mcg/kg on Day 1 only and to 1.6 mcg/kg on Day 1 only.~MTD reflects the highest dose that had a dose-limiting toxicity (DLT) rate of ≤ 17%. DLTs were defined as treatment regimen related: grade ≥ 3 non-hematologic toxicity; grade 4 absolute neutrophil count (ANC) anemia or thrombocytopenia; grade 4 ANC lasting > 7 days; grade ≥ 3 febrile neutropenia; grade ≥ 3 elevation of aspartate aminotransferase (AST)/alanine aminotransferase (ALT), total bilirubin, and creatinine; delay in starting the 2nd cycle of mFOLFIRINOX by > 2 weeks due to drug related toxicity.~DLT were graded using the NCI CTCAE version 4. Note: the third and lowest dose level was not reached." (NCT01959139)
Timeframe: 2 cycles of 14 days
| Intervention | ug/kg (Number) |
|---|---|
| Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 and Day 3/4 | 0 |
| Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 | 3 |
| All Phase 1 Participants | 3 |
"Time from date of registration to date of death due to any cause. Participants last known to be alive are censored at date of last contact.~Assessed using the logrank test." (NCT01959139)
Timeframe: From date of registration to date of death due to any cause, assessed up to 3 years
| Intervention | months (Median) |
|---|---|
| Phase II: mFOLFIRINOX | 14.4 |
| Phase II: mFOLFIRINOX + PEGPH20 | 7.7 |
Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause. Participants last known to be alive without report of progression are censored at date of last contact. (NCT01959139)
Timeframe: From date of registration to date of death due to any cause, assessed up to 3 years
| Intervention | months (Median) |
|---|---|
| Phase II: mFOLFIRINOX | 6.2 |
| Phase II: mFOLFIRINOX + PEGPH20 | 4.3 |
"Adverse Events (AEs) are reported by CTCAE Version 4.0. Only adverse events that are possibly, probably or definitely related to study drug are reported.~Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living e.g. bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.~Grade 4: Life-threatening consequences; urgent intervention indicated.~Grade 5: Death related to adverse event" (NCT01959139)
Timeframe: Duration of treatment and follow up until death or 3 years post registration
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal pain | Acute kidney injury | Alanine aminotransferase increased | Alkaline phosphatase increased | Anemia | Anorexia | Arthralgia | Ascites | Aspartate aminotransferase increased | Blood bilirubin increased | Creatinine increased | Dehydration | Depression | Diarrhea | Esophagitis | Fatigue | Febrile neutropenia | Gallbladder obstruction | Gastrointestinal disorders - Other, specify | General disorders and admin site conditions- Other | Generalized muscle weakness | Hyperglycemia | Hypertension | Hypokalemia | Hyponatremia | Hypophosphatemia | Hypotension | Infections and infestations - Other, specify | Infusion related reaction | Leukocytosis | Lung infection | Lymphocyte count decreased | Mucositis oral | Myalgia | Nausea | Neutrophil count decreased | Pain | Paresthesia | Peripheral motor neuropathy | Peripheral sensory neuropathy | Peritoneal infection | Platelet count decreased | Portal vein thrombosis | Pulmonary hypertension | Resp, thoracic and mediastinal disorders - Other | Sepsis | Skin infection | Small intestine infection | Spasticity | Thromboembolic event | Ventricular tachycardia | Vomiting | Weight loss | White blood cell decreased | |
| Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 and Day 3/4 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 Only | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Phase II: mFOLFIRINOX | 1 | 0 | 0 | 0 | 4 | 2 | 0 | 0 | 0 | 0 | 1 | 7 | 1 | 10 | 0 | 6 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 1 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 8 | 4 | 1 | 1 | 1 | 2 | 0 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 8 | 1 | 2 |
| Phase II: PEGPH20 + mFOLFIRINOX | 3 | 0 | 3 | 2 | 2 | 3 | 1 | 1 | 0 | 1 | 0 | 4 | 0 | 12 | 1 | 11 | 0 | 0 | 1 | 0 | 3 | 1 | 0 | 4 | 3 | 1 | 0 | 0 | 1 | 1 | 0 | 4 | 4 | 2 | 12 | 3 | 0 | 0 | 1 | 5 | 1 | 3 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 0 | 10 | 0 | 2 |
The number of participants that received treatment with proton radiation along with FOLFIRINOX-Losartan and then subsequently underwent attempted surgery and achieved R0 resection. R0 resection means that no cancer cells were seen microscopically at the resection margin. (NCT01821729)
Timeframe: At the time of surgery (approximately 4 months after the start of treatment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Arm | 34 |
"To determine the progression free survival of patients with locally advanced disease who receive FOLFIRINOX-Losartan and proton beam radiation therapy. Disease progression was assessed using Response Evaluation Criteria in Solid Tumors (RECIST 1.1).~Progressive disease (PD): At least a 20% increase in the sum of the longest diameter (LD) of target lesion, taking as reference the smal lest sum LD recorded since the treatment started or the appearance of one or more new lesions (new lesions must be > slice thickness)." (NCT01821729)
Timeframe: From the start of treatment until death or progression, median duration of 17.5 months
| Intervention | Months (Median) |
|---|---|
| Experimental Arm | 17.5 |
Time from surgery to recurrence (NCT00313560)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| Erlotinib and EBRT After Pancreatectomy | 15.6 |
(NCT00313560)
Timeframe: up to 5 years
| Intervention | months (Median) |
|---|---|
| Erlotinib and EBRT After Pancreatectomy | 24.39 |
Quality of life (QOL) was assessed before CRT was started or during the first week of its administration (baseline [BL]), between completion of CRT and starting maintenance chemotherapy (time 1 [t1]), and within 3 months after completion of maintenance chemotherapy (time 2 [t2]). QLQ-PAN 26 questionnaire includes 26 questions, organized into 7 scales, with scores for each ranging from 0-100. Higher scores indicate worse health state. Therefore, decreasing (negative) scores indicate a better outcome. (NCT00313560)
Timeframe: 3 months
| Intervention | score on a scale (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pancreatic Pain (t1 vs. BL) | Pancreatic Pain (t2 vs. BL) | Pancreatic Pain (t2 vs. t1) | Digestive (t1 vs. BL) | Digestive (t2 vs. BL) | Digestive (t2 vs. t1) | Altered Bowel Habits (t1 vs. BL) | Altered Bowel Habits (t2 vs. BL) | Altered Bowel Habits (t2 vs. t1) | Jaundice (t1 vs. BL) | Jaundice (t2 vs. BL) | Jaundice (t2 vs. t1) | Body Image (t1 vs. BL) | Body Image (t2 vs. BL) | Body Image (t2 vs. t1) | Satisfaction with healthcare (t1 vs. BL) | Satisfaction with health care (t2 vs. BL) | Satisfaction with health care (t2 vs. t1) | Sexual function (t1 vs. BL) | Sexual function (t2 vs. BL) | Sexual function (t2 vs. t1) | |
| Erlotinib and EBRT After Pancreatectomy | -1.9 | -3.8 | 2.4 | -0.9 | -4.6 | -1.4 | 14.7 | 7.2 | -4.9 | -1.3 | -2 | 0 | -6.2 | -3.1 | -0.7 | 4.1 | 3.1 | 0 | -0.5 | 14.7 | 14.1 |
Quality of life (QOL) was assessed before chemoradiation therapy (CRT) was started or during the first week of its administration [baseline (BL)], between completion of CRT and starting maintenance chemotherapy [time 1 (t1)], and within 3 months after completion of maintenance chemotherapy [time 2 (t2)]. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) assesses quality of life on three domains: symptoms (score ranges from 7-14); function (score range 21-82); and global health status (score range 2-14). Higher or increasing scores mean worse outcomes; lower or decreasing scores mean better outcomes. (NCT00313560)
Timeframe: Up to 3 months after completion of maintenance chemotherapy
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global (Time 1 vs. BL) | Global (Time 2 vs. BL) | Global (Time 2 vs. Time 1) | Functional (F) - Physical (Time 1 vs. BL) | F - Physical (Time 2 vs. BL) | F - Physical (Time 2 vs. Time 1) | F - Role (Time 1 vs. BL) | F - Role (Time 2 vs. BL) | F - Role (Time 2 vs. Time 1) | F - Cognition (Time 1 vs. BL) | F - Cognition (Time 2 vs. BL) | F - Cognition (Time 2 vs. Time 1) | F - Emotional (Time 1 vs. BL) | F - Emotional (Time 2 vs. BL) | F - Emotional (Time 2 vs. Time 1) | F - Social (Time 1 vs. BL) | F - Social (Time 2 vs. BL) | F - Social (Time 2 vs. Time 1) | Financial (Time 1 vs. BL) | Financial (Time 2 vs. BL) | Financial (Time 2 vs. Time 1) | General Symptoms (GS) - Fatigue (Time 1 vs. BL) | GS - Fatigue (Time 2 vs. BL) | GS - Fatigue (Time 2 vs. Time 1) | GS - Nausea/Vomiting (Time 1 vs. BL) | GS - Nausea/Vomiting (Time 2 vs. BL) | GS - Nausea/Vomiting (Time 2 vs. Time 1) | GS - Pain (Time 1 vs. BL) | GS - Pain (Time 2 vs. BL) | GS - Pain (Time 2 vs. Time 1) | GS - Dyspnea (Time 1 vs. BL) | GS - Dyspnea Time 2 vs. BL) | GS - Dyspnea (Time 2 vs. Time 1) | GS - Insomnia (Time 1 vs. BL) | GS - Insomnia (Time 2 vs. BL) | GS - Insomnia (Time 2 vs. Time 1) | GS - Appetite Loss (Time 1 vs. BL) | GS - Appetite Loss (Time 2 vs. BL) | GS - Appetite Loss (Time 2 vs. Time 1) | GS - Constipation (Time 1 vs. BL) | GS - Constipation (Time 2 vs. BL) | GS - Constipation (Time 2 vs. Time 1) | GS - Diarrhea (Time 1 vs. BL) | GS - Diarrhea (Time 2 vs. BL) | GS - Diarrhea (Time 2 vs. Time 1) | |
| Erlotinib and EBRT After Pancreatectomy | 1 | -1.8 | 4.6 | 0.5 | -3.2 | -6.2 | -3.1 | -0.3 | -4.4 | -2.6 | 1.2 | -1.2 | -0.4 | 2.2 | -0.6 | 3.9 | 4.4 | -3.8 | 1.7 | 2.5 | 0 | 5.7 | 5.2 | 1.7 | 2.5 | 0 | 1.9 | 2.7 | 7.2 | 5 | 1.7 | 3.8 | 1.2 | -2.5 | 0 | 2.5 | -2.5 | -15 | -5 | -4.2 | -2.5 | 0 | 14.7 | 8.8 | -6.2 |
Number of participants experiencing adverse events during chemoradiation and during adjuvant chemotherapy, Grade 2 or higher, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. This is used to determine the Toxicity profile. (NCT00313560)
Timeframe: up to 3 years
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Grade 2 | Grade 3 | Grade 4 | |
| Adjuvant Gemcitabine Plus Erlotinib | 15 | 14 | 3 |
| Chemoradiation Plus Erlotinib | 24 | 15 | 1 |
DLT occurring within 3 weeks of the start of chemoradiation therapy was defined as: Grade 3 non-hematologic or hematologic toxicity requiring interruption of >7 days (d) of chemo or >3d chemoradiation; Grade 4 non-hematologic; Grade 4 neutropenia or thrombocytopenia; Treatment-related death; Delays in surgery >3 weeks due to treatment-related toxicity. A 30% increase in any surgical complication rate beyond those previously established rates (readmission rate: 16%; pancreatic fistula/intra-abdominal abscess/infection rate: 27%, major intra-abdominal bleeding requiring return to OR: 1.6%, delayed gastric emptying: 4.4%, and superficial wound infection rate: 8%) was also considered a DLT. (NCT00889187)
Timeframe: within 3 weeks of the start of chemoradiation therapy
| Intervention | patients with DLT (Number) |
|---|---|
| Phase 1 Cohort 1: Photon Rad (30 Gy/12 Days)+Capecitabine | 0 |
| Phase I Cohort 2: Photon Rad (25 Gy/11 Days)+Capecitabine | 0 |
| Phase I Cohort 3: Photon Rad (25 Gy/5 Days)+Capecitabine | 0 |
Neoadjuvant short-course photon radiation therapy MTD in combination with capecitabine 825 mg/m2 orally BID for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy is determined by the number of patients who experience a dose limiting toxicity (DLT). See subsequent primary outcome measure for the DLT definition. The MTD is defined as the highest dose at which fewer than one-third of patients experience a DLT. If none of 3 initial patients or only 1 of 6 patients have a DLT on dose level 3 then 6 additional patients are treated at this dose. If during this expansion, the rate of DLT exceeds 30% then the next lower dose level is declared the MTD. If no DLTs are observed, the MTD is not reached. (NCT00889187)
Timeframe: within 3 weeks of the start of chemoradiation therapy
| Intervention | Gy per fraction (Number) |
|---|---|
| All Phase I: Photon Rad+Capecitabine | NA |
Number of study participants experiencing toxicity (serious adverse events or adverse events). Study participants assessed for this outcome measure must have received at least one dose of protocol therapy. Toxicity assessed according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE). (NCT00290693)
Timeframe: Up to 1 year
| Intervention | participants (Number) |
|---|---|
| CapTere (Capecitabine + Docetaxel) | 38 |
Overall survival is measured from the time from date of initial protocol therapy to date of death. In the absence of confirmation of death, survival time will be censored to last date of follow-up. (NCT00290693)
Timeframe: Up to 1 year
| Intervention | months (Median) |
|---|---|
| CapTere (Capecitabine + Docetaxel) | 5.3 |
Progression-free survival (PFS) is measured the time from the start of protocol therapy to disease progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00290693)
Timeframe: Up to 1 year
| Intervention | months (Median) |
|---|---|
| CapTere (Capecitabine + Docetaxel) | 3.7 |
Rate of participants achieving a 50% or more reduction in CA 19-9 levels after receiving protocol therapy. Baseline CA-19-9 will be compared to the lowest recorded value on patients receiving therapy on protocol. A 50% drop in CA 19-9 in patients with baseline levels above 100 U/ml will be recorded as a CA 19-9 response if the > 50% drop can be confirmed with at least one more CA 19-9 level thereafter with > 50% drop compared to baseline. (NCT00290693)
Timeframe: Up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| CapTere (Capecitabine + Docetaxel) | 35.48 |
Rate of participants achieving complete response (CR) or partial response (PR) to Captere therapy according to RECIST criteria v 1.0. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00290693)
Timeframe: Up to 1 year
| Intervention | participants (Number) | ||
|---|---|---|---|
| Partial Response (PR) >= 2 cycles | Stable Disease (SD), >= 2 cycles | Complete Response (CR), >= 2 cycles | |
| CapTere (Capecitabine + Docetaxel) | 6 | 25 | 0 |
The number of participants that died within 30 days of undergoing a pancreaticoduodenectomy. (NCT00438256)
Timeframe: 30 days after the time of surgery (Surgery is 28-42 days after start of treatment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Beam Radiation/ Capecitabine | 0 |
"The median amount of time from the start of treatment until death or disease progression, whichever occurs first.~Progressive Disease (PD): A 20% or greater increase in the sum of Longest Diameter (LD) of all target lesions, taking as reference the smallest sum LD recorded since baseline." (NCT00438256)
Timeframe: from the start of treatment until death or progression, median duration of 10.4 months
| Intervention | Months (Median) |
|---|---|
| Proton Beam Radiation/ Capecitabine | 10.4 |
All patients that received surgery underwent a full pathological review of their pancreaticoduodenectomy specimen according to the American Joint Committee on Cancer (AJCC) Staging Classification, 6th. Initial gross evaluation and identification of resection margins was performed jointly by the surgeon and the pathologist. Pathological complete response will be defined as the absence of any viable tumor cells within the pathologic specimen. (NCT00438256)
Timeframe: at the time of surgery (28-42 days after start of treatment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Beam Radiation/ Capecitabine | 0 |
"The number of participants that experienced a dose limiting toxicity in the arm where radiation was administered over 5 consecutive for a total dose of 25 Gray Equivalents (GyE) (Group 4). Participants were monitored for potential Dose Limiting Toxicities (DLT) for three weeks after the start of radiation. DLTs included:~Any grade 3 non-hematologic or hematologic toxicity requiring a greater than 7 day interruption in therapy (excluding alopecia and nausea/vomiting not controlled by optimal supportive care or~Any grade 4 non-hematologic toxicity or~Any grade 4 neutropenia or thrombocytopenia as defined by Common Terminology Criteria for Adverse Events (CTCAE v3.0)" (NCT00438256)
Timeframe: 3 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Beam Radiation/ Capecitabine | 0 |
Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 3). The regimen was considered to be tolerated if less than 20% of participants experienced a grade 3 or greater toxicity. (NCT00438256)
Timeframe: 30 days after the end of treatment, up to approximately 6 months total
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase II: Proton Beam Radiation/ Capecitabine | 2 |
Number of participants with pancreatic or any other anastomotic leakage within 30 days of surgery (NCT00438256)
Timeframe: 30 days post surgery (surgery was 28-42 days after the start of treatment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Beam Radiation/ Capecitabine | 0 |
The number of participants that had treatment related serious adverse events. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 3). Adverse events were considered to be serious adverse events if they were grade 3 or greater and were considered to be possibly, probably, or definitely related to treatment. (NCT00438256)
Timeframe: From the start of treatment until 30 days after the end of treatment, up to approximately 5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Beam Radiation/ Capecitabine Dose Level 1 | 0 |
| Proton Beam Radiation/ Capecitabine Dose Level 2 | 0 |
| Proton Beam Radiation/ Capecitabine Dose Level 3 | 0 |
| Proton Beam Radiation/ Capecitabine Dose Level 4 | 2 |
Pharmacokinetics of 5-FU - Cmax plasma levels (NCT01206465)
Timeframe: 22, 23, 45 & 46 hours during the 48 hour infusion
| Intervention | mg/m^2 (Mean) |
|---|---|
| 22 Hours | 1147 |
| 23 Hours | 1159 |
| 45 Hours | 1123 |
| 46 Hours | 1113 |
Plasma concentrations versus time (at all time points) (NCT01206465)
Timeframe: Pre-treatment, end of infusion, at 15, 30, and 60 min, and then at 2, 4, 6, 8, 12, 22, 23, 24, 45, and 46 hours for PDX.
| Intervention | ng/ml *hr (Mean) |
|---|---|
| 75 mg/m^2 | 12,818 |
| 94 mg/m^2 | 16300 |
| 118 mg/m^2 | 15680 |
| 148 mg/m^2 | 23570 |
| 185 mg/m^2 | 42121 |
Recommended dose of PDX given in combination with a fixed dose of 5-FU administered as a 48-hour infusion given every other weekMaximum tolerated dose will have been exceeded when 2 patients entered at a given dose level experience specified dose-limiting toxicities in the initial cycle (NCT01206465)
Timeframe: During the initial course (day 1 & 15 of a 4 week schedule)
| Intervention | mg per meter square (Number) |
|---|---|
| Treatment (Enzyme Inhibitor Therapy) | 148 |
Time to disease progression in all Participants (NCT01206465)
Timeframe: restaging imaging done after each two 4-week course until time of progression (longest time to progression = 588 days)
| Intervention | days (Median) |
|---|---|
| Treatment (Enzyme Inhibitor Therapy) | 112 |
Participants remained on study as long as they did not progress, and wished to continue on study (no limit on number of cycles) (NCT01206465)
Timeframe: "., From the time the subject signs the consent form and ending 4 weeks following the final chemotherapy, an average of 3 years"
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| gr 3-4 neutropenia | gr 3-4 thrombocytopenia | gr 3-4 anemia | gr 3-4 diarrhea | gr 3-4 mucositis | gr 3-4 dehydration | gr 3-4 fatigue | |
| Treatment (Enzyme Inhibitor Therapy) | 4 | 0 | 4 | 1 | 5 | 1 | 1 |
Number of Participants with Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase (NCT01206465)
Timeframe: Prior to the first dose of protocol therapy
| Intervention | percentage of patients (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| SLC19A1 80G>A | gamma glutamyl hydrolase (GGH) 401C>T | gamma glutamyl hydrolase (GGH) 452C>T | folyl polyglutamate synthase (FPGS) rs10760502A>G | folyl polyglutamate synthase (FPGS) rs1544105C>T | methylene tetrahydrofolate reductase (MTHFR 677C>T | methylene tetrahydrofolate reductase MTHFR 1298A>C | thymidylate synthase 28-bp tandem repeats (2 or 3) | |
| Heterozygous | 40.7 | 37.0 | 11.1 | 4.0 | 55.6 | 25.9 | 33.3 | 48.2 |
| Homozygous Variant | 7.4 | 7.4 | 0 | 0 | 18.5 | 18.5 | 14.8 | 37.0 |
| Wild Type | 51.9 | 55.6 | 88.9 | 96.0 | 25.9 | 55.6 | 51.9 | 14.8 |
Response will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1 by independent radiology review) at 8 week intervals in patients with metastatic disease and in patients with locally advanced disease. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 35.1 |
| LAPC Modified FOLFIRINOX | 17.2 |
Overall survival will be determined in patients with metastatic disease and in patients with locally advanced disease. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 81 |
| LAPC Modified FOLFIRINOX | 100 |
The primary objective of this study is to determine the progression free survival in patients with metastatic pancreatic cancer and in patients with locally advanced unresectable non-metastatic pancreatic cancer treated with a dose-attenuated modification of FOLFIRINOX. Tumour response was determined according to RECIST 1.1 by independent radiology review. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 54 |
| LAPC Modified FOLFIRINOX | 97 |
The rate of surgical resection in the cohort of patients with locally advanced disease will be determined. (NCT01523457)
Timeframe: 24 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total | Unresectable | Borderline | |
| LAPC Modified FOLFIRINOX | 13 | 6 | 7 |
Toxicities will be assessed according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0. Rates of grade 3 and 4 toxicities will be compared to historical controls. MPC and LAPC are combined because they were given the exact same medication. The study aimed to compare this dosage with historical dosage, so this comparison is the most appropriate. (NCT01523457)
Timeframe: 24 weeks
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | Thrombocytopenia | Anaemia | Febrile neutropenia | Diarrhea | Fatigue | Alanine aminotransferase (ALT) increased | Thromboembolic event | Peripheral sensory neuropathy | Vomiting | |
| LAPC Modified FOLFIRINOX | 5 | 2 | 2 | 2 | 4 | 4 | 0 | 0 | 0 | 1 |
| MPC Modified FOLFIRINOX | 4 | 5 | 2 | 1 | 8 | 5 | 3 | 3 | 2 | 1 |
From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT01658943)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| mFOLFOX | 6.7 |
| MK2206 and Selumetinib | 3.9 |
From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression free are censored at date of last contact. (NCT01658943)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| mFOLFOX | 2.0 |
| MK2206 and Selumetinib | 1.9 |
Only adverse events that are possibly, probably or definitely related to study drug are reported. (NCT01658943)
Timeframe: Up to 3 years
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal pain | Alanine aminotransferase increased | Alkaline phosphatase increased | Anemia | Anorexia | Aspartate aminotransferase increased | Blood bilirubin increased | Cognitive disturbance | Dehydration | Device related infection | Diarrhea | Edema face | Encephalopathy | Erythema multiforme | Erythroderma | Fatigue | Generalized muscle weakness | Hepatic failure | Hyperglycemia | Hypertension | Hypokalemia | Hypomagnesemia | Hyponatremia | Hypophosphatemia | Hypotension | Hypoxia | Left ventricular systolic dysfunction | Lung infection | Lymphocyte count decreased | Mucositis oral | Multi-organ failure | Nausea | Neoplasms benign, malignant and unspecified | Neutrophil count decreased | Platelet count decreased | Rash acneiform | Rash maculo-papular | Skin infection | Soft tissue infection | Stevens-Johnson syndrome | Syncope | Vomiting | Weight loss | White blood cell decreased | |
| mFOLFOX | 1 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 8 | 1 | 0 | 3 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 2 |
| MK2206 and Selumetinib | 0 | 4 | 2 | 3 | 1 | 3 | 0 | 1 | 6 | 0 | 4 | 1 | 1 | 1 | 1 | 7 | 1 | 1 | 7 | 5 | 1 | 0 | 4 | 1 | 1 | 1 | 1 | 1 | 0 | 4 | 1 | 0 | 2 | 0 | 0 | 5 | 7 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
Confirmed response (CR) is two or more objective statuses of CR a minimum of four weeks apart documented before progression or symptomatic deterioration. Partial response (PR) is two or more objective statuses of PR or better a minimum of four weeks apart documented before progression or symptomatic deterioration. Unconfirmed CR is one objective status of CR documented before progression or symptomatic deterioration but not qualifying as CR or PR. Unconfirmed PR is one objective status of PR documented before progression or symptomatic deterioration but not qualifying as CR, PR or unconfirmed CR. (NCT01658943)
Timeframe: Up to 3 years
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Partial Response | Unconfirmed Partial Response | Stable/No response | Increasing disease | Symptomatic Deterioration | Assessment Inadequate | |
| mFOLFOX | 4 | 1 | 14 | 29 | 3 | 6 |
| MK2206 and Selumetinib | 0 | 1 | 12 | 34 | 2 | 6 |
Response was evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter; Overall Response (OR) = CR + PR. (NCT00100815)
Timeframe: Pre-treatment and every 6 weeks from treatment.
| Intervention | percentage of participants (Number) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 22.0 |
(NCT00100815)
Timeframe: every 2-4 months for 1 year and then every 6 months for 5 years
| Intervention | months (Median) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 9.8 |
Grade 3, 4 or 5 toxicity rate (NCT00100815)
Timeframe: Subjects were evaluated for adverse events at each study visit for the duration of their participation in the study, up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 70 |
Quality of Life was assessed using EORTC QLQ-PAN26. All measures range in score from 1 to 4 as lower scores indicate better outcomes. The improved Quality of Life is defined as a greater than 5% decrease in 2 consecutive scores compared with the baseline score. (NCT00100815)
Timeframe: assessed at baseline then weekly for 3 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 56.0 |
Progressive Disease is defined using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000], as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions, or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. (NCT00100815)
Timeframe: every 2-4 months for 1 year and then every 6 months for 5 years
| Intervention | months (Median) |
|---|---|
| GEMCITABINE, CAPECITABINE and AVASTIN | 5.7 |
The NCI Common Terminology Criteria for Adverse Events version 3.0 was used for adverse event reporting and toxicity grading. (NCT00320749)
Timeframe: Weekly up to 24 weeks
| Intervention | percent of patients (Number) | ||
|---|---|---|---|
| leukopenia | neutropenia | fatigue | |
| Capecitabine, Docetaxel, Gemcitabine | 29 | 29 | 25 |
MTD will be the dose at which 1 or fewer patients (≤ 1/6) experiences a DLT during the first or second cycle with the next higher dose having at least 2/3 or 2/6 patients experiencing Dose Limiting Toxicities (DLT). (NCT00320749)
Timeframe: Weekly up to 24 weeks
| Intervention | mg/m^2 (Number) | ||
|---|---|---|---|
| docetaxel | gemcitabine | capecitabine | |
| Capecitabine, Docetaxel, Gemcitabine | 36 | 750 | 625 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00320749)
Timeframe: every 8 weeks, up to 24 weeks
| Intervention | percent of patients (Number) | ||
|---|---|---|---|
| Partial Response | Complete Response | Stable Disease | |
| Capecitabine, Docetaxel, Gemcitabine | 11 | 0 | 72 |
(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| Proton Radiation and Chemotherapy | 0 |
Median overall survival is calculated by Kaplan-Meier method. (NCT02704143)
Timeframe: 3 years
| Intervention | months (Median) |
|---|---|
| Combination of Cyberknife With S-1 | 14.4 |
The acute toxicities are determined by RTOG Acute Radiation Morbidity Scoring Criteria. (NCT02704143)
Timeframe: Within 90 days after completion of SBRT
| Intervention | Participants (Count of Participants) |
|---|---|
| Combination of Cyberknife With S-1 | 9 |
The late toxicities are determined by RTOG/EORTC Late Radiation Morbidity Scoring Criteria. (NCT02704143)
Timeframe: 90 days after SBRT
| Intervention | Participants (Count of Participants) |
|---|---|
| Combination of Cyberknife With S-1 | 5 |
One-year overall survival rate is calculated by the ratio of number of patients surviving more than 1 year to the total number of patients enrolled. (NCT02704143)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Combination of Cyberknife With S-1 | 46 |
Progression-free survival is the time from the date of enrollment to the confirmation of disease progression at any sites, including local progression or metastasis, or death from any causes, if this occurred before disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02704143)
Timeframe: 3 years
| Intervention | months (Median) |
|---|---|
| Combination of Cyberknife With S-1 | 10.1 |
The analysis of quality of life is based on The European Organization for Reasearch and Treatment of Cancer (EORTC): Quality of Life Questionnare-Core 30 (QLQ-C30). Higher scores in function domains and global health status indicate better quality of life, while higher scores in symptom domains imply worse quality of life. The scale range of all domains of QLQ-C30 is 0-100 (the minimum and maximum score is 0 and 100 points, respectively). (NCT02704143)
Timeframe: 1 years
| Intervention | units on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global health status | Physical functioning | Role functioning | Emotional functioning | Cognitive functioning | Social functioning | Fatigue | Nausea and vomiting | Pain | Dyspnea | Insomnia | Appetite loss | Constipation | Diarrhea | Financial difficulties | |
| Combination of Cyberknife With S-1 | 50.0 | 64.2 | 54.8 | 68.5 | 73.8 | 74.6 | 46.7 | 55.3 | 48.7 | 9.5 | 19.0 | 59.2 | 13.2 | 13.7 | 31.2 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT02311361)
Timeframe: Date treatment consent signed to date off study, approximately 18 months and 4 days for Cohort 1/Dose Level A1, 23 months and 29 days for Cohort 2/Dose Level A2, 32 months and 19 days for Cohort C/Dose Level C1, and 44 months and 18 days for Cohort C/Dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Durvalumab + 8 Gray (Gy) in 1 Fraction | 14 |
| Durvalumab +5 Gy in 5 Fractions | 10 |
| Durvalumab +Tremelimumab + 8 Gy in 1 Fraction | 19 |
| Durvalumab +Tremelimumab +5 Gy in 5 Fractions | 20 |
Amount of time participants survived after therapy. (NCT02311361)
Timeframe: From study entry to death or date of last contact, whichever occurs first, up to 2 years of follow-up
| Intervention | Months (Median) |
|---|---|
| Cohort A Dose Level A1 | 3.3 |
| Cohort A Dose Level A2 | 9.0 |
| Cohort C Dose Level C1 | 2.1 |
| Cohort C Dose Level C2 | 4.2 |
Participants who survived at least 6 months after therapy. (NCT02311361)
Timeframe: 6 month
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort A Dose Level A1 | 26 |
| Cohort A Dose Level A2 | 58 |
| Cohort C Dose Level C1 | 12 |
| Cohort C Dose Level C2 | 40 |
PFS is the defined as the median amount of time subject survives without disease progression after treatment. Progression is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). NOTE: While RECIST Progressive Disease (PD) will be noted and recorded the immune-related (IR) RECIST criteria will be applied to determine discontinuation of study treatment. For modified Immune-Related Response Criteria (irRC), only target and measurable lesions are taken into account. (NCT02311361)
Timeframe: From study entry to disease progression, death or date of last contact, whichever occurs first, an average of 6 months
| Intervention | Months (Median) |
|---|---|
| Cohort A Dose Level A1 | 1.7 |
| Cohort A Dose Level A2 | 2.5 |
| Cohort C Dose Level C1 | 0.9 |
| Cohort C Dose Level C2 | 2.3 |
Adverse Events (AEs) are reported by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Grade 1=Mild, Grade 2= Moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Fatal. (NCT02311361)
Timeframe: Participants were assessed from the start of study treatment at Cycle 1 then after every cycle (1 cycle = 28 days) of protocol treatment until 30 days after they were taken off treatment, approximately 4.0 months.
| Intervention | Adverse events (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 Abdominal pain | Grade 1 Alanine aminotransferase increased | Grade 1 Alkaline Phosphatase increased | Grade 1 Anemia | Grade 1 Anorexia | Grade 1 Atrial fibrillation | Grade 1 Aspartate aminotransferase increased | Grade 1 Back pain | Grade 1 Blood bilirubin increased | Grade 1 Cough | Grade 1 Creatinine increased | Grade 1 Diarrhea | Grade 1 Dizziness | Grade 1 Dry mouth | Grade 1 Dysgeusia | Grade 1 Endocrine disorders,Other, Elevated T3, T4 | Grade 1 Eye disorders - decr. in near vision,bilat | Grade 1 - Fatigue | Grade 1 Fever | Grade 1 Headache | Grade 1 Hemorrhoidal hemorrhage | Grade 1 Hoarseness | Grade 1 Hyperglycemia | Grade 1 - Hyperkalemia | Grade 1 Hyperuricemia | Grade 1 Hypoalbuminemia | Grade 1 Hypocalcemia | Grade 1 - Hyponatremia | Grade 1 Hypothyroidism | Grade 1 Infusion related reaction | Grade 1 Lymphocyte count decreased | Grade 1 Mucositis | Grade 1 Musculoskeletal & connective tissue | Grade 1 Nausea | Grade 1 Neutrophil count decreased | Grade 1 Pain | Grade 1 Platelet count decreased | Grade 1 Pruritis | Grade 1 Rash maculo-papular | Grade 1 Serum amylase increased | Grade 1 - Skin/subc tissue disorder - Night sweats | Grade 1 Skin/subc tissue disorder - Rash | Grade 1 Skin/subc tissue - Psoriasis | Grade 1 Skin/subc tissue disorder - Itching | Grade 1 Skin/subc tissue disorder-Skinpeeling hand | Grade 1 Vertigo | Grade 1 Vomiting | Grade 1 Weight loss | Grade 1 White blood cell decreased | Grade 2 Abdominal pain | Grade 2 Anemia | Grade 2 Anorexia | Grade 2 Autoimmune disorder | Grade 2 Diarrhea | Grade 2 Dysgeusia | Grade 2 Endocrine disorders - TSH elev-Hypothyroid | Grade 2 Fatigue | Grade 2 Fecal incontinence | Grade 2 Fever | Grade 2 Gastroesophageal reflux disease | Grade 2 Hyperglycemia | Grade 2 Hypoalbuminemia | Grade 2 Hypothyroidism | Grade 2 Hypophosphatemia | Grade 2 Infusion related reaction | Grade 2 Lymphocyte count decreased | Grade 2 Malaise | Grade 2 Nausea | Grade 2 Neutrophil count decreased | Grade 2 Platelet count decreased | Grade 2 Rash maculo-papular | Grade 2 Weight loss | Grade 2 White blood cell count | Grade 3 Anemia | Grade 3 Anorexia | Grade 3 Colitis | Grade 3 Dehydration | Grade 3 Diarrhea | Grade 3 Fatigue | Grade 3 Hyperthyroidism | Grade 3 Lymphocyte count decreased | Grade 3 Nausea | Grade 3 Serum amylase increased | Grade 3 Vomiting | Grade 4 Lymphocyte count decreased | |
| Cohort A Dose Level A1 | 0 | 1 | 0 | 3 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 15 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Cohort A Dose Level A2 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 0 | 3 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 4 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 |
| Cohort C Dose Level C1 | 0 | 0 | 0 | 9 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 17 | 0 | 0 | 3 | 0 | 0 | 7 | 2 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 9 | 0 | 0 | 2 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 15 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 6 | 0 | 1 | 0 | 2 |
| Cohort C Dose Level C2 | 1 | 5 | 2 | 9 | 3 | 1 | 6 | 1 | 1 | 1 | 1 | 7 | 1 | 0 | 0 | 0 | 0 | 7 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 5 | 1 | 4 | 1 | 2 | 26 | 1 | 0 | 2 | 1 | 1 | 13 | 3 | 2 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 7 | 1 | 10 | 2 | 1 | 4 | 1 | 0 | 5 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 30 | 2 | 3 | 1 | 2 | 1 | 2 | 0 | 3 | 1 | 2 | 3 | 3 | 1 | 1 | 18 | 2 | 0 | 2 | 2 |
Progressive disease (PD): >=20% increase in sum of longest diameter (LD) of target lesion(s), taking as reference smallest sum LD recorded since treatment started. Complete response (CR): disappearance of all target lesions. Partial response (PR): >=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD. (NCT02311361)
Timeframe: At screening then every 8 weeks until disease progression or patient is taken off the trial, whichever comes first, approximately 6 months.
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | |
| Cohort A Dose Level A1 | 0 | 1 | 3 | 4 |
| Cohort A Dose Level A2 | 0 | 0 | 4 | 4 |
| Cohort C Dose Level C1 | 0 | 0 | 2 | 6 |
| Cohort C Dose Level C2 | 0 | 1 | 5 | 10 |
297 reviews available for fluorouracil and Cancer of Pancreas
| Article | Year |
|---|---|
Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Ethnicity; Fluorouracil; Ge | 2021 |
Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; DNA Damage; Fluorourac | 2021 |
Neoadjuvant treatment of pancreatic carcinosarcoma: a case report and review of literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Female; Fluorouracil | 2022 |
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Deoxyc | 2022 |
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Pro | 2022 |
Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; ErbB | 2022 |
Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; ErbB | 2022 |
Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; ErbB | 2022 |
Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; ErbB | 2022 |
Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Fluorouracil; H | 2022 |
Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Fluorouracil; H | 2022 |
Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Fluorouracil; H | 2022 |
Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Fluorouracil; H | 2022 |
Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Ir | 2022 |
Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Ir | 2022 |
Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Ir | 2022 |
Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Ir | 2022 |
Efficacy and safety of neoadjuvant Folfirinox and Gemcitabine plus Nab-Paclitaxel for borderline resectable and locally advanced pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Resistance, Neoplasm; Fl | 2022 |
Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Resistance, Neoplasm; Fl | 2022 |
Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Resistance, Neoplasm; Fl | 2022 |
Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Resistance, Neoplasm; Fl | 2022 |
Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Capecitabine; Cisplatin; Fluoro | 2022 |
Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Capecitabine; Cisplatin; Fluoro | 2022 |
Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Capecitabine; Cisplatin; Fluoro | 2022 |
Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Capecitabine; Cisplatin; Fluoro | 2022 |
Maintenance chemotherapy in advanced and metastatic pancreatic cancer, a narrative review and case series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Maintenance Chemot | 2023 |
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2023 |
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2023 |
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2023 |
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2023 |
A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoad | 2023 |
A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoad | 2023 |
A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoad | 2023 |
A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoad | 2023 |
FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Multi | 2023 |
Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; F | 2023 |
Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; F | 2023 |
Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; F | 2023 |
Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; F | 2023 |
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2023 |
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2023 |
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2023 |
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2023 |
Iron-Dependent Cell Death: A New Treatment Approach against Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Death; Fluorourac | 2023 |
Iron-Dependent Cell Death: A New Treatment Approach against Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Death; Fluorourac | 2023 |
Iron-Dependent Cell Death: A New Treatment Approach against Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Death; Fluorourac | 2023 |
Iron-Dependent Cell Death: A New Treatment Approach against Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Death; Fluorourac | 2023 |
Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.
Topics: Albumin-Bound Paclitaxel; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2019 |
[New progress in the treatment of locally advance pancreatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; | 2019 |
[Neoadjuvant and adjuvant treatment of pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoadj | 2020 |
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemorad | 2020 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; DNA Topoisomerases, Type I; Fluorouracil; Humans; Irinotecan; | 2020 |
Second-line treatment for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabi | 2020 |
Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Topics: Adaptive Immunity; Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemothera | 2020 |
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with oth
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Drug-Relat | 2020 |
Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cel | 2020 |
Contemporary management of pancreas cancer in older people.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Enhanced Recovery After Surgery | 2021 |
Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinote | 2021 |
[Diagnostics and therapy of pancreatic carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; | 2021 |
Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluor | 2021 |
Treatment landscape of metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Tri | 2021 |
Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradioth | 2021 |
A review of response in neoadjuvant therapy for exocrine pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2021 |
Neoadjuvant therapy for pancreas cancer: Global perspective and optimal care pathways in low to middle-income countries.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III a | 2021 |
Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinot | 2021 |
Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Tri | 2021 |
Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Deoxycytidine; | 2021 |
Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadj | 2021 |
The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxalip | 2021 |
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytid | 2021 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorou | 2017 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorou | 2017 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorou | 2017 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorou | 2017 |
Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Ir | 2018 |
Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil | 2017 |
Randomized Clinical Trials in Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoadj | 2017 |
Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil | 2018 |
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Fluorouracil; Folic Acid; Hum | 2018 |
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer.
Topics: Animals; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neo | 2018 |
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer.
Topics: Animals; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neo | 2018 |
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer.
Topics: Animals; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neo | 2018 |
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer.
Topics: Animals; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neo | 2018 |
A look at the progress of treating pancreatic cancer over the past 20 years.
Topics: Antineoplastic Agents; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pallia | 2018 |
Chemotherapy and radiotherapy for advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Epirubicin; Fluo | 2018 |
Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carci | 2018 |
Updates in pancreatic cancer: Modest gains and hopeful targets.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dru | 2019 |
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2018 |
Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Hum | 2018 |
Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle C | 2018 |
The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Fluorouracil; Humans | 2018 |
Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug C | 2018 |
Management and supportive treatment of frail patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogeni | 2019 |
Harnessing the Immune System in Pancreatic Cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2018 |
Harnessing the Immune System in Pancreatic Cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2018 |
Harnessing the Immune System in Pancreatic Cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2018 |
Harnessing the Immune System in Pancreatic Cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2018 |
Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Electroporation; | 2018 |
Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant | 2019 |
Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug | 2019 |
Selecting chemotherapy for pancreatic cancer: Far away or so close?
Topics: Albumins; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Neoadjuvant Treatment for Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2019 |
Systemic treatment of pancreatic cancer revisited.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorourac | 2019 |
Managing the economic impact of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost Control; Cost-Benefit Analysis; Deoxycytidine; | 2019 |
Nowadays pancreatic cancer prognosis.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; C | 2019 |
Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2019 |
Adjuvant treatment of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; | 2019 |
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and | 2019 |
Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Germany; H | 2019 |
Locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase | 2013 |
First-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Tri | 2013 |
Second-line therapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2013 |
[Radically resected pancreatic cancer and adjuvant treatment. A review of the literature].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; | 2013 |
The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Esophageal Neopl | 2003 |
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell | 2012 |
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compou | 2013 |
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer.
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemoradiotherapy, Adj | 2013 |
[Current status and future directions of chemotherapy for pancreatic cancer].
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemother | 2013 |
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidin | 2014 |
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidin | 2014 |
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidin | 2014 |
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidin | 2014 |
Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Tri | 2014 |
Role of solute carrier transporters in pancreatic cancer: a review.
Topics: Adenocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Membran | 2014 |
Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; D | 2014 |
Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; | 2014 |
FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Deoxycytid | 2014 |
Recent studies of 5-fluorouracil resistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2014 |
Pancreatic cancer and FOLFIRINOX: a new era and new questions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Clinical Trials, Ph | 2015 |
FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, A | 2015 |
Pancreatic cancer, treatment options, and GI-4000.
Topics: Antineoplastic Agents; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Pancreatic N | 2015 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembr | 2016 |
Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical | 2016 |
Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pa | 2016 |
Systemic Chemotherapy in Advanced Pancreatic Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluoro | 2016 |
Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; | 2016 |
The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2016 |
Localized Pancreatic Cancer: Multidisciplinary Management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouraci | 2016 |
Localized Pancreatic Cancer: Multidisciplinary Management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouraci | 2016 |
Localized Pancreatic Cancer: Multidisciplinary Management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouraci | 2016 |
Localized Pancreatic Cancer: Multidisciplinary Management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouraci | 2016 |
Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic | 2016 |
Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic | 2016 |
Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic | 2016 |
Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic | 2016 |
Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic | 2016 |
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; ErbB Receptors; Fluorouracil; Humans; | 2016 |
Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycyt | 2016 |
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidin | 2016 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.
Topics: Antineoplastic Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Fluorouracil; | 2008 |
Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2009 |
Reflections on some pilot trials of gastrin receptor blockade in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Benzodiazepinones; Clinical Trials as Topic; Cyanoacrylates; Drug De | 2009 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 2009 |
The integration of chemoradiation in the care of patient with localized pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Capecitabine; Clinical Trials as Topic; Combin | 2009 |
Medical management of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aging; Antineoplastic Agents; Black People; Capecitabine; Deoxycytidine; Diabe | 2009 |
Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Chemoth | 2009 |
[Virchow's node as the form of onset of squamous cell carcinoma of the pancreas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplat | 2009 |
Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Tria | 2009 |
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycy | 2009 |
WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Pancreatic Ne | 2009 |
Diagnosis and management of pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Chemotherapy, Adjuvant; Cholangiog | 2009 |
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Drug Therapy; Flu | 2010 |
Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabi | 2010 |
What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Fluorouracil; Ge | 2010 |
Curative radiation therapy for pancreatic malignancies.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Dose-Response Relationship, R | 2010 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2010 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Challenges of drug resistance in the management of pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; | 2010 |
[Histologic assessment of treatment effect of preoperative chemoradiation in patients presenting with resectable pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2011 |
[A surgical (pancreatoduodenectomy) case of lymph node metastatic recurrence of colon cancer after chemotherapy].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Duoden | 2010 |
Pancreatic cancer in 2010: new insights for early intervention and detection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA, Neoplasm; Fluorouracil; Geno | 2011 |
Treatment of early-stage pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; De | 2011 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic | 2011 |
[Second line chemotherapy for pancreatic cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Deoxycytidine; Drug Therapy, Combinatio | 2011 |
Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neopla | 2011 |
Pancreatic cancer.
Topics: Fluorouracil; Humans; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pylorus | 2010 |
FOLFOX regimen in pancreatic acinar cell carcinoma: case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Fluorouracil; Humans; | 2012 |
[Evidences for adjuvant therapy of resected pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Ev | 2011 |
[Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2011 |
Inoperable pancreatic adenocarcinoma rendered complete remission by high-intensity focused ultrasound concurrent with gemcitabine-capecitabine chemotherapy: case report and topic review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cap | 2012 |
What options are available for refractory pancreatic cancer?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug | 2012 |
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Delivery System | 2012 |
Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2014 |
New biomarkers and targets in pancreatic cancer and their application to treatment.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma in Situ; Carcinoma, Pan | 2012 |
Management of diabetes and pancreatic cancer.
Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2012 |
New developments in pancreatic cancer treatment.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Du | 2012 |
FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Fluorouracil; H | 2013 |
The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Top | 2013 |
Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Fluorouraci | 2002 |
Pancreatic cancer: evidence-based diagnosis and treatment.
Topics: Chemotherapy, Adjuvant; Cholestasis; Fluorouracil; Humans; Neoplasm Staging; Neuroendocrine Tumors; | 2002 |
Metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Autonomic Nerve Block; Celiac Plexus; Cholestasis; Clinical Trials as Topic; | 2002 |
New drugs for patients with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2002 |
[Gemcitabine and pancreatic cancer].
Topics: Adenocarcinoma; Analgesia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2002 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati | 2002 |
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabin | 2002 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2002 |
Future directions in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 2002 |
Developments in the systemic therapy of pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2003 |
[Adjuvant and additive therapy for cancer of the pancreas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as T | 2003 |
[Pancreatic cancer. The relative importance of neoadjuvant therapy].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Case-Control Studies; Child; Ci | 2003 |
Systemic therapy for advanced pancreatic cancer.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Cycle; Cycloox | 2002 |
Chemotherapeutic advances in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pa | 2003 |
Gene therapy for pancreatic cancer targeting the genomic alterations of tumor suppressor genes using replication-selective oncolytic adenovirus.
Topics: Adenoviridae; Animals; Fluorouracil; Gene Targeting; Genes, p53; Genes, Retinoblastoma; Genes, Tumor | 2002 |
[Adjuvant treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2003 |
Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical T | 2003 |
Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; | 2003 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 2003 |
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2003 |
[Chemoradiation in pancreatic carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined M | 2003 |
Pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil | 2003 |
New perspectives in the management of pancreas cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2003 |
[The update on pancreatic cancer chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2003 |
Advanced pancreatic cancer: is there a role for combination therapy?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2003 |
[Conservative therapy for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine | 2004 |
[A case of AFP producing pancreatic acinar cell carcinoma diagnosed by EUS FNA and treated by intraarterial injection chemotherapy].
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carc | 2004 |
Systemic chemotherapy for pancreatic cancer.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Fluorouracil; Humans | 2004 |
Emerging drugs in pancreatic cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 2004 |
Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality | 2004 |
New approaches for pancreatic cancer in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Fluorouracil; Gemcitabine; Ge | 2004 |
Poorly differentiated small cell carcinoma of the pancreas. A case report and review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Fatal Outcome; Fluorouracil; Humans; M | 2004 |
The Virginia Mason approach to localized pancreatic cancer.
Topics: Academic Medical Centers; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2004 |
The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials | 2004 |
Pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancreatic Neoplasms; | 2004 |
[Chemoradiation for pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2004 |
Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Combined Mo | 2005 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2005 |
Systemic therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2005 |
Role of adjuvant therapy in the management of pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Can | 2005 |
[Combination chemotherapy in unresectable pancreatic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pa | 2006 |
Current state of adjuvant therapy in resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Combined Modality | 2006 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; D | 2006 |
The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2006 |
Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon alpha: report on several cases and review of the literature [ISRCTN62866759].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Calcium; Cisplatin; Combined Modalit | 2006 |
Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Fluoro | 2006 |
Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; | 2006 |
Capecitabine in carcinoma of the pancreas.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2006 |
[Arterial infusion chemotherapy for patients with advanced pancreatic cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug | 2006 |
The case for routine use of adjuvant therapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemotherapy, Adjuv | 2007 |
Pancreatic cancer: an update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; D | 2007 |
Treatment of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2007 |
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluo | 2007 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; | 2007 |
Adjuvant therapy for pancreatic cancer: to treat or not to treat?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Flu | 2007 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; | 2007 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; | 2007 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; | 2007 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; | 2007 |
[Treatments of pancreatic cancer from the standpoint of medical oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Sch | 2007 |
Locally advanced pancreatic cancer: a review.
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; | 2007 |
Cytotoxic therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Tria | 2007 |
Future chemoradiation strategies in pancreatic cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; | 2007 |
[Gemcitabine and digestive carcinomas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 2007 |
Neoadjuvant and adjuvant strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidin | 2008 |
[Angiogenesis targeting in gastro-intestinal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Safety of capecitabine use in patients with liver dysfunction.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug-Relate | 2007 |
Adjuvant therapy in pancreatic cancer: a critical appraisal.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Che | 2007 |
[Chemotherapy and radiotherapy for inoperable pancreatic cancer. A survey of a Cochrane review].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality T | 2007 |
[Radiation therapy in pancreatic cancer].
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorour | 2008 |
[Chemotherapy for pancreatic cancer].
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidin | 2008 |
Pancreatic cancer--is the wall crumbling?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Ad | 2008 |
New directions in the management of advanced pancreatic cancer: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
[Zollinger-Ellison syndrome].
Topics: Benzimidazoles; Calcium; Cimetidine; Diarrhea; Duodenal Ulcer; Female; Fluorouracil; Gastrectomy; Ga | 1984 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
[Results of considerations on the chemotherapy of pancreatic neoplasms].
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans | 1980 |
Systemic chemotherapy for advanced gastrointestinal cancer.
Topics: Antineoplastic Agents; Apudoma; Biliary Tract Neoplasms; Colonic Neoplasms; Drug Therapy, Combinatio | 1980 |
Possibilities and limitations of the cytostatic treatment of gastrointestinal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Es | 1982 |
Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bilirubin; Combined Modality Therapy; Fatal Outcome; Fe | 1995 |
Cancers of the large bowel and hepatobiliary tract.
Topics: Carcinoma, Hepatocellular; Colorectal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Pancreatic N | 1994 |
Surgery of pancreatic cancer.
Topics: Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognos | 1994 |
Adjuvant postoperative therapy of gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1994 |
Current approaches to multimodality management of advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Tri | 1993 |
Radiotherapy for carcinoma of the pancreas.
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials a | 1996 |
Chemotherapy of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Horm | 1996 |
Chemotherapy for pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Pancreatic Neoplas | 1996 |
Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma.
Topics: Antimetabolites, Antineoplastic; Bromodeoxyuridine; Combined Modality Therapy; Deoxycytidine; Floxur | 1996 |
New developments in chemotherapy for patients with advanced pancreatic cancer.
Topics: Analgesics; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Ph | 1996 |
[Adjuvant therapies in combination with pancreatectomy for carcinoma of the pancreas].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; | 1996 |
[Chemotherapy for pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; F | 1996 |
[A case of alpha-fetoprotein-producing pancreatic carcinoma--review of 41 cases reported in Japan].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 1996 |
Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study.
Topics: Adenocarcinoma; Aged; Antidotes; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease | 1997 |
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: the Royal Marsden Hospital experience.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Esophageal Neoplasms; Fluorouracil; Gastroint | 1997 |
Chemotherapy in advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Pancreatic Neoplasms | 1997 |
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience.
Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Clinical Trials as Topic; | 1996 |
[Evaluation of antitumor effect of chemotherapy for pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic | 1997 |
Clinical experience with gemcitabine in pancreatic carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Drug Evalu | 1997 |
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Deox | 1998 |
Chemotherapy in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 1998 |
Treatment of advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cis | 1998 |
Clinical development of eniluracil: current status.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1998 |
Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancr | 1998 |
[Ways of improving long-term results of treatment in resectable pancreatic cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy; Evaluation | 1998 |
Practical recommendations for the management of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Ther | 1999 |
Chemotherapy for advanced pancreatic cancer: it may no longer be ignored.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deo | 1999 |
Intravenous and intra-arterial chemotherapeutic possibilities in biliopancreatic cancer.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Inf | 1999 |
Adjuvant therapy for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancreatic Neoplasms; | 1999 |
[Adenocarcinoma of the exocrine pancreas: management and therapeutic hopes].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Case-Control Studies; Chemotherapy, Adjuvant; Clini | 1999 |
Adjuvant/neoadjuvant chemoradiation for gastric and pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Fluorour | 1999 |
[Chemotherapy, combined radiochemotherapy and new therapeutic approaches in adenocarcinoma of the pancreas].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1999 |
Current status of and future prospects for the medical management of adenocarcinoma of the exocrine pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Flu | 2000 |
Clinical update of gemcitabine in pancreas cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Com | 2000 |
[Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 2000 |
Chemotherapy in the treatment of neuroendocrine malignant tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Doxorubicin; Etoposide; Fluo | 2000 |
The treatment of pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Pancreatic Ductal; Chemotherapy, | 2000 |
[Primary and adjuvant radiochemotherapy of pancreatic carcinoma].
Topics: Combined Modality Therapy; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreat | 2000 |
[Adjuvant therapy of pancreatic carcinoma].
Topics: Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pa | 2000 |
The role of gemcitabine alone and in combination in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 2000 |
Gemcitabine: progress in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2001 |
[Palliative therapy of pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Ge | 2001 |
Neoadjuvant strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deo | 2001 |
A systematic overview of chemotherapy effects in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; | 2001 |
Islet cell tumors of the pancreas: the medical oncologist's perspective.
Topics: Adenoma, Islet Cell; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Ag | 2001 |
Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phyto | 2001 |
Vision of the future: capecitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2001 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Hu | 2001 |
Pancreatic cancer: what the oncologist can offer for palliation.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Enzyme Inhibitors; Fluoroura | 2002 |
Gemcitabine-based combination treatment of pancreatic cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 2002 |
[Radiotherapy and chemotherapy for unresectable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2002 |
[A new regional arterial infusion chemotherapy for patients with advanced pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Embolization, Therapeutic; Fluorouracil; | 2002 |
[Gene therapy for pancreatic cancer].
Topics: Adenoviridae; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Fluorouracil; Genet | 2002 |
What's new in pancreatic cancer treatment?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow D | 2002 |
Management of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2002 |
Present and future treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clini | 2002 |
[Chemotherapy of gastrointestinal tumors (review of the literature)].
Topics: Ancitabine; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fl | 1978 |
The radiotherapy of pancreatic cancer.
Topics: Clinical Trials as Topic; Fluorouracil; History, 20th Century; Humans; Pancreatic Neoplasms; Radioth | 1979 |
Management of gastrointestinal cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1977 |
Chemotherapy of gastrointestinal cancer.
Topics: Apudoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; Hum | 1978 |
Chemotherapy of pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Fluorour | 1979 |
The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carmustine; Drug Therapy, Combination; Female; F | 1975 |
[Chemotherapy for advanced pancreatic carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclo | 1992 |
Combined radiotherapy and chemotherapy in the treatment of gastrointestinal malignancies.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neo | 1992 |
Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedu | 1992 |
Aggressive therapy for cancer of the pancreas. Does it help?
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Care; Palliative Car | 1990 |
Radiotherapy in the treatment of pancreatic cancer.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Period; Neoplasm Metastasis; Neoplas | 1990 |
Chemotherapy for pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr | 1990 |
Clinical trials with 5-fluorouracil, folinic acid and cisplatin in patients with gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Evaluation; Fl | 1990 |
[Combination radiotherapy and chemotherapy in cancer of the pancreas. Review of the literature and prospects].
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Pancreatic Neoplasms; Prognosis; Ra | 1990 |
Pancreatic cancer in 1988. Possibilities and probabilities.
Topics: Adenocarcinoma; Combined Modality Therapy; Diagnosis, Differential; Fluorouracil; Humans; Lymphatic | 1988 |
The role of chemotherapy in the management of gastric and pancreatic carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1985 |
Potentiation of antimetabolite action by alkylating agents.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brea | 1985 |
The prognosis and management of recurrent abdominal malignancies.
Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Agents; Bile Duct Neoplasms; Chemotherapy, Ca | 1969 |
Recent advances in pancreatic cancer.
Topics: Adenocarcinoma; Angiography; Antigens, Neoplasm; Biopsy; Carcinoembryonic Antigen; Endoscopy; Evalua | 1974 |
[A review of clinical tumor immunology. An approach to immunochemotherapy].
Topics: Animals; Antibiotics, Antineoplastic; BCG Vaccine; Cytarabine; Drug Therapy, Combination; Fluorourac | 1974 |
541 trials available for fluorouracil and Cancer of Pancreas
| Article | Year |
|---|---|
Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dise | 2021 |
Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dise | 2021 |
Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dise | 2021 |
Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dise | 2021 |
Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Femal | 2021 |
Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2021 |
Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dendritic Cells; Fluor | 2021 |
Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dendritic Cells; Fluor | 2021 |
Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dendritic Cells; Fluor | 2021 |
Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dendritic Cells; Fluor | 2021 |
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Hum | 2022 |
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo | 2022 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytid | 2022 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytid | 2022 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytid | 2022 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytid | 2022 |
Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Humans; Irino | 2022 |
Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Humans; Irino | 2022 |
Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Humans; Irino | 2022 |
Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Humans; Irino | 2022 |
Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Granulocyte | 2022 |
Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Granulocyte | 2022 |
Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Granulocyte | 2022 |
Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Granulocyte | 2022 |
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Fluorour | 2022 |
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Fluorour | 2022 |
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Fluorour | 2022 |
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Fluorour | 2022 |
Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxalip | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Flu | 2022 |
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Flu | 2022 |
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Flu | 2022 |
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Flu | 2022 |
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Pancreatic Ductal; Chemotherapy, | 2022 |
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Pancreatic Ductal; Chemotherapy, | 2022 |
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Pancreatic Ductal; Chemotherapy, | 2022 |
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Pancreatic Ductal; Chemotherapy, | 2022 |
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2022 |
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2022 |
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2022 |
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2022 |
Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Circulating Tumor DNA; Clinical Trials | 2022 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorourac | 2023 |
Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Forkhead Transcription Factors; Humans | 2023 |
Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Femal | 2023 |
The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defin
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; | 2023 |
Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Fluorouracil; Human | 2023 |
Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Fluorouracil; Human | 2023 |
Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Fluorouracil; Human | 2023 |
Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Fluorouracil; Human | 2023 |
Comparison of survival for metastatic pancreatic cancer patients treated with CPI-613 versus resected borderline-resectable pancreatic cancer patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
Comparison of survival for metastatic pancreatic cancer patients treated with CPI-613 versus resected borderline-resectable pancreatic cancer patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
Comparison of survival for metastatic pancreatic cancer patients treated with CPI-613 versus resected borderline-resectable pancreatic cancer patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
Comparison of survival for metastatic pancreatic cancer patients treated with CPI-613 versus resected borderline-resectable pancreatic cancer patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
Single-arm, phase II study of intra-arterial chemotherapy plus total neoadjuvant therapy to optimise complete response in distal rectal cancer: a study protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials, Phase II as Topi | 2023 |
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiothe | 2020 |
A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Caprylates; Female; Flu | 2019 |
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemoth | 2019 |
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2020 |
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspa | 2020 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia | 2020 |
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Femal | 2020 |
Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy.
Topics: Abdominal Pain; Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2020 |
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; An | 2020 |
Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2020 |
A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Moda | 2020 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2020 |
Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycyti | 2020 |
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2020 |
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pa | 2020 |
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dose-Resp | 2021 |
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dose-Resp | 2021 |
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dose-Resp | 2021 |
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dose-Resp | 2021 |
R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deo | 2021 |
Adjuvant FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer: A Brown University Oncology Research Group Phase II Study (BrUOG295).
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; | 2020 |
nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug | 2020 |
A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; China; | 2020 |
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineop | 2021 |
A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxalip | 2021 |
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil | 2021 |
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2021 |
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Deoxycytidine; Female; Fluoro | 2022 |
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Deoxycytidine; Female; Fluoro | 2022 |
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Deoxycytidine; Female; Fluoro | 2022 |
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Deoxycytidine; Female; Fluoro | 2022 |
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled t
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemc | 2021 |
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Neuroendocrine; Etopos | 2021 |
Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; F | 2021 |
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2021 |
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leuco | 2021 |
Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; F | 2021 |
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2017 |
Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycyti | 2017 |
Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; | 2017 |
Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; | 2017 |
Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; | 2017 |
Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; | 2017 |
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; | 2019 |
HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free S | 2018 |
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Neuroendocrine | 2018 |
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycyti | 2018 |
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycyti | 2018 |
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycyti | 2018 |
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycyti | 2018 |
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplas | 2018 |
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin | 2018 |
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2018 |
Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug | 2018 |
Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Di | 2019 |
Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; D | 2018 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pa | 2018 |
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2019 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; | 2018 |
FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 | 2019 |
Diffusion kurtosis imaging and conventional diffusion weighted imaging to assess electrochemotherapy response in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidi | 2019 |
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations | 2019 |
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2019 |
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2019 |
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Fluorouracil | 2019 |
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomiz
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fe | 2019 |
Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Disease- | 2013 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related | 2013 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related | 2013 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related | 2013 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related | 2013 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related | 2013 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related | 2013 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related | 2013 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related | 2013 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related | 2013 |
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; | 2013 |
Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Female; Fluorou | 2013 |
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemot | 2013 |
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benztropine; Camptoth | 2013 |
[Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; | 2013 |
Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidin | 2014 |
Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidin | 2014 |
Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidin | 2014 |
Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidin | 2014 |
Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Blood Vessels; Capecitabine; Chemoradiotherap | 2013 |
First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine | 2014 |
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2014 |
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, A | 2014 |
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, A | 2014 |
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, A | 2014 |
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, A | 2014 |
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine | 2014 |
Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease.
Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Rea | 2014 |
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2014 |
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2014 |
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2014 |
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2014 |
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi | 2014 |
Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Che | 2014 |
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
Clinical benefit response in pancreatic cancer trials revisited.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Causality; Comorbidity; Deoxycy | 2014 |
Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 2014 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidin | 2014 |
A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Cohort Studies; De | 2014 |
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Topics: Adolescent; Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Proto | 2014 |
A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Capeci | 2014 |
Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2014 |
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Capecitabine; | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2014 |
Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2014 |
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combin | 2015 |
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combin | 2015 |
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combin | 2015 |
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combin | 2015 |
Oxaliplatin and ototoxicity: is it really safe for hearing?
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co | 2014 |
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine | 2015 |
Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD8-Positi | 2015 |
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2015 |
Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplas | 2015 |
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Camptotheci | 2015 |
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2015 |
A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; | 2015 |
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; | 2016 |
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Clinical Protocols; Deoxycytid | 2015 |
Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Humans; Live | 2015 |
Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Humans; Live | 2015 |
Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Humans; Live | 2015 |
Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Humans; Live | 2015 |
FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Disease-Free | 2016 |
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2018 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alleles; Chemoradiotherapy; Deoxycytidine; Female; F | 2016 |
Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fracti | 2016 |
Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2016 |
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2016 |
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Fe | 2016 |
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancrea | 2016 |
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancrea | 2016 |
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancrea | 2016 |
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancrea | 2016 |
A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fraction | 2016 |
A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fraction | 2016 |
A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fraction | 2016 |
A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fraction | 2016 |
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; | 2016 |
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; | 2016 |
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; | 2016 |
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; | 2016 |
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; | 2016 |
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; | 2016 |
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; | 2016 |
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; | 2016 |
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; | 2016 |
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cam | 2016 |
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, A | 2018 |
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazo | 2017 |
Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Duc | 2017 |
Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial.
Topics: Aged; Deoxycytidine; Duodenum; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancrea | 2017 |
Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradi | 2017 |
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com | 2008 |
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Diseas | 2008 |
Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Fema | 2009 |
Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Deoxycytid | 2009 |
Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2008 |
Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle A | 2008 |
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; | 2009 |
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; | 2009 |
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; | 2009 |
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; | 2009 |
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).
Topics: Adolescent; Adult; Animals; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 2008 |
Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Feasibility | 2008 |
A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combin | 2009 |
Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2008 |
Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; | 2009 |
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Dige | 2009 |
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine | 2009 |
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2009 |
Second-line therapy in refractory pancreatic cancer. results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox | 2009 |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combi | 2009 |
Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Ad | 2009 |
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2009 |
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Combined Modality Therapy; Deo | 2009 |
[Assessment of the value of PEF (cisplatin, epirubicin, 5 fluorouracil) in advanced extrahepatic biliary tract and pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrah | 2008 |
Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; | 2009 |
Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; D | 2010 |
A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapR
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 2009 |
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Feasibility | 2009 |
Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabin | 2009 |
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2009 |
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2009 |
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2009 |
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2009 |
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cross-Over Studies; Deoxy | 2010 |
Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Monitori | 2010 |
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2009 |
Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine | 2010 |
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2009 |
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomis
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2009 |
An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinica
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Fluorouracil; | 2009 |
Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Ca | 2010 |
Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2010 |
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Ne | 2010 |
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Demograph | 2011 |
Chemotherapy followed by chemoradiotherapy for locally advanced non-metastatic pancreatic cancer - a new paradigm?
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Hu | 2010 |
Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2010 |
Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Cyta | 2011 |
Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2010 |
Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2010 |
A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; | 2011 |
Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fl | 2010 |
Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; D | 2010 |
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2011 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2010 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2010 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2010 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2010 |
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2010 |
Nutritional status of patients with locally advanced pancreatic cancer: a pilot study.
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Body Weight; Cachexia; Capecitabine; Combined Modal | 2011 |
FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leuc | 2011 |
[The role of slow-release 5-fluorouracil implantation in treatment of unresectable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Drug Implants; Female; Fluorouracil; Follow-Up Studies; Humans; Mal | 2010 |
Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2012 |
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; | 2012 |
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2011 |
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant | 2011 |
First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Femal | 2011 |
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxyc | 2012 |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; D | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2011 |
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; | 2012 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
Systemic gemcitabine and capecitabine plus intra-arterial epirubicin and cisplatin as second-line chemotherapy in gemcitabine-failure pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free | 2011 |
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2011 |
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Benzimidazoles; Capecitabine; Deoxy | 2012 |
Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Duc | 2012 |
Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Cytidine Deaminase; Deoxycytidine; Dise | 2012 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2012 |
A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Moda | 2011 |
Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2011 |
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Disease-Free Survival | 2011 |
Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2012 |
Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2011 |
The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2012 |
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiot | 2012 |
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.
Topics: Adenoviruses, Human; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemoradiotherapy; Cho | 2012 |
A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2012 |
Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabi | 2012 |
Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Fema | 2013 |
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluor | 2012 |
Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Fr | 2012 |
Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2012 |
VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineopla | 2012 |
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; D | 2013 |
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modal | 2012 |
Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxyc | 2012 |
Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxyc | 2012 |
Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxyc | 2012 |
Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxyc | 2012 |
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2012 |
Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chem | 2012 |
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Proto | 2012 |
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; | 2013 |
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycyti | 2013 |
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2013 |
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canc | 2013 |
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canc | 2013 |
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canc | 2013 |
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canc | 2013 |
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capeci | 2012 |
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2013 |
Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2013 |
Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Diseas | 2013 |
Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2002 |
Palliative MEFLEP therapy in advanced pancreatic cancer: excellent response in a patient with Her-2/neu amplification.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Ph | 2002 |
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxyc | 2002 |
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cis | 2002 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Ne | 2002 |
Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adju | 2002 |
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D | 2002 |
Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Female; Fluor | 2002 |
A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2002 |
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols | 2003 |
Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluoroura | 2003 |
Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxyc | 2003 |
Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu | 2003 |
Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2003 |
Peripancreatic artery ligation and artery infusion chemotherapy for advanced pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arteries; Female; Fluorouracil; Humans; Infusions, I | 2003 |
Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2003 |
Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Fema | 2003 |
A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluorouracil; Hu | 2003 |
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox | 2003 |
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidin | 2003 |
Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; CA-19-9 Antige | 2003 |
Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemc | 2003 |
[Experience with the treatment of advanced pancreatic cancer in Hungary].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedu | 2003 |
Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Admin | 2003 |
Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fea | 2003 |
First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclin G; Cyclin G1; Cycl | 2004 |
Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Caff | 2003 |
Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 2004 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; D | 2004 |
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Infusions | 2004 |
Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluor | 2004 |
Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dose-Res | 2004 |
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Dox | 2004 |
Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplasti | 2004 |
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 2004 |
5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase I-II dose-escalation study.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorourac | 2004 |
Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group.
Topics: Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; D | 2004 |
Neoadjuvant induction chemotherapy followed by chemoradiation: a phase I trial of gemcitabine, cisplatin, and 5-fluorouracil for advanced pancreatic/gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2004 |
[Intraoperative 125I brachytherapy combined with chemotherapy for pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined Modality Therapy; Deox | 2004 |
Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Female; Fluoro | 2003 |
Phase I study of hyperfractionated radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Dose Fractionation, Radiation; Drug Ad | 2004 |
Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2004 |
5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Clinic | 2005 |
[A phase II study of combination chemotherapy with gemcitabine, 5-fluorouracil, and cisplatin for advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluor | 2005 |
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2005 |
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Fem | 2005 |
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2005 |
A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2005 |
Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2005 |
Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; | 2005 |
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; | 2005 |
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; | 2005 |
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; | 2005 |
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cli | 2005 |
Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chi-Square Distributi | 2005 |
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deox | 2005 |
A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; D | 2005 |
Prospective randomized clinical trial of two drug delivery pathway in the treatment of inoperable advanced pancreatic carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2006 |
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2006 |
A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Combined Modality The | 2006 |
A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Ad | 2006 |
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetab | 2006 |
Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dose-Response Relationsh | 2006 |
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Fe | 2006 |
Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2006 |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Ge | 2006 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Drug Administr | 2006 |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxyc | 2006 |
Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2003 |
Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2006 |
Clinical monitoring of innate cellular immunity of monocytes/macrophages by tumor necrosis factor alpha productivity in whole blood stimulated by lipopolysaccharide in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Deoxycytidine; Fem | 2006 |
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidin | 2007 |
Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2006 |
Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2006 |
Phase I/II trial of hyperfractionated accelerated chemoradiotherapy for unresectable advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dose Fra | 2006 |
A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free S | 2006 |
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progres | 2007 |
[Effect of combined treatment methods on quality of life in patients with pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Data Int | 2006 |
FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Fe | 2007 |
Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality | 2007 |
Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2007 |
A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-1 | 2007 |
Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dipy | 2007 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 2006 |
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; G | 2007 |
Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disea | 2007 |
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidin | 2007 |
Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2008 |
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine | 2008 |
[A modified Dworak classification applied to pancreatic adenocarcinoma: a useful prognostic factor].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2007 |
Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891.
Topics: Adult; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Common Bile | 2007 |
The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Fluo | 2007 |
3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Ther | 2008 |
A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fl | 2008 |
Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Pr | 2007 |
Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 2008 |
Intra-arterial chemotherapy of advanced pancreatic cancer: a single center experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemothera | 2007 |
32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phospho | 2008 |
Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en O
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Feasibility Studies; Female; Fluorour | 2008 |
A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoemboliza | 2008 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidin | 2008 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; | 2008 |
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; | 2008 |
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; | 2008 |
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; | 2008 |
Treatment with secretin and a cholecystokinin-like peptide in patients with pancreatic cancer. A pilot study.
Topics: Adenocarcinoma; Aged; Alanine Transaminase; Alkaline Phosphatase; Amylases; Antineoplastic Combined | 1984 |
Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Therapy, | 1983 |
Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.
Topics: Adenoma, Islet Cell; Adolescent; Adult; Aged; Clinical Trials as Topic; Drug Administration Schedule | 1980 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Doxorubicin; Drug Administration Schedu | 1983 |
Combined modality treatment of pancreatic cancer: implications for the surgeon.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Drug Therapy, Combinatio | 1983 |
Treatment of unresectable pancreatic carcinoma with 5-fluorouracil, vincristine, and CCNU.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Fluorouracil | 1983 |
MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxo | 1984 |
[Joint clinical Phase II study of SF-SP].
Topics: Clinical Trials as Topic; Colonic Neoplasms; Delayed-Action Preparations; Drug Evaluation; Female; F | 1984 |
Chemotherapy of pancreatic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combinat | 1981 |
Clinical problems in radiotherapy of carcinoma of the pancreas.
Topics: Adenocarcinoma; Alpha Particles; Clinical Trials as Topic; Fluorouracil; Helium; Humans; Liver Neopl | 1982 |
5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Aged; Agranulocytosis; Anorexia; Antineoplastic Agents; Clinical Trials as Topic; Do | 1980 |
Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorour | 1980 |
Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group.
Topics: Adenocarcinoma; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combinat | 1981 |
The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced gastrointestinal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Dru | 1981 |
Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial.
Topics: Adenocarcinoma; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up | 1981 |
A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic cancer.
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Drug Combinations; Female; Fluorouracil; Humans; | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Hu | 1995 |
Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltran | 1994 |
Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial.
Topics: Adult; Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Th | 1995 |
Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1995 |
5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. GLISP (Gruppo Ligure Studio Pancreas).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1995 |
[Pharmacological study of 5'-DFUR oral administration and the clinical responses against gastrointestinal carcinoma].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Sch | 1995 |
Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Combined Mod | 1994 |
A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Female; Fluorouracil; Humans; Leucovorin; Male; Midd | 1994 |
A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors.
Topics: Adenoma, Islet Cell; Adult; Aged; Carcinoid Tumor; Drug Administration Schedule; Drug Therapy, Combi | 1994 |
Chemotherapy prolongs survival in inoperable pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Depression; | 1994 |
Effectiveness of chemotherapy for advanced adenocarcinoma of the pancreas in combined modality therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Autonomic Nerve Block; Celiac Plexus; Combined Modal | 1994 |
Radiation and chemotherapy. Treatment of localized pancreatic carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 1994 |
Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Combined Modali | 1994 |
Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1994 |
[Concomitant arterial infusion chemotherapy with tamoxifen therapy for hepatic metastases from pancreatic adenocarcinoma--a preliminary report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Inject | 1993 |
High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Humans; Int | 1993 |
Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Evaluation Studies as Top | 1994 |
A phase II study of 5-fluorouracil, leucovorin and interferon-alpha in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; I | 1993 |
Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Duodenal Neoplasms; | 1993 |
Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorourac | 1993 |
5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Interferon-alpha | 1993 |
Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvan | 1993 |
Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Flu | 1993 |
Survival after combined modality therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1993 |
Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis | 1993 |
A phase I study of combined radiation therapy with 5-fluorouracil and low dose folinic acid in patients with locally advanced pancreatic or biliary carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Com | 1996 |
A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; | 1996 |
High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1996 |
Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1996 |
[Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Stu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Doxorubicin; F | 1996 |
Regional chemotherapy for inoperable pancreatic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Infusi | 1996 |
Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1996 |
Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineop | 1996 |
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Body Weight; Deoxycytidine; Disease Pr | 1996 |
Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Topics: Adenocarcinoma; Administration, Oral; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplast | 1996 |
Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Etoposide; Fem | 1996 |
Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Female; Flu | 1996 |
Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1996 |
Pilot study in locally advanced unresectable pancreas carcinoma using a combination of accelerated radiotherapy and continuous infusion of 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Human | 1996 |
Objective outcome measures of quality of life.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Karnofsky Perform | 1996 |
A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplati | 1997 |
Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis | 1997 |
Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease Pro | 1997 |
Concomitant intraarterial cisplatin, intravenous 5-flourouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1997 |
Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neopla | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Huma | 1997 |
Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Clinical Protocols; Combined | 1997 |
The French experience with infusional 5-FU in gastric and pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bio | 1996 |
Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; | 1997 |
Clinical benefit with cisplatin, hydroxyurea and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 1997 |
Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Flu | 1997 |
Palliative and adjuvant regional chemotherapy in pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Celiac Artery; Ch | 1997 |
Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Doxo | 1998 |
Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Female | 1998 |
Continuous venous infusion 5-fluorouracil and interferon-alpha in pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1998 |
Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diterpenes; Epirubicin; | 1998 |
A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ca | 1998 |
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Deox | 1998 |
Combined epirubicin, 5-fluorouracil and folinic acid vs no treatment for patients with advanced pancreatic cancer: a prospective comparative study.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fluorour | 1998 |
Adjuvant therapy for pancreatic cancer: back to the future.
Topics: Antimetabolites, Antineoplastic; Clinical Protocols; Clinical Trials, Phase III as Topic; Combined M | 1998 |
Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma; Cisplatin; Drug Admini | 1999 |
Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; D | 1999 |
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Ge | 1999 |
Complete remission of nonresectable pancreatic cancer after infusional colloidal phosphorus-32 brachytherapy, external beam radiation therapy, and 5-fluorouracil: a preliminary report.
Topics: Aged; Antimetabolites, Antineoplastic; Brachytherapy; CA-19-9 Antigen; Combined Modality Therapy; Fe | 1999 |
Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Carcinoma, Islet Cell; | 1999 |
A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Female; Fluorou | 1999 |
Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxyurac | 1999 |
Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combinatio | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Phase II study with 5-fluorouracil and ginkgo biloba extract (GBE 761 ONC) in patients with pancreatic cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Female; | 1999 |
Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2000 |
A phase II trial of 5-fluorouracil, leucovorin, and interferon alpha 2A (IFN-alpha 2a) in metastatic pancreatic carcinoma: a Penn Cancer Clinical Trials Group (PCCTG) trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Interfero | 2000 |
A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2000 |
Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Ge | 2000 |
Modulation of fluorouracil by methotrexate, leucovorin, and cisplatin (M-FLP) in the treatment of advanced pancreatic cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2000 |
[Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2000 |
Intra-arterial chemotherapy for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2000 |
A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ductal, Breast; Cathet | 2000 |
Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2000 |
Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2000 |
Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2000 |
Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2000 |
A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etop | 2000 |
The feasibility of dose escalation using concurrent radiation and 5-fluorouracil therapy following pancreaticoduodenectomy for pancreatic carcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival | 2000 |
Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; An | 2000 |
Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deo | 2000 |
Neoadjuvant radio-chemotherapy in advanced primarilynon-resectable carcinomas of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Radiation; Fluor | 2000 |
Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer: a North Central Cancer Treatment Group Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Female | 2000 |
A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Ge | 2000 |
A comparison of two dose regimens in pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Fluoro | 2000 |
Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Femal | 2000 |
Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2001 |
Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Disease Pr | 2001 |
Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2001 |
Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Human | 2001 |
Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2001 |
Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease- | 2001 |
A pilot study of chronomodulated infusional 5-fluorouracil chemoradiation for pancreatic cancer.
Topics: Adenocarcinoma; Age Factors; Aged; Chemotherapy, Adjuvant; Chronotherapy; Combined Modality Therapy; | 2001 |
Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Le | 2001 |
A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Dig | 2001 |
Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Feasibility | 2001 |
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality The | 2001 |
Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Consumer Product Safety; | 2002 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2002 |
Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2002 |
Cytoreductive surgery combined with intraoperative chemo-hyperthermia and postoperative radiotherapy in the management of advanced pancreatic adenocarcinoma: feasibility aspects and efficacy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Feasibility Studie | 2001 |
Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; | 2002 |
Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2002 |
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Epiru | 2002 |
Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2002 |
The radiotherapy of pancreatic cancer.
Topics: Clinical Trials as Topic; Fluorouracil; History, 20th Century; Humans; Pancreatic Neoplasms; Radioth | 1979 |
Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide.
Topics: Adenocarcinoma; Aged; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combina | 1977 |
Chemotherapy of gastric and pancreatic carcinoma: a controlled evaluation of combinations of 5-fluorouracil with nitrosoureas and "lactones".
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; N | 1979 |
Management of gastrointestinal cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1977 |
[A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)].
Topics: Adenocarcinoma; Carmustine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Intestinal Neoplasms; | 1979 |
5 FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer: a Southwest Oncology Group Study.
Topics: Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Drug Therapy, Combination; Female; Flu | 1979 |
Chemotherapy of pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Fluorour | 1979 |
Comparative therapeutic trial of radiation with or without chemotherapy in pancreatic carcinoma. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Aged; Bone Marrow; Clinical Trials as Topic; Fluorouracil; Humans; Middle Aged; Panc | 1979 |
A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; | 1979 |
Pancreatic cancer treated with carmustine, fluorouracil, and spironolactone: a randomized study.
Topics: Adult; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neopl | 1978 |
Randomized comparison of melphalan and 5-fluorouracil in the treatment of advanced gastrointestinal cancer.
Topics: Adult; Aged; Biliary Tract Diseases; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; F | 1976 |
Combined treatment with BCG and chemotherapy for metastatic gastrointestinal cancer.
Topics: BCG Vaccine; Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Gastrointestinal Neoplasm | 1977 |
Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.
Topics: Adenoma, Islet Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined | 1992 |
Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study.
Topics: Adenoma, Islet Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administratio | 1992 |
Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Dru | 1992 |
Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1992 |
[Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group o
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, | 1992 |
A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluor | 1992 |
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp | 1992 |
A phase I trial of fluorouracil, leucovorin, and recombinant interferon alpha-2b in patients with advanced malignancy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1992 |
Combination fluorouracil, folinic acid, and interferon alfa-2a: an active regimen in advanced pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Intrav | 1992 |
High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. A preliminary report of a multi-institutional trial (Radiation Therapy Oncology Group Protocol 8801).
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil | 1992 |
Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin.
Topics: Adenoma, Islet Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; C | 1991 |
Surgical palliation combined with synchronous therapy in pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Cholecystostomy; Choledochostomy; Combined Modality Therapy; Female; | 1990 |
[Treatment of advanced pancreatic cancer with 5-fluorouracil, 4-epidoxorubicin and mitomycin C (FEM II). From the Chemotherapy of Gastrointestinal Tumors Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Epirubicin; F | 1990 |
[Chemotherapy for advanced and recurrent cancer patients--the effect of combination chemotherapy using cisplatin, peplomycin, mitomycin C, adriamycin, and 5-fluorouracil].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colorectal Neopla | 1990 |
A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Caffeine; Carboplatin; | 1991 |
Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Fol | 1991 |
Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 1991 |
A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 1991 |
Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer.
Topics: Aged; Antigens, Tumor-Associated, Carbohydrate; Drug Evaluation; Female; Fluorouracil; Humans; Infus | 1991 |
Chemotherapy for pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr | 1990 |
[Chemotherapy of cancer of the exocrine pancreas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Infusions, Intra- | 1990 |
A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Proto | 1990 |
FAM chemotherapy +/- aminoglutethimide in the treatment of pancreatic carcinoma.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxoru | 1990 |
Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alkylating Agents; Antineoplastic Combined Chemother | 1989 |
A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Costs and | 1985 |
Combination chemotherapy with etoposide and 5-fluorouracil in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combinat | 1989 |
Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Humans; Male; Middle A | 1985 |
Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined M | 1988 |
Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fl | 1986 |
Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Admin | 1986 |
[Chemotherapy of advanced pancreatic cancer with 5-fluorouracil, doxorubicin and high-dose methotrexate].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dose-Response | 1988 |
Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topi | 1988 |
Mount Sinai clinical experience with leucovorin and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Drug Administra | 1988 |
Ifosfamide plus 5-fluorouracil for treatment of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1987 |
Combined modality treatment of localized unresectable adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Clinical Trials as To | 1988 |
A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1988 |
Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials | 1986 |
The role of chemotherapy in the management of gastric and pancreatic carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1985 |
Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle A | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer.
Topics: Adenocarcinoma; Clinical Trials as Topic; Fluorouracil; Gastrointestinal Neoplasms; Humans; Intestin | 1969 |
Current therapy approaches of the Division of Cancer Treatment with emphasis on pancreatic carcinoma.
Topics: Adenocarcinoma; Animals; Carcinoma; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials as Topi | 1974 |
Combination therapy with 5-fluorouracil (5-FU; NSC-19893) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) for disseminated gastrointestinal carcinoma.
Topics: Adult; Aged; Anemia, Aplastic; Blood Cell Count; Carcinoma; Clinical Trials as Topic; Colonic Neopla | 1972 |
[Oxytetracycline, vehicle for therapeutic drugs, fluorouracil and nitrogen mustard, in the treatment of gastrointestinal tumors].
Topics: Adenocarcinoma; Adult; Bile Duct Neoplasms; Clinical Trials as Topic; Drug Combinations; Esophagus; | 1970 |
1374 other studies available for fluorouracil and Cancer of Pancreas
| Article | Year |
|---|---|
Constituents of Brazilian red propolis and their preferential cytotoxic activity against human pancreatic PANC-1 cancer cell line in nutrient-deprived condition.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Necrosis; Nutriti | 2008 |
Preparation of novel (Z)-4-ylidenebenzo[b]furo[3,2-d][1,3]oxazines and their biological activity.
Topics: Animals; Antineoplastic Agents; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Proliferat | 2009 |
Chemical constituents of propolis from Myanmar and their preferential cytotoxicity against a human pancreatic cancer cell line.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Drug Screening Assays, Antitumor; Humans; Molecular St | 2009 |
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Multiple; Drug R | 2011 |
Synthesis, σ₁, σ₂-receptors binding affinity and antiproliferative action of new C1-substituted adamantanes.
Topics: Adamantane; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory | 2012 |
Uvaridacols E-H, highly oxygenated antiausterity agents from Uvaria dac.
Topics: Antineoplastic Agents, Phytogenic; Cyclohexenes; Dose-Response Relationship, Drug; Drug Screening As | 2012 |
New adamantane phenylalkylamines with σ-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Fe | 2012 |
Phorbaketals L-N, cytotoxic sesterterpenoids isolated from the marine sponge of the genus Phorbas.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Molecular S | 2014 |
Kaempulchraols A-H, Diterpenoids from the Rhizomes of Kaempferia pulchra Collected in Myanmar.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Crystallography, X-Ray; Diterpenes; Drug Screen | 2015 |
Chemical Constituents of Mangifera indica and Their Antiausterity Activity against the PANC-1 Human Pancreatic Cancer Cell Line.
Topics: Antineoplastic Agents, Phytogenic; Drug Screening Assays, Antitumor; Humans; Mangifera; Molecular St | 2016 |
Benzophenone Compounds, from a Marine-Derived Strain of the Fungus
Topics: Antineoplastic Agents; Benzophenones; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, A | 2019 |
Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cel | 2020 |
Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?
Topics: Age Factors; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Pr | 2022 |
Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Pr | 2022 |
Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy.
Topics: Fluorouracil; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Streptozocin; Treatment Outcome | 2022 |
A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorourac | 2021 |
Localization Defines Streptozotocin/5-FU Response in Primary Pancreatic Neuroendocrine Tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoplasms, Second Primary; Neu | 2022 |
A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fluoroura | 2022 |
Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2021 |
Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadj | 2023 |
Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, Irinotecan, and ctDNA.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Hum | 2021 |
Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Fluorouracil; Humans; Ir | 2021 |
Reviewing the Outcomes of Different Treatment Approaches in Elderly Pancreatic Cancer Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluo | 2021 |
Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Fluorouracil; Humans; Mutation; P | 2021 |
Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Ch | 2021 |
Intraoperative frozen section analysis of para-aortic lymph nodes after neoadjuvant FOLFIRINOX: will it soon become useless?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Frozen Sections; Human | 2022 |
Intraoperative frozen section analysis of para-aortic lymph nodes after neoadjuvant FOLFIRINOX: will it soon become useless?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Frozen Sections; Human | 2022 |
Intraoperative frozen section analysis of para-aortic lymph nodes after neoadjuvant FOLFIRINOX: will it soon become useless?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Frozen Sections; Human | 2022 |
Intraoperative frozen section analysis of para-aortic lymph nodes after neoadjuvant FOLFIRINOX: will it soon become useless?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Frozen Sections; Human | 2022 |
Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic D | 2022 |
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Car | 2021 |
Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Iri | 2022 |
Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxalip | 2022 |
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; | 2021 |
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; | 2021 |
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; | 2021 |
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; | 2021 |
Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model.
Topics: Animals; Carcinoma, Pancreatic Ductal; Fluorouracil; Fuzzy Logic; Humans; Immune Tolerance; Immunity | 2021 |
Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancre | 2021 |
Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
Topics: Aged; Analgesics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bic | 2021 |
[Locally advanced pancreatic cancer after FOLFIRINOX: surgical resection enhances survival].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxalip | 2022 |
Neoadjuvant Therapy for Rectal Cancer: Updates From the UNICANCER-PRODIGE 23 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Humans; Irinotecan; | 2022 |
Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxalip | 2022 |
Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxalip | 2022 |
Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxalip | 2022 |
Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxalip | 2022 |
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Fe | 2022 |
FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gemcitabine; Humans; Leucovori | 2022 |
[A Case of Metastatic Pancreatic Ductal Adenocarcinoma Successfully Treated with Modified FOLFIRINOX and Concurrent Radiotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Hu | 2021 |
[A Case of Pancreas Neuroendocrine Carcinoma Achieved Long-Term Survival by Carboplatin plus Etoposide Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Etopos | 2021 |
Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; | 2022 |
Thymidine phosphorylase induction by ionizing radiation antagonizes 5-fluorouracil resistance in human ductal pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Cell Line, Tumor; Fluorouracil; Humans; Pancreatic Neoplasms; Radiation, Ionizing; R | 2022 |
Thymidine phosphorylase induction by ionizing radiation antagonizes 5-fluorouracil resistance in human ductal pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Cell Line, Tumor; Fluorouracil; Humans; Pancreatic Neoplasms; Radiation, Ionizing; R | 2022 |
Thymidine phosphorylase induction by ionizing radiation antagonizes 5-fluorouracil resistance in human ductal pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Cell Line, Tumor; Fluorouracil; Humans; Pancreatic Neoplasms; Radiation, Ionizing; R | 2022 |
Thymidine phosphorylase induction by ionizing radiation antagonizes 5-fluorouracil resistance in human ductal pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Cell Line, Tumor; Fluorouracil; Humans; Pancreatic Neoplasms; Radiation, Ionizing; R | 2022 |
Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Male; Middle Aged; Neopl | 2022 |
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
5-fluorouracil suppresses stem cell-like properties by inhibiting p38 in pancreatic cancer cell line PANC-1.
Topics: Cell Line, Tumor; Cell Proliferation; Fluorouracil; Humans; Neoplastic Stem Cells; Pancreas; Pancrea | 2022 |
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cost-Benefit | 2022 |
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cost-Benefit | 2022 |
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cost-Benefit | 2022 |
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cost-Benefit | 2022 |
Bias and Pancreatic Cancer Reporting.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bias; Fluorouracil; Humans; Irinotec | 2022 |
Bias and Pancreatic Cancer Reporting.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bias; Fluorouracil; Humans; Irinotec | 2022 |
Bias and Pancreatic Cancer Reporting.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bias; Fluorouracil; Humans; Irinotec | 2022 |
Bias and Pancreatic Cancer Reporting.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bias; Fluorouracil; Humans; Irinotec | 2022 |
FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort | 2022 |
FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort | 2022 |
FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort | 2022 |
FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort | 2022 |
Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, An | 2022 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2022 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2022 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2022 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2022 |
Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Pancreatic Neopl | 2022 |
Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Pancreatic Neopl | 2022 |
Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Pancreatic Neopl | 2022 |
Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Pancreatic Neopl | 2022 |
Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2022 |
Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2022 |
Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2022 |
Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2022 |
Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; | 2022 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; | 2022 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; | 2022 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; | 2022 |
Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Mi | 2022 |
Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Mi | 2022 |
Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Mi | 2022 |
Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Mi | 2022 |
ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Fluorouracil; Humans; In | 2022 |
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Fluorouracil; Humans; In | 2022 |
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Fluorouracil; Humans; In | 2022 |
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Fluorouracil; Humans; In | 2022 |
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Resu
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Resu
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Resu
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Resu
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Response in
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Pancreatic | 2022 |
Response in
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Pancreatic | 2022 |
Response in
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Pancreatic | 2022 |
Response in
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Pancreatic | 2022 |
Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carbon-Sulfur Lyases; Dise | 2022 |
Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carbon-Sulfur Lyases; Dise | 2022 |
Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carbon-Sulfur Lyases; Dise | 2022 |
Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carbon-Sulfur Lyases; Dise | 2022 |
Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Fluorouracil; Huma | 2022 |
Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Fluorouracil; Huma | 2022 |
Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Fluorouracil; Huma | 2022 |
Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Fluorouracil; Huma | 2022 |
Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Fluorouracil; Humans; | 2022 |
Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Fluorouracil; Humans; | 2022 |
Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Fluorouracil; Humans; | 2022 |
Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Fluorouracil; Humans; | 2022 |
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Flu | 2022 |
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Flu | 2022 |
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Flu | 2022 |
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Flu | 2022 |
Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Flavonoids; | 2022 |
Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Flavonoids; | 2022 |
Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Flavonoids; | 2022 |
Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Flavonoids; | 2022 |
Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leuc | 2022 |
Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leuc | 2022 |
Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leuc | 2022 |
Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leuc | 2022 |
A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinot | 2022 |
A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinot | 2022 |
A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinot | 2022 |
A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinot | 2022 |
Continued adjuvant FOLFIRINOX for BRPC or LAPC after neoadjuvant FOLFIRINOX.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans | 2023 |
Continued adjuvant FOLFIRINOX for BRPC or LAPC after neoadjuvant FOLFIRINOX.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans | 2023 |
Continued adjuvant FOLFIRINOX for BRPC or LAPC after neoadjuvant FOLFIRINOX.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans | 2023 |
Continued adjuvant FOLFIRINOX for BRPC or LAPC after neoadjuvant FOLFIRINOX.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans | 2023 |
The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leuc | 2022 |
The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leuc | 2022 |
The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leuc | 2022 |
The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leuc | 2022 |
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Fluo | 2022 |
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Fluo | 2022 |
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Fluo | 2022 |
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Fluo | 2022 |
Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Immune Checkpoint Inhibitors; | 2022 |
Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Immune Checkpoint Inhibitors; | 2022 |
Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Immune Checkpoint Inhibitors; | 2022 |
Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Immune Checkpoint Inhibitors; | 2022 |
Management of elderly patients with unresectable pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2022 |
Management of elderly patients with unresectable pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2022 |
Management of elderly patients with unresectable pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2022 |
Management of elderly patients with unresectable pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2022 |
Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovo | 2023 |
Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovo | 2023 |
Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovo | 2023 |
Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovo | 2023 |
Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Ir | 2022 |
Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Ir | 2022 |
Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Ir | 2022 |
Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Ir | 2022 |
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; | 2022 |
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorou | 2023 |
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorou | 2023 |
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorou | 2023 |
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorou | 2023 |
Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2022 |
Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2022 |
Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2022 |
Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2022 |
Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis.
Topics: Aged; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancreatic Neoplasm | 2022 |
Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis.
Topics: Aged; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancreatic Neoplasm | 2022 |
Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis.
Topics: Aged; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancreatic Neoplasm | 2022 |
Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis.
Topics: Aged; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancreatic Neoplasm | 2022 |
Matairesinol Induces Mitochondrial Dysfunction and Exerts Synergistic Anticancer Effects with 5-Fluorouracil in Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; | 2022 |
Matairesinol Induces Mitochondrial Dysfunction and Exerts Synergistic Anticancer Effects with 5-Fluorouracil in Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; | 2022 |
Matairesinol Induces Mitochondrial Dysfunction and Exerts Synergistic Anticancer Effects with 5-Fluorouracil in Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; | 2022 |
Matairesinol Induces Mitochondrial Dysfunction and Exerts Synergistic Anticancer Effects with 5-Fluorouracil in Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; | 2022 |
Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidin | 2022 |
Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidin | 2022 |
Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidin | 2022 |
Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidin | 2022 |
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Development of 5-FU-modified tumor suppressor microRNAs as a platform for novel microRNA-based cancer therapeutics.
Topics: Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; MicroRNAs; Pa | 2022 |
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Isoliquiritigenin inhibits pancreatic cancer progression through blockade of p38 MAPK-regulated autophagy.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Chalcones; Drugs, Chinese Herbal; Fluorouracil; Mic | 2022 |
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Femal | 2023 |
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Femal | 2023 |
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Femal | 2023 |
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Femal | 2023 |
Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemokine CCL4; Cytoki | 2022 |
Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemokine CCL4; Cytoki | 2022 |
Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemokine CCL4; Cytoki | 2022 |
Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemokine CCL4; Cytoki | 2022 |
Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Carci | 2022 |
Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Carci | 2022 |
Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Carci | 2022 |
Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Carci | 2022 |
Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Carbohydrates; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Neoadjuvant Thera | 2022 |
Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Carbohydrates; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Neoadjuvant Thera | 2022 |
Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Carbohydrates; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Neoadjuvant Thera | 2022 |
Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Carbohydrates; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Neoadjuvant Thera | 2022 |
Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leuco | 2022 |
Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leuco | 2022 |
Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leuco | 2022 |
Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leuco | 2022 |
Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Incidence; Irinotecan; Leucovo | 2022 |
Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Incidence; Irinotecan; Leucovo | 2022 |
Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Incidence; Irinotecan; Leucovo | 2022 |
Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Incidence; Irinotecan; Leucovo | 2022 |
Predicting the chemosensitivity of pancreatic cancer cells as a personalized therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxalip | 2022 |
Predicting the chemosensitivity of pancreatic cancer cells as a personalized therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxalip | 2022 |
Predicting the chemosensitivity of pancreatic cancer cells as a personalized therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxalip | 2022 |
Predicting the chemosensitivity of pancreatic cancer cells as a personalized therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxalip | 2022 |
Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Induction Chemotherapy; Leucov | 2023 |
Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fluorouracil; Humans; Irin | 2023 |
Painful lower limb nodules as first symptom of resectable pancreatic acinar cell cancer: a case report.
Topics: Acinar Cells; Aged; Carcinoma, Acinar Cell; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Li | 2022 |
Painful lower limb nodules as first symptom of resectable pancreatic acinar cell cancer: a case report.
Topics: Acinar Cells; Aged; Carcinoma, Acinar Cell; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Li | 2022 |
Painful lower limb nodules as first symptom of resectable pancreatic acinar cell cancer: a case report.
Topics: Acinar Cells; Aged; Carcinoma, Acinar Cell; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Li | 2022 |
Painful lower limb nodules as first symptom of resectable pancreatic acinar cell cancer: a case report.
Topics: Acinar Cells; Aged; Carcinoma, Acinar Cell; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Li | 2022 |
Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; COVID-19; Deoxycytidine; Fluorouracil; Hum | 2022 |
Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; COVID-19; Deoxycytidine; Fluorouracil; Hum | 2022 |
Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; COVID-19; Deoxycytidine; Fluorouracil; Hum | 2022 |
Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; COVID-19; Deoxycytidine; Fluorouracil; Hum | 2022 |
FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Drug | 2022 |
FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Drug | 2022 |
FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Drug | 2022 |
FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Drug | 2022 |
Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system.
Topics: Antineoplastic Agents; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor | 2022 |
Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system.
Topics: Antineoplastic Agents; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor | 2022 |
Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system.
Topics: Antineoplastic Agents; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor | 2022 |
Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system.
Topics: Antineoplastic Agents; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor | 2022 |
Initiating Treatment with Low Fluorouracil Dose and Titrating According to Blood Levels in Patients Treated with a 46-Hour Continuous Infusion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluor | 2023 |
Initiating Treatment with Low Fluorouracil Dose and Titrating According to Blood Levels in Patients Treated with a 46-Hour Continuous Infusion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluor | 2023 |
Initiating Treatment with Low Fluorouracil Dose and Titrating According to Blood Levels in Patients Treated with a 46-Hour Continuous Infusion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluor | 2023 |
Initiating Treatment with Low Fluorouracil Dose and Titrating According to Blood Levels in Patients Treated with a 46-Hour Continuous Infusion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluor | 2023 |
Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer.
Topics: Biological Products; CA-19-9 Antigen; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoadjuvant Ther | 2023 |
Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer.
Topics: Biological Products; CA-19-9 Antigen; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoadjuvant Ther | 2023 |
Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer.
Topics: Biological Products; CA-19-9 Antigen; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoadjuvant Ther | 2023 |
Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer.
Topics: Biological Products; CA-19-9 Antigen; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoadjuvant Ther | 2023 |
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
Is new risk-assessment score of venous thromboembolism for hospitalized surgical patients with borderline resectable pancreatic adenocarcinoma needed?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2023 |
Is new risk-assessment score of venous thromboembolism for hospitalized surgical patients with borderline resectable pancreatic adenocarcinoma needed?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2023 |
Is new risk-assessment score of venous thromboembolism for hospitalized surgical patients with borderline resectable pancreatic adenocarcinoma needed?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2023 |
Is new risk-assessment score of venous thromboembolism for hospitalized surgical patients with borderline resectable pancreatic adenocarcinoma needed?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2023 |
5-fluorouracil with oxaliplatin and/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreati | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Gemci | 2022 |
Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Gemci | 2022 |
Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Gemci | 2022 |
Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Gemci | 2022 |
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Fluor | 2023 |
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Fluor | 2023 |
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Fluor | 2023 |
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Fluor | 2023 |
Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Ir | 2023 |
The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center Real-World Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2022 |
The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center Real-World Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2022 |
The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center Real-World Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2022 |
The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center Real-World Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2022 |
A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Pancreatic Ductal; Fluorourac | 2023 |
A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Pancreatic Ductal; Fluorourac | 2023 |
A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Pancreatic Ductal; Fluorourac | 2023 |
A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Pancreatic Ductal; Fluorourac | 2023 |
Pancreatectomy After Neoadjuvant FOLFIRINOX Chemotherapy: Identifying Factors Predicting Long-Term Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2023 |
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Fl | 2023 |
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Fl | 2023 |
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Fl | 2023 |
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Fl | 2023 |
The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2023 |
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Leucov | 2023 |
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Leucov | 2023 |
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Leucov | 2023 |
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Leucov | 2023 |
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Leucov | 2023 |
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Leucov | 2023 |
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Leucov | 2023 |
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Leucov | 2023 |
Extracellular vesicles derived from dental mesenchymal stem/stromal cells with gemcitabine as a cargo have an inhibitory effect on the growth of pancreatic carcinoma cell lines in vitro.
Topics: Cell Line; Culture Media, Conditioned; Extracellular Vesicles; Fluorouracil; Gemcitabine; Humans; Pa | 2023 |
Extracellular vesicles derived from dental mesenchymal stem/stromal cells with gemcitabine as a cargo have an inhibitory effect on the growth of pancreatic carcinoma cell lines in vitro.
Topics: Cell Line; Culture Media, Conditioned; Extracellular Vesicles; Fluorouracil; Gemcitabine; Humans; Pa | 2023 |
Extracellular vesicles derived from dental mesenchymal stem/stromal cells with gemcitabine as a cargo have an inhibitory effect on the growth of pancreatic carcinoma cell lines in vitro.
Topics: Cell Line; Culture Media, Conditioned; Extracellular Vesicles; Fluorouracil; Gemcitabine; Humans; Pa | 2023 |
Extracellular vesicles derived from dental mesenchymal stem/stromal cells with gemcitabine as a cargo have an inhibitory effect on the growth of pancreatic carcinoma cell lines in vitro.
Topics: Cell Line; Culture Media, Conditioned; Extracellular Vesicles; Fluorouracil; Gemcitabine; Humans; Pa | 2023 |
Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Diseas | 2023 |
Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Diseas | 2023 |
Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Diseas | 2023 |
Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Diseas | 2023 |
[A Case of Multiple Lung Metastases of Pancreatic Cancer with 50 Months Survival by Sequential Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; | 2022 |
[A Case of Multiple Lung Metastases of Pancreatic Cancer with 50 Months Survival by Sequential Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; | 2022 |
[A Case of Multiple Lung Metastases of Pancreatic Cancer with 50 Months Survival by Sequential Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; | 2022 |
[A Case of Multiple Lung Metastases of Pancreatic Cancer with 50 Months Survival by Sequential Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; | 2022 |
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorourac | 2023 |
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorourac | 2023 |
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorourac | 2023 |
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorourac | 2023 |
Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studi | 2023 |
Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studi | 2023 |
Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studi | 2023 |
Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studi | 2023 |
Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hu | 2023 |
Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hu | 2023 |
Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hu | 2023 |
Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hu | 2023 |
Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer.
Topics: Animals; Fluorouracil; Gadolinium; Liposomes; Mice; Nanoparticles; Pancreatic Neoplasms; Tissue Dist | 2023 |
Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer.
Topics: Animals; Fluorouracil; Gadolinium; Liposomes; Mice; Nanoparticles; Pancreatic Neoplasms; Tissue Dist | 2023 |
Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer.
Topics: Animals; Fluorouracil; Gadolinium; Liposomes; Mice; Nanoparticles; Pancreatic Neoplasms; Tissue Dist | 2023 |
Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer.
Topics: Animals; Fluorouracil; Gadolinium; Liposomes; Mice; Nanoparticles; Pancreatic Neoplasms; Tissue Dist | 2023 |
Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinote | 2023 |
Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinote | 2023 |
Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinote | 2023 |
Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinote | 2023 |
Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic D | 2023 |
Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic D | 2023 |
Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic D | 2023 |
Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic D | 2023 |
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2023 |
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2023 |
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2023 |
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2023 |
Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival: A Retrospective, Multicenter, Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Fluorouracil; Humans; Inflammation; | 2023 |
Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival: A Retrospective, Multicenter, Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Fluorouracil; Humans; Inflammation; | 2023 |
Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival: A Retrospective, Multicenter, Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Fluorouracil; Humans; Inflammation; | 2023 |
Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival: A Retrospective, Multicenter, Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Fluorouracil; Humans; Inflammation; | 2023 |
The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients: A Multicenter Real-Life Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Predicting conversion surgery in patients with locally advanced pancreatic cancer after modified FOLFIRINOX treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therap | 2023 |
Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorou | 2023 |
Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorou | 2023 |
Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorou | 2023 |
Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorou | 2023 |
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Pancre | 2023 |
Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Monitoring; Fluor | 2023 |
Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Monitoring; Fluor | 2023 |
Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Monitoring; Fluor | 2023 |
Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Monitoring; Fluor | 2023 |
Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluoroura | 2023 |
Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluoroura | 2023 |
Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluoroura | 2023 |
Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluoroura | 2023 |
Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2023 |
Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2023 |
Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2023 |
Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2023 |
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorouracil; Gemcit | 2023 |
Changing patterns of care for pancreas cancer in Victoria: the 2022 Pancreas Tumour Summit.
Topics: Fluorouracil; Hospitalization; Humans; Pancreatic Neoplasms | 2023 |
Changing patterns of care for pancreas cancer in Victoria: the 2022 Pancreas Tumour Summit.
Topics: Fluorouracil; Hospitalization; Humans; Pancreatic Neoplasms | 2023 |
Changing patterns of care for pancreas cancer in Victoria: the 2022 Pancreas Tumour Summit.
Topics: Fluorouracil; Hospitalization; Humans; Pancreatic Neoplasms | 2023 |
Changing patterns of care for pancreas cancer in Victoria: the 2022 Pancreas Tumour Summit.
Topics: Fluorouracil; Hospitalization; Humans; Pancreatic Neoplasms | 2023 |
Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Fluorourac | 2023 |
Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Fluorourac | 2023 |
Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Fluorourac | 2023 |
Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Fluorourac | 2023 |
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Continuity of Patient | 2023 |
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Continuity of Patient | 2023 |
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Continuity of Patient | 2023 |
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Continuity of Patient | 2023 |
Trends in treatment patterns and survival outcomes in pancreatic cancer: A nationwide population-based study in Korea.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fl | 2023 |
Trends in treatment patterns and survival outcomes in pancreatic cancer: A nationwide population-based study in Korea.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fl | 2023 |
Trends in treatment patterns and survival outcomes in pancreatic cancer: A nationwide population-based study in Korea.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fl | 2023 |
Trends in treatment patterns and survival outcomes in pancreatic cancer: A nationwide population-based study in Korea.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fl | 2023 |
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cicatrix; De | 2023 |
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cicatrix; De | 2023 |
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cicatrix; De | 2023 |
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cicatrix; De | 2023 |
Co-delivery of three synergistic chemotherapeutics in a core-shell nanoscale coordination polymer for the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; M | 2023 |
Co-delivery of three synergistic chemotherapeutics in a core-shell nanoscale coordination polymer for the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; M | 2023 |
Co-delivery of three synergistic chemotherapeutics in a core-shell nanoscale coordination polymer for the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; M | 2023 |
Co-delivery of three synergistic chemotherapeutics in a core-shell nanoscale coordination polymer for the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; M | 2023 |
Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Ir | 2023 |
Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Ir | 2023 |
Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Ir | 2023 |
Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Ir | 2023 |
Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; | 2023 |
Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; | 2023 |
Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; | 2023 |
Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; | 2023 |
The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Gemcitab | 2023 |
The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Gemcitab | 2023 |
The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Gemcitab | 2023 |
The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Gemcitab | 2023 |
Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2023 |
Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2023 |
Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2023 |
Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2023 |
Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone) synergizes with 5-fluorouracil allowing for dose reduction and reduced off-target toxicity in the treatment of colonic and pancreatic cancers.
Topics: Achyrocline; Animals; Carcinoma; Colonic Neoplasms; Colorectal Neoplasms; Drug Tapering; Fluorouraci | 2023 |
Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone) synergizes with 5-fluorouracil allowing for dose reduction and reduced off-target toxicity in the treatment of colonic and pancreatic cancers.
Topics: Achyrocline; Animals; Carcinoma; Colonic Neoplasms; Colorectal Neoplasms; Drug Tapering; Fluorouraci | 2023 |
Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone) synergizes with 5-fluorouracil allowing for dose reduction and reduced off-target toxicity in the treatment of colonic and pancreatic cancers.
Topics: Achyrocline; Animals; Carcinoma; Colonic Neoplasms; Colorectal Neoplasms; Drug Tapering; Fluorouraci | 2023 |
Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone) synergizes with 5-fluorouracil allowing for dose reduction and reduced off-target toxicity in the treatment of colonic and pancreatic cancers.
Topics: Achyrocline; Animals; Carcinoma; Colonic Neoplasms; Colorectal Neoplasms; Drug Tapering; Fluorouraci | 2023 |
Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2023 |
Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2023 |
Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2023 |
Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2023 |
Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic | 2023 |
Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic | 2023 |
Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic | 2023 |
Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic | 2023 |
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ergocalciferols; Fluorouracil; Gemcitabine; Humans; | 2023 |
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ergocalciferols; Fluorouracil; Gemcitabine; Humans; | 2023 |
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ergocalciferols; Fluorouracil; Gemcitabine; Humans; | 2023 |
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ergocalciferols; Fluorouracil; Gemcitabine; Humans; | 2023 |
Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovo | 2023 |
Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovo | 2023 |
Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovo | 2023 |
Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovo | 2023 |
[Resection of locally advanced pancreatic cancer: careful selection and shared decision making].
Topics: Antineoplastic Combined Chemotherapy Protocols; Decision Making, Shared; Deoxycytidine; Fluorouracil | 2023 |
[Resection of locally advanced pancreatic cancer: careful selection and shared decision making].
Topics: Antineoplastic Combined Chemotherapy Protocols; Decision Making, Shared; Deoxycytidine; Fluorouracil | 2023 |
[Resection of locally advanced pancreatic cancer: careful selection and shared decision making].
Topics: Antineoplastic Combined Chemotherapy Protocols; Decision Making, Shared; Deoxycytidine; Fluorouracil | 2023 |
[Resection of locally advanced pancreatic cancer: careful selection and shared decision making].
Topics: Antineoplastic Combined Chemotherapy Protocols; Decision Making, Shared; Deoxycytidine; Fluorouracil | 2023 |
Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer.
Topics: Carbolines; Fluorouracil; Humans; Irinotecan; Pancreatic Neoplasms | 2023 |
Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer.
Topics: Carbolines; Fluorouracil; Humans; Irinotecan; Pancreatic Neoplasms | 2023 |
Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer.
Topics: Carbolines; Fluorouracil; Humans; Irinotecan; Pancreatic Neoplasms | 2023 |
Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer.
Topics: Carbolines; Fluorouracil; Humans; Irinotecan; Pancreatic Neoplasms | 2023 |
Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; F | 2019 |
Targeting claudin-4 enhances chemosensitivity of pancreatic ductal carcinomas.
Topics: Animals; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; C | 2019 |
[Outcomes of FOLFIRINOX as First-Line Treatment for Recurrent or Unresectable Pancreatic Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Female; F | 2019 |
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2020 |
[Pure laparoscopic DP-CAR procedure with portal vein resection].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Fluorouracil; | 2019 |
FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2019 |
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Fluorouracil | 2019 |
Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cause o | 2019 |
A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; | 2019 |
Port-site metastasis of pancreatic adenocarcinoma following 'successful' completion of neoadjuvant chemoradiation using FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2020 |
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Proto | 2020 |
Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Carcinoma, Ductal, Breast; Carcinoma, | 2019 |
5 Fluorouracil-loaded biosynthesised gold nanoparticles for the in vitro treatment of human pancreatic cancer cell.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Carriers; Drug Compounding; Drug Delivery S | 2019 |
Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemo | 2019 |
Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Car | 2020 |
Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; C | 2019 |
Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Fluoro | 2019 |
The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Female; Fluo | 2020 |
Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2019 |
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cation Transport Proteins; Cell Line, Tumo | 2020 |
Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutrop | 2020 |
Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2020 |
The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Agents; Antineoplastic Combined Ch | 2020 |
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Prot | 2020 |
Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic D | 2020 |
Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic D | 2020 |
Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic D | 2020 |
Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic D | 2020 |
Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2020 |
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, | 2020 |
Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 2020 |
International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradi | 2020 |
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agen | 2020 |
Spatial and phenotypic characterization of pancreatic cancer-associated fibroblasts after neoadjuvant treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer-Associated Fibroblasts; Carcinoma, Panc | 2020 |
Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Fr | 2020 |
Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradi | 2020 |
Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradi | 2020 |
Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradi | 2020 |
Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradi | 2020 |
Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2020 |
Steatohepatitis due to FOLFIRINOX regimen in adjuvant pancreas cancer treatment mimicking liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fatty Liver; Female; Fluorouracil; Humans; Irinoteca | 2020 |
[Whether or not to use thromboprophylaxis in patients treated with chemotherapy for malignant disease].
Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemopreventi | 2019 |
[Whether or not to use thromboprophylaxis in patients treated with chemotherapy for malignant disease].
Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemopreventi | 2019 |
[Whether or not to use thromboprophylaxis in patients treated with chemotherapy for malignant disease].
Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemopreventi | 2019 |
[Whether or not to use thromboprophylaxis in patients treated with chemotherapy for malignant disease].
Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemopreventi | 2019 |
Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Lin | 2020 |
Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Denmark; | 2020 |
Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score matching analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Comb | 2020 |
Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neoplasms; Deoxycytid | 2020 |
Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2020 |
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2020 |
Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox | 2020 |
Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Factor Analysis, Statistical; Febrile N | 2020 |
Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis.
Topics: Aged; Aged, 80 and over; Albumins; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2020 |
Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadj | 2021 |
MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Line, Tumor; Cell Proli | 2020 |
The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema | 2020 |
FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxyc | 2020 |
Resection of Replaced Common Hepatic Artery in Locally Advanced Pancreatic Cancer: A Case Report and Analysis of Technical and Oncological Implications.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modali | 2020 |
Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycyti | 2020 |
Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Hypoxia; | 2020 |
Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2020 |
Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diabetes Mellitus; Female; Flu | 2020 |
The yield of chest computed tomography in patients with locally advanced pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; | 2020 |
Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2020 |
Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Electroporation; Female; | 2020 |
Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2020 |
Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinot | 2021 |
Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2020 |
Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2020 |
Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2020 |
Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2020 |
What is causing this patient's severe pruritus?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; | 2020 |
Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Fluoro | 2020 |
Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Fluoro | 2020 |
Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Fluoro | 2020 |
Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Fluoro | 2020 |
Challenges of pancreatic cancer chemotherapy in the COVID-19 era.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Capeci | 2020 |
Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cholangiopancreatogr | 2020 |
An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cel | 2020 |
[Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Europe; Fluorouracil; Humans; Irinotec | 2020 |
Distal Pancreatectomy with Celiac Axis Resection (Modified Appleby Procedure) and Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma After FOLFIRINOX Chemotherapy and Chemoradiation Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotec | 2021 |
Distal Pancreatectomy with Celiac Axis Resection (Modified Appleby Procedure) and Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma After FOLFIRINOX Chemotherapy and Chemoradiation Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotec | 2021 |
Distal Pancreatectomy with Celiac Axis Resection (Modified Appleby Procedure) and Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma After FOLFIRINOX Chemotherapy and Chemoradiation Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotec | 2021 |
Distal Pancreatectomy with Celiac Axis Resection (Modified Appleby Procedure) and Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma After FOLFIRINOX Chemotherapy and Chemoradiation Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotec | 2021 |
Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Li | 2020 |
FOLFIRINOX
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2020 |
FOLFIRINOX
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2020 |
FOLFIRINOX
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2020 |
FOLFIRINOX
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2020 |
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2020 |
Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2020 |
Pretreatment biomarkers as prognostic predictors of survival in patients with Pancreatic Cancer treated with Gemcitabine-based Therapy and 5-Fluorouracil: Neutrophil-to-lymphocyte ratio
Topics: Aged; Biomarkers, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphocytes; Male | 2020 |
Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bi | 2020 |
Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bi | 2020 |
Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bi | 2020 |
Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bi | 2020 |
NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression.
Topics: Antioxidants; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transpor | 2020 |
NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression.
Topics: Antioxidants; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transpor | 2020 |
NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression.
Topics: Antioxidants; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transpor | 2020 |
NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression.
Topics: Antioxidants; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transpor | 2020 |
Calcium channel blockers in pancreatic cancer: increased overall survival in a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Carcinoma, Pancreati | 2020 |
Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemorad | 2020 |
Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2020 |
A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modalit | 2020 |
Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Di | 2020 |
Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antin | 2020 |
Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2020 |
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2020 |
Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Checkpoint Kinase 2; | 2020 |
Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Checkpoint Kinase 2; | 2020 |
Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Checkpoint Kinase 2; | 2020 |
Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Checkpoint Kinase 2; | 2020 |
Probiotic‑derived ferrichrome inhibits the growth of refractory pancreatic cancer cells.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Ferrichrome; Fluorouracil; | 2020 |
Familial adenomatous polyposis associated with pancreatic neuroendocrine tumour.
Topics: Adenomatous Polyposis Coli; Aged; Antineoplastic Combined Chemotherapy Protocols; Causality; Colonic | 2021 |
Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiothe | 2020 |
TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Cell Line, Tumor; CpG Isla | 2020 |
TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Cell Line, Tumor; CpG Isla | 2020 |
TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Cell Line, Tumor; CpG Isla | 2020 |
TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Cell Line, Tumor; CpG Isla | 2020 |
Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case | 2020 |
Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; | 2021 |
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcita | 2021 |
CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinot | 2021 |
Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause o | 2021 |
Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison.
Topics: Ablation Techniques; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; | 2020 |
The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorour | 2021 |
FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; France; Hu | 2020 |
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross- | 2020 |
Severe Nonbacterial Thrombotic Endocarditis Resulting in Aortic Valve Insufficiency and Multiple Small Strokes in a Patient With Metastatic Pancreatic Cancer: Lessons for Optimal Management.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Aortic Valve Insufficiency; Diffusio | 2020 |
Synopsis of the UK National Institute for Health and Care Excellence Guidelines on the Diagnosis and Management of Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neopla | 2020 |
Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinot | 2020 |
Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasi | 2020 |
Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ant | 2020 |
Hepatic Arterial Infusion Chemotherapy for Liver Metastases Following Standard Chemotherapy for Pancreatic Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Liver Neoplasm | 2021 |
The economic burden of metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost of Illne | 2020 |
FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Glucuro | 2020 |
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Deoxycytidin | 2021 |
Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothe | 2021 |
Long-Term Survival With Nanoliposomal Irinotecan in Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Female; Fluorouracil; Humans; Irinote | 2020 |
Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Fem | 2020 |
Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfami | 2020 |
Comments on "Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma".
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Ele | 2020 |
Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dose-Response Re | 2021 |
Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreati | 2021 |
FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2020 |
Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadj | 2021 |
Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovori | 2021 |
Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Leucovorin; Neur | 2021 |
Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2021 |
Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2021 |
Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gast | 2021 |
Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gast | 2021 |
Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gast | 2021 |
Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gast | 2021 |
Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Ad | 2021 |
Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2021 |
Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxo | 2022 |
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
Topics: Adult; Aged; Albumins; Alleles; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette | 2021 |
Pancreatectomy with Vascular Resection After Neoadjuvant FOLFIRINOX: Who Survives More Than a Year After Surgery?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; | 2021 |
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplat | 2021 |
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Dox | 2021 |
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; | 2021 |
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer: A Letter to the Editor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diet, Ketogenic; Fluorouracil; Gemcit | 2021 |
Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Drug Res | 2021 |
Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboxylestera | 2021 |
Comment: Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison.
Topics: Antineoplastic Combined Chemotherapy Protocols; Electroporation; Fluorouracil; Humans; Irinotecan; L | 2021 |
Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tu | 2021 |
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Che | 2021 |
Distal pancreatectomy with en bloc celiac axis resection (DP-CAR) and arterial reconstruction: Techniques and outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Cohort Studies; Female; Fluorouracil; | 2021 |
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2021 |
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2021 |
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2021 |
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2021 |
Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Ad | 2021 |
Zinc finger protein 91 accelerates tumour progression by activating β-catenin signalling in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Cell Line, Tumor; Cell Moveme | 2021 |
Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Stud | 2021 |
Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrativ | 2021 |
Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrativ | 2021 |
Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrativ | 2021 |
Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrativ | 2021 |
Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2021 |
Are we already in the era of total neoadjuvant treatment for rectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Humans; Irinotecan; | 2021 |
Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Ch | 2021 |
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD4-Po | 2021 |
Endoscopic drainage for management of infected necrosis following EUS-TA in a patient with pancreatic cancer: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Pancreatic Ductal; Drainage | 2021 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compound | 2021 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; De | 2021 |
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aus | 2021 |
Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; | 2021 |
Irreversible Electroporation (IRE) Combined With Chemotherapy Increases Survival in Locally Advanced Pancreatic Cancer (LAPC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2021 |
Chemotherapy-induced early transient increase and surge of CA 19-9 level in patients with pancreatic Adenocarcinoma
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Metastatic pancreatic cancer with complete response to FOLFIRINOX treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinotecan; Leucovorin | 2021 |
Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Follow-Up Studies; Hum | 2021 |
Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
Topics: Animals; Antimetabolites, Antineoplastic; Aptamers, Nucleotide; Carcinoma, Pancreatic Ductal; Cell L | 2021 |
Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fem | 2021 |
Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chromatography, Liquid; Combine | 2021 |
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytid | 2021 |
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; | 2021 |
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2022 |
Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Muscle | 2021 |
Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer.
Topics: Animals; Fluorouracil; Humans; Mice; Pancreatic Neoplasms; Photochemotherapy; Reactive Oxygen Specie | 2021 |
Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-matched Analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow- | 2021 |
Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxyc | 2021 |
Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2021 |
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Topics: Adult; Aged; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diar | 2021 |
Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Insulinoma; Neuroendocrine Tum | 2022 |
Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorour | 2021 |
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Pro | 2021 |
Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Computer Simulatio | 2021 |
Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Hu | 2021 |
Establishment of Pancreatobiliary Cancer Zebrafish Avatars for Chemotherapy Screening.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytid | 2021 |
First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leuc | 2021 |
First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leuc | 2021 |
First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leuc | 2021 |
First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leuc | 2021 |
Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Ch | 2017 |
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cancer Pai | 2017 |
Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Deoxycytidine; Disease-Free Sur | 2017 |
Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Deoxycytidine; Disease-Free Sur | 2017 |
Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Deoxycytidine; Disease-Free Sur | 2017 |
Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Deoxycytidine; Disease-Free Sur | 2017 |
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Proto | 2017 |
Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Hum | 2017 |
Locally-applied 5-fluorouracil-loaded slow-release patch prevents pancreatic cancer growth in an orthotopic mouse model.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Liberation; Fluorouracil; Humans; M | 2017 |
Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitab | 2017 |
Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitab | 2017 |
Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitab | 2017 |
Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitab | 2017 |
Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycyt | 2017 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Calcium Compounds; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoi | 2017 |
Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; | 2017 |
Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2017 |
TS-1 (tegafur/gimeracil/oteracil)-induced systemic lupus erythematosus with skin lesions and anti-Sm antibody.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluo | 2017 |
Magnetically responsive microbubbles as delivery vehicles for targeted sonodynamic and antimetabolite therapy of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Avidin; Cell Line, Tumor; Cell Survival; Ferric Compounds; | 2017 |
ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Pancreatic Ductal; Deoxycytidine; DNA Da | 2017 |
Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
Topics: Aged; Albumins; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort St | 2017 |
A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carc | 2017 |
A Pancreatic Predicament.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Female; Fluorouraci | 2017 |
Appendix 6: Cancer of the pancreas: MCBS eUpdate published online 20 June 2017 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leuc | 2017 |
Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Celiac Artery; Chemo | 2018 |
Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft.
Topics: Administration, Cutaneous; Animals; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Ma | 2017 |
Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2017 |
Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ducta | 2018 |
Notch pathway inhibition targets chemoresistant insulinoma cancer stem cells.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Dogs; Drug Resistance, Neoplasm; Fluorou | 2018 |
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil | 2018 |
Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic D | 2019 |
5-FU resistant EMT-like pancreatic cancer cells are hypersensitive to photochemical internalization of the novel endoglin-targeting immunotoxin CD105-saporin.
Topics: Adenocarcinoma; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Endog | 2017 |
Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders?
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2018 |
Response to the Letter to the Editor "Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders?" by Neoptolemos and Colleagues.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2018 |
Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2018 |
The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cap | 2018 |
Integrated Cancer Treatment in the Course of Metastatic Pancreatic Cancer: Complete Resolution in 2 Cases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Comb | 2018 |
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2018 |
Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Drug Combinations; Dr | 2018 |
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival | 2018 |
Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi | 2018 |
Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; | 2018 |
Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Comb | 2018 |
Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant | 2018 |
Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer.
Topics: Cell Line, Tumor; Cytosine Deaminase; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Pancre | 2018 |
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemci | 2018 |
The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adj | 2018 |
Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy.
Topics: Adenocarcinoma; Allografts; Animals; Antineoplastic Combined Chemotherapy Protocols; Autografts; Car | 2018 |
Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; C | 2018 |
Chest Pain During Chemotherapy: A Case of Severe Myocardial Bridging.
Topics: Antimetabolites, Antineoplastic; Coronary Angiography; Coronary Vasospasm; Drug Substitution; Electr | 2018 |
A population-based analysis of urban-rural disparities in advanced pancreatic cancer management and outcomes.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Deoxycytidine; Dru | 2018 |
Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer.
Topics: Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Weights | 2018 |
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals.
Topics: Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Glycogen | 2018 |
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benef | 2018 |
Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells.
Topics: beta Catenin; Blotting, Western; Cell Line, Tumor; Computational Biology; Fluorouracil; Glypicans; H | 2018 |
Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2019 |
[Maintenance strategies for advanced pancreatic cancer: Rationale and issues].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cl | 2018 |
Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2018 |
Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2018 |
Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2018 |
Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2018 |
Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Chemotherapy, Adjuvant; Fluorouracil; | 2018 |
Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2018 |
Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoth | 2018 |
Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2018 |
Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Deoxycytidine; Disease | 2019 |
Prospective Study of the Clinical, Electrophysiologic, and Sonographic Characteristics of Oxaliplatin-Induced Neuropathy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Male; Middle Age | 2019 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Identification of antitumoral agents against human pancreatic cancer cells from Asteraceae and Lamiaceae plant extracts.
Topics: Antineoplastic Agents; Asteraceae; Caspases; Cell Line, Tumor; Cell Survival; Fluorouracil; Humans; | 2018 |
FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Chemoradiotherapy; Cohor | 2018 |
4-Methylumbelliferone Decreases the Hyaluronan-rich Extracellular Matrix and Increases the Effectiveness of 5-Fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Cell Proliferation; Drug Synergi | 2018 |
Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Case-Cont | 2019 |
ASO Author Reflections: Role of Preoperative Chemotherapy in the Treatment of Pancreatic Neuroendocrine Liver Metastases.
Topics: Doxorubicin; Fluorouracil; Humans; Liver Neoplasms; Pancreatic Neoplasms; Streptozocin | 2018 |
Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2020 |
Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; BRCA2 Protein; | 2018 |
Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; BRCA2 Protein; | 2018 |
Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; BRCA2 Protein; | 2018 |
Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; BRCA2 Protein; | 2018 |
Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fema | 2018 |
EARLY INCREASE of CA 19-9 in ADVANCED PANCREATIC CANCER RECEIVING FOLFIRINOX. Is it a sign of efficacy?.
Topics: Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Drug Combi | 2016 |
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Female; Fluor | 2019 |
Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Female; Fluor | 2019 |
Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Female; Fluor | 2019 |
Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Female; Fluor | 2019 |
Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2019 |
Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Combinations; F | 2018 |
Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2019 |
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Proto | 2019 |
Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home-Results From a Pilot Stu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Circadian Rhythm; Colorect | 2018 |
FOLFIRINOX goes adjuvant.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III | 2019 |
[A Very Elderly Patient Successfully Treated by Multimodality Treatment for Pancreas Cancer with Synchronous Multiple Liver Metastases and Liver Dysfunction].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hepatic Art | 2018 |
FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxalip | 2019 |
Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2018 |
New guideline-sanctioned and emerging interventions for pancreatic cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical | 2018 |
Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2018 |
A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deo | 2018 |
[FOLFIRINOX after resection of pancreatic cancer sets new standards-systemic therapy providing an impulse for local treatment in resectable pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Le | 2019 |
FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer. Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Pancreatic Neoplas | 2019 |
Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dih | 2019 |
Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fem | 2021 |
Long-term survival of a patient with advanced pancreatic cancer under adjunct treatment with
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Magnet | 2019 |
Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinoteca | 2019 |
CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Car | 2019 |
Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2019 |
FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dise | 2019 |
Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2019 |
Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Femal | 2019 |
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemor | 2019 |
Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studie | 2019 |
Undifferentiated Carcinoma of the Pancreas - a Case Report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycy | 2018 |
Undifferentiated Carcinoma of the Pancreas - a Case Report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycy | 2018 |
Undifferentiated Carcinoma of the Pancreas - a Case Report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycy | 2018 |
Undifferentiated Carcinoma of the Pancreas - a Case Report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycy | 2018 |
Extended cycle streptozotocin/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2019 |
Conversion Surgery for Metastatic Pancreatic Mucinous Carcinoma Responsive to Systemic Chemotherapy with Modified FOLFIRINOX: A Case Report.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Endoscopic Ultrasound-Guid | 2019 |
Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, A | 2020 |
Reduced expression of annexin A1 promotes gemcitabine and 5-fluorouracil drug resistance of human pancreatic cancer.
Topics: Animals; Annexin A1; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, | 2020 |
Spontaneous regression of pancreatic cancer with liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; | 2019 |
[FOLFIRINOX for Locally Advanced and Recurrent Pancreatic Cancer with UGT1A1 *6 and or UGT1A1*28 Polymorphisms-A Report of Two Cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Glucuronos | 2019 |
Combined treatment for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2019 |
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Community He | 2019 |
The seemingly innocuous presentation of metastatic pancreatic tail cancer: a case report.
Topics: Abdominal Pain; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Diabe | 2019 |
The seemingly innocuous presentation of metastatic pancreatic tail cancer: a case report.
Topics: Abdominal Pain; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Diabe | 2019 |
The seemingly innocuous presentation of metastatic pancreatic tail cancer: a case report.
Topics: Abdominal Pain; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Diabe | 2019 |
The seemingly innocuous presentation of metastatic pancreatic tail cancer: a case report.
Topics: Abdominal Pain; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Diabe | 2019 |
FOLFIRINOX: a new standard of care in the adjuvant setting of resectable pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcita | 2019 |
Microvascular invasion is a major prognostic factor after pancreatico-duodenectomy for adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Ad | 2019 |
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; C | 2019 |
Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Fema | 2019 |
Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2019 |
Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pa | 2019 |
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Disease Progressio | 2019 |
Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Disease Progressio | 2019 |
Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Disease Progressio | 2019 |
Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Disease Progressio | 2019 |
Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcin | 2020 |
Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters.
Topics: Animals; Cell Line, Tumor; Cricetinae; Cyclophosphamide; Female; Fluorouracil; Immunocompetence; Mes | 2013 |
Reply: To PMID 22623561.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Embolization, Therapeutic; Female; Fluorouracil; Hum | 2013 |
Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2013 |
Chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; | 2013 |
Advancements in the management of pancreatic cancer: 2013.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2013 |
Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.
Topics: Adenocarcinoma; Administration, Oral; Aged; Ampulla of Vater; Capecitabine; Chemoradiotherapy; Commo | 2013 |
Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycyt | 2013 |
Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Deoxycyt | 2013 |
Radiotherapy in the management of pancreatic neuroendocrine tumors (PNET): experience at three institutions.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidin | 2013 |
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy | 2013 |
Multifocal anaplastic pancreatic carcinoma requiring neoadjuvant chemotherapy and total pancreatectomy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; | 2013 |
FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?
Topics: Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; | 2013 |
A bioengineered metastatic pancreatic tumor model for mechanistic investigation of chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bioengineering; Camp | 2013 |
Treatment of borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther | 2013 |
Pancreatic tumor mass in a xenograft mouse model is decreased by treatment with therapeutic stem cells following introduction of therapeutic genes.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferati | 2013 |
Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Clinical | 2013 |
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; | 2013 |
Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; D | 2013 |
Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter | 2013 |
Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro.
Topics: Antineoplastic Agents; Apigenin; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dru | 2013 |
Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptos | 2013 |
A spheroid-based 3-D culture model for pancreatic cancer drug testing, using the acid phosphatase assay.
Topics: Acid Phosphatase; Antimetabolites, Antineoplastic; Cell Culture Techniques; Cell Line, Tumor; Cell S | 2013 |
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2013 |
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy | 2013 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Dise | 2013 |
Topical henna ameliorated capecitabine-induced hand-foot syndrome.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; | 2014 |
Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cancer Vacc | 2013 |
Cisplatin-modified de Gramont in second-line therapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2013 |
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Antineoplastic Agents; Cell Hypoxia; | 2013 |
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Antineoplastic Agents; Cell Hypoxia; | 2013 |
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Antineoplastic Agents; Cell Hypoxia; | 2013 |
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Antineoplastic Agents; Cell Hypoxia; | 2013 |
A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat | 2014 |
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Campto | 2013 |
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycy | 2014 |
Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2013 |
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
Topics: Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD11b Antigen; Deoxycytidine; Fluorour | 2014 |
Inhibition of cell proliferation and increase of chemosensitivity by simultaneous knockdown of XIAP and survivin in pancreatic carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; | 2013 |
Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2016 |
Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidin | 2013 |
Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; D | 2014 |
Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 2014 |
Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad | 2014 |
Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX).
Topics: Animals; Antimetabolites, Antineoplastic; Cisplatin; Deoxycytidine; Disease Models, Animal; Fluorour | 2014 |
5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2013 |
Survival outcomes in patients with early stage, resected pancreatic cancer - a comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Deoxycytidine | 2014 |
Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress.
Topics: Apoptosis; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Forkhead Box | 2014 |
Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs.
Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferati | 2014 |
FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Acinar Cell; Fluorouracil; | 2014 |
Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, | 2014 |
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemothe | 2014 |
[Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP)].
Topics: Antineoplastic Agents; Deoxycytidine; Female; Fluorouracil; Humans; Male; Pancreatic Neoplasms | 2014 |
Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Calcium; Calcium Channels; Calcium Signaling; Cell | 2014 |
Patients with advanced disease: the value of patient reported outcomes.
Topics: Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status | 2014 |
Are we systematically under-dosing patients with fluorouracil?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycy | 2015 |
FOLFIRINOX: from the ACCORD study to 2014.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response R | 2014 |
Updates on first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cam | 2014 |
Pancreatic neuroendocrine tumors: does chemotherapy work?
Topics: Algorithms; Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Drug Ther | 2014 |
dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Nucleus; Chemo | 2014 |
Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2014 |
Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Busulfan; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response | 2014 |
Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Busulfan; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response | 2014 |
Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Busulfan; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response | 2014 |
Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Busulfan; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response | 2014 |
A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Ind | 2014 |
Caring for one of our own.
Topics: Camptothecin; Caregivers; Diphosphonates; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle | 2014 |
Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo | 2014 |
In reply to Ren et al.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluoroura | 2014 |
IMRT with capecitabine in advanced pancreatic cancer. In regard to Passoni et al.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluoroura | 2014 |
Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2014 |
Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2014 |
FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Male | 2014 |
Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diseas | 2014 |
Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell | 2015 |
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2014 |
A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouraci | 2014 |
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2015 |
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cis | 2014 |
Locally advanced unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxy | 2014 |
Second-line treatment for pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, | 2014 |
Role of neoadjuvant therapy in management of pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; | 2014 |
Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreat | 2014 |
Laser-induced drug release for local tumor control--a proof of concept.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; beta-Cyclodextrins; Bromodeoxyuridine; Cel | 2014 |
Evolution in functionality of a metastatic pancreatic neuroendocrine tumour (pNET) causing Cushing's syndrome: treatment response with chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cushing Syndrome; Doxorubicin; Fluorouracil; | 2014 |
Effect of resveratrol on proliferation and apoptosis of human pancreatic cancer MIA PaCa-2 cells may involve inhibition of the Hedgehog signaling pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening A | 2014 |
Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Disease Models, Animal; Drug | 2014 |
Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity.
Topics: Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell S | 2014 |
Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Complete radiological response of an initially locally advanced unresectable pancreatic cancer to chemoradiotherapy using FOLFIRINOX regimen: report of a case.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Female; Fluor | 2015 |
Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemc | 2015 |
Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemc | 2015 |
Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemc | 2015 |
Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemc | 2015 |
Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2015 |
Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; D | 2014 |
Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dr | 2015 |
FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2014 |
JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors | 2015 |
Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype.
Topics: Animals; Blotting, Western; Cell Culture Techniques; Cell Cycle; Cell Proliferation; Colony-Forming | 2015 |
Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype.
Topics: Animals; Blotting, Western; Cell Culture Techniques; Cell Cycle; Cell Proliferation; Colony-Forming | 2015 |
Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype.
Topics: Animals; Blotting, Western; Cell Culture Techniques; Cell Cycle; Cell Proliferation; Colony-Forming | 2015 |
Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype.
Topics: Animals; Blotting, Western; Cell Culture Techniques; Cell Cycle; Cell Proliferation; Colony-Forming | 2015 |
Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Combined Modality The | 2014 |
The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ducta | 2015 |
microRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Transformation, Neoplastic; Down-Regulation; Female; | 2014 |
A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatectomy; Hum | 2015 |
Neoadjuvant therapy for localized pancreatic cancer: support is growing?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; | 2015 |
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2015 |
Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Fluorouraci | 2015 |
[After neoadjuvant therapy of pancreatic cancer the classical radiological criteria for resectability are no longer applicable].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; | 2015 |
Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Adenosquamous; Chemoradioth | 2015 |
Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2015 |
Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combin | 2015 |
Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
The transformation of a nonfunctioning islet cell tumor of the pancreas into a proinsulinoma under conditions of lung metastasis.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Is | 2015 |
[FOLFIRINOX, nab-paclitaxel + gemcitabine].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; De | 2015 |
Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment.
Topics: Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial | 2015 |
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Topics: Adenine; Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur L | 2015 |
Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2015 |
Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2015 |
Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2015 |
Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Line, Tumor; Deoxycytidine; Fluorouracil; G | 2015 |
Recurrence 11 years after complete response to gemcitabine, 5-Fluorouracil, and Cisplatin chemotherapy followed by radiotherapy in a patient with advanced pancreatic cancer: a case report.
Topics: Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, | 2015 |
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboxylesterase; Carcino | 2015 |
Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Pancreatic Du | 2015 |
Retinoic Acid Reduces Stem Cell-Like Features in Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; | 2015 |
Suppression of Reserve MCM Complexes Chemosensitizes to Gemcitabine and 5-Fluorouracil.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Membrane Permeability; D | 2015 |
Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2015 |
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2015 |
Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Fluorou | 2015 |
Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Fluorou | 2015 |
Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Fluorou | 2015 |
Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Fluorou | 2015 |
Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2016 |
Upregulation of microRNA‑138‑5p inhibits pancreatic cancer cell migration and increases chemotherapy sensitivity.
Topics: Antineoplastic Agents; Base Sequence; Binding Sites; Cell Line, Tumor; Cell Movement; Down-Regulatio | 2015 |
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplas | 2017 |
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Clinical Significance of Adjuvant Surgical Resection for Initially Unresectable Pancreatic Cancer Responsive to Arterial Infusion Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; | 2014 |
Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biliary Tract Neoplasms; | 2015 |
Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothec | 2016 |
The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ch | 2015 |
Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2015 |
Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2016 |
Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cross-Sectional | 2015 |
Dual drug loaded chitosan nanoparticles-sugar--coated arsenal against pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Chitosan; Drug Carriers; Fluorouracil; | 2015 |
Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancr | 2015 |
Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2015 |
Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2015 |
Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2015 |
Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2015 |
Pharmacokinetic study and clinical evaluation of a slow-release 5-fluorouracil implant in pancreatic cancer patients.
Topics: Antineoplastic Agents; Drug Implants; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Ne | 2016 |
The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.
Topics: Cell Line, Tumor; Cell Nucleus; Cell Survival; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Fluor | 2016 |
The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Erlotini | 2015 |
Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2015 |
[The progress of chemotherapy for advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Pancreatic Tumor Progression Associated With CD133 Overexpression: Involvement of Increased TERT Expression and Epidermal Growth Factor Receptor-Dependent Akt Activation.
Topics: AC133 Antigen; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferati | 2016 |
Combined sonodynamic and antimetabolite therapy for the improved treatment of pancreatic cancer using oxygen loaded microbubbles as a delivery vehicle.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Fe | 2016 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2016 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2016 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2016 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2015 |
Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; | 2016 |
MicroRNA-21 induces 5-fluorouracil resistance in human pancreatic cancer cells by regulating PTEN and PDCD4.
Topics: Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Fluoroura | 2016 |
Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Chemoradiothe | 2016 |
Optimizing initial chemotherapy for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Le | 2016 |
[Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Disease-Free Surv | 2016 |
Enriched environment housing enhances the sensitivity of mouse pancreatic cancer to chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Deoxycytidine; Fluorouracil; Gemc | 2016 |
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Female; F | 2016 |
Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2016 |
Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Campto | 2016 |
Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; D | 2016 |
Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; D | 2016 |
Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; D | 2016 |
Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; D | 2016 |
CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2016 |
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Diseas | 2016 |
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Diseas | 2016 |
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Diseas | 2016 |
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Diseas | 2016 |
In brief: liposomal irinotecan (Onivyde) for pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Compounding; Fluorouracil; Humans | 2016 |
Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hypoxia-Inducible Facto | 2016 |
Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
Topics: Acetates; Aged; Antidotes; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficien | 2016 |
MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells.
Topics: 3' Untranslated Regions; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Cell Line, | 2016 |
A 3D-printed local drug delivery patch for pancreatic cancer growth suppression.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Delayed-Action Preparations; Drug Delive | 2016 |
GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movem | 2017 |
Transient global ventricular dysfunction in an adolescent affected by pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Male; Pancreatic | 2016 |
Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradi | 2016 |
A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Antimetabolites, Antineoplastic; Deoxycytidine; Feasibilit | 2016 |
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Cam | 2016 |
Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Moda | 2016 |
Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Acinar Cell; Carcinoma, Pan | 2016 |
Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Huma | 2017 |
Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin | 2016 |
Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2018 |
HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.
Topics: Adenocarcinoma; Apoptosis; Benzoquinones; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm | 2017 |
Triple-amiRNA VEGFRs inhibition in pancreatic cancer improves the efficacy of chemotherapy through EMT regulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cell Movement; Cell Prolifer | 2017 |
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Proto | 2017 |
Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colitis; | 2016 |
Granulocyte Colony-stimulating Factor Producing Anaplastic Carcinoma of the Pancreas: Case Report and Review of the Literature.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Fe | 2017 |
When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2017 |
CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line | 2017 |
Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carci | 2016 |
Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiotherapy, | 2017 |
Second-Line Combination Therapies in Pancreatic Cancer: Where Are We Now?
Topics: Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2017 |
The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine | 2017 |
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxyc | 2017 |
Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dise | 2017 |
Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Delivery of Health Car | 2017 |
Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Acinar Cell; Carcinoma, Isl | 2017 |
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA2 Protein; Carci | 2017 |
Survival for patients with pancreatic cancer after addition of gemcitabine to fluorouracil chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycyti | 2008 |
Survival for patients with pancreatic cancer after addition of gemcitabine to Fluorouracil chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycyti | 2008 |
Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion; Cell | 2008 |
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capec | 2008 |
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemotherapy, A | 2008 |
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Cli | 2008 |
Cisplatin, fluorouracil, interferon-alpha, and radiation as adjuvant therapy for resected pancreatic cancer: is there a future for this regimen and/or should we change our approach to research and treatment of patients with pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 2008 |
Efficacy of gemcitabine for locally advanced pancreatic cancer: comparison with 5-fluorouracil-based chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Fem | 2008 |
Establishment and molecular profiling of a novel human pancreatic cancer panel for 5-FU.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Fluor | 2008 |
Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tu | 2008 |
The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Combined Mod | 2008 |
[An autopsy case of pancreatic cancer with poor performance status due to peritonitis carcinomatosa treated successfully with continuous infusion of low-dose 5-FU with octreotide].
Topics: Antimetabolites, Antineoplastic; Ascites; Autopsy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; | 2008 |
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycy | 2008 |
Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Blood Coagulation; Capecitabine; Cholangiopancreatography, Endoscopic Retrogra | 2008 |
Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-alpha in pancreatic and periampullary cancer: results of a feasibility study.
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Feasibility Studies; Female; Fluorourac | 2008 |
Adenoviral-mediated gene transfer of Gadd45a results in suppression by inducing apoptosis and cell cycle arrest in pancreatic cancer cell.
Topics: Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ducta | 2009 |
Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluoroura | 2008 |
Adjuvant chemoradiation for pancreatic cancer: few good data, much debate.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Tri | 2008 |
Personalized medicine for pancreatic cancer: a step in the right direction.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fluorouracil | 2009 |
Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours.
Topics: Acetylgalactosamine; Animals; Antineoplastic Agents; Benzyl Compounds; Cell Line, Tumor; Female; Flu | 2009 |
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; F | 2009 |
ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Multidrug Resistance-Associated P | 2009 |
Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dose Fractionation, Radiati | 2009 |
Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Proliferation; Drug Evaluation, Preclinical; Epide | 2008 |
A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2009 |
Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2009 |
[5-FU based chemoradiotherapy for unresectable locally advanced pancreatic cancer].
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Dose-Response Relations | 2009 |
Adjuvant chemoradiotherapy for high-risk pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined | 2009 |
Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Acinar Cell; Combined Modality Therapy; Fluorourac | 2009 |
Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cardiomyopathy, Dilated; Deoxycytidine; Dihydrouracil | 2009 |
Chemotherapeutic agents potentiate adenoviral gene therapy for pancreatic cancer.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents | 2009 |
Experimental study of combination therapy with S-1 against pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Prolifer | 2009 |
Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Human | 2010 |
Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Fl | 2009 |
Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 2009 |
Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Cell Line, Tumor; ErbB Recep | 2009 |
Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex | 2009 |
Metastatic acinar cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Deoxycytidine; Drug Resistan | 2009 |
Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Combi | 2009 |
Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells.
Topics: Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Flu | 2009 |
Mutations in the mitochondrial genome confer resistance of cancer cells to anticancer drugs.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Cycle; Cell Nucleus; Cisplatin | 2009 |
Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combine | 2009 |
Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Dihydrouracil Dehydro | 2009 |
Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2009 |
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic | 2009 |
Sirolimus can reverse resistance to gemcitabine, capecitabine and docetaxel combination therapy in pancreatic cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deo | 2009 |
Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2009 |
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
Topics: Antineoplastic Agents; Blotting, Western; Cadherins; Cell Line, Tumor; Cisplatin; Cluster Analysis; | 2009 |
Pancreatic cancer: the stealth cancer. Pancreatic cancer is hard to detect and highly resistant to chemotherapy; new research reveals possible resolutions.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers; Diabetes Mellitus; DNA Mismatch Repair; Fluoro | 2009 |
Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Ant | 2010 |
Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Fine-Needle; Capec | 2009 |
Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Do | 2009 |
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized | 2009 |
Call for clarity in the reporting of benefit associated with anticancer therapies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Editorial Policies; Fluorouracil; Ge | 2009 |
Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Cl | 2009 |
[Dramatic efficacy of chemotherapy with 5-fluorouracil and dacarbazine in a patient with metastatic glucagonoma and cardiac insufficiency].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathy, Dilated; Dacarbazine; Female; | 2010 |
Patterns of radiotherapy practice for pancreatic cancer in Japan: results of the Japanese Radiation Oncology Study Group (JROSG) survey.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Fem | 2010 |
Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, | 2010 |
ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Apopt | 2010 |
[Case report of infected pseudo-aneurysm after intra-arterial chemotherapy].
Topics: Aneurysm, False; Aneurysm, Infected; Antimetabolites, Antineoplastic; Femoral Artery; Fluorouracil; | 2009 |
[A case of postoperative multiple liver metastases of pancreatic cancer successfully treated by combination chemotherapy with weekly high-dose 5-FU hepatic arterial infusion plus systemic infusion of gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2009 |
Pancreatic cancer therapy with a novel pump for controlled drug release.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Delayed-Action Preparations; | 2010 |
En bloc resection for right colon cancer directly invading duodenum or pancreatic head.
Topics: Adult; Aged; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Duodena | 2009 |
Pancreatic cancer: progress made.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemo | 2010 |
Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2010 |
Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Dru | 2010 |
Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug-Related Side Effects | 2010 |
Management of borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 2010 |
Update on adjuvant trials for pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials a | 2010 |
Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.
Topics: Administration, Oral; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; | 2010 |
Any progress in pancreatic cancer? Well, but progress for Acta Oncologica.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Congresses as Topic; Deoxycytidine; ErbB Receptors; | 2010 |
Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemothera | 2011 |
Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; | 2010 |
Beneficial effects of 5-Fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative resection of pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 2010 |
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Proliferation; Chemotherapy, Adjuvant; C | 2010 |
Adjuvant pancreatic cancer therapy: no one should go it alone or be left behind.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Fluorouracil; Gentamicins; Humans; Pancreatic Neoplas | 2010 |
Analogs of vitamin E epitomized by alpha-tocopheryl succinate for pancreatic cancer treatment: in vitro results induce caution for in vivo applications.
Topics: alpha-Tocopherol; Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Prot | 2010 |
A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2010 |
Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2010 |
Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2011 |
Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Mod | 2010 |
Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2010 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; | 2010 |
Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity.
Topics: Antimetabolites, Antineoplastic; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Neurotox | 2010 |
[Effect of pylorus-preserving pancreaticoduodenectomy on serum levels of 5-fluorouracil during S-1 treatment for pancreaticobiliary malignancy].
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Drug Combinations; Female; Fluoroura | 2010 |
Assessment of pancreatic carcinoma cell chemosensitivity using a three-dimensional culture system.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Deoxycytidine; Fluo | 2010 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; CASP8 and FADD-Like Apoptosis Reg | 2011 |
Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu | 2010 |
Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blotting, Western; | 2010 |
Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results.
Topics: Aged; Angiopoietins; Antineoplastic Combined Chemotherapy Protocols; Chemokine CXCL12; Deoxycytidine | 2010 |
Current status of adjuvant therapy for pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combi | 2010 |
Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Combined Moda | 2011 |
Effects of capecitabine and celecoxib in experimental pancreatic cancer.
Topics: Animals; Capecitabine; Celecoxib; Cricetinae; Deoxycytidine; Fluorouracil; Lipid Peroxidation; Lipid | 2010 |
Pancreatic metastasis from colon carcinoma treated with radiotherapy with palliative benefit.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Col | 2010 |
Additive growth inhibition after combined treatment of 2-methoxyestradiol and conventional chemotherapeutic agents in human pancreatic cancer cells.
Topics: 2-Methoxyestradiol; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2010 |
Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells.
Topics: Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Curcumin; | 2011 |
CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Pancreatic cancer: will incremental advances begin to make a difference?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycyti | 2010 |
Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antioxidants; Capecitabine; Cricetinae; De | 2011 |
Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, P | 2011 |
[Locally advanced pancreatic cancer successfully treated by arterial infusion chemotherapy combined with stereotactic radiotherapy--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; F | 2010 |
[A case of multiple liver metastases from nonfunctioning neuroendocrine pancreatic tumor curatively resected after successful intra-arterial chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Neuroendocrine; Combined Modality Therapy; Female | 2010 |
Unity is strength: one, two, or more drugs against advanced pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; O | 2011 |
Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Antineoplastic Combined Chemother | 2012 |
Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2011 |
Associations between gene polymorphisms of thymidylate synthase with its protein expression and chemosensitivity to 5-fluorouracil in pancreatic carcinoma cells.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Humans; Minisatellite Repeats | 2011 |
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell | 2011 |
Three-drug combination regimen in pancreatic cancer treatment: are we there yet?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leuc | 2011 |
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as | 2011 |
Adjuvant therapy of pancreatic cancer: beyond gemcitabine. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical Tr | 2011 |
Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; | 2011 |
Ampullary and periampullary tumors: translational efforts to meet a challenge in diagnosis and treatment. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Common Bile Duct Neoplasms; Deoxyc | 2011 |
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Capecitabine; Deoxy | 2011 |
Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistanc | 2011 |
Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer.
Topics: Antimetabolites, Antineoplastic; Chi-Square Distribution; Combined Modality Therapy; Contrast Media; | 2011 |
Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Cathepsin D; Cell Line, Tumor; Cell | 2011 |
Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytokines; Deoxycytidine; Dose-Response Relationship | 2011 |
SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Fluorouracil; Gene Expression Regu | 2011 |
Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; Colorectal Neoplasms; Cytoprotection; DNA Repair; Drug Th | 2011 |
Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leuc | 2011 |
Proteomic differential display analysis for TS-1-resistant and -sensitive pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Combinations; | 2011 |
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2011 |
Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluor | 2011 |
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemot | 2012 |
Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; CA-19-9 Antigen; Cell Line, Tum | 2011 |
New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin | 2011 |
An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Topics: Adenocarcinoma; Adenoviruses, Human; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival | 2011 |
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Do | 2012 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabi | 2011 |
FOLFIRINOX: a small step or a great leap forward?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabi | 2011 |
The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable.
Topics: Aged; Antimetabolites, Antineoplastic; Duodenal Neoplasms; Fluorouracil; Humans; Lutetium; Male; Mid | 2012 |
A patient with a metastatic gastroenteropancreatic endocrine carcinoma causing hyperinsulinaemic hypoglycaemia and the carcinoid syndrome.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Fl | 2011 |
Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Re | 2012 |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clin | 2011 |
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Loss, Surgical; Capecit | 2012 |
A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo.
Topics: Animals; Apoptosis; Blotting, Western; Breast Neoplasms; Caspase 8; Caspase Inhibitors; Colorectal N | 2011 |
Intra-arterial chemoinfusion prior to chemoradiotherapy with full-dose systemic gemcitabine for management of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluoroura | 2011 |
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2012 |
Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224radium-loaded wires releasing alpha-emitting atoms.
Topics: Alpha Particles; Animals; Antimetabolites, Antineoplastic; Brachytherapy; Cell Line, Tumor; Cell Pro | 2012 |
Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antibiotics, Antineoplastic; Antimetabolites, A | 2012 |
Intensity-modulated radiotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; De | 2012 |
Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; | 2012 |
Analysis of local control in patients receiving IMRT for resected pancreatic cancers.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2012 |
Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Cell Line, Tumor; | 2012 |
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose F | 2012 |
Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Ad | 2012 |
5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Line; Dend | 2012 |
Safety and optimal management of hepatic arterial infusion chemotherapy after pancreatectomy for pancreatobiliary cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiography, Digital Subtraction; Biliary Tract Neoplasms; Chi-Squar | 2012 |
Conventional chemotherapy of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clini | 2012 |
[Combined radiochemotherapy of an irresectable carcinoma of the pancreas].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cholangiopancreat | 1998 |
Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Hypoxia; Cell Line | 2012 |
Analysis of polymorphisms and haplotype structure of the human thymidylate synthase genetic region: a tool for pharmacogenetic studies.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Fluorouracil; Haplotypes; Humans; Minisatellite Repe | 2012 |
Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemoradiotherapy, A | 2012 |
A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, P | 2012 |
Unresectable pancreatic cancer: arterial embolization to achieve a single blood supply for intraarterial infusion of 5-fluorouracil and full-dose IV gemcitabine.
Topics: Antimetabolites, Antineoplastic; Contrast Media; Deoxycytidine; Embolization, Therapeutic; Female; F | 2012 |
Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; B | 2012 |
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluor | 2012 |
Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferati | 2012 |
FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase | 2012 |
Clinical and laboratory biomarkers in the management of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers; Capecitabine; Deoxycytid | 2012 |
Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidin | 2012 |
A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing.
Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Colorectal Neoplasms; Dose-Response Relations | 2012 |
Oleanolic acid potentiates the antitumor activity of 5-fluorouracil in pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Ca | 2012 |
[A case of metastatic pancreatic cancer which trastuzumab+capecitabine combination therapy was effective].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2012 |
FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma | 2012 |
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2012 |
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma; Chemoradiotherapy | 2012 |
Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Drug Resistance | 2012 |
Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2012 |
Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Lin | 2012 |
Endoscopic self-expandable metallic stent placement in malignant pyloric or duodenal obstruction: does chemotherapy affect stent patency?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiopancreatography, Endoscopic Retrograd | 2013 |
Double pancreatic and gastric adenocarcinomas: a rare association.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2013 |
miR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKα1.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle C | 2013 |
Concomitant occurrence of pulmonary invasive aspergillosis and Pneumocystis pneumonia during FOLFIRINOX chemotherapy for pancreatic carcinoma.
Topics: Adenocarcinoma; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Proto | 2013 |
Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Deoxycytid | 2012 |
Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Capecitabine; Cell Survival; Deoxycyt | 2013 |
[Resection of the remnant pancreas for recurrent pancreatic cancer after distal pancreatectomy-a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluo | 2012 |
Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma, Neur | 2013 |
Treatment of unresectable pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Embolization, Therapeutic; Female; Fluorouracil; Hum | 2013 |
Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis.
Topics: Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Herpesvi | 2013 |
Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy | 2013 |
G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity.
Topics: Adenocarcinoma; Antimetabolites; Antimetabolites, Antineoplastic; Breast Neoplasms; Bromodeoxyuridin | 2002 |
Treatment with 5-fluorouracil enhances radiosensitivity of the human pancreatic cancer cell line MiaPaCa-2.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Survival; Combined Modality Therapy; Fluoroura | 2002 |
Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2.
Topics: Adenocarcinoma; Adenovirus Infections, Human; Animals; Antimetabolites, Antineoplastic; Cell Divisio | 2002 |
Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Deoxycytidine; Dose-Respon | 2002 |
Advanced pancreatic cancer--5 years on.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; | 2002 |
Unresolved issues in the management of locally advanced non-metastatic pancreas cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality | 2002 |
Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu | 2002 |
Gene therapy for intraperitoneally disseminated pancreatic cancers by Escherichia coli uracil phosphoribosiltransferase (UPRT) gene mediated by restricted replication-competent adenoviral vectors.
Topics: Adenoviridae; Adenovirus E1B Proteins; Animals; Antimetabolites, Antineoplastic; beta-Galactosidase; | 2002 |
[A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr | 2002 |
Nonfunctioning islet cell carcinoma of the pancreas: case report.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Islet Cell; Diagnosi | 2002 |
Comparison of 5-fluorouracil and 5-fluoro-2'-deoxyuridine as an effector in radiation-activated prodrugs.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Colony-Forming Units Assay; Female; Floxuri | 2002 |
[Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progres | 2002 |
Chemoradiation protocols offer only incremental gains for pancreatic cancer patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycyt | 2002 |
[A case of vulval extramammary Paget's disease associated with pancreatic cancer that was successfully treated with chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; D | 2002 |
[Chemotherapy in adenocarcinomas of the pancreas].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2002 |
[Resection of pancreatic cancer and simultaneous lung metastasis--a case report of successful in tumor dormancy mainly by postoperative 5-fluorouracil-based chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2002 |
Quantification of human Alu sequences by real-time PCR--an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants.
Topics: Alu Elements; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Colonic Neoplasms; DNA, N | 2002 |
[Pancreatic islet cell carcinoma with multiple hepatic metastases successfully treated with a streptozocin/5-FU regimen--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Drug Administration Schedule; | 2002 |
[Apoptosis of human pancreatic carcinoma cell lines induced by combinations of chemotherapeutic drugs].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Doxorubicin; Epirubicin; Flu | 1999 |
Chemoradiation of unresectable pancreatic carcinoma: impact of pretreatment hemoglobin level on patterns of failure.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Fema | 2003 |
[A case of advanced pancreatic cancer with multiple liver metastasis that improved remarkably with use of low-dose cisplatin and TS-1].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationshi | 2003 |
A case of aggressive neuroendocrine carcinoma of the stomach.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2003 |
[Pancreatic carcinoma--overcome technically but not oncologically].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; D | 2003 |
Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cis | 2003 |
The recent past and future of adjuvant therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Tri | 2003 |
An experimental study on the pharmacokinetics of 5-fluorouracil regional chemotherapy for pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Dogs; Duodenum; Female; Fluorouracil; Infusions, Intra-Art | 2003 |
[Pancreatic cancer--diagnostics and therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreat | 2003 |
[Operative management in the treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Therapy, Co | 2003 |
Locally advanced acinar cell carcinoma of the pancreas successfully treated by capecitabine and concurrent radiotherapy: report of two cases.
Topics: Adult; Capecitabine; Carcinoma, Acinar Cell; Deoxycytidine; Female; Fluorouracil; Humans; Male; Midd | 2003 |
Small-field radiotherapy in combination with concomitant chemotherapy for locally advanced pancreatic carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cisplatin; Combined Mod | 2003 |
[Change of 5-fluorouracil penetration in blood-pancreatic barrier of rats after high-dose radiotherapy].
Topics: Animals; Antimetabolites, Antineoplastic; Capillary Permeability; Combined Modality Therapy; Fluorou | 2000 |
p14ARF upregulation of p53 and enhanced effects of 5-fluorouracil in pancreatic cancer.
Topics: Fluorouracil; Humans; Pancreatic Neoplasms; Transfection; Tumor Cells, Cultured; Tumor Suppressor Pr | 2003 |
[A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy].
Topics: Adenocarcinoma; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; | 2003 |
Arterial infusion chemotherapy for the patient of unresectable pancreatic carcinoma with multiple liver metastases: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fatal Outcome; Fluo | 2003 |
The effect of 5-fluorouracil upon carcinomas of the gastrointestinal tract and related organs.
Topics: Biliary Tract; Biliary Tract Neoplasms; Digestive System Neoplasms; Fluorouracil; Gastrointestinal T | 1961 |
CHEMOTHERAPY OF METASTATIC LIVER CANCER BY PROLONGED HEPATIC-ARTERY INFUSION.
Topics: Alkaline Phosphatase; Bile Duct Neoplasms; Bilirubin; Chemotherapy, Cancer, Regional Perfusion; Colo | 1964 |
EARLY RESULTS OF COMBINED RADIATION AND CHEMOTHERAPY IN TREATMENT OF MALIGNANT TUMORS.
Topics: Antineoplastic Agents; Colonic Neoplasms; Dactinomycin; Fluorouracil; Humans; Lung Neoplasms; Mitomy | 1963 |
PERCUTANEOUS VISCERAL CATHETERIZATION FOR INFUSION CANCER CHEMOTHERAPY.
Topics: Biomedical Research; Catheterization; Fluorouracil; Geriatrics; Humans; Injections, Intra-Arterial; | 1964 |
VINCRISTINE (NSC-67574) THERAPY OF ADULT PATIENTS WITH SOLID TUMORS.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Bronchogenic; Carcinoma, Squamous | 1964 |
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human | 1964 |
SERIAL ENZYME CHANGES IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Clinical Enzyme Tests; Colonic Neoplasms; D-Alani | 1964 |
TREATMENT OF ADVANCED CANCER WITH 5-FLUOROURACIL.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Humans; Leuko | 1964 |
EXPERIENCE WITH CHEMOTHERAPY OF CANCER AT THE UNIVERSITY OF PRETORIA.
Topics: Antineoplastic Agents; Aziridines; Breast Neoplasms; Cyclophosphamide; Dactinomycin; Fluorouracil; H | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
PROTRACTED AMBULATORY INFUSION CANCER CHEMOTHERAPY BY THE WATKINS CHRONOMETRIC INFUSOR.
Topics: Adenoma; Antineoplastic Agents; Breast Neoplasms; Carcinosarcoma; Colonic Neoplasms; Dermatitis, Exf | 1964 |
STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
Topics: Adenocarcinoma; Agranulocytosis; Biomedical Research; Diarrhea; Diverticulitis; Drug Eruptions; Fluo | 1964 |
CHEMOTHERAPY OF MALIGNANCIES OF THE GASTROINTESTINAL TRACT.
Topics: Antineoplastic Agents; Carcinoid Tumor; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Gastroint | 1965 |
TREATMENT OF MALIGNANT NEOPLASMS OF THE GASTROINTESTINAL TRACT WITH A COMBINATION OF 5-FLUOROURACIL AND RADIATION: A RANDOMIZED DOUBLE-BLIND STUDY.
Topics: Adenocarcinoma; Colonic Neoplasms; Double-Blind Method; Drug Therapy; Fluorouracil; Humans; Neoplasm | 1965 |
Establishment of gemcitabine-resistant human pancreatic cancer cells and effect of brefeldin-a on the resistant cell line.
Topics: Brefeldin A; Cell Division; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Doxor | 2003 |
Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; | 2003 |
Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2003 |
Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.
Topics: Adenoviruses, Human; Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line, Tumor; Comb | 2003 |
[Novel chemoradiotherapy for locally advanced pancreatic cancer using arterial infusion chemotherapy following the alteration of peripancreatic blood flow].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration | 2003 |
EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation.
Topics: Animals; Anoikis; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Transformation, | 2004 |
Marginal effects of regional intra-arterial chemotherapy as an alternative treatment option in advanced pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Cisplat | 2004 |
Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins.
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Cell Survival; Cisplatin; Collagen Type I; C | 2004 |
Complete pathologic responses to preoperative chemoradiation in two patients with adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2004 |
Role of positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans | 2004 |
In response to Li et al.: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. IJROBP 2003;57:98-104.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine | 2004 |
Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; CDC2-CDC28 Kinases; Cell Cycle; Cell | 2004 |
[Hepatic arterial infusion therapy for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Hepatic Artery; Humans; In | 2004 |
5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Pro | 2004 |
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2004 |
Chemotherapy for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancreatic Neoplasms; | 2004 |
Chemotherapy for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancreatic Neoplasms; | 2004 |
Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeuti | 2004 |
[A case of curatively resected gastric cancer through an effective response to chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 2004 |
[Occlusion of central venous port catheters after simultaneous 24 h infusions of 5-FU and calcium-folinic acid in patients with gastrointestinal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Carbonate; Catheterization, Central Ve | 2004 |
Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Bile; Chemotherap | 2004 |
Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ci | 2004 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox | 2003 |
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-fluorouracil and infusional 5-fluorouracil alone in advanced pancreatic carcinoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Fluorouracil; Hu | 2004 |
[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2004 |
Bevacizumab proves active in wide range of cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; D | 2004 |
Peripheral neuropathy associated with capecitabine.
Topics: Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); | 2004 |
[A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with gemcitabine hydrochloride, 5-FU, CDDP and administration of tegafur/uracil].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration | 2004 |
[Pancreatic carcinoma: progress in therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 2004 |
The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines.
Topics: Adenoviridae; Adult; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cell Line, | 2004 |
Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fem | 2004 |
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Dose-Response Re | 2004 |
[Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Deoxycytidin | 2004 |
Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Case- | 2005 |
Mucinous cystic carcinoma of the pancreas: a unique cell line and xenograft model of a preinvasive lesion.
Topics: Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cystadenocarcinoma, Mucinous; Disease Models | 2005 |
[Two-year survivor in response to gemcitabine-based chemotherapy for advanced pancreatic cancer with multiple lung metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Dru | 2005 |
A challenge to the therapeutic nihilism of ESPAC-1.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Bias; Combined Modality Therapy; Data Interpretat | 2005 |
Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages.
Topics: Aged; Capecitabine; Cell Movement; Deoxycytidine; Endothelial Cells; Female; Fluorouracil; Humans; I | 2005 |
Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 2005 |
Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expressi | 2005 |
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; | 2005 |
Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2005 |
Impact of different treatment methods on survival in advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; F | 2005 |
Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspases; Cell Line, | 2005 |
Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Deoxycytidine; Drug Resistance, Neo | 2005 |
Feasibility and efficacy of combination therapy with preoperative and postoperative chemoradiation, extended pancreatectomy, and postoperative liver perfusion chemotherapy for locally advanced cancers of the pancreatic head.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Feasibility Studies; Female; F | 2005 |
Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampullary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Chemotherapy, Adjuvant; Combined M | 2005 |
[Chemotherapy of pancreatic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2005 |
Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm, Abdominal; Deoxycyt | 2005 |
Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modal | 2005 |
Prophylactic hepatic irradiation following curative resection of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemotherapy, A | 2005 |
Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Neuroendocrin | 2005 |
Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2005 |
Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Back Pa | 2005 |
Capecitabine-induced pancolitis.
Topics: Adult; Capecitabine; Colitis; Deoxycytidine; Fluorouracil; Humans; Male; Neoplasm Metastasis; Pancre | 2007 |
Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Costs; Female; Fluorouracil; Gemcitabine; | 2005 |
Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Algorithms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Fluorourac | 2005 |
Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil: a first step to neoadjuvant treatment?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Digestive System Surgical Pro | 2005 |
5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Hepatocel | 2005 |
Fluorouracil and mitomycin for pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Mit | 2005 |
Current and future strategies for treating metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineop | 2004 |
Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): implications to the therapy of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Blotting, Wester | 2005 |
Vanilloids in pancreatic cancer: potential for chemotherapy and pain management.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Cell | 2006 |
Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brain; Breast Neoplasms; Capecitabine; Carcinoma; Deox | 2005 |
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Caspases; Cell Cycle; Cell Line, Tumor; Ce | 2005 |
Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer.
Topics: Aged; Case-Control Studies; Chemotherapy, Adjuvant; Chi-Square Distribution; Female; Fluorouracil; H | 2005 |
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bac | 2003 |
5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gem | 2005 |
[Establishment, characterization, and biological analysis of pancreatic adenocarcinoma cell strain SW1990/FU].
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Drug Resista | 2005 |
High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients.
Topics: Antimetabolites, Antineoplastic; Cohort Studies; Female; Fibrinolytic Agents; Fluorouracil; Humans; | 2006 |
Gemcitabine doublets in advanced pancreatic cancer: should we move on?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical | 2006 |
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2005 |
Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Chi-Square Distribution; Combined Modality Therapy; Female; Flu | 2006 |
In vivo imaging of tumor response to therapy using a dual-modality imaging strategy.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Biomarkers; Female; Fl | 2006 |
Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2006 |
Radiotherapy and chemotherapy in pancreatic cancer. Topical issues and future perspectives.
Topics: Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidin | 2006 |
A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antimetabolites, Antineoplastic; Antineoplastic Agents | 2006 |
Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase Inhibitors | 2006 |
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Contraindications; Deoxycy | 2006 |
Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dihyd | 2006 |
Erlotinib or capecitabine with gemcitabine in pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride | 2006 |
Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modalit | 2006 |
Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modalit | 2006 |
Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modalit | 2006 |
Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modalit | 2006 |
Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modalit | 2006 |
Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modalit | 2006 |
Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modalit | 2006 |
Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modalit | 2006 |
Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modalit | 2006 |
Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients.
Topics: Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Tri | 2006 |
XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics.
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Hu | 2006 |
[Present and future home therapy in advanced stage of pancreatic cancer].
Topics: Ambulatory Care; Analgesics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2006 |
Pancreatoblastoma in a teenage patient.
Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2006 |
[Interferon-alpha+cisplatin+5-FU therapy for gemcitabine-refractory unresectable and recurrent pancreatic cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Admin | 2006 |
On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancr | 2006 |
Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, | 2006 |
[Long-term repeatable chemotherapy for patients with advanced pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality The | 2006 |
Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line Capan-2.
Topics: Antimetabolites, Antineoplastic; Caspase 2; Caspase Inhibitors; Cell Cycle; Cell Division; Cell Line | 2006 |
[Gemcitabine versus combined chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy.
Topics: 5' Untranslated Regions; Alleles; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neop | 2006 |
Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ducta | 2006 |
Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blood Vessels; Cell Di | 2006 |
[A pilot study on the impact of the drug resistance on the radioresistance in human pancreatic cancer cell lines].
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Drug Resistance, Ne | 2006 |
Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidi | 2006 |
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2006 |
DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Topics: Adenocarcinoma; Aged; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP) | 2007 |
Combination therapy with gemcitabine and 5-Fluorouracil: unblocking the pathways to survivin?
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Fluorour | 2006 |
Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidi | 2007 |
Adjuvant therapy for pancreatic cancer: a time that has not yet come.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Thera | 2007 |
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2006 |
[Metastatic pancreatic neuroendocrine tumors and chemotherapy: evidences and perspectives].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease Management; Doxorubi | 2007 |
Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin.
Topics: Apoptosis; Asparagine; Aspartate-Ammonia Ligase; Cell Line, Tumor; Cisplatin; Fluorouracil; Gene Exp | 2007 |
Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy.
Topics: Cisplatin; Fluorouracil; Genetic Therapy; Genetic Vectors; Oncolytic Virotherapy; Oncolytic Viruses; | 2007 |
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitab | 2008 |
Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine | 2007 |
3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy.
Topics: Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Pancr | 2007 |
Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Fluorou | 2007 |
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combin | 2007 |
Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy.
Topics: Adenoma, Islet Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined M | 2007 |
Effects of 5-fluouracil combined with sulfasalazine on human pancreatic carcinoma cell line BxPC-3 proliferation and apoptosis in vitro.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fluorouracil | 2007 |
Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2007 |
[A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedul | 2007 |
Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
[The first report from Sapporo Tsukisamu Hospital--chemotherapy and chemoradiotherapy for patients with advanced pancreatic cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2007 |
Arterial infusion of 5-fluorouracil combined with concurrent radiotherapy for unresectable pancreatic cancer: results from a pilot study.
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Combined Modality Therapy; Contrast Media; Female; Fl | 2007 |
[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2007 |
Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromogranin A; Deoxycytidine; Fluorouracil; Humans; | 2008 |
Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain.
Topics: Acetylgalactosamine; Antimetabolites, Antineoplastic; Benzyl Compounds; Cell Proliferation; Fluoresc | 2007 |
Management of nonfunctioning pancreatic endocrine tumors in the context of multiple endocrine neoplasia type 1 syndrome.
Topics: Adolescent; Adult; Chemotherapy, Adjuvant; Drug Therapy, Combination; Endosonography; Female; Fluoro | 2007 |
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2007 |
[Management of nonfunctioning islet cell tumors of the pancreas].
Topics: Adenoma, Islet Cell; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2007 |
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Deoxycytidine; Dihydroura | 2007 |
Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Injecti | 2008 |
The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resi | 2008 |
Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Cel | 2008 |
Inoperable pancreatic cancer: standard of care.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Com | 2007 |
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Creatinine; Deoxycytidine; | 2008 |
Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil | 2008 |
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; | 2008 |
Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer.
Topics: Angiotensin II; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA- | 2007 |
FP therapy for controlling malignant ascites in advanced pancreatic cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; C-Reactive Pro | 2007 |
Complete response of a pancreatic adenosquamous carcinoma to chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Combined Modali | 2008 |
Intraoperative radiation therapy in resected pancreatic carcinoma: long-term analysis.
Topics: Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluo | 2008 |
Adjuvant therapy for surgically resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil | 2008 |
Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; D | 2008 |
Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Studies; Combi | 2009 |
Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Continuous intra-arterial chemotherapy with 5-fluorouracil and cisplatin for locally advanced anaplastic carcinoma of the pancreas.
Topics: Carcinoma; Cisplatin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Middle Aged; Pancreat | 2008 |
Capecitabine as salvage therapy for a pancreatic cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; F | 2008 |
Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Duct | 2008 |
Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Gem | 2008 |
Disappearance of antibodies to Factor VIII in a patient with acquired haemophilia and carcinoma of the pancreas during cytotoxic therapy with fluorouracil and CCNU.
Topics: Adenocarcinoma; Aged; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Factor VIII; Femal | 1984 |
[Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma].
Topics: Adult; Aged; Alkaline Phosphatase; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Sched | 1984 |
Pancreatic somatostatinoma presenting with hypoglycaemia.
Topics: Adenocarcinoma; Adult; Chlorothiazide; Diazoxide; Female; Fluorouracil; Humans; Hypoglycemia; Pancre | 1980 |
Intra-arterial chemotherapy for patients with inoperable carcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, I | 1980 |
Intraarterial 5-FU infusion with or without oral testolactone treatement in irresectable pancreatic cancer.
Topics: Adult; Aged; Catheterization; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Male; Middle | 1980 |
[A method of radiation and combined treatment in inoperable cancer of the pancreas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1984 |
Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Doxorubicin; Drug Evaluation; Drug Therapy, Comb | 1982 |
Mixed beam radiotherapy and combination chemotherapy in localized pancreatic adenocarcinoma-preliminary results.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Elementary Particles; | 1982 |
Phase II study of 5-FU, doxorubicin, and mitomycin (FAM) and chlorozotocin in advanced measureable pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Hematopoi | 1982 |
Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineop | 1982 |
[Surgery and drug therapy of advanced pancreatic cancer].
Topics: Adult; Aged; Delayed-Action Preparations; Drug Therapy, Combination; Female; Fluorouracil; Humans; M | 1982 |
[Clinical evaluation of neocarzinostatin in digestive system cancer. 2. Clinical studies on the administration of neocarzinostatin in advanced and recurrent carcinoma of the pancreas].
Topics: Antibiotics, Antineoplastic; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, Parenteral; | 1983 |
Phase II trial of methyl-CCNU, vincristine, 5-fluorouracil, and streptozotocin (MOF-Strep) in patients with disseminated pancreatic carcinoma.
Topics: Adenocarcinoma; Adenoma, Islet Cell; Adult; Aged; Drug Evaluation; Drug Therapy, Combination; Female | 1982 |
Pancreatic islet cell carcinoma associated with multiple hormone secretion and pancytopenia. Evidence of a serum factor suppressing hematopoiesis.
Topics: Adenoma, Islet Cell; Aged; Androgens; Animals; Female; Fluorouracil; Hematopoiesis; Hormones; Humans | 1983 |
Glucagonoma and its angiographic diagnosis.
Topics: Adenoma, Islet Cell; Adult; Aged; Angiography; Antineoplastic Agents; Dacarbazine; Drug Therapy, Com | 1982 |
[Antineoplastic effect of UFT therapy (uracil-FT-207 combination therapy) on experimental pancreatic cancer transplanted in the pancreas and subcutaneous region].
Topics: Animals; Antineoplastic Agents; Carcinoma, Intraductal, Noninfiltrating; Cricetinae; Drug Therapy, C | 1982 |
Unsuccessful DTIC treatment of a patient with glucagonoma syndrome.
Topics: Adenoma, Islet Cell; Dacarbazine; Drug Therapy, Combination; Fluorouracil; Glucagonoma; Humans; Live | 1983 |
[Clinical trial on the effect of tegafur (SF-SP)].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Capsules; Carcinoma, Intraductal, Noninfiltrating | 1984 |
Phase II trial of combination chemotherapy for pancreatic cancer with 5-fluorouracil, mitomycin C, and hexamethylmelamine.
Topics: Altretamine; Antibiotics, Antineoplastic; Drug Administration Schedule; Drug Evaluation; Drug Therap | 1983 |
Sensitivity of xenografts of human pancreatic adenocarcinoma in nude mice to heat and heat combined with chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Cisplatin; Fluorouracil; Hot Temperature; | 1983 |
[Analysis of factors affecting clinical cancer chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Fluorouraci | 1983 |
[Cooperative phase II study of releasing tegafur (SF-SP) against advanced digestive cancers].
Topics: Administration, Oral; Adult; Aged; Colonic Neoplasms; Delayed-Action Preparations; Digestive System | 1984 |
[Evaluation of tegafur encapsulated with slow-releasing granules (SF-SP) for patients with cancer of the digestive organs].
Topics: Administration, Oral; Adult; Aged; Capsules; Colonic Neoplasms; Delayed-Action Preparations; Drug Ev | 1984 |
Chemotherapy of pancreatic carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; M | 1984 |
[Chemotherapy of pancreatic cancer is not yet generally recommended].
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Com | 1980 |
Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Mitomycins; Nausea | 1980 |
[Adjuvant chemotherapy in cancers of the stomach, pancreas and intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined M | 1984 |
[Combination of radiotherapy with 5-fluorouracil in advanced cancer of the pancreas].
Topics: Aged; Combined Modality Therapy; Drug Evaluation; Female; Fluorouracil; Humans; Male; Middle Aged; P | 1984 |
Infusion chemotherapy in inoperable pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Intra-Arterial; Pan | 1983 |
Combination chemotherapy for locally advanced pancreatic cancer: equivalence to external beam irradiation and implication for future management.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Huma | 1983 |
Microplate leukocyte adherence inhibition assay in pancreatic cancer. Effect of chemotherapy on the specific antitumor response.
Topics: Doxorubicin; Fluorouracil; Humans; Immunity, Innate; Immunologic Techniques; Leukocyte Adherence Inh | 1982 |
Clotting activation after blood transfusion in patients receiving 5-fluorouracil and mitomycin-C treatment.
Topics: Blood Coagulation; Blood Transfusion; Fluorouracil; Humans; Mitomycin; Mitomycins; Pancreatic Neopla | 1981 |
Correlation between the level of urinary D-glucaric acid and the degree of activation of masked compound (FT-207) in cancer patients.
Topics: Adult; Aged; Biotransformation; Cytochrome P-450 Enzyme System; Esophageal Neoplasms; Female; Fluoro | 1981 |
Fast neutron irradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Colitis; Cost-Benefit Analysis; Energy Transfer; Esophagitis; Evaluation Studies as | 1981 |
Chemotherapy of pancreatic adenocarcinoma: initial report on two transplantable models in the Syrian hamster.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cricetinae; Cyclophosphamide; Disease Models, Animal | 1982 |
[Effect of cancer chemotherapy for unresectable cancer of the pancreas].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver Neoplasms; Mal | 1982 |
[Gastrointestinal tumors: chemotherapeutic preparations].
Topics: Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Gast | 1983 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
Combination chemotherapy with 5-FU 1-(aminomethyl)-3-(2-chloroethyl)-3-nitrosourea (ACNU), and mitomycin (FUM) for carcinoma of the pancreas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Co | 1982 |
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
Topics: Adult; Aged; Aspartic Acid; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Drug Evaluation; Drug Th | 1982 |
Radiation therapy combined with intra-arterial 5-FU chemotherapy for treatment of localized adenocarcinoma of the pancreas: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Cobalt Radioisotopes; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Male; | 1982 |
Long-term, ambulatory, continuous intravenous infusion of 5-fluorouracil for the treatment of metastatic adenocarcinoma in the liver.
Topics: Adenocarcinoma; Aged; Ambulatory Care; Cecal Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; | 1982 |
Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sch | 1982 |
Defect in assimilation following combined radiation and chemotherapy in patients with locally unresectable pancreatic carcinoma.
Topics: Aged; Carotenoids; Dietary Fats; Feces; Female; Fluorouracil; Humans; Intestinal Absorption; Jejunum | 1982 |
[Gastrointestinal tumors. Prognostic factors and chemotherapy of today].
Topics: Carmustine; Colonic Neoplasms; Doxorubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans | 1981 |
Defective function of granulocytes in patients with cancer.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Femal | 1981 |
Long term survival following chemotherapy for carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Female; Fluorouracil; Humans; Pancreatic Neoplasms; Razoxane | 1980 |
Chemotherapy for gastrointestinal malignancy.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Esophageal Neoplasms; Fluoroura | 1980 |
5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Sche | 1980 |
Sequential carcinoembryonic antigen levels. A predictor of response and relapse in combination chemotherapy of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil | 1981 |
[Therapeutic progress in digestive system neoplasms. VII. Treatment of pancreatic neoplasms].
Topics: Antineoplastic Agents; Fluorouracil; Humans; Pancreatic Neoplasms | 1980 |
Vinblastine and 5-fluorouracil sensitivity of xenografts of four pancreatic ductal adenocarcinomas: is there a correlation with histological and cytological tumour differentiation?
Topics: Animals; Antineoplastic Agents; Carcinoma, Ductal, Breast; Cell Differentiation; Female; Fluorouraci | 1995 |
[Chronochemotherapy in two cases of metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Cisplatin; Drug Administration Sch | 1995 |
Combination therapy with 5-fluorouracil and L-canavanine: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Canavanine; Colonic Neoplasms; Dose-Respons | 1995 |
Gene therapy for cancer using tumour-specific prodrug activation.
Topics: Base Sequence; Biotransformation; Breast Neoplasms; Cytosine Deaminase; DNA Primers; Female; Flucyto | 1994 |
New versus old: pancreatic cancer and chemoradiation attempts.
Topics: Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Humans; Liver; Liver Neoplasms; Panc | 1995 |
Gut neuroendocrine tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Diazoxide; Etoposide; Fluoro | 1994 |
[Transfer of carmofur (HCFU) to the serum, bile, pancreatic juice and pancreatic tumor tissue in the cases of peri-pancreatic head cancer].
Topics: Administration, Oral; Antineoplastic Agents; Bile; Biliary Tract Neoplasms; Fluorouracil; Humans; Pa | 1995 |
Case report: diabetic ketoacidosis in a patient with glucagonoma.
Topics: Diabetic Ketoacidosis; Female; Fluid Therapy; Fluorouracil; Glucagonoma; Humans; Insulin; Middle Age | 1995 |
Synchronization of cells in the S phase of the cell cycle by 3'-azido-3'-deoxythymidine: implications for cell cytotoxicity.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Cell Survival; Colonic Neoplasms; | 1995 |
A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgi | 1993 |
Circadian rhythm modulated 5-FUdR infusion with Megace in the treatment of advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; | 1994 |
Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy.
Topics: Actuarial Analysis; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Female; Fluo | 1993 |
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil; Humans; Inf | 1993 |
Enhancement of antitumor effects of combined chemoimmunotherapy.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Animals; CD4-Positive T-Lymphocytes; Chemotherapy, Adjuvant; | 1993 |
[Cardiac toxicity of 5 fluoro-uracil: a case of atrioventricular conduction disorders].
Topics: Adenocarcinoma; Fluorouracil; Heart Block; Humans; Male; Middle Aged; Pancreatic Neoplasms | 1993 |
Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Circadian Rhythm; Diarrhea; Dose-Response Relationship, Drug; Female; F | 1993 |
A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice.
Topics: Animals; Disease Models, Animal; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Liver Neopl | 1993 |
[Importance of systemic administration of pyrimidine after thermochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Gas | 1993 |
[Portal blood levels of 5-FU administered intraperitoneally].
Topics: Fluorouracil; Humans; Infusions, Parenteral; Pancreatic Neoplasms; Portal Vein | 1993 |
[A case of complete response by intermittent intra-arterial injection of 5-fluorouracil and carboplatin for liver metastases due to pancreatic cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Fluorouracil; H | 1993 |
[Evaluation of intra-arterial infusion chemotherapy and radical pancreatectomy in patients with locally advanced pancreatic cancer].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; | 1993 |
Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; | 1993 |
An update of the medical treatment of malignant endocrine pancreatic tumors.
Topics: Adenoma, Islet Cell; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherap | 1993 |
Dihydropyrimidine dehydrogenase activity in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1993 |
Combined modality therapy increasing local control of pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1993 |
Resection of a solid and papillary epithelial neoplasm of the pancreas following treatment with cis-platinum and 5-fluorouracil: a case report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Cisplatin; Combine | 1993 |
[A patient with stage IV gastric cancer responding to combination chemotherapy with 5-FU, leucovorin and CDDP].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio | 1993 |
High-dose folinic acid, 5-fluorouracil bolus and infusion in advanced pancreatic adenocarcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1993 |
Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoplasm Staging; Pancreatic Neoplasms | 1995 |
Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; In | 1996 |
Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth.
Topics: Carcinoma, Ductal, Breast; ErbB Receptors; Fluorouracil; Gastrointestinal Hormones; Humans; Leucovor | 1996 |
Islet cell carcinoma treated by induction regional chemotherapy and radical total pancreatectomy with liver revascularization and small bowel autotransplantation.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1996 |
Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1995 |
Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
Topics: Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Ce | 1996 |
"Chemotherapy for unresectable pancreatoblastoma".
Topics: Adolescent; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant | 1996 |
[Adjuvant regional chemotherapy in resected advanced pancreas carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Mo | 1996 |
Thymidylate synthase in advanced gastrointestinal and breast cancers.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Colonic Neoplasms; Fem | 1996 |
Antiproliferative effects of the arotinoid Ro 40-8757 in human gastrointestinal and pancreatic cancer cell lines: combinations with 5-fluorouracil and interferon-alpha.
Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Drug Synergism; Fluorouracil; Gastrointestinal Neo | 1996 |
Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1995 |
Pancreatic cancer: treatment with neutron irradiation alone and with chemotherapy.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adju | 1996 |
A pilot study of combination therapy with interferon-alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1996 |
Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antine | 1996 |
Intratumoral chemotherapy with a sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations | 1995 |
[A patient with pancreatic acinar cell carcinoma, effectively treated by the infusion chemotherapy through hepatic artery using 5-FU, CDDP and MMC].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Cisplatin; Drug Administrati | 1996 |
[A case of non-resectable pancreatic cancer surviving more than 4 years by intra-arterial infusion chemotherapy with angiotensin-II].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Combined | 1996 |
CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer.
Topics: Adult; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Combined Modality Therapy; Female; Fluorouracil; Hu | 1996 |
In vitro chemosensitivity of human pancreatic cancer cell lines.
Topics: Aged; Antimetabolites; Antineoplastic Agents; Carcinoma, Ductal, Breast; Cisplatin; DNA Replication; | 1996 |
Pilot study of continuous-infusion 5-fluorouracil, oral leucovorin, and upper-abdominal radiation therapy in patients with locally advanced residual or recurrent upper gastrointestinal or extrapelvic colon cancer.
Topics: Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therapy; Fluorourac | 1997 |
[A case of unresectable pancreatic cancer successfully treated with continuous venous daily infusion of 5-FU and low-dose CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Cisplatin; Drug Administr | 1997 |
Chemotherapy for advanced pancreatic cancer--some light at the end of the tunnel?
Topics: Fluorouracil; Humans; Pancreatic Neoplasms | 1997 |
Combined modality therapy for stage II and stage III pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1997 |
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Ac | 1997 |
[Comparison between intraperitoneal and intravenous 5-fluorouracil administration using pancreatic cancer model of nude mouse].
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Infusions, Intravenous; Infusions, P | 1997 |
[A case report of preoperative intra-arterial infusion chemotherapy for pancreatic head carcinoma].
Topics: Adenocarcinoma; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1997 |
Chemo-radiotherapy for localized pancreatic cancer: increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Adm | 1998 |
Acinar-islet cell carcinoma presenting as insulinoma.
Topics: Adenoma, Islet Cell; Adult; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Acinar Cell; Diagn | 1997 |
Clinical benefit as a primary efficacy endpoint.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neopla | 1998 |
[3D-Ct-planned interstitial HDR brachytherapy + percutaneous irradiation and chemotherapy in inoperable pancreatic carcinoma. Methods and clinical outcome].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Brachytherapy; | 1998 |
Diagnosis and management of metastatic gastrinoma by multimodality treatment including liver transplantation: report of a case.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fema | 1998 |
Advanced pancreatic cancer successfully treated with continuous infusion of 5-fluorouracil and low-dose cisplatin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; | 1998 |
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcino | 1998 |
[Long-term follow-up and therapeutic control of a hepatic metastatic acinar cell carcinoma of the pancreas using FDG PET].
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Acinar Cell; Fatal Outcome; Female; Fluorodeoxygl | 1998 |
[Effect of combination chemotherapy of low-dose CDDP. Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug | 1998 |
Penetration kinetics of 5-fluorouracil into pancreatic fluid in post-pancreatoduodenectomy patients.
Topics: Body Fluids; Duodenum; Female; Fluorouracil; Humans; Male; Pancreas; Pancreatic Neoplasms | 1998 |
Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dose Fractionatio | 1998 |
Biochemical modulation therapy for pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplati | 1998 |
[Does neoadjuvant radiochemotherapy augment the resectability of pancreatic cancers?].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 1998 |
Detection of multiple hepatic micrometastases in pancreatic adenocarcinoma with a solitary liver metastasis by direct sequencing of the K-ras gene: a case report.
Topics: Adenocarcinoma; Aged; Base Sequence; Combined Modality Therapy; Dose Fractionation, Radiation; Femal | 1999 |
Effective intra-arterial chemotherapy for acinar cell carcinoma of the pancreas.
Topics: Adult; Angiography; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Com | 1999 |
[A case of unresectable pancreatic cancer responding to MTX/5-FU sequential therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1999 |
Rationale of the so-called extended resection for pancreatic invasive ductal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Femal | 1999 |
The treatment of punctal and canalicular stenosis in patients on systemic 5-FU.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
[The effect of blood-pancreatic juice barrier on antitumor drugs excretion].
Topics: Ampulla of Vater; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Dogs; Fluor | 1997 |
High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Colonic Neoplasms; Digestive System Neo | 1999 |
Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.
Topics: Adenocarcinoma; Cyclin D1; Drug Resistance, Neoplasm; Enzyme Induction; Floxuridine; Fluorouracil; G | 1999 |
Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 | 1999 |
Drug retention and distribution after intratumoral chemotherapy with fluorouracil/epinephrine injectable gel in human pancreatic cancer xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Autoradiography; Epinephrine; Fluorouracil; Gels; Humans; | 1999 |
[Multimodality therapy of operable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Fluorouracil; Hum | 1999 |
Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antimetabolites, Antineoplastic; Combined Modality Thera | 1999 |
Resected pancreatic cancer treated with adjuvant radiotherapy with or without 5-fluorouracil: treatment results and patterns of failure.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu | 1999 |
[Contribution of gemcitabine in the treatment of advanced pancreatic cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deo | 1999 |
Gemcitabine and cancer of the pancreas: new preparation. Helpful or not?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Fluorourac | 1999 |
Adenocarcinoma of the head of the pancreas: effects of surgical and nonsurgical therapy on survival--a ten-year experience.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Life | 1999 |
[A case of recurrent pancreatic cancer brought into a complete response by a multimodal treatment with intraarterial chemotherapy and radiotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2000 |
Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; A | 2000 |
Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 2000 |
Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease Pro | 2000 |
[Has there been progress in the treatment of metastatic pancreatic cancer?].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Human | 2000 |
[Role of radiotherapy in the multidisciplinary approach to pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; In | 2000 |
Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; | 2000 |
Dihydropyrimidine dehydrogenase activity in human pancreatic tumor tissues.
Topics: Adult; Aged; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Middle Aged; Ox | 2000 |
Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; | 2000 |
Squamous cell carcinoma of the pancreas with cystic degeneration.
Topics: Abdominal Pain; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamou | 2000 |
[A patient with gastric cancer with para-aortic lymph node metastases surviving for 9 years after effective preoperative chemotherapy and radical operation].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aorta; Fluorouracil; Gastrectomy; Humans; Lymph Nod | 2000 |
Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Cell Division; Drug Re | 2000 |
[Weekly chemotherapy with alternating low-dose CPT-11 and low-dose FP against a far advanced pancreatic cancer--a case report].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2000 |
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
Topics: Abdominal Pain; Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Catheters, Indwelling; Chr | 2000 |
Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
Topics: Adenocarcinoma; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma; Cell Cycle; Dose | 2000 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region.
Topics: Adenocarcinoma; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluoroura | 2000 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region.
Topics: Adenocarcinoma; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluoroura | 2000 |
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2000 |
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; C | 2000 |
[Intra-arterial infusion chemotherapy in combination with microwave hyperthermia for cancer of head of pancreas and liver metastasis--a case of 16 years survival].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Fluorouracil; | 2000 |
[Hepatic arterial infusion chemotherapy for unresectable liver metastasis of gastrointestinal cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Fluorouracil; Hepati | 2000 |
UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemother | 2000 |
[A case of stage IV gastric cancer responding to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 2000 |
A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabi | 2000 |
Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohort Studies; Drug Administration Sche | 2000 |
Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Combined Modality Th | 2001 |
Usefulness of repeated direct intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cytosine Deaminase; Feasibility Studies; Fe | 2001 |
[Experience with chemotherapy for advanced pancreatic carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; D | 2000 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytid | 2001 |
Endovascular occlusion of branches of hepatic artery with poly(2-hydroxyethyl methacrylate) emboli as a single occlusive measure in hepatology.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Arterial Occlusive Diseases; Carcinoid Tumor; Carcinom | 2000 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com | 2001 |
Nonsurgical treatment of advanced malignant neuroendocrine pancreatic tumors and midgut carcinoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Fluorouracil; Humans; Interferon-al | 2001 |
Determination of 5-fluorouracil and 5-fluoro-2'-deoxyuridine-5'-monophosphate in pancreatic cancer cell line and other biological materials using capillary electrophoresis.
Topics: Antimetabolites, Antineoplastic; Buffers; Culture Media; Electrophoresis, Capillary; Fluorodeoxyurid | 2001 |
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Female; | 2001 |
Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Enzyme Inhibitors; Fluorine Rad | 2001 |
Long-term follow-up of twenty patients with adenocarcinoma of the pancreas: resection following combined modality therapy.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2001 |
Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Antineopla | 2001 |
Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2001 |
High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.
Topics: Biliary Tract Neoplasms; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relati | 2001 |
[Multimodal treatment including intraoperative irradiation for advanced pancreatic cancer with extended metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2001 |
Continuing controversy over adjuvant therapy of pancreatic cancer.
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Europe; Fluorouracil; Humans; Multicenter Studies | 2001 |
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispla | 2001 |
Functional evaluation of the human pancreas before and in the early period after hyperfractionated accelerated radiochemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; C-Peptide; Combined Modality Therapy; Dose Fractionati | 2002 |
Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Fe | 2002 |
Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas: great logic, grim reality.
Topics: Adenocarcinoma; Fluorouracil; Humans; Immunosuppressive Agents; Neoadjuvant Therapy; Neoplasm Stagin | 2001 |
Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2001 |
[Prognosis of pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combin | 2001 |
["Three steps procedure" in the treatment of large pancreatic head cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cholecystostomy; | 2000 |
[Effect of radiotherapy on penetration of 5-FU in blood-pancreatic barrier in rats].
Topics: Animals; Antimetabolites, Antineoplastic; Cobalt Radioisotopes; Combined Modality Therapy; Dose-Resp | 2000 |
[The effect of blood-pancreatic juice barrier on 5-fluorouracil in post-pancreatoduodenectomy patients].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Th | 1999 |
Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemo | 2002 |
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; | 2002 |
Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2002 |
Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.
Topics: Animals; Dihydrouracil Dehydrogenase (NADP); Drug Interactions; Fluorouracil; Maximum Allowable Conc | 2002 |
Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents.
Topics: Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; bcl-X | 2002 |
Treatment of carcinoma of the pancreas with radon seed implantation and intra-arterial infusion of 5-FUDR.
Topics: Adenocarcinoma; Adult; Aged; Fluorouracil; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplas | 1975 |
Carcinoma of the periampullary region: a review of a personal series of 87 patients.
Topics: Adult; Aged; Ampulla of Vater; Bile Duct Neoplasms; Drainage; Duodenum; Female; Fluorouracil; Humans | 1976 |
Current diagnosis and management of pancreatic carcinoma.
Topics: alpha-Fetoproteins; Antigens, Neoplasm; Biopsy; Carmustine; Cholangiography; Drug Therapy, Combinati | 1976 |
[Therapeutic advances in digestive oncology. III. Chemotherapy of digestive system cancers].
Topics: Adenocarcinoma; Digestive System Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Neoplas | 1979 |
[Chemotherapy for digestive carcinomas. Results of a phase II clinical trial (author's transl)].
Topics: Bile Duct Neoplasms; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Esophageal Neopl | 1979 |
Chemotherapy of gastrointestinal cancer.
Topics: Doxorubicin; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Mitomyc | 1976 |
Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer.
Topics: Adult; Aged; Bone Marrow; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1978 |
Islet cell carcinoma of the pancreas.
Topics: Adenoma, Islet Cell; Adolescent; Adult; Aged; Child; Cyclophosphamide; Dactinomycin; Female; Fluorou | 1975 |
Recent trends in chemotherapy of solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neopl | 1975 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenoma, Islet Cell; Carcinoma, Hepatocellular; Carmustine; Colonic Neoplasms; Cytarabine; Drug Ther | 1975 |
Islet cell carcinoma of the pancreas: effective therapy with 5-fluorouracil, streptozotocin, and tubercidin.
Topics: Adenoma, Islet Cell; Adult; Diazoxide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Comb | 1976 |
Walter Hubert lecture Chemotherapy of upper gastrointestinal carcinoma.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, S | 1976 |
Chemotherapy of metastatic gastrointestinal neoplasms with 5-fluorouracil and streptozotocin.
Topics: Adenocarcinoma; Adenoma, Bile Duct; Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Carcinoid | 1977 |
Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozotocin.
Topics: Adenoma, Islet Cell; Carcinoid Tumor; Drug Therapy, Combination; Fluorouracil; Humans; Intestinal Ne | 1979 |
5-FU versus combination therapy with tubercidin, streptozotocin, and 5-FU in the treatment of pancreatic carcinomas: COG protocol 7230.
Topics: Adenocarcinoma; Adenoma, Islet Cell; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; | 1979 |
Neurologic involvement in glucagonoma syndrome: response to combination chemotherapy with 5-fluorouracil and streptozotocin.
Topics: Adenoma, Islet Cell; Adult; Central Nervous System Diseases; Drug Therapy, Combination; Fluorouracil | 1979 |
[A combined immuno-chemotherapy with futraful and picibanil for advanced cancer (author's transl)].
Topics: Aged; Biological Products; Drug Therapy, Combination; Female; Fluorouracil; Humans; Intestinal Neopl | 1977 |
Adriamycin, BCNU, ftorafur chemotherapy of pancreatic and biliary tract cancer.
Topics: Adult; Aged; Biliary Tract Neoplasms; Bone Marrow; Carmustine; Doxorubicin; Drug Therapy, Combinatio | 1979 |
Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gas | 1979 |
Five-day continuous infusion of 5-fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infus | 1979 |
Combination chemotherapy for advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Fem | 1979 |
[Current state of therapy for gastrointestinal tumors].
Topics: Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; | 1978 |
Initial levels of CEA and their rate of change in pancreatic carcinoma following surgery chemotherapy and radiation therapy.
Topics: Alkaline Phosphatase; Carcinoembryonic Antigen; Carcinoma; Cholestasis; Fluorouracil; Humans; Neopla | 1978 |
Cancer of the pancreas in young adults.
Topics: Adenocarcinoma; Adult; Biopsy, Needle; Female; Fluorouracil; Humans; Laparotomy; Liver Neoplasms; Ne | 1978 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Gastrointestinal cancer. Treatment with fluorouracil-nitrosourea combinations.
Topics: Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neo | 1976 |
Combination chemotherapy with mitomycin C, 5-fluorouracil, and cytosine arabinoside in gastrointestinal cancer.
Topics: Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoro | 1976 |
[Digestive tract cancer: planning of chemotherapy].
Topics: Bile Duct Neoplasms; Cytarabine; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Hum | 1975 |
["MFC" therapy for advanced gastrointestinal cancer (author's transl)].
Topics: Cytarabine; Drug Therapy, Combination; Esophageal Neoplasms; Fluorouracil; Gastrointestinal Neoplasm | 1975 |
Combined 5-fluorouracil and hydroxyurea therapy for gastrointestinal cancer.
Topics: Administration, Oral; Ataxia; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointe | 1975 |
[The blood and urine concentration of 5-fluorouracil in patients with pancreatic neoplasms].
Topics: Fluorouracil; Humans; Injections, Intra-Arterial; Injections, Intravenous; Pancreas; Pancreatic Neop | 1975 |
Immunostimulation with intraperitoneally administered bacille Calmette Guérin for advanced malignant tumors of the gastrointestinal tract.
Topics: Adult; Aged; BCG Vaccine; Bile Duct Neoplasms; Carcinoma; Colonic Neoplasms; Cyclophosphamide; Femal | 1976 |
[Pancreatic endocrine tumor with metastases and increase of alpha-fetoprotein. A case report].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Fatal Outcome; Fluoroura | 1992 |
Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas. A phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Combined Modality Therapy; Fe | 1992 |
[Long-term therapy of a metastasizing pancreatic vipoma using the somatostatin derivative octreotide].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Liver Neoplasms; | 1992 |
Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Cancer Care Facilities; Chemotherapy, Adjuvant; Combined Modality Thera | 1992 |
Combined isodose curves of high-dose rate interstitial brachytherapy with external-beam radiation therapy in pancreatic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemotherapy, Adjuvan | 1992 |
Metastatic glucagonoma: clinical response to a combination of 5-fluorouracil and alpha-interferon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Glucagonoma; Humans; Interferon alpha- | 1992 |
[Preoperative administration of 5-FU emulsion for lymph nodes metastasis of pancreatic carcinoma].
Topics: Administration, Oral; Carcinoma; Emulsions; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; | 1992 |
[Evaluation of radiation therapy combined with intra-arterial infusion chemotherapy in patients with non-resectable pancreatic cancer].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Combined Moda | 1992 |
[Histological evaluation of intra-arterial infusion and systemic chemotherapy of pancreatic carcinomas].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 1992 |
Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations.
Topics: Colonic Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Drug Interactions; Fluorourac | 1992 |
[Pharmacokinetic studies on fluorinated pyrimidine in cancer cell and tissue].
Topics: Animals; Carcinoma, Ehrlich Tumor; Colonic Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Gl | 1992 |
Long-term results of combined modality treatment with I-125 implantation for carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined | 1992 |
Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells.
Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Dipyridamole; DNA Replic | 1992 |
Chemotherapy for pancreatic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1991 |
Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Cricetinae; Drug Screening Ass | 1991 |
Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubi | 1990 |
Response of pancreatic carcinoma to 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovo | 1992 |
Treatment perspectives in locally advanced unresectable pancreatic cancer.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Pancreatic Neoplasms | 1991 |
Pancreatic islet cell carcinoma with hypercalcemia: complete remission 5 years after surgical excision and chemotherapy.
Topics: Adenoma, Islet Cell; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluo | 1991 |
Preoperative chemoradiotherapy for adenocarcinoma of the pancreas. Rationale and technique.
Topics: Adenocarcinoma; Adult; Biopsy, Needle; Clinical Protocols; Combined Modality Therapy; Decision Trees | 1991 |
Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 1991 |
[Hepatic arterial infusion chemotherapy and loco-regional treatment and irradiation of pancreas tumor in non-resectable pancreas cancer with liver metastases].
Topics: Administration, Oral; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; | 1991 |
[Long-term arterial infusion chemotherapy combined with external irradiation therapy for unresectable pancreatic cancer--a case report].
Topics: Adenocarcinoma; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Combined Modal | 1991 |
[Combination of a biscoclaurine alkaloid, cepharanthine, and anticancer agents: effects and mechanism in human gastric and pancreatic carcinoma cell lines].
Topics: Alkaloids; Antineoplastic Agents; Benzylisoquinolines; Cell Division; Doxorubicin; Drug Synergism; F | 1991 |
Response to doxorubicin/methotrexate/fluorouracil in advanced adenocarcinoma of pancreas or biliary tract.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Doxo | 1990 |
Doxorubicin/methotrexate/fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1990 |
AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells.
Topics: Animals; Binding, Competitive; Cell Line; Dose-Response Relationship, Drug; Drug Synergism; Female; | 1991 |
Adenocarcinoma of the pancreas: current management of resectable and locally advanced disease.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Period; Pancreatic N | 1991 |
5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bili | 1991 |
Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1991 |
[Myocardial infarcts within the scope of 5-fluorouracil therapy].
Topics: Adenocarcinoma; Adult; Electrocardiography; Fluorouracil; Humans; Infusions, Intravenous; Liver Neop | 1990 |
Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph nodes of patients evaluated by DNA synthesis inhibition assay.
Topics: Breast Neoplasms; Carbazilquinone; Cisplatin; Colorectal Neoplasms; DNA, Neoplasm; Doxorubicin; Drug | 1990 |
[Methodological aspects on the histological evaluation of subrenal capsule assay (SRCA)].
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Cyclophosphamide; Cyclosporins; Female; Fluoroura | 1990 |
[Clinical studies of in vitro chemosensitivity test evaluated by ATP assay of gastrointestinal cancer].
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Scree | 1990 |
Growth-inhibitory effect of combination chemotherapy for human pancreatic cancer cell lines.
Topics: Aclarubicin; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1990 |
Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1990 |
Oral carmofur in advanced gastrointestinal cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Admini | 1990 |
Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion.
Topics: Aged; Circadian Rhythm; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gastrointestinal N | 1990 |
Cystadenocarcinoma of the pancreas: neo-adjuvant therapy and CEA monitoring.
Topics: Carcinoembryonic Antigen; Combined Modality Therapy; Cystadenocarcinoma; Fluorouracil; Humans; Male; | 1990 |
Localized unresectable pancreatic cancer.
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic | 1990 |
Sequential high-dose methotrexate, 5-fluorouracil, and doxorubicin for treatment of advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Female; F | 1990 |
[Combination radiotherapy and chemotherapy in the treatment of locally advanced adenocarcinoma of the pancreas. Experiences of the Gustave Roussy Institute].
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cis | 1990 |
[Intraarterial and intraportal infusion chemotherapy to prevent hepatic metastasis after curative resection of pancreatic cancer].
Topics: Aged; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; P | 1990 |
[Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Li | 1990 |
[Hyperthermia: microwave hyperthermia in combination with intra-arterial infusion chemotherapy of cancer of the pancreas].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Hepatocellular; Combined | 1985 |
[Chemoradiation treatment of pancreatic cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1985 |
[Combination therapy with lentinan, mitomycin c, 5-fluorouracil and radiation--a case of long-term survival of pancreas cancer after palliative surgery].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flu | 1987 |
[Long-term arterial infusion chemotherapy in unresectable pancreatic cancer].
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 1989 |
Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluorouracil; Humans; Infusi | 1989 |
[Intra-arterial infusion chemotherapy in non-resectable pancreatic cancer using angiotensin-II and implantable drug delivery system].
Topics: Adenoma, Bile Duct; Adult; Aged; Aged, 80 and over; Angiotensin II; Antineoplastic Combined Chemothe | 1989 |
[Radiotherapy of pancreas cancer--literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined Modality Therapy; Elec | 1985 |
Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) followed by radiation and 5-fluorouracil in locally advanced pancreatic cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorub | 1989 |
Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomized pilot study.
Topics: Activities of Daily Living; Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemothe | 1989 |
Uric acid nephrolithiasis and acute renal failure secondary to streptozotocin nephrotoxicity.
Topics: Acute Kidney Injury; Adenoma, Islet Cell; Aged; Fluorouracil; Humans; Kidney Calculi; Male; Pancreat | 1988 |
Metastatic islet cell tumour with clinical manifestations of insulin and glucagon excess: successful treatment by hepatic artery embolization and chemotherapy.
Topics: Adenoma, Islet Cell; Combined Modality Therapy; Embolization, Therapeutic; Female; Fluorouracil; Glu | 1988 |
Nonfunctioning islet cell carcinoma of the pancreas. Complete response to continuous 5-fluorouracil infusion.
Topics: Adenoma, Islet Cell; Catheters, Indwelling; Fluorouracil; Humans; Infusions, Intravenous; Male; Midd | 1988 |
[Vipoma. 9-year observations using currently available therapy methods].
Topics: Adenoma, Islet Cell; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combination; Fluo | 1986 |
Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 1986 |
Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma.
Topics: Adenocarcinoma; Cells, Cultured; Colonic Neoplasms; Floxuridine; Fluorine; Fluorouracil; Humans; Mac | 1986 |
Chemotherapy of metastatic islet cell carcinoma. Report of 4 cases and review of the literature.
Topics: Adenoma, Islet Cell; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Ne | 1985 |
Pancreatic islet cell carcinoma with gastrin and vasoactive intestinal polypeptide production.
Topics: Adenoma, Islet Cell; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gastrins; | 1985 |
A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1986 |
[Combination chemotherapy of cis-diamminedichloroplatinum (CDDP) and 5-fluorouracil (5-FU) in gastrointestinal tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; C | 1986 |
[Antitumor effect of interferons with chemotherapeutic agents].
Topics: Antineoplastic Agents; Cell Line; Cells, Cultured; Cisplatin; Drug Therapy, Combination; Fluorouraci | 1986 |
[Combined effect of interferons alpha, beta and gamma on tumor growth in vitro].
Topics: Animals; Cell Line; Cells, Cultured; Drug Therapy, Combination; Fluorouracil; Humans; Interferon Typ | 1986 |
Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Period; Pancreatic N | 1987 |
Metabolism of 5-fluorouracil to an N-cholyl-2-fluoro-beta-alanine conjugate: previously unrecognized role for bile acids in drug conjugation.
Topics: Alanine; beta-Alanine; Bile Acids and Salts; Cholic Acids; Chromatography, High Pressure Liquid; Flu | 1987 |
[Subrenal capsule assay as a chemosensitivity test (III)--Comparison of host reaction, experimental chemotherapy and use of nude mice].
Topics: Animals; Breast Neoplasms; Cell Line; Drug Evaluation, Preclinical; Fluorouracil; Humans; Mice; Mice | 1987 |
[Clinical study on the effect of chemotherapy in the treatment of pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Lymphatic Metastasis; | 1988 |
Cure of advanced gastric cancer by combined chemotherapy with cisplatinum, mitomycin C, and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorourac | 1988 |
[Chemotherapy of pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Female | 1985 |
Treatment of unresectable pancreatic carcinoma using irradiation with concurrent intravenous 5-FU infusion therapy.
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic | 1988 |
Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.
Topics: Adenocarcinoma; Breast Neoplasms; Colonic Neoplasms; Deoxyuracil Nucleotides; Drug Resistance; Fluor | 1988 |
Phase I-II study of prophylactic hepatic irradiation with local irradiation and systemic chemotherapy for adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Fluorouracil; Humans; Liver Neoplasms; Middl | 1988 |
Treatment of probable subclinical liver metastases and gross pancreatic carcinoma with hepatic artery 5-fluorouracil infusion and radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Hepatic Artery; Humans | 1988 |
Cytology of solid and papillary epithelial neoplasms of the pancreas: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Papillary; Cytodia | 1988 |
Pharmacodynamics of 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Animals; Bone Marrow; Colonic Neoplasms; Deoxyuracil Nucleotides; Fluorodeoxyuridyla | 1988 |
External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Fluorouracil; Hum | 1988 |
Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study.
Topics: Adult; Aged; Drug Evaluation; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms | 1988 |
[Clinical evaluation of implantable drug delivery system (Port-A-Cath) in cancer chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1988 |
Comparative effects of selected drug combinations on the growth of a human pancreatic carcinoma cell line (MIA PaCa-2).
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line; Doxorubicin; | 1986 |
An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Epirub | 1987 |
Results in the management of locally unresectable pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1986 |
A case of pancreatic cancer with liver metastasis which responded to chemotherapy.
Topics: Cisplatin; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 1987 |
Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group.
Topics: Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Pancreatic Neoplasms; Prognosis | 1987 |
Radiation therapy with and without chemotherapy in the treatment of localized unresectable pancreatic carcinoma. A retrospective analysis.
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic | 1987 |
Gastrointestinal anastomotic healing during treatment with perioperative 5-fluorouracil.
Topics: Aged; Colonic Neoplasms; Colostomy; Drug Evaluation; Female; Fluorouracil; Gallbladder; Gastrectomy; | 1987 |
[Thermochemotherapy of unresectable pancreatic carcinoma (hot water and intra-arterial chemotherapy using noradrenaline)].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Hyper | 1987 |
[Peroperative radiotherapy in cancer of the pancreas].
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Female; Fluorouracil; Humans; Intraoperative Car | 1987 |
Chemotherapy for advanced gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Mitomycin; Mitomy | 1986 |
125I interstitial implant, precision high-dose external beam therapy, and 5-FU for unresectable adenocarcinoma of pancreas and extrahepatic biliary tree.
Topics: Adenocarcinoma; Aged; Bile Duct Neoplasms; Brachytherapy; Female; Fluorouracil; Humans; Male; Middle | 1986 |
Pancreatic giant cell carcinoma of the osteoclastic type: response to 5-fluorouracil and radiation.
Topics: Aged; Carcinoma; Combined Modality Therapy; Fluorouracil; Humans; Male; Pancreatic Neoplasms | 1986 |
[Clinical study on concentration of FT-207 and 5-FU in serum, lymph nodes and tissues after rectal administration of FT-207 suppositories for malignant diseases of the liver, biliary tract and pancreas].
Topics: Biliary Tract Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Lymph Nodes; Pancreatic Neoplasms; P | 1985 |
[Intra-arterial continuous infusion in patients with advanced and recurrent cancer of the digestive system].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co | 1985 |
[Effects of urokinase on the transfer of 1-hexylcarbamoyl-5-fluorouracil (HCFU) into the blood, bile and pancreatic juice].
Topics: Administration, Oral; Antineoplastic Agents; Bile; Fluorouracil; Humans; Pancreatic Juice; Pancreati | 1985 |
Chemotherapy (5-fluorouracil, adriamycin and cisplatin) preceding irradiation in locally advanced unresectable carcinoma of the pancreas: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorub | 1985 |
Hepatic artery infusion for metastatic malignancy using percutaneously placed catheters.
Topics: Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma, | 1971 |
[Selection of a method for treating cancer of the pancreaticoduodenal region].
Topics: Bile Duct Neoplasms; Cyclophosphamide; Duodenal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Huma | 1971 |
Improved palliation of pancreatic carcinoma.
Topics: Adult; Aged; Carcinoma; Chromium Isotopes; Cobalt Isotopes; Diagnostic Techniques, Surgical; Female; | 1973 |
Inhibition of DNA polymerases and neoplastic cells by selected SH inhibitors.
Topics: Animals; Antineoplastic Agents; Arsenicals; Benzoates; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Ch | 1972 |
Carcinoma of pancreas--palliative radiotherapy.
Topics: Carcinoma; Cobalt Isotopes; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Metastasis; Palliative C | 1973 |
Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Cobalt Radioisotopes; Evaluation Studies as Topic; Female; Fluorouracil | 1973 |
[Comparison of several different methods of antiblastic therapy in advanced carcinomas of the digestive system].
Topics: Antineoplastic Agents; Bleomycin; Cyclophosphamide; Drug Therapy, Combination; Esophageal Neoplasms; | 1974 |
[Therapy of advanced tumors with 5-fluoro-uracil].
Topics: Femoral Neoplasms; Fluorouracil; Humans; Injections, Intra-Arterial; Injections, Intravenous; Intest | 1969 |
Combined telecobalt and 5-fluorouracil therapy in carcinoma of the pancreas: a report of 97 cases.
Topics: Adult; Aged; Cobalt Isotopes; Female; Fluorouracil; Humans; Male; Middle Aged; Palliative Care; Panc | 1970 |
Echographic evaluation of abdominal tumor regression during antineoplastic treatment.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorub | 1974 |
Combination chemotherapy in gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall | 1970 |
Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Bile Duct Neoplasms; Evaluation Studies as Topic; Floxuridine | 1974 |
[Cancer of the body of the pancreas with hepatic metastases].
Topics: Abdomen; Blindness; Catheterization; Cholangiography; Coma; Diagnosis, Differential; Fluorouracil; H | 1968 |
Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumors.
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Cyclophosphamide; Female; Fibrosarcoma; Fluorouraci | 1969 |
Lactic dehydrogenase isoenzyme alterations in malignant disease of the liver.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bronchial Neoplasms; Carcinoma, Hepatocellular; C | 1971 |
Disappearance of disseminated pancreatic carcinoma with combined chemotherapy.
Topics: Adult; Carcinoma, Intraductal, Noninfiltrating; Carmustine; Duodenum; Fluorouracil; Gastrectomy; Hum | 1973 |
Malignant insulinoma with hepatic secondaries treated with hepatic artery ligation.
Topics: Adenoma, Islet Cell; Aged; Fluorouracil; Hepatic Artery; Humans; Ligation; Liver Neoplasms; Male; Ne | 1973 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Alkylating Agents; Biliary Tract; Carcinoid Tumor; Carcinoma, Hepatocellular; Fluoro | 1973 |
Proceedings: Islets of Langerhans.
Topics: Adenoma, Islet Cell; Diarrhea; Fluorouracil; Follow-Up Studies; Gastrectomy; Gastrins; Glucagon; Hum | 1972 |
[Indications and medical therapy of hypoglycemic beta-insular].
Topics: Adenoma, Islet Cell; Adrenal Cortex Hormones; Antineoplastic Agents; Carcinoma; Diazoxide; Diuretics | 1973 |
Effects of sodium warfarin and other carcinostatic agents on malignant cells: a study of drug synergy.
Topics: Animals; Carbon Radioisotopes; Carcinoma, Bronchogenic; Carcinoma, Hepatocellular; Carcinoma, Squamo | 1974 |
An unusual case of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adult; Antibiotics, Antineoplastic; Aorta, Abdominal; Calcinosis; Cystaden | 1974 |
Intra-arterial chemotherapy for patients with inoperable carcinoma of the pancreas.
Topics: Catheterization; Cyclophosphamide; Fluorouracil; Humans; Injections, Intra-Arterial; Jaundice; Metho | 1974 |
Postpancreatectomy insulin-resistant diabetes mellitus. Improvement after prednisone and 5-fluorouracil.
Topics: Diabetes Mellitus; Female; Fluorouracil; Humans; Insulin Resistance; Middle Aged; Pancreatectomy; Pa | 1972 |
The gallbladder as a conduit between the liver and intestine.
Topics: Adenocarcinoma; Adolescent; Adult; Bile Ducts; Carcinoma; Cholangiography; Common Bile Duct; Drainag | 1973 |
Treatment of the patient with adenocarcinoma of unknown origin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Autopsy; Carmustine; Female; Fluorouracil; Human | 1972 |
Leiomyosarcoma of the renal pelvis.
Topics: Female; Fluorouracil; Humans; Kidney Neoplasms; Kidney Pelvis; Leiomyosarcoma; Middle Aged; Neoplasm | 1973 |
Chemotherapy for carcinoma of the pancreas.
Topics: Adult; Aged; Autopsy; Biopsy; Carcinoma; Female; Fluorouracil; Humans; Laparotomy; Male; Middle Aged | 1973 |
Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer.
Topics: Adenocarcinoma; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukopenia; Mal | 1974 |
Chemotherapy in pancreatic carcinoma: 5 fluorouracil (5FU) and 1,3 bis-(2 chloretjyl)-1-nitrosourea (BCNU).
Topics: Adenocarcinoma; Adult; Aged; Biopsy; Carmustine; Drug Therapy, Combination; Evaluation Studies as To | 1974 |
Combined 5-fluorouracil and vinblastine therapy for gastrointestinal and other solid tumors.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1972 |
[Systemic chemotherapy of pancreatic cancer].
Topics: Adult; Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Middle A | 1972 |
[Continuous intra-arterial infusion of antineoplastic agents].
Topics: Antineoplastic Agents; Catheterization; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections | 1972 |
[Combined treatment of cancer of the pancreas].
Topics: Adult; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms | 1972 |
[Regional intra-arterial chemotherapy of cancer of the pancreas].
Topics: Animals; Chemotherapy, Cancer, Regional Perfusion; Dogs; Fluorouracil; Humans; Injections, Intra-Art | 1972 |
5-fluorouracil given once weekly: comparison of intravenous and oral administration.
Topics: Adenocarcinoma; Administration, Oral; Biliary Tract Diseases; Breast Neoplasms; Female; Fluorouracil | 1971 |
[Intra-arterial infusion of drugs into the liver and pancreas].
Topics: Bile Duct Neoplasms; Cyclophosphamide; Duodenal Neoplasms; Fluorouracil; Humans; Injections, Intra-A | 1971 |
Immunosuppression by 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antibody Formation; Antigens; Blood Bactericidal Activity; Blood Platel | 1970 |
[Experience with the treatment of patients with malignant tumors with 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Duodenal Neoplasms; Female; Fluorouracil; Humans; In | 1967 |
Hepatic artery and celiac axis infusion for the treatment of upper abdominal malignant lesions.
Topics: Abdominal Neoplasms; Carcinoma; Celiac Artery; Fluorouracil; Gastrointestinal Neoplasms; Head and Ne | 1968 |
Oral administration of fluorouracil. A preliminary trial.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci | 1968 |
Fluorouracil toxicity following gastrointestinal surgery.
Topics: Adenocarcinoma; Colitis, Ulcerative; Colostomy; Fluorouracil; Humans; Intestinal Mucosa; Intestinal | 1965 |
Remission of carcinoma of the pancreas.
Topics: Aged; Fluorouracil; Humans; Male; Pancreatic Neoplasms; Prognosis | 1966 |